PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Heckmann, M; Ceballos-Baumann, AO; Plewig, G				Heckmann, M; Ceballos-Baumann, AO; Plewig, G		Hyperhidrosis Study Grp	Botulinum toxin a for axillary hyperhidrosis (excessive sweating).	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSTHORACIC ENDOSCOPIC SYMPATHECTOMY; A TOXIN; FOCAL HYPERHIDROSIS; GLAND-FUNCTION; DOUBLE-BLIND; INJECTION; PALMAR; COMPLICATIONS; IONTOPHORESIS; NEUROTOXIN	Background: Treatment of primary focal hyperhidrosis is often unsatisfactory. Botulinum toxin A can stop excessive sweating by blocking the release of acetylcholine, which mediates sympathetic neurotransmission in the sweat glands. Methods: We conducted a multicenter trial of botulinum toxin A in 145 patients with axillary hyperhidrosis. The patients had rates of sweat production greater than 50 mg per minute and had had primary axillary hyperhidrosis that was unresponsive to topical therapy with aluminum chloride for more than one year. In each patient, botulinum toxin A (200 U) was injected into one axilla, and placebo was injected into the other in a randomized, double-blind manner. (The units of the botulinum toxin A preparation used in this study are not identical to those of other preparations.) Two weeks later, after the treatments were revealed, the axilla that had received placebo was injected with 100 U of botulinum toxin A. Changes in the rates of sweat production were measured by gravimetry. Results: At base line, the mean (+/-SD) rate of sweat production was 192+/-136 mg per minute. Two weeks after the first injections the mean rate of sweat production in the axilla that received botulinum toxin A was 24+/-27 mg per minute, as compared with 144+/-113 mg per minute in the axilla that received placebo (P<0.001). Injection of 100 U into the axilla that had been treated with placebo reduced the mean rate of sweat production in that axilla to 32+/-39 mg per minute (P<0.001). Twenty-four weeks after the injection of 100 U, the rates of sweat production (in the 136 patients in whom the rates were measured at that time) were still lower than base-line values, at 67+/-66 mg per minute in the axilla that received 200 U and 65+/-64 mg per minute in the axilla that received placebo and 100 U of the toxin. Treatment was well tolerated; 98 percent of the patients said they would recommend this therapy to others. Conclusions: Intradermal injection of botulinum toxin A is an effective and safe therapy for severe axillary hyperhidrosis. (N Engl J Med 2001;344:488-93.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Munich, Dermatol Klin, Dept Dermatol, D-80337 Munich, Germany; Tech Univ Munich, Dept Neurol, D-8000 Munich, Germany	University of Munich; Technical University of Munich	Heckmann, M (corresponding author), Univ Munich, Dermatol Klin, Dept Dermatol, Frauenlobstr 9-11, D-80337 Munich, Germany.	heckmann@derma.med.uni-muenchen.de						Brisinda G, 1999, NEW ENGL J MED, V341, P624; Bushara KO, 1996, CLIN EXP DERMATOL, V21, P276, DOI 10.1111/j.1365-2230.1996.tb00093.x; BYRNE J, 1990, BRIT J SURG, V77, P1046, DOI 10.1002/bjs.1800770931; de Paiva A, 1999, P NATL ACAD SCI USA, V96, P3200, DOI 10.1073/pnas.96.6.3200; Dressler D, 2000, EUR NEUROL, V43, P13, DOI 10.1159/000008122; DROBIK C, 1995, ACTA OTO-LARYNGOL, V115, P459, DOI 10.3109/00016489509139348; ERBGUTH F, 1993, J NEUROL NEUROSUR PS, V56, P1235, DOI 10.1136/jnnp.56.11.1235; FREEMAN R, 1990, DERMATOL CLIN, V8, P479; Glogau RG, 1998, DERMATOL SURG, V24, P817, DOI 10.1111/j.1524-4725.1998.tb04257.x; GRAZKO MA, 1995, NEUROLOGY, V45, P712, DOI 10.1212/WNL.45.4.712; GUTTMANN L, 1941, P ROY SOC MED, V35, P77; Hallett M, 1999, NEW ENGL J MED, V341, P118, DOI 10.1056/NEJM199907083410209; HAMBLETON P, 1992, J NEUROL, V239, P16, DOI 10.1007/BF00839205; Heckmann M, 1999, J AM ACAD DERMATOL, V41, P987, DOI 10.1016/S0190-9622(99)70258-6; Heckmann M, 1998, HAUTARZT, V49, P101, DOI 10.1007/s001050050707; Heckmann M, 1998, ARCH DERMATOL, V134, P1298, DOI 10.1001/archderm.134.10.1298; Heckmann M, 1998, NEUROSURGERY, V42, P1403, DOI 10.1097/00006123-199806000-00150; Heckmann M, 1997, DERMATOL SURG, V23, P1221, DOI 10.1111/j.1524-4725.1997.tb00480.x; Krack P, 1998, MOVEMENT DISORD, V13, P749, DOI 10.1002/mds.870130425; Lai YT, 1997, NEUROSURGERY, V41, P110, DOI 10.1097/00006123-199707000-00023; LANGE DJ, 1987, MUSCLE NERVE, V10, P552, DOI 10.1002/mus.880100610; LANGE DJ, 1988, MUSCLE NERVE, V11, P520; MACK GW, 1986, J APPL PHYSIOL, V61, P1701, DOI 10.1152/jappl.1986.61.5.1701; Minor V., 1928, DTSCH Z NERVENHEILKD, V101, P302, DOI 10.1007/BF01652699; Naumann M, 1998, ARCH DERMATOL, V134, P301, DOI 10.1001/archderm.134.3.301; Odderson IR, 1998, DERMATOL SURG, V24, P1237, DOI 10.1111/j.1524-4725.1998.tb04104.x; PASRICHA PJ, 1995, NEW ENGL J MED, V333, P75; REINAUER S, 1995, HAUTARZT, V46, P543, DOI 10.1007/s001050050296; REINAUER S, 1993, BRIT J DERMATOL, V129, P166, DOI 10.1111/j.1365-2133.1993.tb03521.x; SATO K, 1989, J AM ACAD DERMATOL, V20, P713, DOI 10.1016/S0190-9622(89)70081-5; SATO K, 1989, J AM ACAD DERMATOL, V20, P537, DOI 10.1016/S0190-9622(89)70063-3; SATO K, 1988, J LAB CLIN MED, V111, P511; Schnider P, 1997, BRIT J DERMATOL, V136, P548, DOI 10.1046/j.1365-2133.1997.d01-1233.x; Schnider P, 1999, BRIT J DERMATOL, V140, P677; SHELLEY WB, 1975, ACTA DERM-VENEREOL, V55, P241; SIATKOWSKI RM, 1993, OPHTHALMOLOGY, V100, P1861; Woolson RF, 1987, STAT METHODS ANAL BI; Zacherl J, 1998, EUR J SURG, V164, P43	38	268	284	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 15	2001	344	7					488	493		10.1056/NEJM200102153440704	http://dx.doi.org/10.1056/NEJM200102153440704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401HL	11172190				2022-12-28	WOS:000166922100004
J	Terry, N				Terry, N			Access vs quality assurance: The e-health conundrum	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									St Louis Univ, Ctr Hlth Law Studies, St Louis, MO 63103 USA	Saint Louis University	Terry, N (corresponding author), St Louis Univ, Ctr Hlth Law Studies, St Louis, MO 63103 USA.							BERG J, 2000, AM PSYCH ASS SEPT 8; Department of Health and Human Services, 2000, FED REG, V65, P82462; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; Terry N P, 2000, J Health Law, V33, P605; Terry NP, 1999, AM J LAW MED, V25, P327	6	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					807	807		10.1001/jama.285.6.807	http://dx.doi.org/10.1001/jama.285.6.807			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176924	hybrid			2022-12-28	WOS:000166817200042
J	Niklason, LE; Langer, R				Niklason, LE; Langer, R			Prospects for organ and tissue replacement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STEM-CELLS; IN-VITRO; TRANSPLANTATION; FAILURE; THERAPY	Damage or loss of a tissue or organ is common, costly, and tragic. Advances in mechanical artificial organs and organ transplantation have improved the treatment of organ failure, and advances in molecular immunology, tissue engineering, and stem cell biology offer the promise of even better therapeutic modalities for treating organ failure in the future. Enhancement of immune tolerance of transplanted tissues, improved understanding of cellular differentiation and tissue development, and advances in biomaterials may enable the de novo creation of implantable tissue and organs for transplantation, Innovative techniques for prevention and treatment of tissue loss and organ failure should improve the quality and length of life.	Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC 27710 USA; Duke Univ, Dept Anesthesia, Durham, NC 27710 USA; MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; MIT, Dept Chem Engn, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Duke University; Duke University; Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Niklason, LE (corresponding author), Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC 27710 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003492, R01HL060435] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03492-04, HL-60435] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baquerizo A, 1999, TRANSPLANTATION, V67, P5, DOI 10.1097/00007890-199901150-00003; BARNARD C N, 1967, South African Medical Journal, V41, P1271; Barrington K, 1997, BRIT MED J, V315, P1215, DOI 10.1136/bmj.315.7117.1215; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; DEVRIES WC, 1984, NEW ENGL J MED, V310, P273, DOI 10.1056/NEJM198402023100501; El-Banayosy A, 2000, J THORAC CARDIOV SUR, V119, P581, DOI 10.1016/S0022-5223(00)70140-1; Giannoukakis N, 1999, GENE THER, V6, P1499, DOI 10.1038/sj.gt.3300981; Goddard MJ, 2000, J CLIN PATHOL, V53, P44, DOI 10.1136/jcp.53.1.44; Gudmundsdottir H, 2000, SEMIN NEPHROL, V20, P209; Guinan EC, 1999, NEW ENGL J MED, V340, P1704, DOI 10.1056/NEJM199906033402202; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hancock WW, 2000, SEMIN NEPHROL, V20, P217; Hattler BG, 1999, PERFUSION-UK, V14, P311, DOI 10.1177/026765919901400411; Helderman JH, 2000, SEMIN NEPHROL, V20, P83; Humes HD, 1999, KIDNEY INT, V55, P2502, DOI 10.1046/j.1523-1755.1999.00486.x; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645; Kolff WJ, 1944, ACTA MED SCAND, V117, P121; Kubota C, 2000, P NATL ACAD SCI USA, V97, P990, DOI 10.1073/pnas.97.3.990; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lanza RP, 1999, NAT BIOTECHNOL, V17, P1171, DOI 10.1038/70709; MURRAY JE, 1976, ANN SURG, V184, P565, DOI 10.1097/00000658-197611000-00006; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Oberpenning F, 1999, NAT BIOTECHNOL, V17, P149, DOI 10.1038/6146; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ramiya VK, 2000, NAT MED, V6, P278; Schwartz RS, 1999, NEW ENGL J MED, V340, P1754, DOI 10.1056/NEJM199906033402209; Shakesheff KM, 1998, J BIOMAT SCI-POLYM E, V9, P507, DOI 10.1163/156856298X00596; Tsai RJ, 2000, NEW ENGL J MED, V343, P86, DOI 10.1056/NEJM200007133430202; *UN NETW ORG SHAR, 2001, CRIT DAT 2000 US FAC; Vacanti JP, 1999, LANCET S1, V354, pSI32	31	74	78	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					573	576		10.1001/jama.285.5.573	http://dx.doi.org/10.1001/jama.285.5.573			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176861	Bronze			2022-12-28	WOS:000166714200014
J	de Lange, M; Snieder, H; Ariens, RAS; Spector, TD; Grant, PJ				de Lange, M; Snieder, H; Ariens, RAS; Spector, TD; Grant, PJ			The genetics of haemostasis: a twin study	LANCET			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ISCHEMIC-HEART-DISEASE; VON-WILLEBRAND-FACTOR; MYOCARDIAL-INFARCTION; PLASMA-LEVELS; PAI-1 ACTIVITY; FACTOR-XIII; RISK; POLYMORPHISMS; FIBRINOGEN	Background The concentrations of fibrinogen, factor VII and VIII, von Willebrand factor, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator have been associated with coronary-heart disease. In addition, polymorphisms in the genes coding for fibrinogen, factor VII, PAI-1, and factor XIII have been reported to affect both protein concentrations and cardiovascular disease risk. Methods We did a classic twin study to assess heritabilities of these haemostatic factors. We enrolled 1002 female twins; 149 pairs of monozygotic and 352 pairs of dizygotic twins. 89 monozygotic and 196 dizygotic twin pairs were analysed for factor VII. Findings Quantitative genetic model fitting showed that genetic factors contributed to about 41-75% of the variation in concentrations of fibrinogen, factor VII, factor VIII, PAI-1, tissue plasminogen activator, factor XIII A-subunit and B-subunit, and von Willebrand factor. Factor XIII activity showed higher (82%) and factor Xlla lower (38%) heritability. Interpretation We have shown that genetic factors have a major effect on plasma concentrations of haemostatic proteins. Our results stress the importance of research into the genetic regulation of proteins involved in haemostasis and atherothrombotic disorders, including myocardial infarction and stroke.	Univ Leeds, Acad Unit Mol Vasc Med, Leeds LS1 3EX, W Yorkshire, England; St Thomas Hosp, Twin Res & Genet Epidemiol Unit, London, England	University of Leeds; Guy's & St Thomas' NHS Foundation Trust	Grant, PJ (corresponding author), Univ Leeds, Acad Unit Mol Vasc Med, Leeds LS1 3EX, W Yorkshire, England.	p.j.grant@leeds.ac.uk	Spector, Tim D/F-6533-2012; Grant, Peter/HIR-3733-2022	Ariens, Robert/0000-0002-6310-5745				Ariens RAS, 2000, BLOOD, V96, P988, DOI 10.1182/blood.V96.3.988.015k57_988_995; Ariens RAS, 1999, ARTERIOSCL THROM VAS, V19, P2012, DOI 10.1161/01.ATV.19.8.2012; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; Bernardi F, 1996, ARTERIOSCL THROM VAS, V16, P72; Catto AJ, 1997, THROMB HAEMOSTASIS, V77, P1104; Cesari M, 1999, ARTERIOSCL THROM VAS, V19, P316, DOI 10.1161/01.ATV.19.2.316; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; FRIEDLANDER Y, 1995, AM J HUM GENET, V56, P1194; Garner C, 2000, BLOOD, V95, P342; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1987, LANCET, V2, P988; Henry M, 1998, ARTERIOSCL THROM VAS, V18, P84, DOI 10.1161/01.ATV.18.1.84; Henry M, 1997, ARTERIOSCL THROM VAS, V17, P851, DOI 10.1161/01.ATV.17.5.851; Hong YL, 1997, ARTERIOSCL THROM VAS, V17, P2776, DOI 10.1161/01.ATV.17.11.2776; Hong YL, 1999, THROMB HAEMOSTASIS, V81, P382; ICHINOSE A, 1994, HAEMOSTASIS THROMBOS; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; Keightley AM, 1999, BLOOD, V93, P4277, DOI 10.1182/blood.V93.12.4277.412k03_4277_4283; Kohler HP, 1998, THROMB HAEMOSTASIS, V79, P14, DOI 10.1055/s-0037-1614210; Kohler HP, 1998, THROMB HAEMOSTASIS, V80, P704; Kohler HP, 1999, THROMB HAEMOSTASIS, V81, P745, DOI 10.1055/s-0037-1614565; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; Lowe GDO, 1998, THROMB HAEMOSTASIS, V79, P129; MacGregor AJ, 2000, TRENDS GENET, V16, P131, DOI 10.1016/S0168-9525(99)01946-0; Mansvelt EPG, 1998, THROMB HAEMOSTASIS, V80, P561; MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; ORSTAVIK KH, 1985, AM J HUM GENET, V37, P89; OsseiGerning N, 1997, ARTERIOSCL THROM VAS, V17, P33, DOI 10.1161/01.ATV.17.1.33; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; SADLER JE, 1994, HAEMOSTASIS THROMBOS; SCHILDKRAUT JM, 1989, AM J CARDIOL, V64, P555, DOI 10.1016/0002-9149(89)90477-3; SPECTOR TD, 2000, ADV TWIN SIBPAIR ANA; YE S, 1995, THROMB HAEMOSTASIS, V74, P837	34	231	233	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2001	357	9250					101	105		10.1016/S0140-6736(00)03541-8	http://dx.doi.org/10.1016/S0140-6736(00)03541-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197396				2022-12-28	WOS:000166476200011
J	Nauwelaers, J				Nauwelaers, J			Eraritjaritjaka	LANCET			English	Editorial Material											Nauwelaers, J (corresponding author), Leemstr 8, B-3990 Wijchmaal Peer, Belgium.								0	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2169	2170		10.1016/S0140-6736(00)03505-4	http://dx.doi.org/10.1016/S0140-6736(00)03505-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191556				2022-12-28	WOS:000165997300037
J	Stewart, L; Tolmie, J; Galea, P; Touitou, I				Stewart, L; Tolmie, J; Galea, P; Touitou, I			Familial Mediterranean fever in a cold climate: read The Lancet	LANCET			English	Article									Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland; Royal Hosp Sick Children, Dept Med Genet, Glasgow G3 8SJ, Lanark, Scotland; Hop Arnaud de Villeneuve, Dept Genet, F-34295 Montpellier, France	University of Glasgow; University of Glasgow; Universite de Montpellier; CHU de Montpellier	Stewart, L (corresponding author), Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland.							Ben-Chetrit E, 1998, LANCET, V351, P659, DOI 10.1016/S0140-6736(97)09408-7; Booth DR, 2000, QJM-INT J MED, V93, P217, DOI 10.1093/qjmed/93.4.217; GEDALIA A, 1992, J RHEUMATOL, V19, P1; Grateau G, 2000, QJM-INT J MED, V93, P223, DOI 10.1093/qjmed/93.4.223; SIEGAL S, 1945, ANN INTERN MED, V23, P1, DOI 10.7326/0003-4819-23-1-1	5	4	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2154	2154		10.1016/S0140-6736(00)03498-X	http://dx.doi.org/10.1016/S0140-6736(00)03498-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191544				2022-12-28	WOS:000165997300015
J	Schulten, K				Schulten, K			Electron transfer - Exploiting thermal motion	SCIENCE			English	Editorial Material							PHOTOSYNTHETIC REACTION-CENTER		Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Schulten, K (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.		Schulten, Klaus/D-5561-2009					Aquino AJA, 1997, CHEM PHYS LETT, V275, P181, DOI 10.1016/S0009-2614(97)00742-2; Balabin IA, 2000, SCIENCE, V290, P114, DOI 10.1126/science.290.5489.114; BETTS JN, 1992, J AM CHEM SOC, V114, P4043, DOI 10.1021/ja00037a004; Graige MS, 1998, P NATL ACAD SCI USA, V95, P11679, DOI 10.1073/pnas.95.20.11679; Hu XC, 1998, P NATL ACAD SCI USA, V95, P5935, DOI 10.1073/pnas.95.11.5935; HUMPHREY WF, 1996, J MOL GRAPHICS, V14, P3361; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; Ray J, 1999, J PHYS CHEM A, V103, P9417, DOI 10.1021/jp9917143; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; WOLFGANG J, 1997, J PHYS CHEM-US, V101, P2386; XU D, 1994, CHEM PHYS, V182, P91, DOI 10.1016/0301-0104(94)00016-6	11	5	6	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 6	2000	290	5489					61	62		10.1126/science.290.5489.61	http://dx.doi.org/10.1126/science.290.5489.61			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	361LP	11183149				2022-12-28	WOS:000089724800028
J	Moses, H; Martin, JB				Moses, H; Martin, JB			Academic relationships with industry - A new model for biomedical research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Boston Consulting Grp, Bethesda, MD 20814 USA; Harvard Univ, Sch Med, Off Dean, Boston, MA USA	Boston Consulting Group (BCG); Harvard University; Harvard Medical School	Moses, H (corresponding author), Boston Consulting Grp, 4800 Hampden Ln, Bethesda, MD 20814 USA.							Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; *BOST CONS GROUP, 1999, SER STRAT PHARM IND; Burstin HR, 1999, AM J MED, V107, P437, DOI 10.1016/S0002-9343(99)00269-7; Commander H, 2000, NAT MED, V6, P118, DOI 10.1038/72181; DeAngelis CD, 2000, JAMA-J AM MED ASSOC, V284, P2237, DOI 10.1001/jama.284.17.2237; Ducor P, 2000, SCIENCE, V289, P873, DOI 10.1126/science.289.5481.873; *ERNST YOUNG CONS, 2000, EC CONTR BIOT IND US, P1; HESSLEBERTH J, 2000, MIT TECH REV, V103, P82; Korn D, 2000, JAMA-J AM MED ASSOC, V284, P2234, DOI 10.1001/jama.284.17.2234; Malakoff D, 2000, SCIENCE, V288, P410, DOI 10.1126/science.288.5465.410; POLLAK M, 1999, NY TIMES        1013, pB13; POLLAK M, 1999, NY TIMES        1013, pB11; Stolberg S G, 2000, N Y Times Web, pA15; *US CENS BUR, 1999, STAT ABSTR US SCI TE, P614	14	88	89	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					933	935		10.1001/jama.285.7.933	http://dx.doi.org/10.1001/jama.285.7.933			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402BE	11180737				2022-12-28	WOS:000166965500031
J	Andress, G				Andress, G			Should depression be managed as a chronic disease?	BRITISH MEDICAL JOURNAL			English	Article							EPISODES; SAMPLE		St Vincents Hosp, Collaborating Ctr Mental Hlth, Sydney, NSW 2010, Australia; St Vincents Hosp, UNSW, Sch Psychiat, Sydney, NSW 2010, Australia	St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney	Andress, G (corresponding author), St Vincents Hosp, Collaborating Ctr Mental Hlth, 299 Forbes St, Sydney, NSW 2010, Australia.							Andrews G, 2000, B WORLD HEALTH ORGAN, V78, P446; Donoghue J, 1998, CLIN DRUG INVEST, V16, P453, DOI 10.2165/00044011-199816060-00005; Enserink M, 1999, SCIENCE, V284, P238, DOI 10.1126/science.284.5412.238; Judd LL, 1998, ARCH GEN PSYCHIAT, V55, P694, DOI 10.1001/archpsyc.55.8.694; Kendler KS, 1997, PSYCHOL MED, V27, P107, DOI 10.1017/S0033291796003893; KILOH LG, 1988, BRIT J PSYCHIAT, V153, P752, DOI 10.1192/bjp.153.6.752; LEE AS, 1988, BRIT J PSYCHIAT, V153, P741, DOI 10.1192/bjp.153.6.741; MCLEOD JD, 1992, J ABNORM PSYCHOL, V101, P277, DOI 10.1037/0021-843X.101.2.277; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Rix S, 1999, BRIT J GEN PRACT, V49, P99; Thompson C, 2000, LANCET, V355, P185, DOI 10.1016/S0140-6736(99)03171-2	11	167	169	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	2001	322	7283					419	421		10.1136/bmj.322.7283.419	http://dx.doi.org/10.1136/bmj.322.7283.419			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	404JH	11179166	Green Published			2022-12-28	WOS:000167093600032
J	Mack, MJ				Mack, MJ			Minimally invasive and robotic surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOPULMONARY BYPASS; OFF-PUMP; CORONARY	Advances in surgery have focused on minimizing the invasiveness of surgical procedures, such that a significant paradigm shift has occurred for some procedures in which surgeons no longer directly touch or see the structures on which they operate. Advancements in video imaging, endoscope technology. and instrumentation have made it possible to convert many procedures in many surgical specialties from open surgeries to endoscopic ones. The use of computers and robotics promises to facilitate complex endoscopic procedures by virtue of voice control over the networked operating room, enhancement of dexterity to facilitate microscale operations, and development of virtual simulator trainers to enhance the ability to learn new complex operations. Future research will focus on delivery of diagnostic and therapeutic modalities through natural orifices in which investigation is under remote control and navigation, so that truly "noninvasive" surgery will be a reality.	Cardiopulm Sci Res & Technol Inst, Dallas, TX 75230 USA		Mack, MJ (corresponding author), Cardiopulm Sci Res & Technol Inst, 7777 Forest Ln,Suite A323, Dallas, TX 75230 USA.							Anderson JH, 1999, J VASC INTERV RADIOL, V10, P1, DOI 10.1016/S1051-0443(99)70001-1; Ascione R, 2000, ANN THORAC SURG, V69, P1198, DOI 10.1016/S0003-4975(00)01152-8; BAUER JJ, 1999, TELEMED J, V5, P27; Boyd WD, 1999, ANN THORAC SURG, V68, P1490, DOI 10.1016/S0003-4975(99)00951-0; Calafiore AM, 1999, ANN THORAC SURG, V67, P450, DOI 10.1016/S0003-4975(98)01194-1; DAMIANO R, 2000, NY TIMES        0404, pD1; Davis CJ, 1995, PRINCIPLES LAPAROSCO, P3, DOI DOI 10.1007/978-1-4612-2480-8_1; Diegeler A, 2000, ANN THORAC SURG, V69, P1162, DOI 10.1016/S0003-4975(99)01574-X; Jacobaeus H-C., 1910, MUNCHEN MED WOCHEN, V57, P2090; Jansen EWL, 1998, J THORAC CARDIOV SUR, V116, P60, DOI 10.1016/S0022-5223(98)70243-0; KOLESSOV VI, 1967, J THORAC CARDIOV SUR, V54, P535, DOI 10.1016/S0022-5223(19)43061-4; Liem MSL, 1997, NEW ENGL J MED, V336, P1541, DOI 10.1056/NEJM199705293362201; Loulmet D, 1999, J THORAC CARDIOV SUR, V118, P4, DOI 10.1016/S0022-5223(99)70133-9; MACK MJ, 1992, ANN THORAC SURG, V54, P403, DOI 10.1016/0003-4975(92)90428-7; PETERS WR, 1993, DIS COLON RECTUM, V36, P751, DOI 10.1007/BF02048366; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; Reichenspurner H, 1999, J THORAC CARDIOV SUR, V118, P11, DOI 10.1016/S0022-5223(99)70134-0; RIVIERE CN, 2000, 21 ANN C IEEE ENG ME; SOPER NJ, 1996, MASTERY SURG, P763; Stevens JH, 1996, J THORAC CARDIOV SUR, V111, P567, DOI 10.1016/S0022-5223(96)70308-2; Subramanian VA, 1997, ANN THORAC SURG, V64, P1648, DOI 10.1016/S0003-4975(97)01099-0; Taylor R, 1999, INT J ROBOT RES, V18, P1201, DOI 10.1177/02783649922067807	22	316	441	1	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					568	572		10.1001/jama.285.5.568	http://dx.doi.org/10.1001/jama.285.5.568			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176860	Bronze			2022-12-28	WOS:000166714200013
J	Heldwein, EEZ; Brennan, RG				Heldwein, EEZ; Brennan, RG			Crystal structure of the transcription activator BmrR bound to DNA and a drug	NATURE			English	Article							MULTIDRUG TRANSPORTER; PROTEIN; SOXR; MERR; EXPRESSION; REPRESSOR; REGULATOR; GENE; RECOGNITION; PROMOTER	The efflux of chemically diverse drugs by multidrug transporters that span the membrane(1) is one mechanism of multidrug resistance in bacteria. The concentrations of many of these transporters are controlled by transcription regulators, such as BmrR in Bacillus subtilis(2), EmrR in Escherichia coli(3) and QacR in Staphylococcus aureus(4). These proteins promote transporter gene expression when they bind toxic compounds. BmrR activates transcription of the multidrug transporter gene, bmr, in response to cellular invasion by certain lipophilic cationic compounds (drugs)(2,5,6). BmrR belongs to the MerR family, which regulates response to stress such as exposure to toxic compounds or oxygen radicals in bacteria(7-12). MerR proteins have homologous aminoterminal DNA-binding domains but different carboxy-terminal domains, which enable them to bind specific 'coactivator' molecules. When bound to coactivator, MerR proteins upregulate transcription by reconfiguring the 19-base-pair spacer found between the -35 and -10 promoter elements to allow productive interaction with RNA polymerase(7,9-12). Here we report the 3.0 Angstrom resolution structure of BmrR in complex with the drug tetraphenylphosphonium (TPP) and a 22-base-pair oligodeoxynucleotide encompassing the bmr promoter. The structure reveals an unexpected mechanism for transcription activation that involves localized base-pair breaking, and base sliding and realignment of the -35 and -10 operator elements.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Brennan, RG (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.			Brennan, Richard/0000-0001-7647-485X; Heldwein, Ekaterina/0000-0003-3113-6958				AHMED M, 1994, J BIOL CHEM, V269, P28506; ANSARI AZ, 1995, NATURE, V374, P371; Bradley TM, 1997, NUCLEIC ACIDS RES, V25, P1469, DOI 10.1093/nar/25.8.1469; Brooun A, 1999, J BACTERIOL, V181, P5131, DOI 10.1128/JB.181.16.5131-5133.1999; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Caguiat JJ, 1999, J BACTERIOL, V181, P3462, DOI 10.1128/JB.181.11.3462-3471.1999; COMESS KM, 1994, BIOCHEMISTRY-US, V33, P4175, DOI 10.1021/bi00180a010; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Hidalgo E, 1997, EMBO J, V16, P1056, DOI 10.1093/emboj/16.5.1056; Hidalgo E, 1997, TRENDS BIOCHEM SCI, V22, P207, DOI 10.1016/S0968-0004(97)01068-2; HOLMES DJ, 1993, EMBO J, V12, P3183, DOI 10.1002/j.1460-2075.1993.tb05987.x; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; Markham PN, 1997, BIOCHEM BIOPH RES CO, V239, P269, DOI 10.1006/bbrc.1997.7467; Outten CE, 1999, J BIOL CHEM, V274, P37517, DOI 10.1074/jbc.274.53.37517; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; Saier MH, 1998, FASEB J, V12, P265, DOI 10.1096/fasebj.12.3.265; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; Zeng QD, 1998, BIOCHEMISTRY-US, V37, P15885, DOI 10.1021/bi9817562; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	29	191	196	0	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					378	382		10.1038/35053138	http://dx.doi.org/10.1038/35053138			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201751				2022-12-28	WOS:000166434300056
J	Keenan, JP; Nelson, A; O'Connor, M; Pascual-Leone, A				Keenan, JP; Nelson, A; O'Connor, M; Pascual-Leone, A			Neurology - Self-recognition and the right hemisphere	NATURE			English	Article									Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Behav Neurol Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Behav Neurol,Div Cognit & Behav Neurol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Keenan, JP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Behav Neurol Unit, Boston, MA 02215 USA.		Pascual-Leone, Alvaro/AAC-5101-2019; Pascual-Leone, Alvaro/G-6566-2011	Pascual-Leone, Alvaro/0000-0001-8975-0382; 				FEINBERG TE, 1990, NEUROLOGY, V40, P1391, DOI 10.1212/WNL.40.9.1391; GALLUP GG, 1970, SCIENCE, V167, P86, DOI 10.1126/science.167.3914.86; LEMAY M, 1975, BRAIN BEHAV EVOLUT, V11, P48, DOI 10.1159/000123623; Meador KJ, 2000, NEUROLOGY, V55, P816, DOI 10.1212/WNL.55.6.816; PINEDA JA, 1994, COGNITIVE BRAIN RES, V2, P1, DOI 10.1016/0926-6410(94)90015-9; SPERRY RW, 1979, NEUROPSYCHOLOGIA, V17, P153, DOI 10.1016/0028-3932(79)90006-X; Tormos JM, 1997, NEUROLOGY, V49, P487, DOI 10.1212/WNL.49.2.487; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331	8	239	257	0	33	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					305	305		10.1038/35053167	http://dx.doi.org/10.1038/35053167			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201730	Bronze			2022-12-28	WOS:000166434300034
J	Hall, A; Stouffer, RJ				Hall, A; Stouffer, RJ			An abrupt climate event in a coupled ocean-atmosphere simulation without external forcing	NATURE			English	Article							FRESH-WATER INPUT; THERMOHALINE CIRCULATION; TRANSIENT RESPONSES; GRADUAL CHANGES; CARBON-DIOXIDE; ICE CORE; MODEL; VARIABILITY; TRANSPORTS; INCREASE	Temperature reconstructions from the North Atlantic region indicate frequent abrupt and severe climate fluctuations during the last glacial and Holocene periods(1-3). The driving forces for these events are unclear and coupled atmosphere-ocean models of global circulation have only simulated such events by inserting large amounts of fresh water into the northern North Atlantic Ocean(4,5). Here we report a drastic cooling event in a 15,000-yr simulation of global circulation with present-day climate conditions without the use of such external forcing. In our simulation, the annual average surface temperature near southern Greenland spontaneously fell 6-10 standard deviations below its mean value for a period of 30-40 yr. The event was triggered by a persistent northwesterly wind that transported large amounts of buoyant cold and fresh water into the northern North Atlantic Ocean. Oceanic convection shut down in response to this flow, concentrating the entire cooling of the northern North Atlantic by the colder atmosphere in the uppermost ocean layer. Given the similarity between our simulation and observed records of rapid cooling events, our results indicate that internal atmospheric variability alone could have generated the extreme climate disruptions in this region.	Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA	Columbia University; National Oceanic Atmospheric Admin (NOAA) - USA	Hall, A (corresponding author), Lamont Doherty Earth Observ, Palisades, NY 10964 USA.		Hall, Alex/D-8175-2014					Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; BRYAN K, 1979, J GEOPHYS RES-OC ATM, V84, P2503, DOI 10.1029/JC084iC05p02503; DANSGAARD W, 1982, SCIENCE, V218, P1273, DOI 10.1126/science.218.4579.1273; DELWORTH T, 1993, J CLIMATE, V6, P1993, DOI 10.1175/1520-0442(1993)006<1993:IVOTTC>2.0.CO;2; Delworth TL, 1997, GEOPHYS RES LETT, V24, P257, DOI 10.1029/96GL03927; deMenocal P, 2000, SCIENCE, V288, P2198, DOI 10.1126/science.288.5474.2198; DICKSON RR, 1988, PROG OCEANOGR, V20, P103, DOI 10.1016/0079-6611(88)90049-3; ENGLAND MH, 1995, GEOPHYS RES LETT, V22, P3051, DOI 10.1029/95GL02670; GORDON CT, 1982, MON WEATHER REV, V110, P625, DOI 10.1175/1520-0493(1982)110<0625:ADOTGG>2.0.CO;2; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; Kattenberg A., 1996, CLIMATE CHANGE 1995, P285; MANABE S, 1969, MON WEATHER REV, V97, P739, DOI 10.1175/1520-0493(1969)097<0739:CATOC>2.3.CO;2; MANABE S, 1992, J CLIMATE, V5, P105, DOI 10.1175/1520-0442(1992)005<0105:TROACO>2.0.CO;2; Manabe S, 1996, J CLIMATE, V9, P376, DOI 10.1175/1520-0442(1996)009<0376:LFVOSA>2.0.CO;2; MANABE S, 1995, NATURE, V378, P165, DOI 10.1038/378165a0; Manabe S, 1988, J CLIMATE, V1, P841, DOI 10.1175/1520-0442(1988)001<0841:TSEOAC>2.0.CO;2; MANABE S, 1991, J CLIMATE, V4, P785, DOI 10.1175/1520-0442(1991)004<0785:TROACO>2.0.CO;2; Manabe S, 1997, PALEOCEANOGRAPHY, V12, P321, DOI 10.1029/96PA03932; MANABE S, 1994, J CLIMATE, V7, P5, DOI 10.1175/1520-0442(1994)007<0005:MCROAC>2.0.CO;2; MAROTZKE J, 1995, J PHYS OCEANOGR, V25, P1350, DOI 10.1175/1520-0485(1995)025<1350:ATTTCA>2.0.CO;2; RABITAILLE DY, 1995, GEOPHYS RES LETT, V22, P2917; Stouffer RJ, 1999, J CLIMATE, V12, P2224, DOI 10.1175/1520-0442(1999)012<2224:ROACOA>2.0.CO;2; Thompson DWJ, 2000, J CLIMATE, V13, P1018, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2; Woodgate RA, 1999, J GEOPHYS RES-OCEANS, V104, P18059, DOI 10.1029/1999JC900146	25	54	55	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					171	174		10.1038/35051544	http://dx.doi.org/10.1038/35051544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196636				2022-12-28	WOS:000166316200038
J	Koeller, KM; Wong, CH				Koeller, KM; Wong, CH			Enzymes for chemical synthesis	NATURE			English	Review							PREPARATIVE ENZYMATIC-SYNTHESIS; ORGANIC-SYNTHESIS; SIALYLATED OLIGOSACCHARIDES; CHEMOENZYMATIC SYNTHESIS; METHANE MONOOXYGENASE; EFFICIENT SYNTHESIS; ONE-POT; ALDOLASE; RESOLUTION; SUGAR	New catalytic synthetic methods in organic chemistry that satisfy increasingly stringent environmental constraints are in great demand by the pharmaceutical and chemical industries. In addition, novel catalytic procedures are necessary to produce the emerging classes of organic compounds that are becoming the targets of molecular and biomedical research. Enzyme-catalysed chemical transformations are now widely recognized as practical alternatives to traditional (non-biological) organic synthesis, and as convenient solutions to certain intractable synthetic problems.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Koeller, KM (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Bader B, 2000, NATURE, V403, P223, DOI 10.1038/35003249; Bordusa F, 1997, ANGEW CHEM INT EDIT, V36, P2473, DOI 10.1002/anie.199724731; Burkart MD, 1999, ANGEW CHEM INT EDIT, V38, P2747, DOI 10.1002/(SICI)1521-3773(19990917)38:18<2747::AID-ANIE2747>3.0.CO;2-2; Burzlaff NI, 1999, NATURE, V401, P721, DOI 10.1038/44400; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Carrea G, 2000, ANGEW CHEM INT EDIT, V39, P2226; DELUCA C, 1995, J AM CHEM SOC, V117, P5869, DOI 10.1021/ja00126a034; DRAUZ K, 1995, ENZYME CATALYSIS ORG; Elliott SJ, 1997, J AM CHEM SOC, V119, P9949, DOI 10.1021/ja971049g; Endo T, 2000, APPL MICROBIOL BIOT, V53, P257, DOI 10.1007/s002530050017; Faber K, 2018, BIOTRANSFORMATIONS O, P134, DOI 10.1007/978-3-319-61590-5; FANG JM, 1994, SYNLETT, P393; Fong S, 2000, CHEM BIOL, V7, P873, DOI 10.1016/S1074-5521(00)00035-1; Fort S, 2000, J AM CHEM SOC, V122, P5429, DOI 10.1021/ja9936520; GAVAGAN JE, 1995, J ORG CHEM, V60, P3957, DOI 10.1021/jo00118a009; Gilbert M, 1998, NAT BIOTECHNOL, V16, P769, DOI 10.1038/nbt0898-769; Guo ZW, 1997, J ORG CHEM, V62, P6700, DOI 10.1021/jo970995c; Haring D, 1998, ANGEW CHEM INT EDIT, V37, P2471, DOI 10.1002/(SICI)1521-3773(19981002)37:18<2471::AID-ANIE2471>3.0.CO;2-V; Hoffmann T, 1998, J AM CHEM SOC, V120, P2768, DOI 10.1021/ja973676b; Hudlicky T, 1996, J AM CHEM SOC, V118, P10752, DOI 10.1021/ja960596j; JACKSON DY, 1994, SCIENCE, V266, P243, DOI 10.1126/science.7939659; Janda KD, 1997, SCIENCE, V275, P945, DOI 10.1126/science.275.5302.945; Jestin JL, 1999, ANGEW CHEM INT EDIT, V38, P1124, DOI 10.1002/(SICI)1521-3773(19990419)38:8<1124::AID-ANIE1124>3.0.CO;2-W; JONES JB, 1986, TETRAHEDRON, V42, P3351, DOI 10.1016/S0040-4020(01)87306-3; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Kazlauskas RJ, 2000, CURR OPIN CHEM BIOL, V4, P81, DOI 10.1016/S1367-5931(99)00056-3; Kidd RD, 1999, PROTEIN SCI, V8, P410; Kimura T, 1996, ANGEW CHEM INT EDIT, V35, P2348, DOI 10.1002/anie.199623481; Klibanov AM, 1997, TRENDS BIOTECHNOL, V15, P97, DOI 10.1016/S0167-7799(97)01013-5; Kobayashi S, 1996, J AM CHEM SOC, V118, P13113, DOI 10.1021/ja963011u; KREN V, 1995, ANGEW CHEM INT EDIT, V34, P893, DOI 10.1002/anie.199508931; Lakner FJ, 1997, J AM CHEM SOC, V119, P443, DOI 10.1021/ja962998x; Li K, 1998, J AM CHEM SOC, V120, P10545, DOI 10.1021/ja9817747; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; Machajewski TD, 2000, ANGEW CHEM INT EDIT, V39, P1352, DOI 10.1002/(SICI)1521-3773(20000417)39:8<1352::AID-ANIE1352>3.0.CO;2-J; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; MARGOLIA AL, 1999, CHIMIA, V50, P670; Miyazaki T, 2000, J AM CHEM SOC, V122, P5678, DOI 10.1021/ja994211j; Nishida Y, 2000, ANGEW CHEM INT EDIT, V39, P2000, DOI 10.1002/1521-3773(20000602)39:11<2000::AID-ANIE2000>3.3.CO;2-V; Nishimura S, 1997, J AM CHEM SOC, V119, P10555, DOI 10.1021/ja971786c; Noguchi T, 1998, BIOSCI BIOTECH BIOCH, V62, P1594, DOI 10.1271/bbb.62.1594; Patel R.N., 2000, STEREOSELECTIVE BIOC, Vfirst; Pathak T, 1998, CURR OPIN CHEM BIOL, V2, P112, DOI 10.1016/S1367-5931(98)80042-2; Persson BA, 1999, J AM CHEM SOC, V121, P1645, DOI 10.1021/ja983819+; Plettner E, 1999, J AM CHEM SOC, V121, P4977, DOI 10.1021/ja9902266; Prigge ST, 1997, SCIENCE, V278, P1300, DOI 10.1126/science.278.5341.1300; Qian XP, 1999, J AM CHEM SOC, V121, P12063, DOI 10.1021/ja993004g; Reetz MT, 2000, CHEM-EUR J, V6, P407, DOI 10.1002/(SICI)1521-3765(20000204)6:3<407::AID-CHEM407>3.3.CO;2-P; ROBERTS SM, 1999, BIOCATALYSIS FINE CH; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schmid RD, 1998, ANGEW CHEM INT EDIT, V37, P1609; Schoemaker HE, 1997, CHIMIA, V51, P308; Schoffers E, 1996, TETRAHEDRON, V52, P3769, DOI 10.1016/S0040-4020(95)01021-1; Shelton MC, 1996, J AM CHEM SOC, V118, P2117, DOI 10.1021/ja952596+; Shimizu S, 1997, Adv Biochem Eng Biotechnol, V58, P45; SIH CJ, 1989, TOP STEREOCHEM, V19, P63; Stein A, 1998, GLYCOCONJUGATE J, V15, P139, DOI 10.1023/A:1006912121278; Stewart JD, 1998, J AM CHEM SOC, V120, P3541, DOI 10.1021/ja972942i; Sugai T, 1999, CURR ORG CHEM, V3, P373; Takayama S, 1999, CHEM COMMUN, P127, DOI 10.1039/a808028c; Tolbert TJ, 2000, J AM CHEM SOC, V122, P5421, DOI 10.1021/ja0000192; Tsuruta O, 1997, BIOORG MED CHEM LETT, V7, P2523, DOI 10.1016/S0960-894X(97)10009-9; Um PJ, 1998, J AM CHEM SOC, V120, P5605, DOI 10.1021/ja980445b; vanDeurzen MPJ, 1997, TETRAHEDRON, V53, P13183, DOI 10.1016/S0040-4020(97)00477-8; Wang JQ, 1999, J AM CHEM SOC, V121, P8174, DOI 10.1021/ja990219h; Wang LX, 1997, J AM CHEM SOC, V119, P11137, DOI 10.1021/ja9712027; Watt GM, 1997, ANGEW CHEM INT EDIT, V36, P2354, DOI 10.1002/anie.199723541; Witte K, 1998, J AM CHEM SOC, V120, P1979, DOI 10.1021/ja9736727; WONG CH, 1995, ANGEW CHEM INT EDIT, V34, P521, DOI 10.1002/anie.199505211; WONG CH, 1995, ANGEW CHEM INT EDIT, V34, P412, DOI 10.1002/anie.199504121; WONG CH, 1994, ENZYMES SYNTHETIC OR; Zaks A, 1998, Curr Opin Drug Discov Devel, V1, P290; Zannetti MT, 1999, CHEM-EUR J, V5, P1882	75	706	761	13	197	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					232	240		10.1038/35051706	http://dx.doi.org/10.1038/35051706			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196651				2022-12-28	WOS:000166316200054
J	Kastner, J				Kastner, J			Astronomy - Orion sheds new light on star and planet formation	SCIENCE			English	Editorial Material							T-TAURI STARS; CIRCUMSTELLAR DISK; GAS		Rochester Inst Technol, Ctr Imaging Sci, Rochester, NY 14623 USA	Rochester Institute of Technology	Kastner, J (corresponding author), Rochester Inst Technol, Ctr Imaging Sci, Rochester, NY 14623 USA.	jhkpci@cis.rit.edu						ADAMS FC, 1988, ASTROPHYS J, V326, P865, DOI 10.1086/166144; CARPENTER JE, UNPUB; GARMIRE G, UNPUB; HILLENBRAND LA, UNPUB; Jayawardhana R, 2000, SCI AM, V283, P62; Schulz N., UNPUB; Telesco CM, 2000, ASTROPHYS J, V530, P329, DOI 10.1086/308332; Webb RA, 1999, ASTROPHYS J, V512, pL63, DOI 10.1086/311856; Weintraub DA, 2000, ASTROPHYS J, V541, P767, DOI 10.1086/309473; ZUCKERMAN B, 1995, NATURE, V373, P494, DOI 10.1038/373494a0	11	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					57	58		10.1126/SCIENCE.1056553	http://dx.doi.org/10.1126/SCIENCE.1056553			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11192011				2022-12-28	WOS:000166259100030
J	Drobniewski, FA				Drobniewski, FA			Multiple-drug-resistant tuberculosis	LANCET			English	Article									Kings Coll Hosp Dulwich, Guys Kings & St Thomas Med Sch, London SE22 9QF, England; UK Publ Hlth Lab Serv, Mycobacterium Reference Unit, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Drobniewski, FA (corresponding author), Kings Coll Hosp Dulwich, Guys Kings & St Thomas Med Sch, London SE22 9QF, England.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S62	S62		10.1016/S0140-6736(00)92048-8	http://dx.doi.org/10.1016/S0140-6736(00)92048-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191522				2022-12-28	WOS:000166074900064
J	Freund, KM; Battaglia, TA				Freund, KM; Battaglia, TA			The two faces of health care for women	LANCET			English	Article									Boston Univ, Med Ctr, Womens Hlth Grp, Womens Hlth Unit, Boston, MA 02118 USA; Boston Univ, Natl Ctr Excellence Womens Hlth, Boston, MA 02118 USA	Boston University; Boston University	Freund, KM (corresponding author), Boston Univ, Med Ctr, Womens Hlth Grp, Womens Hlth Unit, Boston, MA 02118 USA.			Freund, Karen/0000-0002-9049-5574; Battaglia, Tracy/0000-0001-8475-1212					0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S66	S66		10.1016/S0140-6736(00)92053-1	http://dx.doi.org/10.1016/S0140-6736(00)92053-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191526				2022-12-28	WOS:000166074900068
J	Becker, RH				Becker, RH			Planetary science - Nitrogen on the moon	SCIENCE			English	Editorial Material							SOLAR CORPUSCULAR RADIATION; LUNAR REGOLITH; ISOTOPES; SYSTEM		Univ Minnesota, Dept Phys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Becker, RH (corresponding author), Univ Minnesota, Dept Phys, Minneapolis, MN 55455 USA.							Becker R.H., 1975, P LUNAR PLANET SCI C, P2131; BOCHSLER P, 1994, ADV SPACE RES, V14, P161, DOI 10.1016/0273-1177(94)90022-1; BRILLIANT DR, 1992, METEORITICS, V27, P206; GEISS J, 1982, GEOCHIM COSMOCHIM AC, V46, P529, DOI 10.1016/0016-7037(82)90156-9; Hashizume K, 2000, SCIENCE, V290, P1142, DOI 10.1126/science.290.5494.1142; KERRIDGE JF, 1993, REV GEOPHYS, V31, P423, DOI 10.1029/93RG01953; KERRIDGE JF, 1992, P LUNAR PLANET SCI, V22, P239; WIELER R, 1995, ASTROPHYS J, V453, P987, DOI 10.1086/176458; Wieler R, 1999, EARTH PLANET SC LETT, V167, P47, DOI 10.1016/S0012-821X(99)00012-6; Wieler R, 1996, NATURE, V384, P46, DOI 10.1038/384046a0	10	5	5	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 10	2000	290	5494					1110	1111		10.1126/science.290.5494.1110	http://dx.doi.org/10.1126/science.290.5494.1110			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11185009				2022-12-28	WOS:000165228200035
J	Krige, JEJ; Beckingham, IJ				Krige, JEJ; Beckingham, IJ			ABC of diseases of liver, pancreas, and biliary system - Portal hypertension-2. Ascites, encephalopathy, and other conditions	BRITISH MEDICAL JOURNAL			English	Review									Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; Univ Cape Town, ZA-7700 Rondebosch, South Africa; Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England	University of Cape Town; University of Cape Town; University of Nottingham	Krige, JEJ (corresponding author), Groote Schuur Hosp, ZA-7925 Cape Town, South Africa.		Krige, Jake E/G-3496-2015	Krige, Jake E/0000-0002-7057-9156				RIORDAN SM, 2000, SURG LIVER BILIARY T, P1825; Sherlock Sheila, 1996, DIS LIVER BILIARY SY	2	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	2001	322	7283					416	418		10.1136/bmj.322.7283.416	http://dx.doi.org/10.1136/bmj.322.7283.416			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404JH	11179165	Green Published			2022-12-28	WOS:000167093600031
J	Courseaux, A; Nahon, JL				Courseaux, A; Nahon, JL			Birth of two chimeric genes in the Hominidae lineage	SCIENCE			English	Article							MELANIN-CONCENTRATING HORMONE; ANTARCTIC NOTOTHENIOID FISH; DROSOPHILA; EVOLUTION; ORIGIN; JINGWEI; FUSION; RNAS	How genes with newly characterized functions originate remains a fundamental question. PMCHL1 and PMCHL2, two chimeric genes derived from the melanin-concentrating hormone (MCH) gene, offer an opportunity to examine such an issue in the human Lineage. Detailed structural, expression, and phylogenetic analysis showed that the PMCHL1 gene was created near 25 million years ago (Ma) by a complex mechanism of exon shuffling through retrotransposition of an antisense MCH messenger RNA coupled to de novo creation of splice sites. PMCHL2 arose 5 to 10 Ma by an event of duplication involving a large chromosomal region encompassing the PMCHL1 Locus. The RNA expression patterns of those chimeric genes suggest that they have been submitted to strong regulatory constraints during primate evolution.	Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Nahon, JL (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, 660 Route Lucioles Sophia Antipolis, F-06560 Valbonne, France.		NAHON, Jean-Louis/O-7977-2016	NAHON, Jean-Louis/0000-0001-9572-7779				Borsu L, 2000, J BIOL CHEM, V275, P40576, DOI 10.1074/jbc.M006524200; BRETON C, 1993, MOL BRAIN RES, V18, P297, DOI 10.1016/0169-328X(93)90093-5; Brosius J, 1999, GENE, V238, P115, DOI 10.1016/S0378-1119(99)00227-9; BROSIUS J, 1992, P NATL ACAD SCI USA, V89, P10706, DOI 10.1073/pnas.89.22.10706; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3811, DOI 10.1073/pnas.94.8.3811; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3817, DOI 10.1073/pnas.94.8.3817; COURSEAUX A, 1995, LEUKEMIA, V9, P1313; Gilbert W, 1997, P NATL ACAD SCI USA, V94, P7698, DOI 10.1073/pnas.94.15.7698; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; Long M, 1999, GENE, V238, P135, DOI 10.1016/S0378-1119(99)00229-2; Long MY, 2000, GENOME RES, V10, P1655, DOI 10.1101/gr.165700; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; Miller CL, 1998, GENOME RES, V8, P737, DOI 10.1101/gr.8.7.737; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; Nurminsky DI, 1998, NATURE, V396, P572, DOI 10.1038/25126; Patthy L, 1999, GENE, V238, P103, DOI 10.1016/S0378-1119(99)00228-0; Thomson TM, 2000, GENOME RES, V10, P1743, DOI 10.1101/gr.GR-1405R; Viale A, 1998, MOL BIOL EVOL, V15, P196, DOI 10.1093/oxfordjournals.molbev.a025915; Viale A, 2000, MOL BIOL EVOL, V17, P1626, DOI 10.1093/oxfordjournals.molbev.a026262; Wang W, 2000, MOL BIOL EVOL, V17, P1294, DOI 10.1093/oxfordjournals.molbev.a026413	22	107	114	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 16	2001	291	5507					1293	+		10.1126/science.1057284	http://dx.doi.org/10.1126/science.1057284			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	402MX	11181993				2022-12-28	WOS:000166993400039
J	Hsu, J; Go, A; Selby, J				Hsu, J; Go, A; Selby, J			Overuse of administrative data to measure underuse of care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Kaiser Fdn Res Inst, Hlth Policy Working Grp, Div Res, Oakland, CA USA		Hsu, J (corresponding author), Kaiser Fdn Res Inst, Hlth Policy Working Grp, Div Res, Oakland, CA USA.			Kravitz, Richard/0000-0001-5575-529X				Asch SM, 2000, JAMA-J AM MED ASSOC, V284, P2325, DOI 10.1001/jama.284.18.2325; Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					735	735		10.1001/jama.285.6.735	http://dx.doi.org/10.1001/jama.285.6.735			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176905				2022-12-28	WOS:000166817200024
J	Michel, LS; Liberal, V; Chatterjee, A; Kirchwegger, R; Pasche, B; Gerald, W; Dobles, M; Sorger, PK; Murty, VVVS; Benezra, R				Michel, LS; Liberal, V; Chatterjee, A; Kirchwegger, R; Pasche, B; Gerald, W; Dobles, M; Sorger, PK; Murty, VVVS; Benezra, R			MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells	NATURE			English	Article							SISTER-CHROMATID SEPARATION; SPINDLE-ASSEMBLY CHECKPOINT; PROMOTING COMPLEX; HUMAN CANCERS; GENE; MUTATIONS; IDENTIFICATION; CARCINOMAS; MITOSIS	The mitotic checkpoint protein hsMad2 is required to arrest cells in mitosis when chromosomes are unattached to the mitotic spindle(1). The presence of a single, lagging chromosome is sufficient to activate the checkpoint, producing a delay at the metaphase-anaphase transition until the last spindle attachment is made(2). Complete loss of the mitotic checkpoint results in embryonic lethality owing to chromosome mis-segregation in various organisms(3-6). Whether partial loss of checkpoint control leads to more subtle rates of chromosome instability compatible with cell viability remains unknown. Here we report that deletion of one MAD2 allele results in a defective mitotic checkpoint in both human cancer cells and murine primary embryonic fibroblasts. Checkpoint-defective cells show premature sister-chromatid separation in the presence of spindle inhibitors and an elevated rate of chromosome mis-segregation events in the absence of these agents. Furthermore, Mad2(+/-) mice develop lung tumours at high rates after long latencies, implicating defects in the mitotic checkpoint in tumorigenesis.	Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Columbia University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Massachusetts Institute of Technology (MIT)	Benezra, R (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, New York, NY 10021 USA.		Holt, Janet E/B-2415-2013	Sorger, Peter/0000-0002-3364-1838				Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; DeVita VT, 1997, CANC PRINCIPLES PRAC; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; DOHNER H, 1992, GENE CHROMOSOME CANC, V5, P392, DOI 10.1002/gcc.2870050415; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kitagawa R, 1999, NAT CELL BIOL, V1, P514, DOI 10.1038/70309; Krishnan R, 1998, GENOMICS, V49, P475, DOI 10.1006/geno.1998.5233; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Rudner AD, 2000, J CELL BIOL, V149, P1361, DOI 10.1083/jcb.149.7.1361; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Shivapurkar N, 1999, CANCER RES, V59, P3576; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Takahashi N, 1999, SOFTWARE STUDIES, V2, P55; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; Verma RS., 1995, HUMAN CHROMOSOMES PR, V2; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	29	626	644	0	24	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					355	359		10.1038/35053094	http://dx.doi.org/10.1038/35053094			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201745				2022-12-28	WOS:000166434300050
J	Nakazato, M; Murakami, N; Date, Y; Kojima, M; Matsuo, H; Kangawa, K; Matsukura, S				Nakazato, M; Murakami, N; Date, Y; Kojima, M; Matsuo, H; Kangawa, K; Matsukura, S			A role for ghrelin in the central regulation of feeding	NATURE			English	Article							HORMONE SECRETAGOGUE RECEPTOR; MESSENGER-RIBONUCLEIC-ACID; RAT ARCUATE NUCLEUS; GROWTH-HORMONE; NEUROPEPTIDE-Y; GENE-EXPRESSION; LEPTIN ACTION; OBESE GENE; HYPOTHALAMUS; PITUITARY	Ghrelin is an acylated peptide that stimulates the release of growth hormone from the pituitary(1). Ghrelin-producing neurons are located in the hypothalamus, whereas ghrelin receptors are expressed in various regions of the brain(2-4), which is indicative of central-and as yet undefined-physiological functions. Here we show that ghrelin is involved in the hypothalamic regulation of energy homeostasis. Intracerebroventricular injections of ghrelin strongly stimulated feeding in rats and increased body weight gain. Ghrelin also increased feeding in rats that are genetically deficient in growth hormone. Anti-ghrelin immunoglobulin G robustly suppressed feeding. After intracerebroventricular ghrelin administration, Fos protein, a marker of neuronal activation(5), was found in regions of primary importance in the regulation of feeding, including neuropeptide Y-6 (NPY) neurons and agouti-related protein(7) (AGRP) neurons. Antibodies and antagonists of NPY and AGRP abolished ghrelin-induced feeding. Ghrelin augmented NPY gene expression and blocked leptin-induced(8) feeding reduction, implying that there is a competitive interaction between ghrelin and leptin in feeding regulation. We conclude that ghrelin is a physiological mediator of feeding, and probably has a function in growth regulation by stimulating feeding and release of growth hormone.	Miyazaki Med Coll, Dept Internal Med 3, Miyazaki 8891692, Japan; Miyazaki Univ, Dept Vet Physiol, Miyazaki 8892192, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka 5658565, Japan	University of Miyazaki; University of Miyazaki; National Cerebral & Cardiovascular Center - Japan	Nakazato, M (corresponding author), Miyazaki Med Coll, Dept Internal Med 3, Miyazaki 8891692, Japan.							BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/endo-114-5-1537; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; CHENG K, 1989, ENDOCRINOLOGY, V124, P2791; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; DANIELS AJ, 1995, P NATL ACAD SCI USA, V92, P9067, DOI 10.1073/pnas.92.20.9067; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; Dickson SL, 1997, ENDOCRINOLOGY, V138, P771, DOI 10.1210/en.138.2.771; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; Honda K, 1999, NEUROSCIENCE, V90, P875, DOI 10.1016/S0306-4522(98)00532-6; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Ida T, 1999, BRAIN RES, V821, P526, DOI 10.1016/S0006-8993(99)01131-2; Kanatani A, 2000, BIOCHEM BIOPH RES CO, V272, P169, DOI 10.1006/bbrc.2000.2696; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; LOCKE W, 1995, LIFE SCI, V56, P1347, DOI 10.1016/0024-3205(95)00087-9; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; Mercer JG, 1996, J NEUROENDOCRINOL, V8, P733, DOI 10.1046/j.1365-2826.1996.05161.x; Murakami N, 1997, BRAIN RES, V775, P240, DOI 10.1016/S0006-8993(97)01031-7; Okuma S., 1980, EXP ANIM TOKYO, V29, P301; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 1997, DIABETES, V46, P2119, DOI 10.2337/diabetes.46.12.2119; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; STANLEY BG, 1986, PEPTIDES, V7, P1189; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TAKEUCHI T, 1990, ENDOCRINOLOGY, V126, P31, DOI 10.1210/endo-126-1-31; Wieland HA, 1998, BRIT J PHARMACOL, V125, P549, DOI 10.1038/sj.bjp.0702084; Willesen MG, 1999, NEUROENDOCRINOLOGY, V70, P306, DOI 10.1159/000054491; Yamamoto Y, 1999, MOL BRAIN RES, V65, P14, DOI 10.1016/S0169-328X(98)00320-9; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	2724	2863	11	189	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					194	198		10.1038/35051587	http://dx.doi.org/10.1038/35051587			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196643				2022-12-28	WOS:000166316200045
J	Wu, E; Judd, RM; Vargas, JD; Klocke, FJ; Bonow, RO; Kim, RJ				Wu, E; Judd, RM; Vargas, JD; Klocke, FJ; Bonow, RO; Kim, RJ			Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction	LANCET			English	Article							LEFT-VENTRICULAR DYSFUNCTION; CORONARY-ARTERY DISEASE; DILATED CARDIOMYOPATHY; PROGNOSIS; SIZE; INJURY; DTPA; MRI	Background A technical advance in contrast-enhanced magnetic resonance imaging (MRI) has significantly improved image quality. We investigated whether healed myocardial infarction can be visualised as hyperenhanced regions with this new technique, and whether assessment of the transmural extent of infarction yields new physiological data. Methods 82 MRI examinations were carried out in three groups: patients with healed myocardial infarction; patients with non-ischaemic cardiomyopathy; and healthy volunteers. Patients with healed myocardial infarction were prospectively enrolled after enyzmatically proven necrosis and imaged 3 months (SD 1) or 14 months (7) later. The MRI procedure used a segmented inversion-recovery gradient-echo sequence after gadolinium administration. Findings were compared with those of coronary angiography, electrocardiography, cine MRI, and creatine kinase measurements. Findings 29 (91%) of 32 patients with infarcts imaged at 3 months (13 nonQ-wave) and all of 19 imaged at 14 months (eight non-Q-wave) showed hyperenhancement. In patients in whom the infarct-related-artery was identified by angiography, 24 of 25 imaged at 3 months and all of 14 imaged at 14 months had hyperenhancement in the appropriate territory. None of the 20 patients with non-ischaemic cardiomyopathy or the 11 healthy volunteers showed hyperenhancement. Irrespective of the presence or absence of Q waves, the majority of patients with hyperenhancement had only non-transmural involvement. Normal left-ventricular contraction was shown in seven patients examined at 3 months and three examined at 14 months, but in these cases hyperenhancement was limited to the subendocardium. Interpretation The presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction can be accurately determined by contrast-enhanced MRI.	Northwestern Univ, Sch Med, Fainberg Cardiovasc Res Inst, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Fainberg Cardiovasc Res Inst, Dept Biomed Engn, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Kim, RJ (corresponding author), Northwestern Univ, Sch Med, Fainberg Cardiovasc Res Inst, Dept Med, 303 E Chicago Ave,Tarry 12-733, Chicago, IL 60611 USA.		Kim, Raymond J/B-1426-2008	Wu, Edwin/0000-0002-0771-8395	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063268, R29HL053411] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL63268, R29-HL53411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM HEART ASS, 1999, 2000 HEART STROK STA; EICHSTAEDT HW, 1986, CLIN CARDIOL, V9, P527, DOI 10.1002/clc.4960091102; FEDELE F, 1994, AM HEART J, V128, P484, DOI 10.1016/0002-8703(94)90621-1; FICNO DS, 2000, J AM COLL CARDIOL, V36, P1985; Friedrich MG, 1998, CIRCULATION, V97, P1802, DOI 10.1161/01.CIR.97.18.1802; Gibbons RJ, 2000, CIRCULATION, V101, P101, DOI 10.1161/01.CIR.101.1.101; GOLDBERG RJ, 1987, AM HEART J, V113, P273, DOI 10.1016/0002-8703(87)90265-1; GRIMM RH, 1987, CIRCULATION, V75, P116; JUGDUTT BI, 1986, J AM COLL CARDIOL, V7, P91, DOI 10.1016/S0735-1097(86)80265-0; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; Kaul S, 1998, CIRCULATION, V98, P625, DOI 10.1161/01.CIR.98.7.625; Kim RJ, 1999, CIRCULATION, V100, P1992, DOI 10.1161/01.CIR.100.19.1992; Kim RJ, 2000, NEW ENGL J MED, V343, P1445, DOI 10.1056/NEJM200011163432003; KLEIGER RE, 1990, AM J CARDIOL, V65, P23, DOI 10.1016/0002-9149(90)90020-2; LIMA JAC, 1995, CIRCULATION, V92, P1117, DOI 10.1161/01.CIR.92.5.1117; MAHMARIAN JJ, 1988, CIRCULATION, V78, P831, DOI 10.1161/01.CIR.78.4.831; MILLER TD, 1995, CIRCULATION, V92, P334, DOI 10.1161/01.CIR.92.3.334; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; NISHIMURA T, 1989, AM J ROENTGENOL, V153, P715, DOI 10.2214/ajr.153.4.715; PANDIAN NG, 1985, AM J CARDIOL, V55, P551, DOI 10.1016/0002-9149(85)90245-0; PARODI O, 1993, CIRCULATION, V88, P509, DOI 10.1161/01.CIR.88.2.509; Ramani K, 1998, CIRCULATION, V98, P2687, DOI 10.1161/01.CIR.98.24.2687; Rehwald WG, 1999, CIRCULATION, V100, P797; ROBERTS WC, 1987, AM J CARDIOL, V60, P1340, DOI 10.1016/0002-9149(87)90618-7; Sheifer SE, 2000, J AM COLL CARDIOL, V35, P119, DOI 10.1016/S0735-1097(99)00524-0; SIMONETTI OP, IN PRESS RADIOLOGY; VANDIJKMAN PRM, 1991, RADIOLOGY, V180, P147, DOI 10.1148/radiology.180.1.2052683; WEINMANN HJ, 1984, PHYSIOL CHEM PHYS ME, V16, P167; WEISS JL, 1981, CIRCULATION, V63, P401, DOI 10.1161/01.CIR.63.2.401	30	549	565	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					21	28		10.1016/S0140-6736(00)03567-4	http://dx.doi.org/10.1016/S0140-6736(00)03567-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197356				2022-12-28	WOS:000166341500011
J	Breaker, RR				Breaker, RR			Molecular biology - Making catalytic DNAs	SCIENCE			English	Article							CLEAVING DNA; CRYSTAL-STRUCTURE; RNA; ENZYMES; INHIBITION; RIBOZYME; VIRUS; ACID		Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Breaker, RR (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.		Breaker, Ronald/E-9679-2010					Atkins J.F, 1999, RNA WORLD; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Breaker RR, 1997, NAT BIOTECHNOL, V15, P427, DOI 10.1038/nbt0597-427; Breaker RR, 1997, CURR OPIN CHEM BIOL, V1, P26, DOI 10.1016/S1367-5931(97)80105-6; Carmi N, 1998, P NATL ACAD SCI USA, V95, P2233, DOI 10.1073/pnas.95.5.2233; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CUENOUD B, 1995, NATURE, V375, P611, DOI 10.1038/375611a0; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Joyce GF, 1998, P NATL ACAD SCI USA, V95, P5845, DOI 10.1073/pnas.95.11.5845; Li J, 2000, J AM CHEM SOC, V122, P10466, DOI 10.1021/ja0021316; Li YF, 1999, J AM CHEM SOC, V121, P5364, DOI 10.1021/ja990592p; Li YF, 1999, P NATL ACAD SCI USA, V96, P2746, DOI 10.1073/pnas.96.6.2746; Li YF, 2000, BIOCHEMISTRY-US, V39, P3106, DOI 10.1021/bi992710r; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Roth A, 1998, P NATL ACAD SCI USA, V95, P6027, DOI 10.1073/pnas.95.11.6027; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Sheppard TL, 2000, P NATL ACAD SCI USA, V97, P7802, DOI 10.1073/pnas.97.14.7802; Smith RM, 1998, J AM CHEM SOC, V120, P8910, DOI 10.1021/ja9804565; Todd AV, 2000, CLIN CHEM, V46, P625; Unrau PJ, 1998, NATURE, V395, P260, DOI 10.1038/26193; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; Wu YP, 1999, HUM GENE THER, V10, P2847, DOI 10.1089/10430349950016573; Yen LS, 1999, ANN NEUROL, V46, P366, DOI 10.1002/1531-8249(199909)46:3<366::AID-ANA12>3.0.CO;2-D; Zhang XY, 1999, FEBS LETT, V458, P151, DOI 10.1016/S0014-5793(99)01149-7	27	115	144	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2095	2096		10.1126/science.290.5499.2095	http://dx.doi.org/10.1126/science.290.5499.2095			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11187837				2022-12-28	WOS:000165870600040
J	Macnab, RM				Macnab, RM			Microbiology - Action at a distance - Bacterial flagellar assembly	SCIENCE			English	Editorial Material							HOOK-ASSOCIATED PROTEINS; SALMONELLA-TYPHIMURIUM; CAP		Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Macnab, RM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.							ASAKURA S, 1968, J MOL BIOL, V35, P227, DOI 10.1016/S0022-2836(68)80050-6; EMERSON SU, 1970, SCIENCE, V169, P190, DOI 10.1126/science.169.3941.190; HOMMA M, 1984, J BACTERIOL, V159, P1056, DOI 10.1128/JB.159.3.1056-1059.1984; IINO T, 1969, J GEN MICROBIOL, V56, P227, DOI 10.1099/00221287-56-2-227; IKEDA T, 1985, J MOL BIOL, V184, P735, DOI 10.1016/0022-2836(85)90317-1; IKEDA T, 1987, J BACTERIOL, V169, P1168, DOI 10.1128/jb.169.3.1168-1173.1987; Imada K, 1998, J MOL BIOL, V277, P883, DOI 10.1006/jmbi.1998.1662; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; MACNAB RM, IN PRESS ASM NEWS; MORGAN DG, 1995, J MOL BIOL, V249, P88, DOI 10.1006/jmbi.1995.0282; TRACHTENBERG S, 1987, J MOL BIOL, V195, P581, DOI 10.1016/0022-2836(87)90184-7; VONDERVISZT F, 1989, J MOL BIOL, V209, P127, DOI 10.1016/0022-2836(89)90176-9; Yonekura K, 2000, SCIENCE, V290, P2148, DOI 10.1126/science.290.5499.2148	13	11	13	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2086	2087		10.1126/science.290.5499.2086	http://dx.doi.org/10.1126/science.290.5499.2086			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11187835				2022-12-28	WOS:000165870600037
J	Bowman, JM				Bowman, JM			Chemistry - Beyond platonic molecules	SCIENCE			English	Editorial Material							SELF-CONSISTENT-FIELD; MANY-MODE SYSTEMS; WAVE-FUNCTIONS; VIBRATIONS		Emory Univ, Cherry L Emerson Ctr Sci Computat, Atlanta, GA 30309 USA; Emory Univ, Dept Chem, Atlanta, GA 30309 USA	Emory University; Emory University	Bowman, JM (corresponding author), Emory Univ, Cherry L Emerson Ctr Sci Computat, Atlanta, GA 30309 USA.							BOWMAN JM, 1986, ACCOUNTS CHEM RES, V19, P202, DOI 10.1021/ar00127a002; BOWMAN JM, 1991, ADV MOL VIBRATIONS C, V1; BOWMAN JM, 1998, ADV MOL VIBRATIONS C, V3; Carter S, 1998, J CHEM PHYS, V108, P4397, DOI 10.1063/1.475852; Carter S, 1997, J CHEM PHYS, V107, P10458, DOI 10.1063/1.474210; Carter S, 2000, J CHEM PHYS, V113, P987, DOI 10.1063/1.481879; *CECAM, 2000, SPECTR COMP CHALL VI; Chaban GM, 1999, J CHEM PHYS, V111, P1823, DOI 10.1063/1.479452; Christoffel KM, 2000, J CHEM PHYS, V112, P4496, DOI 10.1063/1.481012; *INTR DYN, 2000, TELL SUMM RES C TELL; IRLE S, 2000, J CHEM PHYS, V113; Jung JO, 1996, J CHEM PHYS, V105, P10332, DOI 10.1063/1.472960; ROITBERG A, 1995, SCIENCE, V268, P1319, DOI 10.1126/science.7539156; Yagi K, 2000, J CHEM PHYS, V113, P1005, DOI 10.1063/1.481881	14	28	28	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 27	2000	290	5492					724	725		10.1126/science.290.5492.724	http://dx.doi.org/10.1126/science.290.5492.724			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ND	11184203				2022-12-28	WOS:000090067600029
J	Wood, RD; Mitchell, M; Sgouros, J; Lindahl, T				Wood, RD; Mitchell, M; Sgouros, J; Lindahl, T			Human DNA repair genes	SCIENCE			English	Article							FUNCTIONAL GENOMIC ANALYSIS; SEQUENCE; DAMAGE; CELLS; PROTEINS; DATABASE; SYSTEMS; AGENTS; MGMT	Cellular DNA is subjected to continual attack, both by reactive species inside cells and by environmental agents. Toxic and mutagenic consequences are minimized by distinct pathways of repair, and 130 known human DNA repair genes are described here. Notable features presently include four enzymes that can remove uracil from DNA, seven recombination genes related to RAD51, and many recently discovered DNA polymerases that bypass damage, but only one system to remove the main DNA lesions induced by ultraviolet Light. More human DNA repair genes will be found by comparison with model organisms and as common folds in three-dimensional protein structures are determined. Modulation of DNA repair should Lead to clinical applications including improvement of radiotherapy and treatment with anticancer drugs and an advanced understanding of the cellular aging process.	Imperial Canc Res Fund, Clare Hall Labs, Potters Bar EN6 3LD, Herts, England; Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Wood, RD (corresponding author), Univ Pittsburgh, Inst Canc, 5867 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.		Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892; Sgouros, John G./0000-0002-9141-5257				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; Bearzatto A, 2000, CANCER RES, V60, P3262; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Claij N, 1999, EXP CELL RES, V246, P1, DOI 10.1006/excr.1998.4299; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Duell EJ, 2000, CARCINOGENESIS, V21, P965, DOI 10.1093/carcin/21.5.965; Eisen JA, 1999, MUTAT RES-DNA REPAIR, V435, P171, DOI 10.1016/S0921-8777(99)00050-6; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Friedberg EC, 2000, MUTAT RES-DNA REPAIR, V459, P243, DOI 10.1016/S0921-8777(00)00006-9; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Sekelsky JJ, 2000, J CELL BIOL, V150, pF31, DOI 10.1083/jcb.150.2.F31; Tainer JA, 2000, MUTAT RES-DNA REPAIR, V460, P139, DOI 10.1016/S0921-8777(00)00037-9; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	23	1018	1126	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 16	2001	291	5507					1284	+		10.1126/science.1056154	http://dx.doi.org/10.1126/science.1056154			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	402MX	11181991				2022-12-28	WOS:000166993400037
J	Olefsky, JM				Olefsky, JM			Prospects for research in diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TYPE-2	Diabetes mellitus is the sixth leading cause of death in the United States, and morbidities resulting from diabetes-related complications such as retinopathy, kidney disease, and limb amputation cause a huge burden to the national health care system. Identification of the genetic components of type 1 and type 2 diabetes is the most important area of research because elucidation of the diabetes genes will influence all efforts toward a mechanistic understanding of the disease, its complications, and its treatment, cure, and prevention. Also, the link between obesity and type 2 diabetes mandates a redoubled effort to understand the genetic and behavioral contributions to obesity.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Dept Vet Affairs, San Diego, CA USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.							*C EST DIAB RES WO, 1999, NIH PUBL; DeFronzo RA, 1999, ANN INTERN MED, V131, P281, DOI 10.7326/0003-4819-131-4-199908170-00008; EISENBARTH GS, 1994, JOSLINS DIABETES MEL, P216; Ferris FL, 1999, NEW ENGL J MED, V341, P667, DOI 10.1056/NEJM199908263410907; Harris MI, 1998, DIABETES CARE, V21, pC11, DOI 10.2337/diacare.21.3.C11; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HARRIS MI, 1996, DIABETES SPECTRUM, V9, P26; LeRoith D., 2000, DIABETES MELLITUS FU; OLEFSKY JM, IN PRESS DEGROOT TXB; Reiber GE, 1995, DIABETES AM, P409; Ritz E, 1999, NEW ENGL J MED, V341, P1127, DOI 10.1056/NEJM199910073411506; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UNGER RH, 1998, DIABETES MELLITUS WI, P973; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909	15	35	35	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					628	632		10.1001/jama.285.5.628	http://dx.doi.org/10.1001/jama.285.5.628			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176871	Bronze			2022-12-28	WOS:000166714200024
J	Bernstein, E; Caudy, AA; Hammond, SM; Hannon, GJ				Bernstein, E; Caudy, AA; Hammond, SM; Hannon, GJ			Role for a bidentate ribonuclease in the initiation step of RNA interference	NATURE			English	Article							GENE; PLANTS	RNA interference (RNAi) is the mechanism through which double-stranded RNAs silence cognate genes(1-5). In plants, this can occur at both the transcriptional and the post-transcriptional levels(1,2,5); however, in animals, only post-transcriptional RNAi has been reported to date. In both plants and animals, RNAi is characterized by the presence of RNAs of about 22 nucleotides in length that are homologous to the gene that is being suppressed(6-8). These 22-nucleotide sequences serve as guide sequences that instruct a multicomponent nuclease, RISC, to destroy specific messenger RNAs6. Here we identify an enzyme, Dicer, which can produce putative guide RNAs. Dicer is a member of the RNase III family of nucleases that specifically cleave double-stranded RNAs, and is evolutionarily conserved in worms, flies, plants, fungi and mammals. The enzyme has a distinctive structure, which includes a helicase domain and dual RNase III motifs. Dicer also contains a region of homology to the RDE1/QDE2/ARGONAUTE family that has been genetically linked to RNAi(9,10).	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA; Genetica, Cambridge, MA 01239 USA	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bernstein, E (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Hannon, Gregory/AAB-3568-2019	Caudy, Amy/0000-0001-6307-8137				Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Baulcombe DC, 1996, PLANT MOL BIOL, V32, P79, DOI 10.1007/BF00039378; Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; Catalanotto C, 2000, NATURE, V404, P245, DOI 10.1038/35005169; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Filippov V, 2000, GENE, V245, P213, DOI 10.1016/S0378-1119(99)00571-5; GILLESPIE DE, 1995, GENE DEV, V9, P2495, DOI 10.1101/gad.9.20.2495; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; Matsuda S, 2000, BBA-GENE STRUCT EXPR, V1490, P163, DOI 10.1016/S0167-4781(99)00221-3; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; Nicholson AW, 1999, FEMS MICROBIOL REV, V23, P371, DOI 10.1016/S0168-6445(99)00013-3; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Sijen T, 2000, BIOESSAYS, V22, P520, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;520::AID-BIES5&gt;3.0.CO;2-W; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Yang D, 2000, CURR BIOL, V10, P1191, DOI 10.1016/S0960-9822(00)00732-6; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	23	3481	4290	7	466	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					363	366		10.1038/35053110	http://dx.doi.org/10.1038/35053110			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201747				2022-12-28	WOS:000166434300052
J	Irwin, DE; Bensch, S; Price, TD				Irwin, DE; Bensch, S; Price, TD			Speciation in a ring	NATURE			English	Article							PHYLLOSCOPUS; ENSATINA; WARBLERS; ECOLOGY	The evolutionary divergence of a single species into two has never been directly observed in nature, primarily because speciation can take a long time to occur. A ring species, in which a chain of intergrading populations encircles a barrier and the terminal forms coexist without interbreeding, provides a situation in which variation in space can be used to infer variation in time(1-3). Here we reconstruct the pathway to speciation between two reproductively isolated forms of greenish warbler (Phylloscopus trochiloides). These two taxa do not interbreed in central Siberia but are connected by a long chain of intergrading populations encircling the Tibetan Plateau to the south(4). Molecular data and climatic history imply that the reproductively isolated taxa came into contact following expansions northward around the western and eastern sides of the plateau. Parallel selection pressures for increased song complexity during the northward expansions have been accompanied by divergence in song structure. Playback experiments show that the two Siberian forms do not recognize each other's songs. Our results show how gradual divergence in a trait involved in mate choice leads to the formation of new species.	Univ Calif San Diego, Dept Biol 0116, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Irwin, DE (corresponding author), Univ Lund, Dept Ecol, Sect Anim Ecol, Ecol Bldg, S-22362 Lund, Sweden.		Irwin, Darren E./G-6183-2012	Irwin, Darren E./0000-0002-1050-5841				Bensch S, 2000, MOL BIOL EVOL, V17, P107, DOI 10.1093/oxfordjournals.molbev.a026223; Bensch S, 1997, MOL ECOL, V6, P91, DOI 10.1046/j.1365-294X.1997.00150.x; FRENZEL B, 1968, SCIENCE, V161, P637, DOI 10.1126/science.161.3842.637; Highton R, 1998, HERPETOLOGICA, V54, P254; Irwin DE, 2000, EVOLUTION, V54, P998; IRWIN DE, IN PRESS IBIS; MARCHETTI K, 1993, NATURE, V362, P149, DOI 10.1038/362149a0; Marchetti K, 1997, OIKOS, V79, P410, DOI 10.2307/3546026; Martens Jochen, 1996, P221; Mayr E, 1970, POPULATIONS SPECIES; Mayr E, 1942, SYSTEMATICS ORIGIN S; Menzies Nicholas, 1994, FOREST LAND MANAGEME; Orr MR, 1998, TRENDS ECOL EVOL, V13, P502, DOI 10.1016/S0169-5347(98)01511-0; PRICE T, 1991, J ANIM ECOL, V60, P643, DOI 10.2307/5303; Rundle HD, 2000, SCIENCE, V287, P306, DOI 10.1126/science.287.5451.306; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ticehurst CB., 1938, SYSTEMATIC REV GENUS; Wake D.B., 1989, P134; Wake DB, 1998, HERPETOLOGICA, V54, P279; WANG CW, 1961, MM CABOT FDN PUBLICA, V5; WESTEBERHARD MJ, 1983, Q REV BIOL, V58, P155, DOI 10.1086/413215	22	263	278	2	108	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					333	337		10.1038/35053059	http://dx.doi.org/10.1038/35053059			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201740				2022-12-28	WOS:000166434300045
J	Burman, WJ; Reves, RR; Cohn, DL; Schooley, RT				Burman, WJ; Reves, RR; Cohn, DL; Schooley, RT			Breaking the camel's back: Multicenter clinical trials and local institutional review boards	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RESEARCH ETHICS COMMITTEES; CONSENT FORMS; READABILITY; MORTALITY; SAFETY	Clinical research has undergone remarkable and beneficial expansion in the past 25 years, but with this growth has come an unprecedented increase in workload for the human subjects protection system. Recently, a major change in federal oversight of local institutional review boards (IRBs) became evident. Although it was not announced publicly, in 1998 and 1999 federal regulatory actions against local IRBs increased threefold. Particularly notable was the marked increase in regulatory actions taken against the IRBs of academic medical centers (1 in 1997 compared with 14 in 1999). Ironically, this apparent federal crackdown began at the same time that two federal review panels called for major changes in the regulations governing local IRBs. A key factor in the current crisis in the function of local IRBs is the ascendance of multicenter clinical trials as the dominant form of clinical research. Local IRBs were not designed to handle the initial evaluation and ongoing review required by the rapidly increasing number of multicenter clinical trials. Furthermore, local IRB review of the thousands of safety reports from multicenter clinical trials monopolizes resources without promoting patient safety. Instead of rigid enforcement of outmoded regulations that do not contribute to patient safety. the responsibilities of the local IRE in the oversight of multicenter clinical trials must be systematically evaluated.	Denver Hlth & Hosp Author, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Burman, WJ (corresponding author), Denver Publ Hlth, 605 Bannock St, Denver, CO 80204 USA.	bburman@dhha.org						Alberti KGMM, 2000, BRIT MED J, V320, P1157, DOI 10.1136/bmj.320.7243.1157; ALBERTI KGMM, 1995, BRIT MED J, V311, P639, DOI 10.1136/bmj.311.7006.639; BRONSON JJ, 1989, J MED CHEM, V32, P1457, DOI 10.1021/jm00127a010; Chertow GM, 1996, AM J MED, V101, P49, DOI 10.1016/S0002-9343(96)00075-7; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; CURRAN WJ, 1973, NEW ENGL J MED, V289, P730, DOI 10.1056/NEJM197310042891406; Dal-Re R, 1999, J MED ETHICS, V25, P268, DOI 10.1136/jme.25.3.268; DeMets DL, 1995, CONTROL CLIN TRIALS, V16, P408, DOI 10.1016/S0197-2456(95)00073-9; FISHER E, 1999, 6 C RETR OPP INF CHI, P160; FRIEDMAN L, 1993, STAT MED, V12, P425, DOI 10.1002/sim.4780120505; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GLICK JH, 1998, REPORT NATL CANC I C; Goldstein AO, 1996, J FAM PRACTICE, V42, P606; HAMMERSCHMIDT DE, 1992, AM J MED SCI, V304, P348, DOI 10.1097/00000441-199212000-00003; Jamrozik K, 1999, MED J AUSTRALIA, V170, P26; Kahn J, 1999, JAMA-J AM MED ASSOC, V282, P2305, DOI 10.1001/jama.282.24.2305; Kaplan S, 1999, US News World Rep, V127, P34; LOVERDE ME, 1989, J GEN INTERN MED, V4, P410, DOI 10.1007/BF02599693; Mastroianni A, 1996, J LAW MED ETHICS, V24, P118, DOI 10.1111/j.1748-720X.1996.tb01844.x; MIDDLE C, 1995, BRIT MED J, V311, P659, DOI 10.1136/bmj.311.7006.659; MORROW GR, 1980, JAMA-J AM MED ASSOC, V244, P56, DOI 10.1001/jama.244.1.56; *NAT CANC I, 1999, REC NCI INF CONS WOR; *NIH, 2000, REV POL IRB REV HUM; Phillips DF, 1996, JAMA-J AM MED ASSOC, V276, P1623, DOI 10.1001/jama.276.20.1623; ROCKHOLD FW, 1993, STAT MED, V12, P471, DOI 10.1002/sim.4780120512; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Tully J, 2000, BRIT MED J, V320, P1179, DOI 10.1136/bmj.320.7243.1179; *US DEP HHS, 1999, NIH IN RED REG BURD; *US DEP HHS, 1998, PUBL US DEP HLTH HUM, P1; *US DEP HHS, 1999, OPRR COMPL ACT COMM; *US DEP HHS, 2000, PUBL US DEP HLTH HUM, P1; Volkmar FR, 1999, NEW ENGL J MED, V341, P1842, DOI 10.1056/NEJM199912093412412; Woodward B, 1999, JAMA-J AM MED ASSOC, V282, P1947, DOI 10.1001/jama.282.20.1947	33	116	116	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2001	134	2					152	157		10.7326/0003-4819-134-2-200101160-00016	http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00016			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391KW	11177319				2022-12-28	WOS:000166356000009
J	Ganopolski, A; Rahmstorf, S				Ganopolski, A; Rahmstorf, S			Rapid changes of glacial climate simulated in a coupled climate model	NATURE			English	Article							FRESH-WATER; THERMOHALINE CIRCULATION; INTERMEDIATE COMPLEXITY; NORTHERN-HEMISPHERE; ICE; GREENLAND; OCEAN; VEGETATION; VARIABILITY; TEMPERATURES	Abrupt changes in climate, termed Dansgaard-Oeschger and Heinrich events, have punctuated the last glacial period (similar to 100- 10 kyr ago) but not the Holocene (the past 10 kyr). Here we use an intermediate-complexity climate model to investigate the stability of glacial climate, and we rnd that only one mode of Atlantic Ocean circulation is stable: a cold mode with deep water formation in the Atlantic Ocean south of Iceland. However, a `warm' circulation mode similar to the present-day Atlantic Ocean is only marginally unstable, and temporary transitions to this warm mode can easily be triggered. This leads to abrupt warm events in the model which share many characteristics of the observed Dansgaard-Oeschger events. For a large freshwater input (such as a large release of icebergs), the model's deep water formation is temporarily switched off, causing no strong cooling in Greenland but warming in Antarctica, as is observed for Heinrich events. Our stability analysis provides an explanation why glacial climate is much more variable than Holocene climate.	Potsdam Inst Climate Impact Res, D-14412 Potsdam, Germany	Potsdam Institut fur Klimafolgenforschung	Ganopolski, A (corresponding author), Potsdam Inst Climate Impact Res, POB 60 12 03, D-14412 Potsdam, Germany.	ganopolski@pik-potsdam.de	Ganopolski, Andrey/F-6811-2013; Rahmstorf, Stefan/A-8465-2010	Rahmstorf, Stefan/0000-0001-6786-7723				AAGAARD K, 1989, J GEOPHYS RES-OCEANS, V94, P14485, DOI 10.1029/JC094iC10p14485; Alley RB, 1999, ANNU REV EARTH PL SC, V27, P149, DOI 10.1146/annurev.earth.27.1.149; Alley RB, 1999, GEOPH MONOG SERIES, V112, P385; ALLEY RB, IN PRESS PALEOCEANOG; [Anonymous], 1999, GEOPHYS MONOGR SER; Bard E, 2000, SCIENCE, V289, P1321, DOI 10.1126/science.289.5483.1321; Blunier T, 1998, NATURE, V394, P739, DOI 10.1038/29447; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Brovkin V, 1997, ECOL MODEL, V101, P251, DOI 10.1016/S0304-3800(97)00049-5; Cacho I, 1999, PALEOCEANOGRAPHY, V14, P698, DOI 10.1029/1999PA900044; Clark PU, 1999, SCIENCE, V286, P1104, DOI 10.1126/science.286.5442.1104; Claussen M, 1998, PHILOS T ROY SOC B, V353, P53, DOI 10.1098/rstb.1998.0190; Claussen M, 1999, GEOPHYS RES LETT, V26, P2037, DOI 10.1029/1999GL900494; DahlJensen D, 1998, SCIENCE, V282, P268, DOI 10.1126/science.282.5387.268; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; DANSGAARD W, 1982, SCIENCE, V218, P1273, DOI 10.1126/science.218.4579.1273; Fanning AF, 1997, PALEOCEANOGRAPHY, V12, P307, DOI 10.1029/96PA03726; Ganopolski A, 1998, SCIENCE, V280, P1916, DOI 10.1126/science.280.5371.1916; Ganopolski A, 1998, NATURE, V391, P351, DOI 10.1038/34839; GANOPOLSKI A, IN PRESS CLIM DYN; Grootes PM, 1997, J GEOPHYS RES-OCEANS, V102, P26455, DOI 10.1029/97JC00880; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HEINRICH H, 1988, QUATERNARY RES, V29, P142, DOI 10.1016/0033-5894(88)90057-9; Kageyama M, 2001, CLIM DYNAM, V17, P23, DOI 10.1007/s003820000095; KEIGWIN LD, 1994, NATURE, V371, P323, DOI 10.1038/371323a0; Kubatzki C, 2000, CLIM DYNAM, V16, P799, DOI 10.1007/s003820000078; Manabe S, 1988, J CLIMATE, V1, P841, DOI 10.1175/1520-0442(1988)001<0841:TSEOAC>2.0.CO;2; Manabe S, 1997, PALEOCEANOGRAPHY, V12, P321, DOI 10.1029/96PA03932; MARCHAL O, 1999, MECH GLOBAL CLIMATE, P263; McManus JF, 1999, SCIENCE, V283, P971, DOI 10.1126/science.283.5404.971; Paillard D, 1999, PALEOCEANOGRAPHY, V14, P716, DOI 10.1029/1999PA900045; Petoukhov V, 2000, CLIM DYNAM, V16, P1, DOI 10.1007/PL00007919; Rahmstorf S, 1996, CLIM DYNAM, V12, P799, DOI 10.1007/s003820050144; RAHMSTORF S, 1995, NATURE, V378, P145, DOI 10.1038/378145a0; Rahmstorf S, 1999, CLIMATIC CHANGE, V43, P353, DOI 10.1023/A:1005474526406; SARNTHEIN M, 1994, PALEOCEANOGRAPHY, V9, P209, DOI 10.1029/93PA03301; SOWERS T, 1995, SCIENCE, V269, P210, DOI 10.1126/science.269.5221.210; Stocker TF, 1998, SCIENCE, V282, P61, DOI 10.1126/science.282.5386.61; Stocker TF, 1999, INT J EARTH SCI, V88, P365, DOI 10.1007/s005310050271; Stocker TF, 2000, QUATERNARY SCI REV, V19, P301, DOI 10.1016/S0277-3791(99)00067-0; Stocker TF, 2000, P NATL ACAD SCI USA, V97, P1362, DOI 10.1073/pnas.97.4.1362; STOCKER TF, 1991, NATURE, V351, P729, DOI 10.1038/351729a0; STOCKER TF, 1991, J PHYS OCEANOGR, V21, P1725, DOI 10.1175/1520-0485(1991)021<1725:AZAOMF>2.0.CO;2; Stuiver M, 2000, QUATERNARY RES, V53, P277, DOI 10.1006/qres.2000.2127; van Geel B, 1999, QUATERNARY SCI REV, V18, P331, DOI 10.1016/S0277-3791(98)00088-2; van Kreveld S, 2000, PALEOCEANOGRAPHY, V15, P425, DOI 10.1029/1999PA000464; Yiou P, 1997, J GEOPHYS RES-OCEANS, V102, P26441	47	692	723	1	120	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					153	158		10.1038/35051500	http://dx.doi.org/10.1038/35051500			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196631				2022-12-28	WOS:000166316200033
J	Klibanov, AM				Klibanov, AM			Improving enzymes by using them in organic solvents	NATURE			English	Review							ENZYMATIC CATALYSIS; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; SUBTILISIN CARLSBERG; ALPHA-CHYMOTRYPSIN; SERINE PROTEASES; RATIONAL CONTROL; RACEMIC AMINES; X-RAY; WATER	The technological utility of enzymes can be enhanced greatly by using them in organic solvents rather than their natural aqueous reaction media. Studies over the past 15 years have revealed not only that this change in solvent is feasible, but also that in such seemingly hostile environments enzymes can catalyse reactions impossible in water, become more stable, and exhibit new behaviour such as `molecular memory'. Of particular importance has been the discovery that enzymatic selectivity, including substrate, stereo-, regio- and chemoselectivity, can be markedly affected, and sometimes even inverted, by the solvent. Enzyme-catalysed reactions in organic solvents, and even in supercritical fluids and the gas phase, have found numerous potential applications, some of which are already commercialized.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Klibanov, AM (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	klibanov@mit.edu						AFFLECK R, 1992, P NATL ACAD SCI USA, V89, P5167, DOI 10.1073/pnas.89.11.5167; AHERN TJ, 1988, METHOD BIOCHEM ANAL, V33, P91; Akkara JA, 1999, TRENDS BIOTECHNOL, V17, P67, DOI 10.1016/S0167-7799(98)01270-0; Almarsson O, 1996, BIOTECHNOL BIOENG, V49, P87, DOI 10.1002/(SICI)1097-0290(19960105)49:1<87::AID-BIT11>3.0.CO;2-8; BARZANA E, 1989, ANAL BIOCHEM, V182, P109, DOI 10.1016/0003-2697(89)90726-4; Barzana E., 1995, ADV BIOCHEM ENG BIOT, V53, P1; Bell G, 1995, TRENDS BIOTECHNOL, V13, P468, DOI 10.1016/S0167-7799(00)89004-6; BLACKWOOD AD, 1994, BBA-PROTEIN STRUCT M, V1206, P161, DOI 10.1016/0167-4838(94)90203-8; Bornscheuer UT, 2006, HYDROLASES IN ORGANIC SYNTHESIS: REGIO- AND STEREOSELECTIVE BIOTRANSFORMATIONS, 2ND EDITION, P1; BROOS J, 1995, J CHEM SOC CHEM COMM, P255, DOI 10.1039/c39950000255; BURKE PA, 1993, BIOTECHNOL BIOENG, V42, P87, DOI 10.1002/bit.260420112; Carrea G, 2000, ANGEW CHEM INT EDIT, V39, P2226; CARREA G, 1995, TRENDS BIOTECHNOL, V13, P63, DOI 10.1016/S0167-7799(00)88907-6; CHAUDHARY AK, 1995, J AM CHEM SOC, V117, P3728, DOI 10.1021/ja00118a009; CHEN CS, 1982, J AM CHEM SOC, V104, P7294, DOI 10.1021/ja00389a064; DABULIS K, 1993, BIOTECHNOL BIOENG, V41, P566, DOI 10.1002/bit.260410509; Dai LZ, 1999, P NATL ACAD SCI USA, V96, P9475, DOI 10.1073/pnas.96.17.9475; de Bont JAM, 1998, TRENDS BIOTECHNOL, V16, P493, DOI 10.1016/S0167-7799(98)01234-7; Ebert C, 1996, TETRAHEDRON, V52, P4867, DOI 10.1016/0040-4020(96)00158-5; Faber K., 2000, BIOTRANSFORMATIONS O; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FITZPATRICK PA, 1993, P NATL ACAD SCI USA, V90, P8653, DOI 10.1073/pnas.90.18.8653; GAERTNER H, 1989, EUR J BIOCHEM, V181, P207, DOI 10.1111/j.1432-1033.1989.tb14712.x; Gag XG, 1999, P NATL ACAD SCI USA, V96, P10062, DOI 10.1073/pnas.96.18.10062; GARZARAMOS G, 1990, BIOCHEMISTRY-US, V29, P751, DOI 10.1021/bi00455a023; GILL I, 1994, TRENDS BIOTECHNOL, V12, P118, DOI 10.1016/0167-7799(94)90088-4; Griebenow K, 1997, BIOTECHNOL BIOENG, V53, P351, DOI 10.1002/(SICI)1097-0290(19970220)53:4<351::AID-BIT1>3.0.CO;2-M; Griebenow K, 1996, J AM CHEM SOC, V118, P11695, DOI 10.1021/ja961869d; GRIEBENOW K, 1995, P NATL ACAD SCI USA, V92, P10969, DOI 10.1073/pnas.92.24.10969; GUTMAN AL, 1992, BIOTECHNOL BIOENG, V40, P760, DOI 10.1002/bit.260400703; Jeffrey J. A., 1994, HYDROGEN BONDING BIO; JOHNSON DV, 1999, ADV BIOCHEM ENG BIOT, V63, P31; Ke T, 1998, BIOTECHNOL BIOENG, V57, P746, DOI 10.1002/(SICI)1097-0290(19980320)57:6<746::AID-BIT12>3.0.CO;2-5; Ke T, 1999, J AM CHEM SOC, V121, P3334, DOI 10.1021/ja984283v; Ke T, 1996, J AM CHEM SOC, V118, P3366, DOI 10.1021/ja952674t; KHMELNITSKY YL, 1994, J AM CHEM SOC, V116, P2647, DOI 10.1021/ja00085a066; KIRCHNER G, 1985, J AM CHEM SOC, V107, P7072, DOI 10.1021/ja00310a052; KITAGUCHI H, 1989, J AM CHEM SOC, V111, P3094, DOI 10.1021/ja00190a070; KLIBANOV AM, 1995, NATURE, V374, P596, DOI 10.1038/374596a0; KLIBANOV AM, 1989, TRENDS BIOCHEM SCI, V14, P141, DOI 10.1016/0968-0004(89)90146-1; Klibanov AM, 1997, TRENDS BIOTECHNOL, V15, P97, DOI 10.1016/S0167-7799(97)01013-5; Koskinen A., 1996, ENZYMATIC REACTIONS, DOI [10.1007/978-94-011-0611-5_11, DOI 10.1007/978-94-011-0611-5_11]; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; LAPANJE S, 1978, PHYSICOCHEMICAL ASPE, pCH1; MacManus DA, 1997, ENZYME MICROB TECH, V20, P225, DOI 10.1016/S0141-0229(96)00117-2; Marbrouk P. A, 1995, J AM CHEM SOC, V117, P2141; Margolin AL, 1996, TRENDS BIOTECHNOL, V14, P223, DOI 10.1016/0167-7799(96)10031-7; Mingarro I, 1996, BIOCHEMISTRY-US, V35, P9935, DOI 10.1021/bi960191b; NELSON DL, 2000, LEHNINGER PRINCIPLES, P192; Okahata Y, 1997, TRENDS BIOTECHNOL, V15, P50, DOI 10.1016/S0167-7799(97)84203-5; PARADKAR VM, 1994, J AM CHEM SOC, V116, P5009, DOI 10.1021/ja00090a065; Rich JO, 1997, J AM CHEM SOC, V119, P3245, DOI 10.1021/ja9637715; Roberts S. M., 1995, INTRO BIOCATALYSIS U; RUBIO E, 1991, J AM CHEM SOC, V113, P695, DOI 10.1021/ja00002a060; RUPLEY JA, 1991, ADV PROTEIN CHEM, V41, P37; RUSSELL AJ, 1988, J BIOL CHEM, V263, P11624; RYU K, 1992, BIOCHEMISTRY-US, V31, P2588, DOI 10.1021/bi00124a020; Schmitke JL, 1997, P NATL ACAD SCI USA, V94, P4250, DOI 10.1073/pnas.94.9.4250; Schmitke JL, 1996, J AM CHEM SOC, V118, P3360, DOI 10.1021/ja9539958; STAHL M, 1991, J AM CHEM SOC, V113, P9366; Stinson SC, 1998, CHEM ENG NEWS, V76, P83, DOI 10.1021/cen-v076n038.p083; TAWAKI S, 1993, BIOCATALYSIS, V8, P3, DOI 10.3109/10242429309030952; TAWAKI S, 1992, J AM CHEM SOC, V114, P1882, DOI 10.1021/ja00031a054; UEJI S, 1992, BIOTECHNOL LETT, V14, P163, DOI 10.1007/BF01023352; VOLKIN DB, 1991, BIOTECHNOL BIOENG, V37, P843, DOI 10.1002/bit.260370908; Wangikar PP, 1997, J AM CHEM SOC, V119, P70, DOI 10.1021/ja962620z; WESCOTT CR, 1994, BBA-PROTEIN STRUCT M, V1206, P1, DOI 10.1016/0167-4838(94)90065-5; Wescott CR, 1996, J AM CHEM SOC, V118, P10365, DOI 10.1021/ja961394q; WESCOTT CR, 1993, J AM CHEM SOC, V115, P1629, DOI 10.1021/ja00058a002; WU SH, 1991, BIOORG MED CHEM LETT, V1, P339, DOI 10.1016/S0960-894X(01)80467-4; Xu K, 1996, J AM CHEM SOC, V118, P9815, DOI 10.1021/ja961596m; XU ZF, 1994, BIOTECHNOL BIOENG, V43, P515, DOI 10.1002/bit.260430612; YENNAWAR NH, 1994, BIOCHEMISTRY-US, V33, P7326, DOI 10.1021/bi00189a038; Zaks A, 1997, DRUG DISCOV TODAY, V2, P513, DOI 10.1016/S1359-6446(97)01078-7; ZAKS A, 1986, J AM CHEM SOC, V108, P2767, DOI 10.1021/ja00270a053; ZAKS A, 1985, P NATL ACAD SCI USA, V82, P3192, DOI 10.1073/pnas.82.10.3192; ZAKS A, 1984, SCIENCE, V224, P1249, DOI 10.1126/science.6729453; ZAKS A, 1988, J BIOL CHEM, V263, P3194; ZAKS A, 1988, J BIOL CHEM, V263, P8017; Zhu GY, 1998, BBA-PROTEIN STRUCT M, V1429, P142, DOI 10.1016/S0167-4838(98)00226-X	80	1700	1782	17	467	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					241	246		10.1038/35051719	http://dx.doi.org/10.1038/35051719			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196652				2022-12-28	WOS:000166316200055
J	Seung, HS; Lee, DD				Seung, HS; Lee, DD			Cognition - The manifold ways of perception	SCIENCE			English	Editorial Material							HEAD-DIRECTION		MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Alcatel-Lucent; Lucent Technologies; AT&T	Seung, HS (corresponding author), MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.		Lee, Daniel D./B-5753-2013	Lee, Daniel/0000-0003-4239-8777				Devlin K., 1997, MATH SCI PATTERNS; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; MCFARLAND JL, 1992, J NEUROPHYSIOL, V68, P319, DOI 10.1152/jn.1992.68.1.319; Roweis ST, 2000, SCIENCE, V290, P2323, DOI 10.1126/science.290.5500.2323; Seung HS, 1996, P NATL ACAD SCI USA, V93, P13339, DOI 10.1073/pnas.93.23.13339; Seung HS, 1998, ADV NEUR IN, V10, P654; Taube JS, 1998, PROG NEUROBIOL, V55, P225, DOI 10.1016/S0301-0082(98)00004-5; Tenenbaum JB, 2000, SCIENCE, V290, P2319, DOI 10.1126/science.290.5500.2319; Zhang K, 1996, J NEUROSCI, V16, P2112	9	537	703	6	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	2000	290	5500					2268	+		10.1126/science.290.5500.2268	http://dx.doi.org/10.1126/science.290.5500.2268			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11188725				2022-12-28	WOS:000165995800027
J	Abecassis, M; Adams, M; Adams, P; Arnold, RM; Atkins, CR; Barr, ML; Bennett, WM; Bia, M; Briscoe, DM; Burdick, J; Corry, RJ; Davis, J; Delmonico, FL; Gaston, RS; Harmon, W; Jacobs, CL; Kahn, J; Leichtman, A; Miller, C; Moss, D; Newmann, JM; Rosen, LS; Siminoff, L; Spital, A; Starnes, VA; Thomas, C; Tyler, LS; Williams, L; Wright, FH; Youngner, S				Abecassis, M; Adams, M; Adams, P; Arnold, RM; Atkins, CR; Barr, ML; Bennett, WM; Bia, M; Briscoe, DM; Burdick, J; Corry, RJ; Davis, J; Delmonico, FL; Gaston, RS; Harmon, W; Jacobs, CL; Kahn, J; Leichtman, A; Miller, C; Moss, D; Newmann, JM; Rosen, LS; Siminoff, L; Spital, A; Starnes, VA; Thomas, C; Tyler, LS; Williams, L; Wright, FH; Youngner, S		Authors Live Organ Donor Consensus	Consensus statement on the live organ donor	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSPLANTATION	Objective To recommend practice guidelines for transplant physicians, primary care providers, health care planners, and all those who are concerned about the well-being of the live organ donor. Participants An executive group representing the National Kidney Foundation, and the American Societies of Transplantation, Transplant Surgeons, and Nephrology formed a steering committee of 12 members to evaluate current practices of living donor transplantation of the kidney, pancreas, liver, intestine, and lung. The steering committee subsequently assembled more than 100 representatives of the transplant community (physicians, nurses, ethicists, psychologists, lawyers, scientists, social workers, transplant recipients, and living donors) at a national conference held June 1-2, 2000, in Kansas City, Mo. Consensus Process Attendees participated in 7 assigned work groups. Three were organ specific (lung, liver, and kidney) and 4 were focused on social and ethical concerns (informed consent, donor source, psychosocial issues, and live organ donor registry). Work groups' deliberations were structured by a series of questions developed by the steering committee. Each work group presented its deliberations to an open plenary session of all attendees. This information was stored and shaped into a statement circulated electronically to all attendees for their comments, and finally approved by the steering committee for publication. The term consensus is not meant to convey universal agreement of the participants. The statement identifies issues of controversy; however, the wording of the entire statement is a consensus by approval of all attendees. Conclusion The person who gives consent to be a live organ donor should be competent, willing to donate, free from coercion, medically and psychosocially suitable, fully informed of the risks and benefits as a donor, and fully informed of the risks, benefits, and alternative treatment available to the recipient. The benefits to both donor and recipient must outweigh the risks associated with the donation and transplantation of the living donor organ.	Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School	Delmonico, FL (corresponding author), Harvard Univ, Sch Med, White 505, Boston, MA 02114 USA.		Abecassis, Michael/F-7977-2011; Siminoff, Laura A/H-6277-2012; Tyler, Linda S/AAW-7119-2021; Gaston, Robert/AAR-2932-2020	Briscoe, David/0000-0003-4135-5417				Adams M, 2000, LIVER TRANSPLANT, V6, P815; Barr M. L., 1998, Transplantation Proceedings, V30, P2261, DOI 10.1016/S0041-1345(98)00612-5; BIA MJ, 1995, TRANSPLANTATION, V60, P322, DOI 10.1097/00007890-199508270-00003; Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003; COSIMI B, 1998, CLIN TRANSPLANT, V14, P344; *COUNC ETH JUD AFF, 1994, CODE MED ETHICS REP, V5, P229; DOSSETOR JB, 2000, AM J KIDNEY DIS, V35, P1002; Gruessner RWG, 1997, ANN SURG, V226, P471, DOI 10.1097/00000658-199710000-00008; Marcos A, 2000, TRANSPLANTATION, V69, P2410, DOI 10.1097/00007890-200006150-00034; Margreiter R, 1999, LANGENBECK ARCH SURG, V384, P544, DOI 10.1007/s004230050241; Matas AJ, 2000, NEW ENGL J MED, V343, P433, DOI 10.1056/NEJM200008103430611; Menikoff J, 1999, HASTINGS CENT REP, V29, P28, DOI 10.2307/3527869; Millis JM, 2000, ANN SURG, V232, P104, DOI 10.1097/00000658-200007000-00015; Ross LF, 2000, SEMIN DIALYSIS, V13, P201, DOI 10.1046/j.1525-139x.2000.00054.x; Spital A, 1996, TRANSPLANTATION, V62, P1356, DOI 10.1097/00007890-199611150-00031; Starnes VA, 1999, ANN THORAC SURG, V68, P2279, DOI 10.1016/S0003-4975(99)01155-8	16	358	359	1	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2919	2926						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380RJ	11187711				2022-12-28	WOS:000165717000033
J	Channareth, T; Coghlan, D				Channareth, T; Coghlan, D			Being disabled in Cambodia	LANCET			English	Article									Jesuit Refugee Serv Cambodia, Phnom Penh, Cambodia		Channareth, T (corresponding author), Jesuit Refugee Serv Cambodia, POB 880, Phnom Penh, Cambodia.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S17	S17		10.1016/S0140-6736(00)92003-8	http://dx.doi.org/10.1016/S0140-6736(00)92003-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191472				2022-12-28	WOS:000166074900019
J	Begg, CB				Begg, CB			Cancer, genes, and the environment.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Begg, CB (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.							EASTON D, 1990, CANCER SURV, V9, P395; PETO J, 1980, BANBURY REPORT, V4, P203	2	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1495	1495						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184466				2022-12-28	WOS:000165271300021
J	West, SA; Herre, EA; Sheldon, BC				West, SA; Herre, EA; Sheldon, BC			The benefits of allocating sex	SCIENCE			English	Editorial Material							SELECTION THEORY; KIN SELECTION; FIG WASPS; RATIOS; ANT; STRATEGIES		Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Smithsonian Trop Res Inst, Balboa, Panama; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Edinburgh; Smithsonian Institution; Smithsonian Tropical Research Institute; University of Oxford	West, SA (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	stu.west@ed.ac.uk	Sheldon, Ben C/A-8056-2010; West, Stuart A/M-3608-2014	Sheldon, Ben C/0000-0002-5240-7828; West, Stuart A/0000-0003-2152-3153				BARTON NH, 1989, ANNU REV GENET, V23, P337, DOI 10.1146/annurev.ge.23.120189.002005; BOOMSMA JJ, 1990, EVOLUTION, V44, P1026, DOI [10.2307/2409564, 10.1111/j.1558-5646.1990.tb03823.x]; Campbell DR, 2000, TRENDS ECOL EVOL, V15, P227, DOI 10.1016/S0169-5347(00)01872-3; Chapuisat M, 1999, HEREDITY, V82, P473, DOI 10.1038/sj.hdy.6885340; CHARNOV E L, 1982; EVANS JD, 1995, P NATL ACAD SCI USA, V92, P6514, DOI 10.1073/pnas.92.14.6514; Frank, 1998, FDN SOCIAL EVOLUTION; Frank SA, 1996, Q REV BIOL, V71, P37, DOI 10.1086/419267; FRANK SA, 1985, EVOLUTION, V39, P949, DOI 10.1111/j.1558-5646.1985.tb00440.x; Godfray HCJ, 1996, TRENDS ECOL EVOL, V11, pA59; Greeff JM, 1996, J EVOLUTION BIOL, V9, P855, DOI 10.1046/j.1420-9101.1996.9060855.x; Hamilton W.D., 1979, P167; Hamilton W.D., 1996, NARROW ROADS GENE LA, V1; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; HERRE EA, 1987, NATURE, V329, P627, DOI 10.1038/329627a0; HERRE EA, 1985, SCIENCE, V228, P896, DOI 10.1126/science.228.4701.896; KING BH, 1989, OECOLOGIA, V78, P420, DOI 10.1007/BF00379119; Komdeur J, 1997, NATURE, V385, P522, DOI 10.1038/385522a0; Kruuk LEB, 1999, NATURE, V399, P459, DOI 10.1038/20917; MUELLER UG, 1991, SCIENCE, V254, P442, DOI 10.1126/science.254.5030.442; Paul REL, 2000, SCIENCE, V287, P128, DOI 10.1126/science.287.5450.128; Pickering J, 2000, EVOL ECOL RES, V2, P171; READ AF, 1995, P ROY SOC B-BIOL SCI, V260, P359, DOI 10.1098/rspb.1995.0105; REESE S, 2000, TRENDS ENCOL EVOL, V15, P169; Seger Jon, 1996, P93; Sheldon BC, 1999, NATURE, V402, P874, DOI 10.1038/47239; Shutler D, 1998, OIKOS, V82, P417, DOI 10.2307/3546363; Sundstrom L, 2000, P ROY SOC B-BIOL SCI, V267, P1439, DOI 10.1098/rspb.2000.1161; Sundstrom L, 1996, SCIENCE, V274, P993, DOI 10.1126/science.274.5289.993; SUNDSTROM L, 1994, NATURE, V367, P266, DOI 10.1038/367266a0; TAYLOR PD, 1981, NATURE, V291, P64, DOI 10.1038/291064a0; Tibayrenc M., 1995, Advances in Parasitology, V36, P47, DOI 10.1016/S0065-308X(08)60490-X; WERREN JH, 1984, AM NAT, V124, P143, DOI 10.1086/284259; West SA, 1997, J THEOR BIOL, V186, P213, DOI 10.1006/jtbi.1996.0369; West SA, 1998, EVOLUTION, V52, P475, DOI 10.1111/j.1558-5646.1998.tb01647.x; West SA, 2000, P ROY SOC B-BIOL SCI, V267, P257, DOI 10.1098/rspb.2000.0995	36	113	117	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 13	2000	290	5490					288	290		10.1126/science.290.5490.288	http://dx.doi.org/10.1126/science.290.5490.288			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	363CW	11183376				2022-12-28	WOS:000089818100033
J	Gilbody, SM; House, AO; Sheldon, TA				Gilbody, SM; House, AO; Sheldon, TA			Routinely administered questionnaires for depression and anxiety: systematic review	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; CLINICAL-TRIALS; PRIMARY-CARE; RECOGNITION; DISORDERS; ILLNESS	Objectives To examine the effect of routinely administered psychiatric questionnaires on the recognition, management, and outcome of psychiatric disorders in non-psychiatric settings. Data sources Embase, Medline, PsycLIT, Cinahl, Cochrane Controlled Trials Register,and hand searches of key journals. Methods A systematic review of randomised controlled trials of the administration and routine feedback of psychiatric screening and outcome questionnaires to clinicians in non-psychiatric settings. narrative overview of key design features and end points, together with a random effects quantitative synthesis of comparable studies. Main outcome measures Recognition of psychiatric disorders after feedback of questionnaire results; interventions for psychiatric disorders and outcome of psychiatric disorders. Results Nine randomised studies were identified that examined the use of common psychiatric instruments in primary care and general hospital settings. Studies compared the effect of the administration of these instruments followed by the feedback of the results to clinicians, with administration with no feedback. Meta-analytic pooling was possible for four of these studies (2457 participants), which measured the effect of feedback on the recognition of depressive disorders. Routine administration and feedback of scores for all patients (irrespective of score) did not increase the overall rate of recognition of mental disorders such as anxiety and depression (relative risk of detection of depression by clinician after feedback 0.95, 95% confidence interval 0.83 to 1.09). Two studies showed that routine administration followed by selective feedback for only high scores increased the rate of recognition of depression (relative risk of detection of depression after feedback 2.64, 1.62 to 4.31). This increased recognition, however, did not translate into an increased rate of intervention. Overall, studies of routine administration of psychiatric measures did not show an effect on patient outcome. Conclusions The routine measurement of outcome is a costly exercise. Little evidence shows that it is of benefit in improving psychosocial outcomes of those with psychiatric disorder managed in non-psychiatric settings.	Univ Leeds, Acad Unit Psychiat & Behav Sci, Leeds LS2 9LT, W Yorkshire, England; Univ York, NHS Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England; Univ York, Dept Hlth Studies, York YO10 5DD, N Yorkshire, England	University of Leeds; University of York - UK; University of York - UK	Gilbody, SM (corresponding author), Univ Leeds, Acad Unit Psychiat & Behav Sci, Leeds LS2 9LT, W Yorkshire, England.		Sheldon, Trevor/AAK-7088-2021; Gilbody, Simon/AAY-3720-2021; Gilbody, Simon/E-6543-2010	Sheldon, Trevor/0000-0002-7479-5913; Gilbody, Simon/0000-0002-8236-6983; House, Allan/0000-0001-8721-8026				BECK AT, 1987, BACK DEPRESSION INVE; Campbell MK, 1998, BMJ-BRIT MED J, V317, P1171, DOI 10.1136/bmj.317.7167.1171; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOWRICK C, 1995, BMJ-BRIT MED J, V311, P1274, DOI 10.1136/bmj.311.7015.1274; GERMAN PS, 1987, JAMA-J AM MED ASSOC, V257, P489, DOI 10.1001/jama.257.4.489; GOLDBERG D, 1986, BRIT MED J, V293, P1188, DOI 10.1136/bmj.293.6556.1188; Goldberg D., 1983, INT J REHABIL RES, V6, P127, DOI [10.1097/00004356-198303000-00021, DOI 10.1097/00004356-198303000-00021]; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; HOEPER EW, 1984, LANCET, V1, P33; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOHNSTONE A, 1976, LANCET, V1, P605, DOI 10.1016/S0140-6736(76)90415-3; Lewis G, 1996, FAM PRACT, V13, P120, DOI 10.1093/fampra/13.2.120; LINN LS, 1980, J MED EDUC, V55, P942; MAGRUDERHABIB K, 1990, MED CARE, V28, P239, DOI 10.1097/00005650-199003000-00004; MAZONSON PD, 1994, J AM BOARD FAM PRACT, V3, P336; MOORE JT, 1978, J FAM PRACTICE, V7, P509; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; THOMPSON C, 2000, LANCET, V355, P50; VANHEMERT AM, 1993, PSYCHOL MED, V23, P167, DOI 10.1017/S0033291700038952; WARE JF, 1998, SF 36 HLTH SURVEY MA; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; WRIGHT AF, 1994, BRIT J GEN PRACT, V44, P132; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	24	221	227	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	2001	322	7283					406	409		10.1136/bmj.322.7283.406	http://dx.doi.org/10.1136/bmj.322.7283.406			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	404JH	11179161	Green Accepted, Bronze, Green Published, Green Submitted			2022-12-28	WOS:000167093600028
J	Welliver, R; Monto, AS; Carewicz, O; Schatteman, E; Hassman, M; Hedrick, J; Jackson, HC; Huson, L; Ward, P; Oxford, JS				Welliver, R; Monto, AS; Carewicz, O; Schatteman, E; Hassman, M; Hedrick, J; Jackson, HC; Huson, L; Ward, P; Oxford, JS		Oseltamivir Post Exposure Prop	Effectiveness of oseltamivir in preventing influenza in household contacts - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEURAMINIDASE INHIBITOR OSELTAMIVIR; 1-ADAMANTANAMINE HYDROCHLORIDE; VIRUS INFECTIONS; A VIRUS; FAMILIES; DESIGN; TRANSMISSION; ZANAMIVIR; CHILDREN; MICE	Context Influenza virus is easily spread among the household contacts of an infected person, and prevention of influenza in household contacts can control spread of influenza in the community. Objective To investigate the efficacy of oseltamivir in preventing spread of influenza to household contacts of influenza-infected index cases (ICs). Design and Setting Randomized, double-blind, placebo-controlled study conducted at 76 centers in North America and Europe during the winter of 1998-1999. Participants Three hundred seventy-seven ICs, 163 (43 %) of whom had laboratory-confirmed influenza infection, and 955 household contacts (aged greater than or equal to 12 years) of all ICs (415 contacts of influenza-positive ICs). Interventions Household contacts were randomly assigned by household cluster to take 75 mg of oseltamivir (n=493) or placebo (n=462) once daily for 7 days within 48 hours of symptom onset in the IC. The ICs did not receive antiviral treatment. Main Outcome Measure Clinical influenza in contacts of influenza-positive ICs, confirmed in a laboratory by detection of virus shedding in nose and throat swabs or a 4-fold or greater increase in influenza-specific serum antibody titer between baseline and convalescent serum samples. Results In contacts of an influenza-positive IC, the overall protective efficacy of oseltamivir against clinical influenza was 89% for individuals (95% confidence interval [CI], 67%-97%; P<.001) and 84% for households (95% CI, 49%-95%; P<.001). In contacts of all ICs, oseltamivir also significantly reduced incidence of clinical influenza, with 89% protective efficacy (95% CI, 71%-96%; P<.001). Viral shedding was inhibited in contacts taking oseltamivir, with 84% protective efficacy (95% CI, 57%-95%; P<.001). All virus isolates from oseltamivir recipients retained sensitivity to the active metabolite. Oseltamivir was well tolerated; gastrointestinal tract effects were reported with similar frequency in oseltamivir (9.3 %) and placebo (7.2%) recipients. Conclusion In our sample, postexposure prophylaxis with oseltamivir, 75 mg once daily for 7 days, protected close contacts of influenza-infected persons against influenza illness, prevented outbreaks within households, and was well tolerated.	Childrens Hosp Buffalo, Buffalo, NY USA; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI USA; Comprehens Clin Res, Berlin, Germany; Kentucky Pediat & Adult Res, Bardstown, KY USA; Roche Global Dev, Welwyn Garden City, Herts, England; St Bartholomews & Royal London Hosp Sch Med & Den, London, England; Retroscreen Virol Ltd, London, England	University of Michigan System; University of Michigan; Roche Holding; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; University of London; Queen Mary University London	Oxford, JS (corresponding author), Med Bldg,327 Mile End Rd, London E1 4NS, England.	j.s.oxford@retroscreen.com		Ward, Penelope/0000-0002-7585-4313				[Anonymous], 1997, JAMA-J AM MED ASSOC, V277, P925; [Anonymous], [No title captured]; CLOVER RD, 1986, AM J DIS CHILD, V140, P706, DOI 10.1001/archpedi.1986.02140210104036; COVINGTON E, 2000, J CLIN VIROL, V18, P253; DEBOCK V, 2000, CLIN MICROBIOL INFEC, V6, P140; DEGELAU J, 1992, ARCH INTERN MED, V152, P390, DOI 10.1001/archinte.152.2.390; Donner A, 1998, J R STAT SOC C-APPL, V47, P95, DOI 10.1111/1467-9876.00100; FOX JP, 1982, AM J EPIDEMIOL, V116, P212, DOI 10.1093/oxfordjournals.aje.a113407; FOY HM, 1976, J INFECT DIS, V134, P362, DOI 10.1093/infdis/134.4.362; GALBRAIT.AW, 1969, B WORLD HEALTH ORGAN, V41, P677; GALBRAITH AW, 1969, LANCET, V2, P1026; Gubareva LV, 1998, J INFECT DIS, V178, P1257, DOI 10.1086/314440; Gubareva LV, 2000, LANCET, V355, P827, DOI 10.1016/S0140-6736(99)11433-8; Hayden FG, 2000, NEW ENGL J MED, V343, P1282, DOI 10.1056/NEJM200011023431801; HAYDEN FG, 1991, ANTIMICROB AGENTS CH, V35, P1741, DOI 10.1128/AAC.35.9.1741; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; HAYDEN FG, 1992, CURR TOP MICROBIOL, V176, P119; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; HAYDEN FG, 1981, ANTIMICROB AGENTS CH, V19, P226, DOI 10.1128/AAC.19.2.226; Hurwitz ES, 2000, JAMA-J AM MED ASSOC, V284, P1677, DOI 10.1001/jama.284.13.1677; Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t; LONGINI IM, 1982, AM J EPIDEMIOL, V115, P736, DOI 10.1093/oxfordjournals.aje.a113356; Mendel DB, 1998, ANTIMICROB AGENTS CH, V42, P640, DOI 10.1128/AAC.42.3.640; Sidwell RW, 1998, ANTIVIR RES, V37, P107, DOI 10.1016/S0166-3542(97)00065-X; STUARTHARRIS CH, 1985, INFLUENZA VIRUSES DI, P264; TABER LH, 1981, J HYG-CAMBRIDGE, V86, P303, DOI 10.1017/S0022172400069059; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; WHITLEY RJ, IN PRESS PEDIAT INFE; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92	30	303	328	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					748	754		10.1001/jama.285.6.748	http://dx.doi.org/10.1001/jama.285.6.748			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176912				2022-12-28	WOS:000166817200031
J	Cefalu, WT; Skyler, JS; Kourides, IA; Landschulz, WH; Balagtas, CC; Cheng, SL; Gelfand, RA				Cefalu, WT; Skyler, JS; Kourides, IA; Landschulz, WH; Balagtas, CC; Cheng, SL; Gelfand, RA		Inhaled Insulin Study Grp	Inhaled human insulin treatment in patients with type 2 diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							ABSORPTION; PEPTIDES; DELIVERY; PROTEINS	Background: Despite demonstrated benefits, intensive insulin therapy has not gained widespread clinical acceptance for several reasons: Multiple daily injections are inconvenient, adherence is a concern, and the time-activity profile may not mimic normal insulin secretion, As such, alternate means of administering insulin are being evaluated. Objective: To assess the efficacy and safety of pulmonary delivery of insulin in type 2 diabetic patients who require insulin. Design: Randomized, open-label, 3-month study consisting of a screening visit, a 4-week baseline lead-in phase, and a 12-week treatment phase. Setting: General clinical research center and outpatient research clinics. Patients: 26 patients (16 men, 10 women) with type 2 diabetes (average age, 51.1 years; average duration of diabetes, 11.2 years). Intervention: Patients received inhaled insulin before each meal plus a bedtime injection of ultralente insulin, performed home glucose monitoring, and had weekly adjustment of insulin dose; target level for preprandial plasma glucose was 5.55 to 8.88 mmol/L (100 to 160 mg/dL). Measurements: Glycemic control (hemoglobin A,. level) obtained at baseline and monthly for 3 months, Pulmonary function tests were done at baseline and at the end of the study. Results: Inhaled insulin treatment for 3 months significantly improved glycemic control compared with baseline: Mean hemoglobin A(1c) levels decreased by 0.0071 +/- 0.0072 (0.71% +/- 0.72%). Patients experienced an average of 0.83 mild to moderate hypoglycemic event per month; no severe events were recorded, Patients showed no significant weight gain or change in pulmonary function compared with baseline. Conclusions: Pulmonary delivery of insulin in type 2 diabetic patients who require insulin improved glycemic control, was well tolerated, and demonstrated no adverse pulmonary effects. Larger-scale studies are ongoing to provide long-term efficacy and safety data.	Pfizer Inc, Pfizer Cent Res, Groton, CT 06340 USA; Univ Miami, Med Ctr, Miami, FL 33152 USA; Univ Vermont, Coll Med, Burlington, VT USA	Pfizer; University of Miami; University of Vermont	Cefalu, WT (corresponding author), Univ Vermont, Coll Med, UHC Campus,Arnold 3433,1 S Prospect St, Burlington, VT 05401 USA.		Skyler, Jay S/F-4211-2016	Skyler, Jay/0000-0003-1136-8110				BENSCH KG, 1967, SCIENCE, V157, P1204, DOI 10.1126/science.157.3793.1204; Dahl-Jorgensen K, 1999, ACTA PAEDIATR, V88, P25, DOI 10.1111/j.1651-2227.1999.tb14336.x; EDSBERG B, 1987, BRIT MED J, V294, P1373, DOI 10.1136/bmj.294.6584.1373; Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868; GALLOWAY JA, 1981, DIABETES CARE, V4, P366, DOI 10.2337/diacare.4.3.366; Heinemann L, 1997, DIABETIC MED, V14, P63, DOI 10.1002/(SICI)1096-9136(199701)14:1<63::AID-DIA298>3.3.CO;2-6; Koivisto VA, 1998, ANN MED, V30, P260, DOI 10.3109/07853899809005853; LAUBE BL, 1993, JAMA-J AM MED ASSOC, V269, P2106, DOI 10.1001/jama.269.16.2106; Laube BL, 1998, CHEST, V114, P1734, DOI 10.1378/chest.114.6.1734; LAUBE BL, 1992, J BIOPHARM SCI, V3, P163; PATTON JS, 1994, J CONTROL RELEASE, V28, P79, DOI 10.1016/0168-3659(94)90155-4; PATTON JS, 1992, ADV DRUG DELIVER REV, V8, P179, DOI 10.1016/0169-409X(92)90002-8; Saudek CD, 1997, ENDOCRIN METAB CLIN, V26, P599, DOI 10.1016/S0889-8529(05)70269-3; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WIGLEY FM, 1971, DIABETES, V20, P552, DOI 10.2337/diab.20.8.552; ZIEL FH, 1987, CLIN RES, V35, pA160	17	142	179	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2001	134	3					203	207		10.7326/0003-4819-134-3-200102060-00011	http://dx.doi.org/10.7326/0003-4819-134-3-200102060-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397KR	11177333				2022-12-28	WOS:000166695300004
J	Dohoney, KM; Gelles, J				Dohoney, KM; Gelles, J			chi-Sequence recognition and DNA translocation by single RecBCD helicase/nuclease molecules	NATURE			English	Article							RECOMBINATION HOTSPOT-CHI; ESCHERICHIA-COLI; RECD SUBUNIT; RNA-POLYMERASE; HOMOLOGOUS RECOMBINATION; HELICASE ACTIVITY; ENZYME; KINESIN; ATP; DEOXYRIBONUCLEASE	Major pathways of recombinational DNA repair in Escherichia coli require the RecBCD protein-a heterotrimeric, ATP-driven, DNA translocating motor enzyme. RecBCD combines a highly processive and exceptionally fast helicase (DNA-unwinding) activity with a strand-specific nuclease (DNA-cleaving) activity (refs 1, 2 and references therein). Recognition of the DNA sequence 'chi' (5'-GCTGGTGG-3') switches the polarity of DNA cleavage and stimulates recombination at nearby sequences in vivo. Here we attach microscopic polystyrene beads to biotin-tagged RecD protein subunits and use tethered-particle light microscopy to observe translocation of single RecBCD molecules (with a precision of up to similar to 30 nm at 2 Hz) and to examine the mechanism by which chi modifies enzyme activity. Observed translocation is unidirectional, with each molecule moving at a constant velocity corresponding to the population-average DNA unwinding rate. These observations place strong constraints on possible movement mechanisms. Bead release at chi is negligible, showing that the activity modification at chi does not require ejection of the RecD subunit from the enzyme as previously proposed; modification may occur through an unusual, pure conformational switch mechanism.	Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA	Brandeis University	Gelles, J (corresponding author), Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA.							Anderson DG, 1999, J BIOL CHEM, V274, P27139, DOI 10.1074/jbc.274.38.27139; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FINZI L, 1995, SCIENCE, V267, P378, DOI 10.1126/science.7824935; Gelles J, 1998, CELL, V93, P13, DOI 10.1016/S0092-8674(00)81140-X; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; KOPPEN A, 1995, P NATL ACAD SCI USA, V92, P6249, DOI 10.1073/pnas.92.14.6249; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LOVETT ST, 1988, GENETICS, V120, P37; MYERS RS, 1995, P NATL ACAD SCI USA, V92, P6244, DOI 10.1073/pnas.92.14.6244; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; STAHL FW, 1990, GENETICS, V126, P519; STAHL FW, 1993, GENETICS, V135, P1232; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; Taylor AF, 1999, GENE DEV, V13, P890, DOI 10.1101/gad.13.7.890; TAYLOR AF, 1995, J BIOL CHEM, V270, P24459, DOI 10.1074/jbc.270.41.24459; Thaler D.S., 1988, MECH CONSEQUENCES DN, P413; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0; YOUNG EC, 1995, J BIOL CHEM, V270, P3926, DOI 10.1074/jbc.270.8.3926	31	109	110	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					370	374		10.1038/35053124	http://dx.doi.org/10.1038/35053124			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201749				2022-12-28	WOS:000166434300054
J	Irie-Sasaki, J; Sasaki, T; Matsumoto, W; Opavsky, A; Cheng, M; Welstead, G; Griffiths, E; Krawczyk, C; Richardson, CD; Aitken, K; Iscove, N; Koretzky, G; Johnson, P; Liu, P; Rothstein, DM; Penninger, JM				Irie-Sasaki, J; Sasaki, T; Matsumoto, W; Opavsky, A; Cheng, M; Welstead, G; Griffiths, E; Krawczyk, C; Richardson, CD; Aitken, K; Iscove, N; Koretzky, G; Johnson, P; Liu, P; Rothstein, DM; Penninger, JM			CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling	NATURE			English	Article							CELL MATURATION; ACTIVATION; FAMILY; MICE; INTERFERON; DEFICIENT; STATS	The regulation of tyrosine phosphorylation and associated signalling through antigen, growth-factor and cytokine receptors is mediated by the reciprocal activities of protein tyrosine kinases and protein tyrosine phosphatases (PTPases)(1). The transmembrane PTPase CD45 is a key regulator of antigen receptor signalling in T and B cells(2,3). Src-family kinases have been identified as primary molecular targets for CD45 (ref. 4). However, CD45 is highly expressed in all haematopoietic lineages at all stages of development(5), indicating that CD45 could regulate other cell types and might act on additional substrates. Here we show that CD45 suppresses JAK (Janus kinase) kinases and negatively regulates cytokine receptor signalling. Targeted disruption of the cd45 gene leads to enhanced cytokine and interferon-receptor-mediated activation of JAKs and STAT (signal transducer and activators of transcription) proteins. In vitro, CD45 directly dephosphorylates and binds to JAKs. Functionally, CD45 negatively regulates interleukin-3-mediated cellular proliferation, erythropoietin-dependent haematopoieisis and antiviral responses in vitro and in vivo. Our data identify an unexpected and novel function for CD45 as a haematopoietic JAK phosphatase that negatively regulates cytokine receptor signalling.	Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06529 USA; Univ Toronto, Univ Hlth Network, Lewar Ctr Excellence Cardiovasc Res, Toronto, ON M5G 2C4, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Immunol, Vancouver, BC V6T 1Z3, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Yale University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Pennsylvania; University of British Columbia; University of British Columbia	Sasaki, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Johnson, Pauline/G-9659-2019; Koretzky, Gary/AAU-5381-2021; Aitken, KJ/AAC-5383-2019; Penninger, Josef M/I-6860-2013	Johnson, Pauline/0000-0001-7367-4653; Penninger, Josef M/0000-0002-8194-3777; Sasaki, Takehiko/0000-0003-1837-3748; Aitken, Karen/0000-0003-2995-0205				Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KANDOLF R, 1985, J MOL CELL CARDIOL, V17, P167, DOI 10.1016/S0022-2828(85)80019-5; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kung C, 2000, NAT MED, V6, P343; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MCKENNEY DW, 1995, J BIOL CHEM, V270, P24949, DOI 10.1074/jbc.270.42.24949; Ozdemirli M, 1996, CANCER, V77, P79, DOI 10.1002/(SICI)1097-0142(19960101)77:1<79::AID-CNCR14>3.0.CO;2-5; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; Ratei R, 1998, ANN HEMATOL, V77, P107, DOI 10.1007/s002770050424; Ren JM, 1998, DIABETES, V47, P493, DOI 10.2337/diabetes.47.3.493; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Saad MJA, 1996, J BIOL CHEM, V271, P22100, DOI 10.1074/jbc.271.36.22100; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Ward AC, 2000, BLOOD, V95, P19; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309	27	423	450	1	26	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					349	354		10.1038/35053086	http://dx.doi.org/10.1038/35053086			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201744				2022-12-28	WOS:000166434300049
J	Rosser, WW				Rosser, WW			Aspirin for primary prevention of cardiovascular events	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; GENERAL-PRACTICE		Univ Toronto, Fac Med, Dept Family & Community Med, Toronto, ON M5G 2C1, Canada	University of Toronto	Rosser, WW (corresponding author), Univ Toronto, Fac Med, Dept Family & Community Med, Toronto, ON M5G 2C1, Canada.							Fahey T, 1998, BRIT J GEN PRACT, V48, P1173; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Meade TW, 2000, BMJ-BRIT MED J, V321, P13, DOI 10.1136/bmj.321.7252.13; PRINGLE M, 1995, BRIT MED J, V311, P1382, DOI 10.1136/bmj.311.7017.1382; Rosser WW, 1999, LANCET, V353, P661, DOI 10.1016/S0140-6736(98)09103-X; ROSSER WW, 1998, EVIDENCE BASED FAMIL, P81; VANWEEL C, 1996, EUR J GEN PRACT, V2, P17; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302	8	10	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					84	85		10.1016/S0140-6736(00)03534-0	http://dx.doi.org/10.1016/S0140-6736(00)03534-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197440				2022-12-28	WOS:000166476200004
J	Butko, VY; Adams, PW				Butko, VY; Adams, PW			Quantum metallicity in a two-dimensional insulator	NATURE			English	Article							TRANSITION; FILM	One of the most far-reaching problems in condensed-matter physics is to understand how interactions between electrons, and the resulting correlations, affect the electronic properties of disordered two-dimensional systems. Extensive experimental (1-6) and theoretical (7-11) studies have shown that interaction effects are enhanced by disorder, and that this generally results in a depletion of the density of electronic states. In the limit of strong disorder, this depletion takes the form of a complete gap(12,13) in the density of states. It is known that this `Coulomb gap' can turn a pure metal film that is highly disordered into a poorly conducting insulator(14), but the properties of these insulators are not well understood. Here we investigate the electronic properties of disordered beryllium films, with the aim of disentangling the effects of the Coulomb gap and the underlying disorder. We show that the gap is suppressed by a magnetic field and that this drives the strongly insulating beryllium films into a low-temperature `quantum metal' phase with resistance near the quantum resistance R-Q = h/e(2), where h is Planck's constant and e is the electron charge.	Louisiana State Univ, Dept Phys & Astron, Baton Rouge, LA 70803 USA; Russian Acad Sci, AF Ioffe Phys Tech Inst, St Petersburg 194021, Russia	Louisiana State University System; Louisiana State University; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Ioffe Physical Technical Institute	Adams, PW (corresponding author), Louisiana State Univ, Dept Phys & Astron, Baton Rouge, LA 70803 USA.	adams@rouge.phys.lsu.edu						Adams PW, 1998, PHYS REV B, V58, pR2952, DOI 10.1103/PhysRevB.58.R2952; Al'tshuler BL, 1987, SOV SCI REV A, V9, P223; ANDO T, 1982, REV MOD PHYS, V54, P437, DOI 10.1103/RevModPhys.54.437; BELITZ D, 1994, REV MOD PHYS, V66, P261, DOI 10.1103/RevModPhys.66.261; BISHOP DJ, 1982, PHYS REV B, V26, P773, DOI 10.1103/PhysRevB.26.773; Butko VY, 2000, PHYS REV LETT, V84, P1543, DOI 10.1103/PhysRevLett.84.1543; Butko VY, 2000, PHYS REV LETT, V85, P162, DOI 10.1103/PhysRevLett.85.162; GERSHENZON ME, 1985, JETP LETT+, V41, P534; HSU SY, 1994, PHYS REV B, V49, P16600, DOI 10.1103/PhysRevB.49.16600; IMRY Y, 1982, PHYS REV LETT, V49, P841, DOI 10.1103/PhysRevLett.49.841; LEE PA, 1985, REV MOD PHYS, V57, P287, DOI 10.1103/RevModPhys.57.287; Massey JG, 1996, PHYS REV LETT, V77, P3399, DOI 10.1103/PhysRevLett.77.3399; NISSIM M, 1989, PHYS REV B, V40, P6351, DOI 10.1103/PhysRevB.40.6351; Pastor AA, 1999, PHYS REV LETT, V83, P4642, DOI 10.1103/PhysRevLett.83.4642; Sarma Sankar Das, 1997, PERSPECTIVES QUANTUM; Shklovskii B.I., 1984, ELECT PROPERTIES DOP, P202; SOOD BR, 1982, PHYS REV B, V25, P6064, DOI 10.1103/PhysRevB.25.6064; TINKAM M, 1986, INTRO SUPERCONDUCTIV; Vaknin A, 1998, PHYS REV LETT, V81, P669, DOI 10.1103/PhysRevLett.81.669	20	50	51	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					161	164		10.1038/35051516	http://dx.doi.org/10.1038/35051516			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196633				2022-12-28	WOS:000166316200035
J	Cohen, EP				Cohen, EP			Renal failure after bone-marrow transplantation	LANCET			English	Editorial Material							HEMOLYTIC-UREMIC SYNDROME; TOTAL-BODY IRRADIATION		Med Coll Wisconsin, Div Nephrol, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Cohen, EP (corresponding author), Med Coll Wisconsin, Div Nephrol, Milwaukee, WI 53226 USA.							Burnet N G, 1996, Clin Oncol (R Coll Radiol), V8, P25, DOI 10.1016/S0936-6555(05)80035-4; CHAPPELL ME, 1988, BONE MARROW TRANSPL, V3, P339; Cohen EP, 2000, KIDNEY INT, V58, P903, DOI 10.1046/j.1523-1755.2000.00241.x; Imai H, 2000, AM J KIDNEY DIS, V36, P474, DOI 10.1053/ajkd.2000.9787; JUCKETT MB, IN PRESS BONE MARROW; LUXTON RW, 1953, Q J MED, V22, P215; Miralbell R, 1996, J CLIN ONCOL, V14, P579, DOI 10.1200/JCO.1996.14.2.579; *NAT I DIAB DIG KI, 1999, US REN DAT SYST 1999; SARODE R, 1995, BONE MARROW TRANSPL, V16, P271; SHULMAN H, 1981, NEW ENGL J MED, V305, P1392, DOI 10.1056/NEJM198112033052306; Socie G, 1999, NEW ENGL J MED, V341, P14, DOI 10.1056/NEJM199907013410103; Taskinen M, 2000, LANCET, V356, P993, DOI 10.1016/S0140-6736(00)02717-3; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; ZAGER RA, 1994, KIDNEY INT, V46, P1443, DOI 10.1038/ki.1994.417	15	56	58	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					6	7		10.1016/S0140-6736(00)03561-3	http://dx.doi.org/10.1016/S0140-6736(00)03561-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197374				2022-12-28	WOS:000166341500005
J	James, WPT; Astrup, A; Finer, N; Hilsted, J; Kopelman, P; Rossner, S; Saris, WHM; Van Gaal, LF				James, WPT; Astrup, A; Finer, N; Hilsted, J; Kopelman, P; Rossner, S; Saris, WHM; Van Gaal, LF		STORM Study Grp	Effect of sibutramine on weight maintenance after weight loss: a randomised trial	LANCET			English	Article							DISEASE; METAANALYSIS; CHOLESTEROL; PREVENTION; OBESITY	Background Sibutramine is a tertiary amine that has been shown to induce dose-dependent weight loss and to enhance the effects of a low-calorie diet for up to a year. We did a randomised, double-blind trial to assess the usefulness of sibutramine in maintaining substantial weight loss over 2 years. Methods Eight European centres recruited 605 obese patients (body-mass index 30-45 kg/m(2)) for a 6-month period of weight loss with sibutramine (10 mg/day) and an individualised 600 kcal/day deficit programme based on measured resting metabolic rates. 467 (77%) patients with more than 5% weight toss were then randomly assigned 10 mg/day sibutramine (n=352) or placebo (n=115) for a further 18 months. Sibutramine was increased up to 20 mg/day if weight regain occurred. The primary outcome measure was the number of patients at year 2 maintaining at least 80% of the weight lost between baseline and month 6. Secondary outcomes included changes in uric acid concentrations and glycaemic and lipid variables. Analysis was by intention to treat. Findings 148 (42%) individuals in the sibutramine group and 58 (50%) in the placebo group dropped out. Of the 204 sibutramine-treated individuals who completed the trial, 89 (43%) maintained 80% or more of their original weight loss, compared with nine (16%) of the 57 individuals in the placebo group (odds ratio 4 . 64, p<0<bullet>001). Patients had substantial decreases over the first 6 months with respect to triglycerides, VLDL cholesterol, insulin, C peptide, and uric acid; these changes were sustained in the sibutramine group but not the placebo group. HDL cholesterol concentrations rose substantially in the second year: overall increases were 20 .7% (sibutramine) and 11 .7% (placebo, p<0<bullet>001). 20 (3%) patients were withdrawn because of increases in blood pressure;in the sibutramine group, systolic blood pressure rose from baseline to 2 years by 0 .1 mm Hg (SD 12 .9), diastolic blood pressure by 2 .3 mm Hg (9 .4), and pulse rate by 4 .1 beats/min (11 .9). Interpretation This individualised management programme achieved weight loss in 77% of obese patients and sustained weight loss in most patients continuing therapy for 2 years. Changes in concentrations of HDL cholesterol, VLDL cholesterol, and triglyceride, but not LDL cholesterol, exceed those expected either from weight loss alone or when induced by other selective therapies for tow concentrations of HDL cholesterol relating to coronary heart disease.	Rowett Res Inst, Aberdeen, Scotland; Royal Vet & Agr Univ, Res Dept Human Nutr, Copenhagen, Denmark; Luton & Dunstable Hosp, Obes Res Ctr, Luton, Beds, England; Univ Copenhagen, Hvidovre Hosp, DK-2650 Hvidovre, Denmark; Royal London Hosp, Directorate Diabet & Metab, London E1 1BB, England; Huddinge Univ Hosp, Obes Unit, S-14186 Huddinge, Sweden; Rijksunnersiteit Limburg, Nutr Res Ctr, Limburgerhof, Germany; Univ Antwerp Hosp, Dept Endocrinol, Antwerp, Belgium	University of Aberdeen; University of Copenhagen; University of Copenhagen; Barts Health NHS Trust; Royal London Hospital; Karolinska Institutet; University of Antwerp	James, WPT (corresponding author), Int Obes TaskForce, 231 N Gower St, London NW1 2NS, England.	JeanHJames@aal.com	Finer, Nicholas/B-9981-2009	Finer, Nicholas/0000-0003-2468-6804				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Apfelbaum M, 1999, AM J MED, V106, P179, DOI 10.1016/S0002-9343(98)00411-2; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Bray GA, 1999, OBES RES, V7, P189, DOI 10.1002/j.1550-8528.1999.tb00701.x; CONOVER WJ, 1982, BIOMETRICS, V38, P715, DOI 10.2307/2530051; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; Hansen DL, 1999, INT J OBESITY, V23, P1016, DOI 10.1038/sj.ijo.0801059; HODGE AM, 1994, BAILLIERE CLIN ENDOC, V8, P577, DOI 10.1016/S0950-351X(05)80287-3; Lauterbach K. W., 2000, International Journal of Obesity, V24, pS99; LEAN MEJ, 1986, LANCET, V1, P723; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; Organization WH, 1998, WELLB MEAS PRIM HLTH; Packard CJ, 1997, ARTERIOSCL THROM VAS, V17, P3542, DOI 10.1161/01.ATV.17.12.3542; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Seidell JC, 1999, PROG OBES R, P661; *WHO, 1990, WHO TECH REP SER, V797; Yu-Poth S, 1999, AM J CLIN NUTR, V69, P632; [No title captured]	19	566	594	2	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2119	2125		10.1016/S0140-6736(00)03491-7	http://dx.doi.org/10.1016/S0140-6736(00)03491-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191537				2022-12-28	WOS:000165997300009
J	Fine, P				Fine, P			Commentary: An unexpected finding that needs confirmation or rejection	BRITISH MEDICAL JOURNAL			English	Editorial Material							IMMUNIZATION; MORTALITY		Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Fine, P (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.							AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; ABY P, 2000, CLIN EXP IMMUNOL, V30, P644; FINE PEM, 1986, AM J EPIDEMIOL, V124, P112; HOBCRAFT JN, 1985, POP STUD-J DEMOG, V39, P363, DOI 10.1080/0032472031000141576; Power CA, 1998, INFECT IMMUN, V66, P5743, DOI 10.1128/IAI.66.12.5743-5750.1998; Strachan DP, 1999, LANCET, V353, P1457, DOI 10.1016/S0140-6736(99)90038-7	6	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	2000	321	7274					1439	1439						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382XH	11187939				2022-12-28	WOS:000165852300024
J	Oliver, RTD				Oliver, RTD			Management of women with early breast cancer - New strategies are needed to address inequalities	BRITISH MEDICAL JOURNAL			English	Letter									St Bartholomews Hosp, London EC1A 7BE, England	University of London; Queen Mary University London	Oliver, RTD (corresponding author), St Bartholomews Hosp, London EC1A 7BE, England.							HUNTER DJ, 1993, NEW ENGL J MED, V329, P234, DOI 10.1056/NEJM199307223290403; MACLEOD U, 2000, MACLEOD BMJ, V320, P1442; SCHRIJVERS CTM, 1995, BRIT J CANCER, V72, P738, DOI 10.1038/bjc.1995.403	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	2000	321	7273					1409	1409						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380TT	11187092				2022-12-28	WOS:000165720100045
J	Murthy, RS				Murthy, RS			Reaching the unreached	LANCET			English	Article									WHO, Dept Mental Hlth & Subst Dependence, CH-1204 Geneva, Switzerland; Natl Inst Mental Hlth & Neurosci, Bangalore, Karnataka, India	World Health Organization; National Institute of Mental Health & Neurosciences - India	Murthy, RS (corresponding author), WHO, Dept Mental Hlth & Subst Dependence, CH-1204 Geneva, Switzerland.								0	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S39	S39		10.1016/S0140-6736(00)92025-7	http://dx.doi.org/10.1016/S0140-6736(00)92025-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191496				2022-12-28	WOS:000166074900041
J	Block, GD; Aulisio, MP				Block, GD; Aulisio, MP			Will genetics revolutionize medicine?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; Case Western Reserve Univ, Ctr Biomed Eth, Cleveland, OH 44109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Case Western Reserve University	Block, GD (corresponding author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1496	1496						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184468				2022-12-28	WOS:000165271300024
J	Davidson, SJ; Murphy, DG				Davidson, SJ; Murphy, DG			Missed diagnoses of acute cardiac ischemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Maimonides Hosp, Brooklyn, NY 11219 USA	Maimonides Medical Center	Davidson, SJ (corresponding author), Maimonides Hosp, Brooklyn, NY 11219 USA.			Soldini, Maurizio/0000-0002-4593-1664				EPSTEIN A, 1997, FORUM, P17; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Mehta RH, 2000, NEW ENGL J MED, V342, P1207, DOI 10.1056/NEJM200004203421610; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603	4	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1492	1492						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184459				2022-12-28	WOS:000165271300012
J	Read, AF; Allen, JE				Read, AF; Allen, JE			Evolution and immunology - The economics of immunity	SCIENCE			English	Editorial Material							TRADE-OFFS; RESISTANCE		Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Read, AF (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.		Allen, Judith E/C-9198-2011	Allen, Judith E/0000-0002-3829-066X				BEHNKE JM, 1992, INT J PARASITOL, V22, P861, DOI 10.1016/0020-7519(92)90046-N; BOOTS M, 1993, FUNCT ECOL, V7, P528, DOI 10.2307/2390128; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Ilmonen P, 2000, P ROY SOC B-BIOL SCI, V267, P665, DOI 10.1098/rspb.2000.1053; JARMAN PJ, 1989, BIOL J LINN SOC, V36, P169, DOI 10.1111/j.1095-8312.1989.tb00489.x; Kraaijeveld AR, 1997, NATURE, V389, P278, DOI 10.1038/38483; Laird DJ, 2000, P NATL ACAD SCI USA, V97, P6924, DOI 10.1073/pnas.97.13.6924; Lochmiller RL, 2000, OIKOS, V88, P87, DOI 10.1034/j.1600-0706.2000.880110.x; Lockhart AB, 1996, BIOL REV, V71, P415, DOI 10.1111/j.1469-185X.1996.tb01281.x; Moller AP, 1998, J EVOLUTION BIOL, V11, P703, DOI 10.1007/s000360050114; Moret Y, 2000, SCIENCE, V290, P1166, DOI 10.1126/science.290.5494.1166; Nunn CL, 2000, SCIENCE, V290, P1168, DOI 10.1126/science.290.5494.1168; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; Sheldon BC, 1996, TRENDS ECOL EVOL, V11, P317, DOI 10.1016/0169-5347(96)10039-2; TOLLRIAN R, 1999, ECOLOGY EVOLUTION IN; Webster JP, 1999, P ROY SOC B-BIOL SCI, V266, P391, DOI 10.1098/rspb.1999.0650; Yan G, 1997, EVOLUTION, V51, P441, DOI [10.2307/2411116, 10.1111/j.1558-5646.1997.tb02431.x]	17	58	58	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 10	2000	290	5494					1104	1105		10.1126/science.290.5494.1104	http://dx.doi.org/10.1126/science.290.5494.1104			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11185007				2022-12-28	WOS:000165228200031
J	Catania, JA; Morin, SF; Canchola, J; Pollack, L; Chang, J; Coates, TJ				Catania, JA; Morin, SF; Canchola, J; Pollack, L; Chang, J; Coates, TJ			Health care policy - US priorities - HIV prevention	SCIENCE			English	Editorial Material							SAN-FRANCISCO; UNITED-STATES; PREVALENCE; AMEN; AIDS		Univ Calif San Francisco, AIDS Res Inst, Ctr AIDS Prevent Studies, San Francisco, CA 94105 USA	University of California System; University of California San Francisco	Catania, JA (corresponding author), Univ Calif San Francisco, AIDS Res Inst, Ctr AIDS Prevent Studies, San Francisco, CA 94105 USA.				NIMH NIH HHS [MH42459, MH43892, MH51523] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051523, P50MH042459, R01MH043892] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1993, METHODOLOGICAL ISSUE; Blair J, 1999, J SEX RES, V36, P39, DOI 10.1080/00224499909551965; CATANIA J, IN PRESS AM J PUBL H; CATANIA JA, 1993, J SEX RES, V30, P121, DOI 10.1080/00224499309551691; Cates W, 1999, SEX TRANSM DIS, V26, pS2, DOI 10.1097/00007435-199904001-00002; *CDCP, 1999, HIV AIDS SURVEILL RE, V11, P33; Chesson HW, 1999, AIDS, V13, P1387, DOI 10.1097/00002030-199907300-00017; Des Jarlais DC, 2000, AM J PUBLIC HEALTH, V90, P352, DOI 10.2105/AJPH.90.3.352; FULLILOVE MT, 1992, WESTERN J MED, V157, P32; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; Kaplan EH, 1998, HDB EC EVALUATION HI, P177; McFarland W, 1999, J ACQ IMMUN DEF SYND, V22, P484; OSMOND D, 1998, 12 WORLD AIDS C GEN; Osmond DH, 2000, J ACQ IMMUN DEF SYND, V24, P363; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911; 1999, MORB MORTAL WKLY REP, V48, P873; 1996, MORB MORTAL WKLY REP, V46, P861	18	16	16	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 27	2000	290	5492					717	717		10.1126/science.290.5492.717	http://dx.doi.org/10.1126/science.290.5492.717			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	367ND	11184201				2022-12-28	WOS:000090067600024
J	Olson, L				Olson, L			Biomedicine - Combating Parkinson's disease - Step three	SCIENCE			English	Editorial Material									Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden	Karolinska Institutet	Olson, L (corresponding author), Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden.							BJORKLUND A, 1979, BRAIN RES, V177, P555, DOI 10.1016/0006-8993(79)90472-4; Braak H, 2000, J NEUROL, V247, P3; Brundin P, 2000, BRAIN, V123, P1380, DOI 10.1093/brain/123.7.1380; Buervenich S, 2000, MOVEMENT DISORD, V15, P813, DOI 10.1002/1531-8257(200009)15:5<813::AID-MDS1008>3.0.CO;2-Y; CARLSSON A, 1957, NATURE, V180, P1200, DOI 10.1038/1801200a0; Hottinger AF, 2000, J NEUROSCI, V20, P5587, DOI 10.1523/JNEUROSCI.20-15-05587.2000; Kafri T, 2000, MOL THER, V1, P516, DOI 10.1006/mthe.2000.0083; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Olson L, 1996, NAT MED, V2, P400, DOI 10.1038/nm0496-400; Parkinson J, 1817, ESSAY SHAKING PALSY; PERLOW MJ, 1979, SCIENCE, V204, P643, DOI 10.1126/science.571147; Riess O, 2000, J NEUROL, V247, P69; Trono D, 2000, GENE THER, V7, P20, DOI 10.1038/sj.gt.3301105	15	12	12	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 27	2000	290	5492					721	+		10.1126/science.290.5492.721	http://dx.doi.org/10.1126/science.290.5492.721			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ND	11184202				2022-12-28	WOS:000090067600028
J	Buchman, AL				Buchman, AL			Who is a peer?	ANNALS OF INTERNAL MEDICINE			English	Letter									Northwestern Univ, Sch Med, Chicago, IL 60611 USA	Northwestern University	Buchman, AL (corresponding author), Northwestern Univ, Sch Med, Chicago, IL 60611 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					346	347		10.7326/0003-4819-134-4-200102200-00031	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00031			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NW	11182858				2022-12-28	WOS:000167050200022
J	Illi, S; von Mutius, E; Lau, S; Bergmann, R; Niggemann, B; Sommerfeld, C; Wahn, U				Illi, S; von Mutius, E; Lau, S; Bergmann, R; Niggemann, B; Sommerfeld, C; Wahn, U		MAS Grp	Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYNCYTIAL VIRUS; FAMILY-SIZE; EARLY-LIFE; ATOPY; ASSOCIATION; REACTIVITY; ANTIBODIES; RISK	Objective To investigate the association between early childhood infections and subsequent development of asthma. Design Longitudinal birth cohort study. Setting Five children's hospitals in five German cities. Participants 1314 children born in 1990 followed from birth to the age of 7 years. Main outcome measures Asthma and asthmatic symptoms assessed longitudinally by parental questionnaires; atopic sensitisation assessed longitudinally by determination of IgE, concentrations to various allergens; bronchial hyperreactivity assessed by bronchial histamine challenge at age 7 years. Results Compared with children with less than or equal to1 episode of runny nose before the age of 1 year, those with greater than or equal to2 episodes were less likely to have a doctor's diagnosis of asthma at 7 years old (odds ratio 0.52 (95% confidence interval 0.29 to 0.92)) or to have wheeze at 7 years old (0.60 (0.38 to 0.94)), and were less likely to be atopic before the age of 5 years. Similarly, having greater than or equal to1 viral infection of the herpes type in the first 3 years of life was inversely associated wit asthma at age 7 (odds ratio 0.48 (0.26 to 0.89)). Repeated lower respiratory tract infections in the first 3 years of life showed a positive association with wheeze up to the age of 7 years (odds ratio 3.37 (1.92 to 5.92) for greater than or equal to4 infections v less than or equal to3 infections). Conclusions Repeated viral infections other than lower respiratory tract infections early in life may reduce the risk of developing asthma up to school age.	Univ Childrens Hosp, Dept Pulm & Allergol, D-80337 Munich, Germany; Humboldt Univ, Charite, Dept Paediat Pneumol & Immunol, D-13353 Berlin, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Illi, S (corresponding author), Univ Childrens Hosp, Dept Pulm & Allergol, Lindwurmstr 4, D-80337 Munich, Germany.	sabina.illi@kk-i.med.uni-muenchen.de		von Mutius, Erika/0000-0002-8893-4515				Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; NIGGEMANN B, IN PRESS EUR RESP J; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; SIGURS N, 1995, PEDIATRICS, V95, P500; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WHITLEY RJ, 1990, VIROLOGY, P1849; WIDTMAN V, 1982, DOCUMENTA PADIAT, V2	18	396	410	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	2001	322	7283					390	395		10.1136/bmj.322.7283.390	http://dx.doi.org/10.1136/bmj.322.7283.390			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404JH	11179155	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000167093600023
J	Venter, JC; Adams, MD; Myers, EW; Li, PW; Mural, RJ; Sutton, GG; Smith, HO; Yandell, M; Evans, CA; Holt, RA; Gocayne, JD; Amanatides, P; Ballew, RM; Huson, DH; Wortman, JR; Zhang, Q; Kodira, CD; Zheng, XQH; Chen, L; Skupski, M; Subramanian, G; Thomas, PD; Zhang, JH; Miklos, GLG; Nelson, C; Broder, S; Clark, AG; Nadeau, C; McKusick, VA; Zinder, N; Levine, AJ; Roberts, RJ; Simon, M; Slayman, C; Hunkapiller, M; Bolanos, R; Delcher, A; Dew, I; Fasulo, D; Flanigan, M; Florea, L; Halpern, A; Hannenhalli, S; Kravitz, S; Levy, S; Mobarry, C; Reinert, K; Remington, K; Abu-Threideh, J; Beasley, E; Biddick, K; Bonazzi, V; Brandon, R; Cargill, M; Chandramouliswaran, I; Charlab, R; Chaturvedi, K; Deng, ZM; Di Francesco, V; Dunn, P; Eilbeck, K; Evangelista, C; Gabrielian, AE; Gan, W; Ge, WM; Gong, FC; Gu, ZP; Guan, P; Heiman, TJ; Higgins, ME; Ji, RR; Ke, ZX; Ketchum, KA; Lai, ZW; Lei, YD; Li, ZY; Li, JY; Liang, Y; Lin, XY; Lu, F; Merkulov, GV; Milshina, N; Moore, HM; Naik, AK; Narayan, VA; Neelam, B; Nusskern, D; Rusch, DB; Salzberg, S; Shao, W; Shue, BX; Sun, JT; Wang, ZY; Wang, AH; Wang, X; Wang, J; Wei, MH; Wides, R; Xiao, CL; Yan, CH; Yao, A; Ye, J; Zhan, M; Zhang, WQ; Zhang, HY; Zhao, Q; Zheng, LS; Zhong, F; Zhong, WY; Zhu, SPC; Zhao, SY; Gilbert, D; Baumhueter, S; Spier, G; Carter, C; Cravchik, A; Woodage, T; Ali, F; An, HJ; Awe, A; Baldwin, D; Baden, H; Barnstead, M; Barrow, I; Beeson, K; Busam, D; Carver, A; Center, A; Cheng, ML; Curry, L; Danaher, S; Davenport, L; Desilets, R; Dietz, S; Dodson, K; Doup, L; Ferriera, S; Garg, N; Gluecksmann, A; Hart, B; Haynes, J; Haynes, C; Heiner, C; Hladun, S; Hostin, D; Houck, J; Howland, T; Ibegwam, C; Johnson, J; Kalush, F; Kline, L; Koduru, S; Love, A; Mann, F; May, D; McCawley, S; McIntosh, T; McMullen, I; Moy, M; Moy, L; Murphy, B; Nelson, K; Pfannkoch, C; Pratts, E; Puri, V; Qureshi, H; Reardon, M; Rodriguez, R; Rogers, YH; Romblad, D; Ruhfel, B; Scott, R; Sitter, C; Smallwood, M; Stewart, E; Strong, R; Suh, E; Thomas, R; Tint, NN; Tse, S; Vech, C; Wang, G; Wetter, J; Williams, S; Williams, M; Windsor, S; Winn-Deen, E; Wolfe, K; Zaveri, J; Zaveri, K; Abril, JF; Guigo, R; Campbell, MJ; Sjolander, KV; Karlak, B; Kejariwal, A; Mi, HY; Lazareva, B; Hatton, T; Narechania, A; Diemer, K; Muruganujan, A; Guo, N; Sato, S; Bafna, V; Istrail, S; Lippert, R; Schwartz, R; Walenz, B; Yooseph, S; Allen, D; Basu, A; Baxendale, J; Blick, L; Caminha, M; Carnes-Stine, J; Caulk, P; Chiang, YH; Coyne, M; Dahlke, C; Mays, AD; Dombroski, M; Donnelly, M; Ely, D; Esparham, S; Fosler, C; Gire, H; Glanowski, S; Glasser, K; Glodek, A; Gorokhov, M; Graham, K; Gropman, B; Harris, M; Heil, J; Henderson, S; Hoover, J; Jennings, D; Jordan, C; Jordan, J; Kasha, J; Kagan, L; Kraft, C; Levitsky, A; Lewis, M; Liu, XJ; Lopez, J; Ma, D; Majoros, W; McDaniel, J; Murphy, S; Newman, M; Nguyen, T; Nguyen, N; Nodell, M; Pan, S; Peck, J; Peterson, M; Rowe, W; Sanders, R; Scott, J; Simpson, M; Smith, T; Sprague, A; Stockwell, T; Turner, R; Venter, E; Wang, M; Wen, MY; Wu, D; Wu, M; Xia, A; Zandieh, A; Zhu, XH				Venter, JC; Adams, MD; Myers, EW; Li, PW; Mural, RJ; Sutton, GG; Smith, HO; Yandell, M; Evans, CA; Holt, RA; Gocayne, JD; Amanatides, P; Ballew, RM; Huson, DH; Wortman, JR; Zhang, Q; Kodira, CD; Zheng, XQH; Chen, L; Skupski, M; Subramanian, G; Thomas, PD; Zhang, JH; Miklos, GLG; Nelson, C; Broder, S; Clark, AG; Nadeau, C; McKusick, VA; Zinder, N; Levine, AJ; Roberts, RJ; Simon, M; Slayman, C; Hunkapiller, M; Bolanos, R; Delcher, A; Dew, I; Fasulo, D; Flanigan, M; Florea, L; Halpern, A; Hannenhalli, S; Kravitz, S; Levy, S; Mobarry, C; Reinert, K; Remington, K; Abu-Threideh, J; Beasley, E; Biddick, K; Bonazzi, V; Brandon, R; Cargill, M; Chandramouliswaran, I; Charlab, R; Chaturvedi, K; Deng, ZM; Di Francesco, V; Dunn, P; Eilbeck, K; Evangelista, C; Gabrielian, AE; Gan, W; Ge, WM; Gong, FC; Gu, ZP; Guan, P; Heiman, TJ; Higgins, ME; Ji, RR; Ke, ZX; Ketchum, KA; Lai, ZW; Lei, YD; Li, ZY; Li, JY; Liang, Y; Lin, XY; Lu, F; Merkulov, GV; Milshina, N; Moore, HM; Naik, AK; Narayan, VA; Neelam, B; Nusskern, D; Rusch, DB; Salzberg, S; Shao, W; Shue, BX; Sun, JT; Wang, ZY; Wang, AH; Wang, X; Wang, J; Wei, MH; Wides, R; Xiao, CL; Yan, CH; Yao, A; Ye, J; Zhan, M; Zhang, WQ; Zhang, HY; Zhao, Q; Zheng, LS; Zhong, F; Zhong, WY; Zhu, SPC; Zhao, SY; Gilbert, D; Baumhueter, S; Spier, G; Carter, C; Cravchik, A; Woodage, T; Ali, F; An, HJ; Awe, A; Baldwin, D; Baden, H; Barnstead, M; Barrow, I; Beeson, K; Busam, D; Carver, A; Center, A; Cheng, ML; Curry, L; Danaher, S; Davenport, L; Desilets, R; Dietz, S; Dodson, K; Doup, L; Ferriera, S; Garg, N; Gluecksmann, A; Hart, B; Haynes, J; Haynes, C; Heiner, C; Hladun, S; Hostin, D; Houck, J; Howland, T; Ibegwam, C; Johnson, J; Kalush, F; Kline, L; Koduru, S; Love, A; Mann, F; May, D; McCawley, S; McIntosh, T; McMullen, I; Moy, M; Moy, L; Murphy, B; Nelson, K; Pfannkoch, C; Pratts, E; Puri, V; Qureshi, H; Reardon, M; Rodriguez, R; Rogers, YH; Romblad, D; Ruhfel, B; Scott, R; Sitter, C; Smallwood, M; Stewart, E; Strong, R; Suh, E; Thomas, R; Tint, NN; Tse, S; Vech, C; Wang, G; Wetter, J; Williams, S; Williams, M; Windsor, S; Winn-Deen, E; Wolfe, K; Zaveri, J; Zaveri, K; Abril, JF; Guigo, R; Campbell, MJ; Sjolander, KV; Karlak, B; Kejariwal, A; Mi, HY; Lazareva, B; Hatton, T; Narechania, A; Diemer, K; Muruganujan, A; Guo, N; Sato, S; Bafna, V; Istrail, S; Lippert, R; Schwartz, R; Walenz, B; Yooseph, S; Allen, D; Basu, A; Baxendale, J; Blick, L; Caminha, M; Carnes-Stine, J; Caulk, P; Chiang, YH; Coyne, M; Dahlke, C; Mays, AD; Dombroski, M; Donnelly, M; Ely, D; Esparham, S; Fosler, C; Gire, H; Glanowski, S; Glasser, K; Glodek, A; Gorokhov, M; Graham, K; Gropman, B; Harris, M; Heil, J; Henderson, S; Hoover, J; Jennings, D; Jordan, C; Jordan, J; Kasha, J; Kagan, L; Kraft, C; Levitsky, A; Lewis, M; Liu, XJ; Lopez, J; Ma, D; Majoros, W; McDaniel, J; Murphy, S; Newman, M; Nguyen, T; Nguyen, N; Nodell, M; Pan, S; Peck, J; Peterson, M; Rowe, W; Sanders, R; Scott, J; Simpson, M; Smith, T; Sprague, A; Stockwell, T; Turner, R; Venter, E; Wang, M; Wen, MY; Wu, D; Wu, M; Xia, A; Zandieh, A; Zhu, XH			The sequence of the human genome	SCIENCE			English	Review							SINGLE-NUCLEOTIDE POLYMORPHISMS; DNA-SEQUENCE; CPG ISLANDS; FUNCTIONAL GENOMICS; MESSENGER-RNA; GENE MARKERS; PHYSICAL MAP; CHROMOSOME; EXPRESSION; IDENTIFICATION	A 2.91-billion base pair (bp) consensus sequence of the euchromatic portion of the human genome was generated by the whole-genome shotgun sequencing method. The 14.8-billion bp DNA sequence was generated over 9 months from 27,271,853 high-quality sequence reads (5.11-fold coverage of the genome) from both ends of plasmid clones made from the DNA of five individuals. Two assembly strategies-a whole-genome assembly and a regional chromosome assembly-were used, each combining sequence data from Celera and the publicly funded genome effort. The public data were shredded into 550-bp segments to create a 2.9-fold coverage of those genome regions that had been sequenced, without including biases inherent in the cloning and assembly procedure used by the publicly funded group. This brought the effective coverage in the assemblies to eightfold, reducing the number and size of gaps in the final assembly over what would be obtained with 5.11-fold coverage. The two assembly strategies yielded very similar results that Largely agree with independent mapping data. The assemblies effectively cover the euchromatic regions of the human chromosomes. More than 90% of the genome is in scaffold assemblies of 100,000 bp or more, and 25% of the genome is in scaffolds of 10 million bp or larger. Analysis of the genome sequence revealed 26,588 protein-encoding transcripts for which there was strong corroborating evidence and an additional similar to 12,000 computationally derived genes with mouse matches or other weak supporting evidence. Although gene-dense clusters are obvious, almost half the genes are dispersed in Low G+C sequence separated by large tracts of apparently noncoding sequence. Only 1.1% of the genome is spanned by exons, whereas 24% is in introns, with 75% of the genome being intergenic DNA. Duplications of segmental blocks, ranging in size up to chromosomal Lengths, are abundant throughout the genome and reveal a complex evolutionary history. Comparative genomic analysis indicates vertebrate expansions of genes associated with neuronal function, with tissue-specific developmental regulation, and with the hemostasis and immune systems. DNA sequence comparisons between the consensus sequence and publicly funded genome data provided locations of 2.1 million single-nucleotide polymorphisms (SNPs). A random pair of human haploid genomes differed at a rate of 1 bp per 1250 on average, but there was marked heterogeneity in the Level of polymorphism across the genome. Less than 1% of all SNPs resulted in variation in proteins, but the task of determining which SNPs have functional consequences remains an open challenge.	Celera Genom, Rockville, MD 20850 USA; GenetixXpress, Sydney, NSW 2108, Australia; Univ Calif Berkeley, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA; Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Johns Hopkins Univ, Johns Hopkins Hosp, Sch Med, Baltimore, MD 21287 USA; Rockefeller Univ, New York, NY 10021 USA; New England Biolabs Inc, Beverly, MA 01915 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA; Appl Biosyst Inc, Foster City, CA 94404 USA; Inst Genom Res, Rockville, MD 20850 USA; Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Univ Pompeu Fabra, Inst Municipal Invest Med, Grp Recerca Informat Med, Barcelona, Catalonia, Spain	University of California System; University of California Berkeley; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Case Western Reserve University; Johns Hopkins University; Johns Hopkins Medicine; Rockefeller University; California Institute of Technology; Yale University; Thermo Fisher Scientific; Applied Biosystems; J. Craig Venter Institute; Bar Ilan University; Pompeu Fabra University	Venter, JC (corresponding author), Celera Genom, 45 W Gude Dr, Rockville, MD 20850 USA.	humangenome@celera.com	Holt, Robert A/C-3303-2009; Guigo, Roderic/D-1303-2010; Ferrando, Josep F Abril/B-3877-2014; Tuluc, Petronel/C-2527-2011; Schwartz, Russell/A-1998-2016; Salzberg, Steven/Q-6514-2019; Huson, Daniel H./AAC-5494-2019; Gasull, Martina/J-4076-2019; Salzberg, Steven L/F-6162-2011; Bafna, Vineet/AAY-8111-2020; Hart, Brit/G-6205-2015; Reinert, Knut/V-3327-2019; Scott, Rodney/B-2827-2013	Holt, Robert A/0000-0002-7259-1247; Guigo, Roderic/0000-0002-5738-4477; Ferrando, Josep F Abril/0000-0001-7793-589X; Schwartz, Russell/0000-0002-4970-2252; Salzberg, Steven/0000-0002-8859-7432; Salzberg, Steven L/0000-0002-8859-7432; Bafna, Vineet/0000-0002-5810-6241; Hart, Brit/0000-0002-9389-2786; Reinert, Knut/0000-0003-3078-8129; Ballew, Richard M/0000-0003-4866-284X; Wortman, Jennifer/0000-0002-8713-1227; Stockwell, Timothy/0000-0002-3595-4539; Scott, Rodney/0000-0001-7724-3404; Nguyen, Dac-Trung/0000-0003-2591-9948; Zheng Bradley, Xiangqun/0000-0002-9324-2708; Yooseph, Shibu/0000-0001-5581-5002; Thomas, Russell/0000-0002-2340-0301; Eilbeck, Karen/0000-0002-0831-6427; Bonazzi, Vivien/0000-0002-7359-9072; Clark, Andrew/0000-0001-7159-8511; Harris, Michael/0000-0001-8789-0912; Roberts, Richard/0000-0002-4348-0169; Thomas, Paul/0000-0002-9074-3507				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1994, NATURE, V368, P474, DOI 10.1038/368474a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Altshuler D, 2000, NATURE, V407, P513, DOI 10.1038/35035083; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Bailey JE, 1999, NAT BIOTECHNOL, V17, P616, DOI 10.1038/10794; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Barbazuk WB, 2000, GENOME RES, V10, P1351, DOI 10.1101/gr.144700; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bernardi G, 2000, GENE, V241, P3, DOI 10.1016/S0378-1119(99)00485-0; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BICKMORE WA, 1989, TRENDS GENET, V5, P144, DOI 10.1016/0168-9525(89)90055-3; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Brett D, 2000, FEBS LETT, V474, P83, DOI 10.1016/S0014-5793(00)01581-7; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burt DW, 1999, NATURE, V402, P411, DOI 10.1038/46555; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAPANNA E, 1971, CARYOLOGIA, V24, P471, DOI 10.1080/00087114.1971.10796455; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Carvalho AB, 2000, P NATL ACAD SCI USA, V97, P13239, DOI 10.1073/pnas.230438397; Casaccia-Bonnefil P, 1999, ADV EXP MED BIOL, V468, P275; Chambers DM, 1998, P NATL ACAD SCI USA, V95, P4463, DOI 10.1073/pnas.95.8.4463; CHARLESWORTH D, 1995, GENETICS, V141, P1619; CHAUDHARI N, 1983, SCIENCE, V220, P924, DOI 10.1126/science.6189184; Chen F W, 1999, Int Rev Immunol, V18, P429, DOI 10.3109/08830189909088492; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Collins CA, 2000, NAT STRUCT BIOL, V7, P850; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Cook-Deegan Robert, 1996, GENE WARS SCI POLITI; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Cross SH, 2000, MAMM GENOME, V11, P373, DOI 10.1007/s003350010071; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; CRUTCHFIELD JP, 1989, PHYS REV LETT, V63, P105, DOI 10.1103/PhysRevLett.63.105; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dickson D, 1999, NATURE, V401, P311, DOI 10.1038/43722; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Eddy SR, 1999, CURR OPIN GENET DEV, V9, P695, DOI 10.1016/S0959-437X(99)00022-2; Elliott DJ, 2000, HUM MOL GENET, V9, P2117, DOI 10.1093/hmg/9.14.2117; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 2000, NAT GENET, V25, P232, DOI 10.1038/76115; FEINBERG AP, 2000, CURR TOP MICROBIOL I, V249, P7; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; GARCIAMEUNIER P, 1993, MAMM GENOME, V4, P695, DOI 10.1007/BF00357792; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gell-Mann M., 1996, Complexity, V2, P44, DOI 10.1002/(SICI)1099-0526(199609/10)2:1<44::AID-CPLX10>3.0.CO;2-X; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Goncalves I, 2000, GENOME RES, V10, P672, DOI 10.1101/gr.10.5.672; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Green P, 1997, GENOME RES, V7, P410, DOI 10.1101/gr.7.5.410; Grunau C, 2000, HUM MOL GENET, V9, P2651, DOI 10.1093/hmg/9.18.2651; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Horvath JE, 2000, GENOME RES, V10, P839, DOI 10.1101/gr.10.6.839; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Jensen M A, 1991, DNA Seq, V1, P233, DOI 10.3109/10425179109020778; Jorde LB, 2000, AM J HUM GENET, V66, P979, DOI 10.1086/302825; Kaessmann H, 1999, NAT GENET, V22, P78, DOI 10.1038/8785; Kandel E., 2000, PRINCIPLES NEURAL SC; Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4; Kenmochi N, 1998, GENOME RES, V8, P509, DOI 10.1101/gr.8.5.509; Khalyfa A, 1999, DEV DYNAM, V216, P267, DOI 10.1002/(SICI)1097-0177(199911)216:3<267::AID-DVDY5>3.0.CO;2-V; Kimura M., 1983, NEUTRAL THEORY MOL E; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; KROGH A, 1994, J MOL BIOL, V235, P1501, DOI 10.1006/jmbi.1994.1104; LANDER E S, 1988, Genomics, V2, P231; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LEMKE G, 1993, GLIA, V7, P263, DOI 10.1002/glia.440070402; Li W. H, 1997, MOL EVOLUTION; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; MADSEN HO, 1990, NUCLEIC ACIDS RES, V18, P1513, DOI 10.1093/nar/18.6.1513; MAHY BWJ, 1991, ASM NEWS, V57, P577; Makeyev AV, 1999, J BIOL CHEM, V274, P24849, DOI 10.1074/jbc.274.35.24849; Maleszka R, 1998, P NATL ACAD SCI USA, V95, P3731, DOI 10.1073/pnas.95.7.3731; MANSUR NR, 1993, NUCLEIC ACIDS RES, V21, P993, DOI 10.1093/nar/21.4.993; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Marshall E, 1998, SCIENCE, V280, P994, DOI 10.1126/science.280.5366.994; Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570; Martin-Gallardo A, 1992, DNA Seq, V3, P237, DOI 10.3109/10425179209034023; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; MCCOMBIE WR, 1992, NAT GENET, V1, P348, DOI 10.1038/ng0892-348; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McLysaght A, 2000, YEAST, V17, P22, DOI 10.1002/(SICI)1097-0061(200004)17:1<22::AID-YEA5>3.0.CO;2-S; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MIKLOS GLG, 1979, AM J HUM GENET, V31, P264; MIKLOS GLG, 1993, J NEUROBIOL, V24, P842, DOI 10.1002/neu.480240610; MILNER RJ, 1983, NUCLEIC ACIDS RES, V11, P5497, DOI 10.1093/nar/11.16.5497; Muller H. J., 1967, Heritage from Mendel., P419; MULLER HP, 1967, Z NATURFORSCH PT B, VB 22, P1330, DOI 10.1515/znb-1967-1218; Munroe PB, 1999, NAT GENET, V21, P142, DOI 10.1038/5102; Mural RJ, 1999, METHOD ENZYMOL, V303, P77; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; MYERS EW, 1996, COMPUTATIONAL METHOD, P73; Myers G, 1996, J COMPUT BIOL, V3, P563, DOI 10.1089/cmb.1996.3.563; Nachman MW, 1998, GENETICS, V150, P1133; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; Nei M., 1987, MOL EVOLUTIONARY GEN; Nickerson DA, 2000, GENOME RES, V10, P1532, DOI 10.1101/gr.146900; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; NOUVEL P, 1994, GENETICA, V93, P191, DOI 10.1007/BF01435251; OHNO S, 1985, TRENDS GENET, V1, P160, DOI 10.1016/0168-9525(85)90070-8; Olivier M, 2001, SCIENCE, V291, P1298, DOI 10.1126/science.1057437; Pan YZ, 1999, GENOMICS, V59, P282, DOI 10.1006/geno.1999.5874; Pawson T, 2000, GENE DEV, V14, P1027; Pennisi E, 1998, SCIENCE, V280, P1185, DOI 10.1126/science.280.5367.1185; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Peters J, 2000, GENOME BIOL, V1; POLYMEROPOULOS MH, 1993, NAT GENET, V4, P381, DOI 10.1038/ng0893-381; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; Pruitt KD, 2000, TRENDS GENET, V16, P44, DOI 10.1016/S0168-9525(99)01882-X; Przeworski M, 2000, TRENDS GENET, V16, P296, DOI 10.1016/S0168-9525(00)02030-8; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sampo B, 2000, P NATL ACAD SCI USA, V97, P3666, DOI 10.1073/pnas.97.7.3666; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmitt H, 1996, GENOMICS, V33, P9, DOI 10.1006/geno.1996.0154; Schuler GD, 1998, TRENDS BIOTECHNOL, V16, P456, DOI 10.1016/S0167-7799(98)01232-3; Seeburg P H, 1977, Trans Assoc Am Physicians, V90, P109; Sharon D, 1999, GENOMICS, V61, P24, DOI 10.1006/geno.1999.5900; SINSHEIMER RL, 1989, GENOMICS, V5, P954, DOI 10.1016/0888-7543(89)90142-0; Sjolander K, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P165; Skrabanek L, 1998, CURR OPIN GENET DEV, V8, P694, DOI 10.1016/S0959-437X(98)80039-7; Slavov D, 2000, GENE, V247, P215, DOI 10.1016/S0378-1119(00)00089-5; SMIT AFA, 1995, NUCLEIC ACIDS RES, V23, P98, DOI 10.1093/nar/23.1.98; SMITH JM, 1987, J THEOR BIOL, V128, P247, DOI 10.1016/S0022-5193(87)80172-8; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; Taillon-Miller P, 1999, GENOME RES, V9, P499; Taillon-Miller P, 1998, GENOME RES, V8, P748, DOI 10.1101/gr.8.7.748; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; TAVARE S, 1984, THEOR POPUL BIOL, V26, P119, DOI 10.1016/0040-5809(84)90027-3; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Trask BJ, 1998, HUM MOL GENET, V7, P13, DOI 10.1093/hmg/7.1.13; Uberbacher EC, 1996, METHOD ENZYMOL, V266, P259; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; *US DOE, 1986, SANT FE WORKSH SANT; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Wang SL, 2000, NEURON, V27, P197, DOI 10.1016/S0896-6273(00)00028-3; Warburton PE, 1996, HUMAN GENOME EVOLUTI, P121; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; WHITE O, 1993, NUCLEIC ACIDS RES, V21, P3829, DOI 10.1093/nar/21.16.3829; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; YANDELL M, UNPUB; Zhang JH, 1997, GENOME RES, V7, P649, DOI 10.1101/gr.7.6.649; Zhao S, 2000, GENOMICS, V63, P321, DOI 10.1006/geno.1999.6082; Zoubak S, 1996, GENE, V174, P95, DOI 10.1016/0378-1119(96)00393-9	191	9080	9671	38	1771	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	2001	291	5507					1304	+		10.1126/science.1058040	http://dx.doi.org/10.1126/science.1058040			49	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	402MX	11181995				2022-12-28	WOS:000166993400041
J	Silberstein, LE; Toy, P				Silberstein, LE; Toy, P			Research opportunities in transfusion medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MODIFIED DENDRITIC CELLS; BLOOD; HYPORESPONSIVENESS; REQUIREMENTS; INACTIVATION	In recent years, the translation of basic research in transfusion medicine has led to development of novel cellular therapies using well-characterized cell populations isolated from either bone marrow or blood (eg, hematopoietic stem and progenitor cells, T lymphocytes, dendritic cells). Refinements in cell therapies will make possible optimal stem cell engraftment, gene therapy, immunotherapy of cancer and infectious disease, and even solid organ regeneration. Moreover, the immune consequences of transfusion therapy are better appreciated and opportunities are at hand to prevent or blunt unwanted immune responses, such as platelet refractoriness and graft-vs-host disease. Transfusion medicine has become a broad, multidisciplinary field that has evolved beyond issues related to blood procurement and storage. The next series of advances in transfusion medicine will complement the current approaches of donor blood screening and viral/bacterial inactivation steps to ensure a safe and adequate blood supply.	Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	Harvard University; Harvard Medical School; University of California System; University of California San Francisco	Silberstein, LE (corresponding author), Childrens Hosp, Dana Farber Canc Inst, Joint Program Transfus Med, Bader 4,300 Longwood Ave, Boston, MA 02115 USA.							Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Armstrong B, 2000, CYTOMETRY, V40, P102, DOI 10.1002/(SICI)1097-0320(20000601)40:2<102::AID-CYTO3>3.3.CO;2-W; Blajchman MA, 1999, TRANSFUSION, V39, P665, DOI 10.1046/j.1537-2995.1999.39070665.x; BLAKESLEE S, 2000, NY TIMES        0725; Daniels G, 1999, BLOOD REV, V13, P14, DOI 10.1016/S0268-960X(99)90020-6; GULNAN EC, 1999, NEW ENGL J MED, V340, P1704; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HOROWITZ MM, 1990, BLOOD, V75, P555; Kirk CJ, 2000, HUM GENE THER, V11, P797, DOI 10.1089/10430340050015419; Klein C, 2000, J EXP MED, V191, P1699, DOI 10.1084/jem.191.10.1699; Klein HG, 2000, NEW ENGL J MED, V342, P1666, DOI 10.1056/NEJM200006013422211; KLEINMAN S, 2000, NEW ASPECTS BLOOD TR; Landsteiner K, 1936, SPECIFICITY SEROLOGI; Lin L, 1997, TRANSFUSION, V37, P423, DOI 10.1046/j.1537-2995.1997.37497265344.x; MCCULLOUGH J, 1995, TRANSFUSION, V35, P374, DOI 10.1046/j.1537-2995.1995.35595259145.x; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Murphy WJ, 1999, CURR OPIN IMMUNOL, V11, P509, DOI 10.1016/S0952-7915(99)00002-3; Niimi M, 1998, J IMMUNOL, V161, P5331; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; REED WF, 1999, CURR OPIN HEMATOL, P6432; Reid ME, 2000, TRANSFUSION, V40, P48, DOI 10.1046/j.1537-2995.2000.40010048.x; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; SIENA S, 1989, BLOOD, V74, P1905; SKYES M, 1988, BONE MARROW TRANSPL, V3, P379; Taylor PA, 2000, J IMMUNOL, V164, P612, DOI 10.4049/jimmunol.164.2.612; Thurer RL, 2000, TRANSFUSION, V40, P751, DOI 10.1046/j.1537-2995.2000.40060751.x; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; YANKEE RA, 1969, NEW ENGL J MED, V281, P1208, DOI 10.1056/NEJM196911272812202; Yee C, 1997, CURR OPIN IMMUNOL, V9, P702, DOI 10.1016/S0952-7915(97)80052-0	29	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					577	580		10.1001/jama.285.5.577	http://dx.doi.org/10.1001/jama.285.5.577			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176862				2022-12-28	WOS:000166714200015
J	Weissman, MM				Weissman, MM			Stigma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Weissman, Myrna/0000-0003-3490-3075					0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					261	262		10.1001/jama.285.3.261	http://dx.doi.org/10.1001/jama.285.3.261			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390XD	11176821				2022-12-28	WOS:000166324300001
J	Tanaka, M; Lisberger, SG				Tanaka, M; Lisberger, SG			Regulation of the gain of visually guided smooth-pursuit eye movements by frontal cortex	NATURE			English	Article							MONKEYS; FIELD; MICROSTIMULATION; RESPONSES; ATTENTION; MECHANISMS; SELECTION; SACCADES; AREA; MT	In studies of the neural mechanisms giving rise to behaviour, changes in the neural and behavioural responses produced by a given stimulus have been widely reported. This `gain control' can boost the responses to sensory inputs that are particularly relevant(1-4), select among reflexes for execution by motoneurons(5,6) or emphasize specific movement targets(7). Gain control is also an integral part of the smooth-pursuit eye movement system(8-13). One signature of gain control is that a brief perturbation of a stationary target during fixation causes tiny eye movements, whereas the same perturbation of a moving target during the active state of accurate pursuit causes large responses(9). Here we show that electrical stimulation of the smooth-pursuit eye movement region in the arcuate sulcus of the frontal lobe (`the frontal pursuit area', FPA) mimics the active state of pursuit. Such stimulation enhances the response to a brief perturbation of target motion, regardless of the direction of motion. We postulate that the FPA sets the gain of pursuit, thereby participating in target selection for pursuit.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tanaka, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA.		Tanaka, Masaki/D-9199-2011	Tanaka, Masaki/0000-0002-6177-1314				ADLER SA, 2000, SOC NEUR ABSTR, V26, P1716; CARL JR, 1987, J NEUROPHYSIOL, V57, P1446, DOI 10.1152/jn.1987.57.5.1446; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Fukushima K, 2000, J NEUROPHYSIOL, V83, P563, DOI 10.1152/jn.2000.83.1.563; Gardner J. L., 1999, Society for Neuroscience Abstracts, V25, P1398; GOLDBERG ME, 1989, NEUROBIOLOGY SACCADI, V3, P283; GOTTLIEB JP, 1994, J NEUROPHYSIOL, V72, P1634, DOI 10.1152/jn.1994.72.4.1634; GOTTLIEB JP, 1993, J NEUROPHYSIOL, V69, P786, DOI 10.1152/jn.1993.69.3.786; GRASSE KL, 1992, J NEUROPHYSIOL, V67, P164, DOI 10.1152/jn.1992.67.1.164; Groh JM, 1997, J NEUROSCI, V17, P4312; Keating EG, 1996, BEHAV BRAIN RES, V81, P173, DOI 10.1016/S0166-4328(96)89078-4; KEATING EG, 1991, EXP BRAIN RES, V86, P311; KOMATSU H, 1989, J NEUROPHYSIOL, V62, P31, DOI 10.1152/jn.1989.62.1.31; Krauzlis RJ, 1998, J NEUROPHYSIOL, V80, P2046, DOI 10.1152/jn.1998.80.4.2046; Krauzlis RJ, 1996, J NEUROPHYSIOL, V76, P1622, DOI 10.1152/jn.1996.76.3.1622; Krauzlis RJ, 1999, J COGNITIVE NEUROSCI, V11, P641, DOI 10.1162/089892999563706; Lisberger SG, 1998, J NEUROPHYSIOL, V79, P1918, DOI 10.1152/jn.1998.79.4.1918; LISBERGER SG, 1985, J NEUROSCI, V5, P1662; MacAvoy MG, 1991, CEREB CORTEX, V1, P95, DOI 10.1093/cercor/1.1.95; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; MAY J G, 1985, Society for Neuroscience Abstracts, V11, P79; Pearson KG, 1995, CURR OPIN NEUROBIOL, V5, P786, DOI 10.1016/0959-4388(95)80107-3; POSNER MI, 1994, P NATL ACAD SCI USA, V91, P7398, DOI 10.1073/pnas.91.16.7398; Roy JE, 1998, NAT NEUROSCI, V1, P404, DOI 10.1038/1619; Schall JD, 1999, ANNU REV NEUROSCI, V22, P241, DOI 10.1146/annurev.neuro.22.1.241; SCHWARTZ JD, 1994, VISUAL NEUROSCI, V11, P411, DOI 10.1017/S0952523800002352; Shi DX, 1998, J NEUROPHYSIOL, V80, P458, DOI 10.1152/jn.1998.80.1.458; Tanaka M, 1998, J NEUROPHYSIOL, V80, P28, DOI 10.1152/jn.1998.80.1.28; Treue S, 1999, NATURE, V399, P575, DOI 10.1038/21176; WURTZ RH, 1976, J NEUROPHYSIOL, V39, P745, DOI 10.1152/jn.1976.39.4.745	30	129	130	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					191	194		10.1038/35051582	http://dx.doi.org/10.1038/35051582			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196642				2022-12-28	WOS:000166316200044
J	Cummings, KJ; Lee, SM; West, ES; Cid-Ruzafa, J; Fein, SG; Aoki, Y; Sulkowski, MS; Goodman, SN				Cummings, KJ; Lee, SM; West, ES; Cid-Ruzafa, J; Fein, SG; Aoki, Y; Sulkowski, MS; Goodman, SN			Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon - A meta-analysis of randomized trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							10-YEAR FOLLOW-UP; PLUS RIBAVIRIN; COMBINATION THERAPY; VIRUS GENOTYPES; ALPHA THERAPY; UNITED-STATES; RESISTANT; PATHOGENICITY; EPIDEMIOLOGY; MULTICENTER	Context Hepatitis C is the leading cause of chronic liver disease in the United States. Several trials have found that interferon and ribavirin combination therapy is more efficacious than interferon monotherapy for previously untreated patients and those who relapsed after prior interferon monotherapy, but its effectiveness for nonresponders to prior interferon monotherapy is unclear. Objective To assess the efficacy and safety of interferon and ribavirin vs interferon alone for treatment of patients with chronic hepatitis C who previously did not respond to interferon monotherapy. Data Sources A systematic search was performed using MEDLINE and the Science Citation Index for publications from 1966 to December 1999. A manual reference search and a manual review of relevant specialty journals also were performed, and input from clinical hepatology experts was sought. Study Selection included studies were randomized, controlled clinical trials comparing interferon and ribavirin with interferon alone and reporting virological and biochemical outcomes after a follow-up period. Of 50 identified studies, 12 trials (941 patients) were included in the analysis. Data Extraction Two investigators reviewed trials independently for methods, inclusion and exclusion criteria, and outcomes. Disagreements were resolved by discussion. Abstracted data included study and patient characteristics and virological, biochemical, and histological outcomes. A quality evaluation questionnaire was used to score studies. Data Synthesis The pooled virological response rate for combination therapy was 14% (95% confidence interval [CI], 11%-17%), with a risk difference favoring combination therapy of 7% (95% CI, 2%-13%). Use of interferon alfa-2a/2b and ribavirin, 1000 to 1200 mg/d, was associated with a pooled virological response rate of 18% and a risk difference of 16% (95% CI, 11%-21%). When interferon alfa-n/n3 and a lower dosage of ribavirin (600-800 mg/d) were used, the risk difference was 0% (95% CI, -7% to 7%). Combination therapy was associated with more adverse effects and an increased rate of discontinuation of treatment compared with interferon monotherapy. Conclusions for chronic hepatitis C that is non responsive to prior interferon monotherapy, combination therapy is more effective than re-treatment with interferon alone. Response rates remain less than 20% even in the most responsive subgroups, demonstrating a need for better therapeutic options.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Hlth Serv Res & Dev Ctr, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Lee, SM (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Suite 1103,550 N Broadway, Baltimore, MD 21205 USA.	leesh@jhmi.edu	Gower, Emily/A-9688-2009	Goodman, Steven/0000-0002-3872-5723	NEI NIH HHS [T32 EY07127] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007127] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmed A, 1999, J GASTROEN HEPATOL, V14, pS12, DOI 10.1046/j.1440-1746.1999.01875.x; Ajello A, 1999, HEPATO-GASTROENTEROL, V46, P2447; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Andreone P, 1999, J HEPATOL, V30, P788, DOI 10.1016/S0168-8278(99)80130-5; [Anonymous], 1997, HEPATOLOGY, V26, pS2; Barbaro G, 1998, AM J GASTROENTEROL, V93, P2445, DOI 10.1016/S0002-9270(98)00583-8; Barbaro G, 1999, AM J MED, V107, P112, DOI 10.1016/S0002-9343(99)00160-6; Bell H, 1999, SCAND J GASTROENTERO, V34, P194, DOI 10.1080/00365529950173087; Bellobuono A, 1997, J VIRAL HEPATITIS, V4, P185, DOI 10.1046/j.1365-2893.1997.00142.x; Bonkovsky HL, 1999, HEPATOLOGY, V30, p265A; BRADBURN MJ, 1998, STATA TECHNICAL B, V44, P4; Brillanti S, 1995, J HEPATOL, V23, P13; BRILLANTI S, 1994, GASTROENTEROLOGY, V107, P812, DOI 10.1016/0016-5085(94)90131-7; Buti M, 2000, Forum (Genova), V10, P63; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHEMELLO L, 1995, J HEPATOL, V23, pS8; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DETRE KM, 1996, VIRAL HEPATITIS REV, V2, P219; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703; Hopf U, 1996, J HEPATOL, V24, P67; Idilman R, 1998, HEPATO-GASTROENTEROL, V45, P340; KAKUMU S, 1993, GASTROENTEROLOGY, V105, P507, DOI 10.1016/0016-5085(93)90727-T; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lai MY, 1996, GASTROENTEROLOGY, V111, P1307, DOI 10.1053/gast.1996.v111.pm8898645; Lau DTY, 1998, HEPATOLOGY, V28, P1121, DOI 10.1002/hep.510280430; Lau J, 1999, HEPATOLOGY, V30, p263A; LIGHT RJ, 1984, SUMMING UP SCI REV R; Martinot-Peignoux M, 1999, J VIRAL HEPATITIS, V6, P435, DOI 10.1046/j.1365-2893.1999.00187.x; MATTSSON L, 1989, LIVER, V9, P120; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Milella M, 1999, ITAL J GASTROENTEROL, V31, P211; Pol S, 1999, J HEPATOL, V31, P1, DOI 10.1016/S0168-8278(99)80157-3; Poynard T, 1996, HEPATOLOGY, V24, P778; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; Salmeron J, 1999, LIVER, V19, P275, DOI 10.1111/j.1478-3231.1999.tb00049.x; Schalm SW, 1999, J HEPATOL, V31, P184, DOI 10.1016/S0168-8278(99)80398-5; Scotto G, 1996, ITAL J GASTROENTEROL, V28, P505; Sostegni R, 1998, HEPATOLOGY, V28, P341, DOI 10.1002/hep.510280208; STERN J, 1998, STATA TECH B, V42, P16; Toccaceli F, 1997, HEPATOL RES, V8, P106, DOI 10.1016/S1386-6346(97)00056-9; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P341; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002; 1989, MORB MORTAL WKLY REP, V47, P1	48	118	123	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2001	285	2					193	199		10.1001/jama.285.2.193	http://dx.doi.org/10.1001/jama.285.2.193			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	389FB	11176813				2022-12-28	WOS:000166227000028
J	Schwerzmann, M; Seiler, C; Lipp, E; Guzman, R; Lovblad, KO; Kraus, M; Kucher, N				Schwerzmann, M; Seiler, C; Lipp, E; Guzman, R; Lovblad, KO; Kraus, M; Kucher, N			Relation between directly detected patent foramen ovale and ischemic brain lesions in sport divers	ANNALS OF INTERNAL MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; DECOMPRESSION-SICKNESS	Background: In divers, the significance of a patent foramen ovale and its potential relation to paradoxical gas emboli remain uncertain. Objective: To assess the prevalence of symptoms of decompression illness and ischemic brain lesions in divers with regard to the presence of a patent foramen ovate. Design: Retrospective cohort study. Setting: University hospital and three diving clubs in Switzerland. Participants: 52 sport divers and 52 nondiving controls. Measurements: Prevalence of self-reported decompression events, patent foramen ovale on contrast transesophageal echocardiography, and ischemic brain lesions on magnetic resonance imaging. Results: The risk for decompression illness events was 4.5-fold greater in divers with patent foramen ovate than in divers without patent foramen ovale (risk ratio, 4.5 [95% CI, 1.2 to 18.0]; P = 0,03), Among divers, 1.23 +/- 2.0 and 0.64 +/- 1.22 ischemic brain lesions per person (mean +/- SD) were detected in those with and those without patent foramen ovale, respectively. Among controls, 0.22 +/- 0.44 and 0.12 +/- 0.63 lesion per person were detected (P < 0.001 for all groups). Conclusions: Regardless of whether a diver has a patent foramen ovale, diving is associated with ischemic brain lesions.	Univ Hosp Bern, Dept Cardiol, Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland; Swiss Cardiovasc Ctr Bern, Bern, Switzerland	University of Bern; University Hospital of Bern	Seiler, C (corresponding author), Univ Hosp Bern, Dept Cardiol, Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland.	christian.seiler.cardio@insel.ch	Lövblad, Karl/AAF-7678-2020; Schwerzmann, Markus/AAD-9368-2022	Schwerzmann, Markus/0000-0002-4006-8929; lovblad, karl-olof/0000-0003-2768-9779; Guzman, Raphael/0000-0001-9620-0581				DITULLIO M, 1993, STROKE, V24, P1020, DOI 10.1161/01.STR.24.7.1020; Elliot D. H., 1993, PHYSL MED DIVING, P481; Germonpre P, 1998, J APPL PHYSIOL, V84, P1622, DOI 10.1152/jappl.1998.84.5.1622; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; Knauth M, 1997, BRIT MED J, V314, P701, DOI 10.1136/bmj.314.7082.701; MOON RE, 1989, LANCET, V1, P513; REUL J, 1995, LANCET, V345, P1403, DOI 10.1016/S0140-6736(95)92598-8; RINCK PA, 1991, JMRI-J MAGN RESON IM, V1, P293, DOI 10.1002/jmri.1880010306; TODNEM K, 1991, BRIT J IND MED, V48, P258; WARREN LP, 1988, AM J ROENTGENOL, V151, P1003, DOI 10.2214/ajr.151.5.1003; WILMSHURST P, 1990, LANCET, V336, P1071, DOI 10.1016/0140-6736(90)92546-T; Wilmshurst P, 1997, BRIT MED J, V314, P689, DOI 10.1136/bmj.314.7082.689; WILMSHURST PT, 1986, BRIT MED J, V293, P1277, DOI 10.1136/bmj.293.6557.1277	13	110	114	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2001	134	1					21	24		10.7326/0003-4819-134-1-200101020-00009	http://dx.doi.org/10.7326/0003-4819-134-1-200101020-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386CV	11187416				2022-12-28	WOS:000166043300003
J	Seitz, B; Langenbucher, A				Seitz, B; Langenbucher, A			Lasers in ophthalmology	LANCET			English	Article									Univ Erlangen Nurnberg, Augenklin & Poliklin, D-91054 Erlangen, Germany; Erlangen Eye Bank, Erlangen, Germany	University of Erlangen Nuremberg	Seitz, B (corresponding author), Univ Erlangen Nurnberg, Augenklin & Poliklin, D-91054 Erlangen, Germany.		Seitz, Berthold/AAB-8546-2019	Seitz, Berthold/0000-0001-9701-8204					0	4	4	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S26	S26		10.1016/S0140-6736(00)92012-9	http://dx.doi.org/10.1016/S0140-6736(00)92012-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191482				2022-12-28	WOS:000166074900028
J	Summers, WK; Driscoll, J; Orient, JM				Summers, WK; Driscoll, J; Orient, JM			The pharmaceutical industry - To whom is it accountable?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Alzheimers Corp, Albuquerque, NM 87110 USA; Log Cabin Republicans, Washington, DC 20036 USA; Assoc Amer Phys & Surg, Tucson, AZ 85716 USA		Summers, WK (corresponding author), Alzheimers Corp, Albuquerque, NM 87110 USA.							SUMMERS WK, 2000, WALL STREET J   0621, pA26	1	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1416	1416						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183883				2022-12-28	WOS:000165152800019
J	Glickman, D				Glickman, D			Regulations for the use of laboratory animals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									USDA, Off Commun, Washington, DC 20250 USA	United States Department of Agriculture (USDA)	Glickman, D (corresponding author), USDA, Off Commun, Washington, DC 20250 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					941	941		10.1001/jama.285.7.941	http://dx.doi.org/10.1001/jama.285.7.941			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402BE	11180740				2022-12-28	WOS:000166965500034
J	McIvor, RJ				McIvor, RJ			Drama at night	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					857	858						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402BE	11180710				2022-12-28	WOS:000166965500002
J	McCormack, S; Hayes, R; Lacey, CJN; Johnson, AM				McCormack, S; Hayes, R; Lacey, CJN; Johnson, AM			Science, medicine, and the future - Microbicides in HIV prevention	BRITISH MEDICAL JOURNAL			English	Review							SEXUALLY-TRANSMITTED-DISEASES; NONOXYNOL-9; EFFICACY; TRANSMISSION; INFECTION; TRIAL		MRC, Council Clin Trials Unit, London NW1 2DA, England; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; St Marys Hosp, Imperial Coll Sch Med, London W2 1PG, England; UCL, Dept Sexually Transmitted Dis, London WC1E 6AU, England	Medical Research Council Clinical Trials Unit; University of London; London School of Hygiene & Tropical Medicine; Imperial College London; University of London; University College London	McCormack, S (corresponding author), MRC, Council Clin Trials Unit, London NW1 2DA, England.	s.mccormack@ctu.mrc.ac.uk		Johnson, Anne/0000-0003-1330-7100; Hayes, Richard/0000-0002-1729-9892				Anderson RM, 1996, LANCET, V348, P1010, DOI 10.1016/S0140-6736(96)07100-0; BRANDT A, 1987, NO MAGIC BULLET; *CONTR DEV PROGR C, 1999, ROLE COLPOSCOPY ASSE; Datta S, 1998, STAT MED, V17, P185, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;185::AID-SIM732&gt;3.0.CO;2-4; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Greenhead P, 2000, J VIROL, V74, P5577, DOI 10.1128/JVI.74.12.5577-5586.2000; KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477; NIRUTHISARD S, 1991, SEX TRANSM DIS, V18, P176, DOI 10.1097/00007435-199107000-00010; Pool R, 2000, INT J STD AIDS, V11, P162, DOI 10.1258/0956462001915606; Richens J, 2000, LANCET, V355, P400, DOI 10.1016/S0140-6736(99)09109-6; Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803; Stafford MK, 1998, J ACQ IMMUN DEF SYND, V17, P327, DOI 10.1097/00042560-199804010-00006; *UN PROGR AIDS UNA, 2000, REP GLOB HIV AIDS EP; Williams B, 1998, S AFR MED J, V88, P247	14	44	44	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 17	2001	322	7283					410	413		10.1136/bmj.322.7283.410	http://dx.doi.org/10.1136/bmj.322.7283.410			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404JH	11179162	Green Accepted, Green Published			2022-12-28	WOS:000167093600029
J	Kimberly, RP				Kimberly, RP			Research advances in systemic lupus erythematosus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY	Systemic lupus erythematosus is an autoimmune disease with a significant genetic component to susceptibility. Some environmental risks are known, and identification of specific genetic factors promises to define new molecular targets for therapy. Broad immunosuppression will be replaced by early, selective, and individualized intervention. Mortality rates will decline, and insights into therapy may apply to other autoimmune conditions.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Kimberly, RP (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Tinsley Harrison Tower,Room 429, Birmingham, AL 35294 USA.			Kimberly, Robert/0000-0002-5330-3086				Alarcon GS, 1999, LUPUS, V8, P197, DOI 10.1191/096120399678847704; Gaffney PM, 2000, AM J HUM GENET, V66, P547, DOI 10.1086/302767; Gray-McGuire C, 2000, AM J HUM GENET, V67, P1460, DOI 10.1086/316891; KIMBERLY RP, 1999, GENES GENETICS AUTOI, P99; Uramoto KM, 1999, ARTHRITIS RHEUM, V42, P46, DOI 10.1002/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2; Urowitz MB, 1997, J RHEUMATOL, V24, P1061	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					650	651		10.1001/jama.285.5.650	http://dx.doi.org/10.1001/jama.285.5.650			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176876	Bronze			2022-12-28	WOS:000166714200029
J	Koopman, WJ				Koopman, WJ			Prospects for autoimmune disease - Research advances in rheumatoid arthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METHOTREXATE	Rheumatoid arthritis (RA) is a common chronic inflammatory disease associated with progressive destruction of diarthrodial joints, substantial morbidity and economic burden, and a shortened lifespan. Significant progress has been made in understanding the pathogenesis of RA, and increasingly effective therapies have been introduced, including anti-tumor necrosis factor alpha agents. Advances made in the past quarter century will pale in comparison to those anticipated for the next 25 years, including delineation of the genetic basis of disease susceptibility and severity, genetic definition of disease subtypes that differ in severity and response to therapy, and prompt initiation of effective individualized treatment based on genetic and environmental assessment. Reconstructive surgery will become increasingly unnecessary and the morbidity, economic burden, and mortality due to RA will be reduced substantially.	Univ Alabama, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Koopman, WJ (corresponding author), Univ Alabama, Dept Med, Boshell Diabet Bldg,Room 420, Birmingham, AL 35294 USA.							DELEURAN BW, 1996, SCAND J RHEUMAT S104, V25, P1; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FELSON DT, 2001, ARTHRITIS ALLIED CON, P3; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; Fox D., 2001, ARTHRITIS ALLIED CON, P1085; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; JANOSSY G, 1981, LANCET, V2, P839; MORELAND LW, 2001, ARTHRITIS ALLIED CON, P877; MullerLadner U, 1996, AM J PATHOL, V149, P1607; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; VANBOXEL JA, 1975, NEW ENGL J MED, V293, P517, DOI 10.1056/NEJM197509112931101; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401	12	20	21	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					648	650		10.1001/jama.285.5.648	http://dx.doi.org/10.1001/jama.285.5.648			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176875				2022-12-28	WOS:000166714200028
J	Livingston, DM; Shivdasani, R				Livingston, DM; Shivdasani, R			Toward mechanism-based cancer care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENE; HOMOLOG; PROTEIN; BCL-2; MICE	in the past 25 years, research has elucidated molecular mechanisms directing key aspects of tumor cell behavior. Detailed understanding of these mechanisms has already changed methods for diagnosis, prognosis, and treatment. with continuing advances in cancer science and the emergence of-new technologies for applying basic science to clinical practice, new methods based on molecular mechanisms will dominate cancer care and prevention.	Dana Farber Canc Inst, Div Neoplast Dis Mech, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Livingston, DM (corresponding author), Dana Farber Canc Inst, Div Neoplast Dis Mech, 44 Binney St, Boston, MA 02115 USA.	david_livingston@dfci.harvard.edu						Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Hellman S., 1989, CANCER PRINCIPLES PR, P3; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Horvitz HR, 1999, CANCER RES, V59, p1701S; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Mahmood U, 1999, RADIOLOGY, V213, P866, DOI 10.1148/radiology.213.3.r99dc14866; McLean TW, 1996, BLOOD, V88, P4252; NOWELL PC, 1975, HUMANGENETIK, V30, P13, DOI 10.1007/BF00273627; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosenberg SA, 2000, CANCER J, V6, pS142; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schulman Ira G., 1997, Leukemia (Basingstoke), V11, P376; Semenza GL, 2000, GENE DEV, V14, P1983; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Weiner LM, 1999, SEMIN ONCOL, V26, P43	31	17	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					588	593		10.1001/jama.285.5.588	http://dx.doi.org/10.1001/jama.285.5.588			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176864	Bronze			2022-12-28	WOS:000166714200017
J	Rauch, U; Osende, JI; Fuster, V; Badimon, JJ; Fayad, Z; Chesebro, JH				Rauch, U; Osende, JI; Fuster, V; Badimon, JJ; Fayad, Z; Chesebro, JH			Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences	ANNALS OF INTERNAL MEDICINE			English	Review							TISSUE FACTOR PATHWAY; CORONARY-ARTERY-DISEASE; BEAM COMPUTED-TOMOGRAPHY; BLOOD-COAGULATION FACTOR; ISCHEMIC-HEART-DISEASE; FACTOR XA INHIBITION; C-REACTIVE PROTEIN; MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; RABBIT MODEL	Purpose: To describe the characteristics of thrombus formation on atherosclerotic plaques, the clinical expression of atherothrombosis in Vascular disease, and some of the most recent therapeutic approaches in cardiovascular disease. Data Sources: MEDLINE search for English-language articles on thrombosis and atherosclerosis published up to January 2000. Abstracts of recent international meetings on new aspects of thrombus formation and new therapeutic options were reviewed, and references from identified articles were selected and reviewed. Study Selection: Experimental, basic, clinical, and epidemiologic studies related to the pathophysiology of thrombosis on atherosclerotic lesions. Therapeutic approaches were obtained from experimental studies and large clinical investigations. Data Extraction: Arterial vessel wall substrate, theologic conditions, and blood thrombogenicity influence the process of thrombus formation in arteries. Thrombus formation on disrupted atherosclerotic plaques or arterial erosions frequently causes acute coronary syndromes. Severe atherosclerosis of the aorta has been identified as an important morphologic indicator of an increased risk for thromboembolism. Current antithrombotic therapies available as long-term treatment for patients with cardiovascular disease are often not effective enough to prevent acute thrombotic events and deterioration of atherosclerosis. Data Synthesis: Improved understanding of the pathophysiology of thrombus formation on atherosclerotic plaques has led to the development of new therapeutic approaches. Glycoprotein llb/llla, tissue factor, factor Xa, and thrombin inhibitors as well as combined antithrombotic therapy, such as aspirin plus a thienopyridine plus warfarin, are being evaluated as new possible options for the treatment of arterial thrombosis. Conclusions: Long-term treatment with potent antithrombotic drugs, such as tissue factor or factor Xa inhibitors, that effectively block thrombosis without causing bleeding complications could help reduce death from cardiovascular disease.	CUNY Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Chesebro, JH (corresponding author), CUNY Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, 1 Gustave L Levy Pl,Box 1030, New York, NY 10029 USA.	james.chesebro@mssm.edu	Fayad, Zahi/Z-3272-2019; Fuster, Valentin/H-4319-2015; /GPG-3365-2022	Fayad, Zahi/0000-0002-3439-7347; Fuster, Valentin/0000-0002-9043-9986; 	NHLBI NIH HHS [P50 HL54469] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054469] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achenbach S, 1998, NEW ENGL J MED, V339, P1964, DOI 10.1056/NEJM199812313392702; AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; Amarenco P, 1996, NEW ENGL J MED, V334, P1216; Anand SS, 1998, CIRCULATION, V98, P1064, DOI 10.1161/01.CIR.98.11.1064; Annex BH, 1998, J SURG RES, V80, P164, DOI 10.1006/jsre.1998.5438; ANNEX BH, 1995, CIRCULATION, V91, P619, DOI 10.1161/01.CIR.91.3.619; Arnljots B, 1997, J VASC SURG, V25, P341, DOI 10.1016/S0741-5214(97)70356-2; Aronson D, 1997, ANN INTERN MED, V126, P296, DOI 10.7326/0003-4819-126-4-199702150-00006; ASAKURA H, 1995, THROMB RES, V80, P217, DOI 10.1016/0049-3848(95)00170-V; Badimon JJ, 1999, CIRCULATION, V99, P1780, DOI 10.1161/01.CIR.99.14.1780; BADIMON L, 1992, CIRCULATION, V86, P74; BADIMON L, 1989, BLOOD, V73, P961; BADIMON L, 1989, J CLIN INVEST, V84, P1134, DOI 10.1172/JCI114277; Bajaj MS, 1997, THROMB HAEMOSTASIS, V78, P471; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bata I, 1997, CIRCULATION, V96, P769; Bazzan M, 1998, DIABETOLOGIA, V41, P767, DOI 10.1007/s001250050985; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Berger AK, 1999, J AM COLL CARDIOL, V34, P1831, DOI 10.1016/S0735-1097(99)00420-9; Bertrand ME, 2000, CIRCULATION, V102, P624, DOI 10.1161/01.CIR.102.6.624; Biemond BJ, 1996, CIRCULATION, V93, P153, DOI 10.1161/01.CIR.93.1.153; BLAUTH CI, 1992, J THORAC CARDIOV SUR, V103, P1104; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; BROOK JG, 1988, SEMIN THROMB HEMOST, V14, P258, DOI 10.1055/s-2007-1002787; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Callister TQ, 1998, NEW ENGL J MED, V339, P1972, DOI 10.1056/NEJM199812313392703; Carey MJ, 1998, AM J HEMATOL, V59, P65, DOI 10.1002/(SICI)1096-8652(199809)59:1<65::AID-AJH13>3.0.CO;2-0; Celermajer DS, 1998, NEW ENGL J MED, V339, P2014, DOI 10.1056/NEJM199812313392709; Celermajer DS, 1997, J AM COLL CARDIOL, V30, P325, DOI 10.1016/S0735-1097(97)00189-7; CERIELLO A, 1993, DIABETOLOGIA, V36, P1119, DOI 10.1007/BF00401055; Chesebro JH, 1997, HAEMOSTASIS, V27, P12; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; Coller BS, 1998, CIRCULATION, V97, P4; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; CRONENWETT JL, 1984, ARCH SURG-CHICAGO, V119, P430; Davies MJ, 1996, THROMB RES, V82, P1, DOI 10.1016/0049-3848(96)00035-7; DAVIES MJ, 1990, CIRCULATION, V82, P38; DAVIES MJ, 1993, BRIT HEART J, V69, P377; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVILAROMAN VG, 1994, STROKE, V25, P2010, DOI 10.1161/01.STR.25.10.2010; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Drollinger AG, 1999, SEMIN THROMB HEMOST, V25, P429, DOI 10.1055/s-2007-994945; Elsayed YA, 1996, AM J CLIN PATHOL, V106, P574; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; FARKOUH ME, 1994, J AM COLL CARDIOL, V24, P1290, DOI 10.1016/0735-1097(94)90111-2; Fayad ZA, 1998, CIRCULATION, V98, P515; Felton CV, 1997, ARTERIOSCL THROM VAS, V17, P1337, DOI 10.1161/01.ATV.17.7.1337; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; Fiore L, 2000, J AM COLL CARDIOL, V35, p373A; Fiorino AS, 1998, ANN INTERN MED, V128, P839, DOI 10.7326/0003-4819-128-10-199805150-00008; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FOWKES FGR, 1992, AM J EPIDEMIOL, V135, P331; Fuster V, 1997, LANCET, V350, P389; Fuster V, 1996, J AM COLL CARDIOL, V27, P964, DOI 10.1016/0735-1097(96)00014-9; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; FUSTER V, 1992, NEW ENGL J MED, V326, P310; FUSTER V, 1999, LANCET S2, V353, P5; Gando S, 1998, THROMB HAEMOSTASIS, V79, P1111; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gibson CM, 1998, J AM COLL CARDIOL, V32, P28, DOI 10.1016/S0735-1097(98)00192-2; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GIRARD TJ, 1990, SCIENCE, V248, P1421, DOI 10.1126/science.1972598; Golino P, 1998, CIRC RES, V82, P39; Gould AL, 1998, CIRCULATION, V97, P946; Gutstein DE, 1999, CARDIOVASC RES, V41, P323, DOI 10.1016/S0008-6363(98)00322-8; Han X, 1999, ARTERIOSCL THROM VAS, V19, P2563, DOI 10.1161/01.ATV.19.10.2563; HARA T, 1995, THROMB HAEMOSTASIS, V74, P635; Harker LA, 1997, THROMB HAEMOSTASIS, V78, P736; HASKEL EJ, 1991, CIRCULATION, V84, P821, DOI 10.1161/01.CIR.84.2.821; HAVERKATE F, 1995, THROMB HAEMOSTASIS, V73, P561; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Heeschen C, 2000, LANCET, V355, P330, DOI 10.1016/S0140-6736(99)00464-X; Herbert JM, 1998, BLOOD, V91, P4197, DOI 10.1182/blood.V91.11.4197.411k09_4197_4205; Himber J, 1997, THROMB HAEMOSTASIS, V78, P1142; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; Hirsh J, 1999, LANCET, V353, P1431, DOI 10.1016/S0140-6736(98)09233-2; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; Hoffmeister Hans Martin, 1999, Thrombosis and Haemostasis, V82, P76; Hugel B, 1999, BLOOD, V93, P3451, DOI 10.1182/blood.V93.10.3451.410k27_3451_3456; JANG YS, 1995, CIRCULATION, V92, P3041, DOI 10.1161/01.CIR.92.10.3041; Jauhar R, 1999, AM J CARDIOL, V84, P726, DOI 10.1016/S0002-9149(99)00420-8; JONES EF, 1995, STROKE, V26, P218; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KANNEL WB, 1990, AM HEART J, V120, P672, DOI 10.1016/0002-8703(90)90026-T; KIRCHHOFER D, 1995, ARTERIOSCL THROM VAS, V15, P1098, DOI 10.1161/01.ATV.15.8.1098; Kullo IJ, 1998, ANN INTERN MED, V129, P1050, DOI 10.7326/0003-4819-129-12-199812150-00010; Lagrand WK, 1999, CIRCULATION, V100, P96, DOI 10.1161/01.CIR.100.1.96; LaRosa JC, 1999, AM J CARDIOL, V84, P454; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LEWIS JC, 1995, AM J PATHOL, V147, P1029; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; *LIPID STUD GROUP, 1998, NEW ENGL J MED, V333, P1349; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P672, DOI 10.1161/01.ATV.10.5.672; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Matsuda T, 1996, DIABETES, V45, pS109, DOI 10.2337/diab.45.3.S109; Meigs JB, 2000, JAMA-J AM MED ASSOC, V283, P221, DOI 10.1001/jama.283.2.221; MILLER GJ, 1992, ARCH PATHOL LAB MED, V116, P1318; Mishkel GJ, 1999, J AM COLL CARDIOL, V34, P1884, DOI 10.1016/S0735-1097(99)00443-X; MORENO PR, 1994, CIRCULATION, V90, P775, DOI 10.1161/01.CIR.90.2.775; Moussa I, 1999, CIRCULATION, V99, P2364, DOI 10.1161/01.CIR.99.18.2364; Murayama N, 1999, CLIN PHARMACOL THER, V66, P258, DOI 10.1016/S0009-9236(99)70033-0; Napoli C, 1997, J CLIN INVEST, V100, P2680, DOI 10.1172/JCI119813; NEMERSON Y, 1995, THROMB HAEMOSTASIS, V74, P180; NEMERSON Y, 1988, BLOOD, V71, P1; Nishida T, 1999, CIRC RES, V84, P1446; NUTT EM, 1991, ARCH BIOCHEM BIOPHYS, V285, P37, DOI 10.1016/0003-9861(91)90325-D; Oliver MF, 1998, EUR HEART J, V19, P16; Oltrona L, 1997, CIRCULATION, V96, P646; ORVIM U, 1995, ARTERIOSCL THROM VAS, V15, P2188, DOI 10.1161/01.ATV.15.12.2188; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PEDERSEN TR, 1994, LANCET, V344, P1383; Ragni M, 1996, CIRCULATION, V93, P1913, DOI 10.1161/01.CIR.93.10.1913; RAGOSTA M, 1994, CIRCULATION, V89, P1262, DOI 10.1161/01.CIR.89.3.1262; Rao AK, 1999, DIABETES, V48, P1156, DOI 10.2337/diabetes.48.5.1156; Rauch U, 2000, ATHEROSCLEROSIS, V153, P181, DOI 10.1016/S0021-9150(00)00397-X; Rauch U, 2000, BLOOD, V96, P170, DOI 10.1182/blood.V96.1.170.013k42_170_175; Rauch U, 1999, DIABETIC MED, V16, P848, DOI 10.1046/j.1464-5491.1999.00160.x; Rauch U, 2000, AM J CARDIOL, V86, P246, DOI 10.1016/S0002-9149(00)00871-7; Rauch U, 1998, PLATELETS, V9, P237, DOI 10.1080/09537109876762; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; RUMBERGER JA, 1995, CIRCULATION, V92, P2157, DOI 10.1161/01.CIR.92.8.2157; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Saito Y, 1999, AM J HEMATOL, V61, P238, DOI 10.1002/(SICI)1096-8652(199908)61:4<238::AID-AJH3>3.0.CO;2-8; SALONEN JT, 1993, CIRCULATION, V87, P56; SCHMID HJ, 1962, J CLIN INVEST, V41, P543, DOI 10.1172/JCI104508; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Soejima H, 1999, J AM COLL CARDIOL, V34, P983, DOI 10.1016/S0735-1097(99)00318-6; Soejima H, 1999, CIRCULATION, V99, P2908, DOI 10.1161/01.CIR.99.22.2908; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; STARY HC, 1992, CIRCULATION, V85, P391, DOI 10.1161/01.CIR.85.1.391; STARY HC, 1989, ARTERIOSCLEROSIS, V9, pI19; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; Tcheng JE, 1997, LANCET, V349, P1422; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; Topol CE, 2000, LANCET, V355, P337; TOPOL E, 1994, CIRCULATION, V90, P1631; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; TOUSSAINT JF, 1995, ARTERIOSCL THROM VAS, V15, P1533; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Tschoepe D, 1997, HORM METAB RES, V29, P631, DOI 10.1055/s-2007-979115; Turitto VT, 1998, THROMB RES, V92, pS25, DOI 10.1016/S0049-3848(98)00157-1; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; VIRCHOW R, 1856, GESAMMELTE ABH, P520; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; Wallentin L, 1996, LANCET, V347, P561; Wallentin L, 1999, LANCET, V354, P701; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Williams MJA, 1997, J AM COLL CARDIOL, V30, P364, DOI 10.1016/S0735-1097(97)00153-8; WISSLER RW, 1991, ANN NY ACAD SCI, V623, P26, DOI 10.1111/j.1749-6632.1991.tb43716.x; Wysokinski W, 1996, THROMB HAEMOSTASIS, V76, P1108; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; YOKOYAMA T, 1995, CIRCULATION, V92, P485, DOI 10.1161/01.CIR.92.3.485; Zoldhelyi P, 2000, CIRCULATION, V101, P289, DOI 10.1161/01.CIR.101.3.289	173	223	254	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2001	134	3					224	238		10.7326/0003-4819-134-3-200102060-00014	http://dx.doi.org/10.7326/0003-4819-134-3-200102060-00014			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397KR	11177336				2022-12-28	WOS:000166695300007
J	Tsomides, T				Tsomides, T			Reflections on a death	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Maine Med Ctr, Dept Med, Portland, ME 04102 USA	Maine Medical Center	Tsomides, T (corresponding author), Maine Med Ctr, Dept Med, 22 Bramhall St, Portland, ME 04102 USA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2001	134	3					246	248		10.7326/0003-4819-134-3-200102060-00017	http://dx.doi.org/10.7326/0003-4819-134-3-200102060-00017			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397KR	11177339				2022-12-28	WOS:000166695300010
J	Harris, DR; Gonin, R; Alter, HJ; Wright, EC; Buskell, ZJ; Hollinger, FB; Seeff, LB				Harris, DR; Gonin, R; Alter, HJ; Wright, EC; Buskell, ZJ; Hollinger, FB; Seeff, LB		Natl Heart Lung Blood Inst Study G	The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse	ANNALS OF INTERNAL MEDICINE			English	Article							C VIRUS-INFECTION; LIVER-DISEASE; PROGRESSION; PREVALENCE; DONORS; RISK	Background: Although concomitant alcoholism is widely believed to enhance liver disease progression in persons with hepatitis C virus (HCV) infection, this relationship has not been well quantified. Objective: To quantify the relationship of transfusion-associated HCV infection and history of heavy alcohol abuse to development of cirrhosis. Design: Retrospective cohort study. Setting: river clinics in university and government hospitals. Patients: Extended follow-up of 1030 patients in prospective investigations of transfusion-associated viral hepatitis conducted in the United States between 1968 and 1980. Measurements: Development of cirrhosis and history of heavy alcohol abuse were determined from review of interviews with patients or their proxies, medical records, death certificates, and autopsy and biopsy reports. Logistic regression was used to estimate the risk for cirrhosis associated with transfusion-associated HCV infection and history of heavy alcohol abuse. Results: The absolute risk for cirrhosis was 17% among patients with transfusion-associated HCV; 3.2% among patients with transfusion-associated non-A, non-B, non-C hepatitis; and 2.8% among controls. Patients with transfusion-associated HCV were more likely than controls to develop cirrhosis (odds ratio, 7.8 [95% CI, 4.0 to 15.1]). A history of heavy alcohol abuse was associated with a fourfold increased risk for cirrhosis. Hepatitis C virus infection plus a history of heavy alcohol abuse led to a substantial increase in risk for cirrhosis (odds ratio, 31.1 [CI, 11.4 to 84.5]) compared with controls without such a history. Conclusions: Heavy alcohol abuse greatly exacerbates the risk for cirrhosis among patients with HCV infection. This finding emphasizes the need to counsel such patients about their drinking habits.	NIDDKD, NIH, Bethesda, MD 20892 USA; WESTAT Corp, Rockville, MD 20850 USA; New England Res Inst, Watertown, MA 02172 USA; Vet Affairs Med Ctr, Washington, DC 20422 USA; Georgetown Univ, Sch Med, Washington, DC USA; Baylor Coll Med, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Westat; HealthCore, Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Georgetown University; Baylor College of Medicine	Seeff, LB (corresponding author), NIDDKD, NIH, 31 Ctr Dr,Room 9A18,Mail Drop MSC2560, Bethesda, MD 20892 USA.	seeffl@extra.niddk.nih.gov	Hollinger, F Blaine/AAY-3323-2021		NHLBI NIH HHS [N01-HB-87047, N01-HB-37093] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB037093, N01HB087047] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; Alter HJ, 1997, HEPATOLOGY, V26, pS29, DOI 10.1002/hep.510260705; Alter HJ, 1978, VIRAL HEPATITIS, P359; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Bellentani S, 1999, GUT, V44, P874, DOI 10.1136/gut.44.6.874; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; MENDENHALL CL, 1991, HEPATOLOGY, V14, P581; Niederau C, 1998, HEPATOLOGY, V28, P1687, DOI 10.1002/hep.510280632; Noda K, 1996, ALCOHOL CLIN EXP RES, V20, pA95, DOI 10.1111/j.1530-0277.1996.tb01739.x; Ostapowicz G, 1998, HEPATOLOGY, V27, P1730, DOI 10.1002/hep.510270637; Pessione F, 1998, HEPATOLOGY, V27, P1717, DOI 10.1002/hep.510270635; Schiff ER, 1997, HEPATOLOGY, V26, pS39, DOI 10.1002/hep.510260707; Seeff L B, 1997, Clin Liver Dis, V1, P587, DOI 10.1016/S1089-3261(05)70323-8; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SEEFF LB, 1978, VIRAL HEPATITIS, P371; SUZUKI T, 1993, ANAT REC S, V1, P109; Wiley TE, 2000, GASTROENTEROLOGY, V118, pA1012, DOI 10.1016/S0016-5085(00)86198-3; Wiley TE, 1998, HEPATOLOGY, V28, P805, DOI 10.1002/hep.510280330	19	137	144	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2001	134	2					120	124		10.7326/0003-4819-134-2-200101160-00012	http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391KW	11177315				2022-12-28	WOS:000166356000005
J	Van Trappen, PO; Gyselman, VG; Lowe, DG; Ryan, A; Oram, DH; Bosze, P; Weekes, AR; Shepherd, JH; Dorudi, S; Bustin, SA; Jacobs, IJ				Van Trappen, PO; Gyselman, VG; Lowe, DG; Ryan, A; Oram, DH; Bosze, P; Weekes, AR; Shepherd, JH; Dorudi, S; Bustin, SA; Jacobs, IJ			Molecular quantification and mapping of lymph-node micrometastases in cervical cancer	LANCET			English	Article							POLYMERASE-CHAIN-REACTION; BREAST-CANCER; COLORECTAL-CANCER; REVERSE-TRANSCRIPTASE; PERIPHERAL-BLOOD; MESSENGER-RNA; CELLS; METASTASIS; CARCINOMA; IDENTIFICATION	Background A proportion of patients with cancer and lymph nodes negative on histology will develop recurrence. Reverse-transcriptase PCR (RT-PCR) is a highly sensitive method for detection of lymph-node micrometastases, but accurate quantitative assessment has been difficult. Methods We studied primary tumours and 156 lymph nodes from 32 patients with cervical cancer (stage IA2, IB1, and 1B2) and 32 lymph nodes from nine patients with benign disease. A fully quantitative, real-time RT-PCR assay was used to document absolute copy numbers of the epithelial marker cytokeratin 19. Primers and probe were designed not to amplify either of the two cytokeratin 19 pseudogenes. Findings All primary tumours and histologically involved lymph nodes (six) had more than 10(6) copies of cytokeratin 19 mRNA per mug total RNA. Expression of cytokeratin 19 (up to 1.1x10(5) copies per mug RNA) was detected in 66 (44%) of 150 histologically uninvolved lymph nodes, and in nodes from 16 of 32 patients with cervical cancer. 15 of these 16 patients with evidence of micrometastases had the highest cytokeratin 19 transcription level in a first lymph-node drainage-station (three obturator, six internal, and six external iliac node). Transcription of cytokeratin 19 was found at a low level in just one of 32 lymph nodes obtained from nine patients with benign disease. Median copy number of cytokeratin 19 transcription was significantly higher (>10(3) copies) in association with adverse prognostic features. Interpretation The results suggest that about 50% of early-stage cervical cancers shed tumour cells to the pelvic lymph nodes. The amount of cytokeratin 19 expression was related to clinicopathological features. Further studies are required to document the clinical implications of molecular micrometastases.	St Bartholomews Hosp, Univ London Queen Mary & Westfield Coll, Acad Dept Gynaecol Oncol, London EC1A 7BE, England; Royal London Hosp, Univ London Queen Mary & Westfield Coll, Acad Dept Surg, London E1 1BB, England; St Stephan Hosp, Dept Gynaecol Onocl, Budapest, Hungary; Harold Wood Hosp, Dept Gynaecol, Romford, Essex, England	University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Van Trappen, PO (corresponding author), St Bartholomews Hosp, Univ London Queen Mary & Westfield Coll, Acad Dept Gynaecol Oncol, London EC1A 7BE, England.		Bustin, Stephen/HHT-0617-2022; Jacobs, Ian J/F-1743-2013; Van Trappen, Philippe/ABF-7431-2021; Bustin, Stephen/H-3086-2013	Bustin, Stephen/0000-0003-1870-6098; Jacobs, Ian J/0000-0002-8112-4624; Van Trappen, Philippe/0000-0002-9784-7974; Bustin, Stephen/0000-0003-1870-6098; Jacobs, Ian/0000-0002-5005-2672				ALVAREZ RD, 1989, GYNECOL ONCOL, V35, P130, DOI 10.1016/0090-8258(89)90029-2; Benson JR, 1999, LANCET, V354, P1998, DOI 10.1016/S0140-6736(05)76770-2; Bustin SA, 1999, BRIT J CANCER, V79, P1813, DOI 10.1038/sj.bjc.6690289; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIFUENTES N, 1979, J SURG ONCOL, V11, P193, DOI 10.1002/jso.2930110303; Cote RJ, 1999, LANCET, V354, P896, DOI 10.1016/S0140-6736(98)11104-2; Czegledy J, 1998, J MED VIROL, V54, P183, DOI 10.1002/(SICI)1096-9071(199803)54:3<183::AID-JMV7>3.0.CO;2-1; DARGENT D, 2000, P SGO M, P128; Futamura M, 1998, J SURG ONCOL, V68, P34, DOI 10.1002/(SICI)1096-9098(199805)68:1<34::AID-JSO8>3.0.CO;2-M; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; INOUE T, 1990, CANCER, V65, P1923, DOI 10.1002/1097-0142(19900501)65:9<1923::AID-CNCR2820650909>3.0.CO;2-M; Liefers GJ, 1998, NEW ENGL J MED, V339, P223, DOI 10.1056/NEJM199807233390403; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; McIntosh SA, 1999, LANCET, V354, P570, DOI 10.1016/S0140-6736(99)02155-8; MOLL R, 1983, LAB INVEST, V49, P599; Pao CC, 1997, J CLIN ONCOL, V15, P1008, DOI 10.1200/JCO.1997.15.3.1008; Raj GV, 1998, CANCER-AM CANCER SOC, V82, P1419, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1419::AID-CNCR1>3.0.CO;2-4; Ruud P, 1999, INT J CANCER, V80, P119, DOI 10.1002/(SICI)1097-0215(19990105)80:1<119::AID-IJC22>3.0.CO;2-X; SAVTCHENKO ES, 1988, AM J HUM GENET, V43, P630; SCHOENFELD A, 1994, CANCER RES, V54, P2986; Schoenfeld A, 1996, BRIT J CANCER, V74, P1639, DOI 10.1038/bjc.1996.601; Slade MJ, 1999, J CLIN ONCOL, V17, P870, DOI 10.1200/JCO.1999.17.3.870; SMITH B, 1991, LANCET, V338, P1227, DOI 10.1016/0140-6736(91)92100-G; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; van der Velde-Zimmermann D, 2000, ANN SURG ONCOL, V7, P51, DOI 10.1007/s10434-000-0051-8	30	150	153	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					15	20		10.1016/S0140-6736(00)03566-2	http://dx.doi.org/10.1016/S0140-6736(00)03566-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197354				2022-12-28	WOS:000166341500010
J	Somerville, C; Dangl, L				Somerville, C; Dangl, L			Genomics - Plant biology in 2010	SCIENCE			English	Editorial Material							FUNCTIONAL GENOMICS		Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	Carnegie Institution for Science; University of North Carolina; University of North Carolina Chapel Hill	Somerville, C (corresponding author), Carnegie Inst Washington, Dept Plant Biol, 290 Panama St, Stanford, CA 94305 USA.		Somerville, Christopher R/A-4048-2009	Somerville, Christopher R/0000-0003-4647-0094				Bouchez D, 1998, PLANT PHYSIOL, V118, P725, DOI 10.1104/pp.118.3.725; Chory J, 2000, PLANT PHYSIOL, V123, P423, DOI 10.1104/pp.123.2.423; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Eisenberg RS, 2000, NAT REV GENET, V1, P70, DOI 10.1038/35049590; MacBeath G, 2000, SCIENCE, V289, P1760; Rowen L, 2000, SCIENCE, V289, P1881, DOI 10.1126/science.289.5486.1881; Somerville C, 1999, SCIENCE, V285, P380, DOI 10.1126/science.285.5426.380; UTEZ P, 2000, NATURE, V403, P623; 2000, NATURE, V407, P667	9	83	95	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2077	2078		10.1126/science.290.5499.2077	http://dx.doi.org/10.1126/science.290.5499.2077			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11187833				2022-12-28	WOS:000165870600032
J	Fylkesnes, K				Fylkesnes, K			Consent for HIV counselling and testing	LANCET			English	Article									Univ Tromso, Dept Community Med, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Fylkesnes, K (corresponding author), Univ Tromso, Dept Community Med, N-9037 Tromso, Norway.								0	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S43	S43		10.1016/S0140-6736(00)92029-4	http://dx.doi.org/10.1016/S0140-6736(00)92029-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191501				2022-12-28	WOS:000166074900045
J	Ludwig, M; Diedrich, K				Ludwig, M; Diedrich, K			In-vitro fertilisation: a future with no limits?	LANCET			English	Article									Med Univ Lubeck, Dept Obstet Gynecol, D-23538 Lubeck, Germany	University of Lubeck	Ludwig, M (corresponding author), Med Univ Lubeck, Dept Obstet Gynecol, D-23538 Lubeck, Germany.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S52	S52		10.1016/S0140-6736(00)92038-5	http://dx.doi.org/10.1016/S0140-6736(00)92038-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191511				2022-12-28	WOS:000166074900054
J	Ribeiro, RC; Bonilla, M				Ribeiro, RC; Bonilla, M			A leukaemia treatment programme in El Salvador	LANCET			English	Article									St Jude Childrens Res Hosp, Dept Hematol & Oncol, Int Outreach Program, Memphis, TN 38105 USA; Hosp Nacl Ninos Benjamin Bloom, San Salvador, El Salvador	St Jude Children's Research Hospital	Ribeiro, RC (corresponding author), St Jude Childrens Res Hosp, Dept Hematol & Oncol, Int Outreach Program, 332 N Lauderdale St, Memphis, TN 38105 USA.								0	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S7	S7		10.1016/S0140-6736(00)91993-7	http://dx.doi.org/10.1016/S0140-6736(00)91993-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191527				2022-12-28	WOS:000166074900009
J	Tangcharoensathien, V; Lertiendumrong, J				Tangcharoensathien, V; Lertiendumrong, J			Health-system performance	LANCET			English	Article									Minist Publ Hlth, Hlth Syst Res Inst, Res Programme Hlth Syst, Nonthaburi 11000, Thailand	Ministry of Public Health - Thailand	Tangcharoensathien, V (corresponding author), Minist Publ Hlth, Hlth Syst Res Inst, Res Programme Hlth Syst, Nonthaburi 11000, Thailand.								0	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S31	S31		10.1016/S0140-6736(00)92017-8	http://dx.doi.org/10.1016/S0140-6736(00)92017-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191488				2022-12-28	WOS:000166074900033
J	Weisinger, JR; Bellorin-Font, E				Weisinger, JR; Bellorin-Font, E			Access to medical information in Latin America	LANCET			English	Article									Hosp Univ Caracas, Div Nephrol, Caracas, Venezuela		Weisinger, JR (corresponding author), POB 020010,M-229, Miami, FL 33102 USA.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S15	S15		10.1016/S0140-6736(00)92001-4	http://dx.doi.org/10.1016/S0140-6736(00)92001-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191470				2022-12-28	WOS:000166074900017
J	Kandel, ER; Squire, LR				Kandel, ER; Squire, LR			Neuroscience: Breaking down scientific barriers to the study of brain and mind	SCIENCE			English	Review							CEREBRAL GLUCOSE-UTILIZATION; VISUAL-CORTEX; NEURAL MECHANISMS; MOLECULAR-BASIS; MEMORY SYSTEM; ION CHANNELS; HIPPOCAMPUS; ATTENTION; REPRESENTATION; ORGANIZATION		Univ Calif San Diego, San Diego, CA 92103 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System								ALBRIGHT TD, 1995, P NATL ACAD SCI USA, V92, P2433, DOI 10.1073/pnas.92.7.2433; Andersen RA, 1997, ANNU REV NEUROSCI, V20, P303, DOI 10.1146/annurev.neuro.20.1.303; Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; AXELROD J, 1971, SCIENCE, V173, P598, DOI 10.1126/science.173.3997.598; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BARNODES SH, 1993, MOL MENTAL ILLINESS; Bennett M.V.L., 1972, P221; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Cajal S. R., 1967, NOBEL LECT PHYSL MED, P220; CARLSSON A, 1987, ANNU REV NEUROSCI, V10, P19; CASTELLUCCI V, 1970, SCIENCE, V167, P1745, DOI 10.1126/science.167.3926.1745; CATTERALL WA, IN PRESS NEURON; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CHARNEY DS, 1999, NEUROBIOLOGY MENTAL; COHEN S, 1956, P NATL ACAD SCI USA, V42, P571, DOI 10.1073/pnas.42.9.571; Cowan WM, 1998, NEURON, V20, P413, DOI 10.1016/S0896-6273(00)80985-X; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Desimone R, 1996, P NATL ACAD SCI USA, V93, P13494, DOI 10.1073/pnas.93.24.13494; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Eichenbaum H, 1999, NEURON, V23, P209, DOI 10.1016/S0896-6273(00)80773-4; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; EVARTS EV, 1966, METHOD MED RES, P241; FURSHPAN EJ, 1957, NATURE, V180, P342, DOI 10.1038/180342a0; Garraghty P E, 1992, Curr Opin Neurobiol, V2, P522, DOI 10.1016/0959-4388(92)90191-M; Georgopoulos AP, 2000, CURR OPIN NEUROBIOL, V10, P238, DOI 10.1016/S0959-4388(00)00072-6; Gilbert CD, 1996, P NATL ACAD SCI USA, V93, P10546, DOI 10.1073/pnas.93.20.10546; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; GoldmanRakic PS, 1996, PHILOS T ROY SOC B, V351, P1445, DOI 10.1098/rstb.1996.0129; GRILLNER S, 1986, WENNERGREN CTR INT S, V45; Higuchi S, 1996, P NATL ACAD SCI USA, V93, P739, DOI 10.1073/pnas.93.2.739; HILLARP NA, 1966, PHARMACOL REV, V18, P727; Hille B, 1999, NAT MED, V5, P1105, DOI 10.1038/13415; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P424, DOI 10.1113/jphysiol.1952.sp004716; Hodgkin AL, 1939, NATURE, V144, P710, DOI 10.1038/144710a0; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Houseknecht KL, 1998, J ANIM SCI, V76, P1405; Hubel DH, 1998, NEURON, V20, P401, DOI 10.1016/S0896-6273(00)80984-8; HUBEL DH, 1959, J PHYSIOL-LONDON, V148, P574, DOI 10.1113/jphysiol.1959.sp006308; HUNG RW, 1990, CIRCUITS FUNCTIONS M, P19; Hyman SE, 2000, ARCH GEN PSYCHIAT, V57, P88, DOI 10.1001/archpsyc.57.1.88; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; JESSELL TM, IN PRESS CURR OPIN N; KARLIN A, 1991, HARVEY LECT, V85, P71; KATZ B, 1969, 10 SHERR LECT THOM S; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KETY SS, 1983, AM J PSYCHIAT, V140, P720; Kilduff TS, 2000, TRENDS NEUROSCI, V23, P359, DOI 10.1016/S0166-2236(00)01594-0; KOOB GF, 2000, ANN NY ACAD SCI, V909, P17; LeDoux J. E., 1996, EMOTIONAL BRAIN; Lefkowitz RJ, 2000, NAT CELL BIOL, V2, pE133, DOI 10.1038/35017152; Logothetis NK, 1998, PHILOS T R SOC B, V353, P1801, DOI 10.1098/rstb.1998.0333; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Milner A. D., 1995, VISUAL BRAIN ACTION; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; Nestler EJ, 1997, CURR OPIN NEUROBIOL, V7, P713, DOI 10.1016/S0959-4388(97)80094-3; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Posner M. I., 1994, IMAGES MIND; Posner MI, 1999, P NATL ACAD SCI USA, V96, P2585, DOI 10.1073/pnas.96.6.2585; Price DL, 1999, NATURE, V399, pA3, DOI 10.1038/399a003; REIVICH M, 1979, CIRC RES, V44, P127, DOI 10.1161/01.RES.44.1.127; Rosen BR, 1998, P NATL ACAD SCI USA, V95, P773, DOI 10.1073/pnas.95.3.773; SALZMAN CD, 1990, NATURE, V346, P174, DOI 10.1038/346174a0; Schacter D., 1994, MEMORY SYSTEMS; Schacter DL, 1998, NEURON, V20, P185, DOI 10.1016/S0896-6273(00)80448-1; SCHELLER RH, 1995, NEURON, V14, P893; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SHERRINGTON CS, 1897, CENTRAL NERVOUS SYST, V3; Snyder SH., 1996, DRUGS BRAIN; Softky W R, 1995, Curr Opin Neurobiol, V5, P239, DOI 10.1016/0959-4388(95)80032-8; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Squire LR., 1999, MEMORY MIND MOL; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; van Essen D.C., 1985, P259; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WURTZ RH, 1969, J NEUROPHYSIOL, V32, P727, DOI 10.1152/jn.1969.32.5.727; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0; 1999, NEURON, V24	101	127	131	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	2000	290	5494					1113	1120		10.1126/science.290.5494.1113	http://dx.doi.org/10.1126/science.290.5494.1113			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11185010				2022-12-28	WOS:000165228200036
J	Cohen, SN; Toole, JF				Cohen, SN; Toole, JF			Stroke in patients with asymptomatic internal-carotid-artery stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC 27157 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Cohen, SN (corresponding author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.							Barnett HJM, 2000, JAMA-J AM MED ASSOC, V283, P1429, DOI 10.1001/jama.283.11.1429; Inzitari D, 2000, NEUROLOGY, V54, P660, DOI 10.1212/WNL.54.3.660; Taylor DW, 1999, LANCET, V353, P2179, DOI 10.1016/S0140-6736(99)05388-X; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035	4	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1420	1421						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183888				2022-12-28	WOS:000165152800028
J	Mehta, DJ				Mehta, DJ			The pharmaceutical industry - To whom is it accountable?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											Mehta, DJ (corresponding author), 870 United Nations Plaza, New York, NY 10017 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1417	1417						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183884				2022-12-28	WOS:000165152800021
J	van Wijk, MAM; van der Lei, J; Mosseveld, M; Bohnen, AM; van Bemmel, JH				van Wijk, MAM; van der Lei, J; Mosseveld, M; Bohnen, AM; van Bemmel, JH			Assessment of decision support for blood test ordering in primary care - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							PRACTICE GUIDELINES; GENERAL-PRACTITIONERS; LABORATORY UTILIZATION; PATIENT-OUTCOMES; DIAGNOSTIC-TESTS; COMPUTER; PHYSICIANS; SYSTEMS; DESIGN; NETHERLANDS	Background: Different methods for changing blood test-ordering behavior in primary care have been proven effective. However, randomized trials comparing these methods are lacking. Objective: To compare the effect of two versions of BloodLink, a computer-based clinical decision support system, on blood test ordering among general practitioners. Design: Randomized trial. Setting: 44 practices of general practitioners in the region of Delft, the Netherlands. Participants: 60 general practitioners in 44 practices who used computer-based patient records in their practices. Intervention: After stratification by solo practices and group practices, practices were randomly assigned to use BloodLink-Restricted, which initially displays a reduced list of tests, or BloodLink-Guideline, which is based on the guidelines of the Dutch College of General practitioners. Measurements: Average number of blood tests ordered per order form per practice. Results: General practitioners who used BloodLink-Guideline requested 20% fewer tests on average than did practitioners who used BloodLink-Restricted (mean [+/-SD], 5.5+/-0.9 tests vs. 6.9 +/- 1.6 tests, respectively; P = 0.003, Mann-Whitney test). Conclusions: Decision support based on guidelines is more effective in changing blood test-ordering behavior than is decision support based on initially displaying a limited number of tests. Guideline-driven decision support systems can be effective in reducing the number of laboratory tests ordered by primary care practitioners.	Erasmus Univ, Fac Med & Hlth Sci, Dept Med Informat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Fac Med & Hlth Sci, Dept Primary Care Med, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam	van Wijk, MAM (corresponding author), Erasmus Univ, Fac Med & Hlth Sci, Dept Med Informat, POB 1738, NL-3000 DR Rotterdam, Netherlands.	wijk@mi.fgg.eur.nl	Bohnen, Arthur M/F-7814-2011					AXTADAM P, 1993, MED CARE, V31, P784, DOI 10.1097/00005650-199309000-00003; BAILY GG, 1993, BRIT MED J, V307, P679, DOI 10.1136/bmj.307.6905.679; Boohaker EA, 1996, ARCH INTERN MED, V156, P327, DOI 10.1001/archinte.156.3.327; Cannon DS, 2000, J AM MED INFORM ASSN, V7, P196, DOI 10.1136/jamia.2000.0070196; Chin HL, 1999, J AM MED INFORM ASSN, P221; Connelly DP, 1996, AM J CLIN PATHOL, V105, pS40; Cook DJ, 1997, ANN INTERN MED, V127, P210, DOI 10.7326/0003-4819-127-3-199708010-00006; DeKay ML, 1998, MED DECIS MAKING, V18, P19, DOI 10.1177/0272989X9801800105; DURANDZALESKI I, 1993, LANCET, V342, P150, DOI 10.1016/0140-6736(93)91349-Q; Eccles M, 2000, FAM PRACT, V17, P180, DOI 10.1093/fampra/17.2.180; EISENBERG JM, 1981, MED CARE, V19, P297, DOI 10.1097/00005650-198103000-00005; Elson R B, 1995, Arch Fam Med, V4, P698, DOI 10.1001/archfami.4.8.698; EPSTEIN AM, 1984, AM J PUBLIC HEALTH, V74, P1271, DOI 10.2105/AJPH.74.11.1271; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; Henry SB, 1998, J AM MED INFORM ASSN, V5, P237, DOI 10.1136/jamia.1998.0050237; Hollingworth G R, 1995, Proc Annu Symp Comput Appl Med Care, P635; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; JENDERS RA, 1995, P ANN S COMP APPL ME, P196; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; Kerry SM, 1998, FAM PRACT, V15, P80, DOI 10.1093/fampra/15.1.80; KLUIJT I, 1991, HUISARTS WETENSCHAP, V34, P67; KRISTIANSEN IS, 1992, FAM PRACT, V9, P22, DOI 10.1093/fampra/9.1.22; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; Margolis A, 1995, Proc Annu Symp Comput Appl Med Care, P228; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; Montgomery AA, 2000, BRIT MED J, V320, P686, DOI 10.1136/bmj.320.7236.686; Ohno-Machado L, 1998, J AM MED INFORM ASSN, V5, P357, DOI 10.1136/jamia.1998.0050357; ORNSTEIN SM, 1988, MED CARE, V26, P536, DOI 10.1097/00005650-198806000-00002; Rosser WW, 1996, J FAM PRACTICE, V42, P139; Shiffman RN, 1999, J AM MED INFORM ASSN, V6, P104, DOI 10.1136/jamia.1999.0060104; Smith BJ, 1999, CLIN CHEM, V45, P1168; SMITHUIS LO, 1994, HUISARTS WETENSCHAP, V37, P464; Solomon DH, 1998, JAMA-J AM MED ASSOC, V280, P2020, DOI 10.1001/jama.280.23.2020; Sox HC, 1996, J FAM PRACTICE, V42, P155; TIERNEY WM, 1995, J AM MED INFORM ASSN, V2, P316, DOI 10.1136/jamia.1995.96073834; van Gend J M, 1996, Ned Tijdschr Geneeskd, V140, P495; van Walraven C, 1998, JAMA-J AM MED ASSOC, V280, P550, DOI 10.1001/jama.280.6.550; van Walraven C, 1998, JAMA-J AM MED ASSOC, V280, P2028, DOI 10.1001/jama.280.23.2028; van Wijk M, 1999, METHOD INFORM MED, V38, P355; van Wijk MAM, 1999, J AM MED INFORM ASSN, V6, P322, DOI 10.1136/jamia.1999.0060322; VANBEMMEL JH, 1943, COMPUTER BASED PATIE, P21; VANDERLEI J, 1993, ANN INTERN MED, V119, P1036, DOI 10.7326/0003-4819-119-10-199311150-00011; VANGELDROP WJ, 1992, HUISARTS WET, V35, P192; WONG ET, 1983, JAMA-J AM MED ASSOC, V250, P2510, DOI 10.1001/jama.250.18.2510; ZAAT JOM, 1992, MED CARE, V30, P846, DOI 10.1097/00005650-199209000-00008; ZAAT JOM, 1992, MED CARE, V30, P189, DOI 10.1097/00005650-199203000-00001; Zielstorff RD, 1998, J AM MED INFORM ASSN, V5, P227, DOI 10.1136/jamia.1998.0050227	49	77	78	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					274	281		10.7326/0003-4819-134-4-200102200-00010	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	403NW	11182837				2022-12-28	WOS:000167050200003
J	Kraemer, DE				Kraemer, DE			Diagnosis and reporting of Creutzfeldt-Jakob disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter																		2001, CJD VOICE       0110	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					733	733						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176901				2022-12-28	WOS:000166817200020
J	Merli, G; Spiro, TE; Olsson, CG; Abildgaard, U; Davidson, BL; Eldor, A; Elias, D; Grigg, A; Musset, D; Rodgers, GM; Trowbridge, AA; Yusen, RD; Zawilska, K				Merli, G; Spiro, TE; Olsson, CG; Abildgaard, U; Davidson, BL; Eldor, A; Elias, D; Grigg, A; Musset, D; Rodgers, GM; Trowbridge, AA; Yusen, RD; Zawilska, K		Enoxaparin Clin Trial Grp	Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease	ANNALS OF INTERNAL MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; STANDARD HEPARIN; PULMONARY-EMBOLISM; FRAGMIN; THROMBOCYTOPENIA; DALTEPARIN; PREVENTION; NOMOGRAM; EFFICACY	Background: Low-molecular-weight heparins administered subcutaneously once or twice daily have been reported to be as safe and efficacious as intravenous unfractionated heparin in the treatment of acute venous thromboembolic disease. Objective: To determine whether subcutaneous enoxaparin administered once or twice daily is as effective as continuously infused unfractionated heparin in acute symptomatic venous thromboembolic disease. Design: Randomized, controlled, partially blinded equivalence trial. Setting: 74 hospitals in 16 countries. Patients: 900 patients with symptomatic lower-extremity deep venous thrombosis, including 287 (32%) with confirmed pulmonary embolism. Interventions: Initial therapy with dose-adjusted intravenous unfractionated heparin compared with subcutaneous enoxaparin at fixed dosages of 1.0 mg/kg of body weight twice daily or 1.5 mg/kg once daily. Long-term oral anticoagulation was started in all patients within 72 hours of randomization. Measurements: clinical end points assessed during a 3-month follow-up period. Results: Equivalent efficacy was seen in the heparin group and both enoxaparin groups. Symptomatic venous thromboembolism recurred in 12 of 290 patients receiving unfractionated heparin (4.1%), 13 of 298 patients receiving once-daily enoxaparin (4.4%), and 9 of 312 patients receiving twice-daily enoxaparin (2.9%), Compared with unfractionated heparin, the treatment difference was 0.2% (95% Cl, -3.04% to 3.49%) for once-daily enoxaparin and -1.2% (Cl, -4.2% to 1.7%) for twice-daily enoxaparin. Incidence of major hemorrhage did not differ among the three treatment groups. Major hemorrhage occurred in 6 of 290 patients (2.1%) in the unfractionated heparin group, 5 of 298 patients (1.7%) in the once-daily enoxaparin group, and 4 of 312 patients (1.3%) in the twice-daily enoxaparin group. Conclusions: Subcutaneous enoxaparin once or twice daily is as effective and safe as dose-adjusted, continuously infused unfractionated heparin in the prevention of recurrent symptomatic venous thromboembolic disease.	Med Acad, Poznan, Poland; Washington Univ, Sch Med, St Louis, MO USA; Texas A&M Univ, Temple, TX USA; Univ Utah, Med Ctr, Salt Lake City, UT USA; Univ Lund Hosp, S-22185 Lund, Sweden; Royal Melbourne Hosp, Melbourne, Vic, Australia; Scripps Res Inst, La Jolla, CA 92037 USA; Inst Hematol, Tel Aviv, Israel; Virginia Mason Med Ctr, Seattle, WA 98101 USA; Aker Hosp, Oslo, Norway; Hop Antoine Beclere, Clamart, France; Aventis Pharma SA, Cardiovasc Therapeut Area, F-92165 Antony, France; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Washington University (WUSTL); Texas A&M University System; Utah System of Higher Education; University of Utah; Lund University; Skane University Hospital; Royal Melbourne Hospital; Scripps Research Institute; Virginia Mason Medical Center; University of Oslo; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Sanofi-Aventis; Sanofi France; Jefferson University	Spiro, TE (corresponding author), Aventis Pharma SA, Cardiovasc Therapeut Area, 20 Ave Raymond Aron, F-92165 Antony, France.	theodore.spiro@aventis.com						ALBADA J, 1989, CIRCULATION, V80, P935, DOI 10.1161/01.CIR.80.4.935; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; Charbonnier BA, 1998, THROMB HAEMOSTASIS, V79, P897; Clagett GP, 1998, CHEST, V114, p531S, DOI 10.1378/chest.114.5_Supplement.531S; COLLIGNON F, 1995, THROMB HAEMOSTASIS, V73, P630; COLLIGNON F, 1992, THROMB RES S1, V65, pS167; COLVIN BT, 1993, J CLIN PATHOL, V46, P97, DOI 10.1136/jcp.46.2.97; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; *DIV ANT DRUG PROD, 1992, 44 M INF DIS ADV COM; DUROUX P, 1991, THROMB HAEMOSTASIS, V65, P251; ELLIOTT CG, 1994, ARCH INTERN MED, V154, P999, DOI 10.1001/archinte.154.9.999; FAREED J, 1988, HAEMOSTASIS, V18, P3; Fiessinger JN, 1996, THROMB HAEMOSTASIS, V76, P195; HARKINS RD, 1990, DRUG INF J, V24, P213; Hirsh J, 1998, CHEST, V114, p489S, DOI 10.1378/chest.114.5_Supplement.489S; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; HOLM HA, 1986, HAEMOSTASIS, V16, P30; HUET Y, 1990, ACTA CHIR SCAND, P116; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; Hyers TM, 1998, CHEST, V114, p561S, DOI 10.1378/chest.114.5_Supplement.561S; JANVIER G, 1991, HAEMOSTASIS, V21, P161; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; Meyer G, 1995, THROMB HAEMOSTASIS, V74, P1432; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; PARENT F, 1993, THROMB HAEMOSTASIS, V69, P860; PRANDONI P, 1990, HAEMOSTASIS, V20, P220; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; RASCHKE RA, 1993, ANN INTERN MED, V119, P874, DOI 10.7326/0003-4819-119-9-199311010-00002; SCHMITT BP, 1993, AM J MED SCI, V305, P208, DOI 10.1097/00000441-199304000-00003; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; SPIRO TE, 1994, ANN INTERN MED, V121, P81, DOI 10.7326/0003-4819-121-2-199407150-00001; SUDLOW MF, 1992, LANCET, V340, P873; tenCate JW, 1997, NEW ENGL J MED, V337, P657; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003	39	264	281	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2001	134	3					191	202		10.7326/0003-4819-134-3-200102060-00009	http://dx.doi.org/10.7326/0003-4819-134-3-200102060-00009			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397KR	11177331				2022-12-28	WOS:000166695300003
J	Errington, JR; Debenedetti, PG				Errington, JR; Debenedetti, PG			Relationship between structural order and the anomalies of liquid water	NATURE			English	Article							SUPERCOOLED WATER; PHASE-TRANSITION; HEAT-CAPACITY; ENTROPY; DENSITY; DIFFUSION; BEHAVIOR	In contrast to crystalline solids-for which a precise framework exists for describing structure(1)-quantifying structural order in liquids and glasses has proved more difficult because even though such systems possess short-range order, they lack long-range crystalline order. Some progress has been made using model systems of hard spheres(2,3), but it remains difficult to describe accurately liquids such as water, where directional attractions (hydrogen bonds) combine with short-range repulsions to determine the relative orientation of neighbouring molecules as well as their instantaneous separation. This difficulty is particularly relevant when discussing the anomalous kinetic and thermodynamic properties of water, which have long been interpreted qualitatively in terms of underlying structural causes. Here we attempt to gain a quantitative understanding of these structure- property relationships through the study of translational(2,3) and orientational(4) order in a model(5) of water. Using molecular dynamics simulations, we identify a structurally anomalous region-bounded by loci of maximum orientational order (at low densities) and minimum translational order (at high densities)-in which order decreases on compression, and where orientational and translational order are strongly coupled. This region encloses the entire range of temperatures and densities for which the anomalous diffusivity(6-9) and thermal expansion coefficient(10) of water are observed, and enables us to quantify the degree of structural order needed for these anomalies to occur. We also find that these structural, kinetic and thermodynamic anomalies constitute a cascade: they occur consecutively as the degree of order is increased.	Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA	Princeton University	Debenedetti, PG (corresponding author), Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA.	pdebene@princeton.edu	Errington, Jeffrey/E-8644-2011; Debenedetti, Pablo/ABD-1497-2021	Errington, Jeffrey/0000-0003-0365-0271; Debenedetti, Pablo/0000-0003-1881-1728				Allen MP., 1990, COMPUTER SIMULATION; ANGELL CA, 1976, SCIENCE, V193, P1121, DOI 10.1126/science.193.4258.1121; ANGELL CA, 1982, J PHYS CHEM-US, V86, P998, DOI 10.1021/j100395a032; ANGELL CA, 1976, J CHEM PHYS, V65, P3063, DOI 10.1063/1.433518; Ashcroft N.W, 1976, SOLID STATE PHYS; Bellissent-Funel MC, 1998, EUROPHYS LETT, V42, P161, DOI 10.1209/epl/i1998-00223-5; BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038; Chau PL, 1998, MOL PHYS, V93, P511, DOI 10.1080/002689798169195; Debenedetti P.G., 1996, METASTABLE LIQUIDS C; DEFRIES T, 1977, J CHEM PHYS, V66, P896, DOI 10.1063/1.433995; GOLDSTEIN M, 1969, J CHEM PHYS, V51, P3728, DOI 10.1063/1.1672587; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; Mishima O, 1998, NATURE, V392, P164, DOI 10.1038/32386; NABERUKHIN YI, 1991, MOL PHYS, V73, P917, DOI 10.1080/00268979100101651; NETTLETON RE, 1958, J CHEM PHYS, V29, P1365, DOI 10.1063/1.1744724; Paschek D, 1999, J PHYS CHEM B, V103, P4139, DOI 10.1021/jp984075p; POOLE PH, 1992, NATURE, V360, P324, DOI 10.1038/360324a0; PRIELMEIER FX, 1987, PHYS REV LETT, V59, P1128, DOI 10.1103/PhysRevLett.59.1128; RUOCCO G, 1993, J CHEM PHYS, V99, P8095, DOI 10.1063/1.465635; Scala A, 2000, NATURE, V406, P166, DOI 10.1038/35018034; Sciortino F, 1999, PHYS REV LETT, V83, P3214, DOI 10.1103/PhysRevLett.83.3214; SCIORTINO F, 1991, NATURE, V354, P218, DOI 10.1038/354218a0; SCIORTINO F, 1990, PHYS REV LETT, V64, P1686, DOI 10.1103/PhysRevLett.64.1686; Shiratani E, 1998, J CHEM PHYS, V108, P3264, DOI 10.1063/1.475723; Soper AK, 2000, PHYS REV LETT, V84, P2881, DOI 10.1103/PhysRevLett.84.2881; SPEEDY RJ, 1976, J CHEM PHYS, V65, P851, DOI 10.1063/1.433153; STILLINGER FH, 1995, SCIENCE, V267, P1935, DOI 10.1126/science.267.5206.1935; Tanaka H, 1998, PHYS REV LETT, V80, P5750, DOI 10.1103/PhysRevLett.80.5750; Tanaka H, 1999, J PHYS-CONDENS MAT, V11, pL159, DOI 10.1088/0953-8984/11/15/005; Tanaka H, 2000, J CHEM PHYS, V112, P799, DOI 10.1063/1.480609; Tombari E, 1999, CHEM PHYS LETT, V300, P749, DOI 10.1016/S0009-2614(98)01392-X; Torquato S, 2000, PHYS REV LETT, V84, P2064, DOI 10.1103/PhysRevLett.84.2064; Truskett TM, 2000, PHYS REV E, V62, P993, DOI 10.1103/PhysRevE.62.993	33	1136	1144	12	340	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2001	409	6818					318	321		10.1038/35053024	http://dx.doi.org/10.1038/35053024			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201735				2022-12-28	WOS:000166434300040
J	Alves, JF; Lada, CJ; Lada, EA				Alves, JF; Lada, CJ; Lada, EA			Internal structure of a cold dark molecular cloud inferred from the extinction of background starlight	NATURE			English	Article							STAR-FORMATION; DUST EXTINCTION; CORES; GAS	Stars and planets form within dark molecular clouds, but little is understood about the internal structure of these clouds, and consequently about the initial conditions that give rise to star and planet formation. The clouds are primarily composed of molecular hydrogen, which is virtually inaccessible to direct observation. But the clouds also contain dust, which is well mixed with the gas and which has well understood effects on the transmission of light. Here we use sensitive near-infrared measurements of the light from background stars as it is absorbed and scattered by trace amounts of dust to probe the internal structure of the dark cloud Barnard 68 with unprecedented detail. We rnd the cloud's density structure to be very well described by the equations for a pressure-confined, self-gravitating isothermal sphere that is critically stable according to the Bonnor-Ebert criteria(1,2). As a result we can precisely specify the physical conditions inside a dark cloud on the verge of collapse to form a star.	European So Observ, D-85748 Garching, Germany; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Univ Florida, Dept Astron, Gainesville, FL 32608 USA	European Southern Observatory; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; State University System of Florida; University of Florida	Alves, JF (corresponding author), European So Observ, Karl Schwarzschild Str 2, D-85748 Garching, Germany.	jalves@eso.org	Alves, João/AAH-7435-2019	Alves, João/0000-0002-4355-0921				Alves J, 1999, ASTROPHYS J, V515, P265, DOI 10.1086/307003; Alves J, 1998, ASTROPHYS J, V506, P292, DOI 10.1086/306243; Appenzeller I., 1998, ESO MESSENGER, V94, P1; BASU S, 1994, ASTROPHYS J, V432, P720, DOI 10.1086/174611; BOK B, 1948, HARVARD OBSERVATORY, V7; BOK BJ, 1947, ASTROPHYS J, V105, P255, DOI 10.1086/144901; BONNOR WB, 1956, MON NOT R ASTRON SOC, V116, P351, DOI 10.1093/mnras/116.3.351; BOURKE TL, 1995, MON NOT R ASTRON SOC, V276, P1067; Breitschwerdt D, 2000, ASTRON ASTROPHYS, V361, P303; Chandler CJ, 2000, ASTROPHYS J, V530, P851, DOI 10.1086/308401; Chandrasekhar S., 1967, INTRO STUDY STELLAR, P156; CLEMENS DP, 1988, ASTROPHYS J SUPPL S, V68, P257, DOI 10.1086/191288; DEGEUS EJ, 1989, ASTRON ASTROPHYS, V216, P44; Ebert R, 1955, Z ASTROPHYS, V37, P217, DOI DOI 10.3406/RNORD.1955.2187; Emden R., 1907, GASKUGELN; Lada CJ, 1999, ASTROPHYS J, V512, P250, DOI 10.1086/306756; LADA CJ, 1994, ASTROPHYS J, V429, P694, DOI 10.1086/174354; Lane JH., 1870, AM J SCI ARTS, V4, P57, DOI [10.2475/ajs.s2-50.148.57, DOI 10.2475/AJS.S2-50.148.57]; Launhardt R, 1997, ASTRON ASTROPHYS, V326, P329; LIZANO S, 1989, ASTROPHYS J, V342, P834, DOI 10.1086/167640; MATHIS JS, 1990, ANNU REV ASTRON ASTR, V28, P37, DOI 10.1146/annurev.aa.28.090190.000345; McKee CF, 1999, NATO ADV SCI I C-MAT, V540, P29; MOORWOOD A, 1998, ESO MESSENGER, V91, P9; Mouschovias TC, 1999, NATO ADV SCI I C-MAT, V540, P305; NAKANO T, 1979, PUBL ASTRON SOC JPN, V31, P697; QUIGLEY MJS, 1965, NATURE, V208, P741, DOI 10.1038/208741a0; REIPURTH B, 1983, ASTRON ASTROPHYS, V117, P183; Reipurth B, 1996, ASTRON ASTROPHYS, V314, P258; RUCINSKI SM, 1983, ASTRON ASTROPHYS, V121, P217; Shu FH, 1999, NATO ADV SCI I C-MAT, V540, P193	30	357	358	5	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					159	161		10.1038/35051509	http://dx.doi.org/10.1038/35051509			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196632				2022-12-28	WOS:000166316200034
J	Hu, S; Chapin, FS; Firestone, MK; Field, CB; Chiariello, NR				Hu, S; Chapin, FS; Firestone, MK; Field, CB; Chiariello, NR			Nitrogen limitation of microbial decomposition in a grassland under elevated CO2	NATURE			English	Article							ATMOSPHERIC CARBON-DIOXIDE; NET PRIMARY PRODUCTION; TERRESTRIAL ECOSYSTEMS; SOIL-MICROORGANISMS; ENRICHMENT; COMPETITION; RESPIRATION; RESPONSES; FEEDBACK	Carbon accumulation in the terrestrial biosphere could partially offset the effects of anthropogenic CO2 emissions on atmospheric CO2 (refs 1, 2). The net impact of increased CO2 on the carbon balance of terrestrial ecosystems is unclear, however, because elevated CO2 effects on carbon input to soils and plant use of water and nutrients often have contrasting effects on microbial processes(3-5). Here we show suppression of microbial decomposition in an annual grassland after continuous exposure to increased CO2 for five growing seasons. The increased CO2 enhanced plant nitrogen uptake, microbial biomass carbon, and available carbon for microbes. But it reduced available soil nitrogen, exacerbated nitrogen constraints on microbes, and reduced microbial respiration per unit biomass. These results indicate that increased CO2 can alter the interaction between plants and microbes in favour of plant utilization of nitrogen, thereby slowing microbial decomposition and increasing ecosystem carbon accumulation.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Environm Sci, Berkeley, CA 94720 USA; Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Carnegie Institution for Science	Hu, S (corresponding author), N Carolina State Univ, Dept Plant Pathol, Box 7616, Raleigh, NC 27695 USA.		Chapin, F Stuart/AAZ-3931-2020	Chapin, F Stuart/0000-0002-2558-9910; Hu, Shuijin/0000-0002-3225-5126				Ball AS, 1997, GLOB CHANGE BIOL, V3, P379, DOI 10.1046/j.1365-2486.1997.t01-1-00089.x; Berntson GM, 1996, PLANT SOIL, V187, P119, DOI 10.1007/BF00017085; DeLucia EH, 1999, SCIENCE, V284, P1177, DOI 10.1126/science.284.5417.1177; DIAZ S, 1993, NATURE, V364, P616, DOI 10.1038/364616a0; Field C.B., 1996, CARBON DIOXIDE TERRE, p121e145, DOI DOI 10.1016/B978-012505295-5/50009-4; Fitter AH, 1997, NEW PHYTOL, V137, P247, DOI 10.1046/j.1469-8137.1997.00804.x; Hungate BA, 1997, NATURE, V388, P576, DOI 10.1038/41550; JACKSON RB, 1994, OECOLOGIA, V98, P257, DOI 10.1007/BF00324212; Jones TH, 1998, SCIENCE, V280, P441, DOI 10.1126/science.280.5362.441; Kaye JP, 1997, TRENDS ECOL EVOL, V12, P139, DOI 10.1016/S0169-5347(97)01001-X; Klironomos JN, 1996, FUNCT ECOL, V10, P527, DOI 10.2307/2389946; KOERNER C, 1992, SCIENCE, V257, P1672; Lambers H, 1996, PLANT SOIL, V187, P251, DOI 10.1007/BF00017091; Luo YQ, 1996, OECOLOGIA, V108, P130, DOI 10.1007/BF00333224; MCGUIRE AD, 1995, ANNU REV ECOL SYST, V26, P473, DOI 10.1146/annurev.es.26.110195.002353; Paterson E, 1997, GLOBAL CHANGE BIOL, V3, P363, DOI 10.1046/j.1365-2486.1997.t01-1-00088.x; RAICH JW, 1995, GLOBAL BIOGEOCHEM CY, V9, P23, DOI 10.1029/94GB02723; RICE CW, 1994, PLANT SOIL, V165, P67, DOI 10.1007/BF00009963; Rillig MC, 1998, OECOLOGIA, V113, P252, DOI 10.1007/s004420050376; Rillig MC, 1999, OECOLOGIA, V119, P572, DOI 10.1007/s004420050821; Rillig MC, 1999, NATURE, V400, P628, DOI 10.1038/23168; Schimel D., 1996, CLIMATE CHANGE 1995, P65; SCHIMEL DS, 1995, GLOBAL CHANGE BIOL, V1, P77, DOI 10.1111/j.1365-2486.1995.tb00008.x; Smith JL, 1990, SOIL BIOCH, V6, P357; Stark JM, 1996, SOIL SCI SOC AM J, V60, P1846, DOI 10.2136/sssaj1996.03615995006000060033x; TISDALL JM, 1994, PLANT SOIL, V159, P115, DOI 10.1007/BF00000100; VANCE ED, 1987, SOIL BIOL BIOCHEM, V19, P703, DOI 10.1016/0038-0717(87)90052-6; VITOUSEK PM, 1991, BIOGEOCHEMISTRY, V13, P87; Wang JG, 1997, SOIL BIOL BIOCHEM, V29, P163, DOI 10.1016/S0038-0717(96)00292-1; ZAK DR, 1993, PLANT SOIL, V151, P105, DOI 10.1007/BF00010791	30	271	353	22	310	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					188	191		10.1038/35051576	http://dx.doi.org/10.1038/35051576			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196641				2022-12-28	WOS:000166316200043
J	Karlsson, A; Karlsson, R; Karlsson, M; Cans, AS; Stromberg, A; Ryttsen, F; Orwar, O				Karlsson, A; Karlsson, R; Karlsson, M; Cans, AS; Stromberg, A; Ryttsen, F; Orwar, O			Molecular engineering - Networks of nanotubes and containers	NATURE			English	Article							VESICLES		Univ Gothenburg, Dept Chem, SE-41296 Gothenburg, Sweden	University of Gothenburg	Orwar, O (corresponding author), Univ Gothenburg, Dept Chem, SE-41296 Gothenburg, Sweden.		Cans, Ann-Sofie/A-5987-2011; Karlsson, Roger/AFX-3165-2022; Karlsson, Roger/A-7701-2010	Cans, Ann-Sofie/0000-0002-3059-2399; Karlsson, Roger/0000-0002-5919-2639; Stromberg, Anette/0000-0002-5792-7240				Bucher P, 1998, LANGMUIR, V14, P2712, DOI 10.1021/la971318g; Chiu DT, 1999, SCIENCE, V283, P1892, DOI 10.1126/science.283.5409.1892; Evans E, 1996, SCIENCE, V273, P933, DOI 10.1126/science.273.5277.933; Fredriksson C, 1998, J MATER SCI-MATER M, V9, P785, DOI 10.1023/A:1008927624337; Karlsson M, 2000, ANAL CHEM, V72, P5857, DOI 10.1021/ac0003246; LAPLANTE JP, 1995, J PHYS CHEM-US, V99, P10063, DOI 10.1021/j100025a001; Moscho A, 1996, P NATL ACAD SCI USA, V93, P11443, DOI 10.1073/pnas.93.21.11443; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; WAUGH RE, 1987, BIOPHYS J, V52, P391, DOI 10.1016/S0006-3495(87)83227-7	10	232	235	1	52	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					150	152		10.1038/35051656	http://dx.doi.org/10.1038/35051656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196629				2022-12-28	WOS:000166316200030
J	Bryan, SA; O'Connor, BJ; Matti, S; Leckie, MJ; Kanabar, V; Khan, J; Warrington, SJ; Renzetti, L; Rames, A; Bock, JA; Boyce, MJ; Hansel, TT; Holgate, ST; Barnes, PJ				Bryan, SA; O'Connor, BJ; Matti, S; Leckie, MJ; Kanabar, V; Khan, J; Warrington, SJ; Renzetti, L; Rames, A; Bock, JA; Boyce, MJ; Hansel, TT; Holgate, ST; Barnes, PJ			Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response	LANCET			English	Article							BROWN-NORWAY RATS; ALLERGIC-ASTHMA; CYCLOSPORINE-A; INFLAMMATION; IL-12; INHIBITION; MODULATION; DISEASES; TARGET; CELLS	Background interleukin-12 (IL-12) is a macrophage-derived cytokine that modulates T lymphocyte responses and has the capacity to suppress allergic and eosinophilic inflammation. Methods We carried out a double-blind, randomised, parallel group clinical study, in which patients with mild allergic asthma were given subcutaneous recombinant human IL-12 at increasing weekly injections of 0 .1, 0 . 25, 0 .5 mug/kg (n=19), or placebo (n=20). We compared responses to inhaled allergen challenge 24 h before the first injection and 24 h after the final injection. Airways hyper-responsiveness and concentrations of peripheral blood eosinophils and sputum eosinophils were also assessed. Findings IL-12 caused a significant decrease from baseline in the main peripheral brood eosinophil count 24 h after the fourth injection compared with placebo (p=0 . 0001). Sputum eosinophils were also significantly decreased 24 h after allergen challenge when treated with IL-12 compared with placebo (p=0 . 024). IL-12 caused a non-significant trend towards improvement in airway hyper-responsiveness to histamine, but had no significant effect on the late asthmatic reaction after inhaled allergen challenge. After administration of IL-12, four of 19 patients withdrew prematurely; two with cardiac arrhythmias, one with abnormal liver function, and a single patient with severe flu-like symptoms. Interpretation We have shown that IL-12 lowers numbers of blood and sputum eosinophils, but without any significant effects on airway hyper-responsiveness or the tate asthmatic reaction. This questions the role of eosinophils in mediating these reactions, and has important implications for development of new anti-inflammatory treatments.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; Kings Coll Hosp London, Dept Resp Med, London, England; Southampton Gen Hosp, Univ Med, Southampton, Hants, England; Hammersmith Med Res, London, England; Hoffmann La Roche Inc, Nutley, NJ 07110 USA; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland	Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of Southampton; Roche Holding; Roche Holding	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England.	p.j.barnes@ic.ac.uk	Larché, Margaret J/B-2327-2008	Boyce, Malcolm/0000-0001-8807-612X; Larche, Maggie/0000-0002-9506-1249; Barnes, Peter/0000-0002-5122-4018				CHAPMAN ID, 1993, CLIN EXP ALLERGY, V23, P168, DOI 10.1111/j.1365-2222.1993.tb00877.x; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; ELWOOD W, 1992, AM REV RESPIR DIS, V145, P1289, DOI 10.1164/ajrccm/145.6.1289; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hasko G, 1999, BRIT J PHARMACOL, V127, P1295, DOI 10.1038/sj.bjp.0702689; Kim JJ, 1997, J IMMUNOL, V158, P816; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leonard JP, 1997, BLOOD, V90, P2541; Okano Y, 1998, INT ARCH ALLERGY IMM, V115, P83, DOI 10.1159/000023834; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P1313; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Sihra BS, 1997, THORAX, V52, P447, DOI 10.1136/thx.52.5.447; SUN J, 1994, INT ARCH ALLERGY IMM, V104, P291, DOI 10.1159/000236679; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99, DOI 10.1164/ajrccm.158.1.9709091; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 1998, ALLERGY, V53, P113, DOI 10.1111/j.1398-9995.1998.tb03858.x	27	291	317	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2149	2153		10.1016/S0140-6736(00)03497-8	http://dx.doi.org/10.1016/S0140-6736(00)03497-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191543				2022-12-28	WOS:000165997300014
J	Basnyat, B				Basnyat, B			High-altitude emergency medicine	LANCET			English	Article									Inst Physiol, Kathmandu, Nepal; Patan Hosp, Patan, Nepal; Nepal Int Clin, Kathmandu, Nepal		Basnyat, B (corresponding author), Nepal Int Clin, GPO Box 3596, Kathmandu, Nepal.								0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S1	S1		10.1016/S0140-6736(00)91987-1	http://dx.doi.org/10.1016/S0140-6736(00)91987-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191464				2022-12-28	WOS:000166074900003
J	Edejer, TTT				Edejer, TTT			The ethics of drug trials in less-developed countries	LANCET			English	Article									WHO, Global Programme Evidence Hlth Policy, CH-1211 Geneva 27, Switzerland	World Health Organization	Edejer, TTT (corresponding author), WHO, Global Programme Evidence Hlth Policy, CH-1211 Geneva 27, Switzerland.	tantorres@who.ch							0	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC	2000	356			S			S37	S37		10.1016/S0140-6736(00)92023-3	http://dx.doi.org/10.1016/S0140-6736(00)92023-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191494				2022-12-28	WOS:000166074900039
J	Fainsinger, RL				Fainsinger, RL			A century of progress in palliative care	LANCET			English	Article									Royal Alexandra Hosp, Palliat Cre Program, Edmonton, AB T5H 3V9, Canada	Royal Alexandra Hospital	Fainsinger, RL (corresponding author), Royal Alexandra Hosp, Palliat Cre Program, Edmonton, AB T5H 3V9, Canada.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S24	S24		10.1016/S0140-6736(00)92010-5	http://dx.doi.org/10.1016/S0140-6736(00)92010-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191480				2022-12-28	WOS:000166074900026
J	Rebhandl, E				Rebhandl, E			Everyday life in general practice	LANCET			English	Article											Rebhandl, E (corresponding author), Marktpl 43, A-4170 Haslach, Austria.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S30	S30		10.1016/S0140-6736(00)92016-6	http://dx.doi.org/10.1016/S0140-6736(00)92016-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191487				2022-12-28	WOS:000166074900032
J	Potts, JL; Jordan, D				Potts, JL; Jordan, D			Missed diagnoses of acute cardiac ischemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Meharry Med Coll, Nashville, TN 37208 USA	Meharry Medical College	Potts, JL (corresponding author), Meharry Med Coll, Nashville, TN 37208 USA.							Canto JG, 2000, NEW ENGL J MED, V342, P1094, DOI 10.1056/NEJM200004133421505; Schulman KA, 1999, NEW ENGL J MED, V340, P1130	2	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1493	1493						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184462				2022-12-28	WOS:000165271300016
J	Noselli, S; Perrimon, N				Noselli, S; Perrimon, N			Signal transduction - Are there close encounters between signaling pathways?	SCIENCE			English	Editorial Material							MAP KINASES; ACTIVATION; DROSOPHILA; RECEPTOR		Inst Rech, CNRS, UMR 65643, F-06108 Nice 2, France; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02215 USA	Centre National de la Recherche Scientifique (CNRS); Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Noselli, S (corresponding author), Inst Rech, CNRS, UMR 65643, Parc Valrose, F-06108 Nice 2, France.	noselli@unice.fr; perrimon@rascal.med.harvard.edu	Perrimon, Norbert/F-9766-2011	Perrimon, Norbert/0000-0001-7542-472X; Noselli, stephane/0000-0002-7296-324X				Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; Engstrom L, 1997, CURR TOP DEV BIOL, V35, P229, DOI 10.1016/S0070-2153(08)60261-6; Gabay L, 1997, DEVELOPMENT, V124, P3535; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Therond PP, 1999, DEVELOPMENT, V126, P4039; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	13	27	29	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 6	2000	290	5489					68	69		10.1126/science.290.5489.68	http://dx.doi.org/10.1126/science.290.5489.68			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	361LP	11183153				2022-12-28	WOS:000089724800033
J	Psaty, BM; Smith, NL; Lemaitre, RN; Vos, HL; Heckbert, SR; LaCroix, AZ; Rosendaal, FR				Psaty, BM; Smith, NL; Lemaitre, RN; Vos, HL; Heckbert, SR; LaCroix, AZ; Rosendaal, FR			Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FACTOR-V-LEIDEN; CORONARY HEART-DISEASE; ACTIVATED PROTEIN-C; GENE-ENVIRONMENT INTERACTION; COAGULATION-FACTOR-V; VENOUS THROMBOSIS; 3'-UNTRANSLATED REGION; VASCULAR-DISEASE; YOUNG-WOMEN; FACTOR-II	Context Estrogens are known to be prothrombotic, and findings from the Heart and Estrogen/progestin Replacement Study suggest that in women with clinically recognized heart disease, hormone replacement therapy (HRT) may be associated with early harm and late benefit in terms of coronary events. Objective To assess whether, as hypothesized, prothrombotic mutations modify the association between HRT use and incidence of first myocardial infarction (MI). Design and Setting Population-based, case-control study conducted in a Seattle-based health maintenance organization. Participants Cases were 232 postmenopausal women aged 30 to 79 years who had their first nonfatal MI between 1995 and 1998. Controls were a stratified random sample of 723 postmenopausal women without MI who were frequency-matched to cases by age. calendar year, and hypertension status. Main Outcome Measure Risk of first nonfatal MI based on current use of HRT and the presence or absence of coagulation factor V Leiden and prothrombin 20210 G-->A variants among cases and controls, stratified by hypertension. Results One hundred eight MI cases and 387 controls had hypertension and 124 MI cases and 336 controls did not. Among hypertensive women, the prothrombin variant was a risk factor for MI (odds ratio [OR], 4.32; 95% confidence interval [CI], 1.52-12.1) and, in this stratum, there was also a significant interaction between use of HRT and presence of the prothrombin variant on risk of Mi. Compared with nonusers of HRT with wild-type genotype, women who were current users and who had the prothrombin variant (n=8) had a nearly Ii-fold increase in risk of a nonfatal MI (OR, 10.9; 95% CI, 2.15-55.2). The interaction with the prothrombin variant was more pronounced in analyses assuming 100% compliance than in those assuming 80% compliance with HRT, The interaction was absent among nonhypertensive women and was less pronounced if hypertensive and nonhypertensive women were combined into 1 group. No interaction was found for factor V Leiden in either hypertensive or nonhypertensive women. Among hypertensive women, the estimates were affected only in trivial ways by adjustment, and the interaction with the prothrombin variant was specific to HRT. Conclusions Our results suggest that among postmenopausal hypertensive women, the association between HRT use and MI risk differed between those with and without. the prothrombin 20210 G-->A variant. If these findings are confirmed in other studies. screening for the prothrombin variant may permit a better assessment of the risks and benefits associated with HRT in postmenopausal women.	Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98101 USA; Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98101 USA; Univ Washington, Cardiovasc Hlth Res Unit, Dept Hlth Serv, Seattle, WA 98101 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Group Health Cooperative; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Psaty, BM (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060739, R01HL043201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43201, HL60739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1970, JAMA, V214, P1303; Arruda VR, 1998, CARDIOVASC RES, V37, P42, DOI 10.1016/S0008-6363(97)00211-3; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BARRETTCONNOR E, 1998, ANNU REV PUBL HEALTH, V19, P35; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Cushman M, 1998, THROMB HAEMOSTASIS, V79, P912; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Doggen CJM, 1998, CIRCULATION, V97, P1037, DOI 10.1161/01.CIR.97.11.1037; Franco RF, 1999, BRIT J HAEMATOL, V104, P50, DOI 10.1046/j.1365-2141.1999.01149.x; Gardemann A, 1999, THROMB HAEMOSTASIS, V81, P208; Glueck CJ, 1999, AM J CARDIOL, V84, P549, DOI 10.1016/S0002-9149(99)00375-6; GRADY D, 1992, ANN INTERN MED, V117, P1038; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; Khoury MJ, 1996, AM J EPIDEMIOL, V144, P207; Lip GYH, 2000, HYPERTENSION, V36, P975, DOI 10.1161/01.HYP.36.6.975; Lowe G, 2000, THROMB HAEMOSTASIS, V83, P530; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; PEARCE N, 1993, INT J EPIDEMIOL, V22, P1189, DOI 10.1093/ije/22.6.1189; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; PSATY BM, 1993, ARCH INTERN MED, V153, P1421, DOI 10.1001/archinte.153.12.1421; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; PSATY BM, 1991, STAT MED, V10, P653, DOI 10.1002/sim.4780100416; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; PSATY BM, 1989, JAMA-J AM MED ASSOC, V261, P2087, DOI 10.1001/jama.261.14.2087; Redondo M, 1999, ARTERIOSCL THROM VAS, V19, P1020, DOI 10.1161/01.ATV.19.4.1020; Ridker PM, 1999, CIRCULATION, V99, P999, DOI 10.1161/01.CIR.99.8.999; Rosendaal FR, 1997, BLOOD, V89, P2817, DOI 10.1182/blood.V89.8.2817; Rosendaal FR, 1999, LANCET, V353, P1167, DOI 10.1016/S0140-6736(98)10266-0; Rosendaal FR, 1997, BLOOD, V90, P1747, DOI 10.1182/blood.V90.5.1747; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Sechi LA, 2000, HYPERTENSION, V36, P978, DOI 10.1161/01.HYP.36.6.978; SMITH PG, 1984, INT J EPIDEMIOL, V13, P356, DOI 10.1093/ije/13.3.356; SOTANIEMI EA, 1975, SCAND J UROL NEPHROL, V9, P89, DOI 10.3109/00365597509180912; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; Yang QH, 1997, AM J EPIDEMIOL, V146, P713	43	123	127	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					906	913		10.1001/jama.285.7.906	http://dx.doi.org/10.1001/jama.285.7.906			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402BE	11180734	Bronze			2022-12-28	WOS:000166965500028
J	Kollef, MH; Fraser, VJ				Kollef, MH; Fraser, VJ			Antibiotic resistance in the intensive care unit	ANNALS OF INTERNAL MEDICINE			English	Review							VENTILATOR-ASSOCIATED PNEUMONIA; CENTRAL VENOUS CATHETERS; GRAM-NEGATIVE BACILLI; STAPHYLOCOCCUS-AUREUS MRSA; NOSOCOMIAL INFECTION RISK; BLOOD-STREAM INFECTION; LENGTH-OF-STAY; VANCOMYCIN-RESISTANT; METHICILLIN-RESISTANT; MECHANICAL VENTILATION	Antimicrobial resistance has emerged as an important determinant of outcome for patients in the intensive care unit (ICU). This is largely due to the administration of inadequate antimicrobial treatment which is most often related to bacterial antibiotic resistance. In addition, the escalating problem of antimicrobial resistance has substantially increased overall health care costs. This increase is a result of prolonged hospitalizations and convalescence associated with antibiotic treatment failures, the need to develop new antimicrobial agents, and the implementation of broader infection control and public health interventions aimed at curbing the spread of antibiotic-resistant pathogens. Intensive care units are unique because they house seriously ill patients in confined environments where antibiotic use is extremely common. They have been focal points for the emergence and spread of antibiotic-resistant pathogens. Effective strategies for the prevention of antimicrobial resistance in ICUs have focused on limiting the unnecessary use of antibiotics and increasing compliance with infection control practices, Clinicians caring for critically ill patients should consider antimicrobial resistance as part of their routine treatment plans. Careful, focused attention to this problem at the local ICU level, using a multidisciplinary approach, will have the greatest likelihood of limiting the development and dissemination of antibiotic-resistant infections.	Washington Univ, Sch Med, St Louis, MO 63110 USA; Barnes Jewish Hosp, St Louis, MO 63110 USA	Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Kollef, MH (corresponding author), Washington Univ, Sch Med, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	kollefm@msnotes.wustl.edu		Fraser, Victoria/0000-0001-6251-0733	PHS HHS [UR8/CCU715087] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acar JF, 1997, CLIN INFECT DIS, V24, pS17, DOI 10.1093/clinids/24.Supplement_1.S17; ADAIR CG, 1999, INTENS CARE MED, V116, P1339; Agerberth B, 1999, AM J RESP CRIT CARE, V160, P283, DOI 10.1164/ajrccm.160.1.9807041; Ailani RK, 1999, ARCH INTERN MED, V159, P266, DOI 10.1001/archinte.159.3.266; Alfieri N, 1999, INFECT CONT HOSP EP, V20, P553, DOI 10.1086/501668; AlvarezLerma F, 1996, INTENS CARE MED, V22, P387, DOI 10.1007/BF01712153; Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; Archer GL, 1998, CLIN INFECT DIS, V26, P1179, DOI 10.1086/520289; Archibald L, 1997, CLIN INFECT DIS, V24, P211, DOI 10.1093/clinids/24.2.211; Archibald LK, 1997, PEDIATR INFECT DIS J, V16, P1045, DOI 10.1097/00006454-199711000-00008; Austin DJ, 1999, P NATL ACAD SCI USA, V96, P6908, DOI 10.1073/pnas.96.12.6908; Bach A, 1999, INFECTION, V27, pS11, DOI 10.1007/BF02561611; Bailey TC, 1997, PHARMACOTHERAPY, V17, P277; BALLOW CH, 1992, DIAGN MICROBIOL INFE, V15, P37; Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; Bax RP, 1997, CLIN INFECT DIS, V24, pS151, DOI 10.1093/clinids/24.Supplement_1.S151; BERGOGNEBEREZIN E, 1995, CHEST, V108, pS26, DOI 10.1378/chest.108.2_Supplement.26S; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P12106, DOI 10.1073/pnas.94.22.12106; Bonten MJM, 1998, CRIT CARE MED, V26, P2001, DOI 10.1097/00003246-199812000-00029; Bonten MJM, 1996, INFECT CONT HOSP EP, V17, P193; BOYCE JM, 1985, AM J INFECT CONTROL, V13, P228, DOI 10.1016/0196-6553(85)90063-X; Braga M, 1998, CRIT CARE MED, V26, P24, DOI 10.1097/00003246-199801000-00012; Brun-Buisson C, 1998, CLIN INFECT DIS, V26, P346, DOI 10.1086/516294; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; BRYAN CS, 1983, REV INFECT DIS, V5, P629; Burke JP, 1998, JAMA-J AM MED ASSOC, V280, P1270, DOI 10.1001/jama.280.14.1270; Byl B, 1999, CLIN INFECT DIS, V29, P60, DOI 10.1086/520182; Caballero-Granado FJ, 1998, J CLIN MICROBIOL, V36, P520, DOI 10.1128/JCM.36.2.520-525.1998; Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711; Campbell JR, 1998, INFECT CONT HOSP EP, V19, P924; Carmeli Y, 1999, ARCH INTERN MED, V159, P1127, DOI 10.1001/archinte.159.10.1127; Carr JR, 1997, INFECT CONT HOSP EP, V18, P255; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Clemmer TP, 1998, ANN INTERN MED, V128, P1004, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00008; Climo MW, 1998, ANN INTERN MED, V128, P989, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00005; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Comolli JC, 1999, INFECT IMMUN, V67, P3625, DOI 10.1128/IAI.67.7.3625-3630.1999; Craig WA, 1997, DIAGN MICR INFEC DIS, V27, P49, DOI 10.1016/S0732-8893(97)00022-9; CRAVEN DE, 1991, AM J MED, V91, pS44, DOI 10.1016/0002-9343(91)90343-V; Croce MA, 1995, J TRAUMA, V39, P1134, DOI 10.1097/00005373-199512000-00022; Cunha BA, 1997, POSTGRAD MED, V101, P68, DOI 10.3810/pgm.1997.04.197; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; Dagan O, 1999, CRIT CARE MED, V27, P104, DOI 10.1097/00003246-199901000-00035; Darouiche RO, 1997, NUTRITION, V13, pS26, DOI 10.1016/S0899-9007(97)00219-0; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; Denton M, 1998, CLIN MICROBIOL REV, V11, P57, DOI 10.1128/CMR.11.1.57; DESANTIS G, 1994, MED J AUSTRALIA, V160, P502; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; Dominguez EA, 2000, INFECT CONT HOSP EP, V21, pS4, DOI 10.1086/503166; DUBBERT PM, 1990, INFECT CONT HOSP EP, V11, P191; EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126; Elliott TSJ, 1998, J HOSP INFECT, V40, P193, DOI 10.1016/S0195-6701(98)90137-2; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; Fagon JY, 2000, ANN INTERN MED, V132, P621, DOI 10.7326/0003-4819-132-8-200004180-00004; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; Farrington M, 1998, QJM-MON J ASSOC PHYS, V91, P539, DOI 10.1093/qjmed/91.8.539; Fraser GL, 1997, ARCH INTERN MED, V157, P1689, DOI 10.1001/archinte.157.15.1689; Fridkin SK, 1996, INFECT CONT HOSP EP, V17, P150; Fry D E, 1996, Am J Surg, V172, p20S; Gaynes RP, 1996, JOINT COMM J QUAL IM, V22, P457, DOI 10.1016/S1070-3241(16)30248-6; GERDING DN, 1991, ANTIMICROB AGENTS CH, V35, P1284, DOI 10.1128/AAC.35.7.1284; Giamarellou H, 1997, CIBA F SYMP, V207, P76; Gleason PP, 1997, JAMA-J AM MED ASSOC, V278, P32, DOI 10.1001/jama.278.1.32; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; GOLDMANN D, 1992, NEW ENGL J MED, V327, P120, DOI 10.1056/NEJM199207093270211; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Griffith CH, 1999, CRIT CARE MED, V27, P815, DOI 10.1097/00003246-199904000-00043; Gross PA, 1997, INFECT DIS CLIN N AM, V11, P803, DOI 10.1016/S0891-5520(05)70391-3; Gruson D, 2000, AM J RESP CRIT CARE, V162, P837, DOI 10.1164/ajrccm.162.3.9905050; HALEY RW, 1982, J INFECT DIS, V145, P875, DOI 10.1093/infdis/145.6.875; HAMMOND JMJ, 1995, CRIT CARE MED, V23, P637, DOI 10.1097/00003246-199504000-00010; Hanberger H, 1999, JAMA-J AM MED ASSOC, V281, P67, DOI 10.1001/jama.281.1.67; Hancock REW, 1997, CLIN INFECT DIS, V24, pS148, DOI 10.1093/clinids/24.Supplement_1.S148; HARDBARTH S, 1999, INFECT CONT HOSP EP, V20, P598; HARTSTEIN AI, 1995, INFECT CONT HOSP EP, V16, P405; Hay JA, 1997, JAMA-J AM MED ASSOC, V278, P2151, DOI 10.1001/jama.278.24.2151; Herceg A, 1997, Commun Dis Intell, V21, P173; Herchline T, 1997, INFECT CONT HOSP EP, V18, P38; Heyland DK, 1999, AM J RESP CRIT CARE, V159, P1249, DOI 10.1164/ajrccm.159.4.9807050; HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065; Husni RN, 1999, CHEST, V115, P1378, DOI 10.1378/chest.115.5.1378; Ibrahim EH, 2000, CHEST, V117, P1434, DOI 10.1378/chest.117.5.1434; JARVIS WR, 1994, LANCET, V344, P1311, DOI 10.1016/S0140-6736(94)90687-4; Jernigan JA, 1996, AM J EPIDEMIOL, V143, P496, DOI 10.1093/oxfordjournals.aje.a008770; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; Joiner G A, 1996, Am J Med Qual, V11, P100, DOI 10.1177/0885713X9601100208; Jones RN, 1996, DIAGN MICR INFEC DIS, V25, P153, DOI 10.1016/S0732-8893(96)00099-5; Kaplan SL, 1998, PEDIATRICS, V102, P538, DOI 10.1542/peds.102.3.538; KELLEGHAN SI, 1993, AM J INFECT CONTROL, V21, P322, DOI 10.1016/0196-6553(93)90390-P; KLEIN BS, 1989, NEW ENGL J MED, V320, P1714, DOI 10.1056/NEJM198906293202603; Kollef MH, 1999, INTENS CARE MED, V25, P553, DOI 10.1007/s001340050902; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P466, DOI 10.1164/ajrccm.156.2.9612083; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P1040, DOI 10.1164/ajrccm.156.4.9701046; Kollef MH, 1999, CHEST, V115, P462, DOI 10.1378/chest.115.2.462; Kollef MH, 1999, CHEST, V115, P8, DOI 10.1378/chest.115.1.8; Kollef MH, 1998, CHEST, V113, P412, DOI 10.1378/chest.113.2.412; Kollef MH, 1998, CHEST, V113, P267, DOI 10.1378/chest.113.2.267; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kollef MH, 1997, CHEST, V112, P666, DOI 10.1378/chest.112.3.666; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; Kollef NH, 2000, CRIT CARE MED, V28, P3456, DOI 10.1097/00003246-200010000-00014; Kristensen B, 1999, J MED MICROBIOL, V48, P67, DOI 10.1099/00222615-48-1-67; Lai KK, 1998, INFECT CONT HOSP EP, V19, P647; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; Langley C, 1998, FAM PRACT, V15, P105, DOI 10.1093/fampra/15.2.105; Larson E, 1999, CLIN INFECT DIS, V29, P1287, DOI 10.1086/313468; Leibovici L, 1997, ANTIMICROB AGENTS CH, V41, P1127, DOI 10.1128/AAC.41.5.1127; Leibovici L, 1997, J INTERN MED, V242, P395, DOI 10.1046/j.1365-2796.1997.00232.x; Leibovici L, 1998, J INTERN MED, V244, P379; Livermore DM, 1996, J ANTIMICROB CHEMOTH, V38, P409, DOI 10.1093/jac/38.3.409; Lucas GM, 1998, CLIN INFECT DIS, V26, P1127, DOI 10.1086/520311; Luna CM, 1997, CHEST, V111, P676, DOI 10.1378/chest.111.3.676; Maas A, 1998, J HOSP INFECT, V40, P211, DOI 10.1016/S0195-6701(98)90139-6; Mainous MR, 1997, ARCH SURG-CHICAGO, V132, P76; Mansouri E, 1999, INFECT IMMUN, V67, P1461, DOI 10.1128/IAI.67.3.1461-1470.1999; MARTY L, 1993, INTENS CARE MED, V19, P285, DOI 10.1007/BF01690549; McGowan J E Jr, 1996, New Horiz, V4, P370; MCGOWAN JE, 1991, REV MED MICROBIOL, V2, P161; McGuckin M, 1999, AM J INFECT CONTROL, V27, P309, DOI 10.1016/S0196-6553(99)70049-0; McKenney D, 1999, SCIENCE, V284, P1523, DOI 10.1126/science.284.5419.1523; McNulty C, 1997, J ANTIMICROB CHEMOTH, V40, P707, DOI 10.1093/jac/40.5.707; Mebis J, 1998, LEUKEMIA, V12, P1627, DOI 10.1038/sj.leu.2401158; MERMEL LA, 1994, AM J RESP CRIT CARE, V149, P1020, DOI 10.1164/ajrccm.149.4.8143037; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; Minard G, 1998, WORLD J SURG, V22, P213, DOI 10.1007/s002689900372; Moellering RC, 1999, ANN INTERN MED, V130, P155, DOI 10.7326/0003-4819-130-2-199901190-00012; Molstad S, 1999, SCAND J INFECT DIS, V31, P191, DOI 10.1080/003655499750006263; Montecalvo MA, 1999, ANN INTERN MED, V131, P269, DOI 10.7326/0003-4819-131-4-199908170-00006; Nathens AB, 1999, ARCH SURG-CHICAGO, V134, P170, DOI 10.1001/archsurg.134.2.170; Nava S, 1998, ANN INTERN MED, V128, P721, DOI 10.7326/0003-4819-128-9-199805010-00004; Nichol KL, 1999, JAMA-J AM MED ASSOC, V282, P137, DOI 10.1001/jama.282.2.137; Niederman MS, 1997, AM J RESP CRIT CARE, V156, P1029, DOI 10.1164/ajrccm.156.4.ed-14; Nourdine K, 1999, INTENS CARE MED, V25, P567, DOI 10.1007/s001340050904; OConnor PJ, 1996, JOINT COMM J QUAL IM, V22, P673, DOI 10.1016/S1070-3241(16)30274-7; *OFF TECHN ASS C, 1995, OFF TECHN ASS C PUBL; Onion CWR, 1998, FAM PRACT, V15, P99, DOI 10.1093/fampra/15.2.99; Ortiz J, 1999, HEPATOLOGY, V29, P1064, DOI 10.1002/hep.510290406; PARRAS F, 1994, INFECT CONT HOSP EP, V15, P239; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; PESTOTNIK SL, 1993, ANN PHARMACOTHER, V27, P497, DOI 10.1177/106002809302700418; Peterson WL, 1997, JAMA-J AM MED ASSOC, V278, P2186; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Quale J, 1996, AM J INFECT CONTROL, V24, P372, DOI 10.1016/S0196-6553(96)90025-5; Quale J, 1996, CLIN INFECT DIS, V23, P1020, DOI 10.1093/clinids/23.5.1020; Quinn JP, 1998, CLIN INFECT DIS, V27, pS117, DOI 10.1086/514912; Rahal JJ, 1998, JAMA-J AM MED ASSOC, V280, P1233, DOI 10.1001/jama.280.14.1233; Reboli AC, 1996, INFECT CONT HOSP EP, V17, P741; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Rello J, 1999, AM J RESP CRIT CARE, V160, P608, DOI 10.1164/ajrccm.160.2.9812034; RELLO J, 1994, AM J RESP CRIT CARE, V150, P1545, DOI 10.1164/ajrccm.150.6.7952612; Rello J, 1997, AM J RESP CRIT CARE, V156, P196, DOI 10.1164/ajrccm.156.1.9607030; Rice LB, 1996, CLIN INFECT DIS, V23, P118, DOI 10.1093/clinids/23.1.118; Richards MJ, 1999, CRIT CARE MED, V27, P887, DOI 10.1097/00003246-199905000-00020; Rifenburg RP, 1996, AM J HEALTH-SYST PH, V53, P2054, DOI 10.1093/ajhp/53.17.2054; Rosch W, 1999, INFECTION, V27, pS74, DOI 10.1007/BF02561624; Russell AD, 1997, J APPL MICROBIOL, V83, P155, DOI 10.1046/j.1365-2672.1997.00198.x; Sanders W. Eugene, 1997, Clin Microbiol Infect, V3, P272, DOI 10.1111/j.1469-0691.1997.tb00613.x; Scheckler WE, 1998, AM J INFECT CONTROL, V26, P47, DOI 10.1016/S0196-6553(98)70061-6; Schentag JJ, 1998, CLIN INFECT DIS, V26, P1204, DOI 10.1086/520287; Schiappa DA, 1996, J INFECT DIS, V174, P529, DOI 10.1093/infdis/174.3.529; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1437, DOI 10.1056/NEJM198405313102206; Shlaes DM, 1997, CLIN INFECT DIS, V25, P584, DOI 10.1086/513766; Siegman-Igra Y, 1998, Int J Infect Dis, V2, P211, DOI 10.1016/S1201-9712(98)90055-8; Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704; Singh N, 2000, AM J RESP CRIT CARE, V162, P505, DOI 10.1164/ajrccm.162.2.9909095; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Slaughter S, 1996, ANN INTERN MED, V125, P448, DOI 10.7326/0003-4819-125-6-199609150-00004; Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701; Soifer NE, 1998, ARCH INTERN MED, V158, P473, DOI 10.1001/archinte.158.5.473; Solovova IP, 1996, PETROLOGY, V4, P319; Steinberg DA, 1997, ANTIMICROB AGENTS CH, V41, P1738, DOI 10.1128/AAC.41.8.1738; Steinberg JP, 1996, CLIN INFECT DIS, V23, P255, DOI 10.1093/clinids/23.2.255; Tarkowski A, 1998, MOL MED TODAY, V4, P15, DOI 10.1016/S1357-4310(97)80540-0; THORENS JB, 1995, CRIT CARE MED, V23, P1807, DOI 10.1097/00003246-199511000-00004; Thurn JR, 1996, J HOSP INFECT, V32, P127, DOI 10.1016/S0195-6701(96)90054-7; Trouillet JL, 1998, AM J RESP CRIT CARE, V157, P531, DOI 10.1164/ajrccm.157.2.9705064; URBAN C, 1993, J INFECT DIS, V167, P448, DOI 10.1093/infdis/167.2.448; Van Delden C, 1998, EMERG INFECT DIS, V4, P551, DOI 10.3201/eid0404.980405; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V281, P261, DOI 10.1001/jama.281.3.261; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V282, P554, DOI 10.1001/jama.282.6.554; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014; Vidal F, 1996, ARCH INTERN MED, V156, P2121, DOI 10.1001/archinte.156.18.2121; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Voss A, 1997, INFECT CONT HOSP EP, V18, P205; Waldvogel FA, 1999, NEW ENGL J MED, V340, P556, DOI 10.1056/NEJM199902183400709; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; Wiener J, 1999, JAMA-J AM MED ASSOC, V281, P517, DOI 10.1001/jama.281.6.517; Yates RR, 1999, CHEST, V115, p24S, DOI 10.1378/chest.115.suppl_1.24S; Young RJ, 1997, J ANTIMICROB CHEMOTH, V40, P269, DOI 10.1093/jac/40.2.269; Zaragoza M, 1999, AM J INFECT CONTROL, V27, P258, DOI 10.1053/ic.1999.v27.a97622; Zoutman D, 1998, INFECT CONT HOSP EP, V19, P254	203	321	350	0	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					298	314		10.7326/0003-4819-134-4-200102200-00014	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00014			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NW	11182841				2022-12-28	WOS:000167050200007
J	Edwards, S; Tenant-Flowers, M; Buggy, J; Horne, P; Hulme, N; Easterbrook, P; Taylor, C				Edwards, S; Tenant-Flowers, M; Buggy, J; Horne, P; Hulme, N; Easterbrook, P; Taylor, C			Issues in the management of prisoners infected with HIV-1: the King's College Hospital HIV prison service retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article									Kings Coll London Hosp, Caldecot Ctr, Dept Genitourinary HIV Med, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Edwards, S (corresponding author), Kings Coll London Hosp, Caldecot Ctr, Dept Genitourinary HIV Med, London SE5 9RS, England.	S.Edwards@cichs-tr.nthames.nhs.uk	Easterbrook, Philippa J/A-3937-2009	Easterbrook, Philippa/0000-0002-2603-5418				DIXON PS, 1993, AM J MED, V95, P629, DOI 10.1016/0002-9343(93)90359-W; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; Her Majesty's Chief Inspector for Health Care in Prisons, 1996, PAT PRIS NEW STRAT H; *JOINT PRIS SERV N, 1999, FUT ORG DEL PRIS HL; WALSH JC, 1998, 38 INT C ANT AG CHEM	5	11	12	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 17	2001	322	7283					398	399		10.1136/bmj.322.7283.398	http://dx.doi.org/10.1136/bmj.322.7283.398			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404JH	11179158	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000167093600026
J	Schwetz, BA				Schwetz, BA			New treatment for eczema	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Off Commissioner Food & Drugs, Rockville, MD 20857 USA		Schwetz, BA (corresponding author), Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					724	724		10.1001/jama.285.6.724-a	http://dx.doi.org/10.1001/jama.285.6.724-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176890				2022-12-28	WOS:000166817200005
J	Goldenberg, RL; Jobe, AH				Goldenberg, RL; Jobe, AH			Prospects for research in reproductive health and birth outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MATERNAL MORTALITY; DRUG-THERAPY; PREVENTION; TERMINATION; MECHANISMS; DELIVERY; WEIGHT; WORLD	In the last several decades there have been major improvements in the ability to control fertility, treat infertility, and reduce maternal, fetal, and infant mortality. However, neither the preterm birth rate nor the rate of long-term neurologic disabilities associated with preterm birth has declined. Increasing knowledge of the events leading to preterm birth and the pathophysiology of neonatal brain and lung injury suggests that the mortality and longterm impairments associated with these conditions will decrease. The large disparities in reproductive health and birth outcomes between industrialized and developing countries and between most other ethnic groups and blacks in the United States could be reduced by better access to already existing effective interventions.	Univ Alabama Birmingham, Sch Med, Dept Obstet & Gynecol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Res Womens Hlth, Birmingham, AL 35233 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Cincinnati Children's Hospital Medical Center	Goldenberg, RL (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Obstet & Gynecol, 618 S 20th St, Birmingham, AL 35233 USA.	Robert.Goldenberg@ccc.uab.edu						Barker DJP, 1999, ANN MED, V31, P3, DOI 10.1080/07853890.1999.11904392; BROWN SS, 1995, BEST INTENTIONS UNIN, P2; BWAYO J, 1995, AM J OBSTET GYNECOL, V172, P700, DOI 10.1016/0002-9378(95)90597-9; *CHILD HLTH RES PR, 1999, P USAIDS CHILD HLTH; Christin-Maitre S, 2000, NEW ENGL J MED, V342, P946, DOI 10.1056/NEJM200003303421307; Clyman RI, 1996, J PEDIATR-US, V128, P601, DOI 10.1016/S0022-3476(96)80123-5; *COMM UN PREG DIV, 1995, BEST INT UN PREGN WE, P25; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; Ehrenkranz R.A., 1992, EFFECTIVE CARE NEWBO; Evans MI, 1999, AM J OBSTET GYNECOL, V181, P893, DOI 10.1016/S0002-9378(99)70321-2; Fathalla MF, 1991, ANN NY ACAD SCI, V626, P1; GILSTRAP LC, 1995, JAMA-J AM MED ASSOC, V273, P413, DOI 10.1001/jama.1995.03520290065031; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Guyer B, 1999, PEDIATRICS, V104, P1229, DOI 10.1542/peds.104.6.1229; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; JOBE AH, 1993, NEW ENGL J MED, V328, P861; Jobe AH, 1998, AM J OBSTET GYNECOL, V178, P880, DOI 10.1016/S0002-9378(98)70518-6; Kitano Y, 1999, SEMIN PERINATOL, V23, P448, DOI 10.1016/S0146-0005(99)80024-X; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; LIGGINS GC, 1972, PEDIATRICS, V50, P515; LIGGINS GC, 1969, J ENDOCRINOL, V45, P515, DOI 10.1677/joe.0.0450515; Liljestrand J, 1999, BRIT J OBSTET GYNAEC, V106, P877, DOI 10.1111/j.1471-0528.1999.tb08423.x; Maine D, 1999, AM J PUBLIC HEALTH, V89, P480, DOI 10.2105/AJPH.89.4.480; MCFALLS JA, 2001, POBUL B; Mullen PD, 1999, PRIMARY CARE, V26, P577, DOI 10.1016/S0095-4543(05)70118-4; Nelson KB, 1998, ANN NEUROL, V44, P665, DOI 10.1002/ana.410440413; NOWAK R, 1994, SCIENCE, V269, P780; OAKLEY GP, 1993, JAMA-J AM MED ASSOC, V269, P1292, DOI 10.1001/jama.269.10.1292; ORLEANS CT, 2000, TOP CONTROL S3, V9; Perl AKT, 1999, CLIN GENET, V56, P14, DOI 10.1034/j.1399-0004.1999.560103.x; *PHS HLTH RES SERV, 1997, DHHS PUBL; Ray PF, 1999, PRENATAL DIAG, V19, P1237, DOI 10.1002/(SICI)1097-0223(199912)19:13<1237::AID-PD726>3.0.CO;2-O; RESNIK R, 1998, MATERNAL FETAL MED, P1194; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; ROSENFIELD A, 1985, LANCET, V2, P83; SCIARRA JJ, 1993, AM J OBSTET GYNECOL, V168, P1649, DOI 10.1016/0002-9378(93)90674-8; Stevenson DK, 1998, AM J OBSTET GYNECOL, V179, P1632, DOI 10.1016/S0002-9378(98)70037-7; Stoll BJ, 1997, CLIN PERINATOL, V24, P1; Tarlatzis BC, 2000, ANN NY ACAD SCI, V900, P336; Van Marter LJ, 2000, PEDIATRICS, V105, P1194, DOI 10.1542/peds.105.6.1194; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; *WHO, 2001, INF DIS REP REM OBST; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029	44	61	63	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					633	639		10.1001/jama.285.5.633	http://dx.doi.org/10.1001/jama.285.5.633			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176872				2022-12-28	WOS:000166714200025
J	Wilson, JD				Wilson, JD			Prospects for research for disorders of the endocrine system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LUTEINIZING-HORMONE RECEPTOR; THYROTROPIN RECEPTOR; PRECOCIOUS PUBERTY; THYROID-HORMONE; MUTATIONS; AUTOANTIBODIES; RESISTANCE; GENE	Endocrine disorders, primarily diseases of the thyroid, parathyroids, pituitary, gonad, and adrenal glands, constitute a major health problem in all societies. As a result of improved insight into the diagnosis, pathophysiology, and molecular bases, it is now possible to diagnose the disorders earlier in their development, and the treatment of the deficiency states for most hormones is successful. Furthermore, with recognition that many of these disorders are either the consequence of single-gene mutations or have a major genetic component, it is now possible to diagnose affected fetuses and family members at risk. Therapies for the syndromes of hormone overproduction are less successful and frequently result in destruction of the endocrine organ involved, and the treatment of hormone resistance states is similarly unsatisfactory. These disorders are candidates for the development of superagonists/antagonists and gene therapies.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wilson, JD (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							AHONEN P, 1990, NEW ENGL J MED, V322, P1830; Albright F, 1942, ENDOCRINOLOGY, V30, P922; BESSER GM, 1972, BRIT MED J, V3, P669, DOI 10.1136/bmj.3.5828.669; Blizzard R M, 1966, Clin Exp Immunol, V1, P119; Delange F, 1991, WERNER INGBARS THYRO, P368; DJERASSI C, 1990, STEROIDS MADE IT POS, P205; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; GRIFFIN JE, IN PRESS METABOLIC M; GROLLMAN A, 1962, CLIN ENDOCRINOLOGY I, P20; KARP DR, 1998, WILLIAMS TXB ENDOCRI, P153; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; Ma T., 1993, American Journal of Clinical Nutrition, V57, p264S, DOI 10.1093/ajcn/57.2.264S; Olefsky JM, 2001, JAMA-J AM MED ASSOC, V285, P628, DOI 10.1001/jama.285.5.628; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; POSINI B, 1996, TRENDS GENET, V1, P138; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; SALVI M, 1988, ENDOCR REV, V9, P450, DOI 10.1210/edrv-9-4-450; SAWIN CT, 1989, JAMA-J AM MED ASSOC, V261, P2653, DOI 10.1001/jama.261.18.2653; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SPEISER PW, 1990, J CLIN ENDOCR METAB, V70, P838, DOI 10.1210/jcem-70-4-838; TAKASU N, 1992, NEW ENGL J MED, V326, P513, DOI 10.1056/NEJM199202203260803; UIBO R, 1994, J CLIN ENDOCR METAB, V78, P323, DOI 10.1210/jc.78.2.323; VERHOEVEN GFM, 1979, METABOLISM, V28, P253, DOI 10.1016/0026-0495(79)90072-6; VICKERY BH, 1986, ENDOCR REV, V7, P115, DOI 10.1210/edrv-7-1-115; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403	27	5	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					624	627		10.1001/jama.285.5.624	http://dx.doi.org/10.1001/jama.285.5.624			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176870	Bronze			2022-12-28	WOS:000166714200023
J	Erbacher, J; Huber, BT; Norris, RD; Markey, M				Erbacher, J; Huber, BT; Norris, RD; Markey, M			Increased thermohaline stratification as a possible cause for an ocean anoxic event in the Cretaceous period	NATURE			English	Article							STRATIGRAPHY; EPISODES; SEA	Ocean anoxic events were periods of high carbon burial that led to drawdown of atmospheric carbon dioxide, lowering of bottom-water oxygen concentrations and, in many cases, significant biological extinction(1-5). Most ocean anoxic events are thought to be caused by high productivity and export of carbon from surface waters which is then preserved in organic-rich sediments, known as black shales. But the factors that triggered some of these events remain uncertain. Here we present stable isotope data from a mid-Cretaceous ocean anoxic event that occurred 112 Myr ago, and that point to increased thermohaline stratification as the probable cause. Ocean anoxic event 1b is associated with an increase in surface-water temperatures and runoff that led to decreased bottom-water formation and elevated carbon burial in the restricted basins of the western Tethys and North Atlantic. This event is in many ways similar to that which led to the more recent Plio-Pleistocene Mediterranean sapropels, but the greater geographical extent and longer duration (similar to 46 kyr) of ocean anoxic event 1b suggest that processes leading to such ocean anoxic events in the North Atlantic and western Tethys were able to act over a much larger region, and sequester far more carbon, than any of the Quaternary sapropels.	Bundesanstalt Geowissensch & Rohstoffe, Referat Meeresgeol, D-30655 Hannover, Germany; Smithsonian Inst, Natl Museum Nat Hist, Dept Paleobiol, Washington, DC 20560 USA; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	Smithsonian Institution; Smithsonian National Museum of Natural History; Woods Hole Oceanographic Institution	Erbacher, J (corresponding author), Bundesanstalt Geowissensch & Rohstoffe, Referat Meeresgeol, Stilleweg 2, D-30655 Hannover, Germany.	erbacher@bgr.de		Erbacher, Jochen/0000-0003-2793-0307				[Anonymous], 1999, PROGRAM-ELECTRON LIB; [Anonymous], 1981, ECLOGAE GEOL HELV; [Anonymous], 1998, P OCEAN DRILL PROGR; ARTHUR MA, 1990, NATO ADV SCI I C-MAT, V304, P75; BARKER CE, IN PRESS W N ATLANTI; Bice KL, 1997, GEOLOGY, V25, P951, DOI 10.1130/0091-7613(1997)025<0951:CRAECB>2.3.CO;2; BRALOWER TJ, 1993, GEOPH MONOG SERIES, V77, P5, DOI DOI 10.1029/GM077P0005; Damste JSS, 1998, EARTH PLANET SC LETT, V158, P165; de Boer P. L., 1983, GEOL ULTRIECTIN, V31, P1; Erbacher J, 1996, GEOLOGY, V24, P499, DOI 10.1130/0091-7613(1996)024<0499:EPORAO>2.3.CO;2; Erbacher J, 1999, MAR MICROPALEONTOL, V38, P7, DOI 10.1016/S0377-8398(99)00036-5; EREZ J, 1983, GEOCHIM COSMOCHIM AC, V47, P1025, DOI 10.1016/0016-7037(83)90232-6; Fischer A.G., 1977, SOC EC PALEONTOLOGIS, V25, P19; Hochuli PA, 1999, GEOLOGY, V27, P657, DOI 10.1130/0091-7613(1999)027<0657:EOHPAC>2.3.CO;2; HOLBOURN A, IN PRESS J FORAM RES; Huber BT, 1999, J FORAMIN RES, V29, P392; Hut G., 1987, CONS GROUP M STABL I; JENKYNS HC, 1997, ZBL GEOL PALAONT 1, V7, P943; Kuypers MMM, 1999, NATURE, V399, P342, DOI 10.1038/20659; Menegatti AP, 1998, PALEOCEANOGRAPHY, V13, P530, DOI 10.1029/98PA01793; Mercone D, 2000, PALEOCEANOGRAPHY, V15, P336, DOI 10.1029/1999PA000397; Myers PG, 2000, QUATERNARY RES, V53, P98, DOI 10.1006/qres.1999.2100; Norris R.D., 1998, P OCEAN DRILLING P B, V171, P1; Ogg J.G., 1999, EOS, V80, pF491; ROHLING EJ, 1994, MAR GEOL, V122, P1, DOI 10.1016/0025-3227(94)90202-X; Shackleton N.J., 1975, INITIAL REPORTS DEEP, V29, P743, DOI [DOI 10.2973/DSDP.PROC.29.117.1975, 10.2973/DSDP.PROC.29.117.1975]; THUROW J, 1992, AM GEOPHYSICAL UNION, V70, P253; Weissert H, 1998, PALAEOGEOGR PALAEOCL, V137, P189, DOI 10.1016/S0031-0182(97)00109-0; WILSON PA, 1999, EOS, V80, pF488; Wortmann UG, 1999, PALEOCEANOGRAPHY, V14, P525, DOI 10.1029/1999PA900015	30	207	219	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2001	409	6818					325	327		10.1038/35053041	http://dx.doi.org/10.1038/35053041			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201737				2022-12-28	WOS:000166434300042
J	Gurnett, DA; Zarka, P; Manning, R; Kurth, WS; Hospodarsky, GB; Averkamp, TF; Kaiser, ML; Farrell, WM				Gurnett, DA; Zarka, P; Manning, R; Kurth, WS; Hospodarsky, GB; Averkamp, TF; Kaiser, ML; Farrell, WM			Non-detection at Venus of high-frequency radio signals characteristic of terrestrial lightning	NATURE			English	Article							SPRITES94 AIRCRAFT CAMPAIGN	The detection(1,2) of impulsive low-frequency (10 to 80 kHz) radio signals, and separate very-low-frequency (similar to 100 Hz) radio 'whistler' signals(3-5) provided the first evidence for lightning in the atmosphere of Venus. Later, a small number of impulsive high-frequency (100 kHz to 5.6 MHz) radio signals, possibly due to lightning, were also detected(6). The existence of lightning at Venus has, however, remained controversial(7-13). Here we report the results of a search for high-frequency (0.125 to 16 MHz) radio signals during two close fly-bys of Venus by the Cassini spacecraft. Such signals are characteristic of terrestrial lightning, and are commonly heard on AM (amplitude-modulated) radios during thunderstorms. Although the instrument easily detected signals from terrestrial lightning during a later fly-by of Earth (at a global flash rate estimated to be 70 s(-1), which is consistent with the rate expected for terrestrial lightning), no similar signals were detected from Venus. If lightning exists in the venusian atmosphere, it is either extremely rare, or very different from terrestrial lightning.	Univ Iowa, Dept Phys & Astron, Iowa City, IA 52242 USA; Observ Paris, Space Res Dept, CNRS, UMR 8632, Meudon, France; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	University of Iowa; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Gurnett, DA (corresponding author), Univ Iowa, Dept Phys & Astron, Iowa City, IA 52242 USA.		Kurth, William/AAA-7334-2019; Hospodarsky, George B/A-7996-2015; Farrell, William/I-4865-2013	Kurth, William/0000-0002-5471-6202; Hospodarsky, George B/0000-0001-9200-9878; 				BORUCKI WJ, 1981, GEOPHYS RES LETT, V8, P233, DOI 10.1029/GL008i003p00233; Brace L. H., 1983, Venus, P779; BROWN LW, 1973, ASTROPHYS J, V180, P359, DOI 10.1086/151968; GREBOWSKY JM, 1997, VENUS, V2, P125; GURNETT DA, 1991, SCIENCE, V253, P1522, DOI 10.1126/science.253.5027.1522; GURNETT DA, UNPUB SPACE SCI REV; HANSELL SA, 1995, ICARUS, V117, P345, DOI 10.1006/icar.1995.1160; HUNTEN DM, 1995, ADV SPACE RES, V15, P109, DOI 10.1016/0273-1177(94)00071-8; KRASNOPOLSKY VA, 1983, PLANET SPACE SCI, V31, P1363, DOI 10.1016/0032-0633(83)90072-7; Ksanfomality L. V., 1983, Venus, P565; KSANFOMALITY LV, 1979, COSMIC RES, V17, P747; PIERCE ET, 1977, LIGHTNING, V1, P351; RUSSELL CT, 1991, SPACE SCI REV, V55, P317; SAGDEEV RZ, 1986, SCIENCE, V231, P1411, DOI 10.1126/science.231.4744.1411; Scarf FL, 1980, J GEOPHYS RES-SPACE, V85, P8158, DOI 10.1029/JA085iA13p08158; SENTMAN DD, 1995, GEOPHYS RES LETT, V22, P1205, DOI 10.1029/95GL00583; TAYLOR HA, 1987, J GEOPHYS RES, V92, P9907, DOI 10.1029/JA092iA09p09907; TAYLOR WWL, 1979, NATURE, V282, P614; UMAN MA, 1969, LIGHTNING, P272; WESCOTT EM, 1995, GEOPHYS RES LETT, V22, P1209, DOI 10.1029/95GL00582	20	61	62	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					313	315		10.1038/35053009	http://dx.doi.org/10.1038/35053009			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201733				2022-12-28	WOS:000166434300038
J	Matarasso, A; Hutchinson, OHZ				Matarasso, A; Hutchinson, OHZ			Liposuction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TUMESCENT LIPOSUCTION; SUCTION LIPECTOMY; NATIONAL SURVEY; COMPLICATIONS; EXPERIENCE; IMPACT; CALVES; ANKLES		Cornell Univ, Weill Med Coll, Dept Surg, New York, NY USA; Albert Einstein Montifiore Med Ctr, New York, NY USA; Aesthet Surg Journal, New York, NY USA	Cornell University; Yeshiva University	Matarasso, A (corresponding author), 1009 Pk Ave, New York, NY 10028 USA.							*AM SOC AESTH PLAS, 2000, ASAPS 1998 STAT COSM; Barillo DJ, 1998, SOUTH MED J, V91, P487, DOI 10.1097/00007611-199805000-00018; Berntorp E, 1998, J INTERN MED, V243, P197; Brorson H, 1998, PLAST RECONSTR SURG, V102, P1058, DOI 10.1097/00006534-199809040-00021; Daane SP, 1999, AESTHET PLAST SURG, V23, P303, DOI 10.1007/s002669900289; Grazer FM, 2000, PLAST RECONSTR SURG, V105, P436, DOI 10.1097/00006534-200001000-00070; HANKE CW, 1995, DERMATOL SURG, V21, P459; HARDY KJ, 1993, DIABETES CARE, V16, P929, DOI 10.2337/diacare.16.6.929; Henry F, 1996, DERMATOL SURG, V22, P566, DOI 10.1111/j.1524-4725.1996.tb00375.x; ILLOUZ YG, 1983, PLAST RECONSTR SURG, V72, P591, DOI 10.1097/00006534-198311000-00001; KLEIN JA, 1990, J DERMATOL SURG ONC, V16, P248, DOI 10.1111/j.1524-4725.1990.tb03961.x; Lillis PJ, 1997, DERMATOL SURG, V23, P1161, DOI 10.1111/j.1524-4725.1997.tb00466.x; Liszka TG, 1998, PLAST RECONSTR SURG, V102, P1122, DOI 10.1097/00006534-199809040-00031; MATARASSO A, 1991, PLAST RECONSTR SURG, V87, P709, DOI 10.1097/00006534-199104000-00016; MATARASSO A, 1995, PLAST RECONSTR SURG, V95, P829, DOI 10.1097/00006534-199595050-00010; Matarasso A, 1998, PLAST RECONSTR SURG, V102, P1686, DOI 10.1097/00006534-199810000-00057; Mladick RA, 1999, PLAST RECONSTR SURG, V104, P823, DOI 10.1097/00006534-199909030-00034; *NEW ASPRS, 1999, PLASTIC SURG NEW JUN, P18; *NY STAT DEP HLTH, 1999, APP A CLIN GUID OFF; Pitman GH, 1996, CLIN PLAST SURG, V23, P633; Rankin M, 1998, PLAST RECONSTR SURG, V102, P2139, DOI 10.1097/00006534-199811000-00053; Rohrich RJ, 1998, PLAST RECONSTR SURG, V101, P1090, DOI 10.1097/00006534-199804040-00033; Rohrich RJ, 1999, PLAST RECONSTR SURG, V104, P819, DOI 10.1097/00006534-199909030-00033; SAMDAL F, 1994, SCAND J PLAST RECONS, V28, P123, DOI 10.3109/02844319409071189; SAMDAL F, 1993, J INTERN MED, V234, P489, DOI 10.1111/j.1365-2796.1993.tb00782.x; SAMDAL F, 1995, AESTHET PLAST SURG, V19, P131, DOI 10.1007/BF00450248; TEIMOURIAN B, 1989, PLAST RECONSTR SURG, V84, P628, DOI 10.1097/00006534-198984040-00012; WOODEN WA, 1993, AESTHET PLAST SURG, V17, P103, DOI 10.1007/BF02274729	28	34	34	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					266	268		10.1001/jama.285.3.266	http://dx.doi.org/10.1001/jama.285.3.266			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390XD	11176823				2022-12-28	WOS:000166324300002
J	De Wals, P; De Serres, G; Niyonsenga, T				De Wals, P; De Serres, G; Niyonsenga, T			Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYSACCHARIDE VACCINE; NEISSERIA-MENINGITIDIS; IMMUNOLOGICAL MEMORY; VIRULENT CLONE; GROUP-A; CANADA; INDUCTION; EMERGENCE; CHILDREN; EFFICACY	Context An outbreak of meningococcal disease in Quebec province prompted a mass immunization program. The impact of this campaign on the epidemiology of meningococcal disease has not been studied. Objectives To study the impact of a mass immunization campaign using polysaccharide vaccine on the epidemiology of meningococcal disease (MCD) and to assess serogroup C vaccine effectiveness IVE), Design, setting, and Subjects Analysis of MCD cases reported in Quebec from 1990 to 1998, before and after the mass immunization campaign was conducted during the winter of 1992-1993, when 84% of residents aged 6 months to 20 years (the target population, approximately 1.9 million individuals) were vaccinated, Main Outcome Measures Incidence of MCD in 1990-1998; incidence of culture-proven serogroup C MCD between April 1, 1993, and March 31, 1998, compared among vaccinated and unvaccinated persons in the target population. Results The incidence of serogroup C disease decreased after the mass immunization campaign, from 1.4 per 100000 in 1990-1992 to 0.3 per 100000 in 1993-1998, and the overall incidence of other serogroups remained stable at 0.7 per 100000, with a small increase in the proportion of cases caused by serogroup Y (P=.009). Protection from serogroup C MCD was indicated in the first 2 years after vaccine administration (VE, 65%; 95% confidence interval [CI], 20%-84%), but not in the next 3 years (VE, 0%; 95% CI, -5% to 65%), Vaccine effectiveness was strongly related to age at vaccination: 83% (95% CI, 39%-96%) for ages 15 through 20 years, 75% (95% CI,- 17% to 93%) for ages 10 through 14 years, and 41% (95% CI, -106% to 79%) for ages 2 through 9 years. There was no evidence of protection in children younger than 2 years; all 8 MCD cases in this age group occurred in vaccinees. Conclusions Serogroup C polysaccharide vaccine is effective for controlling outbreaks in teenaged individuals but should not be used in children younger than 2 years. The mass campaign did not induce significant serogroup switching.	Univ Sherbrooke, Dept Community Hlth Sci, Sherbrooke, PQ J1H 5N4, Canada; Sherbrooke Univ Hosp Ctr, Clin Res Ctr, Sherbrooke, PQ, Canada; Univ Laval, Quebec Univ Hosp Ctr, Publ Hlth Res Unit, Quebec City, PQ, Canada	University of Sherbrooke; University of Sherbrooke; Laval University	De Wals, P (corresponding author), Univ Sherbrooke, Dept Community Hlth Sci, 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.		Niyonsenga, Theo/C-3759-2014	Niyonsenga, Theo/0000-0002-6723-0316				*ADV COMM EP, 1991, CAN DIS WKLY REP S3, V17, P29; ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; Cartwright K, 1995, MENINGOCOCCAL DIS; *CYT SOFTW CORP, 1999, STATX 4 WIND; DEVINE JF, 1970, AM J EPIDEMIOL, V92, P25; DeWals P, 1996, B WORLD HEALTH ORGAN, V74, P407; Erickson L, 1998, CLIN INFECT DIS, V26, P1159, DOI 10.1086/520303; GOLD R, 1977, J INFECT DIS, V136, pS31, DOI 10.1093/infdis/136.Supplement.S31; GOLD R, 1971, B WORLD HEALTH ORGAN, V45, P279; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GOLDSCHNEIDER I, 1973, J INFECT DIS, V128, P769, DOI 10.1093/infdis/128.6.769; GOTSCHLICH EC, 1969, J EXP MED, V129, P1385, DOI 10.1084/jem.129.6.1385; Granoff DM, 1998, J INFECT DIS, V178, P870, DOI 10.1086/515346; Kertesz DA, 1998, J INFECT DIS, V177, P1754, DOI 10.1086/517439; King WJ, 1996, J PEDIATR-US, V128, P196, DOI 10.1016/S0022-3476(96)70389-X; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; Lavigne P, 1992, Can Commun Dis Rep, V18, P113; Leach A, 1997, J INFECT DIS, V175, P200, DOI 10.1093/infdis/175.1.200; LEPOW ML, 1977, PEDIATRICS, V60, P673; MacDonald NE, 1998, JAMA-J AM MED ASSOC, V280, P1685, DOI 10.1001/jama.280.19.1685; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; PELTOLA H, 1985, PEDIATRICS, V76, P91; Richmond P, 2000, J INFECT DIS, V181, P761, DOI 10.1086/315284; Rivest D, 1999, CAN J PUBLIC HEALTH, V90, P250, DOI 10.1007/BF03404126; Rosenstein N, 1998, JAMA-J AM MED ASSOC, V279, P435, DOI 10.1001/jama.279.6.435; Salleras L, 1999, VACCINE, V17, pS56, DOI 10.1016/S0264-410X(99)00294-7; SAS Institute Inc, 1997, SAS STAT SOFTW CHANG; Sbyrakis S, 1999, LANCET, V354, P1733, DOI 10.1016/S0140-6736(05)76724-6; STEIN KE, 1992, J INFECT DIS, V165, P549; TAUNAY A E, 1978, Revista do Instituto Adolfo Lutz, V38, P77; *VACC PROGR GROUP, 1999, COMM DIS REP CDR WKL, V9, P261; Vogel U, 2000, NEW ENGL J MED, V342, P219, DOI 10.1056/NEJM200001203420319; WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390; Zhang Q, 2000, INFECT IMMUN, V68, P2692, DOI 10.1128/IAI.68.5.2692-2697.2000	35	66	73	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2001	285	2					177	181		10.1001/jama.285.2.177	http://dx.doi.org/10.1001/jama.285.2.177			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	389FB	11176810	Bronze			2022-12-28	WOS:000166227000025
J	Hochman, JS; Sleeper, LA; White, HD; Dzavik, V; Wong, SC; Menon, V; Webb, JG; Steingart, R; Picard, MH; Menegus, MA; Boland, J; Sanborn, T; Buller, CE; Modur, S; Forman, R; Desvigne-Nickens, P; Jacobs, AK; Slater, JN; LeJemtel, TH				Hochman, JS; Sleeper, LA; White, HD; Dzavik, V; Wong, SC; Menon, V; Webb, JG; Steingart, R; Picard, MH; Menegus, MA; Boland, J; Sanborn, T; Buller, CE; Modur, S; Forman, R; Desvigne-Nickens, P; Jacobs, AK; Slater, JN; LeJemtel, TH		SHOCK Investigators	One-year survival following early revascularization for cardiogenic shock	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; SURGERY; MANAGEMENT; TRIAL	Context Cardiogenic shock (CS) is the leading cause of death for patients hospitalized with acute myocardial infarction (AMI), Objective To assess the effect of early revascularization (ERV) on 1-year survival for patients with AMI complicated by CS. Design The SHOCK (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) Trial, an unblinded, randomized controlled trial from April 1993 through November 1998, Setting Thirty-six referral centers with angioplasty and cardiac surgery facilities. Patients Three hundred two patients with AMI and CS due to predominant left ventricular failure who met specified clinical and hemodynamic criteria. Interventions Patients were randomly assigned to an initial medical stabilization (IMS; n =150) group, which included thrombolysis (63% of patients), intra-aortic balloon counterpulsation (86%), and subsequent revascularization (25%), or to an ERV group (n=152), which mandated revascularization within 6 hours of randomization and included angioplasty (55%) and coronary artery bypass graft surgery (38%). Main Outcome Measures All-cause mortality and functional status at 1 year, compared between the ERV and IMS groups. Results One-year survival was 46.7% for patients in the ERV group compared with 33.6% in the IMS group (absolute difference in survival, 13.2%; 95% confidence interval [CI], 2.2%_24.1%; P<.03; relative risk for death, 0.72; 95% CI, 0.54-0.95). Of the 10 prespecified subgroup analyses, only age (<75 vs greater than or equal to 75 years) interacted significantly (P<.03) with treatment in that treatment benefit was apparent only for patients younger than 75 years (51.6% survival in ERV group vs 33.3% in IMS group). Eighty-three percent of 1-year survivors (85% of ERV group and 80% of IMS group) were in New York Heart Association class I or II. Conclusions For patients with AMI complicated by CS, ERV resulted in improved 1-year survival. We recommend rapid transfer of patients with AMI complicated by CS, particularly those younger than 75 years, to medical centers capable of providing early angiography and revascularization procedures.	Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY 10025 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Hochman, JS (corresponding author), Columbia Univ, St Lukes Roosevelt Hosp Ctr, 1111 Amsterdam Ave, New York, NY 10025 USA.		Menon, Venu/AAF-1871-2019; Picard, Michael/F-1567-2013	Picard, Michael/0000-0002-9264-3243; Slater, James/0000-0003-3888-0317; Jacobs, Alice/0000-0002-2428-2458; Hochman, Judith/0000-0002-5889-5981	NHLBI NIH HHS [R01-HL49970, R01-HL50020] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050020, R01HL049970] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN EL, 1983, CIRCULATION, V68, P785, DOI 10.1161/01.CIR.68.4.785; Becker RC, 1996, J AM COLL CARDIOL, V27, P1321, DOI 10.1016/0735-1097(96)00008-3; Breslow N, 1980, IARC SCI PUB, V32; DZAVIK V, 1998, EUR HEART J SUPPL, V19, P28; ELTCHANINOFF H, 1995, AM HEART J, V130, P459, DOI 10.1016/0002-8703(95)90352-6; Franzosi MG, 1998, CIRCULATION, V98, P2659, DOI 10.1161/01.CIR.98.24.2659; GACIOCH GM, 1992, J AM COLL CARDIOL, V19, P647, DOI 10.1016/S0735-1097(10)80286-4; Goldberg RJ, 1999, NEW ENGL J MED, V340, P1162, DOI 10.1056/NEJM199904153401504; *GUTO 2 ANG SUBST, 1997, NEW ENGL J MED, V336, P1621; Hochman JS, 2000, J AM COLL CARDIOL, V36, P1063, DOI 10.1016/S0735-1097(00)00879-2; Hochman JS, 1999, AM HEART J, V137, P313, DOI 10.1053/hj.1999.v137.95352; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; *SAS I INC, 1996, SAS SYST WIND COMP P; *STAT SCI INC, 1995, S PLUS WIND COMP PRO; TAKARO T, 1976, CIRCULATION, V54, P107; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	19	426	466	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2001	285	2					190	192		10.1001/jama.285.2.190	http://dx.doi.org/10.1001/jama.285.2.190			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	389FB	11176812	Green Published, Bronze			2022-12-28	WOS:000166227000027
J	Galley, HF				Galley, HF			Renal-dose dopamine: will the message now get through?	LANCET			English	Editorial Material							FAILURE		Univ Aberdeen, Dept Med & Therapeut, Acad Unit Anaesthesia & Intens Care, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Galley, HF (corresponding author), Univ Aberdeen, Dept Med & Therapeut, Acad Unit Anaesthesia & Intens Care, Aberdeen AB25 2ZD, Scotland.							BALDWIN L, 1994, ANN INTERN MED, V120, P744, DOI 10.7326/0003-4819-120-9-199405010-00004; Breen D, 1998, KIDNEY INT, V53, pS25; Burton CJ, 1999, POSTGRAD MED J, V75, P269, DOI 10.1136/pgmj.75.883.269; Cuthbertson BH, 1997, BRIT MED J, V314, P690, DOI 10.1136/bmj.314.7082.690; Denton MD, 1996, KIDNEY INT, V50, P4, DOI 10.1038/ki.1996.280; Hoogenberg K, 1998, CRIT CARE MED, V26, P260, DOI 10.1097/00003246-199802000-00022; Juste RN, 1998, INTENS CARE MED, V24, P1217, DOI 10.1007/s001340050747; PAWLIK W, 1976, AM HEART J, V91, P325, DOI 10.1016/S0002-8703(76)80216-5; Perdue PW, 1998, ANN SURG, V227, P470, DOI 10.1097/00000658-199804000-00003; Schaer GL, 1998, CRIT CARE MED, V26, P205, DOI 10.1097/00003246-199802000-00006; Short A, 1999, BRIT MED J, V319, P41, DOI 10.1136/bmj.319.7201.41; SZERLIP HM, 1991, ANN INTERN MED, V115, P153, DOI 10.7326/0003-4819-115-2-153; THOMPSON BT, 1994, LANCET, V344, P7, DOI 10.1016/S0140-6736(94)91044-8; VandenBerghe G, 1996, CRIT CARE MED, V24, P1580, DOI 10.1097/00003246-199609000-00024; WEISBERG LS, 1994, KIDNEY INT, V45, P259, DOI 10.1038/ki.1994.32	15	32	35	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2112	2113		10.1016/S0140-6736(00)03484-X	http://dx.doi.org/10.1016/S0140-6736(00)03484-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191531				2022-12-28	WOS:000165997300002
J	May, RM; Stumpf, MPH				May, RM; Stumpf, MPH			Ecology - Species-area relations in tropical forests	SCIENCE			English	Editorial Material							ABUNDANCE		Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	May, RM (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.							Harte J, 1999, SCIENCE, V284, P334, DOI 10.1126/science.284.5412.334; MAC ARTHUR ROBERT H., 1967; May R.M., 1975, P81; May Robert M., 1995, P1; Plotkin JB, 2000, P NATL ACAD SCI USA, V97, P10850, DOI 10.1073/pnas.97.20.10850; Plotkin JB, 2000, J THEOR BIOL, V207, P81, DOI 10.1006/jtbi.2000.2158; PRESTON FW, 1962, ECOLOGY, V43, P410, DOI 10.2307/1933371; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; SUGIHARA G, 1980, AM NAT, V116, P770, DOI 10.1086/283669	9	58	63	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2084	2086		10.1126/science.290.5499.2084	http://dx.doi.org/10.1126/science.290.5499.2084			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11187834				2022-12-28	WOS:000165870600036
J	Agrawal, A				Agrawal, A			Amersham Pharmacia Biotech & Science Prize - Transposition and evolution of antigen-specific immunity	SCIENCE			English	Editorial Material							V(D)J RECOMBINATION; MU-TRANSPOSASE; INITIATION; RAG1; DNA; COMPLEX; SYSTEM; GENES											Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Livak F, 1996, MOL CELL BIOL, V16, P609; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592	16	6	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1715	1716		10.1126/science.290.5497.1715	http://dx.doi.org/10.1126/science.290.5497.1715			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11186395				2022-12-28	WOS:000165632400031
J	Hall, J				Hall, J			Health for all: the impossible dream?	LANCET			English	Article									CHERE, Camperdown, NSW 2060, Australia; Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia	University of Sydney	Hall, J (corresponding author), CHERE, Level 6 Bldg F,88 Mallett St, Camperdown, NSW 2060, Australia.		Hall, Jane P/I-3469-2014	Hall, Jane/0000-0002-2191-0543					0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S32	S32		10.1016/S0140-6736(00)92018-X	http://dx.doi.org/10.1016/S0140-6736(00)92018-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191489				2022-12-28	WOS:000166074900034
J	Luczak, J; Hunter, GP				Luczak, J; Hunter, GP			Hospice care in eastern Europe	LANCET			English	Article									Palliat Care Dept Poznan, PL-61878 Poznan, Poland		Luczak, J (corresponding author), Palliat Care Dept Poznan, Ul Lakowa 1-2, PL-61878 Poznan, Poland.								0	4	4	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S23	S23		10.1016/S0140-6736(00)92009-9	http://dx.doi.org/10.1016/S0140-6736(00)92009-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191479				2022-12-28	WOS:000166074900025
J	Nocera, A				Nocera, A			Helicopter emergency medical services	LANCET			English	Article									NRMA Careflight, Westmead, NSW 2145, Australia		Nocera, A (corresponding author), NRMA Careflight, POB 159, Westmead, NSW 2145, Australia.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S2	S2		10.1016/S0140-6736(00)91988-3	http://dx.doi.org/10.1016/S0140-6736(00)91988-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191475				2022-12-28	WOS:000166074900004
J	Goldman, KA				Goldman, KA			Genetic technologies - Bioengineered food - Safety and labeling	SCIENCE			English	Article									Georgetown Univ, Ctr Law, Washington, DC 20001 USA; Natl Sci Fdn, Arlington, VA 22230 USA	Georgetown University; National Science Foundation (NSF)	Goldman, KA (corresponding author), Georgetown Univ, Ctr Law, Washington, DC 20001 USA.							*EC RES SERV, 2000, BIOT CORN SOYB CHANG; *EPA, 2000, FED REGISTER, V65, P55929; *EPA, 2000, CRY9C FOOD ALL ASS B; *FDA, 1994, FED REGISTER, V59, P26700; *FDA, 2000, HHS NEWS        0503; Ferber D, 1999, SCIENCE, V286, P1662, DOI 10.1126/science.286.5445.1662; GOLDMAN KA, 2000, GEORGETOWN INT ENV L, V12, P717; Henney JE., 2000, FDA CONSUM, V4, P18; POLLACK A, 2000, NY TIMES        1228, pC1; SMITH N, 2000, UNPUB BASIC RES; U.S. Food and Drug Administration, 1992, FED REGISTER, V57, P22984; *USDA, 2000, 014700 USDA; 1994, FED REG, V59, P60496; 1998, FED REG, V63, P28258; 1996, FED REG, V61, P40340; 1997, FED REG, V62, P52505; 1995, FED REG, V60, P21725; 1997, FED REG, V62, P17717; 1997, FED REG, V62, P17720; 1996, FED REG, V61, P40338	20	6	6	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 20	2000	290	5491					457	+		10.1126/science.290.5491.457	http://dx.doi.org/10.1126/science.290.5491.457			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	365HN	11183767				2022-12-28	WOS:000089946000030
J	Savage, JRK				Savage, JRK			Cancer - Proximity matters	SCIENCE			English	Editorial Material							IN-SITU HYBRIDIZATION; NUCLEAR ARCHITECTURE; ABERRATIONS				Savage, JRK (corresponding author), 34 City Rd, Reading RG31 5HB, Berks, England.							Cremer C, 1996, MUTAT RES-REV GENET, V366, P97, DOI 10.1016/S0165-1110(96)90031-7; EVANS HJ, 1962, INT REV CYTOL, V13, P221; GRIFFIN CS, 1995, INT J RADIAT BIOL, V67, P431, DOI 10.1080/09553009514550491; Lea DA, 1946, ACTIONS RAD LIVING C; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Sachs RK, 1997, INT J RADIAT BIOL, V71, P1, DOI 10.1080/095530097144364; SAVAGE JRK, 1993, ENVIRON MOL MUTAGEN, V22, P234, DOI 10.1002/em.2850220410; Savage JRK, 1998, MUTAT RES-FUND MOL M, V404, P139, DOI 10.1016/S0027-5107(98)00107-9; SIMPSON PJ, 1995, INT J RADIAT BIOL, V67, P37, DOI 10.1080/09553009514550051	9	55	60	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 6	2000	290	5489					62	63		10.1126/science.290.5489.62	http://dx.doi.org/10.1126/science.290.5489.62			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	361LP	11183150				2022-12-28	WOS:000089724800029
J	Smith, O				Smith, O			Cancer - The killer instinct of a p53 target	SCIENCE			English	Editorial Material																		Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8	1	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 6	2000	290	5489					67	67		10.1126/science.290.5489.67	http://dx.doi.org/10.1126/science.290.5489.67			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	361LP	11183152				2022-12-28	WOS:000089724800032
J	Khan, LK; Serdula, MK; Bowman, BA; Williamson, DF				Khan, LK; Serdula, MK; Bowman, BA; Williamson, DF			Use of prescription weight loss pills among US adults in 1996-1998	ANNALS OF INTERNAL MEDICINE			English	Article							PREVALENCE	Background: Pharmacotherapy is recommended for the treatment of obese persons with a body mass index of 30 kg/m(2) or higher or a body mass index of at least 27 kg/m(2) plus an obesity-related comorbid condition. Objective: To estimate the prevalence of use of prescription weight loss pills in the United States in 1996-1998. Design: 1998 Behavioral Risk Factor Surveillance System, a nationally representative telephone survey. Setting: United States. Participants: 139 779 adults 18 years of age and older. Measurements: Self-reported pill use for 1996-1998, body mass index (current and before pill use), age, sex, and race or ethnicity. Results: The 2-year prevalence of pill use was 2.5% (95% CI, 2.1% to 2.9%); or 4.6 million U.S. adults. Use was higher in women than in men (4.0% vs. 0.9%, respectively) and highest among Hispanic respondents (3.2%). Of pill users, 25% were not overweight (body mass index < 27 kg/m(2)) before using pills. Conclusions: Nearly 5 million U.S. adults used prescription weight loss pills in 1996-1998. However, one quarter of users were not overweight. suggesting that weight loss pills may be inappropriately used, especially among women, white persons, and Hispanic persons.	Ctr Dis Control & Prevent, Div Nutr & Phys Activ, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Khan, LK (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Activ, 4770 Buford Highway NE,Mailstop K29, Atlanta, GA 30341 USA.	LDK7@cdc.gov						Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Galuska DA, 1999, JAMA-J AM MED ASSOC, V282, P1576, DOI 10.1001/jama.282.16.1576; *IMS AM LTD NAT PR, 1997, BAS DAT REP IMS AM L; LUMPKIN MM, 1997, FDA B, V27, P2; McKee MD, 1999, J FAM PRACTICE, V48, P993; *MMWR, 1997, MMWR-MORBID MORTAL W, V46, P1061; National Center for Health Statistics, 1996, 3 NAT HLTH NUTR EX S; NELSON DE, 1998, P SECT SURV METH AM; ORADELL NJ, 1997, MED EC; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; Shah BV, 1997, SUDAAN USERS MANUAL	14	34	34	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					282	286		10.7326/0003-4819-134-4-200102200-00011	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NW	11182838				2022-12-28	WOS:000167050200004
J	Iso, H; Rexrode, KM; Stampfer, MJ; Manson, JE; Colditz, GA; Speizer, FE; Hennekens, CH; Willett, WC				Iso, H; Rexrode, KM; Stampfer, MJ; Manson, JE; Colditz, GA; Speizer, FE; Hennekens, CH; Willett, WC			Intake of fish and omega-3 fatty acids and risk of stroke in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; EICOSAPENTAENOIC ACID; CARDIOVASCULAR-DISEASE; PLATELET-FUNCTION; BLOOD-VISCOSITY; OIL; CONSUMPTION; HUMANS; MEN; ATHEROSCLEROSIS	Context Some prospective studies have shown an inverse association between fish intake and risk of stroke, but none has examined the relationship of fish and omega-3 polyunsaturated fatty acid intake with risk of specific stroke subtypes. Objective To examine the association between fish and omega-3 polyunsaturated fatty acid intake and risk of stroke subtypes in women. Design, Setting, and Subjects Prospective cohort study of women in the Nurses' Health Study cohort, aged 34 to 59 years in 1980, who were free from prior diagnosed cardiovascular disease, cancer, and history of diabetes and hypercholesterolemia and who completed a food frequency questionnaire including consumption of fish and other frequently eaten foods. The 79839 women who met our eligibility criteria were followed up for 14 years. Main Outcome Measure Relative risk of stroke in 1980-1994 compared by category of fish intake and quintile of omega-3 polyunsaturated fatty acid intake. Results After 1 086 261 person-years of follow-up, 574 incident strokes were documented, including 119 subarachnoid hemorrhages, 62 intraparenchymal hemorrhages, 303 ischemic strokes (264 thrombotic and 39 embolic infarctions), and 90 strokes of undetermined type. Among thrombotic infarctions, 90 large-artery occlusive infarctions and 142 lacunar infarctions were identified. Compared with women who ate fish less than once per month, those with higher intake of fish had a lower risk of total stroke: the multivariate relative risks (RRs), adjusted for age, smoking, and other cardiovascular risk factors, were 0.93 (95% confidence interval [CI], 0.65-1.34) for fish consumption 1 to 3 times per month, 0.78 (95% CI, 0.55-1.12) for once per week, 0.73 (95% CI, 0.47-1.14) for 2 to 4 times per week, and 0.48 (95% CI, 0.21-1.06) for 5 or more times per week (P for trend = .06). Among stroke subtypes, a significantly reduced risk of thrombotic infarction was found among women who ate fish 2 or more times per week (multivariate RR, 0.49; 95% CI, 0.26-0.93). Women in the highest quintile of intake of long-chain omega-3 polyunsaturated fatty acids had reduced risk of total stroke and thrombotic infarction, with multivariate RRs of 0.72 (95 % CI, 0.53-0.99) and 0.67 (95% CI, 0.42-1.07), respectively. When stratified by aspirin use, fish and omega-3 polyunsaturated fatty acid intakes were inversely associated with risk of thrombotic infarction, primarily among women who did not regularly take aspirin. There was no association between fish or omega-3 polyunsaturated fatty acid intake and risk of hemorrhagic stroke. Conclusions Our data indicate that higher consumption of fish and omega-3 polyunsaturated fatty acids is associated with a reduced risk of thrombotic infarction, primarily among women who do not take aspirin regularly, but is not related to risk of hemorrhagic stroke.	Brigham & Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth Med, Miami, FL USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Miami	Rexrode, KM (corresponding author), Brigham & Womens Hosp, Div Prevent Med, Dept Med, 900 Commonwealth Ave,3rd Floor, Boston, MA 02215 USA.		Rexrode, Kathryn M/I-1177-2018; Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291; Rexrode, Kathryn/0000-0003-3387-8429; Iso, Hiroyasu/0000-0002-9241-7289	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA40346] Funding Source: Medline; NHLBI NIH HHS [HL34594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON CS, 1993, MED J AUSTRALIA, V158, P85, DOI 10.5694/j.1326-5377.1993.tb137529.x; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BANG HO, 1980, AM J CLIN NUTR, V33, P2657, DOI 10.1093/ajcn/33.12.2657; BELL DSH, 1994, DIABETES CARE, V17, P213, DOI 10.2337/diacare.17.3.213; BRUCKNER G, 1987, ATHEROSCLEROSIS, V66, P237, DOI 10.1016/0021-9150(87)90067-0; *CONS FOOD EC I, 1976, COMPOSITION FOODS HD, V8; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DYERBERG J, 1978, LANCET, V2, P117, DOI 10.1016/s0140-6736(78)91505-2; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FESKENS EJM, 1991, DIABETES CARE, V14, P935, DOI 10.2337/diacare.14.11.935; FOX PL, 1988, SCIENCE, V241, P453, DOI 10.1126/science.3393911; GANDOLFO C, 1988, ACTA NEUROL SCAND, V77, P22, DOI 10.1111/j.1600-0404.1988.tb06968.x; Gillum RF, 1996, ARCH INTERN MED, V156, P537, DOI 10.1001/archinte.156.5.537; HEROLD PM, 1986, AM J CLIN NUTR, V43, P566, DOI 10.1093/ajcn/43.4.566; HOSTMARK AT, 1988, BRIT MED J, V297, P180, DOI 10.1136/bmj.297.6642.180; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; Iso H, 2000, ANN EPIDEMIOL, V10, P81, DOI 10.1016/S1047-2797(99)00040-X; KERI SO, 1994, STROKE, V25, P328; KNAPP HR, 1986, NEW ENGL J MED, V314, P937, DOI 10.1056/NEJM198604103141501; KNAPP HR, 1989, NEW ENGL J MED, V320, P1037, DOI 10.1056/NEJM198904203201603; KRISTENSEN MO, 1983, ACTA NEUROCHIR, V67, P37, DOI 10.1007/BF01401666; KROMANN N, 1980, ACTA MED SCAND, V208, P401; LANDS WEM, 1985, PROSTAGLANDINS, V30, P819, DOI 10.1016/0090-6980(85)90010-3; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; MASOTTI G, 1979, LANCET, V2, P1213; MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615; Orencia AJ, 1996, STROKE, V27, P204, DOI 10.1161/01.STR.27.2.204; RAPER NR, 1992, J AM COLL NUTR, V11, P304; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; TERANO T, 1983, ATHEROSCLEROSIS, V46, P321, DOI 10.1016/0021-9150(83)90181-8; THORNGREN M, 1984, BRIT J HAEMATOL, V58, P567, DOI 10.1111/j.1365-2141.1984.tb06103.x; VONSCHACKY C, 1985, J CLIN INVEST, V76, P1626, DOI 10.1172/JCI112147; VONSCHACKY C, 1985, J LIPID RES, V26, P457; Weinfeld, 1981, STROKE S1, V12, pI13; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WOODCOCK BE, 1984, BRIT MED J, V288, P592, DOI 10.1136/bmj.288.6417.592	40	317	330	0	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					304	312		10.1001/jama.285.3.304	http://dx.doi.org/10.1001/jama.285.3.304			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390XD	11176840	Bronze			2022-12-28	WOS:000166324300021
J	Plotz, FB; van Vught, H; Uiterwaal, CSPM; Riedijk, M; van der Ent, CK				Plotz, FB; van Vught, H; Uiterwaal, CSPM; Riedijk, M; van der Ent, CK			Exercise-induced oxygen desaturation as a late complication of meningococcal septic shock syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Utrecht, Med Ctr, Dept Pediat Intens Care, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Patient Oriented Res, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pediat Pulm, Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	Plotz, FB (corresponding author), Univ Utrecht, Med Ctr, Dept Pediat Intens Care, Utrecht, Netherlands.							Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Campbell WN, 1997, CLIN INFECT DIS, V24, P452, DOI 10.1093/clinids/24.3.452; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; de Kleijn ED, 1998, EUR J PEDIATR, V157, P869, DOI 10.1007/s004310050958; GEMKE RJBJ, 1994, ARCH DIS CHILD, V71, P291, DOI 10.1136/adc.71.4.291; van Brakel MJM, 2000, EUR J PEDIATR, V159, P232, DOI 10.1007/s004310050060	6	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					293	294		10.1001/jama.285.3.293-a	http://dx.doi.org/10.1001/jama.285.3.293-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390XD	11176838				2022-12-28	WOS:000166324300019
J	Maiwald, M; von Herbay, A; Persing, DH; Mitchell, PS; Abdelmalek, MF; Thorvilson, JN; Fredricks, DN; Relman, DA				Maiwald, M; von Herbay, A; Persing, DH; Mitchell, PS; Abdelmalek, MF; Thorvilson, JN; Fredricks, DN; Relman, DA			Tropheryma whippelii DNA is rare in the intestinal mucosa of patients without other evidence of Whipple disease	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; BACTERIUM; BACILLUS; DIAGNOSIS	Background: Little is known about the pathogenesis of Whipple disease, the reservoirs of Tropheryma whippelii, and the proportion of persons harboring the bacterium without "classic" intestinal abnormalities. Objective: To assess the presence of T. whippelii in patients undergoing upper endoscopy for a variety of indications. Design: Prospective and routine diagnostic examination of patients. Setting: Three academic medical centers in California; Minnesota; and Heidelberg, Germany. Patients: 342 patients undergoing endoscopy for evaluation of dyspepsia or possible peptic ulcer (group A, 173 patients), malabsorption (group B, 37 patients), or clinical suspicion of Whipple disease (group C, 132 patients). Measurements: Small-intestinal biopsy specimens were tested by polymerase chain reaction for T. whippelii DNA and examined for histopathologic abnormalities. Results: All patients with negative histologic findings also had negative results for T. whippelii DNA. Conclusions: T. whippelii occurs only rarely in intestinal mucosa that lacks histopathologic evidence of Whipple disease. The human small intestinal mucosa is an unlikely reservoir for this organism.	Vet Affairs Palo Alto Hlth Care Syst 154T, Palo Alto, CA 94304 USA; Stanford Univ, Stanford, CA 94305 USA; Heidelberg Univ, Inst Pathol, D-6900 Heidelberg, Germany; Mayo Clin, Rochester, MN USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Ruprecht Karls University Heidelberg; Mayo Clinic	Relman, DA (corresponding author), Vet Affairs Palo Alto Hlth Care Syst 154T, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	relman@cmgm.stanford.edu	Abdelmalek, Manal F/AAW-2203-2020	Relman, David A./0000-0001-8331-1354; Abdelmalek, Manal/0000-0002-5001-8618; Fredricks, David/0000-0003-2735-6800; Maiwald, Matthias/0000-0001-5448-8417	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001360] Funding Source: NIH RePORTER; NIAID NIH HHS [K11 AI01360] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Dobbins 3rd WO, 1987, WHIPPLES DIS; Ehrbar HU, 1999, LANCET, V353, P2214, DOI 10.1016/S0140-6736(99)01776-6; Maiwald M, 1996, INT J SYST BACTERIOL, V46, P1078, DOI 10.1099/00207713-46-4-1078; Maiwald M, 1998, APPL ENVIRON MICROB, V64, P760; Marth T, 1997, GASTROENTEROLOGY, V113, P442, DOI 10.1053/gast.1997.v113.pm9247462; MOORTHY S, 1977, GUT, V18, P152, DOI 10.1136/gut.18.2.152; O'Duffy JD, 1999, ARTHRITIS RHEUM, V42, P812, DOI 10.1002/1529-0131(199904)42:4<812::AID-ANR27>3.0.CO;2-S; Persing D.H., 1993, DIAGNOSTIC MOL MICRO; Pron B, 1999, EUR J CLIN MICROBIOL, V18, P62, DOI 10.1007/s100960050228; Ramzan NN, 1997, ANN INTERN MED, V126, P520, DOI 10.7326/0003-4819-126-7-199704010-00004; Raoult D, 2000, NEW ENGL J MED, V342, P620, DOI 10.1056/NEJM200003023420903; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; RELMAN DA, 1995, INFECT GASTROINTESTI; RICKMAN LS, 1995, NEW ENGL J MED, V332, P363, DOI 10.1056/NEJM199502093320604; Street S, 1999, LANCET, V354, P1178, DOI 10.1016/S0140-6736(99)03065-2; vonHerbay A, 1997, SCAND J GASTROENTERO, V32, P52, DOI 10.3109/00365529709025063; vonHerbay A, 1996, VIRCHOWS ARCH, V429, P335; vonHerbay A, 1996, GASTROENTEROLOGY, V110, P1735, DOI 10.1053/gast.1996.v110.pm8964398; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z	19	51	53	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2001	134	2					115	119		10.7326/0003-4819-134-2-200101160-00011	http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391KW	11177314				2022-12-28	WOS:000166356000004
J	Ward, MR; Herity, NA; Lee, DP; Yeung, AC				Ward, MR; Herity, NA; Lee, DP; Yeung, AC			A 25-year-old with severe coronary artery disease	LANCET			English	Editorial Material							GAUCHERS-DISEASE		Stanford Univ, Med Ctr, Div Cardiovasc Med, Stanford, CA 94305 USA	Stanford University	Yeung, AC (corresponding author), Stanford Univ, Med Ctr, Div Cardiovasc Med, 300 Pasteur Dr, Stanford, CA 94305 USA.							ABRAHAMOV A, 1995, LANCET, V346, P1000, DOI 10.1016/S0140-6736(95)91688-1; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687; Lichtenstein M, 1997, BLOOD CELL MOL DIS, V23, P395, DOI 10.1006/bcmd.1997.0156; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; WILSON ER, 1985, ARCH PATHOL LAB MED, V109, P82	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					116	116		10.1016/S0140-6736(00)03546-7	http://dx.doi.org/10.1016/S0140-6736(00)03546-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197400				2022-12-28	WOS:000166476200015
J	Hollopeter, G; Jantzen, HM; Vincent, D; Li, G; England, L; Ramakrishnan, V; Yang, RB; Nurden, P; Nurden, A; Julius, D; Conley, PB				Hollopeter, G; Jantzen, HM; Vincent, D; Li, G; England, L; Ramakrishnan, V; Yang, RB; Nurden, P; Nurden, A; Julius, D; Conley, PB			Identification of the platelet ADP receptor targeted by antithrombotic drugs	NATURE			English	Article							P2Y(1) RECEPTOR; ADENYLATE-CYCLASE; BLOOD-PLATELETS; CLOPIDOGREL; ACTIVATION; AGGREGATION; PROTEINS; CHANNEL; PATHWAY; BINDING	Platelets have a crucial role in the maintenance of normal haemostasis, and perturbations of this system can lead to pathological thrombus formation and vascular occlusion, resulting in stroke, myocardial infarction and unstable angina. ADP released from damaged vessels and red blood cells induces platelet aggregation through activation of the integrin GPIIb-IIIa and subsequent binding of fibrinogen. ADP is also secreted from platelets on activation, providing positive feedback that potentiates the actions of many platelet activators(1). ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes(2,3). The P2Y(1) receptor couples to G(q) and mobilizes intracellular calcium ions to mediate platelet shape change and aggregation(4,5). The second ADP receptor required for aggregation (variously called P2Y(ADP), P2Y(AC), P2Ycyc or P2T(AC)) is coupled to the inhibition of adenylyl cyclase through G(i). The molecular identity of the G(i)-linked receptor is still elusive, even though it is the target of efrcacious antithrombotic agents, such as ticlopidine and clopidogrel(6-8) and AR-C66096 (ref. 9). Here we describe the cloning of this receptor, designated P2Y(12), and provide evidence that a patient with a bleeding disorder(10) has a defect in this gene. Cloning of the P2Y12 receptor should facilitate the development of better antiplatelet agents to treat cardiovascular diseases.	COR Therapeut Inc, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Hop Cardiol, CNRS, UMR 5533, F-33605 Pessac, France	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); CHU Bordeaux	Conley, PB (corresponding author), COR Therapeut Inc, S San Francisco, CA 94080 USA.		Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714				BENNETT CL, 2000, NEW ENGL J MED, V325, P1371; BOYER JL, 1993, J PHARMACOL EXP THER, V267, P1140; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cattaneo M, 1999, ARTERIOSCL THROM VAS, V19, P2281, DOI 10.1161/01.ATV.19.10.2281; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Filippov AK, 2000, BRIT J PHARMACOL, V129, P1063, DOI 10.1038/sj.bjp.0703185; GACHET C, 1990, BIOCHEM PHARMACOL, V40, P2683, DOI 10.1016/0006-2952(90)90587-B; GACHET C, 1992, THROMB HAEMOSTASIS, V68, P79; Hechler B, 1998, BRIT J HAEMATOL, V103, P858, DOI 10.1046/j.1365-2141.1998.01056.x; HOURANI SMO, 1994, TRENDS PHARMACOL SCI, V15, P103, DOI 10.1016/0165-6147(94)90045-0; Humbert M, 1996, ARTERIOSCL THROM VAS, V16, P1532, DOI 10.1161/01.ATV.16.12.1532; HUMPHRIES RG, 1994, BRIT J PHARMACOL, V113, P1057, DOI 10.1111/j.1476-5381.1994.tb17100.x; Jantzen HM, 1999, THROMB HAEMOSTASIS, V81, P111; Jantzen HM, 1998, BLOOD, V92, p303A; Jarvis GE, 2000, BRIT J PHARMACOL, V129, P275, DOI 10.1038/sj.bjp.0703046; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; MACFARLANE DE, 1983, J CLIN INVEST, V71, P420, DOI 10.1172/JCI110786; MILLS DCB, 1992, ARTERIOSCLER THROMB, V12, P430, DOI 10.1161/01.ATV.12.4.430; Mills DCB, 1996, THROMB HAEMOSTASIS, V76, P835; NURDEN P, 1995, J CLIN INVEST, V95, P1612, DOI 10.1172/JCI117835; Ohlmann P, 1995, BIOCHEM J, V312, P775, DOI 10.1042/bj3120775; Palmer RK, 1998, MOL PHARMACOL, V54, P1118, DOI 10.1124/mol.54.6.1118; SAVI P, IN PRESS THROMB HAEM; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422	28	1128	1183	1	112	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					202	207		10.1038/35051599	http://dx.doi.org/10.1038/35051599			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196645				2022-12-28	WOS:000166316200047
J	Nerlich, AG; Zink, A; Szeimies, U; Hagedorn, HG				Nerlich, AG; Zink, A; Szeimies, U; Hagedorn, HG			Ancient Egyptian prosthesis of the big toe	LANCET			English	Editorial Material									Univ Munich, Dept Pathol, D-80337 Munich, Germany; Univ Munich, Dept Diagnost Radiol, D-80337 Munich, Germany	University of Munich; University of Munich	Nerlich, AG (corresponding author), Univ Munich, Dept Pathol, D-80337 Munich, Germany.		Zink, Albert/P-4024-2015	Zink, Albert/0000-0002-1461-747X; Nerlich, Andreas/0000-0001-6562-1017				BACH H, 1965, ANTHROPOL ANZ, V20, P20; Brothwell Don R., 1963, MAN, V244, P192; CONDON K, 1986, AM J PHYS ANTHROPOL, V71, P321, DOI 10.1002/ajpa.1330710307; Ferembach D., 1979, HOMO, V30, P1; Gray P H, 1967, Med Radiogr Photogr, V43, P34; Gray P. H. K., 1967, J EGYPT ARCHAEOL, V52, P138; HARRIS J E, 1975, Journal of the Michigan Dental Association, V57, P401; Harris J. E., 1980, XRAY ATLAS ROYAL MUM, P328; HOFFMANAXTHELM W, 1976, QUINTESSENZ, V11, P155; Ikram S, 1998, MUMMY ANCIENT EGYPT; JUNKER H, 1929, DENKSCHRIFT KAISERL, V69, P256; Long AR., 1931, ARCH PATHOL, V12, P92; MEREI G, 1959, Z AGYPT SPRACHE ALT, V84, P76; NERLICH AG, 2000, INT C CRAN TREP HUM, P36; Reeves N., 1999, STUDIES HONOUR EGYPT, P73; Ruffer MA, 1911, J PATHOL BACTERIOL, V15, P453, DOI 10.1002/path.1700150403; SANDISON A T, 1962, Med Hist, V6, P77; Smith E, 1924, EGYPTIAN MUMMIES; WAGLE WA, 1994, AM J ROENTGENOL, V162, P999, DOI 10.2214/ajr.162.4.8141038	19	68	71	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2176	2179		10.1016/S0140-6736(00)03507-8	http://dx.doi.org/10.1016/S0140-6736(00)03507-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191558				2022-12-28	WOS:000165997300039
J	Chintu, C; Mwaba, P				Chintu, C; Mwaba, P			Striving for global drug availability	LANCET			English	Article									UNZA UCLMS, Project HIV AIDS & TB Res & Training, Lusaka, Zambia; Univ Teaching Hosp, Lusaka, Zambia; Minist Hlth, Lusaka, Zambia	University of Zambia; University of Zambia	Chintu, C (corresponding author), UNZA UCLMS, Project HIV AIDS & TB Res & Training, POB 50110, Lusaka, Zambia.		Mwaba, Peter/V-6017-2019						0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S5	S5		10.1016/S0140-6736(00)91991-3	http://dx.doi.org/10.1016/S0140-6736(00)91991-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191508	Bronze			2022-12-28	WOS:000166074900007
J	Chockalingam, A				Chockalingam, A			Let's not make the same mistakes	LANCET			English	Article									Hlth Canada, Ottawa, ON K1A 0L2, Canada	Health Canada	Chockalingam, A (corresponding author), 1375 Talcy Crescent, Orleans, ON K4A 3C4, Canada.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S9	S9		10.1016/S0140-6736(00)91995-0	http://dx.doi.org/10.1016/S0140-6736(00)91995-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191529				2022-12-28	WOS:000166074900011
J	Dandona, L				Dandona, L			Blindness control in India: beyond anachronism	LANCET			English	Article									LV Prasad Eye Inst, Int Ctr Advancement Rural Eye Care, Hyderabad 500034, Andhra Pradesh, India	L. V. Prasad Eye Institute	Dandona, L (corresponding author), LV Prasad Eye Inst, Int Ctr Advancement Rural Eye Care, Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.								0	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S25	S25		10.1016/S0140-6736(00)92011-7	http://dx.doi.org/10.1016/S0140-6736(00)92011-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191481				2022-12-28	WOS:000166074900027
J	Henderson, N				Henderson, N			Coping with Usher's syndrome	LANCET			English	Article									Sense, London N4 3SR, England		Henderson, N (corresponding author), Sense, 11-13 Clifton Terrace,Finsbury Pk, London N4 3SR, England.								0	2	2	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S18	S18		10.1016/S0140-6736(00)92004-X	http://dx.doi.org/10.1016/S0140-6736(00)92004-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191473				2022-12-28	WOS:000166074900020
J	Sotos, JG; Rienhoff, HY				Sotos, JG; Rienhoff, HY			Will genetics revolutionize medicine?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									DNA Sci, Mt View, CA 94043 USA		Sotos, JG (corresponding author), DNA Sci, Mt View, CA 94043 USA.			Aulisio, Mark/0000-0002-6423-8523; Marteau, Theresa/0000-0003-3025-1129				ADAMS F, 1972, HIPPOCRATES GENUINE; Holtzman NA, 2000, NEW ENGL J MED, V343, P141, DOI 10.1056/NEJM200007133430213	2	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1496	1496						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184467				2022-12-28	WOS:000165271300023
J	Gould, MK; Maclean, CC; Kuschner, WG; Rydzak, CE; Owens, DK				Gould, MK; Maclean, CC; Kuschner, WG; Rydzak, CE; Owens, DK			Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CELL LUNG-CANCER; POLYMERASE CHAIN-REACTION; HEAD GAMMA-CAMERA; FDG-PET IMAGES; F-18 FLUORODEOXYGLUCOSE; SYSTEMATIC REVIEWS; BAYESIAN-ANALYSIS; COINCIDENCE MODE; HIV-INFECTION; TOMOGRAPHY	Context Focal pulmonary lesions are commonly encountered in clinical practice, and positron emission tomography (PET) with the glucose analog 18-fluorodeoxyglucose (FDG) may be an accurate test for identifying malignant lesions. Objective To estimate the diagnostic accuracy of FDG-PET for malignant focal pulmonary lesions. Data Sources Studies published between January 1966 and September 2000 in the MEDLINE and CANCERLIT databases; reference lists of identified studies; abstracts from recent conference proceedings; and direct contact with investigators. Study Selection Studies that examined FDG-PET or FDG with a modified gamma camera in coincidence mode for diagnosis of focal pulmonary lesions; enrolled at least 10 participants with pulmonary nodules or masses, including at least 10 participants with malignant lesions; and presented sufficient data to permit calculation of sensitivity and specificity were included in the anaylsis. Data Extraction Two reviewers independently assessed study quality and abstracted data regarding prevalence of malignancy and sensitivity and specificity of the imaging test. Disagreements were resolved by discussion. Data Synthesis We used a meta-analytic method to construct summary receiver operating characteristic curves. Forty studies met inclusion criteria. Study methodological quality was fair. Sample sizes were small and blinding was often incomplete. For 1474 focal pulmonary lesions of any size, the maximum joint sensitivity and specificity (the upper left point on the receiver operating characteristic curve at which sensitivity and specificity are equal) of FDG-PET was 91.2% (95% confidence interval, 89.1%-92.9%). In current practice, FDG-PET operates at a point on the summary receiver operating characteristic cu rye that corresponds approximately to a sensitivity and specificity of 96.8% and 77.8%, respectively. There was no difference in diagnostic accuracy for pulmonary nodules compared with lesions of any size (P=.43), for semiquantitative methods of image interpretation compared with qualitative methods (P=.52), or for FDG-PET compared with FDG imaging with a modified gamma camera in coincidence mode (P=.19). Conclusions Positron emission tomography with 18-fluorodeoxyglucose is an accurate noninvasive imaging test for diagnosis of pulmonary nodules and larger mass lesions, although few data exist for nodules smaller than 1 cm in diameter. In current practice, FDG-PET has high sensitivity and intermediate specificity for malignancy.	VA Palo Alto Hlth Care Syst, Hlth Serv Res & Dev Serv, Palo Alto, CA 94304 USA; VA Palo Alto Hlth Care Syst, Med Serv, Palo Alto, CA 94304 USA; Vet Affairs Cooperat Studies Program, Palo Alto, CA USA; Stanford Univ, Sch Med, Div Pulm & Crit Care Med, Stanford, CA USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA USA; Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University; Stanford University	Gould, MK (corresponding author), VA Palo Alto Hlth Care Syst, Pulm Sect 111P, 3801 Miranda Ave, Palo Alto, CA 94304 USA.			Kuschner, Ware/0000-0002-9732-1366				Albes JM, 1999, THORAC CARDIOV SURG, V47, P42, DOI 10.1055/s-2007-1013107; BECKER GL, 1990, ARCH INTERN MED, V150, P557, DOI 10.1001/archinte.150.3.557; Begg C., 1994, HDB RES SYNTHESIS, P399; Bury T, 1996, EUR RESPIR J, V9, P410, DOI 10.1183/09031936.96.09030410; Collins BT, 2000, DIAGN CYTOPATHOL, V22, P92, DOI 10.1002/(SICI)1097-0339(200002)22:2<92::AID-DC6>3.0.CO;2-2; Cook GJR, 1996, CLIN RADIOL, V51, P603, DOI 10.1016/S0009-9260(96)80052-3; Counsell C, 1997, ANN INTERN MED, V127, P380, DOI 10.7326/0003-4819-127-5-199709010-00008; CUMMINGS SR, 1986, AM REV RESPIR DIS, V134, P453; CUMMINGS SR, 1986, AM REV RESPIR DIS, V134, P449; Dewan NA, 1997, CHEST, V112, P416, DOI 10.1378/chest.112.2.416; DEWAN NA, 1995, CHEST, V108, P441, DOI 10.1378/chest.108.2.441; DEWAN NA, 1993, CHEST, V104, P997, DOI 10.1378/chest.104.4.997; DUHAYLONGSOD FG, 1995, ANN THORAC SURG, V60, P1348, DOI 10.1016/0003-4975(95)00754-9; DUHAYLONGSOD FG, 1995, J THORAC CARDIOV SUR, V110, P130, DOI 10.1016/S0022-5223(05)80018-2; Dwamena BA, 1999, RADIOLOGY, V213, P530, DOI 10.1148/radiology.213.2.r99nv46530; Erasmus JJ, 1998, AM J ROENTGENOL, V170, P1369, DOI 10.2214/ajr.170.5.9574618; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Graeber GM, 1999, J THORAC CARDIOV SUR, V117, P719, DOI 10.1016/S0022-5223(99)70292-8; Guhlmann A, 1997, THORAX, V52, P438, DOI 10.1136/thx.52.5.438; Gupta N, 1998, CHEST, V114, P1105, DOI 10.1378/chest.114.4.1105; Gupta NC, 1996, J NUCL MED, V37, P943; GUPTA NC, 1992, RADIOLOGY, V184, P441, DOI 10.1148/radiology.184.2.1620844; GURNEY JW, 1993, RADIOLOGY, V186, P405, DOI 10.1148/radiology.186.2.8421743; Hagberg RC, 1997, EUR J CARDIO-THORAC, V12, P92, DOI 10.1016/S1010-7940(97)00159-0; Higashi K, 1998, J NUCL MED, V39, P1016; *HLTH CAR FIN ADM, 1999, MED PART PROV PROGR; *HLTH CAR FIN ADM, 2000, 1999 NAT PHYS FEE SC; Hoh CK, 1997, SEMIN NUCL MED, V27, P94, DOI 10.1016/S0001-2998(97)80042-6; Hubner KF, 1996, CLIN NUCL MED, V21, P941, DOI 10.1097/00003072-199612000-00005; HUBNER KF, 1995, CLIN NUCL MED, V20, P293; HUGHES JM, 1996, THORAX S2, V51, P516; Kelsey JL., 1996, METHODS OBSERVATIONA; KENT DL, 1992, AM J ROENTGENOL, V158, P1135, DOI 10.2214/ajr.158.5.1533084; Kim S, 1999, CLIN NUCL MED, V24, P945, DOI 10.1097/00003072-199912000-00008; Knight SB, 1996, CHEST, V109, P982, DOI 10.1378/chest.109.4.982; KNOPP MV, 1994, RADIOLOGE, V34, P588; KUBOTA K, 1990, J NUCL MED, V31, P1927; Kubota K, 1989, Nihon Rinsho, V47, P1037; Kubota Kazuo, 1997, Kaku Igaku, V34, P329; Kutlu CA, 1998, LUNG CANCER-J IASLC, V21, P177, DOI 10.1016/S0169-5002(98)00026-9; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; LILLINGTON GA, 1993, CLIN CHEST MED, V14, P111; Lodge MA, 1998, EUR J NUCL MED, V25, P417, DOI 10.1007/s002590050240; Lowe VJ, 1998, J CLIN ONCOL, V16, P1075, DOI 10.1200/JCO.1998.16.3.1075; Lowe VJ, 1997, RADIOLOGY, V202, P435, DOI 10.1148/radiology.202.2.9015070; LOWE VJ, 1994, J NUCL MED, V35, P1771; Lowe VJ, 1998, THORAX, V53, P703, DOI 10.1136/thx.53.8.703; MACFARLANE DJ, 1995, RADIOLOGY, V194, P425, DOI 10.1148/radiology.194.2.7824722; Martin WH, 1996, RADIOLOGY, V198, P225, DOI 10.1148/radiology.198.1.8539384; MATSUMOTO K, 1987, SHITSURYO BUNSEKI, V35, P15; Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; Nettelbladt OS, 1998, J NUCL MED, V39, P640; Orino K, 1998, Jpn J Thorac Cardiovasc Surg, V46, P1267; Owens DK, 1996, JAMA-J AM MED ASSOC, V275, P1342, DOI 10.1001/jama.275.17.1342; Owens DK, 1996, ANN INTERN MED, V124, P803, DOI 10.7326/0003-4819-124-9-199605010-00004; PATZ EF, 1993, RADIOLOGY, V188, P487, DOI 10.1148/radiology.188.2.8327702; PATZ EF, 1994, RADIOL CLIN N AM, V32, P811; Prauer HW, 1998, BRIT J SURG, V85, P1506; REGE SD, 1993, CANCER-AM CANCER SOC, V72, P82, DOI 10.1002/1097-0142(19930701)72:1<82::AID-CNCR2820720117>3.0.CO;2-3; Richter JA, 1999, MED CLIN-BARCELONA, V113, P567; Sarinas P S, 1999, Curr Opin Pulm Med, V5, P201, DOI 10.1097/00063198-199907000-00004; Saunders CAB, 1999, ANN THORAC SURG, V67, P790, DOI 10.1016/S0003-4975(98)01257-0; Sazon DAD, 1996, AM J RESP CRIT CARE, V153, P417, DOI 10.1164/ajrccm.153.1.8542152; Schelbert HR, 1998, J NUCL MED, V39, P1302; SCOTT WJ, 1994, ANN THORAC SURG, V58, P698, DOI 10.1016/0003-4975(94)90730-7; SEELY JM, 1993, RADIOLOGY, V186, P129, DOI 10.1148/radiology.186.1.8416552; Shreve PD, 1998, RADIOLOGY, V207, P431, DOI 10.1148/radiology.207.2.9577492; SIEGELMAN SS, 1986, RADIOLOGY, V160, P307, DOI 10.1148/radiology.160.2.3726105; SLOSMAN DO, 1993, NUCL MED COMMUN, V14, P955, DOI 10.1097/00006231-199311000-00004; Swensen SJ, 1997, ARCH INTERN MED, V157, P849, DOI 10.1001/archinte.157.8.849; Tatsumi M, 1999, J NUCL MED, V40, P566; Tatsumi M, 2000, J COMPUT ASSIST TOMO, V24, P574, DOI 10.1097/00004728-200007000-00011; TRAMPERT L, 1995, NUKLEARMED, V34, P79; Vaylet F., 1998, Revue de Pneumologie Clinique, V54, P187; WAHL RL, 1994, RADIOLOGY, V191, P371, DOI 10.1148/radiology.191.2.8153308; Wang H, 1997, CLIN NUCL MED, V22, P243, DOI 10.1097/00003072-199704000-00008; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weber W, 1999, J NUCL MED, V40, P574; Weber WA, 1999, EUR J NUCL MED, V26, P388, DOI 10.1007/s002590050402; Yasuda Seiei, 1996, Kaku Igaku, V33, P1065; Zimny M, 1999, NUKLEARMED, V38, P108	82	799	861	0	61	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					914	924		10.1001/jama.285.7.914	http://dx.doi.org/10.1001/jama.285.7.914			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402BE	11180735				2022-12-28	WOS:000166965500029
J	Maddrey, WC				Maddrey, WC			Update in hepatology	ANNALS OF INTERNAL MEDICINE			English	Article									Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Maddrey, WC (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.								0	10	10	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2001	134	3					216	223		10.7326/0003-4819-134-3-200102060-00013	http://dx.doi.org/10.7326/0003-4819-134-3-200102060-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397KR	11177335				2022-12-28	WOS:000166695300006
J	Smith, SD; Wheeler, MA; Plescia, J; Colberg, JW; Weiss, RM; Altieri, DC				Smith, SD; Wheeler, MA; Plescia, J; Colberg, JW; Weiss, RM; Altieri, DC			Urine detection of survivin and diagnosis of bladder cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTI-APOPTOSIS GENE; MESSENGER-RNA; PROGNOSIS	Context Dysregulation of apoptosis may favor onset and progression of cancer and influence response to therapy. Survivin is an inhibitor of apoptosis that is selectively overexpressed in common human cancers, but not in normal tissues, and that correlates with aggressive disease and unfavorable outcomes, Objective To investigate the potential suitability of survivin detection in urine as a novel predictive/prognostic molecular marker of bladder cancer, Design, Setting, and Patients Survey of urine specimens from 5 groups: healthy volunteers (n=17) and patients with nonneoplastic urinary tract disease (n=30), genitourinary cancer (n=30), new-onset or recurrent bladder cancer (n=46), or treated bladder cancer (n=35), recruited from 2 New England urology clinics. Main Outcome Measures Detectable survivin levels, analyzed by a novel detection system and confirmed by Western blot and reverse transcriptase polymerase chain reaction (RT-PCR), in urine samples of the 5 participant groups. Results Survivin was detected in the urine samples of all 46 patients with new or recurrent bladder cancer using a novel detection system (31 of 31) and RT-PCR (15 of ? 5) methods. Survivin was not detected in the urine samples of 32 of 35 patients treated for bladder cancer and having negative cystoscopy results. None of the healthy volunteers or patients with prostate, kidney, vaginal, or cervical cancer had detectable survivin in urine samples, Of the 30 patients with nonneoplastic urinary tract disease, survivin was detected in 3 patients who had bladder abnormalities noted using cystoscopy and in 1 patient with an increased prostate-specific antigen level. Patients with low-grade bladder cancer had significantly lower urine survivin levels than patients with carcinoma in situ (P=.002). Conclusions Highly sensitive and specific determination of urine survivin appears to provide a simple, noninvasive diagnostic test to identify patients with new or recurrent bladder cancer.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Surg, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06536 USA	Yale University; Yale University	Altieri, DC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Surg, BCMM436B,295 Congress Ave, New Haven, CT 06536 USA.				NATIONAL CANCER INSTITUTE [R01CA078810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038311, K08DK002499, R01DK047548, R01DK038311] Funding Source: NIH RePORTER; NCI NIH HHS [CA78810] Funding Source: Medline; NIDDK NIH HHS [DK02499, DK38311, DK47548] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Brown FM, 2000, UROL CLIN N AM, V27, P25, DOI 10.1016/S0094-0143(05)70231-7; Dawson C, 1996, BRIT MED J, V312, P1090; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Gazzaniga P, 1996, INT J CANCER, V69, P100, DOI 10.1002/(SICI)1097-0215(19960422)69:2<100::AID-IJC5>3.0.CO;2-4; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Kawasaki H, 1998, CANCER RES, V58, P5071; Lara PC, 1999, INT J RADIAT ONCOL, V43, P1015, DOI 10.1016/S0360-3016(98)00472-6; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lokeshwar VB, 2000, J UROLOGY, V163, P348, DOI 10.1016/S0022-5347(05)68050-0; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Ozen Haluk, 1998, Current Opinion in Oncology, V10, P273; Ramakumar S, 1999, J UROLOGY, V161, P388, DOI 10.1016/S0022-5347(01)61899-8; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Stein JP, 1998, J UROLOGY, V160, P645, DOI 10.1016/S0022-5347(01)62747-2; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tanaka K, 2000, CLIN CANCER RES, V6, P127; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487	20	217	276	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					324	328		10.1001/jama.285.3.324	http://dx.doi.org/10.1001/jama.285.3.324			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390XD	11176843	Bronze			2022-12-28	WOS:000166324300024
J	Hill, DJ; Heine, RG; Hosking, CS				Hill, DJ; Heine, RG; Hosking, CS			Management of peanut and nut allergies	LANCET			English	Editorial Material							NATURAL-HISTORY; FOOD ALLERGY; CHILDREN; ANAPHYLAXIS; ASSOCIATION		Royal Childrens Hosp, Dept Allergy, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Hill, DJ (corresponding author), Royal Childrens Hosp, Dept Allergy, Flemington Rd, Parkville, Vic 3052, Australia.	allergy@cryptic.rch.unimelb.edu.au		Heine, Ralf Gunter/0000-0002-3343-0379				BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Chamberlain D, 1999, J ACCID EMERG MED, V16, P243; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; Hill DJ, 1997, ENVIRON TOXICOL PHAR, V4, P101, DOI 10.1016/S1382-6689(97)10049-7; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Shek LPC, 1999, ASIAN PAC J ALLERGY, V17, P203; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Simons FER, 2000, PEDIATRICS, V106, P1040, DOI 10.1542/peds.106.5.1040; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Skolnick H, 2000, J ALLERGY CLIN IMMUN, V105, pS189, DOI 10.1016/S0091-6749(00)90995-3; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	17	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2001	357	9250					87	88		10.1016/S0140-6736(00)03537-6	http://dx.doi.org/10.1016/S0140-6736(00)03537-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197443				2022-12-28	WOS:000166476200007
J	Khosla, C; Harbury, PB				Khosla, C; Harbury, PB			Modular enzymes	NATURE			English	Review							ERYTHROMYCIN POLYKETIDE SYNTHASE; BINDING DOMAINS; PROTEIN; SUBSTRATE; SPECIFICITY; BIOSYNTHESIS; SELECTIVITY; EVOLUTION; HOMOLOGY; CLEAVAGE	Although modular macromolecular devices are encountered frequently in a variety of biological situations, their occurrence in biocatalysis has not been widely appreciated. Three general classes of modular biocatalysts can be identified: enzymes in which catalysis and substrate specificity are separable, multisubstrate enzymes in which binding sites for individual substrates are modular, and multienzyme systems that can catalyse programmable metabolic pathways. In the postgenomic era, the discovery of such systems can be expected to have a significant impact on the role of enzymes in synthetic and process chemistry.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Chem & Biochem Engn, Stanford, CA 94305 USA	Stanford University; Stanford University	Khosla, C (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	ck@chemeng.stanford.edu		Khosla, Chaitan/0000-0001-6529-495X				Aggarwal AK, 1998, CURR OPIN STRUC BIOL, V8, P19, DOI 10.1016/S0959-440X(98)80005-5; Belshaw PJ, 1999, SCIENCE, V284, P486, DOI 10.1126/science.284.5413.486; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Borisova SA, 1999, ORG LETT, V1, P133, DOI 10.1021/ol9906007; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; Costello CA, 1996, TETRAHEDRON LETT, V37, P7469, DOI 10.1016/0040-4039(96)01752-2; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; Dalal S, 1997, NAT STRUCT BIOL, V4, P548, DOI 10.1038/nsb0797-548; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Done SH, 1998, J MOL BIOL, V284, P463, DOI 10.1006/jmbi.1998.2180; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Fernandes AC, 1999, BIOCHEM J, V342, P105, DOI 10.1042/0264-6021:3420105; Fersht A., 1985, ENZYME STRUCTURE MEC; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; Geck MK, 1999, BIOCHEMISTRY-US, V38, P8032, DOI 10.1021/bi983029c; Goulding CW, 1997, BIOCHEMISTRY-US, V36, P8082, DOI 10.1021/bi9705164; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8764, DOI 10.1021/bi00195a018; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; Huang BH, 1996, J PROTEIN CHEM, V15, P481, DOI 10.1007/BF01886856; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; Jencks W.P., 1987, CATALYSIS CHEM ENZYM, P615; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; Kao CM, 1997, J AM CHEM SOC, V119, P11339, DOI 10.1021/ja972609e; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang DA, 1998, EUR J BIOCHEM, V254, P333, DOI 10.1046/j.1432-1327.1998.2540333.x; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; McDaniel R, 1999, P NATL ACAD SCI USA, V96, P1846, DOI 10.1073/pnas.96.5.1846; Mootz HD, 1999, CURR OPIN BIOTECH, V10, P341, DOI 10.1016/S0958-1669(99)80062-7; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; Olano C, 1999, CHEM BIOL, V6, P845, DOI 10.1016/S1074-5521(00)80004-6; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Pathak T, 1998, CURR OPIN CHEM BIOL, V2, P112, DOI 10.1016/S1367-5931(98)80042-2; Perham RN, 1998, BIOCHEM SOC T, V26, P299, DOI 10.1042/bst0260299; Ptashne M, 1998, CURR BIOL, V8, pR897; RASHIN AA, 1981, NATURE, V291, P85, DOI 10.1038/291085a0; Riley M, 1997, J MOL BIOL, V268, P857, DOI 10.1006/jmbi.1997.1003; Roberts SM, 2000, J CHEM SOC PERK T 1, P611, DOI 10.1039/a908303k; Roberts SM, 1999, J CHEM SOC PERK T 1, P1, DOI 10.1039/a806595k; Roberts SM, 1998, J CHEM SOC PERK T 1, P157, DOI 10.1039/a704412g; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; VILLARREAL DT, 1994, APPL ENVIRON MICROB, V60, P3939, DOI 10.1128/AEM.60.11.3939-3944.1994; Wu N, 2000, J AM CHEM SOC, V122, P4847, DOI 10.1021/ja000023d	56	110	114	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					247	252		10.1038/35051723	http://dx.doi.org/10.1038/35051723			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196653				2022-12-28	WOS:000166316200056
J	Wilde, SA; Valley, JW; Peck, WH; Graham, CM				Wilde, SA; Valley, JW; Peck, WH; Graham, CM			Evidence from detrital zircons for the existence of continental crust and oceans on the Earth 4.4 Gyr ago	NATURE			English	Article							JACK HILLS; U-PB; ISOTOPES; HISTORY	No crustal rocks are known to have survived since the time of the intense meteor bombardment that affected Earth(1) between its formation about 4,550 Myr ago and 4,030 Myr, the age of the oldest known components in the Acasta Gneiss of northwestern Canada(2). But evidence of an even older crust is provided by detrital zircons in metamorphosed sediments at Mt Narryer(3) and Jack Hills(4-8) in the Narryer Gneiss Terrane(9), Yilgarn Craton, Western Australia, where grains as old as similar to4,276 Myr have been found(4). Here we report, based on a detailed micro-analytical study of Jack Hills zircons(10), the discovery of a detrital zircon with an age as old as 4,404 +/- 8 Myr-about 130 million years older than any previously identified on Earth. We found that the zircon is zoned with respect to rare earth elements and oxygen isotope ratios (delta (18) O values from 7.4 to 5.0 parts per thousand), indicating that it formed from an evolving magmatic source. The evolved chemistry, high delta (18) O value and micro-inclusions of SiO2 are consistent with growth from a granitic melt(11,2) with a delta (18) O value from 8.5 to 9.5 parts per thousand. Magmatic oxygen isotope ratios in this range point toward the involvement of supracrustal material that has undergone low-temperature interaction with a liquid hydrosphere. This zircon thus represents the earliest evidence for continental crust and oceans on the Earth.	Curtin Univ Technol, Sch Appl Geol, Perth, WA, Australia; Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; Univ Edinburgh, Dept Geol & Geophys, Edinburgh EH9 3JW, Midlothian, Scotland	Curtin University; University of Wisconsin System; University of Wisconsin Madison; University of Edinburgh	Wilde, SA (corresponding author), Curtin Univ Technol, Sch Appl Geol, GPO Box U1987, Perth, WA, Australia.	wildes@lithos.curtin.edu.au	Valley, John W./B-3466-2011; Wilde, Simon Alexander/C-5174-2009; Facility, Edinburgh Ion Microprobe/AAD-8512-2020; Peck, William H/E-3051-2010	Valley, John W./0000-0003-3530-2722; Wilde, Simon Alexander/0000-0002-4546-8278; Facility, Edinburgh Ion Microprobe/0000-0001-6248-6657; Peck, William/0000-0001-8251-8476				Amelin Y, 1999, NATURE, V399, P252, DOI 10.1038/20426; Amelin YV, 1998, CHEM GEOL, V146, P25, DOI 10.1016/S0009-2541(97)00162-9; Bowring SA, 1999, CONTRIB MINERAL PETR, V134, P3, DOI 10.1007/s004100050465; Claoue-Long J.C., 1995, SOC EC PALEONTOLOGIS; COMPSTON W, 1992, J GEOL SOC LONDON, V149, P171, DOI 10.1144/gsjgs.149.2.0171; COMPSTON W, 1986, NATURE, V321, P766, DOI 10.1038/321766a0; Eiler JM, 1997, CHEM GEOL, V138, P221, DOI 10.1016/S0009-2541(97)00015-6; FROUDE DO, 1983, NATURE, V304, P616, DOI 10.1038/304616a0; Hayes J. M., 1983, EARTHS EARLIEST BIOS, P93; HINTON RW, 1991, GEOCHIM COSMOCHIM AC, V55, P3287, DOI 10.1016/0016-7037(91)90489-R; King EM, 1998, PRECAMBRIAN RES, V92, P365, DOI 10.1016/S0301-9268(98)00082-5; KOBER B, 1989, EARTH PLANET SC LETT, V91, P286, DOI 10.1016/0012-821X(89)90004-6; MAAS R, 1992, GEOCHIM COSMOCHIM AC, V56, P1281, DOI 10.1016/0016-7037(92)90062-N; MATTINSON JM, 1994, CONTRIB MINERAL PETR, V116, P117, DOI 10.1007/BF00310694; MUEHLENBACHS K, 1986, REV MINERAL, V16, P425; Myers J.S., 1995, EARLY PRECAMBRIAN PR, V95, P143, DOI DOI 10.1144/GSL.SP.1995.095.01.09; Nelson D.R, 1997, GEOLOGICAL SURVEY W, P1; Nelson DR, 2000, EARTH PLANET SC LETT, V181, P89, DOI 10.1016/S0012-821X(00)00186-2; PECK WH, UNPUB GEOCHIM COSMOC; Pidgeon R., 1994, 8 INT C GEOCHR COSM; RYDER G, 1992, GEOL SOC AM ABSTR, V21, pA299; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; TAYLOR SR, 1992, SOLAR SYSTEM EVOLUTI, P289; Valley JW, 1998, CONTRIB MINERAL PETR, V133, P1, DOI 10.1007/s004100050432; VALLEY JW, 1994, EARTH PLANET SC LETT, V126, P187, DOI 10.1016/0012-821X(94)90106-6; VALLEY JW, 1998, REV EC GEOLOGY, V7, P73; Wilde S.A., 1990, 3 INT ARCHAEAN S, V21, P82; Williams I.S., 1998, REV EC GEOLOGY, V7, P1, DOI DOI 10.1080/07474938808800138; WILLIAMS IS, 1984, CONTRIB MINERAL PETR, V88, P322, DOI 10.1007/BF00376756	29	1083	1180	10	351	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					175	178		10.1038/35051550	http://dx.doi.org/10.1038/35051550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196637				2022-12-28	WOS:000166316200039
J	Watkins, EJ; Brooksby, P; Schweiger, MS; Enright, SM				Watkins, EJ; Brooksby, P; Schweiger, MS; Enright, SM			Septicaemia in a pig-farm worker	LANCET			English	Editorial Material							STREPTOCOCCUS-SUIS; MENINGITIS		Pinderfields & Pontefract Hosp NHS Trust, Dept Anaesthesia & Intens Care, Pontefract WF8 1PL, W Yorkshire, England; Pinderfields & Pontefract Hosp NHS Trust, Dept Med, Pontefract WF8 1PL, W Yorkshire, England; Leeds Author, Dept Publ Hlth, Leeds, W Yorkshire, England	Pinderfields Hospital; Pinderfields Hospital	Enright, SM (corresponding author), Pinderfields & Pontefract Hosp NHS Trust, Dept Anaesthesia & Intens Care, Pontefract WF8 1PL, W Yorkshire, England.							ARENDS JP, 1988, REV INFECT DIS, V10, P131; CLARKE D, 1991, LANCET, V338, P1147, DOI 10.1016/0140-6736(91)92005-M; GOTTSCHALK M, 1989, J CLIN MICROBIOL, V27, P2633, DOI 10.1128/JCM.27.12.2633-2636.1989; ROBERTSON ID, 1989, EPIDEMIOL INFECT, V101, P1102; TANBYAH PA, 1997, CLIN INFECT DIS, V24, P710	5	40	46	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					38	38		10.1016/S0140-6736(00)03570-4	http://dx.doi.org/10.1016/S0140-6736(00)03570-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197360				2022-12-28	WOS:000166341500014
J	Borst-Eilers, E				Borst-Eilers, E			Availability of pharmaceutical drugs	LANCET			English	Article									Minist Hlth Welf & Sports, The Hague, Netherlands	Ministry of Health, Welfare & Sport	Borst-Eilers, E (corresponding author), Minist Hlth Welf & Sports, The Hague, Netherlands.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S6	S6		10.1016/S0140-6736(00)91992-5	http://dx.doi.org/10.1016/S0140-6736(00)91992-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191519	Bronze			2022-12-28	WOS:000166074900008
J	Geller, JL				Geller, JL			American "community" psychiatry	LANCET			English	Article									Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Geller, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S40	S40		10.1016/S0140-6736(00)92026-9	http://dx.doi.org/10.1016/S0140-6736(00)92026-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191498				2022-12-28	WOS:000166074900042
J	Kulling, P; Norberg, KA				Kulling, P; Norberg, KA			Medical response to disasters in Sweden	LANCET			English	Article									Swedish Natl Board Hlth & Welf, Dept Emergency & Disaster Planning, Stockholm, Sweden	National Board of Health & Welfare	Kulling, P (corresponding author), Swedish Natl Board Hlth & Welf, Dept Emergency & Disaster Planning, Stockholm, Sweden.								0	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S20	S20		10.1016/S0140-6736(00)92006-3	http://dx.doi.org/10.1016/S0140-6736(00)92006-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191476				2022-12-28	WOS:000166074900022
J	Vasconcelos, C; McKenzie, JA				Vasconcelos, C; McKenzie, JA			Biogeochemistry - Sulfate reducers - Dominant players in a low-oxygen world?	SCIENCE			English	Editorial Material							SULFUR		ETH Zurich, Inst Geol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Vasconcelos, C (corresponding author), ETH Zurich, Inst Geol, CH-8092 Zurich, Switzerland.							Burns SJ, 2000, SEDIMENTOLOGY, V47, P49, DOI 10.1046/j.1365-3091.2000.00004.x; CLAYPOOL GE, 1980, CHEM GEOL, V28, P199, DOI 10.1016/0009-2541(80)90047-9; JORGENSEN BB, 1990, DEEP-SEA RES, V37, P695, DOI 10.1016/0198-0149(90)90099-H; Labrenz M, 2000, SCIENCE, V290, P1744, DOI 10.1126/science.290.5497.1744; OHMOTO H, 1993, SCIENCE, V262, P555, DOI 10.1126/science.11539502; PFENNIG N, 1992, PROKARYOTES, P941; Schidlowski M., 1983, P149; VASCONCELOS C, 1995, NATURE, V377, P220, DOI 10.1038/377220a0; Warthmann R, 2000, GEOLOGY, V28, P1091, DOI 10.1130/0091-7613(2000)028<1091:BIDPIA>2.3.CO;2	9	19	22	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1711	1712		10.1126/science.290.5497.1711	http://dx.doi.org/10.1126/science.290.5497.1711			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11186393				2022-12-28	WOS:000165632400028
J	Turner, APF				Turner, APF			Biochemistry - Biosensors sense and sensitivity	SCIENCE			English	Article									Cranfield Univ, Silsoe MK45 4DT, Beds, England	Cranfield University	Turner, APF (corresponding author), Cranfield Univ, Silsoe MK45 4DT, Beds, England.	a.p.turner@cranfield.ac.uk		Turner, Anthony/0000-0002-1815-9699				Billinton N, 1998, BIOSENS BIOELECTRON, V13, P831, DOI 10.1016/S0956-5663(98)00049-9; Bode BW, 1999, DIABETES RES CLIN PR, V46, P183, DOI 10.1016/S0168-8227(99)00113-8; Cardosi MF, 1990, DIABETES ANN, V5, P254; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Harris B, 1999, TRENDS BIOTECHNOL, V17, P290, DOI 10.1016/S0167-7799(99)01308-6; JENKINS SH, 1991, ADV BIOSENSORS, V1, P171; Kroger S, 1999, ANAL CHEM, V71, P3698, DOI 10.1021/ac9811827; Mendelsohn AR, 1999, SCIENCE, V284, P1948, DOI 10.1126/science.284.5422.1948; MOSBACH M, 2000, BIOSENSORS 2000, P164; Rowe-Taitt CA, 2000, BIOSENS BIOELECTRON, V14, P785, DOI 10.1016/S0956-5663(99)00052-4; SUBRAHMANYAM S, 2000, ADV MATER, V2003, P1; Tierney MJ, 1999, CLIN CHEM, V45, P1681; Tombelli S, 2000, BIOSENS BIOELECTRON, V15, P363, DOI 10.1016/S0956-5663(00)00092-0; TURNER APF, 1999, MCGRAWHILL YB SCI TE, P39; WESTON DG, 2000, BIOSENSORS 2000, P92	15	386	401	4	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1315	1317		10.1126/science.290.5495.1315	http://dx.doi.org/10.1126/science.290.5495.1315			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11185408				2022-12-28	WOS:000165379800034
J	Wilkening, KE; Barrie, LA; Engle, M				Wilkening, KE; Barrie, LA; Engle, M			Atmospheric science - Trans-Pacific air pollution	SCIENCE			English	Editorial Material									Univ No British Columbia, Int Studies Program, Prince George, BC V2N 4Z9, Canada; Pacific NW Natl Lab, Walla Walla, WA 99362 USA; US EPA, Off Int Act, Washington, DC 20460 USA	University of Northern British Columbia; United States Department of Energy (DOE); Pacific Northwest National Laboratory; United States Environmental Protection Agency	Wilkening, KE (corresponding author), Univ No British Columbia, Int Studies Program, Prince George, BC V2N 4Z9, Canada.							AMAP, 1998, AMAP ASS REP ARCT PO; Anthony RG, 1999, ENVIRON TOXICOL CHEM, V18, P2054, DOI 10.1002/etc.5620180925; Bailey R, 2000, J GEOPHYS RES-ATMOS, V105, P11805, DOI 10.1029/1999JD901180; Blais JM, 1998, NATURE, V395, P585, DOI 10.1038/26944; DUCE RA, 1980, SCIENCE, V209, P1522, DOI 10.1126/science.209.4464.1522; Edmonds R.L., 1998, SCI MONOGRAPH US DEP; Hoell JM, 1996, J GEOPHYS RES-ATMOS, V101, P1641, DOI 10.1029/95JD00622; HOELL M, 1997, J GEOPHYS RES, V102, P28223; Jacob DJ, 1999, GEOPHYS RES LETT, V26, P2175, DOI 10.1029/1999GL900450; Jaffe D, 1999, GEOPHYS RES LETT, V26, P711, DOI 10.1029/1999GL900100; JAFFE D, IN PRESS J GEOPHYS R; KOTCHENRUTHER R, IN PRESS J GEOPHYS R; MACDONALD RW, 2000, HLTH FRASER RIVER EQ, V1, P23; Perry KD, 1999, J GEOPHYS RES-ATMOS, V104, P18521, DOI 10.1029/1998JD100083; Ross PS, 2000, MAR POLLUT BULL, V40, P504, DOI 10.1016/S0025-326X(99)00233-7; YIENGER JJ, IN PRESS J GEOPHYS R	16	166	173	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 6	2000	290	5489					65	+		10.1126/science.290.5489.65	http://dx.doi.org/10.1126/science.290.5489.65			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	361LP	11183151				2022-12-28	WOS:000089724800031
J	Pacak, K; Linehan, WM; Eisenhofer, G; Walther, MM; Goldstein, DS				Pacak, K; Linehan, WM; Eisenhofer, G; Walther, MM; Goldstein, DS			Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							MULTIPLE ENDOCRINE NEOPLASIA; MEDULLARY-THYROID CARCINOMA; CLONIDINE-SUPPRESSION TEST; HIPPEL-LINDAU-DISEASE; POSITRON-EMISSION-TOMOGRAPHY; TERM-FOLLOW-UP; RET PROTOONCOGENE; FAMILIAL PHEOCHROMOCYTOMA; LAPAROSCOPIC ADRENALECTOMY; CHROMOGRANIN-A	Pheochromocytoma is a rare but important tumor of chromaffin cells that is frequently considered in the evaluation of hypertension, arrhythmias, or panic disorder and in the follow-up of patients with particular genetic diseases. This report provides an update about the genetics, neurochemical diagnosis, localization by imaging, and surgical management of pheochromocytoma. Specific mutations of the RET proto-oncogene cause familial predisposition to pheochromocytoma in multiple endocrine neoplasia type II, and mutations in the von Hippel-Lindau tumor suppressor gene cause familial disposition to pheochromocytoma in von Hippel-Lindau disease. Recent findings demonstrating extraordinarily high sensitivity of plasma levels of metanephrines for detecting pheochromocytoma have led to an algorithm for clinical diagnostic steps. Nuclear imaging approaches, such as (123)l-metaiodobenzylguanidine scintigraphy and 6-[F-18]fluorodopamine positron emission tomography, enhance both diagnosis and localization of the tumor, as described in an algorithm for patients with positive biochemical test results. Since pheochromocytoma is often benign, surgical resection by laparoscopic adrenalectomy can be curative. Areas requiring further work include determining appropriate follow-up of patients with familial pheochromocytoma, elucidating the bases for phenotypic differences, improving both specificity and sensitivity of biochemical tests, optimizing cost-effectiveness of diagnostic imaging, and testing the risk for tumor recurrence after partial adrenalectomy.	NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NINDS, Clin Neurocardiol Sect, NIH, Bethesda, MD 20892 USA; NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pacak, K (corresponding author), NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bldg 10,Room 9D42,10 Ctr Dr MSC-1583, Bethesda, MD 20892 USA.	karel@mail.nih.gov	Eisenhofer, Graeme/AAU-9829-2021	Eisenhofer, Graeme/0000-0002-8601-9903	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002979] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERY DM, 1984, BRIT MED J, V288, P1587, DOI 10.1136/bmj.288.6430.1587; Adams S, 1998, EUR J NUCL MED, V25, P79; ALBANESE CT, 1993, J PEDIATR SURG, V28, P1248, DOI 10.1016/S0022-3468(05)80307-0; Aldrighetti L, 1997, INT SURG, V82, P160; APRILL BS, 1994, ANN INTERN MED, V120, P485, DOI 10.7326/0003-4819-120-6-199403150-00006; BAULIEU JL, 1984, J NUCL MED, V25, pP111; Beatty OL, 1996, EUR J SURG, V162, P695; BOOMSMA F, 1995, CLIN CHIM ACTA, V239, P57, DOI 10.1016/0009-8981(95)06100-R; BOS JL, 1989, CANCER RES, V49, P4682; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; BRAVO EL, 1979, NEW ENGL J MED, V301, P682, DOI 10.1056/NEJM197909273011302; BRAVO EL, 1981, NEW ENGL J MED, V305, P623, DOI 10.1056/NEJM198109103051107; BRAVO EL, 1984, NEW ENGL J MED, V311, P1298, DOI 10.1056/NEJM198411153112007; BRAVO EL, 1994, ENDOCR REV, V15, P356, DOI 10.1210/er.15.3.356; Brunt LR, 1996, J AM COLL SURGEONS, V183, P1; CAMPEAU RJ, 1991, SOUTHERN MED J, V84, P1221, DOI 10.1097/00007611-199110000-00015; CANALE MP, 1994, J CLIN ENDOCR METAB, V78, P1139, DOI 10.1210/jc.78.5.1139; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CAVENEE WK, 1986, NEW ENGL J MED, V314, P1201, DOI 10.1056/NEJM198605083141901; CHATAL JF, 1993, J NUCL MED, V34, P180; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chen F, 1996, J MED GENET, V33, P716, DOI 10.1136/jmg.33.8.716; CROSSEY PA, 1995, J MED GENET, V32, P885, DOI 10.1136/jmg.32.11.885; Davidoff F, 1999, ANN INTERN MED, V130, P1019, DOI 10.7326/0003-4819-130-12-199906150-00022; de Graaf JS, 1999, EUR J SURG, V165, P843; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DUHAYLONGSOD FG, 1995, ANN THORAC SURG, V60, P1348, DOI 10.1016/0003-4975(95)00754-9; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; Eisenhofer G, 2000, EUR J NUCL MED, V27, P611; Eisenhofer G, 1999, NEW ENGL J MED, V340, P1872, DOI 10.1056/NEJM199906173402404; ELLIOTT WJ, 1988, AM J MED, V84, P419, DOI 10.1016/0002-9343(88)90261-6; ELLISON GT, 1988, SURGERY, V103, P484; Eng C, 1996, NEW ENGL J MED, V335, P943, DOI 10.1056/NEJM199609263351307; Eng C, 1998, J CLIN ENDOCR METAB, V83, P4310, DOI 10.1210/jc.83.12.4310; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Favia G, 1998, WORLD J SURG, V22, P689, DOI 10.1007/s002689900454; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; Francis IR, 1996, RADIOL CLIN N AM, V34, P1101; FRANCKE U, 1990, NATURE, V343, P692, DOI 10.1038/343692a0; FrankRaue K, 1996, J CLIN ENDOCR METAB, V81, P1780, DOI 10.1210/jc.81.5.1780; Gagner M, 1996, SURGERY, V120, P1076, DOI 10.1016/S0039-6060(96)80058-4; Gagner M, 1997, ANN SURG, V226, P238, DOI 10.1097/00000658-199709000-00003; GERLO EAM, 1994, CLIN CHEM, V40, P250; Glenn G., 1990, PROBLEMS UROLOGIC SU, P312; GOLDSTEIN DS, 1995, CATECHOLAMINES CARDI; Goldstein RE, 1999, ANN SURG, V229, P755, DOI 10.1097/00000658-199906000-00001; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Gross DJ, 1996, J CLIN ENDOCR METAB, V81, P147, DOI 10.1210/jc.81.1.147; GROSSMAN E, 1991, HYPERTENSION, V17, P733, DOI 10.1161/01.HYP.17.6.733; GUAZZONI G, 1995, J UROLOGY, V153, P1597, DOI 10.1016/S0022-5347(01)67471-8; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOPKIN K, 1994, J NIH RES, V6, P33; HOVEVEYSION D, 1990, NEUROPHARMACOLOGY, V29, P881; HOWE JR, 1993, SURGERY, V114, P1070; HSIAO RJ, 1991, MEDICINE, V70, P33, DOI 10.1097/00005792-199101000-00003; HSIAO RJ, 1990, AM J MED, V88, P607, DOI 10.1016/0002-9343(90)90526-J; HUI TP, 1986, HYPERTENSION, V8, P272, DOI 10.1161/01.HYP.8.4.272; KARLBERG BE, 1986, ACTA MED SCAND, P15; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KOSHIDA H, 1990, J ENDOCRINOL INVEST, V13, P807, DOI 10.1007/BF03349626; LAIRMORE TC, 1993, ANN SURG, V217, P595, DOI 10.1097/00000658-199306000-00001; LATIF F, 1993, CANCER RES, V53, P861; Lee JE, 1996, SURGERY, V120, P1064, DOI 10.1016/S0039-6060(96)80056-0; LENDERS JWM, 1995, ANN INTERN MED, V123, P101, DOI 10.7326/0003-4819-123-2-199507150-00004; Lenz Tomas, 1998, Blood Pressure, V7, P153; Levine S N, 1984, Adv Surg, V17, P281; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; LINEHAN WM, 1998, GENETIC BASIS HUMAN, P455; Linos DA, 1997, AM J SURG, V173, P120, DOI 10.1016/S0002-9610(96)00408-4; Lucon AM, 1997, J UROLOGY, V157, P1208, DOI 10.1016/S0022-5347(01)64925-5; LYNN MD, 1985, RADIOLOGY, V155, P789, DOI 10.1148/radiology.155.3.4001380; Maddock IR, 1996, J MED GENET, V33, P120, DOI 10.1136/jmg.33.2.120; MANGER WM, 1996, CLIN EXP PHEOCHROMOC; MANNELLI M, 1987, J ENDOCRINOL INVEST, V10, P377, DOI 10.1007/BF03348153; Mannelli M, 1999, EUR J ENDOCRINOL, V141, P619, DOI 10.1530/eje.0.1410619; Mantero F, 2000, J CLIN ENDOCR METAB, V85, P637, DOI 10.1210/jc.85.2.637; Marsh DJ, 1996, CANCER RES, V56, P1241; MAUREA S, 1993, J NUCL MED, V34, P173; Maurea S, 1996, Q J Nucl Med, V40, P365; MODLIN IM, 1979, BRIT J SURG, V66, P456, DOI 10.1002/bjs.1800660704; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Musholt TJ, 1997, SURGERY, V122, P1049, DOI 10.1016/S0039-6060(97)90208-7; Nagesser SK, 2000, JPN J CLIN ONCOL, V30, P68, DOI 10.1093/jjco/hyd027; NELLIST M, 1993, CELL, V75, P1305; Neumann DR, 1996, J COMPUT ASSIST TOMO, V20, P312, DOI 10.1097/00004728-199603000-00028; NEUMANN HPH, 1995, JAMA-J AM MED ASSOC, V274, P1149; OBARA T, 1995, SURGERY, V118, P1083, DOI 10.1016/S0039-6060(05)80118-7; Okamoto T, 1996, ENDOCR J, V43, P169, DOI 10.1507/endocrj.43.169; ORCHARD T, 1993, SURGERY, V114, P1153; Pattou FN, 1996, SURGERY, V120, P1006, DOI 10.1016/S0039-6060(96)80047-X; PERRY RR, 1990, ANN SURG, V212, P621, DOI 10.1097/00000658-199011000-00010; Pomares FJ, 1998, CLIN ENDOCRINOL, V48, P195, DOI 10.1046/j.1365-2265.1998.3751208.x; Ponder BAJ, 1999, CANCER RES, V59, p1736S; PULLERITS J, 1988, CAN J ANAESTH, V35, P526, DOI 10.1007/BF03026905; QUINT LE, 1987, RADIOLOGY, V165, P89, DOI 10.1148/radiology.165.1.3628794; Raber W, 2000, ENDOCRINOLOGIST, V10, P65, DOI 10.1097/00019616-200010010-00010; Raue F, 1998, LANGENBECK ARCH SURG, V383, P334, DOI 10.1007/s004230050143; REINIG JW, 1986, RADIOLOGY, V158, P81, DOI 10.1148/radiology.158.1.3940403; REMINE WH, 1974, ANN SURG, V179, P740, DOI 10.1097/00000658-197405000-00029; RICHARD S, 1994, SURGERY, V116, P1076; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCOTT WJ, 1994, ANN THORAC SURG, V58, P698, DOI 10.1016/0003-4975(94)90730-7; SHAPIRO B, 1989, ENDOCRIN METAB CLIN, V18, P443, DOI 10.1016/S0889-8529(18)30378-5; Shapiro B, 1995, Q J Nucl Med, V39, P3; Shawar L, 1996, J La State Med Soc, V148, P535; SHULKIN BL, 1992, J NUCL MED, V33, P1125; SHULKIN BL, 1986, CLIN NUCL MED, V11, P851, DOI 10.1097/00003072-198612000-00012; Shulkin BL, 1999, RADIOLOGY, V212, P35, DOI 10.1148/radiology.212.1.r99jl3035; SHULKIN BL, 1995, J NUCL MED, V36; SINCLAIR D, 1991, ANN CLIN BIOCHEM, V28, P417, DOI 10.1177/000456329102800420; Sisson JC, 1999, Q J NUCL MED, V43, P217; SISSON JC, 1981, NEW ENGL J MED, V305, P12, DOI 10.1056/NEJM198107023050103; SJOBERG RJ, 1992, ARCH INTERN MED, V152, P1193, DOI 10.1001/archinte.152.6.1193; Staren ED, 1996, SURGERY, V120, P706, DOI 10.1016/S0039-6060(96)80020-1; STEWART MF, 1993, J CLIN PATHOL, V46, P280, DOI 10.1136/jcp.46.3.280; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; STRAUSS LG, 1991, J NUCL MED, V32, P623; Stuhrmann M, 1996, HEREDITARY CANCER, P99; SWENSEN SJ, 1985, MAYO CLIN PROC, V60, P299, DOI 10.1016/S0025-6196(12)60536-9; TAYLOR HC, 1986, J CLIN ENDOCR METAB, V63, P238, DOI 10.1210/jcem-63-1-238; Telenius-Berg M, 1989, Henry Ford Hosp Med J, V37, P160; Tewson TJ, 1998, SEMIN NUCL MED, V28, P221, DOI 10.1016/S0001-2998(98)80028-7; Thompson GB, 1997, SURGERY, V122, P1132, DOI 10.1016/S0039-6060(97)90218-X; TISHERMAN SE, 1993, ARCH INTERN MED, V153, P2550; Tsuchimochi S, 1997, CLIN NUCL MED, V22, P687, DOI 10.1097/00003072-199710000-00005; Urbain JLC, 1997, ACTA RADIOL, V38, P21; Vargas HI, 1997, UROLOGY, V49, P673, DOI 10.1016/S0090-4295(97)00083-6; Walther MM, 1999, J UROLOGY, V161, P395, DOI 10.1016/S0022-5347(01)61900-1; Walther MM, 2000, J UROLOGY, V164, P14, DOI 10.1016/S0022-5347(05)67438-1; Walther MM, 1999, WORLD J UROL, V17, P35, DOI 10.1007/s003450050102; Walther MM, 1999, J UROLOGY, V162, P1582, DOI 10.1016/S0022-5347(05)68171-2; Walther MM, 1999, J UROLOGY, V162, P659, DOI 10.1097/00005392-199909010-00004; Walther MM, 1996, JAMA-J AM MED ASSOC, V275, P839, DOI 10.1001/jama.275.11.839; ZBAR B, 1989, IMPORTANT ADV ONCOLO	138	373	402	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					315	329		10.7326/0003-4819-134-4-200102200-00016	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00016			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NW	11182843				2022-12-28	WOS:000167050200008
J	Cowan, WM; Kandel, ER				Cowan, WM; Kandel, ER			Prospects for neurology and psychiatry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBRAL-BLOOD-FLOW; PREFRONTAL CORTEX; SCHIZOPHRENIA; SUSCEPTIBILITY; NEUROPATHOLOGY; DENSITY; NEURONS	Neurological and psychiatric illnesses are among the most common and most serious health problems in developed societies. The most promising advances in neurological and psychiatric diseases will require advances in neuroscience for their elucidation, prevention, and treatment. Technical advances have improved methods for identifying brain regions involved during various types of cognitive activity, for tracing connections between parts of the brain, for visualizing individual neurons in living brain preparations, for recording the activities of neurons, and for studying the activity of single-ion channels and the receptors for various neurotransmitters, The most significant advances in the past 20 years have come from the application to the nervous system of molecular genetics and molecular cell biology, Discovery of the monogenic disorder responsible for Huntington disease and understanding its pathogenesis can serve as a paradigm for unraveling the much more complex, polygenic disorders responsible for such psychiatric diseases as schizophrenia, manic depressive illness, and borderline personality disorder. Thus, a new degree of cooperation between neurology and psychiatry is likely to result, especially for the treatment of patients with illnesses such as autism, mental retardation, cognitive disorders associated with Alzheimer and Parkinson disease that overlap between the 2 disciplines.	Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA; Howard Hughes Med Inst, Chevy Chase, MD USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Howard Hughes Medical Institute	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, 1051 Riverside Dr, New York, NY 10032 USA.							Albright TD, 2000, NEURON, V25, pS1, DOI 10.1016/S0896-6273(00)80912-5; Barinaga M, 2000, SCIENCE, V287, P1421, DOI 10.1126/science.287.5457.1421; Bassett AS, 2000, AM J MED GENET, V97, P45, DOI 10.1002/(SICI)1096-8628(200021)97:1<45::AID-AJMG6>3.0.CO;2-9; Bassett AS, 1999, BIOL PSYCHIAT, V46, P882, DOI 10.1016/S0006-3223(99)00114-6; BASSETT AS, 1988, LANCET, V1, P799; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; Brzustowicz LM, 2000, SCIENCE, V288, P678, DOI 10.1126/science.288.5466.678; Bush G, 1998, HUM BRAIN MAPP, V6, P270, DOI 10.1002/(SICI)1097-0193(1998)6:4<270::AID-HBM6>3.0.CO;2-0; Collins FS, 2001, JAMA-J AM MED ASSOC, V285, P540, DOI 10.1001/jama.285.5.540; Cowan WM, 2000, ANNU REV NEUROSCI, V23, P343, DOI 10.1146/annurev.neuro.23.1.343; *DAN ALL BRAIN IN, 2000, PROGR REP BRAIN RES; DANIEL DG, 1991, BIOL PSYCHIAT, V30, P887, DOI 10.1016/0006-3223(91)90003-5; Daviss SR, 1995, PSYCHIAT RES, V59, P81, DOI 10.1016/0165-1781(95)02720-3; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; Drevets WC, 1998, COGNITION EMOTION, V12, P353, DOI 10.1080/026999398379646; EARLY TS, 1987, P NATL ACAD SCI USA, V84, P561, DOI 10.1073/pnas.84.2.561; EARLY TS, 1989, PSYCHIAT DEV, V7, P109; Fricker J, 1999, MOL MED TODAY, V5, P144, DOI 10.1016/S1357-4310(99)01454-9; Glantz LA, 1997, ARCH GEN PSYCHIAT, V54, P943; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; John E.R, 1967, NEUROSCIENCES STUDY, P690; Karayiorgou M, 1999, BIOL PSYCHIAT, V45, P1178, DOI 10.1016/S0006-3223(98)00319-9; Karayiorgou M, 1997, P NATL ACAD SCI USA, V94, P4572, DOI 10.1073/pnas.94.9.4572; KARAYIORGOU P, 1995, P NATL ACAD SCI USA, V92, P7612, DOI 10.1073/pnas.92.17.7612; Lewis DA, 2000, NEUROSCIENTIST, V6, P208, DOI 10.1177/107385840000600311; Lindvall O, 1999, NAT BIOTECHNOL, V17, P635, DOI 10.1038/10844; McCarley RW, 1999, BIOL PSYCHIAT, V45, P1099, DOI 10.1016/S0006-3223(99)00018-9; Pearlson GD, 1999, BIOL PSYCHIAT, V46, P627, DOI 10.1016/S0006-3223(99)00071-2; Ptacek LJ, 1997, NEUROMUSCULAR DISORD, V7, P250, DOI 10.1016/S0960-8966(97)00046-1; PULVER AE, 1994, AM J MED GENET, V54, P36, DOI 10.1002/ajmg.1320540108; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Schmitt F. O., 1979, NEUROSCIENCES 4 STUD; SCHMITT FO, 1973, NEUROSCIENCES 3 STUD; Schmitt FO, 1970, NEUROSCIENCES 2 STUD; SELEMON LD, 1995, ARCH GEN PSYCHIAT, V52, P805; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	39	58	59	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					594	600		10.1001/jama.285.5.594	http://dx.doi.org/10.1001/jama.285.5.594			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176865	Bronze			2022-12-28	WOS:000166714200018
J	Casarett, D; Kutner, JS; Abrahm, J				Casarett, D; Kutner, JS; Abrahm, J		End Life Care Consensus Panel	Life after death: A practical approach to grief and bereavement	ANNALS OF INTERNAL MEDICINE			English	Article							CONJUGAL BEREAVEMENT; SUICIDAL IDEATION; COMPLICATED GRIEF; ADAPTATION; INTERVENTION; DEPRESSION; PREDICTORS; DISTINCT; SPOUSES; SUPPORT	This consensus paper describes the essential skills that clinicians need to help persons who are experiencing grief after the death of a loved one. Four aspects of the grieving process are reviewed: anticipatory grief, acute grief, normal grief reactions, and complicated grief. Techniques for assessment and recommendations about interventions and indications for referral are provided for each aspect.	Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Penn, Inst Aging, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Casarett, D (corresponding author), Amer Coll Physicians, Amer Soc Internal Med, Ctr Eth & Professionalism, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							Abrahm J L, 1995, J Cancer Educ, V10, P207; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BALL JF, 1976, OMEGA-J DEATH DYING, V7, P307, DOI 10.2190/WEEF-N0HD-0CQ5-18TY; Bowlby J., 1980, ATTACHMENT LOSS; Buckman R., 1992, BREAK BAD NEWS GUIDE; Byrne G J, 1999, Int Psychogeriatr, V11, P67; CAMERON J, 1983, POSTGRAD MED J, V59, P73, DOI 10.1136/pgmj.59.688.73; Eliot TD, 1930, FAMILY, V11, P114; ENGEL GL, 1961, PSYCHOSOM MED, V23, P18, DOI 10.1097/00006842-196101000-00002; FREUD S, 1917, STANDARD EDITION COM, V20; HELSING KJ, 1981, AM J EPIDEMIOL, V114, P41, DOI 10.1093/oxfordjournals.aje.a113172; JACOBS S, 1990, PSYCHIAT ANN, V20, P314, DOI 10.3928/0048-5713-19900601-08; JACOBS S, 1986, BRIT J MED PSYCHOL, V59, P305, DOI 10.1111/j.2044-8341.1986.tb02698.x; JACOBS SC, 1987, PRESENTATIONS DEPRES; LAZARE A, 1979, OUTPATIENT PSYCHIAT; LEVY LH, 1993, AM J COMMUN PSYCHOL, V21, P361, DOI 10.1007/BF00941507; LEVY LH, 1994, OMEGA-J DEATH DYING, V29, P71, DOI 10.2190/5Y05-TPHN-KETW-HLHP; LEWIS CS, 1961, GRIEF OBSERVED, P460; LIEBERMAN MA, 1992, INT J GROUP PSYCHOTH, V42, P117, DOI 10.1080/00207284.1992.11732583; Lindemann E, 1944, AM J PSYCHIAT, V101, P141, DOI 10.1176/ajp.101.2.141; McCorkle R, 1998, NURS RES, V47, P2, DOI 10.1097/00006199-199801000-00002; MILLER SI, 1973, INT J SOC PSYCHIATR, V19, P187, DOI 10.1177/002076407301900305; Nolen-Hoeksema S., 1999, COPING LOSS; PARKES CM, 1981, J PREV PSYCHIAT, V1, P179; Parkes Collin Murray, 1972, BEREAVEMENT STUDIES; PRIGERSON HG, 1995, AM J PSYCHIAT, V152, P22; Prigerson HG, 1996, ANXIETY, V2, P1; Rando T. A., 1993, TREATMENT COMPLICATE; RAPHAEL B, 1977, ARCH GEN PSYCHIAT, V34, P1450; REED MD, 1993, SUICIDE LIFE-THREAT, V23, P204; Rosengard C, 1997, AIDS CARE, V9, P373, DOI 10.1080/713613168; Rush B., 1812, MED INQUIRIES OBSERV; Sanders Catherine M., 1993, P255, DOI 10.1017/CBO9780511664076.018; SANDERS CM, 1979, OMEGA, V10, P303, DOI DOI 10.2190/X565-HW49-CHR0-FYB4; Szanto K, 1997, SUICIDE LIFE-THREAT, V27, P194; THEUT SK, 1991, INT J AGING HUM DEV, V33, P113, DOI 10.2190/4KYG-J2E1-5KEM-LEBA; TOLLE SW, 1986, J GEN INTERN MED, V1, P309, DOI 10.1007/BF02596210; VACHON MLS, 1988, J SOC ISSUES, V44, P175, DOI 10.1111/j.1540-4560.1988.tb02084.x; VACHON MLS, 1980, AM J PSYCHIAT, V137, P1380; VACHON MLS, 1982, AM J PSYCHIAT, V139, P998; WEINBERG N, 1994, DEATH STUD, V18, P583, DOI 10.1080/07481189408252702; Woof WR, 1997, BRIT J GEN PRACT, V47, P509; ZISOOK S, 1987, PSYCHIAT CLIN N AM, V10, P355; Zisook S, 1987, BIOPSYCHOSOCIAL ASPE	44	46	47	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2001	134	3					208	215		10.7326/0003-4819-134-3-200102060-00012	http://dx.doi.org/10.7326/0003-4819-134-3-200102060-00012			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	397KR	11177334				2022-12-28	WOS:000166695300005
J	Ballentine, CJ; Schoell, M; Coleman, D; Cain, BA				Ballentine, CJ; Schoell, M; Coleman, D; Cain, BA			300-Myr-old magmatic CO2 in natural gas reservoirs of the west Texas Permian basin	NATURE			English	Article							CARBON-DIOXIDE; POPPING ROCK; CAP ROCKS; MANTLE; SYSTEMATICS; HELIUM; FLUIDS; EARTH; HE	Except in regions of recent crustal extension(1), the dominant origin of carbon dioxide in fluids in sedimentary basins has been assumed to be from crustal organic matter(2) or mineral reactions(3,4). Here we show, by contrast, that Rayleigh fractionation caused by partial degassing of a magma body can explain the CO2/He-3 ratios and delta C-13(CO2) values observed in CO2-rich natural gases in the west Texas Val Verde basin and also the mantle He-3/Ne-22 ratios observed in other basin systems(5). Regional changes in CO2/He-3 and CO2/CH4 ratios can be explained if the CO2 input pre-dates methane generation in the basin, which occurred about 280 Myr ago(6). Uplift to the north of the Val Verde basin between 310 and 280 Myr ago(6) appears to be the only tectonic event with appropriate timing and location to be the source of the magmatic CO2. Our identification of magmatic CO2 in a foreland basin indicates that the origin of CO2 in other midcontinent basin systems should be re-evaluated. Also, the inferred closed-system preservation of natural gas in a trapping structure for similar to 300 Myr is far longer than the residence time predicted by diffusion models(7,8).	ETH Zentrum, Dept Erdwissensch, IGMR, CH-8092 Zurich, Switzerland; Chevron Res & Technol Co, San Ramon, CA 94583 USA; Isotech Labs Inc, Champaign, IL 61821 USA; Altura Energy LLP, Houston, TX 77210 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Chevron	Ballentine, CJ (corresponding author), ETH Zentrum, Dept Erdwissensch, IGMR, NO CO 61-7, CH-8092 Zurich, Switzerland.			Ballentine, Chris/0000-0001-9382-070X				BALLENTINE CJ, 1991, EARTH PLANET SC LETT, V105, P229, DOI 10.1016/0012-821X(91)90133-3; Ballentine CJ, 1997, EARTH PLANET SC LETT, V152, P233, DOI 10.1016/S0012-821X(97)00142-8; BOTTINGA Y, 1990, CHEM GEOL, V81, P255, DOI 10.1016/0009-2541(90)90050-H; Burnard P, 1997, SCIENCE, V276, P568, DOI 10.1126/science.276.5312.568; Caffee MW, 1999, SCIENCE, V285, P2115, DOI 10.1126/science.285.5436.2115; EWING TE, 1993, NEW MEXICO GEOLOGICA, P155; GRIESSHABER E, 1992, CHEM GEOL, V99, P213, DOI 10.1016/0009-2541(92)90178-8; HENRY CD, 1991, J GEOPHYS RES-SOLID, V96, P13545, DOI 10.1029/91JB00202; Hilton DR, 1998, NATURE, V396, P359, DOI 10.1038/24603; HORAK RL, 1985, OIL GAS J, V83, P124; HUTCHEON I, 1990, GEOLOGY, V18, P541, DOI 10.1130/0091-7613(1990)018<0541:CDICRA>2.3.CO;2; JAVOY M, 1991, EARTH PLANET SC LETT, V107, P598, DOI 10.1016/0012-821X(91)90104-P; JENDEN PD, 1993, PROF PAP US GEOL SUR, V1570, P31; KENNEDY BM, 1990, EARTH PLANET SC LETT, V98, P277, DOI 10.1016/0012-821X(90)90030-2; Kennedy BM, 1997, SCIENCE, V278, P1278, DOI 10.1126/science.278.5341.1278; KHARAKA YK, 1983, GEOCHIM COSMOCHIM AC, V47, P397, DOI 10.1016/0016-7037(83)90262-4; KROOSS BM, 1992, AAPG BULL, V76, P403; Lollar BS, 1997, GEOCHIM COSMOCHIM AC, V61, P2295; MARTY B, 1987, EARTH PLANET SC LETT, V83, P16, DOI 10.1016/0012-821X(87)90047-1; MATTEY DP, 1991, GEOCHIM COSMOCHIM AC, V55, P3467, DOI 10.1016/0016-7037(91)90508-3; Montgomery SL, 1996, AAPG BULL, V80, P987; OXBURGH ER, 1986, NATURE, V324, P632, DOI 10.1038/324632a0; SACKETT WM, 1979, GEOCHIM COSMOCHIM AC, V43; Schlomer S, 1997, MAR PETROL GEOL, V14, P563; Schoell M, 1998, ABSTR PAP AM CHEM S, V215, pU623; SCHUMAKER RC, 1992, AAPG BULL, V76, P1804; TRULL T, 1993, EARTH PLANET SC LETT, V118, P43, DOI 10.1016/0012-821X(93)90158-6; TRULL TW, 1993, GEOCHIM COSMOCHIM AC, V57, P1313, DOI 10.1016/0016-7037(93)90068-8; Weinlich FH, 1999, GEOCHIM COSMOCHIM AC, V63, P3653, DOI 10.1016/S0016-7037(99)00187-8; Ye HZ, 1996, AAPG BULL, V80, P1397	30	83	88	0	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					327	331		10.1038/35053046	http://dx.doi.org/10.1038/35053046			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201738				2022-12-28	WOS:000166434300043
J	Levin, A				Levin, A			Reporting standards and the transparency of trials	ANNALS OF INTERNAL MEDICINE			English	Article																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2001	134	2					169	172		10.7326/0003-4819-134-2-200101160-00025	http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00025			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391KW	11177328				2022-12-28	WOS:000166356000016
J	Ewan, PW; Clark, AT				Ewan, PW; Clark, AT			Long-term prospective observational study of patients with peanut and nut allergy after participation in a management plan	LANCET			English	Article							ANAPHYLACTIC REACTIONS; FOOD; CHILDREN	Background Peanut and nut allergy is common and the most frequent cause of severe or fatal reactions to foods. Current advice is poor-doctors give an epinephrine injector to patients, without training or advice on nut avoidance-so that further reactions are common and deaths occur. We devised and assessed a management programme providing advice on nut avoidance and emergency medication. Methods Unselected referrals with confirmed peanut or tree-nut allergy were recruited. Severity of nut allergy was graded 1-5 and emergency medication allocated accordingly: oral antihistamine with or without inhaled or injected epinephrine. Patients, parents, and school staff received verbal and written advice on nut avoidance as well as training in recognition and self-treatment of reactions, with a written treatment plan. At follow-up (more than 13 610 patient months) retraining was given and details of further reactions obtained. Findings 88 (15%) of 567 patients had a follow-up reaction of reduced severity. 62 of 88 were mild (grades 1-3, mainly cutaneous) and 49 patients used oral antihistamine, six inhaled adrenaline, and ten took no treatment. 12 of 12 patients with a moderate follow-up reaction improved after inhaled epinephrine. Only three (0.5%) of 567 patients, aged 27-40 years, had a severe follow-up reaction (involving dyspnoea) compared with 12% initially. Only one of 567 changed from a mild index reaction to a severe follow-up reaction. Patients with a moderate/severe (grade 4-5) reaction were older (median 18 years vs 9 years; p=0.03) and nine of 26 received injected epinephrine which was always effective. 85% of patients had no further reactions. Severity was related to the amount of nut eaten. Interpretation Self-treatment was effective (inhaled epinephrine for early laryngeal oedema and an epinephrine injector for severe reactions) but provision of this treatment, including who should carry epinephrine, required assessment of allergy severity. Our management plan was effective, and our results indicate that patients should be referred to specialist allergy centres for advice on nut avoidance.	Addenbrookes Hosp, Dept Allergy & Clin Immunol, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Ewan, PW (corresponding author), Addenbrookes Hosp, Dept Allergy & Clin Immunol, Hills Rd, Cambridge CB2 2QQ, England.	pamela.ewan@msexc.addenbrookes.anglox.nhs.uk						Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Ewan PW, 1996, BRIT MED J, V312, P1074; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Vickers DW, 1997, CLIN EXP ALLERGY, V27, P898; WARREN JB, 1986, CLIN PHARMACOL THER, V40, P673, DOI 10.1038/clpt.1986.243; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	12	144	145	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2001	357	9250					111	115		10.1016/S0140-6736(00)03543-1	http://dx.doi.org/10.1016/S0140-6736(00)03543-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197398				2022-12-28	WOS:000166476200013
J	Kristiansen, M; Graversen, JH; Jacobsen, C; Sonne, O; Hoffman, HJ; Law, SKA; Moestrup, SK				Kristiansen, M; Graversen, JH; Jacobsen, C; Sonne, O; Hoffman, HJ; Law, SKA; Moestrup, SK			Identification of the haemoglobin scavenger receptor	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; HIGH-AFFINITY; LIGAND RECOGNITION; PROTEIN; BINDING; CELLS; ENDOCYTOSIS; COMPLEX; PHAGOCYTOSIS; SUPERFAMILY	Intravascular haemolysis is a physiological phenomenon as well as a severe pathological complication when accelerated in various autoimmune, infectious (such as malaria) and inherited (such as sickle cell disease) disorders(1). Haemoglobin released into plasma is captured by the acute phase protein haptoglobin, which is depleted from plasma during elevated haemolysis(1). Here we report the identification of the acute phase-regulated and signal-inducing macrophage protein, CD163, as a receptor that scavenges haemoglobin by mediating endocytosis of haptoglobin-haemoglobin complexes. CD163 binds only haptoglobin and haemoglobin in complex, which indicates the exposure of a receptor-binding neoepitope. The receptor-ligand interaction is Ca2+-dependent and of high affinity. Complexes of haemoglobin and multimeric haptoglobin (the 2-2 phenotype) exhibit higher functional affinity for CD163 than do complexes of haemoglobin and dimeric haptoglobin (the 1-1 phenotype). Specific CD163-mediated endocytosis of haptoglobin-haemoglobin complexes is measurable in cells transfected with CD163 complementary DNA and in CD163-expressing myelo-monocytic lymphoma cells.	Univ Aarhus, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Univ Aarhus, Dept Physiol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus C, Denmark; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	Aarhus University; Aarhus University; Aarhus University; University of Oxford	Moestrup, SK (corresponding author), Univ Aarhus, Dept Med Biochem, Ole Worms Alle, DK-8000 Aarhus C, Denmark.		Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014; Hoffman, Hans Jurgen/I-6969-2018; Law, Alex/A-2212-2011	Moestrup, Søren Kragh/0000-0003-3862-2107; Hoffman, Hans Jurgen/0000-0002-6743-7931; Graversen, Jonas Heilskov/0000-0002-2411-9933; Madsen, Mette/0000-0001-7241-6505; Graversen, Jonas Heilskov/0000-0001-7119-2108				Andrews NC, 1998, BLOOD, V92, P1845, DOI 10.1182/blood.V92.6.1845.418k35_1845_1851; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; Deiss A, 1999, WINTROBES CLIN HEMAT, P267; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; EPSTEIN AL, 1978, CANCER, V42, P2379, DOI 10.1002/1097-0142(197811)42:5<2379::AID-CNCR2820420539>3.0.CO;2-4; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Hogger P, 1998, J IMMUNOL, V161, P1883; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; MITANI K, 1992, BLOOD, V79, P1255; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; Moestrup SK, 1998, J CLIN INVEST, V102, P902, DOI 10.1172/JCI3772; MOESTRUP SK, 1987, BIOCHIM BIOPHYS ACTA, V930, P297, DOI 10.1016/0167-4889(87)90002-4; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PULFORD K, 1992, IMMUNOLOGY, V75, P588; PULFORD K, 1997, LEUKOCYTE TYPING, V6, P1089; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SAMBRANO GR, 1994, P NATL ACAD SCI USA, V91, P3265, DOI 10.1073/pnas.91.8.3265; Van den Heuvel MM, 1999, J LEUKOCYTE BIOL, V66, P858, DOI 10.1002/jlb.66.5.858; WADA T, 1970, J RETICULOENDOTH SOC, V8, P185; WEJMAN JC, 1984, J MOL BIOL, V174, P343, DOI 10.1016/0022-2836(84)90342-5; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	29	1252	1296	1	81	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					198	201		10.1038/35051594	http://dx.doi.org/10.1038/35051594			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196644				2022-12-28	WOS:000166316200046
J	Rutter, CM; Mandelson, MT; Laya, MB; Seger, DJ; Taplin, S				Rutter, CM; Mandelson, MT; Laya, MB; Seger, DJ; Taplin, S			Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAMMOGRAPHIC PARENCHYMAL PATTERNS; CANCER RISK; SCREENING MAMMOGRAPHY; ESTROGEN; SENSITIVITY	Context Initiation of hormone replacement therapy (HRT) has been shown to increase breast density. Evidence exists that increased breast density decreases mammographic sensitivity. The effects on breast density of discontinuing and continuing HRT have not been studied systematically. Objective To examine the effects of initiation, discontinuation, and continued use of HRT on breast density in postmenopausal women. Design, Setting, and Participants Observational cohort study of 5212 naturally postmenopausal women aged 40 to 96 years and enrolled in a large health maintenance organization in western Washington State who had 2 screening mammograms between 1996 and 1998. Main Outcome Measures Breast density, assessed using the clinical radiologists' BI-RADS 4-point scale, compared among women who did not use HRT before either mammogram (nonusers); who used HRT before the first but not before the second mammogram (discontinuers); who used HRT before the second but not before the first mammogram (initiators); and who used HRT prior to both mammograms (continuing users). Results Relative to nonusers, women who initiated HRT were more likely to show increases in breast density (relative risk [RR], 2.57; 95% confidence interval [CI], 2.12-3.08), while women who discontinued HRT use were more likely to show decreases in density (RR, 1.81;95% CI, 1.06-2.98) and women who continued to use HRT were more likely to show both increases in density (RR, 1.33; 95% CI, 1.13-1.55) and sustained high density (RR, 1.45; 95% CI, 1.33-1.58). Conclusions These results indicate that breast density changes associated with HRT are dynamic, increasing with initiation, and decreasing with discontinuation.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Dept Biostat, Div Gen Internal Med, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Div Gen Internal Med, Seattle, WA 98195 USA; Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA; Univ Washington, Dept Family Med, Div Gen Internal Med, Seattle, WA 98195 USA	Group Health Cooperative; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Rutter, CM (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.		Rutter, Carolyn/AAZ-3677-2021		NATIONAL CANCER INSTITUTE [K07CA071869] Funding Source: NIH RePORTER; NCI NIH HHS [CA71869, U01 CA637731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSETT LW, 1998, AM COLL RADIOLOGY AC; BERKOWITZ JE, 1990, RADIOLOGY, V174, P199, DOI 10.1148/radiology.174.1.2152982; BLAND KI, 1980, CANCER, V45, P3027, DOI 10.1002/1097-0142(19800615)45:12<3027::AID-CNCR2820451225>3.0.CO;2-2; Buist DSM, 1999, AM J EPIDEMIOL, V149, P275; Gabrielsson J, 1996, Acta Obstet Gynecol Scand Suppl, V163, P26; Greendale GA, 1999, ANN INTERN MED, V130, P262, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00003; KAUFMAN Z, 1991, CLIN RADIOL, V43, P389, DOI 10.1016/S0009-9260(05)80566-5; Kavanagh AM, 2000, LANCET, V355, P270, DOI 10.1016/S0140-6736(99)07319-5; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; LAYA MB, 1995, RADIOLOGY, V196, P433, DOI 10.1148/radiology.196.2.7617857; Litherland JC, 1999, CLIN RADIOL, V54, P285, DOI 10.1016/S0009-9260(99)90555-X; Lundstrom E, 1999, AM J OBSTET GYNECOL, V181, P348, DOI 10.1016/S0002-9378(99)70560-0; Mandelson MT, 2000, J NATL CANCER I, V92, P1081, DOI 10.1093/jnci/92.13.1081; OZA AM, 1993, EPIDEMIOL REV, V15, P196, DOI 10.1093/oxfordjournals.epirev.a036105; SAFTLAS AF, 1987, EPIDEMIOL REV, V9, P146, DOI 10.1093/oxfordjournals.epirev.a036300; SAFTLAS AF, 1991, CANCER, V67, P2833, DOI 10.1002/1097-0142(19910601)67:11<2833::AID-CNCR2820671121>3.0.CO;2-U; Seradour B, 1999, J MED SCREEN, V6, P99, DOI 10.1136/jms.6.2.99; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; Taplin SH, 1997, CANCER EPIDEM BIOMAR, V6, P625; WARNER E, 1992, CANCER DETECT PREV, V16, P67	21	196	201	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2001	285	2					171	176		10.1001/jama.285.2.171	http://dx.doi.org/10.1001/jama.285.2.171			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	389FB	11176809	Bronze			2022-12-28	WOS:000166227000024
J	Goroll, AH; Morrison, G; Bass, EB; Jablonover, R; Blackman, D; Platt, R; Whelan, A; Hekelman, FP				Goroll, AH; Morrison, G; Bass, EB; Jablonover, R; Blackman, D; Platt, R; Whelan, A; Hekelman, FP			Reforming the core clerkship in internal medicine: The SGIM/CDIM project	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY-CARE; EDUCATION; SETTINGS; STUDENTS; CULTURE	Dramatic changes in health care have stimulated reform of undergraduate medical education. In an effort to improve the teaching of generalist competencies and encourage learning in the outpatient setting, the Society of General Internal Medicine joined with the Clerkship Directors in Internal Medicine in a federally sponsored initiative to develop a new curriculum for the internal medicine core clerkship. Using a broad-based advisory committee and working closely with key stakeholders (especially clerkship directors), the project collaborators helped forge a new national consensus on the leaming agenda for the clerkship (a prioritized set of basic generalist competencies) and on the proportion of time that should be devoted to outpatient care (at least one third of the clerkship). From this consensus emerged a new curricular model that served as the basis for production of a curriculum guide and faculty resource package. The guide features the prioritized set of basic generalist competencies and specifies the requisite knowledge, skills, and attitudes/values needed to master them, as well as a list of suggested training problems. it also includes recommended training experiences, schedules, and approaches to faculty development, precepting, and student evaluation. Demand for the guide has been strong and led to production of a second edition, which includes additional materials, an electronic version, and a pocket guide for students and faculty. A follow-up survey of clerkship directors administered soon after completion of the first edition revealed widespread use of the curricular guide but also important barriers to full implementation of the new curriculum, Although this collaborative effort appears to have initiated clerkship reform, long-term success will require an enhanced educational infrastructure to support teaching in the outpatient setting.	Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Mt Sinai Sch Med, New York, NY USA; Washington Univ, Sch Med, St Louis, MO USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Pennsylvania; Johns Hopkins University; Icahn School of Medicine at Mount Sinai; Washington University (WUSTL); Case Western Reserve University	Goroll, AH (corresponding author), Massachusetts Gen Hosp, ACC Suite 645, Boston, MA 02114 USA.			Bass, Eric/0000-0001-9106-527X				[Anonymous], 1993, ACAD MED, V68, P1; Bass EB, 1997, AM J MED, V102, P564; BLANK LL, 1992, ANN INTERN MED, V117, P778; Block SD, 1998, ACAD MED, V73, P1087, DOI 10.1097/00001888-199810000-00020; Boex JR, 1998, ACAD MED, V73, P943, DOI 10.1097/00001888-199809000-00011; Bordage G, 1998, ACAD MED, V73, P743, DOI 10.1097/00001888-199807000-00009; Colwill JM, 1997, ACAD MED, V72, P745, DOI 10.1097/00001888-199709000-00007; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; *COUNC GRAD MED ED, 1992, 3 PHS DEP HLTH HUM S; *COUNC GRAD MED ED, 1994, 4 PHS US DEP HLTH HU; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; GOROLL AH, 1998, SGIM CDIM CORE MED C; GOROLL AH, 1995, SGIM CDIM CORE MED C; IRBY DM, 1995, ACAD MED, V70, P898, DOI 10.1097/00001888-199510000-00014; Jablonover RS, 2000, J GEN INTERN MED, V15, P484, DOI 10.1046/j.1525-1497.2000.06429.x; Kassebaum D G, 1997, Acad Med, V72, P1127, DOI 10.1097/00001888-199712000-00029; KASSEBAUM DG, 1992, ACAD MED, V67, P800, DOI 10.1097/00001888-199211000-00020; KERMAN WN, 1996, CONN MED, V60, P203; Kern D, 1998, CURRICULUM DEV MED E; MCMURRAY JE, 1993, ANN INTERN MED, V119, P812, DOI 10.7326/0003-4819-119-8-199310150-00007; NUCKOLLS JG, 1992, ANN INTERN MED, V116, P1051, DOI 10.7326/0003-4819-116-12-1051; Pardes H, 1997, ACAD MED, V72, P97, DOI 10.1097/00001888-199702000-00009; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; Skeff KM, 1997, ACAD MED, V72, P694, DOI 10.1097/00001888-199708000-00014; Skeff KM, 1997, J GEN INTERN MED, V12, pS56, DOI 10.1046/j.1525-1497.12.s2.8.x; SWANSON AG, 1993, ACAD MED, V68, pS1, DOI 10.1097/00001888-199306000-00014	26	29	33	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2001	134	1					30	37		10.7326/0003-4819-134-1-200101020-00011	http://dx.doi.org/10.7326/0003-4819-134-1-200101020-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386CV	11187418				2022-12-28	WOS:000166043300005
J	Bellomo, R; Chapman, M; Finfer, S; Hickling, K; Myburgh, J; Belessis, A; Bell, A; Bellomo, R; Bersten, A; Boots, R; Bristow, P; Chapman, M; Myburgh, J; Clayton, D; Cook, D; Dobb, G; Finfer, S; Hart, G; Hickling, K; Jenkins, I; Langton, D; McArthur, C; Parkin, R; Richards, B; Skowronski, G; Smith, A; Ulyatt, D; Williams, D				Bellomo, R; Chapman, M; Finfer, S; Hickling, K; Myburgh, J; Belessis, A; Bell, A; Bellomo, R; Bersten, A; Boots, R; Bristow, P; Chapman, M; Myburgh, J; Clayton, D; Cook, D; Dobb, G; Finfer, S; Hart, G; Hickling, K; Jenkins, I; Langton, D; McArthur, C; Parkin, R; Richards, B; Skowronski, G; Smith, A; Ulyatt, D; Williams, D		ANZICS Clin Trials Grp	Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial	LANCET			English	Article							CRITICALLY ILL PATIENTS; TRANSPLANTATION; CLEARANCE; RESPONSES; ISCHEMIA; INFUSION; SURGERY; FAILURE	Background Low-dose dopamine is commonly administered to critically ill patients in the belief that it reduces the risk of renal failure by increasing renal blood flow. However, these effects have not been established in a large randomised controlled trial, and use of dopamine remains controversial. We have done a multicentre, randomised, double-blind, placebo-controlled study of low-dose dopamine in patients with at least two criteria for the systemic inflammatory response syndrome and clinical evidence of early renal dysfunction (oliguria or increase in serum creatinine concentration). Methods 328 patients admitted to 23 participating intensive-care units (ICUs) were randomly assigned a continuous intravenous infusion of tow-dose dopamine (2 mug kg(-1) min(-1)) or placebo administered through a central venous catheter while in the ICU. The primary endpoint was the peak serum creatinine concentration during the infusion. Analyses excluded four patients with major protocol violations. Findings The groups assigned dopamine (n=161) and placebo (n=163) were similar in terms of baseline characteristics, renal function, and duration of trial infusion. There was no difference between the dopamine and placebo groups in peak serum creatinine concentration during treatment (245 [SD 144] vs 249 [147] mu mol/L; p=0 . 93), in the increase from baseline to highest value during treatment (62 [107] vs 66 [108] mu mol/L; p=0 . 82), or in the numbers of patients whose serum creatinine concentration exceeded 300 mu mol/L (56 vs 56; p=0 . 92) or who required renal replacement therapy (35 vs 40; p=0 . 55). Durations of ICU stay (13 [14] vs 14 [15] days; p=0 . 67) and of hospital stay (29 [27] vs 33 [39] days; p=0 . 29) were also similar. There were 69 deaths in the dopamine group and 66 in the placebo group. Interpretation Administration of low-dose dopamine by continuous intravenous infusion to critically ill patients at risk of renal failure does not confer clinically significant protection from renal dysfunction.	ANZICS House, Carlton, Vic 3503, Australia		Bellomo, R (corresponding author), ANZICS House, 233 Rathdowne St, Carlton, Vic 3503, Australia.	anzicsoc@ozemail.com.au	Boots, Robert/K-1159-2013; Cook, David/D-7318-2013	Boots, Robert/0000-0002-2436-7654; Bellomo, Rinaldo/0000-0002-1650-8939				Allen E, 1997, CRIT CARE MED, V25, P181, DOI 10.1097/00003246-199701000-00032; BALDWIN L, 1994, ANN INTERN MED, V120, P744, DOI 10.7326/0003-4819-120-9-199405010-00004; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BREZIS M, 1984, KIDNEY INT, V26, P375, DOI 10.1038/ki.1984.185; Chertow GM, 1996, AM J MED, V101, P49, DOI 10.1016/S0002-9343(96)00075-7; Cuthbertson BH, 1997, BRIT MED J, V314, P690, DOI 10.1136/bmj.314.7082.690; DENTON MD, 1996, KIDNEY INT, V49, P4; DEVINS SS, 1992, CRIT CARE MED, V20, P1644, DOI 10.1097/00003246-199212000-00007; DUKE GJ, 1994, CRIT CARE MED, V22, P1919; GRUNDMANN R, 1982, KLIN WOCHENSCHR, V60, P193, DOI 10.1007/BF01715586; HALL KA, 1992, J SURG RES, V53, P317, DOI 10.1016/0022-4804(92)90054-4; HOLLENBERG NK, 1973, CLIN SCI MOL MED, V45, P733, DOI 10.1042/cs0450733; Juste RN, 1998, INTENS CARE MED, V24, P1217, DOI 10.1007/s001340050747; KADIEVA VS, 1993, ANESTH ANALG, V76, P362; Kellum, 1997, Crit Care, V1, P53, DOI 10.1186/cc103; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE MR, 1993, CLIN SCI, V84, P357, DOI 10.1042/cs0840357; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MCDONALD RH, 1964, J CLIN INVEST, V43, P1116, DOI 10.1172/JCI104996; MYLES PS, 1993, ANAESTH INTENS CARE, V21, P56, DOI 10.1177/0310057X9302100114; PARKS RW, 1994, BRIT J SURG, V81, P437, DOI 10.1002/bjs.1800810338; POLSON RJ, 1987, ANAESTHESIA, V42, P15, DOI 10.1111/j.1365-2044.1987.tb02938.x; SANDBERG J, 1992, TRANSPLANT P, V24, P357; SEGAL JM, 1992, J APPL PHYSIOL, V73, P1159, DOI 10.1152/jappl.1992.73.3.1159; SWYGERT TH, 1991, ANESTHESIOLOGY, V75, P571, DOI 10.1097/00000542-199110000-00005; SZERLIP HM, 1991, ANN INTERN MED, V115, P153, DOI 10.7326/0003-4819-115-2-153; THOMPSON BT, 1994, LANCET, V344, P7, DOI 10.1016/S0140-6736(94)91044-8; VandenBerghe G, 1996, CRIT CARE MED, V24, P1580, DOI 10.1097/00003246-199609000-00024; WEISBERG LS, 1993, RENAL FAILURE, V15, P61, DOI 10.3109/08860229309065574	29	542	593	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2000	356	9248					2139	2143						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191541				2022-12-28	WOS:000165997300012
J	Masip, J; Betbese, AJ; Paez, J; Vecilla, F; Canizares, R; Padro, J; Paz, MA; de Otero, J; Ballus, J				Masip, J; Betbese, AJ; Paez, J; Vecilla, F; Canizares, R; Padro, J; Paz, MA; de Otero, J; Ballus, J			Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary oedema: a randomised trial	LANCET			English	Article							POSITIVE AIRWAY PRESSURE; ACUTE RESPIRATORY-FAILURE; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; FACE MASK; NONINVASIVE VENTILATION; EDEMA; MORTALITY; EMERGENCY; DISEASE	Background Non-invasive pressure support ventilation (NIPSV) is an effective treatment for acute respiratory failure in patients with chronic obstructive pulmonary disease. We assessed the efficacy of this therapy in acute cardiogenic pulmonary oedema in a randomised comparison with conventional oxygen therapy. Methods 40 patients were randomly assigned conventional oxygen therapy or NIPSV supplied by a standard ventilator through a face mask, with adjustment of tidal volume and pressure support in addition to a positive end-expiratory pressure of 5 cm water. Physiological measurements were obtained in the first 2 h and at 3 h, 4 h, and 10 h. The main endpoints were intubation rate and resolution time. Analyses were by intention to treat. Findings Three patients were withdrawn on the basis of clinical and chest radiography results. Endotracheal intubation was required in one (5%) of 19 patients assigned NIPSV and in six (33%) of 18 assigned conventional oxygen therapy (p=0 . 037). Resolution time (defined as a clinical improvement with oxygen saturation of 96% or more and respiratory rate less than 30 breaths/min) was significantly shorter in the NIPSV group (median 30 [IQR 15-53] vs 105 [50-230] min, p=0 . 002). NIPSV led to a rapid improvement in oxygenation in the first 2 h. There were no differences in hospital length of stay or mortality. Interpretation In this study of acute cardiogenic pulmonary oedema, NIPSV was superior to conventional oxygen therapy. Further studies should compare NIPSV with continuous positive airway pressure.	Univ Barcelona, Hosp Creu Roja Barcelona, Consorci Sanitari Creu Roja Catalunya, Dept Intens Care,Intens Care Unit, Barcelona 08025, Spain; Univ Barcelona, Hosp Creu Roja Barcelona, Consorci Sanitari Creu Roja Catalunya, Dept Cardiol, Barcelona 08025, Spain	University of Barcelona; University of Barcelona	Masip, J (corresponding author), Univ Barcelona, Hosp Creu Roja Barcelona, Consorci Sanitari Creu Roja Catalunya, Dept Intens Care,Intens Care Unit, Dos Maig 301, Barcelona 08025, Spain.		Escribano-Paez, Jose M./X-7741-2018; Betbesé, Antoni/H-3419-2013	Escribano-Paez, Jose M./0000-0002-8995-4200; Betbesé, Antoni/0000-0002-9059-4046				Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; BATTLER A, 1980, CIRCULATION, V61, P1004, DOI 10.1161/01.CIR.61.5.1004; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; Bouquin V, 1998, ARCH MAL COEUR VAISS, V91, P1243; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; Hillberg RE, 1997, NEW ENGL J MED, V337, P1746, DOI 10.1056/NEJM199712113372407; Hoffmann B, 1999, INTENS CARE MED, V25, P15, DOI 10.1007/s001340050781; Keenan SP, 1997, CRIT CARE MED, V25, P1685, DOI 10.1097/00003246-199710000-00018; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; Lenique F, 1997, AM J RESP CRIT CARE, V155, P500, DOI 10.1164/ajrccm.155.2.9032185; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; Mehta S, 1997, CRIT CARE MED, V25, P620, DOI 10.1097/00003246-199704000-00011; NAUGHTON MT, 1995, CIRCULATION, V91, P1725, DOI 10.1161/01.CIR.91.6.1725; NAVA S, 1993, CHEST, V103, P143, DOI 10.1378/chest.103.1.143; Pang D, 1998, CHEST, V114, P1185, DOI 10.1378/chest.114.4.1185; Philip-Joet F, 1999, RESPIRATION, V66, P136, DOI 10.1159/000029355; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Poponick JM, 1999, CHEST, V116, P166, DOI 10.1378/chest.116.1.166; RASANEN J, 1985, AM J CARDIOL, V55, P296, DOI 10.1016/0002-9149(85)90364-9; Remme WJ, 1997, EUR HEART J, V18, P736; Rusterholtz T, 1999, INTENS CARE MED, V25, P21, DOI 10.1007/s001340050782; Takeda S, 1998, JPN CIRC J, V62, P553, DOI 10.1253/jcj.62.553; VIALE JP, 1988, CHEST, V93, P506, DOI 10.1378/chest.93.3.506; WILLIAMS JF, 1995, J AM COLL CARDIOL, V26, P1376; Wood KA, 1998, CHEST, V113, P1339, DOI 10.1378/chest.113.5.1339; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761	28	281	311	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2126	2132		10.1016/S0140-6736(00)03492-9	http://dx.doi.org/10.1016/S0140-6736(00)03492-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191538				2022-12-28	WOS:000165997300010
J	Lygerou, Z; Nurse, P				Lygerou, Z; Nurse, P			Cell cycle - License withheld - Geminin blocks DNA replication	SCIENCE			English	Editorial Material							CDC6 PROTEIN; INITIATION; YEAST		Univ Patras, Sch Med, Lab Gen Biol, GR-26110 Patras, Greece; Imperial Canc Res Fund, Cell Cycle Lab, London WC2A 3PX, England	University of Patras; Cancer Research UK	Lygerou, Z (corresponding author), Univ Patras, Sch Med, Lab Gen Biol, GR-26110 Patras, Greece.							BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; TADA S, IN PRESS NAT CELL BI; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309	11	43	43	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2271	+						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11188727				2022-12-28	WOS:000165995800030
J	Peled, IJ				Peled, IJ			Facial surgery: body and soul	LANCET			English	Article									Rambam Med Ctr, Dept Plast Surg & Burns, IL-31096 Haifa, Israel; Rambam Univ Hosp, Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus	Peled, IJ (corresponding author), Rambam Med Ctr, Dept Plast Surg & Burns, IL-31096 Haifa, Israel.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S46	S46		10.1016/S0140-6736(00)92032-4	http://dx.doi.org/10.1016/S0140-6736(00)92032-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191504	Bronze			2022-12-28	WOS:000166074900048
J	Suarez, H; Velluti, RA				Suarez, H; Velluti, RA			Research resurgence in Uruguay	LANCET			English	Article									Sch Med Montevideo, Lab Audiol & Fisiopatol Vestibular, Montevideo 11400, Uruguay; Univ Republ, Dept Fisiol Neurofisiol, Montevideo, Uruguay; Sch Med Montevideo, Dept Physiol, Montevideo 11400, Uruguay	Universidad de la Republica, Uruguay	Suarez, H (corresponding author), Sch Med Montevideo, Lab Audiol & Fisiopatol Vestibular, Montevideo 11400, Uruguay.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S53	S53		10.1016/S0140-6736(00)92039-7	http://dx.doi.org/10.1016/S0140-6736(00)92039-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191512				2022-12-28	WOS:000166074900055
J	ter Meulen, J				ter Meulen, J			Response to haemorrhagic fevers in Europe	LANCET			English	Article									Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Hop Donka, Conakry, Guinea	Philipps University Marburg	ter Meulen, J (corresponding author), Hop Donka, Conakry, Guinea.								0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S64	S64		10.1016/S0140-6736(00)92050-6	http://dx.doi.org/10.1016/S0140-6736(00)92050-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191524				2022-12-28	WOS:000166074900066
J	Curtis, CF				Curtis, CF			Infectious disease - The case of deemphasizing genomics in malaria control	SCIENCE			English	Article									Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Curtis, CF (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.							BOJANG KA, UNPUB; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; Curtis CF, 2000, PARASITOL TODAY, V16, P119, DOI 10.1016/S0169-4758(99)01605-1; CURTIS CF, IN PRESS B WHO; LINES JD, 1987, MED VET ENTOMOL, V1, P37, DOI 10.1111/j.1365-2915.1987.tb00321.x; Maxwell CA, 1999, T ROY SOC TROP MED H, V93, P4, DOI 10.1016/S0035-9203(99)90158-X; MUTABINGWA TK, UNPUB; RAO TR, 1984, MONOGRAPHS MALARIA R; Thomas DD, 2000, SCIENCE, V287, P2474, DOI 10.1126/science.287.5462.2474	9	28	29	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1508	1508		10.1126/science.290.5496.1508	http://dx.doi.org/10.1126/science.290.5496.1508			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11185507				2022-12-28	WOS:000165446200022
J	Lindberg, DAB				Lindberg, DAB			The National Library of Medicine's web site for physicians and patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Natl Lib Med, NIH, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Lindberg, DAB (corresponding author), Natl Lib Med, NIH, Bethesda, MD 20894 USA.								0	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					806	806		10.1001/jama.285.6.806	http://dx.doi.org/10.1001/jama.285.6.806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176923				2022-12-28	WOS:000166817200041
J	Smith-Warner, SA; Spiegelman, D; Yaun, SS; Adami, HO; Beeson, WL; van den Brandt, PA; Folsom, AR; Fraser, GE; Freudenheim, JL; Goldbohm, RA; Graham, S; Miller, AB; Potter, JD; Rohan, TE; Speizer, FE; Toniolo, P; Willett, WC; Wolk, A; Zeleniuch-Jacquotte, A; Hunter, DJ				Smith-Warner, SA; Spiegelman, D; Yaun, SS; Adami, HO; Beeson, WL; van den Brandt, PA; Folsom, AR; Fraser, GE; Freudenheim, JL; Goldbohm, RA; Graham, S; Miller, AB; Potter, JD; Rohan, TE; Speizer, FE; Toniolo, P; Willett, WC; Wolk, A; Zeleniuch-Jacquotte, A; Hunter, DJ			Intake of fruits and vegetables and risk of breast cancer - A pooled analysis of cohort studies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							VITAMIN-A; DIETARY FIBER; BETA-CAROTENE; FOOD GROUPS; CONSUMPTION; FAT; EPIDEMIOLOGY; METAANALYSIS; ASSOCIATION; SUPPLEMENTS	Context Some epidemiologic studies suggest that elevated fruit and vegetable consumption is associated with a reduced risk of breast cancer. However, most have been case-control studies in which recall and selection bias may influence the results. Additionally, publication bias may have influenced the literature on associations for specific fruit and vegetable subgroups. Objective To examine the association between breast cancer and total and specific fruit and vegetable group intakes using standardized exposure definitions. Data Sources/Study Selection Eight prospective studies that had at least 200 incident breast cancer cases, assessed usual dietary intake, and completed a validation study of the diet assessment method or a closely related instrument were included in these analyses. Data Extraction Using the primary data from each of the studies, we calculated study-specific relative risks (RRs) that were combined using a random-effects model. Data Synthesis The studies included 7377 incident invasive breast cancer cases occurring among 351825 women whose diet was analyzed at baseline. For comparisons of the highest vs lowest quartiles of intake, weak, nonsignificant associations were observed for total fruits (pooled multivariate RR, 0.93; 95% confidence interval [CI], 0.86-1.00; P for trend =.08), total vegetables (RR, 0.96; 95% CI, 0.89-1.04; P for trend=.54), and total fruits and vegetables (RR, 0.93; 95% CI, 0.86-1.00; P for trend=.12). No additional benefit was apparent in comparisons of the highest and lowest deciles of intake. No associations were observed for green leafy vegetables, 8 botanical groups, and 17 specific fruits and vegetables. Conclusion These results suggest that fruit and vegetable consumption during adulthood is not significantly associated with reduced breast cancer risk.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Ctr Canc Prevent, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Ctr Canc Prevent, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Ctr Canc Prevent, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Ctr Canc Prevent, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden; Loma Linda Univ, Sch Med, Ctr Hlth Res, Loma Linda, CA USA; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA; TNO, Nutr & Food Res Inst, NL-3700 AJ Zeist, Netherlands; Deutsch Krebsforschungszentrum, Div Clin Epidemiol, D-6900 Heidelberg, Germany; Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA; Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA; NYU, Sch Med, Dept Obstet & Gynecol, New York, NY USA; NYU, Sch Med, Nelson Inst Environm Med, New York, NY USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Karolinska Institutet; Loma Linda University; Maastricht University; University of Minnesota System; University of Minnesota Twin Cities; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Netherlands Organization Applied Science Research; Helmholtz Association; German Cancer Research Center (DKFZ); Fred Hutchinson Cancer Center; Yeshiva University; Albert Einstein College of Medicine; New York University; New York University; New York University	Smith-Warner, SA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Ctr Canc Prevent, 665 Huntington Ave, Boston, MA 02115 USA.			Freudenheim, Jo/0000-0002-9301-0499; van den Brandt, Piet/0000-0001-8781-8099; Zeleniuch-Jacquotte, Anne/0000-0001-9350-1303; Potter, John/0000-0001-5439-1500	NCI NIH HHS [CA55075] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Braga C, 1997, NUTR CANCER, V28, P258, DOI 10.1080/01635589709514585; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Franceschi S, 1995, INT J CANCER, V63, P785, DOI 10.1002/ijc.2910630606; Gandini S, 2000, EUR J CANCER, V36, P636, DOI 10.1016/S0959-8049(00)00022-8; GRAHAM S, 1982, AM J EPIDEMIOL, V116, P68, DOI 10.1093/oxfordjournals.aje.a113403; GRAHAM S, 1992, AM J EPIDEMIOL, V136, P1327, DOI 10.1093/oxfordjournals.aje.a116445; HIROSE K, 1995, JPN J CANCER RES, V86, P146, DOI 10.1111/j.1349-7006.1995.tb03032.x; HISLOP TG, 1986, CANCER DETECT PREV, V9, P47; HOLMBERG L, 1994, ARCH INTERN MED, V154, P1805, DOI 10.1001/archinte.154.16.1805; Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; KATO I, 1992, BREAST CANCER RES TR, V24, P51, DOI 10.1007/BF01832358; KATSOUYANNI K, 1986, INT J CANCER, V38, P815, DOI 10.1002/ijc.2910380606; Key TJA, 1996, BMJ-BRIT MED J, V313, P775, DOI 10.1136/bmj.313.7060.775; KREBSSMITH SM, 1995, J NUTR EDUC, V27, P80, DOI 10.1016/S0022-3182(12)80346-3; Kushi LH, 1996, AM J EPIDEMIOL, V144, P165, DOI 10.1093/oxfordjournals.aje.a008904; LANGHOLZ B, 1990, AM J EPIDEMIOL, V131, P169, DOI 10.1093/oxfordjournals.aje.a115471; Law MR, 1998, EUR J CLIN NUTR, V52, P549, DOI 10.1038/sj.ejcn.1600603; Longnecker MP, 1997, CANCER EPIDEM BIOMAR, V6, P887; *MICR, 1993, EPICURE US GUID PEAN; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; PENNINGTON JAT, 1998, BOWES CHURCHS FOOD V; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; ROHAN TE, 1993, CANCER CAUSE CONTROL, V4, P29, DOI 10.1007/BF00051711; Rothman K., 1998, MODERN EPIDEMIOLOGY; SAS Institute, 1991, SAS STAT SOFTW PHREG; SHIBATA A, 1992, BRIT J CANCER, V66, P673, DOI 10.1038/bjc.1992.336; SMITH SA, 1995, CANCER CAUSE CONTROL, V6, P292, DOI 10.1007/BF00051404; Smith-Warner S. A., 1999, NUTR ONCOLOGY, P153; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; TONIOLO P, 1994, EPIDEMIOLOGY, V5, P391, DOI 10.1097/00001648-199407000-00003; TRICHOPOULOU A, 1995, JNCI-J NATL CANCER I, V87, P110, DOI 10.1093/jnci/87.2.110; *USDA, 1996, USDA NUTR DAT STAND; Verhoeven DTH, 1997, BRIT J CANCER, V75, P149, DOI 10.1038/bjc.1997.25; Wolk A, 1998, ARCH INTERN MED, V158, P41, DOI 10.1001/archinte.158.1.41; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Zhang SM, 1999, JNCI-J NATL CANCER I, V91, P547, DOI 10.1093/jnci/91.6.547	37	354	361	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					769	776		10.1001/jama.285.6.769	http://dx.doi.org/10.1001/jama.285.6.769			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176915	Green Published			2022-12-28	WOS:000166817200034
J	Anhalt, GJ; Diaz, LA				Anhalt, GJ; Diaz, LA			Research advances in pemphigus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLIACEUS FOGO-SELVAGEM; HIGH-DOSE CYCLOPHOSPHAMIDE; SEVERE AUTOIMMUNE-DISEASE; STEM-CELL RESCUE; PARANEOPLASTIC PEMPHIGUS; VULGARIS ANTIGEN; PASSIVE TRANSFER; AUTOANTIBODIES; MICE; CADHERIN	Pemphigus is an autoimmune disorder, known to be caused by autoantibodies directed against critical adhesion molecules of squamous epithelial cells, the desmogleins. These autoantibodies induce blistering of skin and mucosal surfaces and lead to severe morbidity and, potentially, death. Key factors include associated major histocompatibility complex class II genes, the structure of the desmoglein antigens, and the role of autoantibody in impairing cellular adhesion. This article discusses the precise structure of the major histocompatibility complex class II gene-peptide-T-cell receptor complex involved and of the environmental and genetic factors that induce autoimmunity against desmoglein 1. Discovery of antigen-specific immunotherapy and insight into environmental factors that initiate autoimmunity in genetically susceptible individuals are needed.	Johns Hopkins Univ, Sch Med, Div Dermatoimmunol, Baltimore, MD 21205 USA; Univ N Carolina, Dept Dermatol, Chapel Hill, NC USA	Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill	Anhalt, GJ (corresponding author), Johns Hopkins Univ, Sch Med, Div Dermatoimmunol, 720 Rutland Ave,Room 771, Baltimore, MD 21205 USA.				NIAMS NIH HHS [R01 AR032081] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHMED AR, 1991, P NATL ACAD SCI USA, V88, P7658; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Amagai M, 2000, J CLIN INVEST, V105, P625, DOI 10.1172/JCI8748; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; ANHALT GJ, 1986, J IMMUNOL, V136, P113; ANHALT GJ, 1990, NEW ENGL J MED, V323, P1729, DOI 10.1056/NEJM199012203232503; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; Aoyama Y, 1999, EUR J IMMUNOL, V29, P2233, DOI 10.1002/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4; BEUTNER EH, 1964, P SOC EXP BIOL MED, V117, P505; Brodsky RA, 1998, ANN INTERN MED, V129, P1031, DOI 10.7326/0003-4819-129-12-199812150-00007; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; DIAZ LA, 1989, J AM ACAD DERMATOL, V20, P657, DOI 10.1016/S0190-9622(89)70079-7; DIAZ LA, 1989, J INVEST DERMATOL, V92, P4, DOI 10.1111/1523-1747.ep13070394; EYRE RW, 1987, J EXP MED, V165, P1719, DOI 10.1084/jem.165.6.1719; EYRE RW, 1988, J CLIN INVEST, V81, P807, DOI 10.1172/JCI113387; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; KORMAN NJ, 1991, J INVEST DERMATOL, V96, P273, DOI 10.1111/1523-1747.ep12464471; LABIB RS, 1991, J INVEST DERMATOL, V96, P144, DOI 10.1111/1523-1747.ep12515943; Mahoney MG, 1999, J INVEST DERMATOL, V113, P22, DOI 10.1046/j.1523-1747.1999.00632.x; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; Moraes ME, 1997, TISSUE ANTIGENS, V49, P35, DOI 10.1111/j.1399-0039.1997.tb02707.x; Nousari HC, 1999, LANCET, V354, P667, DOI 10.1016/S0140-6736(99)03007-X; Nousari HC, 1999, J AM ACAD DERMATOL, V40, P750, DOI 10.1016/S0190-9622(99)70157-X; Nousari HC, 1999, NEW ENGL J MED, V340, P1406, DOI 10.1056/NEJM199905063401805; ROSCOE JT, 1985, J INVEST DERMATOL, V85, P538, DOI 10.1111/1523-1747.ep12277362; SINHA AA, 1988, SCIENCE, V239, P1026, DOI 10.1126/science.2894075; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; Warren KG, 1997, J NEUROL SCI, V152, P31, DOI 10.1016/S0022-510X(97)00130-5; WARREN SJ, IN PRESS N ENGL J ME; WUCHERPFENNIG KW, 1995, P NATL ACAD SCI USA, V92, P11935, DOI 10.1073/pnas.92.25.11935	32	43	46	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					652	654		10.1001/jama.285.5.652	http://dx.doi.org/10.1001/jama.285.5.652			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176877				2022-12-28	WOS:000166714200030
J	Kaji, EH; Leiden, JM				Kaji, EH; Leiden, JM			Gene and stem cell therapies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; FAMILIAL HYPERCHOLESTEROLEMIA; BONE-MARROW; IN-VIVO; IDENTIFICATION; BRAIN; MICE; TRANSPLANTATION; RETINOBLASTOMA; DIFFERENTIATE	Gene and stem cell therapies hold promise for the treatment of a wide variety of inherited and acquired human diseases. Identification of genes involved in human disease and development of novel vectors and devices for delivering therapeutic genes to different tissues in vivo have resulted in significant progress in the area of gene therapy. Isolation of stem cells from organs formerly thought to have no regenerative potential, the demonstration of stem cell plasticity, and the creation of human embryonic stem cells clearly demonstrate the feasibility of human stem cell therapy. Much additional work remains to be done in the areas of vector development and stem cell biology before the full therapeutic potential of these approaches can be realized. Of equal importance, the ethical issues surrounding gene- and cell-based therapies must be confronted.	Abbott Labs, Dept Execut, Abbott Pk, IL 60064 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, Jamaica Plain, MA USA	Abbott Laboratories; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Leiden, JM (corresponding author), Abbott Labs, Dept Execut, Bldg AP6D,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048987] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK48987-07] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2000, Nature, V405, P599; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; Binley K, 1999, GENE THER, V6, P1721, DOI 10.1038/sj.gt.3301001; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Bohl D, 1997, NAT MED, V3, P299, DOI 10.1038/nm0397-299; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GROSSMAN M, 1994, NAT GENET, V6, P335, DOI 10.1038/ng0494-335; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Marshall DJ, 2000, MOL THER, V1, P423, DOI 10.1006/mthe.2000.0059; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monahan PE, 2000, GENE THER, V7, P24, DOI 10.1038/sj.gt.3301109; MORGAN JE, 1994, HUM GENE THER, V5, P165, DOI 10.1089/hum.1994.5.2-165; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Perry D, 2000, SCIENCE, V287, P1423, DOI 10.1126/science.287.5457.1423; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Restifo NP, 2000, GENE THER, V7, P89, DOI 10.1038/sj.gt.3301117; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Thomson JA, 1998, SCIENCE, V282, P1827; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Trono D, 2000, GENE THER, V7, P20, DOI 10.1038/sj.gt.3301105; Vile RG, 2000, GENE THER, V7, P2, DOI 10.1038/sj.gt.3301084; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wilmut I, 1997, NATURE, V386, P200, DOI 10.1038/386200a0; Ye XH, 1999, SCIENCE, V283, P88, DOI 10.1126/science.283.5398.88; Young FE, 2000, SCIENCE, V287, P1424, DOI 10.1126/science.287.5457.1424	48	60	77	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					545	550		10.1001/jama.285.5.545	http://dx.doi.org/10.1001/jama.285.5.545			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176856	Bronze			2022-12-28	WOS:000166714200009
J	Ledergerber, B; Mocroft, A; Reiss, P; Furrer, H; Kirk, O; Bickel, M; Uberti-Foppa, C; Pradier, C; Monforte, AD; Schneider, MME; Lundgren, JD				Ledergerber, B; Mocroft, A; Reiss, P; Furrer, H; Kirk, O; Bickel, M; Uberti-Foppa, C; Pradier, C; Monforte, AD; Schneider, MME; Lundgren, JD		Eight European Study Grp	Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	7th Conference on Retroviruses and Opportunistic Infections	JAN 29-FEB 03, 2000	SAN FRANCISCO, CA				ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TRIMETHOPRIM-SULFAMETHOXAZOLE; OPPORTUNISTIC INFECTIONS; AEROSOLIZED PENTAMIDINE; HIV-1-INFECTED PATIENTS; COTRIMOXAZOLE; PROGRESSION; PREVENTION; MUTATIONS; MORTALITY	Background: Patients with human immunodeficiency virus (HIV) infection and a history of Pneumocystis carinii pneumonia are at high risk for relapse if they are not given secondary prophylaxis. Whether secondary prophylaxis against P. carinii pneumonia can be safely discontinued in patients who have a response to highly active antiretroviral therapy is not known. Methods: We analyzed episodes of recurrent P. carinii pneumonia in 325 HIV-infected patients (275 men and 50 women) in eight prospective European cohorts. Between October 1996 and January 2000, these patients discontinued secondary prophylaxis during treatment with at least three anti-HIV drugs after they had at least one peripheral-blood CD4 cell count of more than 200 cells per cubic millimeter. Results: Secondary prophylaxis was discontinued at a median CD4 cell count of 350 per cubic millimeter; the median nadir CD4 cell count had been 50 per cubic millimeter. The median duration of the increase in the CD4 cell count to more than 200 per cubic millimeter after discontinuation of secondary prophylaxis was 11 months. The median follow-up period after discontinuation of secondary prophylaxis was 13 months, yielding a total of 374 person-years of follow-up; for 355 of these person-years, CD4 cell counts remained at or above 200 per cubic millimeter. No cases of recurrent P. carinii pneumonia were diagnosed during this period; the incidence was thus 0 per 100 patient-years (99 percent confidence interval, 0 to 1.2 per 100 patient-years, on the basis of the entire follow-up period, and 0 to 1.3 per 100 patient-years, on the basis of the follow-up period during which CD4 cell counts remained at or above 200 per cubic millimeter). Conclusions: It is safe to discontinue secondary prophylaxis against P. carinii pneumonia in patients with HIV infection who have an immunologic response to highly active antiretroviral therapy. (N Engl J Med 2001;344:168-74.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland; UCL Royal Free & Univ Coll Med Sch, London, England; Univ Amsterdam, Acad Med Ctr, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Natl AIDS Therapy Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands; Univ Hosp Bern, Div Infect Dis, CH-3010 Bern, Switzerland; Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark; Goethe Univ Frankfurt, Ctr Internal Med, D-6000 Frankfurt, Germany; Hosp San Raffaele, Dept Infect Dis, I-20132 Milan, Italy; Hop Archet, Trop & Infect Dis Dept, Nice, France; Univ Milan, Inst Infect & Trop Dis, Milan, Italy; Univ Utrecht, Med Ctr, Dept Internal Med, Div Infect Dis & AIDS, Utrecht, Netherlands	University of Zurich; University Zurich Hospital; University of London; University College London; UCL Medical School; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Bern; University Hospital of Bern; University of Copenhagen; Goethe University Frankfurt; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; CHU Nice; University of Milan; Utrecht University	Ledergerber, B (corresponding author), Univ Zurich Hosp, Div Infect Dis, CH-8091 Zurich, Switzerland.	infled@usz.unizh.ch	Mocroft, Amanda/C-1527-2008; Ledergerber, Bruno/B-5656-2009; Foppa, Caterina Uberti/ABH-3089-2020; Furrer, Hansjakob/G-6768-2013; Mocroft, Amanda/G-8748-2011; Pradier, Christian/AFE-8255-2022; Pradier, Christian/AAE-9669-2022; Lundgren, Jens/AAE-6876-2019; kirk, ole/ABB-4746-2021	Ledergerber, Bruno/0000-0002-6881-4401; Foppa, Caterina Uberti/0000-0001-5271-9138; Furrer, Hansjakob/0000-0002-1375-3146; Mocroft, Amanda/0000-0001-8316-1122; Lundgren, Jens/0000-0001-8901-7850				[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BENFIELD TL, 1995, AM J RESP CRIT CARE, V151, P1058; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; El-Sadr WM, 1998, NEW ENGL J MED, V339, P1889, DOI 10.1056/NEJM199812243392604; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Helweg-Larsen J, 1999, LANCET, V354, P1347, DOI 10.1016/S0140-6736(99)03320-6; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Kirk O, 1999, AIDS, V13, P1647, DOI 10.1097/00002030-199909100-00007; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; LUNDGREN JD, 1995, CLIN INFECT DIS, V21, P106, DOI 10.1093/clinids/21.1.106; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; Mei Q, 1998, LANCET, V351, P1631, DOI 10.1016/S0140-6736(05)77687-X; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft AJ, 1997, INT J EPIDEMIOL, V26, P400, DOI 10.1093/ije/26.2.400; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; MONTANER JSG, 1991, ANN INTERN MED, V114, P948, DOI 10.7326/0003-4819-114-11-948; Navin TR, 2000, J INFECT DIS, V181, P158, DOI 10.1086/315196; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PHILLIPS AN, 1991, LANCET, V337, P389; Pradier C, 1997, AIDS, V11, P832; Rizzardi GP, 1996, J INFECTION, V32, P123, DOI 10.1016/S0163-4453(96)91312-2; RodriguezBarradas MC, 1997, J INFECT DIS, V175, P590, DOI 10.1093/infdis/175.3.590; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; SHELHAMER JH, 1984, AM REV RESPIR DIS, V130, P1161; Soriano V, 2000, AIDS, V14, P383, DOI 10.1097/00002030-200003100-00011; [U.S. Public Health Service (USPHS) Infectious Diseases Society of America (IDSA)], 1999, MMWR-MORBID MORTAL W, V48, p[1, 61]; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0	38	109	112	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2001	344	3					168	174		10.1056/NEJM200101183440302	http://dx.doi.org/10.1056/NEJM200101183440302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	392GF	11188837	Green Published, Bronze			2022-12-28	WOS:000166402800002
J	Yamamoto, J; Tanaka, H				Yamamoto, J; Tanaka, H			Transparent nematic phase in a liquid-crystal-based microemulsion	NATURE			English	Article							TRANSITION; ELASTOMERS; EMULSIONS; BEHAVIOR; TOPOLOGY; MODEL; ORDER	Complex fluids(1,2) are usually produced by mixing together several distinct components, the interactions between which can give rise to unusual optical and rheological properties of the system as a whole. For example, the properties of microemulsions (composed of water, oil and surfactants) are determined by the microscopic structural organization of the fluid that occurs owing to phase separation of the component elements. Here we investigate the effect of introducing an additional organizing factor into such a fluid system, by replacing the oil component of a conventional water-in-oil microemulsion with an intrinsically anisotropic fluid-a nematic liquid crystal. As with the conventional case, the fluid phase-separates into an emulsion of water microdroplets (stabilized by the surfactant as inverse micelles) dispersed in the 'oil' phase. But the properties are further influenced by a significant directional coupling between the liquid-crystal molecules and the surfactant tails that emerge (essentially radially) from the micelles. The result is a modified bulk-liquid crystal that is an ordered nematic at the mesoscopic level, but which does not exhibit the strong light scattering generally associated with bulk nematic order(2): the bulk material here is essentially isotropic and thus transparent.	Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan	University of Tokyo	Tanaka, H (corresponding author), Univ Tokyo, Inst Ind Sci, Meguro Ku, 4-6-1 Komaba, Tokyo 1538505, Japan.		Tanaka, Hajime/A-9653-2008; Tanaka, Hajime/ABF-1451-2021	Tanaka, Hajime/0000-0002-4444-1890; Tanaka, Hajime/0000-0002-4444-1890				BELLINI T, 1992, PHYS REV LETT, V69, P788, DOI 10.1103/PhysRevLett.69.788; Clarke SM, 1998, MACROMOLECULES, V31, P4862, DOI 10.1021/ma980195j; Copic M, 1998, PHYS REV LETT, V80, P1449, DOI 10.1103/PhysRevLett.80.1449; DAOUD M, 1999, SOFT MATTER PHYSICS; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; FABRE P, 1990, PHYS REV LETT, V64, P539, DOI 10.1103/PhysRevLett.64.539; Fridrikh SV, 1997, PHYS REV LETT, V79, P4661, DOI 10.1103/PhysRevLett.79.4661; GRAWFORD GP, 1996, PHYS REV E, V53, P3647; IANNACCHIONE GS, 1993, PHYS REV LETT, V71, P2595, DOI 10.1103/PhysRevLett.71.2595; Kuksenok OV, 1996, PHYS REV E, V54, P5198, DOI 10.1103/PhysRevE.54.5198; LAMMERT PE, 1995, PHYS REV E, V52, P1778, DOI 10.1103/PhysRevE.52.1778; Lubensky TC, 1998, PHYS REV E, V57, P610, DOI 10.1103/PhysRevE.57.610; OTT A, 1990, EUROPHYS LETT, V12, P395, DOI 10.1209/0295-5075/12/5/003; POULIN P, 1994, J PHYS II, V4, P1557, DOI 10.1051/jp2:1994217; Poulin P, 1998, PHYS REV E, V57, P626, DOI 10.1103/PhysRevE.57.626; SEO DS, 1995, JPN J APPL PHYS 1, V34, P3607, DOI 10.1143/JJAP.34.3607; TERENTJEV EM, 1995, EUROPHYS LETT, V32, P607, DOI 10.1209/0295-5075/32/7/012; Terentjev EM, 1998, MODERN ASPECTS OF COLLOIDAL DISPERSIONS, P257; TONER J, 1995, PHYS REV E, V52, P1801, DOI 10.1103/PhysRevE.52.1801; WU L, 1995, PHYS REV E, V51, P2157, DOI 10.1103/PhysRevE.51.2157	20	113	115	3	66	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					321	325		10.1038/35053035	http://dx.doi.org/10.1038/35053035			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201736				2022-12-28	WOS:000166434300041
J	Steiner, MJ; Lovvorn, AE; Schulz, KF				Steiner, MJ; Lovvorn, AE; Schulz, KF			Bogus participation in clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Family Hlth Int, Res Triangle Pk, NC 27709 USA		Steiner, MJ (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.							Mayor S, 2000, BRIT MED J, V321, P725, DOI 10.1136/bmj.321.7263.725; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; *US DEP HHS, 2000, RECR HUM SUBJ PRESS; Weber W, 2000, LANCET, V356, P53, DOI 10.1016/S0140-6736(05)73393-6	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					293	293		10.1001/jama.285.3.293	http://dx.doi.org/10.1001/jama.285.3.293			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390XD	11176837				2022-12-28	WOS:000166324300018
J	Parulkar, AA; Pendergrass, ML; Granda-Ayala, R; Lee, TR; Fonseca, VA				Parulkar, AA; Pendergrass, ML; Granda-Ayala, R; Lee, TR; Fonseca, VA			Nonhypoglycemic effects of thiazolidinediones	ANNALS OF INTERNAL MEDICINE			English	Review							ACTIVATED RECEPTOR-GAMMA; LOW-DENSITY-LIPOPROTEIN; VASCULAR SMOOTH-MUSCLE; TYPE-2 DIABETES-MELLITUS; AMELIORATES INSULIN-RESISTANCE; IMPAIRED GLUCOSE-TOLERANCE; POLYCYSTIC-OVARY-SYNDROME; LOWERS BLOOD-PRESSURE; IN-VITRO OXIDATION; BETA-CELL FUNCTION	The thiazolidinediones are a new class of compounds for treatment of type 2 diabetes. Troglitazone became available in the United States in 1997 but was withdrawn from the market in March 2000 because it caused severe idiosyncratic liver injury. Rosiglitazone and pioglitazone have been available since 1999. Because these drugs directly improve insulin resistance and decrease plasma insulin levels (a risk factor for coronary artery disease), they may decrease risk for cardiovascular disease in patients with type 2 diabetes. Research on the non-glucose lowering effects of troglitazone and, to a lesser extent, of rosiglitazone and pioglitazone have demonstrated changes in several cardiovascular risk factors associated with the insulin resistance syndrome. These beneficial effects include a decrease in blood pressure, correction of diabetic dyslipidemia, improvement of fibrinolysis, and decrease in carotid artery intima-media thickness. Other in vitro effects related to the ability of these agents tb bind a newly described class of receptors (peroxisome proliferator-activated receptors) may also have implications for atherosclerosis. However, these drugs increase low-density lipoprotein (LDL) cholesterol levels and may favorably change LDL particle size and susceptibility to oxidation (although the implications of the latter changes are not clear). Furthermore, these drugs tend to cause weight gain. The authors' enthusiasm for these drugs has diminished somewhat because of reported adverse events, including rare liver failure. Nevertheless, because of the mechanism of action of the thiazolidinediones, clinical trials designed to determine whether they (or similar "insulin sensitizers") decrease cardiovascular events in people with type 2 diabetes will be of interest.	Louisiana State Univ, Med Ctr, Dept Med, Endocrinol Sect, New Orleans, LA 70112 USA	Louisiana State University System	Fonseca, VA (corresponding author), Louisiana State Univ, Med Ctr, Dept Med, Endocrinol Sect, SL53,1430 Tulane Ave, New Orleans, LA 70112 USA.	vfonseca@tulane.edu						Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Al-Salman J, 2000, ANN INTERN MED, V132, P121, DOI 10.7326/0003-4819-132-2-200001180-00006; Anand MM, 1999, PRACT DIABETOL, V18, P23; Antonucci T, 1997, DIABETES CARE, V20, P188, DOI 10.2337/diacare.20.2.188; AUSTIN MA, 1989, AM J EPIDEMIOL, V129, P249, DOI 10.1093/oxfordjournals.aje.a115130; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Avena R, 1998, J VASC SURG, V28, P1024, DOI 10.1016/S0741-5214(98)70028-X; Bakris G, 1999, DIABETOLOGIA, V42, pA230; BROWN JA, 1996, NEUROSURG FOCUS, V1, P2; BUCHANAN TA, 1995, J CLIN INVEST, V96, P354, DOI 10.1172/JCI118041; Buckingham RE, 1998, DIABETES, V47, P1326, DOI 10.2337/diabetes.47.8.1326; Cavaghan MK, 1997, J CLIN INVEST, V100, P530, DOI 10.1172/JCI119562; CHAIT A, 1993, AM J MED, V94, P350, DOI 10.1016/0002-9343(93)90144-E; Cominacini L, 1997, DIABETOLOGIA, V40, P1211, DOI 10.1007/s001250050809; Cominacini L, 1997, DIABETOLOGIA, V40, P165, DOI 10.1007/s001250050658; Cominacini L, 1998, DIABETES, V47, P130, DOI 10.2337/diabetes.47.1.130; Cominacini L, 1994, Diabetes Res, V26, P173; DAVIDSON MB, 1995, AM J MED, V99, P420, DOI 10.1016/S0002-9343(99)80191-0; Deedwania Prakash C., 1998, American Journal of Medicine, V105, p1S, DOI 10.1016/S0002-9343(98)00204-6; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Eastman RC, 1997, LANCET, V350, pSI29; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; *EL LILL CO, 1999, PRESCR INF PIOGL; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fonseca V, 2000, JAMA-J AM MED ASSOC, V283, P1695, DOI 10.1001/jama.283.13.1695; Fonseca VA, 1998, J DIABETES COMPLICAT, V12, P181, DOI 10.1016/S1056-8727(97)00109-8; Forman LM, 2000, ANN INTERN MED, V132, P118, DOI 10.7326/0003-4819-132-2-200001180-00005; Fujii M, 1997, METABOLISM, V46, P981, DOI 10.1016/S0026-0495(97)90264-X; Fujishima S, 1998, AM J HYPERTENS, V11, P1134, DOI 10.1016/S0895-7061(98)00130-7; Gasic S, 1998, ENDOCRINOLOGY, V139, P4962, DOI 10.1210/en.139.12.4962; Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433; Gitlin N, 1998, ANN INTERN MED, V129, P36, DOI 10.7326/0003-4819-129-1-199807010-00008; Hsueh Willa A., 1998, American Journal of Medicine, V105, p4S, DOI 10.1016/S0002-9343(98)00205-8; Imano E, 1998, DIABETES CARE, V21, P2135, DOI 10.2337/diacare.21.12.2135; Ishizuka T, 1998, DIABETES, V47, P1494, DOI 10.2337/diabetes.47.9.1494; Izumino K, 1997, J CLIN ENDOCR METAB, V82, P2391, DOI 10.1210/jc.82.8.2391; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jokl R, 1997, DIABETES REV, V5, P316; KAUFMAN LN, 1995, METABOLISM, V44, P1105, DOI 10.1016/0026-0495(95)90000-4; Kawasaki J, 1998, CIRCULATION, V98, P2446, DOI 10.1161/01.CIR.98.22.2446; Kelly IE, 1999, DIABETES CARE, V22, P288, DOI 10.2337/diacare.22.2.288; King AB, 2000, DIABETES CARE, V23, P557, DOI 10.2337/diacare.23.4.557b; Kubota T, 1998, CANCER RES, V58, P3344; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; Lehmann ED, 1997, LANCET, V350, pSI14; Maggs DG, 1998, ANN INTERN MED, V128, P176, DOI 10.7326/0003-4819-128-3-199802010-00002; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Matthews DR, 1999, DIABETOLOGIA, V42, pA228; MATTOCK MB, 1992, DIABETES, V41, P736, DOI 10.2337/diabetes.41.6.736; Melidonis A, 2000, CLIN CARDIOL, V23, P160, DOI 10.1002/clc.4960230306; Minamikawa J, 1998, J CLIN ENDOCR METAB, V83, P1818, DOI 10.1210/jc.83.5.1818; MURAKAMI T, 1998, CIRCULATION S, V98, pA1; NAGI DK, 1993, DIABETES CARE, V16, P621, DOI 10.2337/diacare.16.4.621; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nestler JE, 1998, NEW ENGL J MED, V338, P1876, DOI 10.1056/NEJM199806253382603; Neuschwander-Tetri BA, 1998, ANN INTERN MED, V129, P38, DOI 10.7326/0003-4819-129-1-199807010-00009; Noguchi N, 1996, ATHEROSCLEROSIS, V123, P227, DOI 10.1016/0021-9150(96)05811-X; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Nordt TK, 2000, J CLIN ENDOCR METAB, V85, P1563, DOI 10.1210/jc.85.4.1563; Nuttall ME, 1998, J BONE MINER RES, V13, P371, DOI 10.1359/jbmr.1998.13.3.371; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; OGIHARA T, 1995, AM J HYPERTENS, V8, P316, DOI 10.1016/0895-7061(95)96214-5; Peuler JD, 1996, AM J HYPERTENS, V9, P188, DOI 10.1016/0895-7061(95)00393-2; Prigeon RL, 1998, J CLIN ENDOCR METAB, V83, P819, DOI 10.1210/jc.83.3.819; Ranganathan S, 1998, J BIOL CHEM, V273, P26117, DOI 10.1074/jbc.273.40.26117; REAVEN GM, 1994, J INTERN MED, V236, P13; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Rosenstock J, 1988, Cardiol Clin, V6, P547; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Santomauro ATMG, 1999, DIABETES, V48, P1836, DOI 10.2337/diabetes.48.9.1836; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Satoh H, 1999, BIOCHEM BIOPH RES CO, V254, P757, DOI 10.1006/bbrc.1998.0126; Shibuya A, 1998, DIABETES CARE, V21, P2140, DOI 10.2337/diacare.21.12.2140; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; SIMONSON DC, 1988, DIABETES CARE, V11, P821, DOI 10.2337/diacare.11.10.821; *SMITHKL BEECH PHA, 1999, PRESCR INF ROS; Sobel Burton E., 1999, Thrombosis and Haemostasis, V82, P8; Song JB, 1997, DIABETES, V46, P659, DOI 10.2337/diabetes.46.4.659; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; Sung BH, 1999, HYPERTENSION, V34, P83, DOI 10.1161/01.HYP.34.1.83; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; Sutton MS, 1999, DIABETES, V48, pA102; Tack CJJ, 1998, DIABETES CARE, V21, P796, DOI 10.2337/diacare.21.5.796; Tack CJJ, 1998, DIABETOLOGIA, V41, P569, DOI 10.1007/s001250050948; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; *TROGL STUD GROUP, 1997, DIABETES S1, V46, pA149; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; VAMECQ J, 2000, CURR OPIN ENDOCRINOL, V7, P8; Walker AB, 1999, DIABETES, V48, P1448, DOI 10.2337/diabetes.48.7.1448; Walker AB, 1998, DIABETES, V47, P810, DOI 10.2337/diabetes.47.5.810; Yamasaki Y, 1997, TOHOKU J EXP MED, V183, P173, DOI 10.1620/tjem.183.173; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; ZHANG F, 1994, HYPERTENSION, V24, P170, DOI 10.1161/01.HYP.24.2.170	102	301	315	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2001	134	1					61	71		10.7326/0003-4819-134-1-200101020-00014	http://dx.doi.org/10.7326/0003-4819-134-1-200101020-00014			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386CV	11187421				2022-12-28	WOS:000166043300008
J	Graham, A				Graham, A			Development - Hear, hear, for the inner ear	SCIENCE			English	Editorial Material							HINDBRAIN		Kings Coll London, MRC, Ctr Dev Neurobiol, London SE1 1UL, England	University of London; King's College London	Graham, A (corresponding author), Kings Coll London, MRC, Ctr Dev Neurobiol, London SE1 1UL, England.	anthony.graham@kcl.ac.uk	graham, anthony/B-1864-2008	graham, anthony/0000-0003-2011-7188				HUME CR, 1993, DEVELOPMENT, V119, P1147; JACOBSON AG, 1966, SCIENCE, V152, P25, DOI 10.1126/science.152.3718.25; Ladher RK, 2000, SCIENCE, V290, P1965, DOI 10.1126/science.290.5498.1965; MARIN F, 1995, EUR J NEUROSCI, V7, P1714, DOI 10.1111/j.1460-9568.1995.tb00693.x; Muhr J, 1999, NEURON, V23, P689, DOI 10.1016/S0896-6273(01)80028-3	5	4	4	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1904	1905		10.1126/science.290.5498.1904	http://dx.doi.org/10.1126/science.290.5498.1904			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11187047				2022-12-28	WOS:000165810000031
J	Decosas, J				Decosas, J			Children and AIDS in Africa	LANCET			English	Article									S African AIDS Training Programme, Harare, Zimbabwe		Decosas, J (corresponding author), S African AIDS Training Programme, POB 390, Harare, Zimbabwe.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S33	S33		10.1016/S0140-6736(00)92019-1	http://dx.doi.org/10.1016/S0140-6736(00)92019-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191490				2022-12-28	WOS:000166074900035
J	Gibb, DM; Giaquinto, C				Gibb, DM; Giaquinto, C			Children with HIV infection: special cases	LANCET			English	Article									MRC, Clin Trials Unit, London NW1 2DA, England; Univ Padua, Dept Pediat, I-35100 Padua, Italy	Medical Research Council Clinical Trials Unit; University of Padua	Gibb, DM (corresponding author), MRC, Clin Trials Unit, London NW1 2DA, England.		Giaquinto, Carlo/AAB-5016-2020	Gibb, Diana/0000-0002-9738-5490					0	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S34	S34		10.1016/S0140-6736(00)92020-8	http://dx.doi.org/10.1016/S0140-6736(00)92020-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191491				2022-12-28	WOS:000166074900036
J	Neto, UF; Scaletsky, ICA				Neto, UF; Scaletsky, ICA			Escherichia coli infections and malnutrition	LANCET			English	Article									Univ Fed Sao Paulo, Escola Paulista Med, Div Paediat Gastroenterol, Sao Paulo, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	Neto, UF (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Div Paediat Gastroenterol, Sao Paulo, Brazil.	ulvneto@osite.com.br	Scaletsky, Isabel/A-9983-2015						0	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC	2000	356			S			S27	S27		10.1016/S0140-6736(00)92013-0	http://dx.doi.org/10.1016/S0140-6736(00)92013-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191483				2022-12-28	WOS:000166074900029
J	Barbaro, G; Giancaspro, G; Soldini, M				Barbaro, G; Giancaspro, G; Soldini, M			Missed diagnoses of acute cardiac ischemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ La Sapienza, I-00161 Rome, Italy	Sapienza University Rome	Barbaro, G (corresponding author), Univ La Sapienza, I-00161 Rome, Italy.		Soldini, Maurizio/F-9433-2012					Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802	1	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1492	1492						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184460				2022-12-28	WOS:000165271300013
J	Gruber, T				Gruber, T			Missed diagnoses of acute cardiac ischemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							ADMISSION RATES; IMPACT		Monmouth Med Ctr, Long Branch, NJ 07740 USA		Gruber, T (corresponding author), Monmouth Med Ctr, Long Branch, NJ 07740 USA.							Daumit GL, 1999, ANN INTERN MED, V130, P173, DOI 10.7326/0003-4819-130-3-199902020-00002; Josephson GW, 1997, AM J MANAG C, V3, P49; PEARSON SD, 1994, HEALTH SERV RES, V29, P59	3	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1493	1493						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184461				2022-12-28	WOS:000165271300015
J	Khoury, MJ				Khoury, MJ			Will genetics revolutionize medicine?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Ctr Dis Control & Prevent, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Khoury, MJ (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.							Cogswell ME, 1998, ANN INTERN MED, V129, P971, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00008; Holtzman NA, 2000, NEW ENGL J MED, V343, P141, DOI 10.1056/NEJM200007133430213; Hoover RN, 2000, NEW ENGL J MED, V343, P135, DOI 10.1056/NEJM200007133430210; Khoury MJ, 1996, AM J HUM GENET, V58, P253; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201	5	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1497	1497						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184470				2022-12-28	WOS:000165271300025
J	Peto, R				Peto, R			Cancer, genes, and the environment.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ Oxford, Oxford OX2 6HE, England	University of Oxford	Peto, R (corresponding author), Univ Oxford, Oxford OX2 6HE, England.							DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; TOMATIS L, 1990, IARC SCI PUBLICATION, V100	2	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1495	1495						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184465				2022-12-28	WOS:000165271300020
J	Shapiro, BL				Shapiro, BL			Cancer, genes, and the environment.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ Minnesota, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Shapiro, BL (corresponding author), Univ Minnesota, Minneapolis, MN 55455 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1494	1495						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184463				2022-12-28	WOS:000165271300019
J	Rightor, N				Rightor, N			The pharmaceutical industry - To whom is it accountable?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									MXCIX, Needham, MA 02492 USA		Rightor, N (corresponding author), MXCIX, Needham, MA 02492 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1416	1416						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183882				2022-12-28	WOS:000165152800018
J	Yancik, R; Wesley, MN; Ries, LAG; Havlik, RJ; Edwards, BK; Yates, JW				Yancik, R; Wesley, MN; Ries, LAG; Havlik, RJ; Edwards, BK; Yates, JW			Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LYMPH-NODE DISSECTION; AXILLARY DISSECTION; WOMEN; CARE; SURVIVAL; PATTERNS; IMPACT	Context Postmenopausal women aged 55 years and older have 66% of incident breast tumors and experience 77% of breast cancer mortality, but other age-related health problems may affect tumor prognosis and treatment decisions. Objective To document the comorbidity burden of postmenopausal breast cancer patients and evaluate its relationship with age on disease stage, treatment, and early mortality. Design and Setting Data were collected on breast cancer patients' comorbidities by retrospective hospital medical records review and merged with information on patients' tumor characteristics collected from 6 regional National Cancer Institute Surveillance, Epidemiology, and End Results cancer registries. Patients were followed up until death or for 30 months from breast cancer diagnosis. Participants Population-based random sample of 1800 postmenopausal breast cancer patients diagnosed in 1992 stratified by 3 age groups: 55 to 64 years, 65 to 74 years, and 75 years and older. Main Outcome Measures Extent of disease, therapy received, comorbidity, cause of death, and survival. Results Seventy-three percent (1312 of 1800) of the sample was diagnosed with stage I and II breast cancer, 10% (n=188) with stage III and IV breast cancer, and 17% (n=300) did not have a stage assignment. Of the 1017 patients with stage I and stage II node-negative breast cancer, 95% received therapy in agreement with the National Institutes of Health consensus statement recommendation for early-stage breast cancer. Patients in older age groups were less likely to:receive therapy consistent with the consensus statement (P<.001), and women aged 70 years and older were significantly less likely to receive axillary lymph node dissection as determined by logistic regression analysis (P<.01). Diabetes, renal failure, stroke, liver disease, a previous malignant tumor, and smoking were significant in predicting early mortality in a statistical model that included age and disease stage. Breast cancer was the underlying cause of death for 135 decedents (51.3%). Heart disease (n=45, 17.1%) and previous cancers (n=22, 8.4%) were the next major underlying causes. In the 30-month follow-up period, 263 patients (15%) died. Conclusion Patient care decisions occur in the context of breast cancer and other age-related conditions. Comorbidity in older patients may limit the ability to obtain prognostic information (ie, axillary lymph node dissection), tends to minimize treatment options (eg, breast-conserving therapy), and increases the risk of death from causes other than breast cancer.	NIA, Canc Sect, Geriatr Program, NIH, Bethesda, MD 20892 USA; NIA, Epidemiol Biometry & Demog Program, NIH, Bethesda, MD 20892 USA; NCI, Surveillance Res Program, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA; Informat Management Serv Inc, Silver Spring, MD USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Information Management Services, Inc.; Roswell Park Cancer Institute	Yancik, R (corresponding author), NIA, Canc Sect, Geriatr Program, NIH, Bethesda, MD 20892 USA.							*ACS, 2001, FACTS FIG 2001; ALLEN C, 1986, J AM GERIATR SOC, V34, P637, DOI 10.1111/j.1532-5415.1986.tb04904.x; American Joint Committee on Cancer, 1992, MAN STAG CANC; [Anonymous], 1996, US BUREAU CENSUS CUR; AUGUST DA, 1994, ANN SURG ONCOL, V1, P45, DOI 10.1007/BF02303540; BallardBarbash R, 1996, JNCI-J NATL CANCER I, V88, P716, DOI 10.1093/jnci/88.11.716; BERGMAN L, 1991, BREAST CANCER RES TR, V18, P189, DOI 10.1007/BF01990035; Busch E, 1996, CANCER, V78, P101, DOI 10.1002/(SICI)1097-0142(19960701)78:1<101::AID-CNCR15>3.0.CO;2-3; CABANES PA, 1992, LANCET, V339, P1245, DOI 10.1016/0140-6736(92)91591-U; CADY B, 1994, CANCER, V73, P505, DOI 10.1002/1097-0142(19940201)73:3<505::AID-CNCR2820730302>3.0.CO;2-B; CHU J, 1987, J GERONTOL, V42, P185, DOI 10.1093/geronj/42.2.185; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1970, ANAL BINARY DATA; Du XL, 1999, BREAST CANCER RES TR, V53, P137, DOI 10.1023/A:1006170811237; Goodwin JS, 1996, JNCI-J NATL CANCER I, V88, P1031, DOI 10.1093/jnci/88.15.1031; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; Guralnik JM, 1996, ANN EPIDEMIOL, V6, P376, DOI 10.1016/S1047-2797(96)00060-9; Havlik RJ, 1994, CANCER S, V74, P2102; Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KUZNETSOVA M, 1995, RADIOLOGY, V197, P507, DOI 10.1148/radiology.197.2.7480703; LIN PP, 1993, J CLIN ONCOL, V11, P1536, DOI 10.1200/JCO.1993.11.8.1536; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Newschaffer CJ, 1996, ARCH INTERN MED, V156, P85, DOI 10.1001/archinte.156.1.85; *NIH, 1990, TREATM EARL STAG BRE, V8, P1; Piccirillo JF, 1996, CANCER, V77, P834, DOI 10.1002/(SICI)1097-0142(19960301)77:5<834::AID-CNCR5>3.3.CO;2-Z; Ries LAG .M.K.C, 2001, SEER CANC STAT REV 1; SATARIANO WA, 1994, ANN INTERN MED, V120, P104, DOI 10.7326/0003-4819-120-2-199401150-00002; SATARIANO WA, 1992, J GERONTOL, V47, P24; Satariano WA, 1989, CANC ELDERLY APPROAC, P71; Seeman T E, 1989, J Aging Health, V1, P50, DOI 10.1177/089826438900100104; SILLIMAN RA, 1993, JNCI-J NATL CANCER I, V85, P190, DOI 10.1093/jnci/85.3.190; SILLIMAN RA, 1989, J GERONTOL, V44, P46; STEINFELD AD, 1989, J AM GERIATR SOC, V347, P335; Sun A, 1998, RADIOTHER ONCOL, V48, P191, DOI 10.1016/S0167-8140(98)00029-2; TRIMBLE EL, 1994, CANCER, V74, P2208, DOI 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#; Warmuth MA, 1998, CANCER, V83, P1362, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1362::AID-CNCR13>3.0.CO;2-2; West DW, 1996, ANN EPIDEMIOL, V6, P413, DOI 10.1016/S1047-2797(96)00096-8; WETLE T, 1987, JAMA-J AM MED ASSOC, V258, P516, DOI 10.1001/jama.1987.03400040114035; Yancik R, 1996, ANN EPIDEMIOL, V6, P399, DOI 10.1016/S1047-2797(96)00063-4; YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A	41	662	678	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					885	892		10.1001/jama.285.7.885	http://dx.doi.org/10.1001/jama.285.7.885			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402BE	11180731	Bronze			2022-12-28	WOS:000166965500025
J	Deeks, SG; Wrin, T; Liegler, T; Hoh, R; Hayden, M; Barbour, JD; Hellmann, NS; Petropoulos, CJ; McCune, JM; Hellerstein, MK; Grant, RM				Deeks, SG; Wrin, T; Liegler, T; Hoh, R; Hayden, M; Barbour, JD; Hellmann, NS; Petropoulos, CJ; McCune, JM; Hellerstein, MK; Grant, RM			Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VIVO; FAILURE; FITNESS	Background: In many patients with human immunodeficiency virus (HIV) infection, therapy with potent antiretroviral drugs does not result in complete suppression of HIV replication. The effect of cessation of therapy in these patients is unknown. Methods: Sixteen patients who had a plasma HIV RNA level of more than 2500 copies per milliliter during combination antiretroviral-drug therapy were randomly assigned, in a 2:1 ratio, to discontinue or continue therapy. Plasma HIV RNA levels, CD4 cell counts, and drug susceptibility were measured weekly. Viral replicative capacity was measured at base line and at week 12. Results: Discontinuation of therapy for 12 weeks was associated with a median decrease in the CD4 cell count of 128 cells per cubic millimeter and an increase in the plasma HIV RNA level of 0.84 log copies per milliliter. Virus from all patients with detectable resistance at entry became susceptible to HIV-protease inhibitors within 16 weeks after the discontinuation of therapy. Drug susceptibility began to increase a median of six weeks after the discontinuation of therapy and was temporally associated with increases in plasma HIV RNA levels and decreases in CD4 cell counts. Viral replicative capacity, measured by means of a recombinant-virus assay, was low at entry into the study and increased after therapy was discontinued. Despite the loss of detectable resistance in plasma, resistant virus was cultured from peripheral-blood mononuclear cells in five of nine patients who could be evaluated. Plasma HIV RNA levels, CD4 cell counts, and drug susceptibility remained stable in the patients who continued therapy. Conclusions: Despite the presence of reduced drug susceptibility, antiretroviral-drug therapy can provide immunologic and virologic benefit. This benefit reflects continued antiviral-drug activity and the maintenance of a viral population with a reduced replicative capacity. (N Engl J Med 2001;344:472-80.) Copyright (C) 2001 Massachusetts Medical Society.	San Francisco Gen Hosp, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; ViroLogic, S San Francisco, CA USA; Gladstone Inst Virol & Immunol, San Francisco, CA USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California Berkeley	Deeks, SG (corresponding author), San Francisco Gen Hosp, 995 Potrero Ave, San Francisco, CA 94110 USA.		Hayden, Matthew/C-1263-2008	Grant, Robert/0000-0002-0851-7085; Hayden, Matthew/0000-0003-1670-6430	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041401, R01AI141401, U01AI043864, R01AI043864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH059037] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43864, AI41401] Funding Source: Medline; NIMH NIH HHS [P30 MH59037] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Martinez-Picado J, 1999, J VIROL, V73, P3744, DOI 10.1128/JVI.73.5.3744-3752.1999; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; Zennou V, 1998, J VIROL, V72, P3300, DOI 10.1128/JVI.72.4.3300-3306.1998; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; 1998, MMWR MORB MORTAL WKL, V47, P619; 1998, MMWR MORB MORTAL WKL, V47, P43	15	541	548	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	2001	344	7					472	480		10.1056/NEJM200102153440702	http://dx.doi.org/10.1056/NEJM200102153440702			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401HL	11172188				2022-12-28	WOS:000166922100002
J	Lie, RT; Wilcox, AJ; Skjaerven, R				Lie, RT; Wilcox, AJ; Skjaerven, R			Survival and reproduction among males with birth defects and risk of recurrence in their children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Few systematic data exist on survival and reproduction among males with birth defects and their contribution to occurrence of birth defects in the next generation. Objective To estimate survival of males with registered birth defects, their subsequent reproduction rates, and their risk of transmitting birth defects to their offspring. Design and Setting Population-based cohort study of data from the Medical Birth Registry of Norway. Subjects A total of 486207 males born in Norway between 1967 and 1982, 12292 of whom had a recorded birth defect. Main Outcome Measures Survival rates through 1992, reproduction rates through 1998, and risk of birth defects among offspring of males with vs without birth defects. Results Survival through 1992 was lower among males with birth defects (84% vs 97%). Compared with males without birth defects, affected males were 28% less likely to have had a child. Among offspring of affected males, 5.1% had a registered birth defect compared with 2.1% of offspring of males without birth defects (relative risk [RR], 2.4; 95% confidence interval [CI], 1.9-3.0), Offspring of affected fathers had an increased risk of the same defect as their fathers (RR, 6.5; 95% CI, 4.0-10.4) and an increased risk of dissimilar defects (RR, 1.8; 95% CI, 1.3-2.5). Conclusions Compared with unaffected males, males with birth defects have higher mortality and survivors are less likely to have a child. Fathers with birth defects are significantly more likely than unaffected fathers to have an affected child.	Univ Bergen, Med Birth Registry Norway, N-5021 Bergen, Norway; Univ Bergen, Sect Med Stat, N-5021 Bergen, Norway; NIEHS, Res Triangle Pk, NC 27709 USA	University of Bergen; University of Bergen; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Lie, RT (corresponding author), Univ Bergen, Sect Med Stat, Amauer Hansens Bldg, N-5021 Bergen, Norway.		Wilcox, Allen J/C-7723-2019	Wilcox, Allen J/0000-0002-3376-1311	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES049027, Z01ES049027] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Burn J, 1998, LANCET, V351, P311, DOI 10.1016/S0140-6736(97)06486-6; CHATKUPT S, 1992, AM J MED GENET, V44, P508, DOI 10.1002/ajmg.1320440426; Chung C S, 1975, Birth Defects Orig Artic Ser, V11, P1; LIE RT, 1994, NEW ENGL J MED, V331, P1, DOI 10.1056/NEJM199407073310101; LIE RT, 1994, BIOMETRICS, V50, P433, DOI 10.2307/2533386; METHA C, 1999, STATXACT WINDOWS; NORA JJ, 1987, AM J CARDIOL, V59, P459, DOI 10.1016/0002-9149(87)90956-8; Norusis M J, 1993, SPSS WINDOWS ADV STA; Rothman K, 1986, MODERN EPIDEMIOLOGY; Skjaerven R, 1999, NEW ENGL J MED, V340, P1057, DOI 10.1056/NEJM199904083401401; *STAT NORW, 1995, POP STAT 1994, V3; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	12	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					755	760		10.1001/jama.285.6.755	http://dx.doi.org/10.1001/jama.285.6.755			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176913				2022-12-28	WOS:000166817200032
J	Collins, FS; McKusick, VA				Collins, FS; McKusick, VA			Implications of the Human Genome Project for medical science	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DNA-SEQUENCE; GENE-EXPRESSION; THERAPY; DISEASE	The year 2000 marked both the start of the new millennium and the announcement that the vast majority of the human genome had been sequenced. Much work remains to understand how this "instruction book for human biology" carries out its multitudes of functions. But the consequences for the practice of medicine are likely to be profound. Genetic prediction of individual risks of disease and responsiveness to drugs will reach the medical mainstream in the next decade or so. The development of designer drugs, based on a genomic approach to targeting molecular pathways that are disrupted in disease, will follow soon after. Potential misuses of genetic information, such as discrimination in obtaining health insurance and in the workplace, will need to be dealt with swiftly and effectively. Genomic medicine holds the ultimate promise of revolutionizing the diagnosis and treatment of many illnesses.	NHGRI, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Johns Hopkins University	Collins, FS (corresponding author), NHGRI, NIH, 31 Ctr Dr,MSC 2152,Bldg 31,Room 4B09, Bethesda, MD 20892 USA.	fc23a@nih.gov						Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; Collins FS, 1997, JAMA-J AM MED ASSOC, V278, P1285, DOI 10.1001/jama.278.15.1285; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Henig RM., 2000, MONK GARDEN; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; *NAT CTR BIOT INF, 2000, ONL MEND INH MAN; National Research Council Committee on Mapping and Sequencing the Human Genome, 2000, MAPP SEQ HUM GEN; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; *US DEPT HHS, 1990, UND OUR GEN INH US H; Verma IM, 2000, MOL THER, V1, P493, DOI 10.1006/mthe.2000.0084; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	27	464	486	2	47	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					540	544		10.1001/jama.285.5.540	http://dx.doi.org/10.1001/jama.285.5.540			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176855	Bronze			2022-12-28	WOS:000166714200008
J	Hou, JG; Yang, JL; Wang, HQ; Li, QX; Zeng, CG; Yuan, LF; Wang, B; Chen, DM; Zhu, QS				Hou, JG; Yang, JL; Wang, HQ; Li, QX; Zeng, CG; Yuan, LF; Wang, B; Chen, DM; Zhu, QS			Surface science - Topology of two-dimensional C-60 domains	NATURE			English	Article									Univ Sci & Technol China, Struct Res Lab, Hefei 230026, Peoples R China; Univ Sci & Technol China, Open Lab Bond Select Chem, Hefei 230026, Peoples R China; Rowland Inst Sci Inc, Cambridge, MA 02142 USA	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Hou, JG (corresponding author), Univ Sci & Technol China, Struct Res Lab, Hefei 230026, Peoples R China.		Li, Qunxiang/D-3705-2009; Wang, Bing/D-3535-2009; Yang, Jinlong/D-3465-2009; HAIQIAN, WANG/A-6559-2014; Hou, Jianguo/G-5076-2010	Li, Qunxiang/0000-0003-1988-1971; Wang, Bing/0000-0002-2953-2196; HAIQIAN, WANG/0000-0001-9992-9773; 				BIRGENEAU RJ, 1986, SCIENCE, V232, P329, DOI 10.1126/science.232.4748.329; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; EVANS SD, 1990, CHEM PHYS LETT, V170, P462, DOI 10.1016/S0009-2614(90)87085-6; FENTER P, 1998, THIN FILMS SELF ASSE, V24, P121; Hou JG, 1999, PHYS REV LETT, V83, P3001, DOI 10.1103/PhysRevLett.83.3001; LU JP, 1992, PHYS REV LETT, V68, P1551, DOI 10.1103/PhysRevLett.68.1551; SAKURAI T, 1996, PROG SURF SCI, V51, P266; SINHA SK, 1980, ORDERING 2 DIMENSION	8	93	104	4	129	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					304	305		10.1038/35053163	http://dx.doi.org/10.1038/35053163			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201729				2022-12-28	WOS:000166434300033
J	Mojzsis, SJ; Harrison, TM; Pidgeon, RT				Mojzsis, SJ; Harrison, TM; Pidgeon, RT			Oxygen-isotope evidence from ancient zircons for liquid water at the Earth's surface 4,300 Myr ago	NATURE			English	Article							NARRYER GNEISS COMPLEX; OLD DETRITAL ZIRCONS; U-PB AGES; WESTERN-AUSTRALIA; JACK HILLS; GEOCHEMISTRY; FRACTIONATION; SYSTEMATICS; CRUST; ROCKS	Granitoid gneisses and supracrustal rocks that are 3,800- 4,000 Myr old are the oldest recognized exposures of continental crust(1). To obtain insight into conditions at the Earth's surface more than 4 Gyr ago requires the analysis of yet older rocks or their mineral remnants. Such an opportunity is presented by detrital zircons more than 4 Gyr old found within 3-Gyr-old quartzitic rocks in the Murchison District of Western Australia(2,3). Here we report in situ U-Pb and oxygen isotope results for such zircons that place constraints on the age and composition of their sources and may therefore provide information about the nature of the Earth's early surface. We rnd that 3,910-4,280 Myr old zircons have oxygen isotope (delta (18) O) values ranging from 5:4 +/- 0.6 parts per thousand to 15.0 +/- 0:4 parts per thousand. On the basis of these results, we postulate that the similar to4,300-Myr-old zircons formed from magmas containing a significant component of re-worked continental crust that formed in the presence of water near the Earth's surface. These data are therefore consistent with the presence of a hydrosphere interacting with the crust by 4,300 Myr ago.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, IGPP Ctr Astrobiol, Los Angeles, CA 90095 USA; Curtin Univ Technol, Dept Appl Geol, Perth, WA 6001, Australia	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Curtin University	Mojzsis, SJ (corresponding author), Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA.		MOJZSIS, STEPHEN/AAU-9527-2020; Harrison, Timothy M/E-7443-2012	MOJZSIS, STEPHEN/0000-0003-0000-125X; 				Amelin Y, 1999, NATURE, V399, P252, DOI 10.1038/20426; CHIVAS AR, 1982, NATURE, V300, P139, DOI 10.1038/300139a0; COMPSTON W, 1986, NATURE, V321, P766, DOI 10.1038/321766a0; DELONG SE, 1990, EARTH PLANET SC LETT, V101, P206, DOI 10.1016/0012-821X(90)90154-P; Eiler JM, 1997, GEOCHIM COSMOCHIM AC, V61, P2281, DOI 10.1016/S0016-7037(97)00075-6; FROUDE DO, 1983, NATURE, V304, P616, DOI 10.1038/304616a0; GALER SJG, 1991, GEOCHIM COSMOCHIM AC, V55, P227, DOI 10.1016/0016-7037(91)90413-Y; Goodwin A., 1996, PRINCIPLES PRECAMBRI; Halliday AN, 2000, EARTH PLANET SC LETT, V176, P17, DOI 10.1016/S0012-821X(99)00317-9; HARMON RS, 1995, CONTRIB MINERAL PETR, V120, P95, DOI 10.1007/BF00311010; LONGSTAFFE FJ, 1977, GEOCHIM COSMOCHIM AC, V41, P1303, DOI 10.1016/0016-7037(77)90074-6; MAAS R, 1991, GEOCHIM COSMOCHIM AC, V55, P1915, DOI 10.1016/0016-7037(91)90033-2; MAAS R, 1992, GEOCHIM COSMOCHIM AC, V56, P1281, DOI 10.1016/0016-7037(92)90062-N; MATTEY D, 1994, EARTH PLANET SC LETT, V128, P231, DOI 10.1016/0012-821X(94)90147-3; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; MYERS JS, 1985, PRECAMBRIAN RES, V27, P153, DOI 10.1016/0301-9268(85)90010-5; MYERS JS, 1988, PRECAMBRIAN RES, V38, P297, DOI 10.1016/0301-9268(88)90029-0; Nelson DR, 2000, EARTH PLANET SC LETT, V181, P89, DOI 10.1016/S0012-821X(00)00186-2; NUTMAN AP, 1991, PRECAMBRIAN RES, V52, P275, DOI 10.1016/0301-9268(91)90084-N; ONEIL JR, 1977, J GEOL SOC LONDON, V133, P559, DOI DOI 10.1144/GSJGS.133.6.0559; PACES JB, 1993, J GEOPHYS RES-SOL EA, V98, P13997, DOI 10.1029/93JB01159; Quidelleur X, 1997, J GEOPHYS RES-SOL EA, V102, P2659, DOI 10.1029/96JD02483; SCHUMACHER M, 1994, SECONDARY ION MASS S, V9, P919; TAYLOR HP, 1986, REV MINERAL, V16, P227; Valley JW, 1998, CONTRIB MINERAL PETR, V133, P1, DOI 10.1007/s004100050432; VALLEY JW, 1994, EARTH PLANET SC LETT, V126, P187, DOI 10.1016/0012-821X(94)90106-6; Watson EB, 1997, EARTH PLANET SC LETT, V148, P527, DOI 10.1016/S0012-821X(97)00057-5; WHITE AJR, 1977, TECTONOPHYSICS, V43, P7, DOI 10.1016/0040-1951(77)90003-8; ZHENG YF, 1993, GEOCHIM COSMOCHIM AC, V57, P1079	29	548	575	5	162	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					178	181		10.1038/35051557	http://dx.doi.org/10.1038/35051557			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196638				2022-12-28	WOS:000166316200040
J	Pujolle-Robic, C; Noirez, L				Pujolle-Robic, C; Noirez, L			Observation of shear-induced nematic-isotropic transition in side-chain liquid crystal polymers	NATURE			English	Article							PHASE-TRANSITION; EQUILIBRIUM POLYMERS; MOLECULAR-WEIGHT; FLOW; CONFORMATION; BEHAVIOR; ORDER	Flow-induced phase transitions are a fundamental (but poorly understood) property of non-equilibrium systems, and are also of practical importance for tuning the processing conditions for plastics, petroleum products, and other related materials(21). Recognition that polymers may exhibit liquid crystal properties has led to the discovery of the first tailored side-chain liquid crystal polymers (SCLCPs), which are formed by inserting a spacer between the main polymer chain and the lateral mesogen liquid-crystalline graftings(22). Subsequent research has sought to understand the nature of the coupling between the main polymer chain and the mesogens, with a view to obtaining better control of the properties of these tailored structures(22). We show here that the parallel or perpendicular orientation of the mesogens with respect to the main chain can be reversed by the application of an external field produced by a shear flow, demonstrating the existence of an isotropic nematic phase transition in SCLCPs. Such a transition, which was theoretically predicted(1,2) for low-molecular-weight liquid crystals but never observed, is shown to be a general property of SCLCPs too. We expect that these SCLCPs will prove to be good candidate systems for the experimental study of these non-equilibrium phenomena.	Ce Saclay, CNRS, CEA, Leon Brillouin Lab, F-91191 Gif Sur Yvette, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Noirez, L (corresponding author), Ce Saclay, CNRS, CEA, Leon Brillouin Lab, F-91191 Gif Sur Yvette, France.							BERRET JF, 1994, EUROPHYS LETT, V25, P521, DOI 10.1209/0295-5075/25/7/008; BRAND HR, 1994, J PHYS II, V4, P543, DOI 10.1051/jp2:1994144; Cappelaere E, 1997, PHYS REV E, V56, P1869, DOI 10.1103/PhysRevE.56.1869; Dealy J.M., 1990, MELT RHEOLOGY ITS RO; DEGEMMES PG, 1979, SCALING CONCEPTS POL, V165, P224; DEGENNES PG, 1993, PHYS LIQUID CRYSTALS, P66; FINKELMANN H, 1978, MAKROMOL CHEM, V179, P273; Fourmaux-Demange V, 1998, MACROMOLECULES, V31, P801, DOI 10.1021/ma9712864; GALLANI JL, 1994, PHYS REV LETT, V72, P2109, DOI 10.1103/PhysRevLett.72.2109; GLEIM W, 1991, MAKROMOL CHEM, V192, P2555; Mather PT, 1997, MACROMOLECULES, V30, P7977, DOI 10.1021/ma970737h; Noirez L, 1998, PHYS REV LETT, V80, P1453, DOI 10.1103/PhysRevLett.80.1453; Noirez L, 2000, PHYS REV LETT, V84, P2164, DOI 10.1103/PhysRevLett.84.2164; NOIREZ L, 1995, LIQ CRYST, V18, P129, DOI 10.1080/02678299508036602; Noirez L, 1996, PHYS REV E, V53, P6115, DOI 10.1103/PhysRevE.53.6115; OLMSTED PD, 1990, PHYS REV A, V41, P4578, DOI 10.1103/PhysRevA.41.4578; OLMSTED PD, 1992, PHYS REV A, V46, P4966, DOI 10.1103/PhysRevA.46.4966; PIERANSK.P, 1974, PHYS REV A, V9, P404, DOI 10.1103/PhysRevA.9.404; PLEINER H, 1992, MACROMOLECULES, V25, P895, DOI 10.1021/ma00028a060; REYS V, 1988, PHYS REV LETT, V61, P2340, DOI 10.1103/PhysRevLett.61.2340; RUBIN SF, 1995, MACROMOLECULES, V28, P3521, DOI 10.1021/ma00114a005; SCHMITT V, 1994, LANGMUIR, V10, P955, DOI 10.1021/la00015a057; WANG XJ, 1987, J PHYS A-MATH GEN, V20, P713, DOI 10.1088/0305-4470/20/3/033	23	97	96	0	44	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					167	171		10.1038/35051537	http://dx.doi.org/10.1038/35051537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196635				2022-12-28	WOS:000166316200037
J	Schumacher, MA; Hurlburt, BK; Brennan, RG				Schumacher, MA; Hurlburt, BK; Brennan, RG			Crystal structures of SarA, a pleiotropic regulator of virulence genes in S-aureus	NATURE			English	Article							STAPHYLOCOCCUS-AUREUS; AGR; LOCUS; TRANSCRIPTION; DIFFRACTION; EXPRESSION	Staphylococcus aureus is a major human pathogen, the potency of which can be attributed to the regulated expression of an impressive array of virulence determinants. A key pleiotropic transcriptional regulator of these virulence factors is SarA, which is encoded by the sar (staphylococcal accessory regulator) locus(1-3). SarA was characterized initially as an activator of a second virulence regulatory locus, agr, through its interaction with a series of heptad repeats (AGTTAAG) within the agr promoter(4). Subsequent DNA-binding studies have revealed that SarA binds readily to multiple AT-rich sequences of variable lengths(4-11). Here we describe the crystal structure of SarA and a SarA-DNA complex at resolutions of 2.50 Angstrom and 2.95 Angstrom, respectively. SarA has a fold consisting of a four-helix core region and `inducible regions' comprising a beta -hairpin and a carboxy-terminal loop. On binding DNA, the inducible regions undergo marked conformational changes, becoming part of extended and distorted alpha -helices, which encase the DNA. SarA recognizes an AT-rich site in which the DNA is highly overwound and adopts a D-DNA-like conformation by indirect readout. These structures thus provide insight into SarA-mediated transcription regulation.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	Oregon Health & Science University; Oregon Health & Science University; University of Arkansas System; University of Arkansas Medical Sciences	Brennan, RG (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.			Brennan, Richard/0000-0001-7647-485X				BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Blevins JS, 1999, MOL MICROBIOL, V33, P317, DOI 10.1046/j.1365-2958.1999.01475.x; Chan PF, 1998, J BACTERIOL, V180, P6232; CHEUNG AL, 1994, J BACTERIOL, V176, P580, DOI 10.1128/jb.176.3.580-585.1994; CHEUNG AL, 1992, P NATL ACAD SCI USA, V89, P6462, DOI 10.1073/pnas.89.14.6462; CHEUNG AL, 1994, J BACTERIOL, V176, P4168, DOI 10.1128/JB.176.13.4168-4172.1994; Chien YT, 1999, J BIOL CHEM, V274, P37169, DOI 10.1074/jbc.274.52.37169; *COLL COMP PROJ NU, 1994, J APPL CRYSTALLOGR D, V50, P760; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GASKILL ME, 1988, J BIOL CHEM, V263, P6276; Heinrichs JH, 1996, J BACTERIOL, V178, P418, DOI 10.1128/jb.178.2.418-423.1996; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MAHENDRASINGAM A, 1986, SCIENCE, V233, P195, DOI 10.1126/science.3726529; Manna AC, 1998, J BACTERIOL, V180, P3828, DOI 10.1128/JB.180.15.3828-3836.1998; Morfeldt E, 1996, MOL MICROBIOL, V21, P1227, DOI 10.1046/j.1365-2958.1996.751447.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OBERTO J, 1994, BIOCHIMIE, V76, P901, DOI 10.1016/0300-9084(94)90014-0; PROJAN SJ, 1997, STAPHYLOCOCCI HUMAN, P55; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; Rechtin TM, 1999, MOL MICROBIOL, V33, P307, DOI 10.1046/j.1365-2958.1999.01474.x; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Saenger W., 1984, PRINCIPLES NUCL ACID; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Wolz C, 2000, MOL MICROBIOL, V36, P230, DOI 10.1046/j.1365-2958.2000.01853.x	29	48	51	2	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					215	219		10.1038/35051623	http://dx.doi.org/10.1038/35051623			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196648				2022-12-28	WOS:000166316200050
J	Walsh, C				Walsh, C			Enabling the chemistry of life	NATURE			English	Article							CATALYSIS; ENZYMES; DNA; BIOSYNTHESIS; POLYKETIDE; EVOLUTION; SYNTHASE; PROTEINS	Enzymes are the subset of proteins that catalyse the chemistry of life, transforming both macromolecular substrates and small molecules. The precise three-dimensional architecture of enzymes permits almost unerring selectivity in physical and chemical steps to impose remarkable rate accelerations and specificity in product-determining reactions. Many enzymes are members of families that carry out related chemical transformations and offer opportunities for directed in vitro evolution, to tailor catalytic properties to particular functions.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walsh, C (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.							Atkins J.F, 1999, RNA WORLD; Babbitt PC, 1996, BIOCHEMISTRY-US, V35, P16489, DOI 10.1021/bi9616413; BERTINO I, 1994, BIOINORGANIC CHEM; Bizily SP, 1999, P NATL ACAD SCI USA, V96, P6808, DOI 10.1073/pnas.96.12.6808; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Cane DE, 1997, CHEM REV, V97, P2463, DOI 10.1021/cr970097g; Cech TR, 1999, RNA WORLD, P321; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P11637, DOI 10.1021/bi9812571; Gerlt JA, 1998, CURR OPIN CHEM BIOL, V2, P607, DOI 10.1016/S1367-5931(98)80091-4; Lewis RJ, 1996, BIOESSAYS, V18, P661, DOI 10.1002/bies.950180810; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Madison LL, 1999, MICROBIOL MOL BIOL R, V63, P21, DOI 10.1128/MMBR.63.1.21-53.1999; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; Narlikar GJ, 1997, ANNU REV BIOCHEM, V66, P19, DOI 10.1146/annurev.biochem.66.1.19; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PEISER GD, 1984, P NATL ACAD SCI-BIOL, V81, P3059, DOI 10.1073/pnas.81.10.3059; Quadri LEN, 1999, BIOCHEMISTRY-US, V38, P14941, DOI 10.1021/bi991787c; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Schofield CJ, 1997, CURR OPIN STRUC BIOL, V7, P857, DOI 10.1016/S0959-440X(97)80158-3; Sheppard TL, 2000, P NATL ACAD SCI USA, V97, P7802, DOI 10.1073/pnas.97.14.7802; Smithrud DB, 1997, CURR OPIN BIOTECH, V8, P459, DOI 10.1016/S0958-1669(97)80069-9; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Wackett LP, 1999, ASM NEWS, V65, P87; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; WALSH CT, 1987, BIOCHEMISTRY-US, V26, P4901, DOI 10.1021/bi00390a001; Watt RK, 1999, CELL MOL LIFE SCI, V56, P604, DOI 10.1007/s000180050456; Zhang BL, 1997, NATURE, V390, P96, DOI 10.1038/36375	30	92	97	0	26	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					226	231		10.1038/35051697	http://dx.doi.org/10.1038/35051697			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196650				2022-12-28	WOS:000166316200053
J	Bradley, C				Bradley, C			Importance of differentiating health status from quality of life	LANCET			English	Editorial Material							IMPACT		Univ London, Royal Holloway & Bedford New Coll, Dept Psychol, Egham TW20 0EX, Surrey, England	University of London; Royal Holloway University London	Bradley, C (corresponding author), Univ London, Royal Holloway & Bedford New Coll, Dept Psychol, Egham TW20 0EX, Surrey, England.	C.Bradley@rhbnc.ac.uk		Bradley, Clare/0000-0002-4079-0364				[Anonymous], 1996, DIABETES ANN; Bradley C, 1999, QUAL LIFE RES, V8, P79, DOI 10.1023/A:1026485130100; BRALDEY C, 1999, P BRIT PSYCHOL SO S2, V7, P143; BRALDEY C, 1994, HDB PSYCHOL DIABETES, P89; Bulpitt CJ, 1998, DIABETES CARE, V21, P111, DOI 10.2337/diacare.21.1.111; Diabet Control Complications Trial Res Grp, 1996, DIABETES CARE, V19, P195; *EUR ASS STUD DIAB, 2000, DIABETOLOGIA S1, V43, pA224; Jacobson AM, 1994, HDB PSYCHOL DIABETES, P65; JOYCE CRB, 1994, QUALITY LIFE FOLLOWI, P43; MCGEE HM, 1991, PSYCHOL MED, V21, P749, DOI 10.1017/S0033291700022388; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Speight J, 2000, DIABETOLOGIA, V43, pA225; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UK Prospective Diabetes Study Grp, 1999, DIABETES CARE, V22, P1125; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	16	165	171	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2001	357	9249					7	8		10.1016/S0140-6736(00)03562-5	http://dx.doi.org/10.1016/S0140-6736(00)03562-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197385				2022-12-28	WOS:000166341500006
J	Lagaaij, EL; Cramer-Knijnenburg, GF; van Kemenade, FJ; van Es, LA; Bruijn, JA; van Krieken, JHJM				Lagaaij, EL; Cramer-Knijnenburg, GF; van Kemenade, FJ; van Es, LA; Bruijn, JA; van Krieken, JHJM			Endothelial cell chimerism after renal transplantation and vascular rejection	LANCET			English	Article							MONOCLONAL-ANTIBODIES; INSITU HYBRIDIZATION; ALLOGRAFTS; IMMUNOHISTOCHEMISTRY; SENSITIVITY; XENOGRAFTS; ADAPTATION	Background The blood vessels of a transplanted organ are the interface between donor and recipient. The endothelium in the blood vessels is thought to be the major target for graft rejection. Endothelial cells of a transplanted organ are believed to remain of donor origin after transplantation. We aimed to verify this concept. Methods We studied biopsy samples from 12 renal transplants for the presence of endothelial cells of recipient origin. We used three different techniques: immunohistochemistry for MHC class-I antigens, immunohistochemistry for ABO-blood-group antigens, and in-situ hybridisation for X and Y chromosomes. After we had conformed that these techniques did identify endothelial cells of recipient origin, tests were done in a second group of 26 patients to find out whether endothelial chimerism correlated with graft rejection. Findings We found a strong correlation between the percentage of recipient endothelial cells in the peritubular capillaries and the type of graft rejection (r=0.71, p<0.0001). These cells were found mainly in grafts of patients who had had rejection, especially among patients with vascular rejection. In grafts of patients without rejection only sporadically recipient endothelial cells were delectable. Interpretation Our data show that endothelial cells of the recipient can replace those of the donor. This replacement is associated with graft rejection, We postulate that endothelium that is damaged by vascular rejection is repaired by endothelial cells of the recipient.	Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Nephrol, NL-2300 RC Leiden, Netherlands; Univ Nijmegen Hosp, Dept Pathol, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen	Lagaaij, EL (corresponding author), Leiden Univ, Med Ctr, Dept Pathol, POB 9600, NL-2300 RC Leiden, Netherlands.		van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040				ANDERSEN CB, 1991, APMIS, V99, P645, DOI 10.1111/j.1699-0463.1991.tb01240.x; ASHARA T, 1997, SCIENCE, V275, P964; BOGMAN MJJT, 1987, TRANSPLANT P, V19, P205; BURDICK JF, 1979, J IMMUNOL, V123, P1732; HART DNJ, 1980, TRANSPLANTATION, V30, P73, DOI 10.1097/00007890-198007000-00016; JOOSTE SV, 1981, J EXP MED, V154, P1332, DOI 10.1084/jem.154.5.1332; KIBBELAAR RE, 1992, J CLIN PATHOL, V45, P149, DOI 10.1136/jcp.45.2.149; KOENE RAP, 1989, KIDNEY INT, V35, P1073, DOI 10.1038/ki.1989.92; Lagaaij EL, 1997, HISTOPATHOLOGY, V31, P284, DOI 10.1046/j.1365-2559.1997.2590861.x; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Lubin BH, 1997, NEW ENGL J MED, V337, P1623, DOI 10.1056/NEJM199711273372210; MEDAWAR PB, 1965, BRIT MED BULL, V21, P97, DOI 10.1093/oxfordjournals.bmb.a070392; NAKANE PK, 1968, J HISTOCHEM CYTOCHEM, V16, P557, DOI 10.1177/16.9.557; SINCLAIR RA, 1972, BRIT MED J, V4, P15, DOI 10.1136/bmj.4.5831.15; Solez K, 1996, TRANSPLANT P, V28, P441; Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203; VANSAASE JLCM, 1995, TRANSPLANTATION, V59, P1280, DOI 10.1097/00007890-199505000-00010; WILLIAMS GM, 1973, TRANSPL P, V5, P819; WOODRUFF MFA, 1953, TRANSPLAN B, V1, P221	19	242	254	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					33	37		10.1016/S0140-6736(00)03569-8	http://dx.doi.org/10.1016/S0140-6736(00)03569-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197359				2022-12-28	WOS:000166341500013
J	Stevens, VJ; Obarzanek, E; Cook, NR; Lee, IM; Appel, LJ; West, DS; Milas, NC; Mattfeldt-Beman, M; Belden, L; Bragg, C; Millstone, M; Raczynski, J; Brewer, A; Singh, B; Cohen, J				Stevens, VJ; Obarzanek, E; Cook, NR; Lee, IM; Appel, LJ; West, DS; Milas, NC; Mattfeldt-Beman, M; Belden, L; Bragg, C; Millstone, M; Raczynski, J; Brewer, A; Singh, B; Cohen, J		Trials Hypertension Prevention Res	Long-term weight loss and changes in blood pressure: Results of the trials of hypertension prevention, phase II	ANNALS OF INTERNAL MEDICINE			English	Article							FINAL REPORT; THERAPY; OBESITY; POPULATION; RISK	Background: Weight loss appears to be an effective method for primary prevention of hypertension. However, the long-term effects of weight loss on blood pressure have not been extensively studied. Objective: To present detailed results from the weight loss arm of Trials of Hypertension Prevention (TOHP) II. Design: Multicenter, randomized clinical trial testing the efficacy of lifestyle interventions for reducing blood pressure over 3 to 4 years, Participants in TOHP II were randomly assigned to one of four groups. This report focuses only on participants assigned to the weight loss (n=595) and usual care control (n=596) groups. Patients: Men and women 30 to 54 years of age who had nonmedicated diastolic blood pressure of 83 to 89 mm Hg and systolic blood pressure less than 140 mm Hg and were 110% to 165% of their ideal body weight at baseline. Intervention: The weight loss intervention included a 3-year program of group meetings and individual counseling focused on dietary change, physical activity, and social support. Measurements: Weight and blood pressure data were collected every 6 months by staff who were blinded to treatment assignment Results: Mean weight change from baseline in the intervention group was -4.4 kg at 6 months, -2.0 kg at 18 months, and -0.2 kg at 36 months. Mean weight change in the control group at the same time points was 0.1, 0.7, and 1.8 kg, Blood pressure was significantly lower in the intervention group than in the control group at 6, 18, and 36 months. The risk ratio for hypertension in the intervention group was 0.58 (95% CI, 0.36 to 0.94) at 6 months, 0.78 (CI, 0.62 to 1.00) at 18 months, and 0.81 (CI, 0.70 to 0.95) at 36 months. In subgroup analyses, intervention participants who lost at least 4.5 kg at 6 months and maintained this weight reduction for the next 30 months had the greatest reduction in blood pressure and a relative risk for hypertension of 0.35 (a, 0.20 to 0.59). Conclusions: Clinically significant long-term reductions in blood pressure and reduced risk for hypertension can be achieved with even modest weight loss.	Kaiser Permanente Ctr Hlth Res, Portland, OR USA; NHLBI, Bethesda, MD 20892 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Pittsburgh, Pittsburgh, PA USA; St Louis Univ, Sch Med, St Louis, MO USA; Univ Calif Davis, Sch Med, Davis, CA 95616 USA; Univ Tennessee, Memphis, TN USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA	Kaiser Permanente; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Saint Louis University; University of California System; University of California Davis; University of Tennessee System; University of Tennessee Health Science Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Stevens, VJ (corresponding author), Kaiser Permanente Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR USA.	victor.j.stevens@kpchr.org	Appel, Larry/GLT-2608-2022; Lee, I-Min/ABD-5409-2021; West, Delia Smith/GWV-5839-2022	West, Delia Smith/0000-0002-4375-2785	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL037924, U01HL037852, U01HL037907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37852, HL37907, HL37924] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Appel Lawrence J., 1995, Annals of Epidemiology, V5, P149, DOI 10.1016/1047-2797(94)00059-3; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Corrigan S A, 1991, Am J Health Promot, V5, P208; Cutler Jeffrey A., 1991, Annals of Epidemiology, V1, P363, DOI 10.1016/1047-2797(91)90046-F; ELLIOTT P, 1988, J HYPERTENS, V6, pS584; FITZWATER SL, 1991, J AM DIET ASSOC, V91, P421; Hebert Patricia R., 1995, Annals of Epidemiology, V5, P130, DOI 10.1016/1047-2797(94)00057-Z; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; Hollis Jack F., 1995, Annals of Epidemiology, V5, P140, DOI 10.1016/1047-2797(94)00058-2; KUMANYAKA SK, 1991, AM J CLIN NUTR, V53, pS1631, DOI 10.1093/ajcn/53.6.1631S; LANGFORD HG, 1985, JAMA-J AM MED ASSOC, V253, P657, DOI 10.1001/jama.253.5.657; Lasser Vera I., 1995, Annals of Epidemiology, V5, P156, DOI 10.1016/1047-2797(94)00060-7; MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57; Meltzer AA, 1996, OBES RES, V4, P479, DOI 10.1002/j.1550-8528.1996.tb00257.x; *METR LIF INS CO, 1983, STAT B METR LIF INS, V64, P4; PERRI MG, 1993, DIABETES CARE, V16, P200, DOI 10.2337/diacare.16.1.200; PERRI MG, 1989, J CONSULT CLIN PSYCH, V57, P450, DOI 10.1037/0022-006X.57.3.450; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; REISIN E, 1983, ANN INTERN MED, V98, P315, DOI 10.7326/0003-4819-98-3-315; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STEVENS VJ, 1993, ARCH INTERN MED, V153, P849, DOI 10.1001/archinte.153.7.849; WADDEN T A, 1992, American Journal of Clinical Nutrition, V56, p271S, DOI 10.1093/ajcn/56.1.271S; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; WING RR, 1995, ARCH INTERN MED, V155, P1416, DOI 10.1001/archinte.155.13.1416; WRIGHT BM, 1970, LANCET, V1, P337	31	596	621	1	25	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2001	134	1					1	11		10.7326/0003-4819-134-1-200101020-00007	http://dx.doi.org/10.7326/0003-4819-134-1-200101020-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386CV	11187414				2022-12-28	WOS:000166043300001
J	Knipschild, P				Knipschild, P			Alternative treatments: do they work?	LANCET			English	Article									Maastricht Univ, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands	Maastricht University	Knipschild, P (corresponding author), Maastricht Univ, Dept Gen Practice, POB 616, NL-6200 MD Maastricht, Netherlands.								0	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S4	S4		10.1016/S0140-6736(00)91990-1	http://dx.doi.org/10.1016/S0140-6736(00)91990-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191497				2022-12-28	WOS:000166074900006
J	Obaro, SK				Obaro, SK			Respiratory diseases in Africa: causes and effects	LANCET			English	Article									MRC Labs, Basse Field Stn, Fajara, Gambia	MRC Laboratory Molecular Biology	Obaro, SK (corresponding author), MRC Labs, Basse Field Stn, POB 273, Fajara, Gambia.								0	1	1	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S55	S55		10.1016/S0140-6736(00)92041-5	http://dx.doi.org/10.1016/S0140-6736(00)92041-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191514				2022-12-28	WOS:000166074900057
J	Holmer, AF				Holmer, AF			The pharmaceutical industry - To whom is it accountable?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Pharmaceut Res & Manufacturers Amer, Washington, DC 20005 USA		Holmer, AF (corresponding author), Pharmaceut Res & Manufacturers Amer, Washington, DC 20005 USA.							Angell M, 2000, NEW ENGL J MED, V342, P1902, DOI 10.1056/NEJM200006223422509; *BOST CONS GROUP, 1996, SUST INN US PHARM IN; *HLTH CAR FIN ADM, 1999, NAT HLTH EXP TABL; *PHARM RES MAN AM, 1996, NEW DRUG APPR 1995; *PHARM RES MAN AM, 1995, NEW DRUG APPR 1994; 2000, TIME            0703, P19; [No title captured]	7	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1415	1415						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183877				2022-12-28	WOS:000165152800013
J	Lorenz, RD				Lorenz, RD			Planetary science - The weather on Titan	SCIENCE			English	Editorial Material							METHANE; NITROGEN		Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Lorenz, RD (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.		Lorenz, Ralph D/B-8759-2016	Lorenz, Ralph D/0000-0001-8528-4644				BAXTER S, 1998, TITAN, P501; Flasar FM, 1998, NATURE, V395, P541, DOI 10.1038/26847; Gibbard SG, 1999, ICARUS, V139, P189, DOI 10.1006/icar.1999.6095; Griffith CA, 2000, SCIENCE, V290, P509, DOI 10.1126/science.290.5491.509; Griffith CA, 1998, NATURE, V395, P575, DOI 10.1038/26920; HIDAYAT T, 1998, ANN GEOPHYS, V16, pC988; HUYGENS C, 1722, CELESTIAL WORLDS DIS, P27; KOUVARIS LC, 1991, ICARUS, V91, P112, DOI 10.1016/0019-1035(91)90131-C; Lammer H, 2000, PLANET SPACE SCI, V48, P529, DOI 10.1016/S0032-0633(00)00043-X; LORENZ R, 1999, B AM ASTRON SOC, V31, P1137; LORENZ R, 1995, B AM ASTRON SOC, V27, P1107; Lorenz RD, 1999, PLANET SPACE SCI, V47, P1503, DOI 10.1016/S0032-0633(99)00038-0; LORENZ RD, 1993, PLANET SPACE SCI, V41, P647, DOI 10.1016/0032-0633(93)90048-7; LUNINE JI, 1987, ICARUS, V70, P61, DOI 10.1016/0019-1035(87)90075-3; Lunine JI, 1999, PLANET SPACE SCI, V47, P1291, DOI 10.1016/S0032-0633(99)00052-5; MCKAY CP, 1991, SCIENCE, V253, P1118, DOI 10.1126/science.11538492; Meier R, 2000, ICARUS, V145, P462, DOI 10.1006/icar.2000.6360; Owen TC, 2000, PLANET SPACE SCI, V48, P747, DOI 10.1016/S0032-0633(00)00040-4; Smith PH, 1996, ICARUS, V119, P336, DOI 10.1006/icar.1996.0023; WENKERT DD, 1987, B AM ASTRON SOC, V19, P875	20	41	41	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 20	2000	290	5491					467	468		10.1126/science.290.5491.467	http://dx.doi.org/10.1126/science.290.5491.467			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	365HN	11183770				2022-12-28	WOS:000089946000036
J	Aravind, L; Dixit, VM; Koonin, EV				Aravind, L; Dixit, VM; Koonin, EV			Apoptotic molecular machinery: Vastly increased complexity in vertebrates revealed by genome comparisons	SCIENCE			English	Article							EVOLUTIONARY INFORMATION; CELL-DEATH; PROTEINS; ACTIVATION; IDENTIFICATION; EUKARYOTES; DIVERGENCE; INHIBITOR; SEQUENCE; YEAST	A comparison of the proteins encoded in the recently (nearly) completed human genome to those from the fly and nematode genomes reveals a major increase in the complexity of the apoptotic molecular machinery in vertebrates, in terms of both the number of proteins involved and their domain architecture. Several components of the apoptotic system are shared by humans and flies, to the exclusion of nematodes, which seems to support the existence of a coelomate clade in animal evolution. A considerable repertoire of apoptotic protein domains was detected in Actinomycetes and Cyanobacteria, which suggests a major contribution of horizontal gene transfer to the early evolution of apoptosis.	Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Roche Holding; Genentech	Koonin, EV (corresponding author), Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.	koonin@ncbi.nlm.nih.gov	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Aravind, L/0000-0003-0771-253X				Ackerman SL, 1998, GENOMICS, V52, P205, DOI 10.1006/geno.1998.5425; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Aravind L, 2000, P NATL ACAD SCI USA, V97, P11319, DOI 10.1073/pnas.200346997; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Chinnaiyan Arul M., 1999, Neoplasia (New York), V1, P5; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Diez E, 2000, J IMMUNOL, V164, P1470, DOI 10.4049/jimmunol.164.3.1470; Eichinger A, 1999, EMBO J, V18, P5453, DOI 10.1093/emboj/18.20.5453; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HLAING T, IN PRESS J BIOL CHEM; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Kumar S, 1996, J MOL EVOL, V42, P183, DOI 10.1007/BF02198844; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rost B, 1997, J MOL BIOL, V270, P471, DOI 10.1006/jmbi.1997.1101; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	42	270	289	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	2001	291	5507					1279	+		10.1126/science.291.5507.1279	http://dx.doi.org/10.1126/science.291.5507.1279			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	402MX	11181990				2022-12-28	WOS:000166993400036
J	Letvin, NL; Bloom, BR; Hoffman, SL				Letvin, NL; Bloom, BR; Hoffman, SL			Prospects for vaccines to protect against AIDS, tuberculosis, and malaria	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; CYTOTOXIC T-LYMPHOCYTES; IMMUNE-RESPONSES; DNA; IMMUNIZATION; EFFICACY; VIREMIA; VACCINATION; INDUCTION; MORTALITY	Given the scope of the worldwide health problems caused by the acquired immunodeficiency syndrome, tuberculosis, and malaria, it is imperative that vaccines be developed to prevent these infections. Recent advances in the understanding of these diseases suggest that T-lymphocyte-mediated immunity is important in containing these infections. The application of novel vaccine technologies for eliciting this type of immunity promises to provide successful vaccines for controlling the spread of these deadly infections.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Viral Pathogenesis, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Off Dean, Boston, MA 02115 USA; USN, Med Res Ctr, Malaria Dept, Silver Spring, MD USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; United States Department of Defense; United States Navy	Letvin, NL (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Viral Pathogenesis, 41 Ave Louis Pasteur,Res E 113, Boston, MA 02115 USA.	nletvin@caregroup.harvard.edu						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Baily G V, 1980, Indian J Med Res, V72 Suppl, P1; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Bloom Barry R., 1994, P531; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; HART PD, 1967, BRIT MED J, V1, P587, DOI 10.1136/bmj.1.5540.587; Hoffman S L, 2000, Dev Biol (Basel), V104, P121; Hoffman SL, 1998, NAT MED, V4, P1351, DOI 10.1038/3934; Hoffman SL, 1996, MALARIA VACCINE DEV; Holder AA, 1981, NATURE, V294, P361, DOI 10.1038/294361a0; *JOINT UN PROGR HI, 2000, REP GLOB HIV AIDS EP; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kuroda MJ, 1999, J IMMUNOL, V162, P5127; Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875; Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; McKinney JD, 1998, BIOMED RES REP, P51; Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; *NIH, 2001, TUB VACC STAT OF THE; *NIH, 2001, BLUEPR TUB VACC DEV; NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SACHS JD, IN PRESS EC MALARIA; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Sedegah M, 2000, J IMMUNOL, V164, P5905, DOI 10.4049/jimmunol.164.11.5905; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; *WHO, 1994, WHOTB97179; World Health Organization, 2000, WORLD HLTH REP 2000; Young DB, 2000, CLIN INFECT DIS, V30, pS254, DOI 10.1086/313871	39	28	29	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					606	611		10.1001/jama.285.5.606	http://dx.doi.org/10.1001/jama.285.5.606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176867				2022-12-28	WOS:000166714200020
J	Endy, D; Brent, R				Endy, D; Brent, R			Modelling cellular behaviour	NATURE			English	Article							DIVISION INHIBITOR MINC; ESCHERICHIA-COLI; POLE OSCILLATION; GENE; CYTOPLASM; CYCLE; EXPRESSION; EVOLUTION; RHYTHMS; LAMBDA	Representations of cellular processes that can be used to compute their future behaviour would be of general scientific and practical value. But past attempts to construct such representations have been disappointing. This is now changing. Increases in biological understanding combined with advances in computational methods and in computer power make it possible to foresee construction of useful and predictive simulations of cellular processes.	Inst Mol Sci, Berkeley, CA 94704 USA	The Molecular Sciences Institute	Endy, D (corresponding author), Inst Mol Sci, 2168 Shattuck Ave, Berkeley, CA 94704 USA.			Endy, Drew/0000-0001-6952-8098				AHO AC, 1988, NATURE, V334, P348, DOI 10.1038/334348a0; Arkin A, 1998, GENETICS, V149, P1633; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; BLOCK SM, 1982, CELL, V31, P215, DOI 10.1016/0092-8674(82)90421-4; Branicky R, 2000, BIOESSAYS, V22, P48, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;48::AID-BIES9&gt;3.0.CO;2-F; Brent R, 2000, CELL, V100, P169, DOI 10.1016/S0092-8674(00)81693-1; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; COLMANLERNER A, 2000, TRENDS CELL BI S DEC, P56; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Endy D, 2000, P NATL ACAD SCI USA, V97, P5375, DOI 10.1073/pnas.090101397; Endy D, 1997, BIOTECHNOL BIOENG, V55, P375, DOI 10.1002/(SICI)1097-0290(19970720)55:2<375::AID-BIT15>3.0.CO;2-G; Endy D, 2000, ANTIMICROB AGENTS CH, V44, P1097, DOI 10.1128/AAC.44.4.1097-1099.2000; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Gibson MA, 2000, J PHYS CHEM A, V104, P1876, DOI 10.1021/jp993732q; GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3; Gillespie DT, 2000, J CHEM PHYS, V113, P297, DOI 10.1063/1.481811; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Hu ZL, 1999, MOL MICROBIOL, V34, P82, DOI 10.1046/j.1365-2958.1999.01575.x; HUTCHESON GD, 1996, SCI AM           JAN, P54; KANANYAN GK, 1980, GENETIKA+, V16, P2009; Kauffman S.A., 1993, ORIGINS ORDER; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; KOURILSKY P, 1973, MOL GEN GENET, V122, P183, DOI 10.1007/BF00435190; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Morton-Firth CJ, 1998, J THEOR BIOL, V192, P117, DOI 10.1006/jtbi.1997.0651; Raskin DM, 1999, J BACTERIOL, V181, P6419, DOI 10.1128/JB.181.20.6419-6424.1999; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Schmidt-Dannert C, 2000, NAT BIOTECHNOL, V18, P750, DOI 10.1038/77319; Soong NW, 2000, NAT GENET, V25, P436, DOI 10.1038/78132; STUDIER FW, 1979, VIROLOGY, V95, P70; SUSSMAN GJ, 1992, SCIENCE, V257, P56, DOI 10.1126/science.257.5066.56; TYSON JJ, 1991, P NATL ACAD SCI USA, V88, P7328, DOI 10.1073/pnas.88.16.7328; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WONG A, 1995, GENETICS, V139, P1247; Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	41	273	288	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2001	409	6818					391	395		10.1038/35053181	http://dx.doi.org/10.1038/35053181			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201753	Bronze			2022-12-28	WOS:000166434300061
J	Harrap, SB; Hopper, JL				Harrap, SB; Hopper, JL			Genetics of haemostasis	LANCET			English	Editorial Material							MENSTRUAL-CYCLE; WOMEN		Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia; Univ Melbourne, Ctr Genet Epidemiol, Parkville, Vic 3010, Australia	University of Melbourne; University of Melbourne	Harrap, SB (corresponding author), Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia.			Harrap, Stephen/0000-0003-2907-6714				Andersson O, 1997, THROMB HAEMOSTASIS, V77, P901; Harrap SB, 2000, AM J EPIDEMIOL, V152, P704, DOI 10.1093/aje/152.8.704; Hopper JL, 2000, ADV TWIN SIB PAIR AN, P151; Humphries S E, 1999, Blood Coagul Fibrinolysis, V10 Suppl 1, pS17; HUNT SC, 1989, AM J EPIDEMIOL, V129, P625, DOI 10.1093/oxfordjournals.aje.a115175; Kadir RA, 1999, THROMB HAEMOSTASIS, V82, P1456; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; MacGregor AJ, 2000, TRENDS GENET, V16, P131, DOI 10.1016/S0168-9525(99)01946-0; MOLL PP, 1979, GENETIC ANAL COMMON, P307; Oosthuizen W, 2000, EUR J CLIN NUTR, V54, P373, DOI 10.1038/sj.ejcn.1600966; PHILLIPS DIW, 1993, LANCET, V341, P1008, DOI 10.1016/0140-6736(93)91086-2; Souto JC, 2000, CIRCULATION, V101, P1546, DOI 10.1161/01.CIR.101.13.1546; STEVENSON ET, 1995, ARTERIOSCL THROM VAS, V15, P669, DOI 10.1161/01.ATV.15.5.669; Wartiovaara U, 2000, THROMB HAEMOSTASIS, V84, P595; Zito F, 2000, CIRCULATION, V102, P2058, DOI 10.1161/01.CIR.102.17.2058	15	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					83	84		10.1016/S0140-6736(00)03533-9	http://dx.doi.org/10.1016/S0140-6736(00)03533-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197439				2022-12-28	WOS:000166476200003
J	Tworetzky, W; Bristow, J; Moore, P; Brook, MM; Segal, MR; Brasch, RC; Hawgood, S; Fineman, JR				Tworetzky, W; Bristow, J; Moore, P; Brook, MM; Segal, MR; Brasch, RC; Hawgood, S; Fineman, JR			Inhaled nitric oxide in neonates with persistent pulmonary hypertension	LANCET			English	Article								To investigate the oxygenation and haemodynamic dose response to inhaled nitric oxide in neonates with persistent pulmonary hypertension (PPHN), we gave seven neonates nitric oxide and measured directly pulmonary arterial pressure. Inhaled nitric oxide produced peak improvement in oxygenation at 5 parts per million (ppm) whereas peak improvement in the pulmonary-to-systemic arterial pressure ratio did not occur until a nitric oxide dose of 20 ppm, which suggests that an initial dose of 20 ppm is optimum for the treatment of PPHN.	Univ Calif San Francisco, Med Ctr, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Fineman, JR (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Pediat, 505 Parnassus Ave,Box 0106, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR01271] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Finer NN, 1997, SEMIN PERINATOL, V21, P426, DOI 10.1016/S0146-0005(97)80008-0; FINER NN, 1994, J PEDIATR-US, V124, P302, DOI 10.1016/S0022-3476(94)70324-8; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; Kinsella J P, 1996, J Perinatol, V16, pS24; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X	5	36	37	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					118	120		10.1016/S0140-6736(00)03548-0	http://dx.doi.org/10.1016/S0140-6736(00)03548-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197402				2022-12-28	WOS:000166476200017
J	Podos, J				Podos, J			Correlated evolution of morphology and vocal signal structure in Darwin's finches	NATURE			English	Article							SPECIATION; SELECTION; SONG; PHYLOGENY; TRACT; RESPONSES; MOVEMENTS; BIRDSONG; SPARROWS	Speciation in many animal taxa is catalysed by the evolutionary diversification of mating signals(1). According to classical theories of speciation, mating signals diversify, in part, as an incidental byproduct of adaptation by natural selection to divergent ecologies(2,3), although empirical evidence in support of this hypothesis has been limited(4-6). Here I show, in Darwin's finches of the Galapagos Islands, that diversification of beak morphology and body size has shaped patterns of vocal signal evolution, such that birds with large beaks and body sizes have evolved songs with comparatively low rates of syllable repetition and narrow frequency bandwidths. The converse is true for small birds. Patterns of correlated evolution among morphology and song are consistent with the hypothesis that beak morphology constrains vocal evolution, with different beak morphologies differentially limiting a bird's ability to modulate vocal tract configurations during song production. These data illustrate how morphological adaptation may drive signal evolution and reproductive isolation, and furthermore identify a possible cause for rapid speciation in Darwin's finches.	Univ Arizona, Dept Ecol & Evolut Biol, Tucson, AZ 85721 USA	University of Arizona	Podos, J (corresponding author), Univ Arizona, Dept Ecol & Evolut Biol, Tucson, AZ 85721 USA.		Podos, Jeff/I-3843-2019	Podos, Jeffrey/0000-0002-2546-7999				Bowman R.I., 1983, P237; BOWMAN ROBERT I., 1961, UNIV CALIFORNIA PUBL ZOOL, V58, P1; CUTLER B, 1970, ANATOMICAL STUDIES S; Dobzhansky T., 1951, COPEIA; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Fletcher NH, 1999, J ACOUST SOC AM, V105, P35, DOI 10.1121/1.424620; GIBBS HL, 1987, NATURE, V327, P511, DOI 10.1038/327511a0; Grant BR, 1996, EVOLUTION, V50, P2471, DOI 10.1111/j.1558-5646.1996.tb03633.x; Grant P.R., 1999, RECOGNITION STATES L, V2; Grant PR, 1996, PHILOS T ROY SOC B, V351, P765, DOI 10.1098/rstb.1996.0071; GRANT PR, 1995, EVOLUTION, V49, P241, DOI 10.1111/j.1558-5646.1995.tb02236.x; Hoese WJ, 2000, J EXP BIOL, V203, P1845; MARTINS EP, 1999, COMPARE VERSION 4 2; Mayr E., 1963, ANIMAL SPECIES EVOLU; Mooers AO, 1999, AM NAT, V154, P249, DOI 10.1086/303226; NOWICKI S, 1987, NATURE, V325, P53, DOI 10.1038/325053a0; Nowicki Stephen, 1992, Seminars in the Neurosciences, V4, P385, DOI 10.1016/1044-5765(92)90046-5; Petren K, 1999, P ROY SOC B-BIOL SCI, V266, P321, DOI 10.1098/rspb.1999.0641; PODOS J, 1995, ANIM BEHAV, V50, P1287, DOI 10.1016/0003-3472(95)80044-1; Podos J, 1997, EVOLUTION, V51, P537, DOI 10.1111/j.1558-5646.1997.tb02441.x; Podos J, 1996, ANIM BEHAV, V51, P1061, DOI 10.1006/anbe.1996.0107; RATCLIFFE LM, 1985, ANIM BEHAV, V33, P290, DOI 10.1016/S0003-3472(85)80143-3; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Rundle HD, 2000, SCIENCE, V287, P306, DOI 10.1126/science.287.5451.306; RYAN MJ, 1985, AM NAT, V126, P87, DOI 10.1086/284398; Sato A, 1999, P NATL ACAD SCI USA, V96, P5101, DOI 10.1073/pnas.96.9.5101; SCHLUTER D, 1995, AM NAT, V146, P292, DOI 10.1086/285799; SCHLUTER D, 1985, SCIENCE, V227, P1056, DOI 10.1126/science.227.4690.1056; WESTEBERHARD MJ, 1983, Q REV BIOL, V58, P155, DOI 10.1086/413215; WESTNEAT MW, 1993, J EXP BIOL, V182, P147	30	512	526	1	352	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					185	188		10.1038/35051570	http://dx.doi.org/10.1038/35051570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196640				2022-12-28	WOS:000166316200042
J	Boushey, HA; Fahy, JV				Boushey, HA; Fahy, JV			Targeting cytokines in asthma therapy: round one	LANCET			English	Editorial Material							AIRWAY HYPERREACTIVITY; ALLERGIC-ASTHMA; MURINE MODEL; INFLAMMATION		Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Boushey, HA (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.							Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; Garlisi CG, 1999, AM J RESP CELL MOL, V20, P248, DOI 10.1165/ajrcmb.20.2.3327; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; Magone MT, 2000, J ALLERGY CLIN IMMUN, V105, P299, DOI 10.1016/S0091-6749(00)90080-0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 1998, ALLERGY, V53, P113, DOI 10.1111/j.1398-9995.1998.tb03858.x	11	34	34	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2114	2116		10.1016/S0140-6736(00)03486-3	http://dx.doi.org/10.1016/S0140-6736(00)03486-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191533				2022-12-28	WOS:000165997300004
J	Bosman, M; Mwinga, A				Bosman, M; Mwinga, A			Tropical diseases and the 10/90 gap	LANCET			English	Article									WHO, Stop TB Initiat, CH-1211 Geneva 27, Switzerland; Univ Teaching Hosp, Lusaka, Zambia; Royal Netherlands TB Assoc, The Hague, Netherlands; Minist Hlth, Tech TB Working Grp, Lusaka, Zambia	World Health Organization; University of Zambia	Bosman, M (corresponding author), WHO, Stop TB Initiat, CH-1211 Geneva 27, Switzerland.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S63	S63		10.1016/S0140-6736(00)92049-X	http://dx.doi.org/10.1016/S0140-6736(00)92049-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191523				2022-12-28	WOS:000166074900065
J	Golay, A				Golay, A			Treatment of obesity: mission possible	LANCET			English	Article									Univ Hosp Geneva, Div Therapeut Educ Chron Dis, CH-1211 Geneva 14, Switzerland	University of Geneva	Golay, A (corresponding author), Univ Hosp Geneva, Div Therapeut Educ Chron Dis, CH-1211 Geneva 14, Switzerland.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S42	S42		10.1016/S0140-6736(00)92028-2	http://dx.doi.org/10.1016/S0140-6736(00)92028-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191500	Bronze			2022-12-28	WOS:000166074900044
J	Hayes, TA				Hayes, TA			The pharmaceutical industry - To whom is it accountable?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											Hayes, TA (corresponding author), 98 Poplar Ridge, Grand Haven, MI 49417 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1416	1416						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183881				2022-12-28	WOS:000165152800017
J	Tunick, PA; Kronzon, I				Tunick, PA; Kronzon, I			Stroke in patients with asymptomatic internal-carotid-artery stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									NYU, Sch Med, New York, NY 10016 USA	New York University	Tunick, PA (corresponding author), NYU, Sch Med, New York, NY 10016 USA.							DEMOPOULOS LA, 1995, AM HEART J, V129, P40, DOI 10.1016/0002-8703(95)90040-3	1	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1421	1421						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183890				2022-12-28	WOS:000165152800029
J	Coburn, J; Leong, JM				Coburn, J; Leong, JM			Arresting features of bacterial toxins	SCIENCE			English	Editorial Material							CYTOLETHAL DISTENDING TOXIN; T-CELLS; PROTEIN; FAMILY		Tufts Univ, New England Med Ctr, Dept Med, Div Rheumatol & Immunol, Boston, MA 02111 USA; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	Tufts Medical Center; Tufts University; University of Massachusetts System; University of Massachusetts Worcester	Coburn, J (corresponding author), Tufts Univ, New England Med Ctr, Dept Med, Div Rheumatol & Immunol, Boston, MA 02111 USA.							Comayras C, 1997, INFECT IMMUN, V65, P5088, DOI 10.1128/IAI.65.12.5088-5095.1997; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Elwell CA, 2000, MOL MICROBIOL, V37, P952, DOI 10.1046/j.1365-2958.2000.02070.x; Gelfanova V, 1999, INFECT IMMUN, V67, P6394; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Pickett CL, 1999, TRENDS MICROBIOL, V7, P292, DOI 10.1016/S0966-842X(99)01537-1; Shenker BJ, 1999, J IMMUNOL, V162, P4773	7	5	5	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 13	2000	290	5490					287	288		10.1126/science.290.5490.287	http://dx.doi.org/10.1126/science.290.5490.287			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	363CW	11183375				2022-12-28	WOS:000089818100032
J	Friedman, MS; Powell, KE; Hutwagner, L; Graham, LM; Teague, WG				Friedman, MS; Powell, KE; Hutwagner, L; Graham, LM; Teague, WG			Impact of changes in transportation and commuting behaviors during the 1996 Summer Olympic Games in Atlanta on air quality and childhood asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL-FACTORS; HOSPITAL ADMISSIONS; RESPIRATORY HEALTH; UNITED-KINGDOM; MEXICO-CITY; POLLUTION; CHILDREN; OZONE; PREVALENCE; MORTALITY	Context Vehicle exhaust is a major source of ozone and other air pollutants. Although high ground-level ozone pollution is associated with transient increases in asthma morbidity, the impact of citywide transportation changes on air quality and childhood asthma has not been studied. The alternative transportation strategy implemented during the 1996 Summer Olympic Games in Atlanta, Ga, provided such an opportunity. Objective To describe traffic changes in Atlanta, Ca, during the 1996 Summer Olympic Games and concomitant changes in air quality and childhood asthma events. Design Ecological study comparing the 17 days of the Olympic Games (July 19-August 4, 1996) to a baseline period consisting of the 4 weeks before and 4 weeks after the Olympic Games. Setting and Subjects Children aged 1 to 16 years who resided in the 5 central counties of metropolitan Atlanta and whose data were captured in 1 of 4 databases. Main Outcome Measures Citywide acute care visits and hospitalizations for asthma (asthma events) and nonasthma events, concentrations of major air pollutants, meteorological variables, and traffic counts. Results During the Olympic Games, the number of asthma acute care events decreased 41.6% (4.23 vs 2.47 daily events) in the Georgia Medicaid claims file, 44.1% (1.36 vs 0.76 daily events) in a health maintenance organization database, 11.1% (4.77 vs 4.24 daily events) in 2 pediatric emergency departments, and 19.1% (2.04 vs 1.65 daily hospitalizations) in the Georgia Hospital Discharge Database. The number of nonasthma acute care events in the 4 databases changed -3.1%, +1.3%, -2.1%, and +1.0%, respectively. In multivariate regression analysis, only the reduction in asthma events recorded in the Medicaid database was significant (relative risk, 0.48; 95% confidence interval, 0.44-0.86). Peak daily ozone concentrations decreased 27.9%, from 81.3 ppb during the baseline period to 58.6 ppb during the Olympic Games (P<.001). Peak weekday morning traffic counts dropped 22.5% (P<.001). Traffic counts were significantly correlated with that day's peak ozone concentration (average r=0.36 for all 4 roads examined). Meteorological conditions during the Olympic Games did not differ substantially from the baseline period. Conclusions Efforts to reduce downtown traffic congestion in Atlanta during the Olympic Games resulted in decreased traffic density, especially during the critical morning period. This was associated with a prolonged reduction in ozone pollution and significantly lower rates of childhood asthma events. These data provide support for efforts to reduce air pollution and improve health via reductions in motor vehicle traffic.	Georgia Div Publ Hlth, Epidem Intelligence Serv, Atlanta, GA USA; Georgia Div Publ Hlth, Chron Dis Injury & Environm Epidemiol Sect, Epidemiol & Prevent Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA USA; Morehouse Sch Med, Dept Pediat, Atlanta, GA 30310 USA; Egleston Childrens Hosp, Div Pediat Pulm & Crit Care, Atlanta, GA USA; Georgia Pediat Pulm Associates, Atlanta, GA USA; Emory Univ, Atlanta, GA 30322 USA	Centers for Disease Control & Prevention - USA; Morehouse School of Medicine; Emory University	Friedman, MS (corresponding author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.	mff7@cdc.gov						Abramson M, 1996, J ASTHMA, V33, P189, DOI 10.3109/02770909609054551; ABRAMSON MJ, 1995, MED J AUSTRALIA, V163, P542, DOI 10.5694/j.1326-5377.1995.tb124724.x; Anderson HR, 1996, BMJ-BRIT MED J, V312, P665; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; AVOL EL, 1985, AM REV RESPIR DIS, V132, P619; Balagas R, 1996, IMPROVED AIR QUALITY; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; Becklake MR, 1997, LANCET, V350, P10; BRUNEKREEF B, 1995, ENVIRON HEALTH PERSP, V103, P3, DOI 10.2307/3432443; Buchdahl R, 1996, BRIT MED J, V312, P661; Busse W, 1995, ASTHMA RHINITIS; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P153; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, pSS1; *CDCP, 1993, MMWR-MORBID MORTAL W, V45, P350; *CDCP, 1995, MMWR-MORBID MORTAL W, V43, P952; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P908; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.2307/3434265; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223, DOI 10.1080/00039896.1994.9937471; Goren AI, 1997, J EPIDEMIOL COMMUN H, V51, P227, DOI 10.1136/jech.51.3.227; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; HAYES SR, 1991, J AIR WASTE MANAGE, V41, P161, DOI 10.1080/10473289.1991.10466833; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; Livingstone AE, 1996, BRIT MED J, V312, P676; *METR ATL RAP TRAN, 1996, WAY GAM REP MASS TRA; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MULLALLY DI, 1984, ANN ALLERGY, V53, P15; MURAKAMI M, 1990, Journal of Human Ergology, V19, P101; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; PORTER C, 1997, 833 NCHRP; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546, DOI 10.1093/oxfordjournals.aje.a117470; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300, DOI 10.1164/ajrccm.154.2.8756798; Samet J., 1999, AIR POLLUTION HLTH; SCHENKER M, 1993, NEW ENGL J MED, V329, P1807, DOI 10.1056/NEJM199312093292410; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; Tattersfield AE, 1996, THORAX, V51, P13, DOI 10.1136/thx.51.1.13; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654, DOI 10.1164/ajrccm.155.2.9032209; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798, DOI 10.1093/oxfordjournals.aje.a010280; *US EPA, 1992, EPA450K92002 US EPA; *US EPA, 1994, EPA451K94001 US EPA; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WJST M, 1993, BRIT MED J, V307, P596, DOI 10.1136/bmj.307.6904.596; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 2001, CLEAN AIR CAMPAIGN	45	378	386	2	101	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					897	905		10.1001/jama.285.7.897	http://dx.doi.org/10.1001/jama.285.7.897			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402BE	11180733	Bronze			2022-12-28	WOS:000166965500027
J	Lynn, J				Lynn, J			Serving patients who may die soon and their families - The role of hospice and other services	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; END; MANAGEMENT; HOUSE	case story of a 47-year-old man with advanced rectal carcinoma illustrates the professional services and care system strategies available to help clinicians serve patients coming to the end of life. For this patient, who understands his prognosis, primary care physician services include (1) prevention and relief of symptoms, (2) assessment of each treatment before and during implementation, (3) ensuring that the patient designates a surrogate decision-maker and makes advance plans, and (4) preparation of patient and family for the time near death. Good care may entail enduring unavoidably difficult times with patients and their families. Enrollment in a hospice program requires that decisionmakers confront the prognosis and their uncertainties about it, consider the desirability of other services, recognize variations among available hospice programs, address financial issues, and weigh the distress of patients and loved ones at being labeled as "dying." Hospice provides competent, continuous, and reasonably comprehensive care, but it has some constraints. Function and symptoms for those living with serious chronic illness at the end of life generally follow 1 of 3 trajectories: (a) a short period of obvious decline at the end, which is typical of cancer; (b) long-term disability, with periodic exacerbations, and unpredictable timing of death, which characterizes dying with chronic organ system failures; or (c) self-care deficits and a slowly dwindling course to death, which usually results from frailty or dementia. Effective and reliable care for persons coming to the end of life will require changes in the organization and financing of care to match these trajectories, as well as compassionate and skillful clinicians.	RAND Corp, Ctr Improve Care Dying, Arlington, VA 22202 USA	RAND Corporation	Lynn, J (corresponding author), RAND Corp, Ctr Improve Care Dying, 1200 S Hayes St, Arlington, VA 22202 USA.							BUCKMAN R, 1993, BREAK BAD NEWS GUIDE; Buckman R, 1998, BREAK BAD NEWS PATIE, P203; Corr C A, 1994, Crit Care Nurs Clin North Am, V6, P545; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; DEPARLE L, 2000, COMMUNICATION   0912; Du Pen SL, 1999, J CLIN ONCOL, V17, P361, DOI 10.1200/JCO.1999.17.1.361; Field MJ, 1997, APPROACHING DEATH IM; FWLER NM, 2000, J PALLIAT MED, V3, P165; Gage B., 2000, IMPORTANT QUESTIONS; GAGE B, 2000, MEDICARES HOSPICE BE; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; *HLTH CAR FIN ADM, 2000, OV MED PROGR; *HLTH CAR FIN ADM, 2000, MED HOSP BEN SPEC CA; *HLTH CAR FIN ADM, 2000, HOSP MAN, pCH4; HOGAN C, 2000, MEDICARE BENEFICIARI; HUSKAMP H, IN PRESS HLTH AFF MI; KIDDER D, 1992, HEALTH SERV RES, V27, P195; Lee W, 1998, GERIATRICS, V53, P62; LEWIN LS, 1995, ANAL COST SAVINGS ME; LORENZ K, 2000, 12 ANN ASS AM AC HOS; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, New Horiz, V5, P56; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; Lynn J, 1997, JAMA-J AM MED ASSOC, V277, P1633, DOI 10.1001/jama.277.20.1633; Lynn J, 1998, J Palliat Med, V1, P337, DOI 10.1089/jpm.1998.1.337; Lynn J, 2000, Jt Comm J Qual Improv, V26, P254; Lynn J, 1999, J AM GERIATR SOC, V47, P1058, DOI 10.1111/j.1532-5415.1999.tb05227.x; LYNN J, 1999, HDB MORTALS GUIDANCE; LYNN J, 2000, IMPROVING CARE END L; *MED EC CO, 2000, 2000 DRUG TOP RED BO; *MISS DEM PROJ, 2000, MISS DEM PROJ QUAL L; *NAT CTR HLTH STAT, 2000, BIRTHS MARR DIV DEAT; *NAT ELD REF SYST, 2000, COST NURS HOM CAR; *NAT HOSP ORG, 2000, MED GUID DET PROGN S; *NAT HOSP PALL CAR, 2000, FACTS FIG HOSP CAR A; National Health and Medical Research Council and the Australian Research Council, 1999, NAT GAMBL IMP STUD C, P6; Pantilat SZ, 1999, JAMA-J AM MED ASSOC, V282, P171, DOI 10.1001/jama.282.2.171; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Rich MW, 1999, J CARD FAIL, V5, P64, DOI 10.1016/S1071-9164(99)90026-X; Sachs GA, 2000, JAMA-J AM MED ASSOC, V284, P2423, DOI 10.1001/jama.284.19.2423; SAMUELSON RJ, 1995, DETROIT NEWS    0813; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285; *US GEN ACC OFF, 2000, MED BEN US HOSP FEW; WILKINSON A, 1999, J HLTH CARE LAW POLI, V12, P501; WILKINSON AM, 2000, CRITICAL ISSUES AGIN	46	193	196	2	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					925	932		10.1001/jama.285.7.925	http://dx.doi.org/10.1001/jama.285.7.925			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	402BE	11180736				2022-12-28	WOS:000166965500030
J	Prutkin, JM				Prutkin, JM			Cybermedical skills for the Internet age	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Yale Univ, Sch Med, New Haven, CT 06520 USA	Yale University	Prutkin, JM (corresponding author), Yale Univ, Sch Med, New Haven, CT 06520 USA.							Biermann JS, 1999, CANCER, V86, P381, DOI 10.1002/(SICI)1097-0142(19990801)86:3<381::AID-CNCR4>3.3.CO;2-7; Hamadeh H, 2000, AM SCI, V88, P508, DOI 10.1511/2000.41.874; Institute of Medicine, 1996, TEL GUID ASS TEL HLT; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; Powsner SM, 1998, LANCET, V352, P1617, DOI 10.1016/S0140-6736(98)08309-3; Spielberg AR, 1998, JAMA-J AM MED ASSOC, V280, P1353, DOI 10.1001/jama.280.15.1353	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					808	808		10.1001/jama.285.6.808	http://dx.doi.org/10.1001/jama.285.6.808			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176925				2022-12-28	WOS:000166817200043
J	Alley, RB				Alley, RB			The key to the past?	NATURE			English	Editorial Material									Penn State Univ, Inst Environm, University Pk, PA 16802 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Alley, RB (corresponding author), Penn State Univ, Inst Environm, 204A Deike Bldg, University Pk, PA 16802 USA.							Alley R., 2000, 2 MILE TIME MACHINE	1	7	7	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					289	289		10.1038/35053245	http://dx.doi.org/10.1038/35053245			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201719	Bronze			2022-12-28	WOS:000166434300022
J	Schrag, DP; Hoffman, PF				Schrag, DP; Hoffman, PF			Geophysics - Life, geology and snowball Earth	NATURE			English	Article							GLACIATION		Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	Harvard University	Schrag, DP (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.							BUDYKO MI, 1969, TELLUS, V21, P611, DOI 10.3402/tellusa.v21i5.10109; CALDEIRA K, 1992, NATURE, V359, P226, DOI 10.1038/359226a0; Fairchild I. J., 1993, SEDIMENTOLOGY REV, V1, P1; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hyde WT, 2000, NATURE, V405, P425, DOI 10.1038/35013005; Kennedy MJ, 1996, J SEDIMENT RES, V66, P1050, DOI 10.2110/jsr.66.1050; McKay CP, 2000, GEOPHYS RES LETT, V27, P2153, DOI 10.1029/2000GL008525; Runnegar B, 2000, NATURE, V405, P403, DOI 10.1038/35013168; Sohl LE, 1999, GEOL SOC AM BULL, V111, P1120, DOI 10.1130/0016-7606(1999)111<1120:PPRIMC>2.3.CO;2	9	44	49	6	37	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					306	306		10.1038/35053170	http://dx.doi.org/10.1038/35053170			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201731	Bronze			2022-12-28	WOS:000166434300035
J	Freeman, C; Ostle, N; Kang, H				Freeman, C; Ostle, N; Kang, H			An enzymic 'latch' on a global carbon store - A shortage of oxygen locks up carbon in peatlands by restraining a single enzyme.	NATURE			English	Article							ORGANIC-MATTER; PHENOLIC MATERIALS; ECOSYSTEMS; WATER; SOIL		Univ Coll N Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales	Bangor University	Freeman, C (corresponding author), Univ Coll N Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales.		Ostle, Nick J/K-6891-2012; Ostle, Nicholas J/E-4847-2014; Kang, Hojeong/C-7208-2011	Ostle, Nicholas J/0000-0003-3263-3702; 				CARPENTER A, 1976, ANAL CHEM, V48, P225, DOI 10.1021/ac60365a067; Freeman C., 1993, CHEM ECOL, V8, P49, DOI DOI 10.1080/02757549308035300; GORHAM E, 1991, ECOL APPL, V1, P182, DOI 10.2307/1941811; Kang HJ, 1999, SOIL BIOL BIOCHEM, V31, P449, DOI 10.1016/S0038-0717(98)00150-3; Lee SS, 1999, ASIAN AUSTRAL J ANIM, V12, P988, DOI 10.5713/ajas.1999.988; McLatchey GP, 1998, J ENVIRON QUAL, V27, P1268, DOI 10.2134/jeq1998.00472425002700050036x; MITCHELL JFB, 1987, NATURE, V330, P238, DOI 10.1038/330238a0; NYBROE O, 1992, WATER RES, V26, P579, DOI 10.1016/0043-1354(92)90230-2; OECHEL WC, 1993, NATURE, V361, P520, DOI 10.1038/361520a0; PAINTER TJ, 1991, CARBOHYD POLYM, V15, P123, DOI 10.1016/0144-8617(91)90028-B; PIND A, 1994, PLANT SOIL, V159, P227, DOI 10.1007/BF00009285; Vuorinen AH, 1996, SOIL BIOL BIOCHEM, V28, P1477, DOI 10.1016/S0038-0717(96)00166-6; WETZEL RG, 1992, HYDROBIOLOGIA, V229, P181, DOI 10.1007/BF00007000	13	793	848	28	496	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					149	149		10.1038/35051650	http://dx.doi.org/10.1038/35051650			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196627				2022-12-28	WOS:000166316200028
J	Bacchetti, P				Bacchetti, P			Unexamined assumptions in explorations of upper limit for cases of variant Creutzfeldt-Jakob disease	LANCET			English	Editorial Material							INCUBATION PERIOD; AIDS; INFECTION; EPIDEMIC		Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bacchetti, P (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.							BACCHETTI P, 1993, STAT SCI, V8, P82, DOI 10.1214/ss/1177010994; BACCHETTI P, 1990, J AM STAT ASSOC, V85, P1002, DOI 10.2307/2289596; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BROOKMEYER R, 1986, LANCET, V2, P1320; *CJD SURV UN, 2000, CJD STAT; COOPER JD, 2000, J EPIDEMIOL BIOSTAT, V4, P209; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; Donnelly C. A., 2000, STAT ASPECTS BSE VCJ; Ghani AC, 2000, NATURE, V406, P583, DOI 10.1038/35020688; Ironside JW, 2000, LANCET, V355, P1693, DOI 10.1016/S0140-6736(00)02243-1; Verity CM, 2000, LANCET, V356, P1224, DOI 10.1016/S0140-6736(00)02785-9	11	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					3	4		10.1016/S0140-6736(00)03559-5	http://dx.doi.org/10.1016/S0140-6736(00)03559-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197358				2022-12-28	WOS:000166341500003
J	Colley, NJ				Colley, NJ			Cell biology - Actin up with Rac1	SCIENCE			English	Editorial Material							RETINITIS-PIGMENTOSA; RHO-GTPASES; MOLECULAR-GENETICS; P115 RHOGEF; G-PROTEINS; G-ALPHA(13); DROSOPHILA; VISION		Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Colley, NJ (corresponding author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.	njcolley@facstaff.wisc.edu			NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008768] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; Chang HY, 2000, SCIENCE, V290, P1978, DOI 10.1126/science.290.5498.1978; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LEONARD DS, 1992, J NEUROBIOL, V23, P605, DOI 10.1002/neu.480230602; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WILLIAMS DS, 1991, BIOESSAYS, V13, P171, DOI 10.1002/bies.950130405; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	19	11	13	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	2000	290	5498					1902	1903		10.1126/science.290.5498.1902	http://dx.doi.org/10.1126/science.290.5498.1902			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11187046				2022-12-28	WOS:000165810000029
J	Eke, N				Eke, N			Female genital mutilation: what can be done?	LANCET			English	Article											Eke, N (corresponding author), 27 Old Aba Rd,POB 5575, Port Harcourt, Nigeria.								0	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S57	S57		10.1016/S0140-6736(00)92043-9	http://dx.doi.org/10.1016/S0140-6736(00)92043-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191516	Bronze			2022-12-28	WOS:000166074900059
J	Marteau, P				Marteau, P			Role of the intestinal flora in gastrointestinal diseases	LANCET			English	Article									Hop Europeen Georges Pompidou, Serv Hepatogastroenterol, F-75908 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Marteau, P (corresponding author), Hop Europeen Georges Pompidou, Serv Hepatogastroenterol, F-75908 Paris, France.			philippe, marteau/0000-0002-7621-6719					0	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S28	S28		10.1016/S0140-6736(00)92014-2	http://dx.doi.org/10.1016/S0140-6736(00)92014-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191484				2022-12-28	WOS:000166074900030
J	Rosenthal, D; Dowsett, G				Rosenthal, D; Dowsett, G			The changing perceptions of sex and sexuality	LANCET			English	Article									La Trobe Univ, Fac Hlth Sci, Melbourne, Vic, Australia	La Trobe University	Rosenthal, D (corresponding author), La Trobe Univ, Fac Hlth Sci, Melbourne, Vic, Australia.			Dowsett, Gary W./0000-0002-0841-3964					0	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S58	S58		10.1016/S0140-6736(00)92044-0	http://dx.doi.org/10.1016/S0140-6736(00)92044-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191517				2022-12-28	WOS:000166074900060
J	Hoffman, SL				Hoffman, SL			Infectious disease - Research (genomics) is crucial to attacking malaria	SCIENCE			English	Article									USN, Med Res Ctr, Silver Spring, MD 20910 USA	United States Department of Defense; United States Navy	Hoffman, SL (corresponding author), USN, Med Res Ctr, Silver Spring, MD 20910 USA.							EDELMAN R, 1993, J INFECT DIS, V168, P1066, DOI 10.1093/infdis/168.4.1066; GALLUP JL, 1998, EC BURDEN MALARIA; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7	4	18	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1509	1509		10.1126/science.290.5496.1509	http://dx.doi.org/10.1126/science.290.5496.1509			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11185508				2022-12-28	WOS:000165446200023
J	Goldstein, LB; Howard, G				Goldstein, LB; Howard, G			Stroke in patients with asymptomatic internal-carotid-artery stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Duke Univ, Durham, NC 27710 USA; Univ Alabama, Birmingham, AL 35254 USA	Duke University; University of Alabama System; University of Alabama Birmingham	Goldstein, LB (corresponding author), Duke Univ, Durham, NC 27710 USA.			Howard, George/0000-0002-3068-5720				Barnett HJM, 2000, JAMA-J AM MED ASSOC, V283, P1429, DOI 10.1001/jama.283.11.1429; Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302; SACKETT DL, 1986, CHEST S, V89, P2; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035	4	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1420	1420						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183889				2022-12-28	WOS:000165152800027
J	Vandenbroucke, JP				Vandenbroucke, JP			In defense of case reports and case series	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ACTIVATED PROTEIN-C; FACTOR-V-LEIDEN; PULMONARY-EMBOLISM; VENOUS THROMBOEMBOLISM; ANTIPSYCHOTIC-DRUGS; RISK; RESISTANCE; DISCOVERY; DEAFNESS; WOMEN	Case reports and case series have their own role in the progress of medical science. They permit discovery of new diseases and unexpected effects (adverse or beneficial) as well as the study of mechanisms, and they play an important role in medical education. Case reports and series have a high sensitivity for detecting novelty and therefore remain one of the cornerstones of medical progress; they provide many new ideas in medicine. At the same time, good case reporting demands a clear focus to make explicit to the audience why a particular observation is important In the context of existing knowledge.	Leiden Univ Hosp, Dept Clin Epidemiol, Med Ctr, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC)	Vandenbroucke, JP (corresponding author), Leiden Univ Hosp, Dept Clin Epidemiol, Med Ctr, Box 9600, NL-2300 RC Leiden, Netherlands.	vdbroucke@mail.medfac.leidenuniv.nl	Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				[Anonymous], 1999, LANCET, V354, P1221, DOI 10.1016/S0140-6736(99)00177-4; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; Bassetti C, 2000, LANCET, V356, P484, DOI 10.1016/S0140-6736(00)02561-7; BEGAUD B, 1994, BRIT J CLIN PHARMACO, V38, P401, DOI 10.1111/j.1365-2125.1994.tb04373.x; Bounameaux H, 2000, LANCET, V356, P182, DOI 10.1016/S0140-6736(00)02476-4; CHALMERS I, 1989, EFFECTIVE CARE PREGN, P3; Covey LS, 2000, DRUGS, V59, P17, DOI 10.2165/00003495-200059010-00003; Dahlback B, 1995, ADV GENET, V33, P135, DOI 10.1016/S0065-2660(08)60333-8; DEANA DG, 1995, AM J SURG PATHOL, V19, P454, DOI 10.1097/00000478-199504000-00007; Desmarais S, 1996, LANCET, V347, P1374, DOI 10.1016/S0140-6736(96)91013-2; FAGOTLARGEAULT A, 1989, CAUSES MORT HIST NAT; Friedman MA, 1999, JAMA-J AM MED ASSOC, V281, P1728, DOI 10.1001/jama.281.18.1728; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; GOODWIN JS, 1991, PERSPECT BIOL MED, V35, P20; Hoffman JR, 1999, WESTERN J MED, V170, P253; Jenicek M, 1999, CLIN CASE REPORTING, P117; Kern DG, 1998, ANN INTERN MED, V129, P261, DOI 10.7326/0003-4819-129-4-199808150-00001; LEE JAH, 1985, EPIDEMIOLOGY QUANTIT, P307; Lennox BR, 1999, LANCET, V353, P644, DOI 10.1016/S0140-6736(98)05923-6; Oosterkamp HM, 1998, BRIT J HAEMATOL, V103, P315; Parsonnet J, 1999, JAMA-J AM MED ASSOC, V282, P2240, DOI 10.1001/jama.282.23.2240; POPPER K, 1972, GROWTH SCI KNOWLEDGE, P47; Sackett DL, 1997, BRIT MED J, V315, P1636, DOI 10.1136/bmj.315.7123.1636; Tapson VF, 2000, LANCET, V356, P1206, DOI 10.1016/S0140-6736(00)02776-8; Thomassen R, 2000, LANCET, V356, P252, DOI 10.1016/S0140-6736(05)74502-5; TUBERT P, 1992, J CLIN EPIDEMIOL, V45, P283, DOI 10.1016/0895-4356(92)90088-5; Vandenbroucke JP, 1998, THROMB HAEMOSTASIS, V79, P511; Vandenbroucke JP, 1999, J ROY SOC MED, V92, P159, DOI 10.1177/014107689909200401; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VENNING GR, 1982, BMJ-BRIT MED J, V284, P249, DOI 10.1136/bmj.284.6311.249; Zornberg GL, 2000, LANCET, V356, P1219, DOI 10.1016/S0140-6736(00)02784-7	31	315	335	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					330	334		10.7326/0003-4819-134-4-200102200-00017	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00017			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NW	11182844				2022-12-28	WOS:000167050200009
J	Hilbert, G; Gruson, D; Vargas, F; Valentino, R; Gbikpi-Benissan, G; Dupon, M; Reiffers, J; Cardinaud, JP				Hilbert, G; Gruson, D; Vargas, F; Valentino, R; Gbikpi-Benissan, G; Dupon, M; Reiffers, J; Cardinaud, JP			Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE-PRESSURE VENTILATION; INTENSIVE-CARE-UNIT; MECHANICAL VENTILATION; NEUTROPENIC PATIENTS; SUPPORT VENTILATION; MALIGNANCIES; TRANSPLANTATION; COMPLICATIONS; MASK	Background: Avoiding intubation is a major goal in the management of respiratory failure, particularly in immunosuppressed patients. Nevertheless, there are only limited data on the efficacy of noninvasive ventilation in these high-risk patients. Methods: We conducted a prospective, randomized trial of intermittent noninvasive ventilation, as compared with standard treatment with supplemental oxygen and no ventilatory support, in 52 immunosuppressed patients with pulmonary infiltrates, fever, and an early stage of hypoxemic acute respiratory failure. Periods of noninvasive ventilation delivered through a face mask were alternated every three hours with periods of spontaneous breathing with supplemental oxygen. The ventilation periods lasted at least 45 minutes. Decisions to intubate were made according to standard, predetermined criteria. Results: The base-line characteristics of the two groups were similar; each group of 26 patients included 15 patients with hematologic cancer and neutropenia. Fewer patients in the noninvasive-ventilation group than in the standard-treatment group required endotracheal intubation (12 vs. 20, P=0.03), had serious complications (13 vs. 21, P=0.02), died in the intensive care unit (10 vs. 18, P=0.03), or died in the hospital (13 vs. 21, P=0.02). Conclusions: In selected immunosuppressed patients with pneumonitis and acute respiratory failure, early initiation of noninvasive ventilation is associated with significant reductions in the rates of endotracheal intubation and serious complications and an improved likelihood of survival to hospital discharge. (N Engl J Med 2001;344:481-7.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Hosp, Div Med Intens Care, Bordeaux, France; Univ Hosp, Dept Med & Infect Dis, Bordeaux, France; Univ Hosp, Dept Hematol, Bordeaux, France	CHU Bordeaux; CHU Bordeaux; CHU Bordeaux	Hilbert, G (corresponding author), Hop Pellegrin, F-33076 Bordeaux, France.	gilles.hilbert@chu-bordeaux.fr						Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; Antonelli M, 2000, JAMA-J AM MED ASSOC, V283, P235, DOI 10.1001/jama.283.2.235; Blot F, 1997, EUR J CANCER, V33, P1031, DOI 10.1016/S0959-8049(97)00042-7; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Conti G, 1998, INTENS CARE MED, V24, P1283, DOI 10.1007/s001340050763; CRAWFORD SW, 1988, AM REV RESPIR DIS, V137, P682, DOI 10.1164/ajrccm/137.3.682; ESTOPA R, 1984, CRIT CARE MED, V12, P26, DOI 10.1097/00003246-198401000-00007; Ewig S, 1998, EUR RESPIR J, V12, P116, DOI 10.1183/09031936.98.12010116; FANTA CH, 1989, RESPIRATORY INFECTIO, P221; Gruson D, 2000, CRIT CARE MED, V28, P2224, DOI 10.1097/00003246-200007000-00007; Guerin C, 1997, INTENS CARE MED, V23, P1024, DOI 10.1007/s001340050452; Hilbert G, 1997, INTENS CARE MED, V23, P955, DOI 10.1007/s001340050438; Hilbert G, 1998, EUR RESPIR J, V11, P1349, DOI 10.1183/09031936.98.11061349; Hilbert G, 2000, CRIT CARE MED, V28, P3185, DOI 10.1097/00003246-200009000-00012; Keenan SP, 1997, CRIT CARE MED, V25, P1685, DOI 10.1097/00003246-199710000-00018; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MASUR H, 1985, JAMA-J AM MED ASSOC, V253, P1769, DOI 10.1001/jama.253.12.1769; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; Meduri GU, 1998, LUNG BIOL HEALTH DIS, V118, P921; OGNIBENE FP, 1986, NEW ENGL J MED, V315, P547, DOI 10.1056/NEJM198608283150904; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; Rubenfeld GD, 1996, ANN INTERN MED, V125, P625, DOI 10.7326/0003-4819-125-8-199610150-00001; Stauffer JL, 1994, PRINCIPLES PRACTICE, P711; TEASDALE G, 1974, LANCET, V2, P81; Tognet E, 1994, Clin Intensive Care, V5, P282	28	738	777	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 15	2001	344	7					481	487		10.1056/NEJM200102153440703	http://dx.doi.org/10.1056/NEJM200102153440703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401HL	11172189				2022-12-28	WOS:000166922100003
J	Cohen, LG				Cohen, LG			Tactile	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					703	703		10.1001/jama.285.6.703	http://dx.doi.org/10.1001/jama.285.6.703			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176885				2022-12-28	WOS:000166817200001
J	Patsos, M				Patsos, M			The Internet and medicine: Building a community for patients with rare diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Isselbacher E, 1997, HEART DIS TXB CARDIO, P1546; LICHTENBURG GC, 1996, INT THESAURUS QUOTAT, P102	2	18	18	2	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					805	805		10.1001/jama.285.6.805	http://dx.doi.org/10.1001/jama.285.6.805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176922				2022-12-28	WOS:000166817200040
J	Schwetz, BA				Schwetz, BA			New anticoagulant approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Off Commissioner Food & Drugs, Rockville, MD 20857 USA		Schwetz, BA (corresponding author), Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					724	724		10.1001/jama.285.6.724-a	http://dx.doi.org/10.1001/jama.285.6.724-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176890				2022-12-28	WOS:000166817200006
J	Blumberg, RS; Strober, W				Blumberg, RS; Strober, W			Prospects for research in inflammatory bowel disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CROHNS-DISEASE; ULCERATIVE-COLITIS; MICE; INTERLEUKIN-12; ANTIBODIES; CELLS; ALPHA	Inflammatory bowel disease is a chronic inflammatory condition of the gastrointestinal tract that manifests as ulcerative colitis and Crohn disease. Both these clinical entities result from interrelated genetic and environmental factors that may be channeled through an abnormality in mucosal immune function, possibly due to dysregulated or excessive T helper cell (T-H)1 (Crohn disease) or T(H)2 (ulcerative colitis) responses. This article reviews current knowledge of the role of immune factors in inflammatory bowel disease and the potential therapeutic strategies that target the pathways of T(H)1- or T(H)2-induced inflammation.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol, Boston, MA 02115 USA; NIH, Mucosal Immun Sect, Bethesda, MD USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA	Blumberg, RS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000354, Z01AI000354] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andres PG, 1999, GASTROENTEROL CLIN N, V28, P255, DOI 10.1016/S0889-8553(05)70056-X; Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952-7915(99)00032-1; Boirivant M, 1998, J EXP MED, V188, P1929, DOI 10.1084/jem.188.10.1929; Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Friedman S, HARRISONS PRINCIPLES, V20; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Gionchetti P, 2000, GASTROENTEROLOGY, V119, P305, DOI 10.1053/gast.2000.9370; HAY JW, 1992, J CLIN GASTROENTEROL, V14, P309, DOI 10.1097/00004836-199206000-00009; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HOLLANDER GA, 1995, IMMUNITY, V3, P27, DOI 10.1016/1074-7613(95)90156-6; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Ludviksson BR, 1997, J IMMUNOL, V159, P3622; Mizoguchi A, 1996, J EXP MED, V183, P847, DOI 10.1084/jem.183.3.847; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; MORDSSEY PJ, 1993, J EXP MED, V178, P237; Nakajima A, 1996, J IMMUNOL, V157, P5683; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; Probert CS, 1996, J IMMUNOL, V157, P3183; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; SHANAHAN F, 1992, GASTROENTEROLOGY, V103, P456, DOI 10.1016/0016-5085(92)90834-L; Soderholm JD, 1999, GASTROENTEROLOGY, V117, P65, DOI 10.1016/S0016-5085(99)70551-2; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; TARGAN SR, IN PRESS INFLAMMATOR	25	109	125	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					643	647		10.1001/jama.285.5.643	http://dx.doi.org/10.1001/jama.285.5.643			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176874	Bronze			2022-12-28	WOS:000166714200027
J	Hu, FB; Stampfer, MJ; Solomon, C; Liu, SM; Colditz, GA; Speizer, FE; Willett, WC; Manson, JE				Hu, FB; Stampfer, MJ; Solomon, C; Liu, SM; Colditz, GA; Speizer, FE; Willett, WC; Manson, JE			Physical activity and risk for cardiovascular events in diabetic women	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; CARDIORESPIRATORY FITNESS; LOGISTIC-REGRESSION; INSULIN SENSITIVITY; LIFE-STYLE; EXERCISE; WALKING; WEIGHT; MORTALITY; MELLITUS	Background: increased physical activity has been associated with reduced risk for cardiovascular disease in the general population, but data are limited on its role among persons with type 2 diabetes mellitus. Objective: To determine whether physical activity decreases risk for cardiovascular disease among diabetic women. Design: Prospective cohort study. Setting: The Nurses' Health Study. Patients: 5125 female nurses with diabetes. Measurements: Physical activity was first assessed in 1980 and was updated in 1982, 1986, 1988, and 1992 through validated questionnaires. Average hours of moderate or vigorous exercise and a metabolic equivalent of task (MET) score were computed. Results: During 14 years of follow-up (31 432 person-years), 323 new cases of cardiovascular disease were documented (225 cases of coronary heart disease and 98 cases of stroke). The age-adjusted relative risks according to average hours of moderate or vigorous activity per week (<1, 1 to 1.9, 2 to 3.9, 4 to 6.9, <greater than or equal to>7) were 1.0, 0.93 (95% CI, 0.69 to 1.26), 0.82 (CI, 0.61 to 1.10), 0.54 (CI, 0.39 to 0.76), and 0.52 (CI, 0.25 to 1.09) (P < 0.001 for trend). These figures did not change materially after adjustment for smoking, body mass index, and other cardiovascular risk factors (1.0, 1.02, 0.87, 0.61, and 0.55, respectively; P = 0.001 for trend). In separate analyses, levels of physical activity were inversely associated with coronary heart disease and ischemic stroke. Among women who did not exercise vigorously, the multivariate relative risks for cardiovascular disease across quartiles of MET score for walking were 1.0, 0.85, 0.63, and 0.56 (P = 0.03 for trend). Faster usual walking pace was independently associated with lower risk. Conclusion: Among diabetic women, increased physical activity, including regular walking, is associated with substantially reduced risk for cardiovascular events.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	Frank.hu@channing.harvard.edu	Liu, Simin/I-3689-2014; Hu, Frank/C-1919-2013; Colditz, Graham/A-3963-2009; Liu, Simin/GSN-4159-2022	Liu, Simin/0000-0003-2098-3844; Colditz, Graham/0000-0002-7307-0291; 	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; NIDDK NIH HHS [DK 36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH BE, 1993, J CLIN EPIDEMIOL, V46, P1403, DOI 10.1016/0895-4356(93)90140-V; AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; *AM DIAB ASS, DIAB FACTS FIG; Andersen RE, 1999, JAMA-J AM MED ASSOC, V281, P335, DOI 10.1001/jama.281.4.335; ANNUZZI G, 1991, EUR J CLIN INVEST, V21, P6, DOI 10.1111/j.1365-2362.1991.tb01351.x; [Anonymous], 1996, JAMA, V276, P241; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; Bray GA, 1999, DIABETES CARE, V22, P623; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DEVLIN JT, 1992, DIABETES CARE, V15, P1690, DOI 10.2337/diacare.15.11.1690; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; Eriksson JG, 1999, SPORTS MED, V27, P381, DOI 10.2165/00007256-199927060-00003; FORD ES, 1991, AM J EPIDEMIOL, V133, P1220, DOI 10.1093/oxfordjournals.aje.a115834; Gavin JR, 1997, DIABETES CARE, V20, P1183; GOODYEAR LJ, 1992, MED SPORT SCI, V37, P201; Halle M, 1999, METABOLISM, V48, P641, DOI 10.1016/S0026-0495(99)90064-1; HARRIS M, 1979, DIABETES, V28, P1039; Henriksson J, 1995, J Cardiovasc Risk, V2, P303, DOI 10.1097/00043798-199508000-00004; Hosmer DW, 1997, STAT MED, V16, P965; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433; LEHMANN R, 1995, DIABETOLOGIA, V38, P1313; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MANSON JE, 1996, PREVENTION MYOCARDIA; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; ROSE GA, 1982, WHO MONOGRAPH, V56; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Walker KZ, 1999, DIABETES CARE, V22, P555, DOI 10.2337/diacare.22.4.555; Wei M, 2000, ANN INTERN MED, V132, P605, DOI 10.7326/0003-4819-132-8-200004180-00002; WING RR, 1988, DIABETOLOGIA, V31, P902; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; YAMANOUCHI K, 1995, DIABETES CARE, V18, P775, DOI 10.2337/diacare.18.6.775; Zinman B, 1997, DIABETES CARE, V20, P1908	34	265	275	1	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2001	134	2					96	105		10.7326/0003-4819-134-2-200101160-00009	http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391KW	11177312				2022-12-28	WOS:000166356000002
J	Wahid, S; Ball, S				Wahid, S; Ball, S			Clinical picture: The pituitary gland and hereditary haemochromatosis	LANCET			English	Article									Univ Newcastle Upon Tyne, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Wahid, S (corresponding author), Univ Newcastle Upon Tyne, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.								0	4	4	2	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					115	115		10.1016/S0140-6736(00)03544-3	http://dx.doi.org/10.1016/S0140-6736(00)03544-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197399	Bronze			2022-12-28	WOS:000166476200014
J	Arnold, FH				Arnold, FH			Combinatorial and computational challenges for biocatalyst design	NATURE			English	Review							DIRECTED EVOLUTION; SUBSTRATE-SPECIFICITY; CATALYTIC-ACTIVITY; IN-VITRO; ENZYME; STABILITY; PROTEINS; RNA	Nature provides a fantastic array of catalysts extremely well suited to supporting life, but usually not so well suited for technology. Whether biocatalysis will have a significant technological impact depends on our finding robust routes for tailoring nature's catalysts or redesigning them anew. Laboratory evolution methods are now used widely to fine-tune the selectivity and activity of enzymes. The current rapid development of these combinatorial methods promises solutions to more complex problems, including the creation of new biosynthetic pathways. Computational methods are also developing quickly. The marriage of these approaches will allow us to generate the efficient, effective catalysts needed by the pharmaceutical, food and chemicals industries and should open up new opportunities for producing energy and chemicals from renewable resources.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.			Arnold, Frances H./0000-0002-4027-364X				Adams MWW, 1998, TRENDS BIOTECHNOL, V16, P329, DOI 10.1016/S0167-7799(98)01193-7; Affholter J, 1999, CHEM BRIT, V35, P48; Altamirano MM, 2000, NATURE, V403, P617, DOI 10.1038/35001001; ARNOLD EH, DIRECTED ENZYME EVOL; ARNOLD FH, 2000, ADV PROTEIN CHEM, V55; Babbitt PC, 2001, ADV PROTEIN CHEM, V55, P1, DOI 10.1016/S0065-3233(01)55001-9; Barbas CF, 2001, ADV PROTEIN CHEM, V55, P317; Benson DE, 2000, P NATL ACAD SCI USA, V97, P6292, DOI 10.1073/pnas.97.12.6292; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; Bull AT, 2000, MICROBIOL MOL BIOL R, V64, P573, DOI 10.1128/MMBR.64.3.573-606.2000; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Cedrone F, 2000, CURR OPIN STRUC BIOL, V10, P405, DOI 10.1016/S0959-440X(00)00106-8; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Encell LP, 1998, CANCER RES, V58, P1013; Jaenicke R, 2000, J BIOTECHNOL, V79, P193, DOI 10.1016/S0168-1656(00)00236-4; Lanio T, 1998, J MOL BIOL, V283, P59, DOI 10.1006/jmbi.1998.2088; Liebeton K, 2000, CHEM BIOL, V7, P709, DOI 10.1016/S1074-5521(00)00015-6; Liu DR, 1997, P NATL ACAD SCI USA, V94, P10092, DOI 10.1073/pnas.94.19.10092; Malakauskas SM, 1998, NAT STRUCT BIOL, V5, P470, DOI 10.1038/nsb0698-470; Matsumura I, 1999, NAT BIOTECHNOL, V17, P696, DOI 10.1038/10910; May O, 2000, NAT BIOTECHNOL, V18, P317, DOI 10.1038/73773; Ness JE, 2001, ADV PROTEIN CHEM, V55, P261, DOI 10.1016/S0065-3233(01)55006-8; Olsen M, 2000, CURR OPIN BIOTECH, V11, P331, DOI 10.1016/S0958-1669(00)00108-7; Orencia MC, 2001, ADV PROTEIN CHEM, V55, P227, DOI 10.1016/S0065-3233(01)55005-6; Ostermeier M, 2001, ADV PROTEIN CHEM, V55, P29, DOI 10.1016/S0065-3233(01)55002-0; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Pluckthun A, 2001, ADV PROTEIN CHEM, V55, P367, DOI 10.1016/S0065-3233(01)55009-3; Reetz MT, 1999, TOP CURR CHEM, V200, P31; Riechmann L, 2000, P NATL ACAD SCI USA, V97, P10068, DOI 10.1073/pnas.170145497; Roberts RW, 1999, CURR OPIN CHEM BIOL, V3, P268, DOI 10.1016/S1367-5931(99)80042-8; Rondon MR, 1999, TRENDS BIOTECHNOL, V17, P403, DOI 10.1016/S0167-7799(99)01352-9; Sandmann G, 1999, TRENDS BIOTECHNOL, V17, P233, DOI 10.1016/S0167-7799(99)01307-4; Schmidt-Dannert C, 2000, NAT BIOTECHNOL, V18, P750, DOI 10.1038/77319; Shanklin J, 2000, CURR OPIN PLANT BIOL, V3, P243, DOI 10.1016/S1369-5266(00)00071-6; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; Short JM, 1997, NAT BIOTECHNOL, V15, P1322, DOI 10.1038/nbt1297-1322; SIEBER V, IN PRESS NATURE BIOT; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; VOIGT CA, IN PRESS P NATL ACAD; Wintrode PL, 2001, ADV PROTEIN CHEM, V55, P161, DOI 10.1016/S0065-3233(01)55004-4; Xiang H, 1999, BIOCHEMISTRY-US, V38, P7638, DOI 10.1021/bi9901432; Yano T, 1998, P NATL ACAD SCI USA, V95, P5511, DOI 10.1073/pnas.95.10.5511	45	299	343	13	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					253	257		10.1038/35051731	http://dx.doi.org/10.1038/35051731			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196654				2022-12-28	WOS:000166316200057
J	Sastry, S				Sastry, S			The relationship between fragility, configurational entropy and the potential energy landscape of glass-forming liquids	NATURE			English	Article							TRANSITION; RELAXATION; EXCITATIONS; POLYMERS; MIXTURE; MODEL	Glass is a microscopically disordered, solid form of matter that results when a fluid is cooled or compressed in such a manner that it does not crystallize. Almost all types of materials are capable of glass formation, including polymers, metal alloys and molten salts. Given such diversity, general principles by which different glass-forming materials can be systematically classified are invaluable. One such principle is the classification of glass-formers according to their fragility(1). Fragility measures the rapidity with which a liquid's properties (such as viscosity) change as the glassy state is approached. Although the relationship between the fragility, configurational entropy and features of the energy landscape (the complicated dependence of energy on configuration) of a glass-former have been analysed previously(2), a detailed understanding of the origins of fragility is lacking. Here I use simulations to analyse the relationship between fragility and quantitative measures of the energy landscape for a model liquid whose fragility depends on its bulk density. The results reveal that fragility depends on changes in the vibrational properties of individual energy minima in addition to their total number and spread in energy. A thermodynamic expression for fragility is derived, which is in quantitative agreement with kinetic fragilities obtained from the liquid's diffusivity.	Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Sastry, S (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Jakkur Campus, Bangalore 560064, Karnataka, India.	sastry@jncasr.ac.in	Sastry, Srikanth/F-7232-2014	Sastry, Srikanth/0000-0001-7399-1835				ADAM G, 1965, J CHEM PHYS, V43, P139, DOI 10.1063/1.1696442; ANGELL CA, 1972, J CHEM PHYS, V57, P470, DOI 10.1063/1.1677987; Angell CA, 1997, J RES NATL INST STAN, V102, P171, DOI 10.6028/jres.102.013; ANGELL CA, 1991, J NON-CRYST SOLIDS, V131, P13, DOI 10.1016/0022-3093(91)90266-9; Angell CA, 2000, J PHYS-CONDENS MAT, V12, P6463, DOI 10.1088/0953-8984/12/29/318; Buchner S, 1999, PHYS REV E, V60, P6507, DOI 10.1103/PhysRevE.60.6507; Coluzzi B, 2000, J CHEM PHYS, V112, P2933, DOI 10.1063/1.480866; GOLDSTEIN M, 1976, J CHEM PHYS, V64, P4767, DOI 10.1063/1.432063; Green JL, 1999, J PHYS CHEM B, V103, P3991, DOI 10.1021/jp983927i; Heuer A, 2000, J PHYS-CONDENS MAT, V12, P6535, DOI 10.1088/0953-8984/12/29/325; Ito K, 1999, NATURE, V398, P492, DOI 10.1038/19042; Johari GP, 2000, J CHEM PHYS, V112, P7518, DOI 10.1063/1.481349; Johari GP, 2000, J CHEM PHYS, V112, P8958, DOI 10.1063/1.481509; KOB W, 1995, PHYS REV E, V51, P4626, DOI 10.1103/PhysRevE.51.4626; LAUGHLIN WT, 1972, J PHYS CHEM-US, V76, P2317, DOI 10.1021/j100660a023; Ngai KL, 1999, J CHEM PHYS, V111, P10403, DOI 10.1063/1.480394; Sastry S, 1998, NATURE, V393, P554, DOI 10.1038/31146; SASTRY S, 1996, J PHYS-CONDENS MAT, V12, P6515; Scala A, 2000, NATURE, V406, P166, DOI 10.1038/35018034; Sciortino F, 1999, PHYS REV LETT, V83, P3214, DOI 10.1103/PhysRevLett.83.3214; SCIORTINO F, IN PRESS PHYS REV LE; Speedy RJ, 1999, J PHYS CHEM B, V103, P4060, DOI 10.1021/jp983830w; Speedy RJ, 1998, MOL PHYS, V95, P169, DOI 10.1080/00268979809483148; Speedy RJ, 1996, MOL PHYS, V88, P1293, DOI 10.1080/00268979650025849; STARR FW, THERMODYNAMIC STRUCT; STILLINGER FH, 1984, SCIENCE, V225, P983, DOI 10.1126/science.225.4666.983; STILLINGER FH, 1995, SCIENCE, V267, P1935, DOI 10.1126/science.267.5206.1935; Xia XY, 2000, P NATL ACAD SCI USA, V97, P2990, DOI 10.1073/pnas.97.7.2990; Yamamuro O, 1998, J PHYS CHEM B, V102, P1605, DOI 10.1021/jp973439v	30	543	551	8	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					164	167		10.1038/35051524	http://dx.doi.org/10.1038/35051524			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196634	Green Submitted			2022-12-28	WOS:000166316200036
J	Glick, ID; Suppes, T; DeBattista, C; Hu, RJ; Marder, S				Glick, ID; Suppes, T; DeBattista, C; Hu, RJ; Marder, S			Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia	ANNALS OF INTERNAL MEDICINE			English	Review							CONTROLLED CLINICAL-TRIAL; DOUBLE-BLIND; OUTCOMES RESEARCH; MAINTENANCE; FLUOXETINE; CLOZAPINE; HALOPERIDOL; RISPERIDONE; OLANZAPINE; PLACEBO	Patients with serious psychiatric disorders are frequently treated by primary care physicians, who may have difficulty keeping up with recent advances in psychiatry. This paper presents an updated synopsis for three major psychiatric illnesses: major depression, bipolar disorder, and schizophrenia. Current definitions, updated diagnostic criteria, short- and long-term treatment strategies with algorithms, and special challenges for the clinician are discussed for each of these illnesses. On the basis of each illness's distinct characteristics, five treatment principles are emphasized: 1) Treatment strategies should be long-term and should emphasize adherence, 2) treatment choice should be empirical, 3) combinations of medications may be helpful, 4) a combination of psychosocial and pharmacologic treatments may be more useful than either alone, and 5) the family or "significant others" as well as a consumer organization need to be involved. Some of the new directions in clinical research to refine these strategies and meet these challenges are also described.	Stanford Univ, Sch Med, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Univ Calif Los Angeles, Los Angeles, CA USA	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Los Angeles	Glick, ID (corresponding author), Stanford Univ, Sch Med, 401 Quarry Rd,Suite 2122, Stanford, CA 94305 USA.	iraglick@stanford.edu						ALTSHULER LL, 1993, BIOL PSYCHIAT, V33, P563, DOI 10.1016/0006-3223(93)90093-S; *AM PSYCH ASS, 1997, AM J PSYCHIAT S, V154, P26; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P327; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P328; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, V285; [Anonymous], 1993, AM J PSYCHIAT, V150, P1; ANTON RF, 1983, AM J PSYCHIAT, V140, P1344; Bennett J, 1997, J CLIN PSYCHOPHARM, V17, P141, DOI 10.1097/00004714-199704000-00029; Bondolfi G, 1998, AM J PSYCHIAT, V155, P499, DOI 10.1176/ajp.155.4.499; BONGAR B, 1992, SUICIDE GUIDELINES A, P17; BORYS DJ, 1992, AM J EMERG MED, V10, P115, DOI 10.1016/0735-6757(92)90041-U; CALABRESE J, 1999, J CLIN PSYCHIAT, V60, P245; Casey DE, 1997, INT CLIN PSYCHOPHARM, V12, pS19, DOI 10.1097/00004850-199702001-00004; Clarkin JF, 1998, PSYCHIAT SERV, V49, P531, DOI 10.1176/ps.49.4.531; Conley RR, 1999, AM J PSYCHIAT, V156, P863, DOI 10.1176/ajp.156.6.863; CORYELL W, 1993, AM J PSYCHIAT, V150, P720; DEMONTIGNY C, 1981, BRIT J PSYCHIAT, V138, P252, DOI 10.1192/bjp.138.3.252; Dixon LB, 1995, SCHIZOPHRENIA BULL, V21, P631, DOI 10.1093/schbul/21.4.631; FAVA M, 1994, AM J PSYCHIAT, V151, P1372; FOGELSON DL, 1992, J CLIN PSYCHIAT, V53, P443; FRANK E, 1992, LONG TERM TREATMENT, P187; Gifford F, 1996, HASTINGS CENT REP, V26, P38, DOI 10.2307/3528575; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; Hamilton J. A., 1995, RACISM SEXISM MENTAL, P297; HIMMELHOCH JM, 1991, AM J PSYCHIAT, V148, P910; HIMMELHOCH JM, 1976, ARCH GEN PSYCHIAT, V33, P1062; HOTTON SD, 1992, ARCH GEN PSYCHIAT, V49, P774; JANICAK PG, 1993, PRINCIPLES PRACTICE, P93; Jibson MD, 1998, J PSYCHIAT RES, V32, P215, DOI 10.1016/S0022-3956(98)00023-5; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KANE JM, 1986, J CLIN PSYCHIAT, V47, P30; KECK PE, 1993, J CLIN PSYCHIAT, V54, P305; KINON BJ, 1993, PSYCHOPHARMACOL BULL, V29, P309; Kocsis JH, 1996, ARCH GEN PSYCHIAT, V53, P769; Kornstein SG, 1997, J CLIN PSYCHIAT, V58, P12; KUPFER DJ, 1992, ARCH GEN PSYCHIAT, V49, P769; Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P1; Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P11, DOI 10.1093/oxfordjournals.schbul.a033303; LENOX RH, 1992, J CLIN PSYCHIAT, V53, P47; LEWANDER T, 1990, ACTA PSYCHIAT SCAND, V82, P92, DOI 10.1111/j.1600-0447.1990.tb05297.x; Liberman RP, 1998, AM J PSYCHIAT, V155, P1087, DOI 10.1176/ajp.155.8.1087; Marder SR, 1997, J CLIN PSYCHIAT, V58, P538, DOI 10.4088/JCP.v58n1205; MARDER SR, 1987, ARCH GEN PSYCHIAT, V44, P518; MARDER SR, 1994, ARCH GEN PSYCHIAT, V51, P280; MCELROY SL, 1992, AM J PSYCHIAT, V149, P1633; MCGRATH PJ, 1992, J CLIN PSYCHOPHARM, V12, P197; Meltzer HY, 1998, J CLIN PSYCHIAT, V59, P41; MICHELS R, 1993, NEW ENGL J MED, V329, P552, DOI 10.1056/NEJM199308193290808; *NAT DEPR MAN DEPR, 1996, NAT DEPR MAN DEPR AS; NIERENBERG AA, 1995, AM J PSYCHIAT, V152, P1500; PICKAR D, 1992, ARCH GEN PSYCHIAT, V49, P345; POST RM, 1992, HDB AFFECTIVE DISORD, P387; PRANGE AJ, 1969, AM J PSYCHIAT, V126, P457, DOI 10.1176/ajp.126.4.457; PRIEN RF, 1988, J AFFECT DISORDERS, V15, P391; REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934; Robinson DG, 1999, AM J PSYCHIAT, V156, P544; RUSH AJ, 1995, PSYCHIAT ANN, V25, P704, DOI 10.3928/0048-5713-19951201-03; SACHS GS, 1994, J CLIN PSYCHIAT, V55, P391; Schooler NR, 1997, ARCH GEN PSYCHIAT, V54, P453; Sclar DA, 1995, J INT MED RES, V23, P395, DOI 10.1177/030006059502300601; SUPPES T, 1994, BIOL PSYCHIAT, V36, P338, DOI 10.1016/0006-3223(94)90631-9; SUPPES T, 1996, MOOD DISORDERS LIFE, P3; THASE ME, 1994, PSYCHOPHARMACOLOGY 4, P1081; ThiesFlechtner K, 1996, PHARMACOPSYCHIATRY, V29, P103, DOI 10.1055/s-2007-979553; Tohen M, 1999, AM J PSYCHIAT, V156, P702; Tohen M, 1996, J CLIN PSYCHIAT, V57, P249; Tollefson GD, 1997, AM J PSYCHIAT, V154, P457; Tollefson GD, 1997, AM J PSYCHIAT, V154, P466; Tollefson GD, 1997, AM J PSYCHIAT, V154, P1248; Tondo L, 1997, ANN NY ACAD SCI, V836, P339, DOI 10.1111/j.1749-6632.1997.tb52369.x; VANPUTTEN T, 1981, ARCH GEN PSYCHIAT, V38, P187; WYATT RJ, 1991, SCHIZOPHRENIA BULL, V17, P325, DOI 10.1093/schbul/17.2.325; Yonkers KA, 1997, J CLIN PSYCHIAT, V58, P4; ZORNBERG GL, 1993, J CLIN PSYCHOPHARM, V13, P397	74	29	34	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2001	134	1					47	60		10.7326/0003-4819-134-1-200101020-00013	http://dx.doi.org/10.7326/0003-4819-134-1-200101020-00013			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	386CV	11187420				2022-12-28	WOS:000166043300007
J	Jellinek, EH				Jellinek, EH			Dr H C Bastian, scientific Jekyll and Hyde	LANCET			English	Biographical-Item								The neurological library of S A Kinnier Wilson, now in the Royal College of Physicians of Edinburgh, contains two books by Henry Charlton Bastian. Various forms of hysterical or functional paralysis (1893) is inscribed "To Dr Wilson by the Author, July 1906". Wilson was Bastian's house-physician at the time. The second book, given to Wilson's son by Bastian's daughter in 1940, is a lavishly illustrated tome, Studies in heterogenesis (1903). The two books testify to a scientific Jekyll and Hyde-one of the founders of neurology and a wildly unorthodox biologist.			Jellinek, EH (corresponding author), 14 Moray Pl, Edinburgh EH3 6DT, Midlothian, Scotland.							BASTIAN HC, PUBLICATION LIST; BRAIN R, 1961, SPEECH DISORDERS APH; Head H., 1926, APHASIA KINDRED DISO; HOLMES G, 1954, NATL HOSPITAL QUEEN, P38; Kirshner Howard S., 1996, P131; MACNALTY AS, 1909, BRAIN, V32, P237; MAUDSLEY H, 1868, LANCET, V2, P721; MAUDSLEY H, 1868, LANCET, V2, P690; Spencer H., 1904, AUTOBIOGRAPHY; 1881, LANCET, V2, P290	10	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2180	2183						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191559				2022-12-28	WOS:000165997300040
J	Volgushev, M; Eysel, UT				Volgushev, M; Eysel, UT			Neuroscience - Noise makes sense in neuronal computing	SCIENCE			English	Editorial Material							CAT VISUAL-CORTEX; ORIENTATION SELECTIVITY; NEOCORTICAL NEURONS; CORTICAL-NEURONS; OSCILLATIONS; MECHANISMS		Ruhr Univ Bochum, Fac Med, Dept Neurophysiol, D-44780 Bochum, Germany	Ruhr University Bochum	Volgushev, M (corresponding author), Ruhr Univ Bochum, Fac Med, Dept Neurophysiol, D-44780 Bochum, Germany.		Volgushev, Maxim/AAO-6793-2020	Volgushev, Maxim/0000-0002-8080-1136; Eysel, Ulf/0000-0001-6087-957X				Anderson JS, 2000, SCIENCE, V290, P1968, DOI 10.1126/science.290.5498.1968; Azouz R, 2000, P NATL ACAD SCI USA, V97, P8110, DOI 10.1073/pnas.130200797; Azouz R, 1999, J NEUROSCI, V19, P2209; Carandini M, 2000, J NEUROSCI, V20, P470, DOI 10.1523/JNEUROSCI.20-01-00470.2000; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; GRANIT R, 1963, J PHYSIOL-LONDON, V168, P911, DOI 10.1113/jphysiol.1963.sp007230; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1992, SCIENCE, V257, P552, DOI 10.1126/science.1636094; Kerr RA, 2000, SCIENCE, V290, P697, DOI 10.1126/science.290.5492.697; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Nowak LG, 1997, CEREB CORTEX, V7, P487, DOI 10.1093/cercor/7.6.487; SCLAR G, 1982, EXP BRAIN RES, V46, P457; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; Sompolinsky H, 1997, CURR OPIN NEUROBIOL, V7, P514, DOI 10.1016/S0959-4388(97)80031-1; Volgushev M, 2000, EUR J NEUROSCI, V12, P128; Volgushev M, 2000, EUR J NEUROSCI, V12, P257, DOI 10.1046/j.1460-9568.2000.00909.x; Volgushev M, 1998, NEUROSCIENCE, V83, P15, DOI 10.1016/S0306-4522(97)00380-1; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0	18	16	16	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1908	1909		10.1126/science.290.5498.1908	http://dx.doi.org/10.1126/science.290.5498.1908			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11187048				2022-12-28	WOS:000165810000034
J	de Vargas, PRM				de Vargas, PRM			Avoidable infant and perinatal deaths?	LANCET			English	Article									Espirito Santo Fed Univ, Vitoria, ES, Brazil		de Vargas, PRM (corresponding author), Rua Dom Pedro 1,131 Maruipe, BR-29043470 Vitoria, ES, Brazil.	vargaspm@zaz.cam.br							0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC	2000	356			S			S13	S13		10.1016/S0140-6736(00)91999-8	http://dx.doi.org/10.1016/S0140-6736(00)91999-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191468				2022-12-28	WOS:000166074900015
J	Kullavanijaya, P				Kullavanijaya, P			More than just eczema	LANCET			English	Article									Inst Dermatol, Bangkok 10400, Thailand		Kullavanijaya, P (corresponding author), Inst Dermatol, 420-7 Rajavithi Rd, Bangkok 10400, Thailand.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S59	S59		10.1016/S0140-6736(00)92045-2	http://dx.doi.org/10.1016/S0140-6736(00)92045-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191518				2022-12-28	WOS:000166074900061
J	Peltola, H				Peltola, H			What would happen if we stopped vaccination?	LANCET			English	Article									Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00029 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Peltola, H (corresponding author), Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, POB 281, FIN-00029 Helsinki, Finland.								0	5	5	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S22	S22		10.1016/S0140-6736(00)92008-7	http://dx.doi.org/10.1016/S0140-6736(00)92008-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191478	Bronze			2022-12-28	WOS:000166074900024
J	Kohn, MA				Kohn, MA			Missed diagnoses of acute cardiac ischemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kohn, MA (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.							Selker HP, 1998, ANN INTERN MED, V129, P845, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00002	1	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1492	1493						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184458				2022-12-28	WOS:000165271300014
J	Bohrer, RA				Bohrer, RA			The pharmaceutical industry - To whom is it accountable?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Calif Western Sch Law, San Diego, CA 92101 USA		Bohrer, RA (corresponding author), Calif Western Sch Law, San Diego, CA 92101 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1416	1416						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183880				2022-12-28	WOS:000165152800016
J	Ewert, R; Wensel, R; Opitz, CF				Ewert, R; Wensel, R; Opitz, CF			Aerosolized iloprost for primary pulmonary hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Deutsch Herzzentrum Berlin, D-13353 Berlin, Germany	German Heart Center Berlin	Ewert, R (corresponding author), Deutsch Herzzentrum Berlin, D-13353 Berlin, Germany.		Opitz, Christian/L-3438-2019					Hoeper MM, 2000, NEW ENGL J MED, V342, P1866, DOI 10.1056/NEJM200006223422503; Olschewski H, 2000, ANN INTERN MED, V132, P435, DOI 10.7326/0003-4819-132-6-200003210-00003; Opitz CF, 2000, J AM COLL CARDIOL, V35, p286A; Wensel R, 2000, CIRCULATION, V101, P2388, DOI 10.1161/01.CIR.101.20.2388	4	9	14	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1421	1422						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183891				2022-12-28	WOS:000165152800031
J	Bravo, AA; Sheth, SG; Chopra, S				Bravo, AA; Sheth, SG; Chopra, S			Current concepts: Liver biopsy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PRIMARY BILIARY-CIRRHOSIS; NEEDLE BIOPSY; COMPLICATIONS; ULTRASOUND; DISEASE; EXPERIENCE; ULTRASONOGRAPHY; SITE		Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol,Liver Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Bravo, AA (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol,Liver Ctr, Boston, MA 02215 USA.							Bach N, 1998, ARCH PATHOL LAB MED, V122, P342; Brown KE, 2000, LIVER DIS DIAGNOSIS, P47; Cadranel JF, 2000, HEPATOLOGY, V32, P477, DOI 10.1053/jhep.2000.16602; Castera L, 1999, HEPATOLOGY, V30, P1529, DOI 10.1002/hep.510300624; Caturelli E, 1996, AM J GASTROENTEROL, V91, P1318; COLOMBO M, 1988, GASTROENTEROLOGY, V95, P487, DOI 10.1016/0016-5085(88)90509-4; De Hoyos A, 1999, DIGEST DIS SCI, V44, P177, DOI 10.1023/A:1026678806368; DIEHL AM, 1989, MED CLIN N AM, V73, P815, DOI 10.1016/S0025-7125(16)30640-X; EISENBERG PJ, 1994, FINE NEEDLE ASPIRATI, P3; FROEHLICH F, 1993, DIGEST DIS SCI, V38, P1480, DOI 10.1007/BF01308607; GARCIATSAO G, 1993, ANN INTERN MED, V118, P150, DOI 10.7326/0003-4819-118-2-199301150-00013; HANAFEE W, 1967, RADIOLOGY, V88, P35, DOI 10.1148/88.1.35; HEDERSTROM E, 1989, J HEPATOL, V8, P94, DOI 10.1016/0168-8278(89)90167-0; HULTCRANTZ R, 1993, J INTERN MED, V233, P7, DOI 10.1111/j.1365-2796.1993.tb00640.x; JACOBS WH, 1989, DIGEST DIS SCI, V34, P322, DOI 10.1007/BF01536249; JANES CH, 1993, ANN INTERN MED, V118, P96, DOI 10.7326/0003-4819-118-2-199301150-00003; Klatskin G, 1993, HISTOPATHOLOGY LIVER, V1, P3; LEBREC D, 1982, GASTROENTEROLOGY, V83, P338; Lee RG, 1994, DIAGNOSTIC LIVER PAT, P1; LICHTENSTEIN DR, 1992, AM J GASTROENTEROL, V87, P1833; Lindor KD, 1996, HEPATOLOGY, V23, P1079; Locke GR, 1996, HEPATOLOGY, V23, P52, DOI 10.1002/hep.510230108; Lundquist A, 1971, Acta Med Scand Suppl, V520, P1; MCAFEE JH, 1992, HEPATOLOGY, V15, P726, DOI 10.1002/hep.1840150429; MCGILL DB, 1990, GASTROENTEROLOGY, V99, P1396, DOI 10.1016/0016-5085(90)91167-5; MENGHINI G, 1958, GASTROENTEROLOGY, V35, P190; Pasha T, 1998, HEPATOLOGY, V27, P1220, DOI 10.1002/hep.510270506; PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7; POLSON RJ, 1989, GASTROENTEROLOGY, V97, P715, DOI 10.1016/0016-5085(89)90643-4; RAINES DR, 1974, GASTROENTEROLOGY, V67, P284; Reddy KR, 1997, GASTROINTESTINAL EME, P959; Reddy KR, 1999, SCHIFFS DIS LIVER, V1, P245; Riemann B, 2000, SCAND J GASTROENTERO, V35, P102; Riley TR, 1999, AM J GASTROENTEROL, V94, P3320, DOI 10.1111/j.1572-0241.1999.01545.x; RUBEN RA, 1987, AM J GASTROENTEROL, V82, P265; Smith C. I., 1995, Hepatology, V22, p384A; SMITH EH, 1991, RADIOLOGY, V178, P253, DOI 10.1148/radiology.178.1.1984314; Stanley AJ, 1996, EUR J GASTROEN HEPAT, V8, P869; VANLEEUWEN DJ, 1995, SEMIN LIVER DIS, V15, P340, DOI 10.1055/s-2007-1007286; VANTHIEL DH, 1993, TRANSPLANTATION, V55, P1087, DOI 10.1097/00007890-199305000-00029; VARGAS C, 1995, AM J GASTROENTEROL, V90, P1258; VAUTIER G, 1994, BRIT MED J, V309, P1455, DOI 10.1136/bmj.309.6967.1455; Younossi ZM, 1998, DIGEST DIS SCI, V43, P46, DOI 10.1023/A:1018815802500	43	1655	1720	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	2001	344	7					495	500		10.1056/NEJM200102153440706	http://dx.doi.org/10.1056/NEJM200102153440706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401HL	11172192				2022-12-28	WOS:000166922100006
J	Fournier, AE; GrandPre, T; Strittmatter, SM				Fournier, AE; GrandPre, T; Strittmatter, SM			Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration	NATURE			English	Article							NEURITE GROWTH-INHIBITORS; CONE COLLAPSE; SPINAL-CORD; MYELIN; NEUROPILIN-1	Nogo has been identified as a component of the central nervous system (CNS) myelin that prevents axonal regeneration in the adult vertebrate CNS. Analysis of Nogo-A has shown that an axon-inhibiting domain of 66 amino acids is expressed at the extracellular surface and at the endoplasmic reticulum lumen of transfected cells and oligodendrocytes(1). The acidic amino terminus of Nogo-A is detected at the cytosolic face of cellular membranes(1) and may contribute to inhibition of axon regeneration at sites of oligodendrocyte injury(2,3). Here we show that the extracellular domain of Nogo (Nogo-66) inhibits axonal extension, but does not alter non-neuronal cell morphology. In contrast, a multivalent form of the N terminus of Nogo-A affects the morphology of both neurons and other cell types. Here we identify a brain-specific, leucine-rich-repeat protein with high affinity for soluble Nogo-66. Cleavage of the Nogo-66 receptor and other glycophosphatidylinositol-linked proteins from axonal surfaces renders neurons insensitive to Nogo-66. Nogo-66 receptor expression is sufficient to impart Nogo-66 axonal inhibition to unresponsive neurons. Disruption of the interaction between Nogo-66 and its receptor provides the potential for enhanced recovery after human CNS injury.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06520 USA	Yale University; Yale University	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, POB 208018, New Haven, CT 06520 USA.		Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				Buffo A, 2000, J NEUROSCI, V20, P2275; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373	13	883	1028	0	44	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					341	346		10.1038/35053072	http://dx.doi.org/10.1038/35053072			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201742				2022-12-28	WOS:000166434300047
J	Jones, AG; Ferguson, IJ				Jones, AG; Ferguson, IJ			The electric moho	NATURE			English	Article							LOWER CRUST; NORTHWEST-TERRITORIES; CONTINENTAL-CRUST; CONDUCTIVITY; MANTLE; CANADA; REFLECTION; INVERSION; COMPLEX; ROCKS	Since Mohorovicic(1) discovered a dramatic increase in compressional seismic velocity at a depth of 54 km beneath the Kulpa Valley in Croatia, the 'Moho' has become arguably the most important seismological horizon in Earth owing to its role in defining the crust-mantle boundary. It is now known to be a ubiquitous feature of the Earth, being found beneath both the continents and the oceans, and is commonly assumed to separate lower-crustal marc rocks from upper-mantle ultramafic rocks. Electromagnetic experiments conducted to date, however, have failed to detect a corresponding change in electrical conductivity at the base of the crust, although one might be expected on the basis of laboratory measurements(2). Here we report electromagnetic data from the Slave craton, northern Canada, which show a step-change in conductivity at Moho depths. Such resolution is possible because the Slave craton is highly anomalous, exhibiting a total crustal conductance of less than 1 Siemens-more than an order of magnitude smaller than other Archaean cratons. We also found that the conductivity of the uppermost continental mantle directly beneath the Moho is two orders of magnitude more conducting than laboratory studies on olivine would suggest, inferring that there must be a connected conducting phase.	Geol Survey Canada, Ottawa, ON K1A 0E9, Canada; Univ Manitoba, Dept Geol Sci, Winnipeg, MB R3T 2N2, Canada	Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada; University of Manitoba	Jones, AG (corresponding author), Geol Survey Canada, Ottawa, ON K1A 0E9, Canada.		Jones, Alan G/A-3241-2009	Jones, Alan G/0000-0002-3482-2518				BERDICHEVSKY MN, 1976, KAPG GEOPHYSICAL MON, P165; Bleeker W, 1999, CAN J EARTH SCI, V36, P1083, DOI 10.1139/e98-102; Bostock MG, 1998, J GEOPHYS RES-SOL EA, V103, P21183, DOI 10.1029/98JB01069; CAMPBELL WH, 1987, PURE APPL GEOPHYS, V125, P193, DOI 10.1007/BF00874494; CLOWES RM, 1997, LITHOPROBE PHASE 5 P; CONSTABLE S, 1992, J GEOPHYS RES-SOL EA, V97, P3397, DOI 10.1029/91JB02453; CONSTABLE SC, 1987, GEOPHYSICS, V52, P289, DOI 10.1190/1.1442303; Cook FA, 1999, TECTONICS, V18, P1, DOI 10.1029/1998TC900016; FERGUSON IJ, 1994, GEOPHYS J INT, V117, P48, DOI 10.1111/j.1365-246X.1994.tb03303.x; FISCHER G, 1981, GEOPHYS J ROY ASTR S, V67, P279, DOI 10.1111/j.1365-246X.1981.tb02750.x; FROST BR, 1989, NATURE, V340, P134, DOI 10.1038/340134a0; GARCIA X, UNPUB GEOPHYSICS; GOUGH DI, 1986, NATURE, V323, P143, DOI 10.1038/323143a0; HAAK V, 1982, NUMERICAL DATA FUNCT, V1, P291; Jones A.G, 1992, DEV GEOTECTONICS, P81; JONES AG, 1987, GEOPHYS J INT, V89, P7, DOI 10.1111/j.1365-246X.1987.tb04380.x; Jones AG, 1997, J GEOMAGN GEOELECTR, V49, P1619, DOI 10.5636/jgg.49.1619; JONES AG, 1989, J GEOPHYS RES-SOLID, V94, P14201, DOI 10.1029/JB094iB10p14201; JONES AG, 1988, GEOPHYSICS, V53, P967, DOI 10.1190/1.1442533; JONES AG, 1982, GEOPHYS J ROY ASTR S, V68, P371, DOI 10.1111/j.1365-246X.1982.tb04906.x; Jones AG, 1999, LITHOS, V48, P57, DOI 10.1016/S0024-4937(99)00022-5; MCNEICE G, IN PRESS GEOPHYSICS; Mohorovicic A., 1910, GODISNJE IZVJESCE ZA, P1; Mohoroviic A., 1992, GEOFIZIKA, V9, P3; OLHOEFT GR, 1981, J GEOPHYS RES, V86, P931, DOI 10.1029/JB086iB02p00931; Parker RL, 1996, PHYS EARTH PLANET IN, V98, P269, DOI 10.1016/S0031-9201(96)03191-3; PARKER RL, 1980, J GEOPHYS RES, V85, P4421, DOI 10.1029/JB085iB08p04421; SCHULTZ A, 1993, GEOPHYS RES LETT, V20, P2941, DOI 10.1029/93GL02833; Stern RA, 1998, GEOSCI CAN, V25, P27; Viejo GF, 1999, GEOPHYS RES LETT, V26, P2809, DOI 10.1029/1999GL005373; Yardley BWD, 1997, J GEOPHYS RES-SOL EA, V102, P12173, DOI 10.1029/97JB00508; YARDLEY BWD, 1986, NATURE, V323, P111, DOI 10.1038/323111a0	32	61	64	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					331	333		10.1038/35053053	http://dx.doi.org/10.1038/35053053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201739				2022-12-28	WOS:000166434300044
J	Szostak, JW; Bartel, DP; Luisi, PL				Szostak, JW; Bartel, DP; Luisi, PL			Synthesizing life	NATURE			English	Article							RNA; FUSION; MEMBRANE; PERMEABILITY; RIBOZYMES; TEMPLATE; MICELLES; VESICLES; CALCIUM; ORIGIN	Advances in directed evolution and membrane biophysics make the synthesis of simple living cells, if not yet foreseeable reality, an imaginable goal. Overcoming the many scientific challenges along the way will deepen our understanding of the essence of cellular life and its origin on Earth.	Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; ETH Zentrum, Inst Polymere, CH-8092 Zurich, Switzerland	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Swiss Federal Institutes of Technology Domain; ETH Zurich	Szostak, JW (corresponding author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA.							Albalak A, 1996, BIOCHEMISTRY-US, V35, P7936, DOI 10.1021/bi960497i; BACHMANN PA, 1992, NATURE, V357, P57, DOI 10.1038/357057a0; Bartel D.P, 1999, RNA WORLD 2 NAT MOD, V37, P143; Bartel David P., 1999, Trends in Cell Biology, V9, pM9, DOI 10.1016/S0962-8924(99)01669-4; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BERCLAZ N, IN PRESS J PHYS CH B; Bergman NH, 2000, BIOCHEMISTRY-US, V39, P3115, DOI 10.1021/bi992654u; Blochliger E, 1998, J PHYS CHEM B, V102, P10383, DOI 10.1021/jp981234w; CHAKRABARTI AC, 1994, J MOL EVOL, V39, P555, DOI 10.1007/BF00160400; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; EKLAND EH, 1995, NUCLEIC ACIDS RES, V23, P3231, DOI 10.1093/nar/23.16.3231; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; Hager AJ, 1996, CHEM BIOL, V3, P717, DOI 10.1016/S1074-5521(96)90246-X; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; INGOLIA TD, 1978, J BIOL CHEM, V253, P3821; Joyce G. F., 1993, COLD SPRING HARB SYM, V24, P49; JOYCE GF, 1991, NEW BIOL, V3, P399; Khvorova A, 1999, P NATL ACAD SCI USA, V96, P10649, DOI 10.1073/pnas.96.19.10649; Luisi PL, 1998, ORIGINS LIFE EVOL B, V28, P613, DOI 10.1023/A:1006517315105; LUISI PL, 1996, ADV CHEM PHYS, V92, P425; Norris V, 1998, ORIGINS LIFE EVOL B, V28, P523, DOI 10.1023/A:1006568226145; OBERHOLZER T, 1995, CHEM BIOL, V2, P677, DOI 10.1016/1074-5521(95)90031-4; PARENTE RA, 1988, J BIOL CHEM, V263, P4724; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; UENO M, 1989, BIOCHEMISTRY-US, V28, P5631, DOI 10.1021/bi00439a044; WALDE P, 1994, J AM CHEM SOC, V116, P7541, DOI 10.1021/ja00096a010; WALDE P, 1994, J AM CHEM SOC, V116, P11649, DOI 10.1021/ja00105a004; WILSCHUT J, 1980, BIOCHEMISTRY-US, V19, P6011, DOI 10.1021/bi00567a011	33	1114	1150	7	380	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 18	2001	409	6818					387	390		10.1038/35053176	http://dx.doi.org/10.1038/35053176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201752				2022-12-28	WOS:000166434300060
J	Wendler, D; Dickert, N				Wendler, D; Dickert, N			The consent process for cadaveric organ procurement - How does it work? How can it be improved?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DONORS; DONATION; ISSUES; CARDS	Context Understanding the consent process that organ procurement organizations (OPOs) use is crucial to improving the process and thereby reducing the number of individuals who die each year for want of an organ transplant. However, no data exist on OPOs' current consent practices. Objective To assess whose wishes OPOs follow when procuring solid organs from deceased individuals and whether advance directives and computerized registries might improve the consent process for solid organ procurement. Design, Setting, and Participants Telephone survey conducted from June to August 1999 of all 61 active OPOs, Main Outcome Measures Responses to the 49-question survey addressing consent practices in specific scenarios of deceased and next of kin wishes. Results Widespread divergence exists in OPOs' consent practices for cadaveric solid organ procurement. Regarding overall consent practices, 19 (31%) OPOs reported that they follow the deceased's wishes, 19 (31%) follow the next of kin's wishes, 13 (21%) procure organs if neither party objects, 8 (13%) procure organs if either party consents or neither objects, and 2 (3%) do not follow any of these 4 overall practices. These differences appear to be traceable to implicit ethical disagreements about whose wishes should be followed. A total of 29 (48%) OPOs reported having an official policy to address whether they follow the family's or deceased's wishes. Regarding factors that influence OPOs' choice of consent practice, 29 (48%) respondents ranked impact on the deceased's family as the most important factor, 13 (21%) ranked state law as most important, and 7 (11%) ranked the priority of the deceased's wishes as most important. Durable power of attorney appeared to have substantial weight in OPOs' decisions; for example, in the scenario in which the deceased supported organ donation and the next of kin opposed it, 34 (56%) OPOs reported they were likely to procure organs based on the consent of the holder of the deceased's durable power of attorney, whereas only 7 (11%) reported they were likely to procure organs based on a document of gift (a living will, donor card, or driver's license). Conclusions Expanding the legal scope of living wills to cover individuals' organ donation preferences would likely have little impact on procurement rates. In contrast, expanding the legal scope of durable powers of attorney for health care may have a significant impact. A national discussion should take place addressing the underlying ethical issues that appear to account for much of the divergence among OPOs' consent practices for cadaveric solid organ procurement.	NIH, Ctr Clin Bioeth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Wendler, D (corresponding author), NIH, Ctr Clin Bioeth, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.							Arnold RM, 1996, CRIT CARE CLIN, V12, P29, DOI 10.1016/S0749-0704(05)70213-X; *ASS ORG PROC ORG, 1999, ASS ORG PROC ORG 199; CAPLAN AL, 1984, HASTINGS CENT REP, V14, P9, DOI 10.2307/3561088; CHILDRESS JF, 1989, J HEALTH POLIT POLIC, V14, P87, DOI 10.1215/03616878-14-1-87; Edinger W, 1990, J Med Humanit, V11, P135, DOI 10.1007/BF01149321; GLASSON J, 1994, JAMA-J AM MED ASSOC, V272, P809, DOI 10.1001/jama.1994.03520100071036; HARRIS RJ, 1991, J APPL SOC PSYCHOL, V21, P3, DOI 10.1111/j.1559-1816.1991.tb00438.x; Klassen AC, 1996, ANN INTERN MED, V125, P70, DOI 10.7326/0003-4819-125-1-199607010-00011; Kluge EH, 1997, CAN MED ASSOC J, V157, P160; OVERCAST TD, 1984, JAMA-J AM MED ASSOC, V251, P1559, DOI 10.1001/jama.251.12.1559; PELLEGRINO ED, 1991, JAMA-J AM MED ASSOC, V265, P1305, DOI 10.1001/jama.265.10.1305; PETERS DA, 1986, MILBANK Q, V64, P241, DOI 10.2307/3349972; WRIGHT DH, 2000, ADV DIRECTIVES DONOR	13	61	68	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					329	333		10.1001/jama.285.3.329	http://dx.doi.org/10.1001/jama.285.3.329			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	390XD	11176844				2022-12-28	WOS:000166324300025
J	Locasciulli, A; Arcese, W; Locatelli, F; Di Bona, E; Bacigalupo, A				Locasciulli, A; Arcese, W; Locatelli, F; Di Bona, E; Bacigalupo, A		Italian Aplastic Anaemia Study Grp	Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy	LANCET			English	Article							ANEMIA	Granulocyte-colony stimulating factor (G-CSF) is being increasingly used in healthy volunteers to harvest haemopoietic stem cells, A possible role of G-CSF in the development of clonal disorders or leukaemia has been suggested. We analysed 144 patients with aplastic anaemia treated with immunosuppression protocols with or without G-CSF, with normal cytogenetics at diagnosis or immediately after immunosuppression, Our findings indicated that the risk of developing myelodysplasia or leukaemia was similar in patients with aplastic anaemia on immunosuppressive treatment with or without G-CSF. Therefore, it seems unlikely that G-CSF causes leukaemia in healthy volunteers.	S Camillo Hosp, Dept Haematol, I-00152 Rome, Italy; Univ La Sapienza, Rome, Italy; San Bortolo Hosp, Dept Haematol, Vicenza, Italy; S Matteo Hosp, Paediat Clin, Pavia, Italy; S Martino Hosp, Dept Haematol, Genoa, Italy	Sapienza University Rome; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; University of Genoa; IRCCS AOU San Martino IST	Locasciulli, A (corresponding author), S Camillo Hosp, Dept Haematol, I-00152 Rome, Italy.			ARCESE, WILLIAM/0000-0001-5697-366X				Bacigalupo A, 2000, BLOOD, V95, P1931, DOI 10.1182/blood.V95.6.1931; Cavallaro AM, 2000, BONE MARROW TRANSPL, V25, P85, DOI 10.1038/sj.bmt.1702072; Fuhrer M, 1998, BLOOD, V92, p156A; MOORE MAS, 1991, NEW ENGL J MED, V324, P1358, DOI 10.1056/NEJM199105093241909; Ohara A, 1997, BLOOD, V90, P1009, DOI 10.1182/blood.V90.3.1009.1009_1009_1013	5	56	64	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					43	44		10.1016/S0140-6736(00)03574-1	http://dx.doi.org/10.1016/S0140-6736(00)03574-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197365				2022-12-28	WOS:000166341500018
J	Crabtree, RH				Crabtree, RH			Chemistry - Switched-on nickel	SCIENCE			English	Editorial Material									Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA	Yale University	Crabtree, RH (corresponding author), Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA.	robert.crabtree@yale.edu						Adams MWW, 1998, SCIENCE, V282, P1842, DOI 10.1126/science.282.5395.1842; SCHRAUZER GN, 1970, J AM CHEM SOC, V92, P1935; Wang K, 2001, SCIENCE, V291, P106, DOI 10.1126/science.291.5501.106	3	4	4	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					56	57		10.1126/science.291.5501.56	http://dx.doi.org/10.1126/science.291.5501.56			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11192010				2022-12-28	WOS:000166259100029
J	Cusack, S				Cusack, S			Workplace bullying: icebergs in sight, soundings needed	LANCET			English	Editorial Material									British Med Assoc, Reg Serv Dept, Bristol BS1 4TR, Avon, England		Cusack, S (corresponding author), British Med Assoc, Reg Serv Dept, Bristol BS1 4TR, Avon, England.							HANIKIN R, 2000, BULLYING CULTURE; Kivimaki M, 2000, OCCUP ENVIRON MED, V57, P656, DOI 10.1136/oem.57.10.656; Quine L, 1999, BRIT MED J, V318, P228, DOI 10.1136/bmj.318.7178.228; Rayner C, 1997, J COMMUNITY APPL SOC, V7, P181, DOI 10.1002/(SICI)1099-1298(199706)7:3<181::AID-CASP416>3.0.CO;2-Y; ZUCKER A, 1996, WELTTOOCHE      0725	5	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2000	356	9248					2118	2118		10.1016/S0140-6736(00)03489-9	http://dx.doi.org/10.1016/S0140-6736(00)03489-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	385HD	11191536				2022-12-28	WOS:000165997300007
J	Alvarez-Dardet, C; Ruiz, MT				Alvarez-Dardet, C; Ruiz, MT			Rethinking the map for health inequalities	LANCET			English	Article									Univ Alicante, Dept Salud Publ, Edificio Ciencias Sociales, E-03080 Alicante, Spain	Universitat d'Alacant	Alvarez-Dardet, C (corresponding author), Univ Alicante, Dept Salud Publ, Edificio Ciencias Sociales, Campus San Vicente, E-03080 Alicante, Spain.			Alvarez-Dardet, Carlos/0000-0003-3530-7451					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S36	S36		10.1016/S0140-6736(00)92022-1	http://dx.doi.org/10.1016/S0140-6736(00)92022-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191493	Bronze			2022-12-28	WOS:000166074900038
J	Bloom, BR				Bloom, BR			Public-health priorities in the industrialised world	LANCET			English	Article									Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Bloom, BR (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.								0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S50	S50		10.1016/S0140-6736(00)92036-1	http://dx.doi.org/10.1016/S0140-6736(00)92036-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191509				2022-12-28	WOS:000166074900052
J	Sjogren, B				Sjogren, B			Childbirth: expectations, choices, and trends	LANCET			English	Article									Karolinska Inst, Stockholm, Sweden; Karolinska Hosp, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Sjogren, B (corresponding author), Dept Womens & Childrens Hlth, Div Obstet & Gynecol, SE-17176 Stockholm, Sweden.								0	10	10	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S12	S12		10.1016/S0140-6736(00)91998-6	http://dx.doi.org/10.1016/S0140-6736(00)91998-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191467	Bronze			2022-12-28	WOS:000166074900014
J	Clerc, P; Avner, P				Clerc, P; Avner, P			Genetics - Reprogramming X inactivation	SCIENCE			English	Editorial Material							CHROMOSOME INACTIVATION		Inst Pasteur, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Clerc, P (corresponding author), Inst Pasteur, F-75015 Paris, France.							Costanzi C, 2000, DEVELOPMENT, V127, P2283; Eggan K, 2000, SCIENCE, V290, P1578, DOI 10.1126/science.290.5496.1578; Hadjantonakis AK, 1998, NAT GENET, V19, P220, DOI 10.1038/896; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Lee JT, 2000, CELL, V103, P17, DOI 10.1016/S0092-8674(00)00101-X; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Okamoto I, 2000, DEVELOPMENT, V127, P4137; PRISSETTE M, IN PRESS HUM MOL GEN; Rideout WM, 2000, NAT GENET, V24, P109, DOI 10.1038/72753; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; Wakayama T, 2000, NAT GENET, V24, P108, DOI 10.1038/72749	12	9	10	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1518	1519		10.1126/science.290.5496.1518	http://dx.doi.org/10.1126/science.290.5496.1518			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11185510				2022-12-28	WOS:000165446200028
J	Quillen, K				Quillen, K			Hypotensive transfusion reactions in patients taking angiotensin-converting-enzyme inhibitors	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Boston Med Ctr, Boston, MA 02118 USA	Boston Medical Center	Quillen, K (corresponding author), Boston Med Ctr, Boston, MA 02118 USA.			Quillen, Karen/0000-0002-4243-0864				*AM ASS BLOOD BANK, 1998, AABB WKLY REP, V4, P1; Goodnough LT, 1999, NEW ENGL J MED, V340, P438, DOI 10.1056/NEJM199902113400606; Hume HA, 1996, TRANSFUSION, V36, P904, DOI 10.1046/j.1537-2995.1996.361097017178.x; KLEIN HG, 1998, HEMATOLOGY 1998, P158; Sweeney JD, 1998, TRANSFUSION, V38, P410, DOI 10.1046/j.1537-2995.1998.38498257382.x	5	19	19	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1422	1423		10.1056/NEJM200011093431918	http://dx.doi.org/10.1056/NEJM200011093431918			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183892				2022-12-28	WOS:000165152800033
J	Fawcett, J; Pawson, T				Fawcett, J; Pawson, T			Signal transduction - N-WASP regulation - the sting in the tail	SCIENCE			English	Editorial Material							ACTIN		Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Fawcett, J (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Pawson, Tony J/E-4578-2013	Fawcett, Jim/0000-0003-0043-2164				Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Pawson T, 2000, GENE DEV, V14, P1027; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1	7	19	19	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 27	2000	290	5492					725	726		10.1126/science.290.5492.725	http://dx.doi.org/10.1126/science.290.5492.725			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ND	11184204				2022-12-28	WOS:000090067600030
J	Cassell, GH; Mekalanos, J				Cassell, GH; Mekalanos, J			Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IDENTIFICATION; EXPRESSION; MULTIDRUG; TRENDS; GENES	During the past 2 decades, new infectious diseases have appeared and old ones previously thought to be controlled have reemerged. New and reemerging infectious agents will continue to pose serious threats well into the 21st century. The prediction that the threat of infectious disease may not diminish is supported by evidence that infectious agents cause many chronic diseases and cancer of previous unknown etiology, Moreover, the utility of existing antimicrobial agents is rapidly eroding, tipping the balance in favor of multidrug-resistant pathogens, and there appear to be few, if any, new classes of drugs currently in clinical development. The need for research directed toward development of new antibiotics has never been greater. Advances in research technologies and microbial genome sequencing in the past decade have led to identification of a large number of new targets. Functional genomics and integrative biology should validate these targets and provide the best opportunity for developing effective new therapies, improved diagnostic techniques, and better tools to understand host-pathogen interactions.	Eli Lilly & Co, Lilly Res Labs, Infect Dis Res & Clin Invest, Indianapolis, IN 46285 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Eli Lilly; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School	Cassell, GH (corresponding author), Eli Lilly & Co, Lilly Res Labs, Infect Dis Res & Clin Invest, Drop Code 0438,LCC, Indianapolis, IN 46285 USA.	cassell_gail@lilly.com						Akerley BJ, 1998, P NATL ACAD SCI USA, V95, P8927, DOI 10.1073/pnas.95.15.8927; [Anonymous], PREV EM INF DIS STRA; Arigoni F, 1998, NAT BIOTECHNOL, V16, P851, DOI 10.1038/nbt0998-851; BURBAUM JJ, 1995, P NATL ACAD SCI USA, V92, P6027, DOI 10.1073/pnas.92.13.6027; Cassell GH, 1998, EMERG INFECT DIS, V4, P475, DOI 10.3201/eid0403.980339; *CDCP, 1994, ADD EM INF DIS THREA; Center for Disease Control and Prevention (CDC), 1999, MMWR-MORBID MORTAL W, V48, P890; Cohen ML, 2000, NATURE, V406, P762, DOI 10.1038/35021206; Enserink M, 2000, SCIENCE, V289, P842, DOI 10.1126/science.289.5481.842; Forum on Emerging Infections Institute of Medicine, 1998, ANT RES ISS OPT; *GOV PRINT OFF, 1997, FOOD SAF FARM TABL N; GREER J, 1994, J MED CHEM, V37, P1035, DOI 10.1021/jm00034a001; Harris AG, 2000, J ANTIMICROB CHEMOTH, V45, P591, DOI 10.1093/jac/45.5.591; HOSHINO K, 1994, ANTIMICROB AGENTS CH, V38, P2623, DOI 10.1128/AAC.38.11.2623; Ichikawa JK, 2000, P NATL ACAD SCI USA, V97, P9659, DOI 10.1073/pnas.160140297; Institute of Medicine, 1992, EM INF MICR THREATS; Judson N, 2000, NAT BIOTECHNOL, V18, P740, DOI 10.1038/77305; Khan AS, 1996, J INFECT DIS, V173, P1297, DOI 10.1093/infdis/173.6.1297; Marwick C, 1998, JAMA-J AM MED ASSOC, V279, P643, DOI 10.1001/jama.279.9.643; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; Nikaido H, 1998, CLIN INFECT DIS, V27, pS32, DOI 10.1086/514920; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; Saier MH, 1998, FASEB J, V12, P265, DOI 10.1096/fasebj.12.3.265; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Tan DS, 1998, J AM CHEM SOC, V120, P8565, DOI 10.1021/ja981746o; Trias J, 1997, CURR OPIN BIOTECH, V8, P757, DOI 10.1016/S0958-1669(97)80131-0; *US NAT INT COUNC, 2000, PUBL NIE D, V9917; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; World Health Organisation (WHO), 1999, WHO REP INF DIS REM	33	115	125	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					601	605		10.1001/jama.285.5.601	http://dx.doi.org/10.1001/jama.285.5.601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176866				2022-12-28	WOS:000166714200019
J	Bauer, TH; Lalvani, A; Fehrenbach, J; Steffen, I; Aponte, JJ; Segovia, R; Vila, J; Philippczik, G; Steinbruckner, B; Frei, R; Bowler, I; Kist, M				Bauer, TH; Lalvani, A; Fehrenbach, J; Steffen, I; Aponte, JJ; Segovia, R; Vila, J; Philippczik, G; Steinbruckner, B; Frei, R; Bowler, I; Kist, M			Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENTERIC PATHOGENS; SALMONELLA OUTBREAK; NOSOCOMIAL DIARRHEA; COST; CIPROFLOXACIN	Context The yield of in-hospital stool cultures performed more than 72 hours after admission is low, and a commonly used policy dictates that laboratories reject these cultures to save costs. However, enteropathogenic bacteria other than Clostridium difficile (EPB) may cause nosocomial illness that would be missed by use of such a "3-day rule." Objective To develop guidelines for hospital use of stool cultures that are sensitive to clinically relevant cases of sporadic and epidemic nosocomial diarrhea. Design Five-part study that incorporated a derivation sample based on retrospective chart review and a prospective cohort study (including cost savings analysis), and a validation sample based on retrospective chart review. Setting Four European academic health care centers. Patients Derivation sample: 1735 adult inpatients from whom 3416 stool cultures were obtained during a 19-month period (1995-1997) and 68 adult inpatients for whom EPB were grown from stool cultures during a 10-year period (1988-1998); validation sample: 65 patients with sporadic isolation of EPB (1993-1998), 56 patients involved in 2 nosocomial Salmonella outbreaks (1992 and 1997), and 330 patients who had stool cultures performed (1998). Main Outcome Measure Performance of derived criteria in detecting pathogenic bacteria and outbreaks and reducing total number of stool cultures performed. Results Stool cultures grew EPB in 3.3% of samples obtained less than or equal to 72 hours after admission and 0.5% of samples obtained thereafter (P<.001). Isolation of EPB >72 hours after admission was not associated with clinical symptoms or signs but was associated with community-acquired diarrhea (24%), age 65 years or older with pre existing comorbid disease (25%), neutropenia (13%), HIV infection (10%), and nondiarrheal manifestations of enteric infections (16%). Twelve percent were asymptomatic carriers. These characteristics were used to create criteria for selecting patients for whom stool cultures would be indicated. These criteria were applied post hoc to a series of 1025 stool cultures; the number of stool cultures would have been reduced by 52% and no clinically significant cases would have been missed. Annual savings to a 355-bed institution would be approximately $7800 for reagent costs and 75 hours of technician time. In the validation samples, only 2 patients of 65 who had EPB would not have been identified, and neither required treatment. if the 3-day rule had been applied, 52 cases would not have been identified, 28 of which required antibiotic treatment. Conclusion Our modified 3-day rule for use in selecting cases for stool culture is sensitive to sporadic and epidemic cases of nosocomial diarrhea in hospitalized adults.	Univ Hosp Freiburg, Dept Internal Med 2, D-79106 Freiburg, Germany; Univ Hosp Freiburg, Inst Med Microbiol & Hyg, D-79106 Freiburg, Germany; Univ Oxford, Nuffield Dept Clin Med, Oxford, England; John Radcliffe Hosp, Dept Microbiol, Oxford OX3 9DU, England; Univ Basel Hosp, Bacteriol Lab, CH-4031 Basel, Switzerland; Univ Barcelona, IDIBAPS, Hosp Clin, Dept Microbiol, Barcelona, Spain; Univ Barcelona, IDIBAPS, Hosp Clin, Dept Gastroenterol & Hepatol, Barcelona, Spain; Univ Barcelona, IDIBAPS, Hosp Clin, Epidemiol & Biostat Unit, Barcelona, Spain	University of Freiburg; University of Freiburg; University of Oxford; University of Oxford; University of Basel; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bauer, TH (corresponding author), Univ Hosp Freiburg, Dept Internal Med 2, Hugstetterstr 55, D-79106 Freiburg, Germany.		Vila, Jordi/P-3613-2016	Vila, Jordi/0000-0002-8025-3926; Lalvani, Ajit/0000-0002-2396-246X				AHMAD F, 1991, J HOSP INFECT, V17, P171, DOI 10.1016/0195-6701(91)90228-Z; Arnow PM, 1997, LANCET, V350, P575, DOI 10.1016/S0140-6736(97)07061-X; AVALOS ME, 1992, DIGEST DIS SCI, V37, P1772, DOI 10.1007/BF01299874; BARBUT F, 1995, EUR J CLIN MICROBIOL, V14, P346, DOI 10.1007/BF02116530; BARNASS S, 1989, EPIDEMIOL INFECT, V103, P227, DOI 10.1017/S0950268800030570; Chitkara YK, 1996, ARCH INTERN MED, V156, P1445, DOI 10.1001/archinte.156.13.1445; COHEN J, 1996, OXFORD TXB MED, P1027; CRUICKSHANK JG, 1984, J HOSP INFECT, V5, P241, DOI 10.1016/0195-6701(84)90072-0; Danilowicz D, 1974, Am J Cardiol, V34, P864, DOI 10.1016/0002-9149(74)90711-5; DRYDEN MS, 1994, J HOSP INFECT, V28, P195, DOI 10.1016/0195-6701(94)90102-3; DYSON C, 1995, J HOSP INFECT, V29, P287, DOI 10.1016/0195-6701(95)90275-9; EDES TE, 1989, SOUTHERN MED J, V82, P1497, DOI 10.1097/00007611-198912000-00010; FAN K, 1993, J CLIN MICROBIOL, V31, P2233, DOI 10.1128/JCM.31.8.2233-2235.1993; GROSS PA, 1988, INFECT CONT HOSP EP, V9, P497, DOI 10.2307/30146545; Hogenauer C, 1998, CLIN INFECT DIS, V27, P702, DOI 10.1086/514958; HUNTER PR, 1987, J HOSP INFECT, V10, P73, DOI 10.1016/0195-6701(87)90035-1; KOPLAN JP, 1980, LANCET, V2, P413; LEcuyer PB, 1996, CLIN INFECT DIS, V23, P734, DOI 10.1093/clinids/23.4.734; MCFARLAND LV, 1993, GASTROENTEROL CLIN N, V22, P563; MCFARLAND LV, 1995, AM J INFECT CONTROL, V23, P295, DOI 10.1016/0196-6553(95)90060-8; MISHU B, 1994, J INFECT DIS, V169, P547, DOI 10.1093/infdis/169.3.547; Morris AJ, 1996, J CLIN MICROBIOL, V34, P1776, DOI 10.1128/JCM.34.7.1776-1778.1996; Ozerek AE, 1999, J HOSP INFECT, V41, P159, DOI 10.1016/S0195-6701(99)90055-5; PAVIA AT, 1991, BACTERIAL INFECT HUM, P573; Philippczik Gabi, 1999, Clin Microbiol Infect, V5, P586, DOI 10.1111/j.1469-0691.1999.tb00442.x; PORTNOY DA, 1984, INFECT IMMUN, V43, P108, DOI 10.1128/IAI.43.1.108-114.1984; Rabasa M, 1993, Enferm Infecc Microbiol Clin, V11, P479; Rohner P, 1997, J CLIN MICROBIOL, V35, P1427, DOI 10.1128/JCM.35.6.1427-1432.1997; SIEGEL D, 1987, ARCH PATHOL LAB MED, V111, P715; SIEGEL DL, 1990, JAMA-J AM MED ASSOC, V263, P979, DOI 10.1001/jama.263.7.979; Valenstein P, 1996, ARCH PATHOL LAB MED, V120, P206; Wall PG, 1996, J HOSP INFECT, V33, P181, DOI 10.1016/S0195-6701(96)90001-8; YANNELLI B, 1988, AM J INFECT CONTROL, V16, P246, DOI 10.1016/S0196-6553(88)80003-8	33	74	88	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					313	319		10.1001/jama.285.3.313	http://dx.doi.org/10.1001/jama.285.3.313			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390XD	11176841	Bronze			2022-12-28	WOS:000166324300022
J	Jha, AK; Shlipak, MG; Hosmer, W; Frances, CD; Browner, WS				Jha, AK; Shlipak, MG; Hosmer, W; Frances, CD; Browner, WS			Racial differences in mortality among men hospitalized in the Veterans Affairs health care system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; CARDIOVASCULAR PROCEDURES; MEDICAL SYSTEM; RISK-FACTORS; LUNG-CANCER; DEPRESSIVE SYMPTOMS; PATIENT RACE; RESOURCE USE; SURVIVAL	Context Racial disparities in health care delivery and outcomes may be due to differences in health care access and, therefore, may be mitigated in an equal-access health care system. Few studies have examined racial differences in health outcomes in such a system. Objective To study racial differences in mortality among patients admitted to hospitals in the Veterans Affairs (VA) system, a health care system that potentially offers equal access to care. Design, Setting, and Participants Cohort study of 28934 white and 7575 black men admitted to 147 VA hospitals for 1 of 6 common medical diagnoses (pneumonia, angina, congestive heart failure, chronic obstructive pulmonary disease, diabetes, and chronic renal failure) between October 1, 1995, and September 30, 1996. Main Outcome Measures The primary outcome measure was 30-day mortality among black compared with white patients. Secondary outcome measures were in-hospital mortality and 6-month mortality. Results Overall mortality at 30 days was 4.5% in black patients and 5.8% in white patients (relative risk [RR], 0.77; 95% confidence interval [CI], 0.69-0.87; P = .001). Mortality was lower among blacks for each of the 6 medical diagnoses. Multivariate adjustment for patient and hospital characteristics had a small effect (RR, 0.75; 95% CI, 0.66-0.85; P < .001). Black patients also had lower adjusted in-hospital and 6-month mortality. These findings were consistent among all subgroups evaluated. Conclusions Black patients admitted to VA hospitals with common medical diagnoses have lower mortality rates than white patients. The survival advantage of black patients is not readily explained; however, the absence of a survival disadvantage for blacks may reflect the benefits of equal access to health care and the quality of inpatient treatment at VA medical centers.	Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Jha, AK (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.							AKERLEY WL, 1993, ARCH INTERN MED, V153, P1681, DOI 10.1001/archinte.153.14.1681; ALEXANDER M, 1995, JAMA-J AM MED ASSOC, V274, P1037, DOI 10.1001/jama.274.13.1037; ARONOW WS, 1991, J AM GERIATR SOC, V39, P567, DOI 10.1111/j.1532-5415.1991.tb03594.x; Arozullah AM, 1999, J AM COLL SURGEONS, V188, P604, DOI 10.1016/S1072-7515(99)00047-2; Ashton CM, 1999, NEW ENGL J MED, V340, P32, DOI 10.1056/NEJM199901073400106; AXTELL LM, 1978, JNCI-J NATL CANCER I, V60, P1209, DOI 10.1093/jnci/60.6.1209; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; BENNETT CL, 1995, ARCH INTERN MED, V155, P1586, DOI 10.1001/archinte.155.15.1586; BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; Borzak S, 1999, AM HEART J, V137, P338, DOI 10.1053/hj.1999.v137.92523; BUCKLE JM, 1992, ARCH INTERN MED, V152, P1596, DOI 10.1001/archinte.152.8.1596; Burns RB, 1996, ANN INTERN MED, V125, P173, DOI 10.7326/0003-4819-125-3-199608010-00002; Carlisle DM, 1997, AM J PUBLIC HEALTH, V87, P263, DOI 10.2105/AJPH.87.2.263; CASTANER A, 1988, ANN INTERN MED, V109, P33, DOI 10.7326/0003-4819-109-1-33; Chin MH, 1997, AM J CARDIOL, V79, P1640, DOI 10.1016/S0002-9149(97)00214-2; Conigliaro J, 2000, ARCH INTERN MED, V160, P1329, DOI 10.1001/archinte.160.9.1329; Covinsky KE, 1999, ANN INTERN MED, V130, P563, DOI 10.7326/0003-4819-130-7-199904060-00004; Cushman WC, 2000, ARCH INTERN MED, V160, P825, DOI 10.1001/archinte.160.6.825; Dominitz JA, 1998, CANCER, V82, P2312, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2312::AID-CNCR3>3.0.CO;2-U; Dries DL, 1999, NEW ENGL J MED, V340, P609, DOI 10.1056/NEJM199902253400804; EBELL MH, 1995, J FAM PRACTICE, V40, P571; Eggers P W, 1995, Health Care Financ Rev, V17, P89; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; Farmer IP, 1996, BEHAV MED, V22, P59, DOI 10.1080/08964289.1996.9933765; Glass TA, 1999, BRIT MED J, V319, P478, DOI 10.1136/bmj.319.7208.478; Gordon HS, 1996, JAMA-J AM MED ASSOC, V276, P1639, DOI 10.1001/jama.276.20.1639; Gottdiener JS, 1997, J AM COLL CARDIOL, V29, P651, DOI 10.1016/S0735-1097(96)00554-2; Gray RJ, 1996, ARCH INTERN MED, V156, P769, DOI 10.1001/archinte.156.7.769; Greenwald HP, 1998, AM J PUBLIC HEALTH, V88, P1681, DOI 10.2105/AJPH.88.11.1681; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; HARIHARAN S, 1993, CLIN TRANSPLANT, V7, P235; HERD D, 1994, J STUD ALCOHOL, V55, P61, DOI 10.15288/jsa.1994.55.61; HORNER RD, 1991, HEALTH SERV RES, V26, P531; Hutchinson RG, 1997, ANGIOLOGY, V48, P279, DOI 10.1177/000331979704800401; Ifudu O, 1999, AM J KIDNEY DIS, V33, P728, DOI 10.1016/S0272-6386(99)70226-X; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; Lanska DJ, 1996, STROKE, V27, P1055, DOI 10.1161/01.STR.27.6.1055; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; Mickelson JK, 1997, J AM COLL CARDIOL, V29, P915, DOI 10.1016/S0735-1097(97)00034-X; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; Myers M H, 1981, Prog Clin Biol Res, V53, P151; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; RICHARDS MS, 1990, J STUD ALCOHOL, V51, P396, DOI 10.15288/jsa.1990.51.396; Rosenthal GE, 1997, JAMA-J AM MED ASSOC, V278, P485, DOI 10.1001/jama.278.6.485; Siddique RM, 1996, ARCH INTERN MED, V156, P2343, DOI 10.1001/archinte.156.20.2343; Smith TJ, 1995, LUNG CANCER-J IASLC, V13, P235, DOI 10.1016/0169-5002(95)00496-3; Taylor AJ, 1997, J AM COLL CARDIOL, V30, P901, DOI 10.1016/S0735-1097(97)00271-4; Taylor HA, 1998, AM J CARDIOL, V82, P1019, DOI 10.1016/S0002-9149(98)00547-5; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Whooley MA, 1998, ARCH INTERN MED, V158, P2129, DOI 10.1001/archinte.158.19.2129; Wilt TJ, 1996, ARCH INTERN MED, V156, P1181, DOI 10.1001/archinte.156.11.1181; Wray NP, 1997, MED CARE RES REV, V54, P326, DOI 10.1177/107755879705400306; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003	60	159	159	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					297	303		10.1001/jama.285.3.297	http://dx.doi.org/10.1001/jama.285.3.297			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	390XD	11176839	Bronze			2022-12-28	WOS:000166324300020
J	David, SP; Greer, DS				David, SP; Greer, DS			Social marketing: Application to medical education	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIANS	Medical education is often a frustrating endeavor, particularly when it attempts to change practice behavior. Traditional lecture-based educational methods are limited in their ability to sustain concentration and interest and to promote learner adherence to best-practice guidelines. Marketing techniques have been very effective in changing consumer behavior and physician behavior. However, the techniques of social marketing-goal identification, audience segmentation, and market research-have not been harnessed and applied to medical education. Social marketing can be applied to medical education in the effort to go beyond inoculation of learners with information and actually change behaviors. The tremendous potential of social marketing for medical education should be pilot-tested and systematically evaluated.	Brown Univ, Sch Med, Providence, RI 02912 USA; Brown Univ, Ctr Primary Care & Prevent, Providence, RI 02912 USA	Brown University; Brown University	Greer, DS (corresponding author), Brown Univ, Sch Med, Box G-B497, Providence, RI 02912 USA.			David, Sean/0000-0002-4922-2603				AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; CARNEY PA, 1995, ACAD MED, V70, P52, DOI 10.1097/00001888-199501000-00014; Dev P, 1996, Acad Med, V71, P523, DOI 10.1097/00001888-199605000-00036; KOTLER P, 1971, J MARKETING, V35, P3, DOI 10.2307/1249783; MORROW DJ, 1998, NY TIMES        0607, V7, P1; MORROW DJ, 1998, NY TIMES        0607, P10; ORLOWSKI JP, 1992, CHEST, V102, P270, DOI 10.1378/chest.102.1.270; Petrusa ER, 1999, ACAD MED, V74, P123, DOI 10.1097/00001888-199902000-00011; Sonnad S S, 1999, Jt Comm J Qual Improv, V25, P630; STUART J, 1978, LANCET, V2, P514; Troein M, 1997, J INTERN MED, V242, P173, DOI 10.1046/j.1365-2796.1997.00182.x; Tropman SE, 1999, BREAST CANCER RES TR, V56, P59, DOI 10.1023/A:1006279117650; WALSH DC, 1993, HEALTH AFFAIR, V12, P104, DOI 10.1377/hlthaff.12.2.104; WEIBE G, 1952, PUBLIC OPIN QUART, V15, P679; WEINER JP, 1995, JAMA-J AM MED ASSOC, V273, P1503, DOI 10.1001/jama.273.19.1503; Werk LN, 2000, PEDIATRICS, V105, P585, DOI 10.1542/peds.105.3.585	16	20	20	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2001	134	2					125	127		10.7326/0003-4819-134-2-200101160-00013	http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	391KW	11177316				2022-12-28	WOS:000166356000006
J	Horton, R				Horton, R			We all make mistakes: tell us yours	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Horton, R (corresponding author), Lancet, London WC1X 8RR, England.							Gostin L, 2000, JAMA-J AM MED ASSOC, V283, P1742, DOI 10.1001/jama.283.13.1742; Horton R, 1999, LANCET, V353, P422, DOI 10.1016/S0140-6736(99)00036-7	2	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					88	88		10.1016/S0140-6736(00)03538-8	http://dx.doi.org/10.1016/S0140-6736(00)03538-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197444				2022-12-28	WOS:000166476200008
J	Daar, ES; Little, S; Pitt, J; Santangelo, J; Ho, P; Harawa, N; Kerndt, P; Giorgi, JV; Bai, JX; Gaut, P; Richman, DD; Mandel, S; Nichols, S				Daar, ES; Little, S; Pitt, J; Santangelo, J; Ho, P; Harawa, N; Kerndt, P; Giorgi, JV; Bai, JX; Gaut, P; Richman, DD; Mandel, S; Nichols, S		Los Angeles Cty Primary HIV Infect	Diagnosis of primary HIV-1 infection	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PLASMA; RNA	Background: The optimal approach for diagnosing primary HIV-1 infection has not been defined. Objective: To determine the usefulness of symptoms and virologic tests for diagnosing primary HIV-1 infection. Design: Prospective cohort study. Setting: A teaching hospital in Los Angeles and a university research center in San Diego, California. Patients: 436 patients who had symptoms consistent with primary HIV infection. Measurements: Clinical information and levels of HIV antibody, HIV RNA, and p24 antigen. Results: Primary infection was diagnosed in 54 patients (12.4%). The sensitivity and specificity of the p24 antigen assay were 88.7% (95% CI, 77.0% to 95.7%) and 100% (CI, 99.3% to 100%), respectively. For the HIV RNA assay, sensitivity was 100% and specificity was 97.4% (CI, 94.9% to 98,9%), Fever, myalgia, rash, night sweats, and arthralgia occurred more frequently in patients with primary infection (P < 0.05). Conclusions: No sign or symptom allows targeted screening for primary infection. Although assays for HIV RNA are more sensitive than those for p24 antigen in diagnosing primary infection, they are more expensive and are more likely to yield false-positive results.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Burns & Allen Res Inst, Los Angeles Cty HIV Epidemiol Program, Los Angeles, CA USA; Los Angeles Free Clin, Los Angeles, CA USA; Ctr AIDS Res, Los Angeles, CA USA; Univ Calif San Diego, San Diego, CA 92103 USA; San Diego Vet Affairs Healthcare Syst, San Diego, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Diego	Daar, ES (corresponding author), Cedars Sinai Med Ctr, Div Infect Dis, B217,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	Daar@CSHS.org	Little, Susan/AAA-6116-2019	Harawa, Nina T./0000-0002-7486-8393	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI043638, U01AI027670] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00425] Funding Source: Medline; NIAID NIH HHS [AI 27670, AI 43638] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bollinger RC, 1997, JAMA-J AM MED ASSOC, V278, P2085, DOI 10.1001/jama.278.23.2085; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; ERICE A, 2000, 7 C RETR OPP INF SAN; *FDN RETR HUM HLTH, 1999, 6 C RETR OPP INF CHI; HENRARD DR, 1994, TRANSFUSION, V34, P376, DOI 10.1046/j.1537-2995.1994.34594249046.x; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; Lentner C., 1982, GEIGY SCI TABLES, V2, P89; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Niu MT, 1998, J INFECT DIS, V178, P80, DOI 10.1086/515612; Phair JP, 1997, J INFECT DIS, V175, P959, DOI 10.1086/514000; Rich JD, 1999, ANN INTERN MED, V130, P37, DOI 10.7326/0003-4819-130-1-199901050-00007; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Vanhems P, 1997, CLIN INFECT DIS, V24, P965, DOI 10.1093/clinids/24.5.965	15	140	152	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2001	134	1					25	29		10.7326/0003-4819-134-1-200101020-00010	http://dx.doi.org/10.7326/0003-4819-134-1-200101020-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386CV	11187417				2022-12-28	WOS:000166043300004
J	Colman, EG				Colman, EG			Hippocrates ridens: a 17th century medico-political journal	LANCET			English	Editorial Material									US FDA, Div Metab & Endocrine Drug Prod, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Colman, EG (corresponding author), US FDA, Div Metab & Endocrine Drug Prod, Rockville, MD 20857 USA.							Clark G. N., 1964, HIST ROYAL COLL PHYS; Cook Harold, 1986, DECLINE OLD MED REGI; CRIST TJ, 1977, THESIS CAMBRIDGE U; DENT JD, 1682, LOYAL CITIZEN SEDITI; DUNTON J, 1818, LIFE ERROR J DUNTON; FILMER R, 1680, POWER KINGS PARTICUL; HARRIS W, 1683, PHARM ANTIEMPERICA; Johns A, 1999, NATURE BOOK; LEFANU WR, 1984, BRIT PERIODICALS MED; MIDGLEY R, 1689, POPERY BANISHED; Midgley R., 1687, NEW TREATISE NATURAL; Munk William, 1861, ROLL ROYAL COLL PHYS; Parker Samuel, 1681, CASE CHURCH ENGLAND, P263; *SAL CIT COUNC, 1681, ADDR HIS MAJ COMM CO; SMITH F, 1681, DEMOCRITUS RIDENS CO; Summers Montague, 1927, COMPLETE WORKS T SHA; WILLIAM R, 1974, HIST J, V2, P247; WING D, 1994, SHORT TITLE CATALOGU; 1681, HERACLITUS RIDENTS D; 1686, HIPPOCRATES RIDENTS; 1953, DICT NATL BIOGRAPHY	21	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2184	2186		10.1016/S0140-6736(00)03509-1	http://dx.doi.org/10.1016/S0140-6736(00)03509-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191560				2022-12-28	WOS:000165997300041
J	Richardson, R				Richardson, R			Silent pirates of the shore: Robert Louis Stevenson and medical negligence	LANCET			English	Editorial Material																		BALFOUR G, 2001, LIFE RL STEVENSON, V1, P199; BRADFORD B, 1994, LETT RL STEVENSON, P3; CALDER J, 1990, RLS LIFE STUDY, P168; CAUTY HE, 1874, DIS SKIN, P326; COLVIN S, 1921, MEMORIES NOTES PERSO, P111; CROCKETT SR, 1924, RL STEVENSON HIS WOR, P14; Hartley J., 1966, PRIVATE PRESS VENTUR, P3; MACKAY D, 1911, APPIN MURDER; MEHEW E, 1997, SELECTED LETT RL STE, P181; PLATT R, 1995, PIRATE, P59; RANKIN N, 1987, DEAD MANS CHEST; RICHARDSON R, 1989, BRIT MED J, V299, P1507, DOI 10.1136/bmj.299.6714.1507; RICHARDSON R, 2000, LANCET, V355, P1476; STEVENSON RL, 1921, MORAL EMBLEMS OTHER, P59; WILSON E, 1869, LECT CUTANEOUS MED, V3, P347; Yudkin JS, 2000, LANCET, V355, P919, DOI 10.1016/S0140-6736(99)09225-9	16	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2171	2175		10.1016/S0140-6736(00)03506-6	http://dx.doi.org/10.1016/S0140-6736(00)03506-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191557				2022-12-28	WOS:000165997300038
J	Rutgeerts, P; Vermeire, S				Rutgeerts, P; Vermeire, S			Serological diagnosis of inflammatory bowel disease	LANCET			English	Editorial Material							SACCHAROMYCES-CEREVISIAE BAKERS; CROHNS-DISEASE; ANTIBODY; YEAST		Univ Louvain, Dept Med, B-3000 Louvain, Belgium		Rutgeerts, P (corresponding author), Univ Louvain, Dept Med, B-3000 Louvain, Belgium.			Vermeire, Severine/0000-0001-9942-3019				Joossens S, 2000, GASTROENTEROLOGY, V118, pA886, DOI 10.1016/S0016-5085(00)85682-6; MAIN J, 1988, BRIT MED J, V297, P1105, DOI 10.1136/bmj.297.6656.1105; MCKENZIE H, 1990, GUT, V31, P536, DOI 10.1136/gut.31.5.536; PEETERS M, IN PRESS AM J GASTRO; Quinton JF, 1998, GUT, V42, P788, DOI 10.1136/gut.42.6.788; Ruemmele FM, 1998, GASTROENTEROLOGY, V115, P822, DOI 10.1016/S0016-5085(98)70252-5; RUMP JA, 1990, IMMUNOBIOLOGY, V181, P406, DOI 10.1016/S0171-2985(11)80509-7; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P202, DOI 10.1016/S0091-6749(05)80067-3; Sendid B, 1996, CLIN DIAGN LAB IMMUN, V3, P219, DOI 10.1128/CDLI.3.2.219-226.1996; SURTON CL, 2000, GASTROENTEROLOGY, V119, P23; Timmer A, 1999, INFLAMM BOWEL DIS, V5, P79, DOI 10.1097/00054725-199905000-00002; Vasiliauskas EA, 2000, GUT, V47, P487, DOI 10.1136/gut.47.4.487; VERMEIRE S, IN PRESS GASTROENTER	13	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2117	2118		10.1016/S0140-6736(00)03488-7	http://dx.doi.org/10.1016/S0140-6736(00)03488-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191535				2022-12-28	WOS:000165997300006
J	Smith, O				Smith, O			Cell biology - The export business	SCIENCE			English	Editorial Material																		Ho J., UNPUB; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Ho JHN, 2000, RNA, V6, P1625, DOI 10.1017/S1355838200001291	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 15	2000	290	5499					2087	2087		10.1126/science.290.5499.2087	http://dx.doi.org/10.1126/science.290.5499.2087			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	383ER	11187836				2022-12-28	WOS:000165870600038
J	Amowitz, L; Iacopino, V				Amowitz, L; Iacopino, V			Women's health and human rights needs	LANCET			English	Article									Phys Human Rights, Boston, MA 02116 USA		Amowitz, L (corresponding author), Phys Human Rights, Boston, MA 02116 USA.		Lawry, Lynn/ABE-8391-2021	Lawry, Lynn/0000-0001-8229-8768					0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S65	S65		10.1016/S0140-6736(00)92052-X	http://dx.doi.org/10.1016/S0140-6736(00)92052-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191525				2022-12-28	WOS:000166074900067
J	Fedosejeva, R; Girgensons, R				Fedosejeva, R; Girgensons, R			The mentally ill in prison: developments in Latvia	LANCET			English	Article									Latvian Prison Adm, Dept Med, LV-1009 Riga, Latvia		Fedosejeva, R (corresponding author), Latvian Prison Adm, Dept Med, LV-1009 Riga, Latvia.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S47	S47		10.1016/S0140-6736(00)92033-6	http://dx.doi.org/10.1016/S0140-6736(00)92033-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191505	Bronze			2022-12-28	WOS:000166074900049
J	Roger, VL				Roger, VL			Cardiovascular disease: an unwomanly disorder?	LANCET			English	Article									Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Roger, VL (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.		Roger, Veronique/AAV-5951-2020						0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S10	S10		10.1016/S0140-6736(00)91996-2	http://dx.doi.org/10.1016/S0140-6736(00)91996-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191465				2022-12-28	WOS:000166074900012
J	Barton, N				Barton, N			Ecology - The rapid origin of reproductive isolation	SCIENCE			English	Editorial Material							SPECIATION		Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh, Midlothian, Scotland	University of Edinburgh	Barton, N (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh, Midlothian, Scotland.							Blows MW, 1998, AM NAT, V152, P826, DOI 10.1086/286211; Coyne JA, 1997, EVOLUTION, V51, P295, DOI [10.1111/j.1558-5646.1997.tb02412.x, 10.2307/2410984]; Dobzhansky T, 1940, AM NAT, V74, P312, DOI 10.1086/280899; Hendry AP, 2000, SCIENCE, V290, P516, DOI 10.1126/science.290.5491.516; Hendry AP, 1999, EVOLUTION, V53, P1637, DOI 10.1111/j.1558-5646.1999.tb04550.x; Higgie M, 2000, SCIENCE, V290, P519, DOI 10.1126/science.290.5491.519; HUBBELL S, IN PRESS UNIFIED NEU; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Wallace A. R., 1889, DARWINISM	9	12	12	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 20	2000	290	5491					462	463		10.1126/science.290.5491.462	http://dx.doi.org/10.1126/science.290.5491.462			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	365HN	11183768				2022-12-28	WOS:000089946000033
J	Fischer, KS; Barton, J; Khush, GS; Leung, H; Cantrell, R				Fischer, KS; Barton, J; Khush, GS; Leung, H; Cantrell, R			Genomics and agriculture - Collaborations in rice	SCIENCE			English	Article							YIELD; XA21		Int Rice Res Inst, Makati 1271, Philippines; Stanford Univ, Sch Law, Stanford, CA 94305 USA	CGIAR; International Rice Research Institute (IRRI); Stanford University	Leung, H (corresponding author), Int Rice Res Inst, POB 3127, Makati 1271, Philippines.		Khush, Gurdev Singh/C-5109-2009					Cassman KG, 1999, P NATL ACAD SCI USA, V96, P5952, DOI 10.1073/pnas.96.11.5952; Devos KM, 2000, PLANT CELL, V12, P637, DOI 10.1105/tpc.12.5.637; DUVICK DN, 1992, MAYDICA, V37, P69; *GEN M ROCK FDN IN, 1999, RIC FUNCT GEN WORKSH; HOSSAIIN M, 1999, IN PRESS AGR BIOTECH; Hossain M., 1998, Sustainability of rice in the global food system., P19; IRRI, 1998, SUST FOOD SEC YEAR 2; KHUSH GS, IN PRESS NEW FRONTIE; Marshall E, 1999, SCIENCE, V284, P406, DOI 10.1126/science.284.5413.406; Normile D, 1999, SCIENCE, V286, P24; PERSLEY G, 1999, P INT C WASH DC 21 2; Reich MR, 2000, SCIENCE, V287, P1979, DOI 10.1126/science.287.5460.1979; RONALD PC, 1992, MOL GEN GENET, V236, P113, DOI 10.1007/BF00279649; Somerville C, 1999, SCIENCE, V285, P380, DOI 10.1126/science.285.5426.380; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; WALBOT V, COMMUNICATION; 2000, INT RIC GEN M 8 9 FE	17	33	35	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 13	2000	290	5490					279	280		10.1126/science.290.5490.279	http://dx.doi.org/10.1126/science.290.5490.279			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	363CW	11183373				2022-12-28	WOS:000089818100026
J	Girardi, AM; Pyenson, LR; Morris, J; Brickfield, FX				Girardi, AM; Pyenson, LR; Morris, J; Brickfield, FX			Impact of coronary heart disease on world leaders	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Previous studies have shown that from 1965 to 1996, coronary heart disease was a frequent natural cause of death among world leaders. Objective: To assess incidence of and death from coronary heart disease among world leaders and to determine the effect of this disease on office-holding ability. Design: Archive search of worldwide English-language and translated press and media reports from 1970 to 1999 for reference to coronary events. Setting: U.S. federal government medical analytic unit. Participants: National principal decision makers in countries with populations greater than 250 000. Measurements: Reports of angina, heart attack, myocardial infarction, and arrhythmia attributed to coronary artery disease: use of cardiac procedures; receipt of foreign care; death; and removal from office. Results: 64 leaders had initial coronary heart disease events while holding their nation's highest office. Initial event rates decreased from the 1970s to the 1990s (1.9 events per 100 person-years vs. 1.1 events per 100 person-years). Survival, use of procedures, and receipt of foreign care increased over time. Most leaders who survived an acute event continued to function in office. Conclusions: Incidence of and death from coronary heart disease among office-holding world leaders has decreased over the past 30 years, possibly because of increased use of cardiac procedures. A coronary event in a world leader is unlikely to presage a change in government.	Cent Intelligence Agcy, Washington, DC 20505 USA		Pyenson, LR (corresponding author), Cent Intelligence Agcy, Washington, DC 20505 USA.							Bienen Henry S., 1991, TIME POWER LEADERSHI; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; *CTR INT AG, 1985, WORLD FACT BOOK; *CTR INT AG, 1975, WORLD FACT BOOK; *CTR INT AG, 1995, WORLD FACT BOOK; Pyenson LR, 1998, MIL MED, V163, P797, DOI 10.1093/milmed/163.12.797; THOM TJ, 1998, HEART ARTERIES VEINS, P5; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155	9	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					287	290		10.7326/0003-4819-134-4-200102200-00012	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NW	11182839				2022-12-28	WOS:000167050200005
J	Tempany, CMC; McNeil, BJ				Tempany, CMC; McNeil, BJ			Advances in biomedical imaging	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITRON-EMISSION-TOMOGRAPHY; PROSTATE-CANCER; MR; ACCURACY; SYSTEM; LIVER; CARCINOMA; THERAPY; MOTION; STROKE	In the 21st century, diseases will be diagnosed and treated using increasingly less invasive, more sophisticated imaging and image-guided procedures, During the past 100 years, the field of biomedical imaging has developed from Roentgen's original discovery of the x-ray to the imaging tools of today, such as magnetic resonance imaging, computed tomography, positron emission tomography, and ultrasonography, The benefits of using these sophisticated noninvasive imaging toots are already evident: move accurate and timely diagnosis of disease has translated into improved patient care. Recent advances in imaging research have shown the potential to change many aspects of clinical medicine within the next decade. Major new areas of research focus on development of the molecular, functional, cellular, and genetic imaging tools of the future, aided by new information technology and image fusion/integration capabilities. Image-guided therapy is growing rapidly, with advances in computer science, technology, and noninvasive treatment methods, such as focused ultrasonography. Undoubtedly, these and other new imaging techniques will enhance the ability to accurately diagnose and recognize disease and allow understanding of the molecular mechanisms of diseases and their respective responses to therapy. Given this explosion in new technologies, the next 25 years promise to result in dramatic changes in diagnostic imaging, particularly with respect to detection and recognition of disease.	Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Hlth Care Policy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Tempany, CMC (corresponding author), Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.							AXEL L, 1989, RADIOLOGY, V172, P349, DOI 10.1148/radiology.172.2.2748813; Beauchamp NJ, 1999, RADIOLOGY, V212, P307, DOI 10.1148/radiology.212.2.r99au16307; Black PM, 1999, NEUROSURGERY, V45, P423, DOI 10.1097/00006123-199909000-00001; Bosniak MA, 1997, NEW ENGL J MED, V336, P810; CHANGLAI SP, 1999, J NUCL MED, V40, P56; Cormack RA, 2000, INT J RADIAT ONCOL, V46, P207, DOI 10.1016/S0360-3016(99)00422-8; D'Amico AV, 2000, J UROLOGY, V164, P385, DOI 10.1016/S0022-5347(05)67366-1; D'Amico AV, 1998, INT J RADIAT ONCOL, V42, P507, DOI 10.1016/S0360-3016(98)00271-5; D'Amico AV, 1998, UROLOGY, V51, P287, DOI 10.1016/S0090-4295(97)00610-9; Fielding JR, 1997, J COMPUT ASSIST TOMO, V21, P635, DOI 10.1097/00004728-199707000-00022; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; Getty DJ, 1997, RADIOLOGY, V204, P471, DOI 10.1148/radiology.204.2.9240538; Harpole LH, 1997, J AM MED INFORM ASSN, V4, P511, DOI 10.1136/jamia.1997.0040511; HATA N, IN PRESS RADIOLOGY; *HLTH CAR FIN ADM, 2001, CAG00065 HLTH CAR FI; Hubbard AM, 1999, SEMIN PERINATOL, V23, P437, DOI 10.1016/S0146-0005(99)80023-8; Jolesz FA, 1997, RADIOLOGY, V204, P601, DOI 10.1148/radiology.204.3.9280232; JOLESZ FA, 1994, MAGN RESON QUART, V10, P85; Kettenbach J, 1999, COMPUT MED IMAG GRAP, V23, P245, DOI 10.1016/S0895-6111(99)00022-1; Kurhanewicz J, 2000, RADIOL CLIN N AM, V38, P115, DOI 10.1016/S0033-8389(05)70152-4; Levine D, 1999, AM J ROENTGENOL, V172, P813, DOI 10.2214/ajr.172.3.10063888; Lowe VJ, 2000, J CLIN ONCOL, V18, P651, DOI 10.1200/JCO.2000.18.3.651; Maier SE, 1998, AM J ROENTGENOL, V171, P85, DOI 10.2214/ajr.171.1.9648769; MATSUMOTO R, 1993, JMRI-J MAGN RESON IM, V3, P770, DOI 10.1002/jmri.1880030513; MAZZIOTTA JC, 1992, SEMIN NUCL MED, V22, P233, DOI 10.1016/S0001-2998(05)80118-7; McTayish JD, 2000, RADIOLOGY, V217, P225; MOOH F, 1998, RADIOLOGY, V206, P475; Morrish PK, 1996, BRAIN, V119, P585, DOI 10.1093/brain/119.2.585; Nagel E, 1999, J MAGN RESON IMAGING, V10, P411, DOI 10.1002/(SICI)1522-2586(199909)10:3<411::AID-JMRI24>3.0.CO;2-#; Norwitz ER, 2000, NEW ENGL J MED, V343, P399, DOI 10.1056/NEJM200008103430604; Perlmutter JS, 1999, Q J NUCL MED, V43, P140; Perrotti M, 1999, J UROLOGY, V162, P1314, DOI 10.1016/S0022-5347(05)68275-4; Provenzale JM, 1999, AM J ROENTGENOL, V173, P1459, DOI 10.2214/ajr.173.6.10584783; SCHENCK JF, 1995, RADIOLOGY, V195, P805, DOI 10.1148/radiology.195.3.7754014; Seltzer SE, 1997, RADIOLOGY, V202, P219, DOI 10.1148/radiology.202.1.8988214; SILVERMAN SG, 1995, RADIOLOGY, V197, P175, DOI 10.1148/radiology.197.1.7568819; Smith NB, 1999, INT J RADIAT ONCOL, V43, P217, DOI 10.1016/S0360-3016(98)00366-6; SMITH SJ, 1989, RADIOLOGY, V170, P699, DOI 10.1148/radiology.170.3.2644658; Steiner MS, 2000, J UROLOGY, V164, P1121, DOI 10.1016/S0022-5347(05)67127-3; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; TEMPANY CM, 1994, RADIOLOGY, V192, P47, DOI 10.1148/radiology.192.1.8208963; THERASSE P, 2000, JNCI-J NATL CANCER I, V92, P179; Tung CH, 2000, CANCER RES, V60, P4953; Tung CH, 1999, BIOCONJUGATE CHEM, V10, P892, DOI 10.1021/bc990052h; VALK PE, 1996, NUCL MED BIOL, V212, P803; Vitola JV, 1996, AM J SURG, V171, P21, DOI 10.1016/S0002-9610(99)80067-1; VOGL TJ, 1995, RADIOLOGY, V196, P257, DOI 10.1148/radiology.196.1.7540310; Weissleder R, 1999, RADIOLOGY, V212, P609, DOI 10.1148/radiology.212.3.r99se18609; WEISSLEDER R, 2000, RADIOLOGY, V6, P351; Yu KK, 1999, RADIOLOGY, V213, P481, DOI 10.1148/radiology.213.2.r99nv26481; ZERHOUNI EA, 1988, RADIOLOGY, V169, P59, DOI 10.1148/radiology.169.1.3420283	52	103	112	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					562	567		10.1001/jama.285.5.562	http://dx.doi.org/10.1001/jama.285.5.562			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176859	Bronze			2022-12-28	WOS:000166714200012
J	Kapan, DD				Kapan, DD			Three-butterfly system provides a field test of mullerian mimicry	NATURE			English	Article							MIMETIC ADVANTAGE; NATURAL-SELECTION; BUTTERFLIES; HELICONIUS; DIVERSITY; RESPONSES; EVOLUTION; DYNAMICS	In 1879, Muller proposed that two brightly coloured distasteful butterfly species (co-models) that share a single warning-colour pattern would benefit by spreading the selective burden of educating predators(1-5). The mutual benefit of sharing warning signals among distasteful species, so-called mullerian mimicry, is supported by comparative evidence(2,3), theoretical studies(5,6) and laboratory simulations(7); however, to date, this key exemplar of adaptive evolution has not been experimentally tested in the field. To measure natural selection generated by mullerian mimicry, I exploited the unusual polymorphism of Heliconius cydno (Lepidoptera: Nymphalidae)(8). Here I show increased survival of H. cydno morphs that match locally abundant monomorphic co-model species. This study demonstrates mullerian mimicry in the field. It also shows that mullerian mimicry with several co-models generates geographically divergent selection, which explains the existence of polymorphism in distasteful species with warning coloration(9).	Univ British Columbia, Dept Zool, Ctr Biodivers Res, Vancouver, BC V6T 1Z4, Canada; Univ Texas, Patterson Labs, Sect Integrat Biol, Austin, TX 78712 USA	University of British Columbia; University of Texas System; University of Texas Austin	Kapan, DD (corresponding author), Univ Puerto Rico, Dept Biol, Rio Piedras, PR 00931 USA.	dkapan@rrpac.upr.clu.edu						Akaike H, 1973, P 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; Alatalo RV, 1996, NATURE, V382, P708, DOI 10.1038/382708a0; BENSON WW, 1972, SCIENCE, V176, P936, DOI 10.1126/science.176.4037.936; BROWER LINCOLN PIERSON, 1963, ZOOLOGICA [NEW YORK], V48, P65; BROWER LP, 1967, EVOLUTION, V21, P11, DOI 10.1111/j.1558-5646.1967.tb00126.x; BROWN K S JR, 1974, Biotropica, V6, P205, DOI 10.2307/2989666; CHAI P, 1986, BIOL J LINN SOC, V29, P161, DOI 10.1111/j.1095-8312.1986.tb01772.x; COOK LM, 1969, EVOLUTION, V23, P339, DOI 10.1111/j.1558-5646.1969.tb03516.x; DUNLAPPIANKA H, 1977, SCIENCE, V197, P487, DOI 10.1126/science.197.4302.487; Edwards AWF, 1992, LIKELIHOOD; ENDLER JA, 1988, PHILOS T R SOC B, V319, P505, DOI 10.1098/rstb.1988.0062; Fisher, 1958, GENETICAL THEORY NAT; Gavrilets S, 1998, J THEOR BIOL, V191, P415, DOI 10.1006/jtbi.1997.0615; Gilbert L.E., 1991, P403; Holmgren NMA, 1999, BIOL J LINN SOC, V66, P145; Joron M, 1998, TRENDS ECOL EVOL, V13, P461, DOI 10.1016/S0169-5347(98)01483-9; KAPAN DD, 1998, THESIS U BRIT COLUMB; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; MALLET J, 1990, GENETICS, V124, P921; MALLET J, 1987, BIOL J LINN SOC, V32, P337, DOI 10.1111/j.1095-8312.1987.tb00435.x; Mallet J, 1999, ANNU REV ECOL SYST, V30, P201, DOI 10.1146/annurev.ecolsys.30.1.201; MALLET J, 1987, J ANIM ECOL, V56, P377, DOI 10.2307/5054; Mallet J, 1998, ENDLESS FORMS, P390; MALLET J, 1989, EVOLUTION, V43, P421, DOI 10.1111/j.1558-5646.1989.tb04237.x; MULLER F., 1879, T ENTOMOL SOC LOND, V1879, pxx; Skalski J.R., 1993, P9; Turner J. R. G., 1977, Evolutionary Biol, V10, P163; TURNER JRG, 1996, PHILOS T R SOC B, V351, P835; WALDBAUER GP, 1975, EVOLUTION, V29, P650, DOI 10.1111/j.1558-5646.1975.tb00859.x; Wickler W., 1968, MIMICRY PLANTS ANIMA	30	217	219	1	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2001	409	6818					338	340		10.1038/35053066	http://dx.doi.org/10.1038/35053066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201741				2022-12-28	WOS:000166434300046
J	Vijayaraghavan, K				Vijayaraghavan, K			Vitamin A deficiency	LANCET			English	Article									Natl Inst Nutr, Hyderabad 500007, Andhra Pradesh, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Nutrition (NIN)	Vijayaraghavan, K (corresponding author), Natl Inst Nutr, Hyderabad 500007, Andhra Pradesh, India.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S41	S41		10.1016/S0140-6736(00)92027-0	http://dx.doi.org/10.1016/S0140-6736(00)92027-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191499				2022-12-28	WOS:000166074900043
J	Baulcombe, DC				Baulcombe, DC			Molecular biology - Unwinding RNA silencing	SCIENCE			English	Editorial Material							GENE		John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Baulcombe, DC (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.			Baulcombe, David/0000-0003-0780-6878				Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Domeier ME, 2000, SCIENCE, V289, P1928, DOI 10.1126/science.289.5486.1928; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gura T, 2000, NATURE, V404, P804, DOI 10.1038/35009245; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90338-A; Marx J, 2000, SCIENCE, V288, P1370, DOI 10.1126/science.288.5470.1370; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Plasterk RHA, 2000, CURR OPIN GENET DEV, V10, P562, DOI 10.1016/S0959-437X(00)00128-3; Wu-Scharf D, 2000, SCIENCE, V290, P1159, DOI 10.1126/science.290.5494.1159; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	14	39	50	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 10	2000	290	5494					1108	1109		10.1126/science.290.5494.1108	http://dx.doi.org/10.1126/science.290.5494.1108			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11185008				2022-12-28	WOS:000165228200033
J	Sigmund, K; Nowak, MA				Sigmund, K; Nowak, MA			Evolution and social science - A tale of two selves	SCIENCE			English	Editorial Material							COOPERATION		Univ Vienna, Inst Math, Laxenburg, Austria; Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria; Inst Adv Study, Princeton, NJ 08540 USA	University of Vienna; International Institute for Applied Systems Analysis (IIASA); Institute for Advanced Study - USA	Sigmund, K (corresponding author), Univ Vienna, Inst Math, Laxenburg, Austria.	karl.sigmund@univie.ac.at; nowak@ias.edu	Nowak, Martin A/A-6977-2008					BOYD R, 1992, ETHOL SOCIOBIOL, V13, P171, DOI 10.1016/0162-3095(92)90032-Y; Colman AM, 2013, GAME THEORY ITS APPL; de Waal FBM, 2000, NATURE, V404, P563, DOI 10.1038/35007138; FEHR E, 1998, EUR ECON REV, V42, P232; HAIG D, IN PRESS ANN REV ECO; Hofbauer J, 1998, EVOLUTIONARY GAMES P; HOPFIELD JJ, 1999, CRITICAL PROBLEMS PH, P29; Jackendoff R, 1997, ARCHITECTURE LANGUAG; Krakauer DC, 1999, NATURE, V400, P125, DOI 10.1038/22026; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; Maynard Smith J., 1982, pi; MILINSKI M, 1987, NATURE, V325, P433, DOI 10.1038/325433a0; Nowak MA, 2000, NATURE, V404, P495, DOI 10.1038/35006635; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; Pinker Steven, 1994, LANGUAGE INSTINCT; Smith J. M., 1999, ORIGINS LIFE; STRINGER C, 1999, HUMAN INHERITANCE, P33; TABORSKY M, 1994, ADV STUD BEHAV, V23, P1, DOI 10.1016/S0065-3454(08)60351-4; Wedekind C, 2000, SCIENCE, V288, P850, DOI 10.1126/science.288.5467.850; 2000, EUROPEAN SCI DAYS EV	20	5	5	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	2000	290	5493					949	950		10.1126/science.290.5493.949	http://dx.doi.org/10.1126/science.290.5493.949			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11184736				2022-12-28	WOS:000165103200037
J	Kendrick, D; Fielding, K; Bentley, E; Kerslake, R; Miller, P; Pringle, M				Kendrick, D; Fielding, K; Bentley, E; Kerslake, R; Miller, P; Pringle, M			Radiography of the lumbar spine in primary care patients with low back pain: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article								Objective To test the hypothesis that radiography of the lumbar spine inpatients with low back pain is not associated with improved clinical outcomes or satisfaction with care. Design Randomised unblinded controlled trial. Setting 73 general practices in Nottingham, north Nottinghamshire, southern Derbyshire, north Lincolnshire,and north Leicestershire, 52 practices recruited participants to the trial. Subjects 421 patients with low back pain of a median duration of 10 weeks. Intervention Radiography of the lumbar spine. Main outcome measures Roland adaptation of the sickness impact profile, visual analogue scale for pain, health status, EuroQol, satisfaction with care, use of primary and secondary care services, and reporting of low back pain at three and nine months after randomisation. Results The intervention roup were more likely to report low back pain at three months (relative risk 1.26, 95% confidence interval 1.00 to 1.60) and had a lower overall health status score and borderline higher Roland and pain scores. A higher proportion of participants consulted their doctor in the three months after radiography (1.62, 1.33 to 1.97). Satisfaction wit care was greater in the group receiving radiography at nine but not three months after randomisation. Overall, 80% of participants in both groups at three and nine months would have radiography if the choice was available. Abnormal finding on radiography made no difference to the outcome, as measured by the Roland score. Conclusions Radiography of the lumbar spine in primary care patients with low back pain of at least six weeks' duration is not associated with improved patient functioning severity of pain, or overall health status but is associated with an increase in doctor workload. Guidelines on the management of low back pain in primary care should be consistent about not recommending radiography of the lumber spine in patients with low back pain in the absence of indicators for serious spinal disease, even if it has persisted for at least six weeks. Patients receiving radiography are more satisfied with the care they received. The challenge for primary care is to increase satisfaction without recourse to radiography.	Sch Community Hlth Sci, Div Gen Practice, Nottingham NG7 2RD, England; Queens Med Ctr, Div Publ Hlth Med & Epidemiol, Nottingham NG7 2UH, England	University of Nottingham	Kendrick, D (corresponding author), Sch Community Hlth Sci, Div Gen Practice, Univ Pk, Nottingham NG7 2RD, England.		Kerslake, Robert/H-5410-2012	Kerslake, Robert/0000-0002-3694-2345; Kendrick, Denise/0000-0003-3603-6542				Clinical Standards Advisory Group for Back Pain, 1994, BACK PAIN REP CSAG C; Croft PR, 1998, BRIT MED J, V316, P1356, DOI 10.1136/bmj.316.7141.1356; DEYO RA, 1987, ARCH INTERN MED, V147, P141, DOI 10.1001/archinte.147.1.141; DEYO RA, 1986, SPINE, V11, P28, DOI 10.1097/00007632-198601000-00008; HALPIN SFS, 1991, BRIT MED J, V303, P813, DOI 10.1136/bmj.303.6806.813; KAPLAN DM, 1986, SOUTHERN MED J, V79, P811, DOI 10.1097/00007611-198607000-00007; KERRY S, 2000, HLTH TECHNOL ASSESS, V4, P19; NACHEMSON A L, 1976, Spine, V1, P59, DOI 10.1097/00007632-197603000-00009; OWEN JP, 1990, BRIT J GEN PRACT, V40, P98; ROCKEY PH, 1978, J FAM PRACTICE, V7, P455; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; *ROYAL COLL RAD WP, 1998, MAK BEST US DEP CLIN; Royal College of General Practitioners Office of Population Consensus & Survey. Department of Health, 1995, MORB STAT GEN PRACT; Waddell G, 1999, LOW BACK PAIN EVIDEN; WALL BF, 1981, BRIT J RADIOL, V54, P719, DOI 10.1259/0007-1285-54-645-719; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; 1994, ACUTE LOW BACK PROBL	17	158	163	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	2001	322	7283					400	405		10.1136/bmj.322.7283.400	http://dx.doi.org/10.1136/bmj.322.7283.400			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404JH	11179160	Green Accepted, Green Published, Bronze, Green Submitted			2022-12-28	WOS:000167093600027
J	Caron, H; van Schaik, B; van der Mee, M; Baas, F; Riggins, G; van Sluis, P; Hermus, MC; van Asperen, R; Boon, K; Voute, PA; Heisterkamp, S; van Kampen, A; Versteeg, R				Caron, H; van Schaik, B; van der Mee, M; Baas, F; Riggins, G; van Sluis, P; Hermus, MC; van Asperen, R; Boon, K; Voute, PA; Heisterkamp, S; van Kampen, A; Versteeg, R			The human transcriptome map: Clustering of highly expressed genes in chromosomal domains	SCIENCE			English	Article								The chromosomal position of human genes is rapidly being established. We integrated these mapping data with genome-wide messenger RNA expression profiles as provided by SAGE (serial analysis of gene expression). Over 2.45 million SAGE transcript tags, including 160,000 tags of neuroblastomas, are presently known for 12 tissue types. We developed algorithms to assign these tags to UniGene clusters and their chromosomal position. The resulting Human Transcriptome Map generates gene expression profiles for ant chromosomal region in 12 normal and pathologic tissue types. The map reveals a clustering of highly expressed genes to specific chromosomal regions. It provides a tool to search for genes that are overexpressed or silenced in cancer.	Emma Childrens Hosp, Acad Med Ctr, Dept Human Genet, NL-1100 DE Amsterdam, Netherlands; Emma Childrens Hosp, Acad Med Ctr, Dept Pediat Oncol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Bioinformat Lab, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Neurozintuigen Lab, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Duke University; Duke University	Caron, H (corresponding author), Emma Childrens Hosp, Acad Med Ctr, Dept Human Genet, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Versteeg, Rogier/AAQ-1765-2020; van Kampen, Antoine HC/C-1925-2008; Baas, Frank/F-9574-2010	Baas, Frank/0000-0003-3912-5428; van Schaik, Barbera/0000-0002-5568-8127; Versteeg, Rogier/0000-0001-7172-0388				Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; Lal A, 1999, CANCER RES, V59, P5403; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SPIEKER N, IN PRESS GENOMICS; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543	14	573	616	3	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 16	2001	291	5507					1289	+		10.1126/science.1056794	http://dx.doi.org/10.1126/science.1056794			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	402MX	11181992				2022-12-28	WOS:000166993400038
J	Woolf, SH; Rothemich, SF				Woolf, SH; Rothemich, SF			Overuse of administrative data to measure underuse of care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Virginia Commonwealth Univ, Dept Family Practice, Richmond, VA 23284 USA	Virginia Commonwealth University	Woolf, SH (corresponding author), Virginia Commonwealth Univ, Dept Family Practice, Med Coll Virginia Campus, Richmond, VA 23284 USA.							Asch SM, 2000, JAMA-J AM MED ASSOC, V284, P2325, DOI 10.1001/jama.284.18.2325; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Woolf SH, 1999, JAMA-J AM MED ASSOC, V282, P2358, DOI 10.1001/jama.282.24.2358	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					736	736						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176907				2022-12-28	WOS:000166817200026
J	Newman, AB; Arnold, AM; Burke, GL; O'Leary, DH; Manolio, TA				Newman, AB; Arnold, AM; Burke, GL; O'Leary, DH; Manolio, TA			Cardiovascular disease and mortality in older adults with small abdominal aortic aneurysms detected by ultrasonography: The cardiovascular health study	ANNALS OF INTERNAL MEDICINE			English	Article							RISK-FACTORS; PREVALENCE; ATHEROSCLEROSIS; RUPTURE; FATE	Background: Persons with abdominal aortic aneurysm are more likely to have a higher prevalence of risk factors for and clinical manifestations of cardiovascular disease. It is unknown whether these factors explain the high mortality rate associated with abdominal aortic aneurysm. Objective: To describe the risk for mortality, cardiovascular mortality, and cardiovascular morbidity in persons screened for abdominal aortic aneurysm. Design: Longitudinal cohort study. Setting: Four communities in the United States. Participants: 4734 men and women older than 65 years of age recruited from Medicare eligibility lists. Measurements: Abdominal ultrasonography was used to measure the aortic diameter and the ratio of infrarenal to suprarenal measurement of aortic diameter in 1992-1993. Abdominal aortic aneurysm was defined as aortic diameter of 3 cm or greater or infrarenal-to-suprarenal ratio of 1.2 or greater. Mortality, cardiovascular disease mortality, incident cardiovascular disease, and repair or rupture were assessed after 4.5 years. Results: The prevalence of aneurysm was 8.8%, and 87.7% of aneurysms were 3.5 cm or less in diameter, Rates of total mortality (65.1 vs. 32.8 per 1000 person-years), cardiovascular mortality (34.3 vs. 13.8 per 1000 person-years), and incident cardiovascular disease (47.3 vs. 31.0 per 1000 person-years) were higher in participants with aneurysm than in those without aneurysm; after adjustment for age, risk factors, and presence of other cardiovascular disease, the respective relative risks were 1.32, 1.36, and 1.57. Rates of repair and rupture were low. Conclusions: Rates of total mortality, cardiovascular disease mortality, and incident cardiovascular disease were higher in participants with abdominal aortic aneurysm than in those without aneurysm, independent of age, sex, other clinical cardiovascular disease, and extent of atherosclerosis detected by noninvasive testing. Persons with smaller aneurysms detected by ultrasonography should be advised to modify risk factors for cardiovascular disease while under surveillance for increase in the size of the aneurysm.	Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA 15213 USA; Univ Washington, Seattle, WA 98195 USA; Wake Forest Univ, Winston Salem, NC 27109 USA; Tufts Univ New England Med Ctr, Boston, MA USA; NHLBI, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; Wake Forest University; Tufts Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Newman, AB (corresponding author), Univ Pittsburgh, Sch Med, Div Geriatr Med, 3520 5th Ave,Suite 300, Pittsburgh, PA 15213 USA.	anewman+@pitt.edu	Newman, Anne B./C-6408-2013	Newman, Anne B./0000-0002-0106-1150				Alcorn HG, 1996, ARTERIOSCL THROM VAS, V16, P963, DOI 10.1161/01.ATV.16.8.963; Blanchard JF, 2000, AM J EPIDEMIOL, V151, P575; Brown LC, 1999, ANN SURG, V230, P289, DOI 10.1097/00000658-199909000-00002; Choksy SA, 1999, ANN ROY COLL SURG, V81, P27; Collet D, 1994, MODELING SURVIVAL DA; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R; Galland RB, 1998, EUR J VASC ENDOVASC, V16, P104, DOI 10.1016/S1078-5884(98)80150-0; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Kanagasabay R, 1996, J Med Screen, V3, P208; Lederle FA, 1997, ANN INTERN MED, V126, P441, DOI 10.7326/0003-4819-126-6-199703150-00004; MITTELMARK MB, 1993, AM J EPIDEMIOL, V137, P311, DOI 10.1093/oxfordjournals.aje.a116678; Moore WS, 1999, ANN SURG, V230, P298, DOI 10.1097/00000658-199909000-00003; Naydeck BL, 1999, AM J CARDIOL, V83, P759, DOI 10.1016/S0002-9149(98)00985-0; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155; Pleumeekers HJCM, 1995, AM J EPIDEMIOL, V142, P1291, DOI 10.1093/oxfordjournals.aje.a117596; Powell JT, 1998, LANCET, V352, P1649; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; SZILAGYI DE, 1972, ARCH SURG-CHICAGO, V104, P600; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; Vardulaki KA, 1998, BRIT J SURG, V85, P1674; Veith FJ, 1999, ANN SURG, V230, P306	24	118	124	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2001	134	3					182	190		10.7326/0003-4819-134-3-200102060-00008	http://dx.doi.org/10.7326/0003-4819-134-3-200102060-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397KR	11177330				2022-12-28	WOS:000166695300002
J	Bianco, PR; Brewer, LR; Corzett, M; Balhorn, R; Yeh, Y; Kowalczykowski, SC; Baskin, RJ				Bianco, PR; Brewer, LR; Corzett, M; Balhorn, R; Yeh, Y; Kowalczykowski, SC; Baskin, RJ			Processive translocation and DNA unwinding by individual RecBCD enzyme molecules	NATURE			English	Article							DOUBLE-STRANDED DNA; ESCHERICHIA-COLI; HELICASE ACTIVITY; DUPLEX DNA; BINDING; ASSAY; DISPLACEMENT; FLUORESCENT; RECA	RecBCD enzyme is a processive DNA helicase(1) and nuclease(2) that participates in the repair of chromosomal DNA through homologous recombination(3,4). We have visualized directly the movement of individual RecBCD enzymes on single molecules of double-stranded DNA (dsDNA). Detection involves the optical trapping of solitary, fluorescently tagged dsDNA molecules that are attached to polystyrene beads, and their visualization by fluorescence microscopy(5,6). Both helicase translocation and DNA unwinding are monitored by the displacement of fluorescent dye from the DNA by the enzyme(7). Here we show that unwinding is both continuous and processive, occurring at a maximum rate of 972 +/- 172 base pairs per second (0.30 mum s(-1)), with as many as 42,300 base pairs of dsDNA unwound by a single RecBCD enzyme molecule. The mean behaviour of the individual RecBCD enzyme molecules corresponds to that observed in bulk solution.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Appl Sci, Davis, CA 95616 USA; Univ Calif Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA; Univ Calif Lawrence Livermore Natl Lab, Biotechnol Res Program, Livermore, CA 94550 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA.							Anderson DG, 1998, J MOL BIOL, V282, P275, DOI 10.1006/jmbi.1998.2013; ARNOLD DA, 1999, ENCY LIFE SCI; Bennink ML, 1999, CYTOMETRY, V36, P200, DOI 10.1002/(SICI)1097-0320(19990701)36:3<200::AID-CYTO9>3.0.CO;2-T; Bianco PR, 2000, NATURE, V405, P368, DOI 10.1038/35012652; Brewer LR, 1999, SCIENCE, V286, P120, DOI 10.1126/science.286.5437.120; EGGLESTON AK, 1993, J MOL BIOL, V231, P621, DOI 10.1006/jmbi.1993.1314; Eggleston AK, 1996, NUCLEIC ACIDS RES, V24, P1179, DOI 10.1093/nar/24.7.1179; GANESAN S, 1993, J MOL BIOL, V229, P67, DOI 10.1006/jmbi.1993.1008; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0; Zaitsev EN, 1998, NUCLEIC ACIDS RES, V26, P650, DOI 10.1093/nar/26.2.650	19	269	275	0	46	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					374	378		10.1038/35053131	http://dx.doi.org/10.1038/35053131			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201750				2022-12-28	WOS:000166434300055
J	Johns, A				Johns, A			The birth of scientific reading	NATURE			English	Editorial Material									CALTECH, Div Humanities & Social Sci, Pasadena, CA 91125 USA	California Institute of Technology	Johns, A (corresponding author), CALTECH, Div Humanities & Social Sci, Pasadena, CA 91125 USA.								0	11	11	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					287	287		10.1038/35053242	http://dx.doi.org/10.1038/35053242			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201718	Bronze			2022-12-28	WOS:000166434300021
J	Beaglehole, R				Beaglehole, R			Uses of error: Clinical and epidemiological	LANCET			English	Article									Univ Auckland, Sch Med, Auckland 1, New Zealand	University of Auckland	Beaglehole, R (corresponding author), Univ Auckland, Sch Med, Auckland 1, New Zealand.								0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					140	140		10.1016/S0140-6736(00)03545-5	http://dx.doi.org/10.1016/S0140-6736(00)03545-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197416				2022-12-28	WOS:000166476200035
J	Callen, JP				Callen, JP			Relation between dermatomyositis and polymyositis and cancer	LANCET			English	Editorial Material							MALIGNANCY; RISK		Univ Louisville, Dept Med, Div Dermatol, Louisville, KY 40202 USA	University of Louisville	Callen, JP (corresponding author), Univ Louisville, Dept Med, Div Dermatol, Louisville, KY 40202 USA.							ARIO A, 1995, J RHEUMATOL, V22, P1300; BARNES BE, 1976, ANN INTERN MED, V84, P68, DOI 10.7326/0003-4819-84-1-68; BOHAN A, 1975, NEW ENGL J MED, V292, P403, DOI 10.1056/NEJM197502202920807; CALLEN JP, 1980, ARCH DERMATOL, V116, P295, DOI 10.1001/archderm.116.3.295; CHOW WH, 1995, CANCER CAUSE CONTROL, V6, P9, DOI 10.1007/BF00051675; PENG JC, 1995, ARCH OTOLARYNGOL, V121, P1298; SIGURGEIRSSON B, 1992, NEW ENGL J MED, V326, P363, DOI 10.1056/NEJM199202063260602	7	35	37	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					85	86		10.1016/S0140-6736(00)03535-2	http://dx.doi.org/10.1016/S0140-6736(00)03535-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197441				2022-12-28	WOS:000166476200005
J	Horton, R				Horton, R			The real lessons from Harold Frederick Shipman	LANCET			English	Editorial Material							CARE; MODEL		Lancet, London WC1X 8RR, England		Horton, R (corresponding author), Lancet, London WC1X 8RR, England.							Baker R, 1999, QUAL HEALTH CARE, V8, P154, DOI 10.1136/qshc.8.3.154; Baker R, 2000, QUAL HEALTH CARE, V9, P83, DOI 10.1136/qhc.9.2.83; Baker R, 1999, BRIT MED J, V318, P779, DOI 10.1136/bmj.318.7186.779; Field MJ, 2000, EXTENDING MEDICARE C, P63; Grol R, 2000, BRIT J GEN PRACT, V50, P882; *STAT OFF, 2001, H SHIPM CLIN PRACT 1; Tomlinson J, 2000, J EVAL CLIN PRACT, V6, P225, DOI 10.1046/j.1365-2753.2000.00228.x; Waghorn A, 2000, J EVAL CLIN PRACT, V6, P273	8	18	18	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2001	357	9250					82	83		10.1016/S0140-6736(00)03532-7	http://dx.doi.org/10.1016/S0140-6736(00)03532-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197438				2022-12-28	WOS:000166476200002
J	Nolan, T; Angos, P; Cunha, AJLA; Muhe, L; Qazi, S; Simoes, EAF; Tamburlini, G; Weber, M; Pierce, NF				Nolan, T; Angos, P; Cunha, AJLA; Muhe, L; Qazi, S; Simoes, EAF; Tamburlini, G; Weber, M; Pierce, NF			Quality of hospital care for seriously ill children in less-developed countries	LANCET			English	Article							EMERGENCY TRIAGE ASSESSMENT; MANAGEMENT; GUIDELINES; MORTALITY	Background improving the quality of care for sick children referred to hospitals in less-developed countries may lead to better outcomes, including reduced mortality. Data are lacking, however, on the quality of priority screening (triage), emergency care, diagnosis, and inpatient treatment in these hospitals, and on aspects of these potential targets that would benefit most from interventions leading to improved health outcomes. Methods We did a qualitative study in 13 district hospitals and eight teaching hospitals in seven less-developed countries. Experienced paediatricians used a structured survey instrument to assess initial triage, emergency and inpatient care, staff knowledge and practices, and hospital support services. Findings Overall quality of care differed between countries and among hospitals and was generally better in teaching hospitals. 14 of 21 hospitals lacked an adequate system for triage. Initial patient assessment was often inadequate and treatment delayed. Most emergency treatment areas were poorly organised and lacked essential supplies; families were routinely required to buy emergency drugs before they could be given. Adverse factors in case management, including inadequate assessment, inappropriate treatment, and inadequate monitoring occurred in 76% of inpatient children. Most doctors in district hospitals, and nurses and medical assistants in leaching and district hospitals, had inadequate knowledge and reported practice for managing important childhood illnesses. Interpretation Strengthening care for sick children referred to hospital should focus on achievable objectives with the greatest potential benefit for health outcome. Possible targets for improvement include initial triage, emergency care, assessment, inpatient treatment, and monitoring. Priority targets for individual hospitals may be determined by assessing each hospital.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Royal Childrens Hosp, Murdock Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; Vicente Soto Mem Med Ctr, Cebu, Philippines; Univ Fed Rio de Janeiro, IPPMG, Dept Pediat, BR-21941 Rio De Janeiro, Brazil; Univ Addis Ababa, Dept Pediat & Child Hlth, Addis Ababa, Ethiopia; WHO, Dept Child & Adolescent Hlth, CH-1211 Geneva, Switzerland; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Infect Dis Sect, Denver, CO 80262 USA; Childrens Hosp, Denver, CO 80218 USA; IRCCS Burlo Garofolo, Unit Hlth Serv Res & Int Hlth, Trieste, Italy	Johns Hopkins University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Universidade Federal do Rio de Janeiro; Addis Ababa University; World Health Organization; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; IRCCS Burlo Garofolo	Pierce, NF (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.		Nolan, Terry/A-2236-2008	Nolan, Terry/0000-0001-6018-3863				Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Gove S, 1999, ARCH DIS CHILD, V81, P473, DOI 10.1136/adc.81.6.473; GOVE S, 1997, B WHO S1, V75, pS7; Islam MA, 1996, J TROP PEDIATRICS, V42, P342, DOI 10.1093/tropej/42.6.342; KALTER HD, 1997, B WHO S1, V75, pS65; Meehan TP, 1997, JAMA-J AM MED ASSOC, V278, P2080, DOI 10.1001/jama.278.23.2080; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; MURRAY CJL, 1996, GLOBAL DIS COMPREHEN; Simoes EAF, 1997, B WORLD HEALTH ORGAN, V75, P43; Sodemann M, 1997, B WORLD HEALTH ORGAN, V75, P205; Tamburlini G, 1999, ARCH DIS CHILD, V81, P478, DOI 10.1136/adc.81.6.478; Tulloch J., 1999, Lancet (British edition), V354, P16, DOI 10.1016/S0140-6736(99)90252-0; *UNICEF, 1998, STAT WORLDS CHILDREN; *WHO DIV CHILD HLT, 1997, B WHO S1, V75, pS55; World Health Organization, 2000, GUID CAR 1 REF LEV D; World Health Organization, 1995, TREATM DIARRH MAN PH; World Health Organization, 1990, AC RESP INF CHILDR C	17	279	286	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					106	110		10.1016/S0140-6736(00)03542-X	http://dx.doi.org/10.1016/S0140-6736(00)03542-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197397				2022-12-28	WOS:000166476200012
J	Greenspan, NS				Greenspan, NS			You can't have it all - Compromise is a major unifying thread in the fabric of contemporary thought.	NATURE			English	Editorial Material									Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Greenspan, NS (corresponding author), Case Western Reserve Univ, Inst Pathol, Euclid Ave, Cleveland, OH 44106 USA.		Greenspan, Neil/AAJ-4795-2020						0	7	7	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					137	137		10.1038/35051668	http://dx.doi.org/10.1038/35051668			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196619	Bronze			2022-12-28	WOS:000166316200020
J	Ferrand, E; Robert, R; Ingrand, P; Lemaire, F				Ferrand, E; Robert, R; Ingrand, P; Lemaire, F		French LATAREA Grp	Withholding and withdrawal of life support in intensive-care units in France: a prospective survey	LANCET			English	Article							SUSTAINING TREATMENT; DECISIONS; LIMIT	Background In France, there are no guidelines available on withholding and withdrawal of life-sustaining treatments, and information on the frequency of such decisions is scarce. Methods We undertook a prospective 2-month survey in 113, of a total of 220, intensive-care units (ICUs) in France to study the frequency of, and processes leading to, decisions to withhold and withdraw life-sustaining treatments. Findings Life-supporting therapies were withheld or withdrawn in 807 (11.0%) of 7309 patients (withholding in 336 [4.6%] and withdrawal in 471 [6.4%], preceded in 358 by withholding). Of 1175 deaths in ICU, 628 (53%) were preceded by a decision to limit life-supporting therapies. Futility and poor expected quality of life were the most frequently cited reasons. Decisions were strongly correlated with the simplified acute physiological score, but an independent centre effect persisted after adjustment for this score. Decisions were mostly taken by all the ICU medical staff, with (54%) or without (34%) the nursing staff; however, a single physician made decisions in 12% of cases. The patient's family was involved in the decision-making process in 44% of cases. The patient's willingness to limit his or her own care was known in only 8% of the cases; only 0.5% of the patients were involved in decisions. Interpretation Withholding and withdrawal of life-support therapies are widely practised in French ICUs, despite their prohibition by the French legislation. The lack of an official statement from French scientific bodies may explain several limitations on the various steps of the decision-making process.	Henri Mondor Univ Hosp, Surg Unit, Creteil, France; Henri Mondor Univ Hosp, Med Unit, Creteil, France; Henri Mondor Univ Hosp, Intens Care Unit, Creteil, France; Jean Bernard Univ Hosp, Dept Biostat, Poitiers, France; Jean Bernard Univ Hosp, Med Intens Care Unit, Poitiers, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU Poitiers; CHU Poitiers	Ferrand, E (corresponding author), Hop Henri Mondor, Unite Reanimat Chirurg & Traumatol, Serv Anesthesie Reanimat, 51 Rue M de Lattre de Tassigny, F-94010 Creteil, France.	eferrand@club-internet.fr						[Anonymous], 1990, CRIT CARE MED, V18, P1435; [Anonymous], 1991, Am Rev Respir Dis, V144, P726; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; *APPL INT C, 1992, J MED ETHICS S, V18, P1; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; *CCNE, 1998, CAH COM CONS NAT ETH, P3; COHEN LM, 1993, ARCH INTERN MED, V153, P2481, DOI 10.1001/archinte.153.21.2481; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Danis M, 1997, CRIT CARE MED, V25, P887; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; FAVEREAU E, 1998, LIBERATION      0312, P1; Keenan SP, 1997, CRIT CARE MED, V25, P1324, DOI 10.1097/00003246-199708000-00019; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Peillon D, 1997, ANN FR ANESTH, V16, P25, DOI 10.1016/S0750-7658(97)84274-8; PEILLON D, 1995, REAN URG, V4, P3; Portes L., 1954, RECHERCHE ETHIQUE ME; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE, P121; Robert R, 1996, REAN URG, V5, P611; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPRUNG CL, 1992, CRIT CARE MED, V20, P320; Turner JS, 1996, INTENS CARE MED, V22, P1020, DOI 10.1007/s001340050207; VINCENT JL, 1990, INTENS CARE MED, V16, P256, DOI 10.1007/BF01705162; WOOD GG, 1995, CAN J ANAESTH, V42, P186, DOI 10.1007/BF03010673	27	348	362	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2001	357	9249					9	14		10.1016/S0140-6736(00)03564-9	http://dx.doi.org/10.1016/S0140-6736(00)03564-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197395				2022-12-28	WOS:000166341500008
J	Willard, HF				Willard, HF			Genomics and gene therapy - Artificial chromosomes coming to life	SCIENCE			English	Editorial Material							ALPHA-SATELLITE; DNA-SEQUENCES; CENTROMERE; CONSTRUCTION; GENERATION; YEAST; MINICHROMOSOMES; RECOMBINATION; VECTORS; CELLS		Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Willard, HF (corresponding author), Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.	hfw@po.CWRU.edu						Brown WRA, 2000, TRENDS BIOTECHNOL, V18, P218, DOI 10.1016/S0167-7799(00)01438-4; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; Calos MP, 1996, TRENDS GENET, V12, P463, DOI 10.1016/0168-9525(96)40049-X; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Choo KHA, 1997, AM J HUM GENET, V61, P1225, DOI 10.1086/301657; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; Csink AK, 1998, TRENDS GENET, V14, P200, DOI 10.1016/S0168-9525(98)01444-9; Ebersole TA, 2000, HUM MOL GENET, V9, P1623, DOI 10.1093/hmg/9.11.1623; GRIMES B, UNPUB; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; Henning KA, 1999, P NATL ACAD SCI USA, V96, P592, DOI 10.1073/pnas.96.2.592; Higgins AW, 1999, CHROMOSOMA, V108, P256, DOI 10.1007/s004120050376; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kuroiwa Y, 1998, NUCLEIC ACIDS RES, V26, P3447, DOI 10.1093/nar/26.14.3447; Mahtani MM, 1998, GENOME RES, V8, P100, DOI 10.1101/gr.8.2.100; MAYS RW, UNPUB; Mills W, 1999, HUM MOL GENET, V8, P751, DOI 10.1093/hmg/8.5.751; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; Rosenberg LE, 2000, SCIENCE, V287, P1751, DOI 10.1126/science.287.5459.1751; Shen MH, 2000, CURR BIOL, V10, P31, DOI 10.1016/S0960-9822(99)00261-4; Shen MH, 1997, HUM MOL GENET, V6, P1375, DOI 10.1093/hmg/6.8.1375; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; Tomizuka K, 2000, P NATL ACAD SCI USA, V97, P722, DOI 10.1073/pnas.97.2.722; Tyler-Smith C, 2000, CELL, V102, P5, DOI 10.1016/S0092-8674(00)00004-0; TYLERSMITH C, 1993, NAT GENET, V5, P368, DOI 10.1038/ng1293-368; Verma IM, 2000, MOL THER, V1, P493, DOI 10.1006/mthe.2000.0084; Vos JMH, 1998, CURR OPIN GENET DEV, V8, P351, DOI 10.1016/S0959-437X(98)80093-2; WEVRICK R, 1990, MOL CELL BIOL, V10, P6374, DOI 10.1128/MCB.10.12.6374; Willard HF, 1998, CURR OPIN GENET DEV, V8, P219, DOI 10.1016/S0959-437X(98)80144-5; Yoshimi K, 2000, NAT BIOTECHNOL, V18, P1086, DOI 10.1038/80287	34	48	52	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1308	1309		10.1126/science.290.5495.1308	http://dx.doi.org/10.1126/science.290.5495.1308			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11185406				2022-12-28	WOS:000165379800030
J	Spector, N				Spector, N			Cancer, genes, and the environment.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ Fed Rio de Janeiro, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Spector, N (corresponding author), Univ Fed Rio de Janeiro, BR-21941590 Rio De Janeiro, Brazil.			Kaprio, Jaakko/0000-0002-3716-2455				Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201	1	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1494	1494						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184464				2022-12-28	WOS:000165271300018
J	Schatz, GC				Schatz, GC			Chemistry - Stretched water is more reactive	SCIENCE			English	Editorial Material							BIMOLECULAR REACTIONS; CHEMICAL-REACTIONS; MODE		Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University	Schatz, GC (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.		Schatz, George C./ABF-1341-2020					Assion A, 1998, SCIENCE, V282, P919, DOI 10.1126/science.282.5390.919; BRONIKOWSKI MJ, 1993, J PHYS CHEM-US, V97, P2204, DOI 10.1021/j100112a022; Crim FF, 1999, ACCOUNTS CHEM RES, V32, P877, DOI 10.1021/ar950046a; Pogrebnya SK, 2000, PHYS CHEM CHEM PHYS, V2, P693, DOI 10.1039/a908080e; SCHATZ GC, 1984, J PHYS CHEM-US, V88, P2971, DOI 10.1021/j150658a011; SINHA A, 1991, J CHEM PHYS, V94, P4928, DOI 10.1063/1.460578; Strazisar BR, 2000, SCIENCE, V290, P958, DOI 10.1126/science.290.5493.958; Wu G, 2000, J CHEM PHYS, V113, P3150, DOI 10.1063/1.1287329; Zare RN, 1998, SCIENCE, V279, P1875, DOI 10.1126/science.279.5358.1875; Zhang DH, 2000, SCIENCE, V290, P961, DOI 10.1126/science.290.5493.961	10	8	8	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	2000	290	5493					950	951		10.1126/science.290.5493.950	http://dx.doi.org/10.1126/science.290.5493.950			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11184737				2022-12-28	WOS:000165103200038
J	Attwood, TK				Attwood, TK			Genomics - The babel of bioinformatics	SCIENCE			English	Article							EVOLUTION; PROTEINS		Univ Manchester, Sch Biol Sci, Manchester, Lancs, England	University of Manchester	Attwood, TK (corresponding author), Univ Manchester, Sch Biol Sci, Manchester, Lancs, England.	attwood@bioinf.man.ac.uk		Attwood, Teresa/0000-0003-2409-4235				APWEILER R, IN PRESS BIOINFORMAT; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Attwood TK, 2000, NUCLEIC ACIDS RES, V28, P225, DOI 10.1093/nar/28.1.225; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Gold L, 1997, CURR OPIN GENET DEV, V7, P848, DOI 10.1016/S0959-437X(97)80050-0; Henikoff JG, 2000, NUCLEIC ACIDS RES, V28, P228, DOI 10.1093/nar/28.1.228; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Olszewski KA, 2000, COMPUT CHEM, V24, P499, DOI 10.1016/S0097-8485(99)00078-9; Panchenko AR, 2000, J MOL BIOL, V296, P1319, DOI 10.1006/jmbi.2000.3541; REECK GR, 1987, CELL, V50, P667, DOI 10.1016/0092-8674(87)90322-9; Reese MG, 2000, GENOME RES, V10, P483, DOI 10.1101/gr.10.4.483; Rost B, 1997, COMPUT APPL BIOSCI, V13, P345; Sternberg MJE, 1999, CURR OPIN STRUC BIOL, V9, P368, DOI 10.1016/S0959-440X(99)80050-5; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189	16	44	514	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	2000	290	5491					471	473		10.1126/science.290.5491.471	http://dx.doi.org/10.1126/science.290.5491.471			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	365HN	11183771				2022-12-28	WOS:000089946000037
J	Montanaro, A; Tilles, SA				Montanaro, A; Tilles, SA			Update in allergy and immunology	ANNALS OF INTERNAL MEDICINE			English	Review							ASTHMA; EFFICACY		Oregon Hlth & Sci Univ, Div Allergy & Immunol, Portland, OR 97201 USA	Oregon Health & Science University	Montanaro, A (corresponding author), Oregon Hlth & Sci Univ, Div Allergy & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	amontanaro@ohsu.edu						Arlian LG, 1999, J ALLERGY CLIN IMMUN, V104, P852, DOI 10.1016/S0091-6749(99)70298-8; Demoly P, 1998, J ALLERGY CLIN IMMUN, V102, P1033, DOI 10.1016/S0091-6749(98)70343-4; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; *NIH, 1997, 974051 NIH; Osborne ML, 1999, CHEST, V115, P85, DOI 10.1378/chest.115.1.85; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Woessner KM, 1999, J ALLERGY CLIN IMMUN, V104, P305, DOI 10.1016/S0091-6749(99)70371-4; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	13	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					291	297		10.7326/0003-4819-134-4-200102200-00013	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NW	11182840				2022-12-28	WOS:000167050200006
J	Burke, BP; White, JC				Burke, BP; White, JC			Wellbeing of gay, lesbian and bisexual doctors (Reprinted from Western Journal of Medicine, vol 174, pg 59-62, 2001)	BRITISH MEDICAL JOURNAL			English	Reprint							PHYSICIANS; HOMOSEXUALITY; ATTITUDES; STUDENTS		Legacy Clin NW, Portland, OR 97210 USA; Oregon Hlth Sci Univ, Columbia Univ, Joseph Mailman Sch Publ Hlth, Legacy Portland Hosp, Portland, OR 97210 USA	Columbia University; Oregon Health & Science University	Burke, BP (corresponding author), Legacy Clin NW, 1130 NW 22nd Ave,Suite 220, Portland, OR 97210 USA.							Brogan DJ, 1999, JAMA-J AM MED ASSOC, V282, P1290, DOI 10.1001/jama.282.13.1290; Burke BP, 2001, WESTERN J MED, V174, P59, DOI 10.1136/ewjm.174.1.59; FLETCHER JL, 1984, SOUTHERN MED J, V77, P149, DOI 10.1097/00007611-198402000-00001; GOLDFARB A, 1997, J GAY LESBIAN ASS, V1, P245; HAYWARD RA, 1993, J GEN INTERN MED, V8, P10, DOI 10.1007/BF02600286; KATSUFRAKIS PJ, 1997, J GAY LESBIAN MED AS, V1, P181; MAKADON HJ, 1998, J GAYLESBIAN MED ASS, V2, P153; MATHEWS WC, 1986, WESTERN J MED, V144, P106; MULLER MJ, 1997, J GAY LESBIAN MED AS, V1, P155; Olsen C., 1997, J GAY LESBIAN MED AS, V1, P149; Oriel K A, 1996, Fam Med, V28, P720; PRICHARD JG, 1988, J FAM PRACTICE, V27, P637; Ramos MM, 1998, ACAD MED, V73, P436, DOI 10.1097/00001888-199804000-00020; Schatz B, 1994, ANTIGAY DISCRIMINATI; Townsend MH, 1996, ACAD MED, V71, P1012, DOI 10.1097/00001888-199609000-00018; WALLICK MM, 1992, ACAD MED, V67, P601, DOI 10.1097/00001888-199209000-00013	16	22	22	3	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	2001	322	7283					422	424		10.1136/bmj.322.7283.422	http://dx.doi.org/10.1136/bmj.322.7283.422			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404JH	11179168	Green Published			2022-12-28	WOS:000167093600033
J	Vaccarino, V; Krumholz, HM; Yarzebski, J; Gore, JM; Goldberg, RJ				Vaccarino, V; Krumholz, HM; Yarzebski, J; Gore, JM; Goldberg, RJ			Sex differences in 2-year mortality after hospital discharge for myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; COMMUNITY-WIDE PERSPECTIVE; WORCESTER HEART-ATTACK; CASE-FATALITY RATES; RISK-FACTORS; PREMENOPAUSAL WOMEN; GENDER-DIFFERENCES; SURVIVAL RATES; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS	Background: An interaction between sex and age is thought to affect hospital mortality after myocardial infarction; younger, but not older, women have been shown to have higher mortality rates than men. It is currently unknown whether findings are similar after hospital discharge. Objective: To determine whether an interaction between sex and age affects a-year mortality after myocardial infarction. Design: Community-based prospective cohort study. Setting: 16 community hospitals serving the Worcester, Massachusetts, metropolitan area. Patients: 6826 patients who survived hospitalization for acute myocardial infarction during ten 1-year periods between 1975 and 1995. Measurements: Mortality 2 years after hospital discharge. Results: The overall 2-year mortality rate was higher in women (28.9%) than in men (19.6%). When patients were examined by age group, however, only women younger than 60 years of age had a higher mortality rate than men of similar age. The sex difference decreased with increasing age; among the oldest patients, women had a lower mortality rate than men (P = 0.009 for the interaction between sex and age). This relationship was not affected by adjustment for demographic characteristics and medical history, clinical characteristics, and hospital and discharge treatments; the hazard of 2-year death for women compared with men increased 15.4% (95% Cl, 4.3% to 27.6%) for every 10-year decrease in age. In absolute terms, after adjustment for demographic characteristics and medical history, among patients younger than 60 years of age women were at greater risk than men (risk difference, 1.8 percentage points). At older ages, however, women were at lower risk than men. Conclusions: Younger, but not older, women who survive hospitalization for myocardial infarction have a higher long-term mortality rate than men. This provides additional evidence that younger women with myocardial infarction are at greater risk for death than men.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale New Haven Med Ctr, New Haven, CT 06504 USA; Univ Massachusetts, Sch Med, Worcester, MA USA; Emory Univ, Sch Med, Dept Med Cardiol, Atlanta, GA 30306 USA	Yale University; Yale University; University of Massachusetts System; University of Massachusetts Worcester; Emory University	Vaccarino, V (corresponding author), Emory Univ, Sch Med, Dept Med Cardiol, Emory W,1256 Briarcliff Rd,Suite 1 N, Atlanta, GA 30306 USA.		, Harlan/AAI-2875-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035434] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL35434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Albert CM, 1996, CIRCULATION, V93, P1170, DOI 10.1161/01.CIR.93.6.1170; Behar S, 1997, AM HEART J, V133, P290, DOI 10.1016/S0002-8703(97)70222-9; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; Burke AP, 1998, CIRCULATION, V97, P2110, DOI 10.1161/01.CIR.97.21.2110; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Coronado BE, 1997, J AM COLL CARDIOL, V29, P1490, DOI 10.1016/S0735-1097(97)00077-6; COX DR, 1972, J R STAT SOC B, V34, P187; CUNNINGHAM MA, 1989, J GEN INTERN MED, V4, P392, DOI 10.1007/BF02599688; DONAHUE RP, 1993, J CLIN EPIDEMIOL, V46, P245, DOI 10.1016/0895-4356(93)90072-9; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FLANDERS WD, 1987, J CHRON DIS, V40, P697, DOI 10.1016/0021-9681(87)90106-8; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; Gabbay FH, 1996, J AM COLL CARDIOL, V27, P585, DOI 10.1016/0735-1097(95)00510-2; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; Goldberg RJ, 1999, J AM COLL CARDIOL, V33, P1533, DOI 10.1016/S0735-1097(99)00040-6; GOLDBERG RJ, 1986, JAMA-J AM MED ASSOC, V255, P2774, DOI 10.1001/jama.255.20.2774; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; Hanke H, 1997, CORONARY ARTERY DIS, V8, P511; Hochman JS, 1999, NEW ENGL J MED, V341, P226, DOI 10.1056/NEJM199907223410402; Hochman JS, 1997, J AM COLL CARDIOL, V30, P141, DOI 10.1016/S0735-1097(97)00107-1; Hu FB, 1999, ARCH INTERN MED, V159, P1061, DOI 10.1001/archinte.159.10.1061; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; Kober L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; LAVECCHIA C, 1987, AM J OBSTET GYNECOL, V157, P1108, DOI 10.1016/S0002-9378(87)80271-5; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LIAO YL, 1992, JAMA-J AM MED ASSOC, V268, P1867, DOI 10.1001/jama.268.14.1867; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; Marrugat J, 1998, JAMA-J AM MED ASSOC, V280, P1405, DOI 10.1001/jama.280.16.1405; Maynard C, 1997, ARCH INTERN MED, V157, P1379, DOI 10.1001/archinte.157.12.1379; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; Miettinen H, 1998, DIABETES CARE, V21, P69, DOI 10.2337/diacare.21.1.69; Nohria Anju, 1998, Cardiology Clinics, V16, P45, DOI 10.1016/S0733-8651(05)70383-0; OLIVER MF, 1974, BMJ-BRIT MED J, V4, P253, DOI 10.1136/bmj.4.5939.253; ORENCIA A, 1993, JAMA-J AM MED ASSOC, V269, P2392, DOI 10.1001/jama.269.18.2392; PAGLEY PR, 1993, ARCH INTERN MED, V153, P625, DOI 10.1001/archinte.153.5.625; PETER T, 1978, MED J AUSTRALIA, V1, P189, DOI 10.5694/j.1326-5377.1978.tb107829.x; POHJOLA S, 1980, BRIT HEART J, V43, P176, DOI 10.1136/hrt.43.2.176; Punnonen R, 1997, MATURITAS, V27, P231, DOI 10.1016/S0378-5122(97)00040-6; RAHE RH, 1974, ARCH INTERN MED, V133, P221, DOI 10.1001/archinte.133.2.221; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; ROBINSON K, 1992, EUR HEART J, V13, P67, DOI 10.1093/oxfordjournals.eurheartj.a060050; Rosen M, 1999, NEW ENGL J MED, V341, P1931; Rozanski A, 1999, CIRCULATION, V99, P2192, DOI 10.1161/01.CIR.99.16.2192; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; Vaccarino V, 1996, J AM GERIATR SOC, V44, P1174, DOI 10.1111/j.1532-5415.1996.tb01366.x; Vaccarino V, 1998, ARCH INTERN MED, V158, P2054, DOI 10.1001/archinte.158.18.2054; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; Vaccarino V, 1999, NEW ENGL J MED, V341, P217, DOI 10.1056/NEJM199907223410401; Vaccarino V, 2000, AM J CARDIOL, V85, P1486, DOI 10.1016/S0002-9149(00)00800-6; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WEINBLATT E, 1978, NEW ENGL J MED, V299, P60, DOI 10.1056/NEJM197807132990202; Wexler LF, 1999, NEW ENGL J MED, V341, P275, DOI 10.1056/NEJM199907223410409; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360	64	262	270	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2001	134	3					173	181		10.7326/0003-4819-134-3-200102060-00007	http://dx.doi.org/10.7326/0003-4819-134-3-200102060-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397KR	11177329				2022-12-28	WOS:000166695300001
J	Beck, LH				Beck, LH			Update in preventive medicine	ANNALS OF INTERNAL MEDICINE			English	Article									Cleveland Clin Florida, Dept Internal Med, Ft Lauderdale, FL 33309 USA	Cleveland Clinic Foundation	Beck, LH (corresponding author), Cleveland Clin Florida, Dept Internal Med, 2900 W Cypress Creek Rd, Ft Lauderdale, FL 33309 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2001	134	2					128	135		10.7326/0003-4819-134-2-200101160-00014	http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00014			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391KW	11177317				2022-12-28	WOS:000166356000007
J	Higgins, JR; de Swiet, M				Higgins, JR; de Swiet, M			Blood-pressure measurement and classification in pregnancy	LANCET			English	Article							KOROTKOFF PHASE-IV; WHITE COAT HYPERTENSION; MANAGEMENT; PREDICTOR	Pre-eclampsia is usually defined on the basis of new onset hypertension and albuminuria developing after 20 weeks of pregnancy. There are difficulties with measurement of these variables. Conventional sphygmomanometry remains the gold standard for blood-pressure measurement. The value of ambulatory blood-pressure measurement has yet to be established. Oedema is now omitted from all definitions of pre-eclampsia, although the finding of widespread severe oedema of sudden onset should not be ignored for clinical purposes. Definitions of pre-eclampsia based solely on hypertension and proteinuria ignore the wide clinical variability in this syndrome. Women with no proteinuria but who do have hypertension and other features such as severe headache or other symptoms, thrombocytopenia, hyperuricaemia, disordered liver function, and fetal compromise are likely to have pre-eclampsia. This notion is accepted in the new Australasian definition of pre-eclampsia and more than hinted at in the new American College of Obstetricians and Gynecologists' definition. Definitions used for clinical purposes should be as safe as practical; they are likely to include a considerable number of false positives. Most research studies are weakened if patients without the disease are included. Therefore, a separate stringent research definition of pre-eclampsia we also suggest.	Hammersmith Hosp, Queen Charlottes Hosp Women, London W12 0NN, England; Univ Melbourne, Mercy Hosp Women, Dept Obstet & Gynaecol, Melbourne, Vic 3002, Australia	Imperial College London; University of Melbourne	de Swiet, M (corresponding author), Hammersmith Hosp, Queen Charlottes Hosp Women, London W12 0NN, England.	mdeswiet@ic.ac.uk						[Anonymous], 1990, AM J OBSTET GYNECOL, V163, P1691; Bell SC, 1999, BRIT J OBSTET GYNAEC, V106, P1177, DOI 10.1111/j.1471-0528.1999.tb08144.x; Bellomo G, 1999, JAMA-J AM MED ASSOC, V282, P1447, DOI 10.1001/jama.282.15.1447; Brown MA, 1998, LANCET, V352, P777, DOI 10.1016/S0140-6736(98)03270-X; Brown MA, 1999, BRIT J OBSTET GYNAEC, V106, P474, DOI 10.1111/j.1471-0528.1999.tb08301.x; BROWN MA, 1992, MED J AUSTRALIA, V156, P306, DOI 10.5694/j.1326-5377.1992.tb139782.x; Brown MA, 2000, AUST NZ J OBSTET GYN, V40, P139, DOI 10.1111/j.1479-828X.2000.tb01137.x; Cook HW, 1903, J HOPKINS HOSP REP, V11, P451; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; HALLIGAN A, 1993, J HYPERTENS, V11, P869, DOI 10.1097/00004872-199308000-00014; Halligan AWF, 1997, BRIT J OBSTET GYNAEC, V104, P559, DOI 10.1111/j.1471-0528.1997.tb11532.x; Hauth JC, 2000, OBSTET GYNECOL, V95, P24, DOI 10.1016/S0029-7844(99)00462-7; Higgins JR, 1997, BRIT J OBSTET GYNAEC, V104, P356, DOI 10.1111/j.1471-0528.1997.tb11468.x; HOEGHOLM A, 1992, AM J HYPERTENS, V5, P64, DOI 10.1093/ajh/5.2.64; HOEGHOLM A, 1994, HYPERTENSION, V24, P101, DOI 10.1161/01.HYP.24.1.101; Hughes EC., 1972, OBSTET GYNECOLOGIC T; KHOURY S, 1992, AM J HYPERTENS, V5, P616, DOI 10.1093/ajh/5.9.616; MACGILLIVRAY I, 1969, CLIN SCI, V37, P395; Natarajan P, 1999, AM J OBSTET GYNECOL, V181, P1203, DOI 10.1016/S0002-9378(99)70109-2; Peek M, 1996, OBSTET GYNECOL, V88, P1030, DOI 10.1016/S0029-7844(96)00350-X; Penny JA, 1998, AM J OBSTET GYNECOL, V178, P521, DOI 10.1016/S0002-9378(98)70432-6; PERRY IJ, 1991, BRIT J OBSTET GYNAEC, V98, P241, DOI 10.1111/j.1471-0528.1991.tb13386.x; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; REDMAN CWG, 1988, LANCET, V1, P809; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Saudan P, 1998, BRIT J OBSTET GYNAEC, V105, P1177, DOI 10.1111/j.1471-0528.1998.tb09971.x; SAUDAN PJ, 1998, BRIT J OBSTET GYNAEC, V158, P892; Shennan A, 1996, LANCET, V347, P139, DOI 10.1016/S0140-6736(96)90338-4; SHENNAN AH, 1993, BRIT J OBSTET GYNAEC, V100, P904, DOI 10.1111/j.1471-0528.1993.tb15104.x; Walker SP, 1998, MED J AUSTRALIA, V169, P203, DOI 10.5694/j.1326-5377.1998.tb140223.x; WICHMAN K, 1984, ACTA OBSTET GYN SCAN, P25	33	121	125	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2001	357	9250					131	135		10.1016/S0140-6736(00)03552-2	http://dx.doi.org/10.1016/S0140-6736(00)03552-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197413				2022-12-28	WOS:000166476200032
J	Peters, FPJ; Vermeulen, A; Kho, TL				Peters, FPJ; Vermeulen, A; Kho, TL			Anderson-Fabry's disease: alpha-galactosidase deficiency	LANCET			English	Article									Maasland Hosp Sittard, Dept Internal Med, NL-6131 BK Sittard, Netherlands; Univ Hosp Maastricht, Dept Internal Med, Maastricht, Netherlands; Univ Hosp Maastricht, Dept Pathol, Maastricht, Netherlands	Maasland Hospital; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Peters, FPJ (corresponding author), Maasland Hosp Sittard, Dept Internal Med, NL-6131 BK Sittard, Netherlands.							Desnick RJ, 1996, METABOLIC MOL BASES, P2741; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; NAKAO S, 1995, NEW ENGL J MED, V333, P288, DOI 10.1056/NEJM199508033330504; Peters FPJ, 1997, POSTGRAD MED J, V73, P710, DOI 10.1136/pgmj.73.865.710; Takenaka T, 1999, HUM GENE THER, V10, P1931, DOI 10.1089/10430349950017293	5	41	48	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					138	140		10.1016/S0140-6736(00)03554-6	http://dx.doi.org/10.1016/S0140-6736(00)03554-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197415				2022-12-28	WOS:000166476200034
J	Rain, JC; Selig, L; De Reuse, H; Battaglia, V; Reverdy, C; Simon, S; Lenzen, G; Petel, F; Wojcik, J; Schachter, V; Chemama, Y; Labigne, A; Legrain, P				Rain, JC; Selig, L; De Reuse, H; Battaglia, V; Reverdy, C; Simon, S; Lenzen, G; Petel, F; Wojcik, J; Schachter, V; Chemama, Y; Labigne, A; Legrain, P			The protein-protein interaction map of Helicobacter pylori	NATURE			English	Article							ESCHERICHIA-COLI; COMPLETE GENOME; RNA-POLYMERASE; SEQUENCE; UREASE; YEAST	With the availability of complete DNA sequences for many prokaryotic and eukaryotic genomes, and soon for the human genome itself, it is important to develop reliable proteome-wide approaches for a better understanding of protein function(1). As elementary constituents of cellular protein complexes and pathways, protein-protein interactions are key determinants of protein function. Here we have built a large-scale protein-protein interaction map of the human gastric pathogen Helicobacter pylori. We have used a high-throughput strategy of the yeast two-hybrid assay to screen 261 H. pylori proteins against a highly complex library of genome-encoded polypeptides(2). Over 1,200 interactions were identired between H. pylori proteins, connecting 46.6% of the proteome. The determination of a reliability score for every single protein-protein interaction and the identification of the actual interacting domains permitted the assignment of unannotated proteins to biological pathways.	Hybrigen SA, F-75012 Paris, France; Inst Pasteur, UnitePathogenie Bacterienne Muqueuses, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Legrain, P (corresponding author), Hybrigen SA, 180 Ave Daumesnil, F-75012 Paris, France.	plegrain@hybrigenics.fr		RAIN, Jean-Christophe/0000-0001-8110-0641; DE REUSE, Hilde/0000-0002-0100-4826				Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; CUSSAC V, 1992, J BACTERIOL, V174, P2466, DOI 10.1128/jb.174.8.2466-2473.1992; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FERRERO RL, 1992, J BACTERIOL, V174, P4212, DOI 10.1128/JB.174.13.4212-4217.1992; Fields S, 1997, NAT GENET, V15, P325, DOI 10.1038/ng0497-325; Flajolet M, 2000, GENE, V242, P369, DOI 10.1016/S0378-1119(99)00511-9; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; LIU XY, 1995, GENE, V164, P81, DOI 10.1016/0378-1119(95)00480-T; McCraith S, 2000, P NATL ACAD SCI USA, V97, P4879, DOI 10.1073/pnas.080078197; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; Mooney RA, 1999, CELL, V98, P687, DOI 10.1016/S0092-8674(00)81483-X; Moszer I, 1998, FEBS LETT, V430, P28, DOI 10.1016/S0014-5793(98)00620-6; Skouloubris S, 1998, INFECT IMMUN, V66, P4517; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vidal M, 1999, NUCLEIC ACIDS RES, V27, P919, DOI 10.1093/nar/27.4.919; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Weeks DL, 2000, SCIENCE, V287, P482, DOI 10.1126/science.287.5452.482; Welch M, 1998, NAT STRUCT BIOL, V5, P25, DOI 10.1038/nsb0198-25; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	23	835	901	1	52	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					211	215		10.1038/35051615	http://dx.doi.org/10.1038/35051615			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196647				2022-12-28	WOS:000166316200049
J	Botkin, JR				Botkin, JR			Protecting the privacy of family members in survey and pedigree research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The recent controversy at Virginia Commonwealth University involving research ethics raises important and complex issues in survey and pedigree research. The primary questions are whether family members of survey respondents themselves become subjects of the project and if they are subjects whether informed consent must be obtained for investigators to retain private information on these individuals. This article provides an analysis of the ethical issues and regulatory standards involved in this debate for consideration by investigators and institutional review boards. The analysis suggests that strong protections for the rights and welfare of subjects and their family members can be incorporated into survey and pedigree research protocols without hindering projects with extensive consent requirements.	Univ Utah, Dept Pediat, Salt Lake City, UT USA; Univ Utah, Dept Med Eth, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Botkin, JR (corresponding author), Primary Childrens Med Ctr, 100 N Med Dr, Salt Lake City, UT 84113 USA.				NATIONAL CANCER INSTITUTE [R43CA078117, R44CA078117] Funding Source: NIH RePORTER; NCI NIH HHS [1U24 CA78117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen AL, 1997, GENETIC SECRETS PROT, P31; *AM SOC HUM GEN, 2000, SHOULD FAMILY MEMBER; Amber D, 2000, SCIENTIST, V14, P1; [Anonymous], 1995, RANDOM HOUSE WEBSTER; Botkin JR, 1998, JAMA-J AM MED ASSOC, V279, P1808, DOI 10.1001/jama.279.22.1808; *DEP HLTH HUM SERV, 1979, DHEW PUBL; Department of Agriculture Department of Energy National Aeronautics and Space Administration Department of Commerce Consumer Product Safety Commission International Development Cooperation Agency Agency for International Development Department of Housing and Urban Development Department of Justice Department of Defense Department of Education Department of Veterans Affairs Environmental Protection Agency Department of Health and Human Services National Science Foundation and Department of Transportation, 1991, FED REGISTER, V56, P28003; Fuller BP, 1999, SCIENCE, V285, P1359, DOI 10.1126/science.285.5432.1359; LeBris S., 1997, GENETIC SECRETS, P418; MATHEWS J, 2000, WASHINGTON POST 0112, pB7; *NAT CANC I, 2000, CONF DAT SEC CANC RE; *OFF PROT RES RISK, 1993, PROT HUM RES SUBJ, P3	12	67	67	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2001	285	2					207	211		10.1001/jama.285.2.207	http://dx.doi.org/10.1001/jama.285.2.207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	389FB	11176815				2022-12-28	WOS:000166227000030
J	Holick, MF				Holick, MF			Sunlight "D"ilemma: risk of skin cancer or bone disease and muscle weakness	LANCET			English	Editorial Material							VITAMIN-D; CALCIUM		Boston Univ, Sch Med, Dept Med, Vitamin D Skin & Bone Res Lab, Boston, MA 02118 USA	Boston University	Holick, MF (corresponding author), Boston Univ, Sch Med, Dept Med, Vitamin D Skin & Bone Res Lab, Boston, MA 02118 USA.	mfholick@bu.edu		Holick, Michael/0000-0001-6023-9062				Ahonen MH, 2000, CANCER CAUSE CONTROL, V11, P847, DOI 10.1023/A:1008923802001; [Anonymous], 1956, BRIT MED J, V2, P149; BELL NH, 1985, J CLIN INVEST, V76, P470, DOI 10.1172/JCI111995; DawsonHughes B, 1997, AM J CLIN NUTR, V65, P67, DOI 10.1093/ajcn/65.1.67; GARLAND CF, 1991, AM J CLIN NUTR, V54, pS193, DOI 10.1093/ajcn/54.1.193S; GILCHREST BA, 1993, NEW ENGL J MED, V329, P1193, DOI 10.1056/NEJM199310143291611; Glerup H, 2000, CALCIFIED TISSUE INT, V66, P419, DOI 10.1007/s002230010085; Glerup H, 2000, J INTERN MED, V247, P260, DOI 10.1046/j.1365-2796.2000.00595.x; GLOTH FM, 1995, JAMA-J AM MED ASSOC, V274, P1683, DOI 10.1001/jama.274.21.1683; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; HOLICK MF, 1994, AM J CLIN NUTR, V60, P619, DOI 10.1093/ajcn/60.4.619; Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140-6736(05)78933-9; MCKENNA MJ, 1992, AM J MED, V93, P69, DOI 10.1016/0002-9343(92)90682-2; REID IR, 1986, AGE AGEING, V15, P35, DOI 10.1093/ageing/15.1.35; Schwartz GG, 1998, CANCER EPIDEM BIOMAR, V7, P391; SEDRANI SH, 1984, ANN NUTR METAB, V28, P181, DOI 10.1159/000176801	16	147	154	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2001	357	9249					4	6		10.1016/S0140-6736(00)03560-1	http://dx.doi.org/10.1016/S0140-6736(00)03560-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197362				2022-12-28	WOS:000166341500004
J	Schechter, CP; Dave, HPG; Alving, BM				Schechter, CP; Dave, HPG; Alving, BM			Update in hematology	ANNALS OF INTERNAL MEDICINE			English	Review							TRANSPLANTATION		Vet Affairs Med Ctr, Washington, DC 20422 USA; George Washington Univ, Washington, DC USA; NIH, Bethesda, MD 20892 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); George Washington University; National Institutes of Health (NIH) - USA	Schechter, CP (corresponding author), Vet Affairs Med Ctr, 50 Irving St NW,Room 4D-115, Washington, DC 20422 USA.							Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; Franks AL, 1999, ANN INTERN MED, V130, P1018, DOI 10.7326/0003-4819-130-12-199906150-00021; Harrison L, 1997, ANN INTERN MED, V126, P133, DOI 10.7326/0003-4819-126-2-199701150-00006; Spitzer TR, 1999, BLOOD, V94, p709A; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x	5	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2001	134	1					38	46		10.7326/0003-4819-134-1-200101020-00012	http://dx.doi.org/10.7326/0003-4819-134-1-200101020-00012			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386CV	11187419				2022-12-28	WOS:000166043300006
J	Demine, AK				Demine, AK			Public health in eastern Europe	LANCET			English	Article											Demine, AK (corresponding author), 22 Stroenie 1,Room 27, Moscow 101000, Russia.		Demin, Andrey/U-3810-2019	Demin, Andrey/0000-0002-5650-5636					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S49	S49		10.1016/S0140-6736(00)92035-X	http://dx.doi.org/10.1016/S0140-6736(00)92035-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191507				2022-12-28	WOS:000166074900051
J	Harnad, S				Harnad, S			Ingelfinger over-ruled	LANCET			English	Article									Univ Southampton, Elect & Comp Sci Ctr, Southampton SO17 1BJ, Hants, England	University of Southampton	Harnad, S (corresponding author), Univ Southampton, Elect & Comp Sci Ctr, Southampton SO17 1BJ, Hants, England.		Harnad, Stevan R/A-1010-2008						0	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S16	S16		10.1016/S0140-6736(00)92002-6	http://dx.doi.org/10.1016/S0140-6736(00)92002-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191471				2022-12-28	WOS:000166074900018
J	Lindahl, S				Lindahl, S			Academic medicine sets focus on clinical research	LANCET			English	Article									Karolinska Hosp & Inst, Dept Surg Sci, Sect Anaesthesiol & Intens Care, SE-17176 Stockholm, Sweden; Karolinska Inst, Dept Anaesthesiol & Intens Care Med, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Lindahl, S (corresponding author), Karolinska Hosp & Inst, Dept Surg Sci, Sect Anaesthesiol & Intens Care, SE-17176 Stockholm, Sweden.								0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S54	S54		10.1016/S0140-6736(00)92040-3	http://dx.doi.org/10.1016/S0140-6736(00)92040-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191513				2022-12-28	WOS:000166074900056
J	Rustamadji				Rustamadji			Family medicine between west and east	LANCET			English	Article											Rustamadji (corresponding author), Rancho Indah Estate,JI Tanjung 10,Blok B-2, Jakarta 12530, Indonesia.	Rufo@CBN.net.id							0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC	2000	356			S			S29	S29		10.1016/S0140-6736(00)92015-4	http://dx.doi.org/10.1016/S0140-6736(00)92015-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191485				2022-12-28	WOS:000166074900031
J	Schwarcz, R; Fescina, R				Schwarcz, R; Fescina, R			Maternal mortality in Latin America and the Caribbean	LANCET			English	Article									OPAS OMS, Setor Embaixadas Norte, Brasilia, DF, Brazil		Schwarcz, R (corresponding author), Ayacucho 1249,Piso 7A, RA-1111 Buenos Aires, DF, Argentina.		Schwarcz, Robert/P-3134-2018						0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S11	S11		10.1016/S0140-6736(00)91997-4	http://dx.doi.org/10.1016/S0140-6736(00)91997-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191466				2022-12-28	WOS:000166074900013
J	Zeleke, SA				Zeleke, SA			Difficulties with vaccine programmes	LANCET			English	Article									Gondar Coll Med Sci, Dept Paediat & Child Hlth, Gondar, Ethiopia	University of Gondar	Zeleke, SA (corresponding author), Gondar Coll Med Sci, Dept Paediat & Child Hlth, POB 196, Gondar, Ethiopia.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S21	S21		10.1016/S0140-6736(00)92007-5	http://dx.doi.org/10.1016/S0140-6736(00)92007-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191477	Bronze			2022-12-28	WOS:000166074900023
J	Brauman, JI				Brauman, JI			Twist and fluoresce	SCIENCE			English	Editorial Material							PHOTOISOMERIZATION; STILBENES		Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Brauman, JI (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.							G?rner H., 2007, ADV PHOTOCHEM, V19, P1; MALKIN S, 1964, J PHYS CHEM-US, V68, P1153, DOI 10.1021/j100787a032; SALTIEL J, 1972, J AM CHEM SOC, V94, P6445, DOI 10.1021/ja00773a031; SALTIEL J, 1979, J AM CHEM SOC, V101, P2982, DOI 10.1021/ja00505a027; SALTIEL J, 1990, STUD ORG CHEM, V40, P64; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Simeonov A, 2000, SCIENCE, V290, P307, DOI 10.1126/science.290.5490.307; WALDECK DH, 1991, CHEM REV, V91, P415, DOI 10.1021/cr00003a007; Wentworth P, 1998, CURR OPIN CHEM BIOL, V2, P138, DOI 10.1016/S1367-5931(98)80046-X	9	4	4	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 13	2000	290	5490					286	287		10.1126/science.290.5490.286	http://dx.doi.org/10.1126/science.290.5490.286			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	363CW	11183374				2022-12-28	WOS:000089818100031
J	Mast, ST; Jollis, JG; Ryan, T; Anstrom, KJ; Crary, JL				Mast, ST; Jollis, JG; Ryan, T; Anstrom, KJ; Crary, JL			The progression of fenfluramine-associated valvular heart disease assessed by echocardiography	ANNALS OF INTERNAL MEDICINE			English	Article							APPETITE-SUPPRESSANT DRUGS; AORTIC REGURGITATION; VALVE ABNORMALITIES; OBESE-PATIENTS; DEXFENFLURAMINE; PHENTERMINE; PREVALENCE; RISK	Background: An association between the dietary suppressants fenfluramine and dexfenfluramine and valvular heart disease was first described in patients from North Dakota and Minnesota in 1997. Limited data are available on the natural history of this valvulopathy after discontinuation of drug therapy. Objective: To follow the progression of fenfluramine-associated valvular heart disease after discontinuation of therapy by using serial echocardiography. Design: Retrospective cohort study. Setting: Regional medical center in Fargo, North Dakota. Patients: 50 patients with previous exposure to fenfluramines who had at least mild mitral regurgitation or aortic regurgitation after exposure to fenfluramines on serial echocardiography between December 1994 and February 1999 (96% were female, mean body mass index was 36.6 kg/m(2), and mean duration of drug exposure was 447 days). Measurements: serial echocardiograms were reviewed by two echocardiographers who were blinded to the order of image acquisition. The severity of valvular regurgitation and presence or absence of valve leaflet restriction were assessed. Results: As described in the initial report, significant valvular disease on initial postexposure echocardiography was common in this cohort; 38 patients (76%) had at least mild mitral regurgitation and 43 patients (86%) had at least mild aortic regurgitation. On serial echocardiograms obtained an average of 356 days apart, mitral regurgitation improved by at least one grade in 17 patients (P = 0.001) and aortic regurgitation improved by at least one grade in 19 patients (P = 0.004). Nineteen and 22 patients, respectively, experienced no change in severity of mitral and aortic regurgitation. Two patients in each group experienced worsening of regurgitation by at least one grade. Results were similar for tricuspid (P = 0.002) and pulmonic (P = 0.012) regurgitation. Conclusion: On serial echocardiography, fenfluramine-associated valvular regurgitation improved or remained stable in most patients after therapy ended. Worsening of valvular regurgitation was uncommon. The potential for stabilization or regression of valvular regurgitation should be taken into account when counseling patients and considering the need for and timing of valve surgery.	Duke Univ, Med Ctr, Durham, NC USA; MeritCare Med Ctr, Fargo, ND USA	Duke University	Jollis, JG (corresponding author), Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.				NHLBI NIH HHS [HL03995-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burger AJ, 1999, J AM COLL CARDIOL, V34, P1153, DOI 10.1016/S0735-1097(99)00321-6; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Gardin JM, 2000, JAMA-J AM MED ASSOC, V283, P1703, DOI 10.1001/jama.283.13.1703; HENRY WL, 1980, CIRCULATION, V62, P212, DOI 10.1161/01.CIR.62.2.212; Hensrud DD, 1999, MAYO CLIN PROC, V74, P1191, DOI 10.4065/74.12.1191; Jick H, 1998, NEW ENGL J MED, V339, P719, DOI 10.1056/NEJM199809103391102; Jollis JG, 2000, CIRCULATION, V101, P2071, DOI 10.1161/01.CIR.101.17.2071; Khan MA, 1998, NEW ENGL J MED, V339, P713, DOI 10.1056/NEJM199809103391101; LIN M, 1994, J AM COLL CARDIOL, V24, P1046, DOI 10.1016/0735-1097(94)90868-0; Schiller NB, 1999, J AM COLL CARDIOL, V34, P1159; SCOGNAMIGLIO R, 1994, NEW ENGL J MED, V331, P689, DOI 10.1056/NEJM199409153311101; Wee CC, 1998, ANN INTERN MED, V129, P870, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00005; Weissman NJ, 1999, J AM COLL CARDIOL, V34, P2088, DOI 10.1016/S0735-1097(99)00445-3; Weissman NJ, 1998, NEW ENGL J MED, V339, P725, DOI 10.1056/NEJM199809103391103; 1997, MMWR MORB WKLY REP, V46, P1061	15	42	44	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					261	266		10.7326/0003-4819-134-4-200102200-00008	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NW	11182835				2022-12-28	WOS:000167050200001
J	Grossman, SA; Celano, P				Grossman, SA; Celano, P			Neoplastic meningitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Greater Baltimore Med Ctr, Baltimore, MD 21204 USA	Johns Hopkins University; Johns Hopkins Medicine; Greater Baltimore Medical Center	Grossman, SA (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	2001	344	7					494	494		10.1056/NEJM200102153440705	http://dx.doi.org/10.1056/NEJM200102153440705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401HL	11172191				2022-12-28	WOS:000166922100005
J	Gilbert, PB; DeGruttola, V; Hammer, SM; Kuritzkes, DR				Gilbert, PB; DeGruttola, V; Hammer, SM; Kuritzkes, DR			Virologic and regimen termination surrogate end points in AIDS clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV-1 RNA LEVELS; IMMUNODEFICIENCY-VIRUS-INFECTION; COMBINATION ANTIRETROVIRAL THERAPY; CD4 CELL COUNT; REPORTING OUTCOMES; VIRAL LOAD; PROGRESSION; ZIDOVUDINE; INDINAVIR; LYMPHOCYTES	Suppression of plasma human immunodeficiency virus (HIV) RNA levels has been widely accepted as an appropriate surrogate end point for HIV disease progression, and it is currently used as the primary end point to determine efficacy in many antiretroviral trials. However, this end point does not always measure other important effects of treatment, such as inducement of multidrug resistance, which depletes future therapy options, and toxic effects. An alternative that directly factors in these treatment costs is a composite regimen termination end point, defined as a protocol-determined change in regimen due to either virologic failure or treatment-related toxic effects. Pros and cons for using purely virologic vs various composite primary end points are discussed. Conclusions include (1) a trial's clinical objective guides the choice of primary end point, (2) a purely virologic end point is often preferable, (3) it may be important to analyze both end point types in interpreting study results, and (4) long-term clinical outcome studies are needed for identifying the most predictive surrogate end points.	Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Columbia Presbyterian Ctr, Div Infect Dis, New York, NY USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Harvard University; Harvard T.H. Chan School of Public Health; Columbia University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gilbert, PB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA.	pgilbert@hsph.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI028076, U01AI038855, R01AI028076] Funding Source: NIH RePORTER; NIAID NIH HHS [5-U01-AI38855, 5-U01-AI28076] Funding Source: Medline; PHS HHS [A1-32770] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBRECHT M, 2000, 7 C RETR OPP INF JAN; ANDERSON JR, 1988, J CLIN ONCOL, V6, P559, DOI 10.1200/JCO.1988.6.3.559; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1998, MMWR Recomm Rep, V47, P43; Babiker A, 2000, AIDS RES HUM RETROV, V16, P1123; *CARD ARRH PIL STU, 1988, AM J CARDIOL, V61, P501; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; DEGRUTTOLA V, 1993, J ACQ IMMUN DEF SYND, V6, P359; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; DIXON DO, 1987, J CLIN ONCOL, V5, P1670, DOI 10.1200/JCO.1987.5.10.1670; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; Fisher L.D., 1990, STAT ISSUES DRUG RES, P331, DOI DOI 10.1201/9780203738610; Fleming T. R., 1992, STAT SCI, V7, P428; FLEMING TR, 1990, J ACQ IMMUN DEF SYND, V3, pS82; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; FLEMING TR, 1994, STAT MED, V13, P1423, DOI 10.1002/sim.4780131318; Friedman L. M., 1998, FUNDAMENTALS CLIN TR; Gilbert PB, 2000, AIDS RES HUM RETROV, V16, P1325, DOI 10.1089/08892220050140874; Gilbert PB, 2000, AIDS, V14, P1961, DOI 10.1097/00002030-200009080-00012; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 2000, J INFECT DIS, V182, P1375, DOI 10.1086/315867; HAMMER S, 1999, 6 C RETR OPP INF JAN; HAMMER S, 2000, 7 C RETR OPP INF JAN; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; Hoyert D L, 1999, Natl Vital Stat Rep, V47, P1; Hughes MD, 1998, AIDS, V12, P1823, DOI 10.1097/00002030-199814000-00014; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Katzenstein D A, 1997, J Assoc Nurses AIDS Care, V8 Suppl, P10, DOI 10.1016/S1055-3290(97)80003-9; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kuritzkes DR, 2000, AIDS, V14, P1553, DOI 10.1097/00002030-200007280-00011; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LIN DY, 1993, STAT MED, V12, P835, DOI 10.1002/sim.4780120904; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Murphy RL, 1999, J INFECT DIS, V179, P808, DOI 10.1086/314668; Murray JS, 1999, AIDS, V13, P797, DOI 10.1097/00002030-199905070-00008; *NAT I ALL INF DIS, 1998, 25 AIDS CLIN TRIALS; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Painter George R., 1996, Drugs of the Future, V21, P347; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PARTALEDIS JA, 1995, J VIROL, V69, P5228, DOI 10.1128/JVI.69.9.5228-5235.1995; Phillips AN, 1996, AIDS, V10, P859, DOI 10.1097/00002030-199607000-00009; Piketty C, 1998, AIDS, V12, P745, DOI 10.1097/00002030-199807000-00011; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; SADLER BM, 1995, 5 EUR C CLIN ASP TRE; Scharfstein DO, 1999, J AM STAT ASSOC, V94, P1096, DOI 10.2307/2669923; SHCOOLEY RT, 1996, 36 INT C ANT AG CHEM; SMEATON L, IN PRESS CONTROL CLI; SQUIRES K, 2000, 7 C RETR OPP INF JAN; Staszewski S, 1998, AIDS, V12, P1991, DOI 10.1097/00002030-199815000-00010; StClair MH, 1996, ANTIVIR RES, V29, P53, DOI 10.1016/0166-3542(95)00916-7; Stone VE, 1998, J GEN INTERN MED, V13, P586, DOI 10.1046/j.1525-1497.1998.00180.x; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704; Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623; Welles SL, 1996, J INFECT DIS, V174, P696, DOI 10.1093/infdis/174.4.696; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yeh KC, 1998, ANTIMICROB AGENTS CH, V42, P332	67	34	35	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					777	784		10.1001/jama.285.6.777	http://dx.doi.org/10.1001/jama.285.6.777			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176916				2022-12-28	WOS:000166817200035
J	Kline, JA; Israel, EG; Michelson, EA; O'Neil, BJ; Plewa, MC; Portelli, DC				Kline, JA; Israel, EG; Michelson, EA; O'Neil, BJ; Plewa, MC; Portelli, DC			Diagnostic accuracy of a bedside D-dimer assay and alveolar dead-space measurement for rapid exclusion of pulmonary embolism - A multicenter study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-MODEL; ANGIOGRAPHY; CAPNOGRAM; EXCLUDE; UTILITY	Context A previous study suggested that the combination of a normal D-dimer assay and normal alveolar dead-space fraction is a highly sensitive screening test for pulmonary embolism (PE). Objective To determine if the combination of a normal alveolar dead-space fraction (volume of alveolar dead space/tidal volume less than or equal to 20%) and a normal whole-blood agglutination D-dimer assay can exclude PE in emergency department (ED) patients. Design Prospective, noninterventional study conducted in 1998-1999, Study data were obtained prior to standard testing for PE, consisting of radionuclide lung scanning or contrast-enhanced computed tomography and 6-month follow-up plus selective use of venous ultrasonography and pulmonary angiography. Imaging studies were interpreted by blinded observers. Setting Six urban teaching hospitals in the United States. Patients A total of 380 hemodynamically stable ED patients aged 18 years or older with suspected acute PE. Main Outcome Measures Sensitivity and specificity for PE with a positive test defined as having either alveolar dead-space fraction or D-dimer assay results abnormal. Alveolar dead-space fraction was determined by subtracting airway dead space from physiological dead space (determined using the modified Bohr equation) and D-dimer assay, assayed at bedside using 20 muL of arterial blood. Results Pulmonary embolism was diagnosed in 64 patients (16.8%), of those 20 had an abnormal D-dimer assay result, 3 had an abnormal alveolar dead-space fraction, 40 had abnormal results in both, and 1 had normal results for both tests. The sensitivity for diagnosis of PE was 98.4% (95% confidence interval [CI], 91.6%-100.0%). Among the 316 patients without PE, both D-dimer and dead-space results were normal in 163, for a specificity of 51.6% (95% CI, 46.1%-57.1%). Posterior probability of PE with normal results on both tests was 0.75% (95% CI, 0%-3.4%). Conclusion In this multicenter study of ED patients, a normal D-dimer assay result plus a normal alveolar dead-space fraction was associated with a low prevalence of PE.	Carolinas Med Ctr, Dept Emergency Med, Charlotte, NC 28232 USA; Washington Univ, Sch Med, Barnes Hosp, Div Emergency Med, St Louis, MO USA; Northwestern Univ, Sch Med, Dept Med, Div Emergency Med, Chicago, IL 60611 USA; Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI USA; St Vincent Mercy Med Ctr, Dept Emergency Med, Toledo, OH USA; Henry Ford Hosp, Dept Emergency Med, Detroit, MI 48202 USA	Carolinas Medical Center; Washington University (WUSTL); Northwestern University; Wayne State University; Henry Ford Health System; Henry Ford Hospital	Kline, JA (corresponding author), Carolinas Med Ctr, Dept Emergency Med, Charlotte, NC 28232 USA.	jkline@carolinas.org		Plewa, Michael/0000-0001-8701-4277				COURTNEY DM, IN PRESS RESUSCITATI; de Groot MR, 1999, THROMB HAEMOSTASIS, V82, P1588; Enghoff Henrik, 1938, UPSALA LAKAREFOREN FORHANDL, V44, P191; Farrell S, 2000, ANN EMERG MED, V35, P121, DOI 10.1016/S0196-0644(00)70130-2; FLETCHER R, 1984, BRIT J ANAESTH, V56, P109, DOI 10.1093/bja/56.2.109; Gallagher EJ, 1998, ANN EMERG MED, V31, P391, DOI 10.1016/S0196-0644(98)70352-X; Gardner MJ, 1989, STAT CONFIDENCE, P28; Ginsberg JS, 1998, ANN INTERN MED, V129, P1006, DOI 10.7326/0003-4819-129-12-199812150-00003; HENRY JW, 1995, CHEST, V107, P1375, DOI 10.1378/chest.107.5.1375; Jackson RE, 2000, ACAD EMERG MED, V7, P994, DOI 10.1111/j.1553-2712.2000.tb02090.x; Johanning JM, 1999, AM J SURG, V178, P98, DOI 10.1016/S0002-9610(99)00136-1; KIPPER MS, 1982, CHEST, V82, P411, DOI 10.1378/chest.82.4.411; Kline JA, 2000, ANN EMERG MED, V35, P168, DOI 10.1016/S0196-0644(00)70137-5; Kline JA, 1998, ANN EMERG MED, V32, P289, DOI 10.1016/S0196-0644(98)70004-6; Kline JA, 1997, ACAD EMERG MED, V4, P856, DOI 10.1111/j.1553-2712.1997.tb03809.x; Kline JA, 2000, ACAD EMERG MED, V7, P611, DOI 10.1111/j.1553-2712.2000.tb02033.x; Kutinsky I, 1999, ARCH INTERN MED, V159, P1569, DOI 10.1001/archinte.159.14.1569; Mauron T, 1998, THROMB HAEMOSTASIS, V79, P1217, DOI 10.1055/s-0037-1615046; Patel MM, 1999, CHEST, V116, P1325, DOI 10.1378/chest.116.5.1325; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; Perrier A, 1999, LANCET, V353, P190, DOI 10.1016/S0140-6736(98)05248-9; Remy-Jardin M, 1999, RADIOLOGY, V212, P615, DOI 10.1148/radiology.212.3.r99se02615; RemyJardin M, 1996, RADIOLOGY, V200, P699, DOI 10.1148/radiology.200.3.8756918; Susec O, 1997, ACAD EMERG MED, V4, P891; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002; Wells PS, 2000, THROMB HAEMOSTASIS, V83, P416; WORSLEY DF, 1995, J NUCL MED, V36, P2380	28	96	108	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					761	768		10.1001/jama.285.6.761	http://dx.doi.org/10.1001/jama.285.6.761			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176914	Bronze			2022-12-28	WOS:000166817200033
J	Lindsay, R; Silverman, SL; Cooper, C; Hanley, DA; Barton, I; Broy, SB; Licata, A; Benhamou, L; Geusens, P; Flowers, K; Stracke, H; Seeman, E				Lindsay, R; Silverman, SL; Cooper, C; Hanley, DA; Barton, I; Broy, SB; Licata, A; Benhamou, L; Geusens, P; Flowers, K; Stracke, H; Seeman, E			Risk of new vertebral fracture in the year following a fracture	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN; OSTEOPOROSIS	Context Vertebral fractures significantly increase lifetime risk of future fractures, but risk of further vertebral fractures in the period immediately following a vertebral fracture has not been evaluated. Objective To determine the incidence of further vertebral fracture in the year following a vertebral fracture. Design and setting Analysis of data from 4 large 3-year osteoporosis treatment trials conducted at 373 study centers in North America, Europe, Australia, and New Zealand from November 1993 to April 1998. Subjects Postmenopausal women who had been randomized to a placebo group and for whom vertebral fracture status was known at entry (n=2725). Main Outcome Measure Occurrence of radiographically identified vertebral fracture during the year following an incident vertebral fracture. Results Subjects were a mean age of 74 years and had a mean of 28 years since menopause. The cumulative incidence of new vertebral fractures in the first year was 6.6%. Presence of 1 or more vertebral fractures at baseline increased risk of sustaining a vertebral fracture by 5-fold during the initial year of the study compared with the incidence in subjects without prevalent vertebral fractures at baseline (relative risk [RR], 5.1;95% confidence interval [CI], 3.1-8.4; P<.001). Among the 381 participants who developed an incident vertebral fracture, the incidence of a new vertebral fracture in the subsequent year was 19.2% (95% CI, 13.6%-24.8%). This risk was also increased in the presence of prevalent vertebral fractures (RR, 9.3; 95% CI, 1.2-71.6; P=.03). Conclusion Our data indicate that women who develop a vertebral fracture are at substantial risk for additional fracture within the next year.	Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY 10993 USA; Cedars Sinai Med Ctr, Osteoporosis Med Ctr, Los Angeles, CA 90048 USA; Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA; Univ Southampton, MRC, Environm Epidemiol Unit, Southampton, Hants, England; Univ Calgary, Hlth Sci Ctr, Calgary, AB, Canada; Procter & Gamble Pharmaceut, Staines, Middx, England; Illinois Bone & Joint Inst, Ctr Arthrit & Osteoporosis, Des Plaines, IL USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Ctr Hosp Orleans, Orleans, France; Limburgs Univ Ctr, Diepenbeek, Belgium; Univ Maastricht, Maastricht, Netherlands; Procter & Gamble Co, Cincinnati, OH USA; Univ Giessen, Giessen, Germany; Univ Melbourne, Melbourne, Vic, Australia	Cedars Sinai Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of Southampton; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; Procter & Gamble; Cleveland Clinic Foundation; Centre Hospitalier Regional d'Orleans; Hasselt University; Maastricht University; Procter & Gamble; Justus Liebig University Giessen; University of Melbourne	Lindsay, R (corresponding author), Helen Hayes Hosp, Reg Bone Ctr, Route 9W, W Haverstraw, NY 10993 USA.		Seeman, Ego/AAC-3656-2019	Seeman, Ego/0000-0002-9692-048X; Cooper, Cyrus/0000-0003-3510-0709				Black DM, 1999, J BONE MINER RES, V14, P821, DOI 10.1359/jbmr.1999.14.5.821; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Kado DM, 1999, ARCH INTERN MED, V159, P1215, DOI 10.1001/archinte.159.11.1215; KANIS JA, 1984, LANCET, V1, P27; Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721; LAURITZEN JB, 1993, ACTA ORTHOP SCAND, V64, P297, DOI 10.3109/17453679308993629; Melton LJ, 1999, OSTEOPOROSIS INT, V10, P214, DOI 10.1007/s001980050218; Miller P, 1999, ARTHRITIS RHEUM, V42, pS287; Nevitt MC, 2000, ARCH INTERN MED, V160, P77, DOI 10.1001/archinte.160.1.77; Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; ROSS PD, 1993, OSTEOPOROSIS INT, V3, P120, DOI 10.1007/BF01623272; Ross Philip D., 1997, American Journal of Medicine, V103, p30S, DOI 10.1016/S0002-9343(97)90025-5	14	1193	1285	0	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					320	323		10.1001/jama.285.3.320	http://dx.doi.org/10.1001/jama.285.3.320			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390XD	11176842	Bronze, Green Published			2022-12-28	WOS:000166324300023
J	Selman, M; King, TE; Pardo, A				Selman, M; King, TE; Pardo, A			Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy	ANNALS OF INTERNAL MEDICINE			English	Review							USUAL INTERSTITIAL PNEUMONIA; ALVEOLAR EPITHELIAL-CELLS; GROWTH-FACTOR-BETA; HUMAN-LUNG FIBROBLASTS; EPSTEIN-BARR-VIRUS; CIRCULATING IMMUNE-COMPLEXES; BLEOMYCIN HAMSTER MODEL; RESOLUTION CT FINDINGS; PRESSURE-VOLUME CURVE; LOW-DOSE PREDNISOLONE	Idiopathic pulmonary fibrosis is a progressive and usually fatal lung disease characterized by fibroblast proliferation and extracellular matrix remodeling, which result in irreversible distortion of the lung's architecture. Although the pathogenetic mechanisms remain to be determined, the prevailing hypothesis holds that fibrosis is preceded and provoked by a chronic inflammatory process that injures the lung and modulates lung fibrogenesis, leading to the end-stage fibrotic scar. However, there is little evidence that inflammation is prominent in early disease, and it is unclear whether inflammation is relevant to the development of the fibrotic process. Evidence suggests that inflammation does not play a pivotal role. Inflammation is not a prominent histopathologic finding, and epithelial injury in the absence of ongoing inflammation is sufficient to stimulate the development of fibrosis. In addition, the inflammatory response to a lung fibrogenic insult is not necessarily related to the fibrotic response. Clinical measurements of inflammation fail to correlate with stage or outcome, and potent anti-inflammatory therapy does not improve outcome. This review presents a growing body of evidence suggesting that idiopathic pulmonary fibrosis involves abnormal wound healing in response to multiple, microscopic sites of ongoing alveolar epithelial injury and activation associated with the formation of patchy fibroblast-myofibroblast foci, which evolve-to fibrosis. Progress in understanding the fibrogenic mechanisms in the lung is likely to yield more effective therapies.	Inst Nacl Enfermedades Resp, Mexico City 14080, DF, Mexico; Univ Nacl Autonoma Mexico, Mexico City 04510, DF, Mexico; Univ Calif San Francisco, San Francisco, CA 94143 USA	Universidad Nacional Autonoma de Mexico; University of California System; University of California San Francisco	Selman, M (corresponding author), Inst Nacl Enfermedades Resp, Tlalpan 4502, Mexico City 14080, DF, Mexico.	mselman@conacyt.mx						ADAMSON IYR, 1988, AM J PATHOL, V130, P377; AKIRA M, 1993, RADIOLOGY, V189, P687, DOI 10.1148/radiology.189.3.8080483; ALTON EWFW, 1989, RESP MED, V83, P277, DOI 10.1016/S0954-6111(89)80196-9; *AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; [Anonymous], 1999, Thorax, V54 Suppl 1, pS1; ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Barrios R, 1997, AM J PHYSIOL-LUNG C, V273, pL451; BAUER EA, 1982, J INVEST DERMATOL, V79, P398, DOI 10.1111/1523-1747.ep12530243; Baumgartner KB, 2000, AM J EPIDEMIOL, V152, P307, DOI 10.1093/aje/152.4.307; Baumgartner KB, 1997, AM J RESP CRIT CARE, V155, P242, DOI 10.1164/ajrccm.155.1.9001319; Behr J, 1997, AM J RESP CRIT CARE, V156, P1897, DOI 10.1164/ajrccm.156.6.9706065; BILLINGS CG, 1994, EUR RESPIR J, V7, P1172; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BITTERMAN PB, 1986, NEW ENGL J MED, V314, P1343, DOI 10.1056/NEJM198605223142103; Bjoraker JA, 1998, AM J RESP CRIT CARE, V157, P199, DOI 10.1164/ajrccm.157.1.9704130; BOWDEN DH, 1994, EXP LUNG RES, V20, P251, DOI 10.3109/01902149409064386; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; BURKHARDT A, 1989, AM REV RESPIR DIS, V140, P513, DOI 10.1164/ajrccm/140.2.513; CANTIN AM, 1989, AM REV RESPIR DIS, V139, P370, DOI 10.1164/ajrccm/139.2.370; CANTIN AM, 1990, AM J RESP CELL MOL, V3, P79, DOI 10.1165/ajrcmb/3.1.79; CARRILLO G, 2000, AM J RESP CRIT CARE, V161, pA528; CARRINGTON CB, 1978, NEW ENGL J MED, V298, P801, DOI 10.1056/NEJM197804132981501; CHAPMAN HA, 1986, AM REV RESPIR DIS, V133, P437; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Cornelissen AMH, 1999, ARCH ORAL BIOL, V44, P541, DOI 10.1016/S0003-9969(99)00037-0; Cottin V, 1998, EUR RESPIR J, V12, P702, DOI 10.1183/09031936.98.12030702; Cottin V, 1998, AM J RESP CRIT CARE, V158, P1286, DOI 10.1164/ajrccm.158.4.9802119; COULTAS DB, 1994, AM J RESP CRIT CARE, V150, P967, DOI 10.1164/ajrccm.150.4.7921471; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; CRYSTAL RG, 1981, AM J MED, V70, P542, DOI 10.1016/0002-9343(81)90577-5; CRYSTAL RG, 1991, LUNG, P2031; Daly HE, 1998, LAB INVEST, V78, P393; De Lara LV, 2000, AM J PHYSIOL-LUNG C, V279, pL950, DOI 10.1152/ajplung.2000.279.5.L950; Desmouliere A, 1997, INT J BIOCHEM CELL B, V29, P19, DOI 10.1016/S1357-2725(96)00117-3; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Douglas WW, 1998, AM J RESP CRIT CARE, V158, P220, DOI 10.1164/ajrccm.158.1.9709089; Douglas WW, 2000, AM J RESP CRIT CARE, V161, P1172, DOI 10.1164/ajrccm.161.4.9907002; DREISIN RB, 1978, NEW ENGL J MED, V298, P353, DOI 10.1056/NEJM197802162980701; Egan JJ, 1997, EUR RESPIR J, V10, P1433; EGAN JJ, 1995, THORAX, V50, P1234, DOI 10.1136/thx.50.12.1234; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; ELLIS RH, 1965, POSTGRAD MED J, V41, P150, DOI 10.1136/pgmj.41.473.150; Entzian P, 1997, LUNG, V175, P41, DOI 10.1007/PL00007555; FEIGIN DS, 1980, AM J ROENTGENOL, V134, P91, DOI 10.2214/ajr.134.1.91; Fukuda Y, 1998, LAB INVEST, V78, P687; FULMER JD, 1978, AM REV RESPIR DIS, V118, P141; FULMER JD, 1979, J CLIN INVEST, V63, P665, DOI 10.1172/JCI109349; Gay SE, 1998, AM J RESP CRIT CARE, V157, P1063, DOI 10.1164/ajrccm.157.4.9703022; GEDDES DM, 1977, LANCET, V2, P1049; GEISMAR LS, 1986, CHEST, V89, pS153, DOI 10.1378/chest.89.3_Supplement.153S; GIBSON GJ, 1976, BRIT J DIS CHEST, V70, P143, DOI 10.1016/0007-0971(76)90027-9; GIBSON GJ, 1979, AM REV RESPIR DIS, V120, P799; GOLDSTEIN RH, 1995, CHEST, V108, P848, DOI 10.1378/chest.108.3.848; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GRENIER P, 1991, RADIOLOGY, V179, P123, DOI 10.1148/radiology.179.1.2006262; GUERRYFORCE ML, 1987, AM REV RESPIR DIS, V135, P705; Gurujeyalakshmi G, 1999, AM J PHYSIOL-LUNG C, V276, pL311, DOI 10.1152/ajplung.1999.276.2.L311; Hartman TE, 1996, CHEST, V110, P378, DOI 10.1378/chest.110.2.378; HASLAM PL, 1980, THORAX, V35, P9, DOI 10.1136/thx.35.1.9; HASLAM PL, 1979, CLIN EXP IMMUNOL, V37, P381; HASLAM PL, 1980, THORAX, V35, P328, DOI 10.1136/thx.35.5.328; Hayashi T, 1996, AM J PATHOL, V149, P1241; HERBERT CM, 1974, LANCET, V1, P187, DOI 10.1016/S0140-6736(74)92494-5; Heyneman LE, 1999, AM J ROENTGENOL, V173, P1617, DOI 10.2214/ajr.173.6.10584810; HIROHATA S, 1994, ARTHRITIS RHEUM, V37, P942, DOI 10.1002/art.1780370625; Huaux F, 1998, AM J RESP CELL MOL, V18, P51, DOI 10.1165/ajrcmb.18.1.2911; Hubbard R, 1998, AM J RESP CRIT CARE, V157, P743, DOI 10.1164/ajrccm.157.3.9701093; Hubbard R, 1996, LANCET, V347, P284, DOI 10.1016/S0140-6736(96)90465-1; Hubbard R, 1997, EUR RESPIR J, V10, P2881, DOI 10.1183/09031936.97.10122881; HUGHES EW, 1965, POSTGRAD MED J, V41, P150; HUNNINGHAKE GW, 1981, AM REV RESPIR DIS, V123, P407; Imokawa S, 1997, AM J RESP CRIT CARE, V156, P631, DOI 10.1164/ajrccm.156.2.9608094; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; IRVING WL, 1993, AM REV RESPIR DIS, V148, P1683, DOI 10.1164/ajrccm/148.6_Pt_1.1683; IWAI K, 1994, AM J RESP CRIT CARE, V150, P670, DOI 10.1164/ajrccm.150.3.8087336; Iyer SN, 1999, J PHARMACOL EXP THER, V291, P367; IZUMI T, 1992, American Review of Respiratory Disease, V145, pA218; JAKAB GJ, 1990, AM REV RESPIR DIS, V142, P374, DOI 10.1164/ajrccm/142.2.374; JAKAB GJ, 1990, AM REV RESPIR DIS, V141, P1307, DOI 10.1164/ajrccm/141.5_Pt_1.1307; JIWA M, 1990, AM J CLIN PATHOL, V93, P491, DOI 10.1093/ajcp/93.4.491; Johns CJ, 1999, MEDICINE, V78, P65, DOI 10.1097/00005792-199903000-00001; JOHNSON MA, 1989, THORAX, V44, P280, DOI 10.1136/thx.44.4.280; Johnston IDA, 1997, THORAX, V52, P38, DOI 10.1136/thx.52.1.38; KALLENBERG CGM, 1987, J CLIN PATHOL, V40, P725, DOI 10.1136/jcp.40.7.725; KAPANCI Y, 1995, AM J RESP CRIT CARE, V152, P2163, DOI 10.1164/ajrccm.152.6.8520791; Kasper M, 1996, HISTOL HISTOPATHOL, V11, P463; KASPER M, 1995, HISTOCHEM CELL BIOL, V104, P397, DOI 10.1007/BF01458134; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; KAWANAMI O, 1982, LAB INVEST, V46, P39; Keane MP, 1999, J IMMUNOL, V163, P5686; Keane MP, 1999, J IMMUNOL, V162, P5511; Keane MP, 1997, J IMMUNOL, V159, P1437; KEOGH BA, 1982, THORAX, V37, P1, DOI 10.1136/thx.37.1.1; Khalil N, 1996, AM J RESP CELL MOL, V14, P131, DOI 10.1165/ajrcmb.14.2.8630262; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; Kim EY, 1999, AM J ROENTGENOL, V173, P949, DOI 10.2214/ajr.173.4.10511155; Kondo H, 1996, MECH AGEING DEV, V87, P141, DOI 10.1016/0047-6374(95)01699-6; KOTANI I, 1995, THROMB RES, V77, P493, DOI 10.1016/0049-3848(95)00025-9; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; KUHN C, 1991, AM J PATHOL, V138, P1257; Kuwano K, 1996, AM J RESP CRIT CARE, V154, P477, DOI 10.1164/ajrccm.154.2.8756825; Lappi-Blanco E, 1999, LUNG, V177, P367, DOI 10.1007/PL00007654; LIBBY DM, 1983, AM REV RESPIR DIS, V127, P618, DOI 10.1164/arrd.1983.127.5.618; LINE BR, 1978, AM REV RESPIR DIS, V118, P355; Mannino DM, 1996, AM J RESP CRIT CARE, V153, P1548, DOI 10.1164/ajrccm.153.5.8630600; Mapel DW, 1996, CHEST, V110, P1058, DOI 10.1378/chest.110.4.1058; Marshall RP, 2000, THORAX, V55, P143, DOI 10.1136/thorax.55.2.143; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MATHIESON JR, 1989, RADIOLOGY, V171, P111, DOI 10.1148/radiology.171.1.2928513; MCCORMAC FX, 1995, AM J RESP CRIT CARE, V152, P751, DOI 10.1164/ajrccm.152.2.7633738; MCCORMACK FX, 1991, AM REV RESPIR DIS, V144, P160, DOI 10.1164/ajrccm/144.1.160; MCLAUGHLIN GE, 1994, CRIT CARE MED, V22, P313, DOI 10.1097/00003246-199402000-00024; MEIERSYDOW J, 1994, SEMIN RESP CRIT CARE, V15, P77, DOI 10.1055/s-2007-1006351; MEIERSYDOW J, 1979, PRAX KLIN PNEUMOL, V33, P680; Meliconi R, 1996, THORAX, V51, P315, DOI 10.1136/thx.51.3.315; MERRILL WW, 1983, CLIN CHEST MED, V4, P71; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; MURPHY A, 1981, IRISH J MED SCI, V150, P204, DOI 10.1007/BF02938236; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; MUSK AW, 1986, CHEST, V89, P206, DOI 10.1378/chest.89.2.206; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NASH JRG, 1993, HISTOPATHOLOGY, V22, P343, DOI 10.1111/j.1365-2559.1993.tb00133.x; NGUYEN L, 1994, P SOC EXP BIOL MED, V205, P80; NISHIMURA K, 1992, RADIOLOGY, V182, P337, DOI 10.1148/radiology.182.2.1732946; Nishiyama O, 2000, J COMPUT ASSIST TOMO, V24, P41, DOI 10.1097/00004728-200001000-00008; OKADA T, 1993, LYMPHOKINE CYTOK RES, V12, P87; PARADIS IL, 1986, AM REV RESPIR DIS, V133, P855; Pardo A, 1997, INT J BIOCHEM CELL B, V29, P901, DOI 10.1016/S1357-2725(97)00030-7; Pardo A, 1996, AM J RESP CRIT CARE, V154, P1067, DOI 10.1164/ajrccm.154.4.8887609; Pardo A, 1998, AM J PATHOL, V153, P833, DOI 10.1016/S0002-9440(10)65625-8; Paulnock DM, 2000, J LEUKOCYTE BIOL, V67, P677, DOI 10.1002/jlb.67.5.677; PEAO MND, 1994, ANAT REC, V238, P57, DOI 10.1002/ar.1092380108; PEREZPADILLA R, 1993, AM REV RESPIR DIS, V148, P49, DOI 10.1164/ajrccm/148.1.49; PETERS SG, 1993, CHEST, V103, P101, DOI 10.1378/chest.103.1.101; PETERSON MW, 1987, CHEST, V92, P51, DOI 10.1378/chest.92.1.51; PEYROL S, 1990, AM J PATHOL, V137, P155; PINSKER KL, 1981, CHEST, V80, P123, DOI 10.1378/chest.80.2.123; RAGHU G, 1985, AM REV RESPIR DIS, V131, P281, DOI 10.1164/ajrccm/138.3.703; RAGHU G, 1991, AM REV RESPIR DIS, V144, P291, DOI 10.1164/ajrccm/144.2.291; Raghu G, 1999, AM J RESP CRIT CARE, V159, P1061, DOI 10.1164/ajrccm.159.4.9805017; RAGHU G, 1998, INTERSTITIAL LUNG DI; REMYJARDIN M, 1993, RADIOLOGY, V189, P111, DOI 10.1148/radiology.189.1.8372179; REMYJARDIN M, 1993, RADIOLOGY, V189, P693, DOI 10.1148/radiology.189.3.8234692; RENNARD SI, 1988, AM REV RESPIR DIS, V137, P181, DOI 10.1164/ajrccm/137.1.181; RENZI G, 1982, B EUR PHYSIOPATH RES, V18, P461; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROSENBERG DM, 1982, CLIN CHEST MED, V3, P635; RUDD RM, 1981, AM REV RESPIR DIS, V124, P1; Sang Q X, 1998, Cell Res, V8, P171; SCHWARTZ DA, 1994, AM J RESP CRIT CARE, V149, P450, DOI 10.1164/ajrccm.149.2.8306044; SCHWARZ MI, 1978, J LAB CLIN MED, V91, P929; SCOTT J, 1990, BRIT MED J, V301, P1015, DOI 10.1136/bmj.301.6759.1015; Segura-Valdez L, 2000, CHEST, V117, P684, DOI 10.1378/chest.117.3.684; SELMAN M, 1986, THORAX, V41, P355, DOI 10.1136/thx.41.5.355; Selman M, 2000, AM J PHYSIOL-LUNG C, V279, pL562, DOI 10.1152/ajplung.2000.279.3.L562; Selman M, 1998, CHEST, V114, P507, DOI 10.1378/chest.114.2.507; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Stewart JP, 1999, AM J RESP CRIT CARE, V159, P1336, DOI 10.1164/ajrccm.159.4.9807077; Tan A, 1999, AM J RESP CRIT CARE, V159, P220, DOI 10.1164/ajrccm.159.1.9802104; TERRIFF BA, 1992, RADIOLOGY, V184, P445, DOI 10.1148/radiology.184.2.1620845; Tobin RW, 1998, AM J RESP CRIT CARE, V158, P1804, DOI 10.1164/ajrccm.158.6.9804105; TUNG KT, 1993, THORAX, V48, P334, DOI 10.1136/thx.48.4.334; TURNER-WARWICK MARGARET, 1963, THORAX, V18, P225, DOI 10.1136/thx.18.3.225; TURNERWARWICK M, 1987, AM REV RESPIR DIS, V135, P26; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171; TURTON CWG, 1978, LANCET, V1, P507; UEDA T, 1992, AM REV RESPIR DIS, V146, P266, DOI 10.1164/ajrccm/146.1.266; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; Uhal BD, 1995, AM J PHYSIOL-LUNG C, V269, pL819, DOI 10.1152/ajplung.1995.269.6.L819; Uhal BD, 1998, AM J PHYSIOL-LUNG C, V275, pL1013, DOI 10.1152/ajplung.1998.275.5.L1013; Uhal Bruce D., 1998, American Journal of Physiology, V275, pL1192; Unemori EN, 1996, J CLIN INVEST, V98, P2739, DOI 10.1172/JCI119099; VERGNON JM, 1984, LANCET, V2, P768; Wang RG, 1999, AM J PHYSIOL-LUNG C, V277, pL1158, DOI 10.1152/ajplung.1999.277.6.L1158; WARD WF, 1992, INT J RADIAT ONCOL, V22, P623, DOI 10.1016/0360-3016(92)90890-T; WARD WF, 1983, RADIOLOGY, V146, P533, DOI 10.1148/radiology.146.2.6849102; WATTERS LC, 1987, AM REV RESPIR DIS, V135, P696; WATTERS LC, 1986, SEMIN RESPIR MED, V7, P317, DOI 10.1055/s-2007-1012627; Wells AU, 1997, AM J RESP CRIT CARE, V155, P1657, DOI 10.1164/ajrccm.155.5.9154872; Wells AU, 1997, EUR RESPIR J, V10, P280, DOI 10.1183/09031936.97.10020280; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yaguchi T, 1998, PATHOL INT, V48, P954, DOI 10.1111/j.1440-1827.1998.tb03866.x; Yano T, 1996, AM J RESP CELL MOL, V15, P433, DOI 10.1165/ajrcmb.15.4.8879176; YERNAULT JC, 1975, B PHYSIO-PATHOL RESP, V11, P231; Yi ES, 1996, AM J PATHOL, V149, P1963; Yokozeki M, 1999, FEBS LETT, V442, P61, DOI 10.1016/S0014-5793(98)01626-3; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703	193	1341	1441	6	161	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2001	134	2					136	151		10.7326/0003-4819-134-2-200101160-00015	http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00015			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391KW	11177318				2022-12-28	WOS:000166356000008
J	Shackleton, N				Shackleton, N			Paleoclimate - Climate change across the hemispheres	SCIENCE			English	Editorial Material							ICE-SHEET; GREENLAND; TEMPERATURE; CYCLE		Univ Cambridge, Dept Earth Sci, Godwin Lab, Cambridge CB2 2SA, England	University of Cambridge	Shackleton, N (corresponding author), Univ Cambridge, Dept Earth Sci, Godwin Lab, Cambridge CB2 2SA, England.	njs5@cam.ac.uk						Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Cuffey KM, 1997, J GEOPHYS RES-OCEANS, V102, P26383, DOI 10.1029/96JC03981; Indermuhle A, 2000, GEOPHYS RES LETT, V27, P735, DOI 10.1029/1999GL010960; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; Kanfoush SL, 2000, SCIENCE, V288, P1815, DOI 10.1126/science.288.5472.1815; Meese DA, 1997, J GEOPHYS RES-OCEANS, V102, P26411, DOI 10.1029/97JC00269; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; Shackleton NJ, 2000, PALEOCEANOGRAPHY, V15, P565, DOI 10.1029/2000PA000513	9	19	19	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					58	59		10.1126/SCIENCE.1057253	http://dx.doi.org/10.1126/SCIENCE.1057253			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11192012				2022-12-28	WOS:000166259100031
J	Tramo, MJ				Tramo, MJ			Biology and music - Music of the hemispheres	SCIENCE			English	Editorial Material							DISCRIMINATION; PITCH; REPRESENTATION; PERCEPTION; INFANTS		Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Tramo, MJ (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02114 USA.							BERNSTEIN L, 1983, UNANSWERED QUESTION; Blood AJ, 1999, NAT NEUROSCI, V2, P382, DOI 10.1038/7299; CARLANI PA, 1996, J NEUROPHYSIOL, V76, P1698; Cole MG, 1997, AM J GERIAT PSYCHIAT, V5, P4; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; Gardiner MF, 1996, NATURE, V381, P284, DOI 10.1038/381284a0; HULSE SH, 1995, J EXP PSYCHOL GEN, V124, P409, DOI 10.1037/0096-3445.124.4.409; Kaas JH, 1999, CURR OPIN NEUROBIOL, V9, P164, DOI 10.1016/S0959-4388(99)80022-1; Krumhansl CL, 1997, CAN J EXP PSYCHOL, V51, P336, DOI 10.1037/1196-1961.51.4.336; Lerdahl Fred, 1983, GENERATIVE THEORY TO; Liberman M C, 1978, Acta Otolaryngol Suppl, V358, P1; Ligeois-Chauvel C, 1998, BRAIN, V121, P1853, DOI 10.1093/brain/121.10.1853; LORE D, 1999, ATLANTA J CONST 0705; PANDYA DN, 1995, REV NEUROL, V151, P486; Pantev C, 1998, NATURE, V392, P811, DOI 10.1038/33918; Patel AD, 2000, NATURE, V404, P80, DOI 10.1038/35003577; PERETZ I, 1990, BRAIN, V113, P1185, DOI 10.1093/brain/113.4.1185; Rauschecker JP, 1999, TRENDS NEUROSCI, V22, P74, DOI 10.1016/S0166-2236(98)01303-4; Rauscher FH, 1997, NEUROL RES, V19, P2; Repp BH, 1998, J ACOUST SOC AM, V104, P1085, DOI 10.1121/1.423325; Sakai K, 1999, J NEUROSCI, V19, P10074; SCHLAUG G, 1995, NEUROPSYCHOLOGIA, V33, P1047, DOI 10.1016/0028-3932(95)00045-5; SCHLAUG G, 1995, SCIENCE, V267, P699, DOI 10.1126/science.7839149; SIDTIS JJ, 1988, BRAIN LANG, V34, P235, DOI 10.1016/0093-934X(88)90135-6; TRAINOR LJ, 1993, MUSIC PERCEPT, V11, P185; Tramo M. J., 1992, Society for Neuroscience Abstracts, V18, P382; TRAMO MJ, 1991, NEUROPSYCHOLOGIA, V29, P313, DOI 10.1016/0028-3932(91)90045-A; TRAMO MJ, 1993, CONTEMP MUSIC REV, V9, P113, DOI DOI 10.1080/07494469300640381; TRATRAMO JM, 1993, NEUROPSYCHOLOGIA, V9, P113; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767; ZATORRE RJ, 1988, J ACOUST SOC AM, V84, P566, DOI 10.1121/1.396834; Zentner MR, 1998, INFANT BEHAV DEV, V21, P483, DOI 10.1016/S0163-6383(98)90021-2	32	70	74	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					54	56		10.1126/SCIENCE.1056899	http://dx.doi.org/10.1126/SCIENCE.1056899			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	389VJ	11192009				2022-12-28	WOS:000166259100028
J	Hernandez-Pando, R; Jeyanathan, M; Mengistu, G; Aguilar, D; Orozco, H; Harboe, M; Rook, GAW; Bjune, G				Hernandez-Pando, R; Jeyanathan, M; Mengistu, G; Aguilar, D; Orozco, H; Harboe, M; Rook, GAW; Bjune, G			Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; TUBERCLE-BACILLI; EXOGENOUS REINFECTION; EPITHELIAL-CELLS; AVIUM COMPLEX; SITUATION; INVASION; LESIONS; MODELS	Background A third of the world's population has latent infection with Mycobacterium tuberculosis, and in areas of low endemicity, most cases of active tuberculosis arise as a result of reactivation of latent bacilli. We sought to establish the cellular location of these latent organisms to facilitate their elimination. Methods We applied in-situ PCR to sections of macroscopically normal lung tissue from 13 individuals from Ethiopia and 34 from Mexico who had died from causes other than tuberculosis. Sections of lung tissue from six Norwegian individuals (ie, individuals from a non-endemic population) acted as negative. controls, and six Ethiopian tuberculosis cases acted as positive controls. Findings Control necropsy samples from the Norwegian individuals were all negative by in-situ PCR and conventional PCR,whereas all samples from known Ethiopian tuberculosis cases were positive by both methods. However, in macroscopically normal lung tissue from Ethiopian and Mexican individuals without tuberculous lesions, the in-situ PCR revealed five of 13 and ten of 34 positive individuals respectively. These results were confirmed by conventional PCR with extracted DNA. Positive cells included alveolar and interstitial macrophages, type II pneumocytes, endothelial cells, and fibroblasts. Interpretation M tuberculosis can persist intracellularly in lung tissue without histological evidence of tuberculous lesions. M tuberculosis DNA is situated not only in macrophages but also inother non-professional phagocytic cells. These findings contradict the dominant view that latent organisms exist in old classic tuberculous lesions, and have important implications for strategies aimed at the elimination of latent and persistent bacilli.	UCL Royal Free & Univ Coll Med Sch, Windeyer Inst Med Sci, Dept Bacteriol, London W1T 4JF, England; Inst Nacl Nutr Salvador Zubiran, Dept Pathol, Expt Pathol Sect, Mexico City 14000, DF, Mexico; Armauer Hansen Res Inst, Addis Ababa, Ethiopia; Univ Oslo, Natl Hosp, Inst Immunol, Oslo, Norway; Univ Oslo, Inst Gen Practice & Community Med, Oslo, Norway	University of London; University College London; UCL Medical School; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; University of Oslo; National Hospital Norway; University of Oslo	Rook, GAW (corresponding author), UCL Royal Free & Univ Coll Med Sch, Windeyer Inst Med Sci, Dept Bacteriol, London W1T 4JF, England.	g.rook@ucl.ac.uk		Rook, Graham/0000-0002-8041-8110; Hernandez-Pando, Rogelio/0000-0003-1292-3833				BALASUBRAMANIAN V, 1994, TUBERCLE LUNG DIS, V75, P168, DOI 10.1016/0962-8479(94)90002-7; BERMUDEZ LE, 1994, INFECT IMMUN, V62, P2021, DOI 10.1128/IAI.62.5.2021-2026.1994; BERMUDEZ LE, 1991, CLIN IMMUNOL IMMUNOP, V61, P225, DOI 10.1016/S0090-1229(05)80026-1; DANNENBERG AM, 1993, HOSP PRACT, V28, P51, DOI 10.1080/21548331.1993.11442738; Dhillon J, 1998, INT J TUBERC LUNG D, V2, P736; DICKINSON JM, 1981, AM REV RESPIR DIS, V123, P367; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Donoghue HD, 1998, LETT APPL MICROBIOL, V27, P265; EISENACH KD, 1991, AM REV RESPIR DIS, V144, P1160, DOI 10.1164/ajrccm/144.5.1160; FILLEY EA, 1991, INFECT IMMUN, V59, P2567, DOI 10.1128/IAI.59.8.2567-2572.1991; FILLEY EA, 1992, IMMUNOLOGY, V77, P505; Fine PEM, 1999, NEW ENGL J MED, V341, P1226, DOI 10.1056/NEJM199910143411609; Griffith AS, 1929, J PATHOL BACTERIOL, V32, P813, DOI 10.1002/path.1700320411; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; MAPOTHER ME, 1984, INFECT IMMUN, V45, P67, DOI 10.1128/IAI.45.1.67-73.1984; Mehta PK, 1996, INFECT IMMUN, V64, P2673, DOI 10.1128/IAI.64.7.2673-2679.1996; Opie EL, 1927, ARCH PATHOL LAB MED, V4, P1; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; Phyu S, 1998, SCAND J INFECT DIS, V30, P59; RAMAKRISHNAN L, 1994, INFECT IMMUN, V62, P3222, DOI 10.1128/IAI.62.8.3222-3229.1994; REA TH, 1991, SEMIN DERMATOL, V10, P188; Rook Graham A. W., 1994, P485; SHEPARD CC, 1957, J EXP MED, V105, P39, DOI 10.1084/jem.105.1.39; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491	26	304	319	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2133	2138		10.1016/S0140-6736(00)03493-0	http://dx.doi.org/10.1016/S0140-6736(00)03493-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191539				2022-12-28	WOS:000165997300011
J	Keegan, LP; Gallo, A; O'Connell, MA				Keegan, LP; Gallo, A; O'Connell, MA			Development - Survival is impossible without an editor	SCIENCE			English	Editorial Material							INOSINE CONVERSION; MESSENGER-RNA; MITOCHONDRIA; ADENOSINE; GENE		Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Keegan, LP (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.		O'Connell, Mary Anne/U-7693-2019; Gallo, Angela/E-7837-2011; Keegan, Liam P./AAL-3753-2021; OConnell, Mary Anne/G-4740-2015; Gallo, Angela/AAA-5003-2020; Keegan, Liam P/F-1106-2017	O'Connell, Mary Anne/0000-0003-3844-6174; Gallo, Angela/0000-0003-0297-1807; Keegan, Liam P./0000-0001-7915-5790; OConnell, Mary Anne/0000-0003-3844-6174; Gallo, Angela/0000-0003-0297-1807; Keegan, Liam P/0000-0001-7915-5790				BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Keller W, 1999, FEBS LETT, V452, P71, DOI 10.1016/S0014-5793(99)00590-6; Maas S, 2000, BIOESSAYS, V22, P790, DOI 10.1002/1521-1878(200009)22:9<790::AID-BIES4>3.0.CO;2-0; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; OCONNELL MA, 1997, CURR BIOL, V7, P437; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765	16	11	15	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	2000	290	5497					1707	+		10.1126/science.290.5497.1707	http://dx.doi.org/10.1126/science.290.5497.1707			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11186391				2022-12-28	WOS:000165632400026
J	Klein, BS				Klein, BS			Microbiology - Turning up the heat on Histoplasma capsulatum	SCIENCE			English	Editorial Material							GENE; DISRUPTION; EXPRESSION; MACROPHAGES; ANTIGEN; CALCIUM		Univ Wisconsin, Dept Pediat, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Klein, BS (corresponding author), Univ Wisconsin, Dept Pediat, Madison, WI 53792 USA.	bsklein@facstaff.wisc.edu						Batanghari JW, 1998, MOL MICROBIOL, V27, P531, DOI 10.1046/j.1365-2958.1998.00697.x; Brandhorst TT, 1999, J EXP MED, V189, P1207, DOI 10.1084/jem.189.8.1207; CHANG YC, 1994, MOL CELL BIOL, V14, P4912, DOI 10.1128/MCB.14.7.4912; Colonna-Romano S, 1998, MICROB PATHOGENESIS, V25, P55, DOI 10.1006/mpat.1998.0209; CURRIE BP, 1994, CLIN INFECT DIS, V19, P1029, DOI 10.1093/clinids/19.6.1029; Deepe GS, 1998, RES IMMUNOL, V149, P397, DOI 10.1016/S0923-2494(98)80763-3; Fisher KL, 1999, INFECT IMMUN, V67, P3312, DOI 10.1128/IAI.67.7.3312-3316.1999; KEATH EJ, 1989, INFECT IMMUN, V57, P1384, DOI 10.1128/IAI.57.5.1384-1390.1989; Kugler S, 2000, CELL MICROBIOL, V2, P537, DOI 10.1046/j.1462-5822.2000.00078.x; MARESCA B, 1989, MICROBIOL REV, V53, P186, DOI 10.1128/MMBR.53.2.186-209.1989; MEDOFF G, 1986, SCIENCE, V231, P476, DOI 10.1126/science.3001938; Newman SL, 1999, TRENDS MICROBIOL, V7, P67, DOI 10.1016/S0966-842X(98)01431-0; Reichard U, 2000, INFECT IMMUN, V68, P5830, DOI 10.1128/IAI.68.10.5830-5838.2000; Retallack DM, 2000, MICROB PATHOGENESIS, V28, P169, DOI 10.1006/mpat.1999.0337; Sebghati TS, 2000, SCIENCE, V290, P1368, DOI 10.1126/science.290.5495.1368; Vescovi EG, 1997, J BIOL CHEM, V272, P1440, DOI 10.1074/jbc.272.3.1440; Woods JP, 1998, J BACTERIOL, V180, P5135, DOI 10.1128/JB.180.19.5135-5143.1998; WOODS JP, 1992, MOL MICROBIOL, V6, P3603, DOI 10.1111/j.1365-2958.1992.tb01796.x; WOODS JP, 1993, J BACTERIOL, V175, P636, DOI 10.1128/JB.175.3.636-641.1993	19	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1311	1312		10.1126/science.290.5495.1311	http://dx.doi.org/10.1126/science.290.5495.1311			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11185407				2022-12-28	WOS:000165379800032
J	Hendrie, HC; Ogunniyi, A; Hall, KS; Baiyewu, O; Unverzagt, FW; Gureje, O; Gao, SJ; Evans, RM; Ogunseyinde, AO; Adeyinka, AO; Musick, B; Hui, SL				Hendrie, HC; Ogunniyi, A; Hall, KS; Baiyewu, O; Unverzagt, FW; Gureje, O; Gao, SJ; Evans, RM; Ogunseyinde, AO; Adeyinka, AO; Musick, B; Hui, SL			Incidence of dementia and Alzheimer disease in 2 communities - Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COGNITIVE DECLINE; RISK-FACTORS; OLD-OLD; POPULATION; AGE; PREVALENCE; DIAGNOSIS; SAMPLE; METAANALYSIS; PERFORMANCE	Context Alzheimer disease (AD) represents a major and increasing public health problem. If populations were identified with significantly lower or higher incidence rates of AD, the search for risk factors in the genesis of AD could be greatly enhanced. Objective To compare incidence rates of dementia and AD in 2 diverse, elderly community-dwelling populations. Design The Indianapolis-Ibadan Dementia Project, a longitudinal, prospective population-based study consisting of a baseline survey (1992-1993) and 2 subsequent follow-up waves after 2 years (1994-1995) and 5 years (1997-1998). Each wave followed a 2-stage design, with an in-home screening interview followed by a full diagnostic workup of a subsample of participants based on screening performance. Setting and Participants A total of 2459 community-dwelling Yoruba residents of Ibadan, Nigeria, without dementia, and 2147 community-dwelling African American residents of Indianapolis, Ind, without dementia (all aged 65 years or older). The cohorts were followed up for a mean of 5.1 years and 4.7 years, respectively. Main Outcome Measures Incident cases of dementia and AD in each of the 2 populations. Results The age-standardized annual incidence rates were significantly lower among Yoruba than among African Americans for dementia (Yoruba, 1.35% [95% confidence interval {Cl}, 1.13%-1.56%]; African Americans, 3.24% [95% CI, 2.11%-4.38%]) and for AD (Yoruba, 1.15% [95% CI, 0.96%-1.35%]; African Americans, 2.52% [95% CI, 1.40%-3.64%]). Conclusion This is the first report of incidence rate differences for dementia and AD in studies of 2 populations from nonindustrialized and industrialized countries using identical methods and the same group of investigators in both sites. Further explorations of these population differences may identify potentially modifiable environmental or genetic factors to account for site differences in dementia and AD.	Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA; Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Regenstrief Inst, Indianapolis, IN USA; Univ Ibadan, Dept Med, Ibadan, Nigeria; Univ Ibadan, Dept Radiol, Ibadan, Nigeria	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; University of Ibadan; University of Ibadan	Hendrie, HC (corresponding author), Indiana Univ, Sch Med, Dept Psychiat, 541 Clin Dr,Room 394A, Indianapolis, IN 46202 USA.		Gureje, Oye/J-1183-2014	Gureje, Oye/0000-0003-0094-5947	NIA NIH HHS [R01 AGO9956] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009956] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aevarsson O, 1996, J AM GERIATR SOC, V44, P1455, DOI 10.1111/j.1532-5415.1996.tb04070.x; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ARONSON MK, 1991, ARCH INTERN MED, V151, P989, DOI 10.1001/archinte.1991.00400050129024; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; BOOTHBY H, 1994, PSYCHOL MED, V24, P89, DOI 10.1017/S0033291700026866; BRAYNE C, 1995, BRIT J PSYCHIAT, V167, P255, DOI 10.1192/bjp.167.2.255; Brayne C, 1999, J AM GERIATR SOC, V47, P1283, DOI 10.1111/j.1532-5415.1999.tb07426.x; Breslow NE, 1989, STAT METHODS CANC RE; BRETELER MMB, 1999, EPIDEMIOLOGY ALZHEIM, P79; CORRADA M, 1995, INT J EPIDEMIOL, V24, P1000, DOI 10.1093/ije/24.5.1000; Di Bari M, 1999, J AM GERIATR SOC, V47, P1380; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; Fichter MM, 1996, EUR ARCH PSY CLIN N, V246, P320, DOI 10.1007/BF02189026; Fillenbaum GG, 1998, J CLIN EPIDEMIOL, V51, P587, DOI 10.1016/S0895-4356(98)00024-9; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; Gao S, 1998, ARCH GEN PSYCHIAT, V55, P809, DOI 10.1001/archpsyc.55.9.809; Gureje O, 1995, W AFR J MED, V14, P29; HAGNELL O, 1992, NEUROEPIDEMIOLOGY, V11, P61, DOI 10.1159/000110981; Hall KS, 2000, INT J GERIATR PSYCH, V15, P521, DOI 10.1002/1099-1166(200006)15:6<521::AID-GPS182>3.0.CO;2-F; Hall KS, 1996, INT J METHOD PSYCH, V6, P129, DOI 10.1002/(SICI)1234-988X(199610)6:3<129::AID-MPR164>3.3.CO;2-A; HEBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354, DOI 10.1001/jama.273.17.1354; HENDRIE HC, 1995, AM J PSYCHIAT, V152, P1485; Jorm AF, 1998, NEUROLOGY, V51, P728, DOI 10.1212/WNL.51.3.728; LETENNEUR L, 1994, INT J EPIDEMIOL, V23, P1256, DOI 10.1093/ije/23.6.1256; Levy R, 1994, Int Psychogeriatr, V6, P63, DOI 10.1017/S1041610294001626; LI G, 1991, ACTA PSYCHIAT SCAND, V83, P99, DOI 10.1111/j.1600-0447.1991.tb07373.x; MAESTRE G, 1995, ANN NEUROL, V37, P154; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORGAN K, 1993, BRIT J PSYCHIAT, V163, P467, DOI 10.1192/bjp.163.4.467; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Ogunniyi A, 2000, EUR J NEUROL, V7, P485, DOI 10.1046/j.1468-1331.2000.00124.x; Ogunniyi A, 1993, West Afr J Med, V12, P189; OSUNTOKUN BO, 1995, ANN NEUROL, V38, P463, DOI 10.1002/ana.410380319; PAYKEL ES, 1994, ARCH GEN PSYCHIAT, V51, P325; Prince M, 1997, TROP MED INT HEALTH, V2, P993, DOI 10.1046/j.1365-3156.1997.d01-156.x; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Sahota A, 1997, ANN NEUROL, V42, P659, DOI 10.1002/ana.410420418; SKOOG I, 1999, ALZHEIMERS DIS RELAT, V58, P523; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Unverzagt FW, 1996, CLIN NEUROPSYCHOL, V10, P180, DOI 10.1080/13854049608406679; *WHO, 1992, INT CLASS DIS 10TH R; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161	45	278	292	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					739	747		10.1001/jama.285.6.739	http://dx.doi.org/10.1001/jama.285.6.739			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	399MP	11176911	Bronze			2022-12-28	WOS:000166817200030
J	Le, T; Stein, ML				Le, T; Stein, ML			Medical education and the Internet: This changes everything	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		*ADV DISTR LEARN N, 2000, SHAR COURS OBJ REF M; Barzansky B, 2000, JAMA-J AM MED ASSOC, V284, P1114, DOI 10.1001/jama.284.9.1114; MASIE E, 2000, TECHLEARN TREND 0804; PETERSON RW, 1999, E LEARNING, P51; Shortliffe EH, 1998, ANN INTERN MED, V129, P138, DOI 10.7326/0003-4819-129-2-199807150-00017	5	15	19	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					809	809		10.1001/jama.285.6.809	http://dx.doi.org/10.1001/jama.285.6.809			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176926	hybrid			2022-12-28	WOS:000166817200044
J	Griffith, LG; Grodzinsky, AJ				Griffith, LG; Grodzinsky, AJ			Advances in biomedical engineering	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTEIN; FUTURE	The most visible contributions of biomedical engineering to clinical practice involve instrumentation for diagnosis, therapy, and rehabilitation. Cell and tissue engineering also have emerged as clinical realities. In the next 25 years, advances in electronics, optics, materials, and miniaturization will accelerate development of more sophisticated devices for diagnosis and therapy, such as imaging and virtual surgery. The emerging new field of bioengineering-engineering based in the science of molecular cell biology-will greatly expand the scope of biomedical engineering to tackle challenges in molecular and genomic medicine.	MIT, Ctr Biomed Engn, Dept Chem Engn, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Dept Mech Engn, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Dept Elect Engn, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Griffith, LG (corresponding author), MIT, Ctr Biomed Engn, Dept Chem Engn, Div Bioengn & Environm Hlth, 77 Mass Ave,Room 66-466, Cambridge, MA 02139 USA.			Griffith, Linda/0000-0002-1801-5548				Bronzino J. D., 2000, BIOMEDICAL ENG HDB; BROWN CS, IN PRESS P NATL ACAD; CORMACK AM, 1980, MED PHYS, V7, P277, DOI 10.1118/1.594708; COWIN SC, 1991, J BIOMECH ENG-T ASME, V113, P191, DOI 10.1115/1.2891234; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Fagette P, 1997, IEEE ENG MED BIOL, V16, P164, DOI 10.1109/51.620510; GEDDES LA, 1983, AM J CARDIOL, V52, P403, DOI 10.1016/0002-9149(83)90147-9; Griffith LG, 2000, ACTA MATER, V48, P263, DOI 10.1016/S1359-6454(99)00299-2; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HOUNSFIELD GN, 1980, MED PHYS, V7, P283, DOI 10.1118/1.594709; KISIDAY J, 2001, SELF ASSEMBLING PEPT, V26; Lanza R.P., 2000, PRINCIPLES TISSUE EN; Lardo AC, 2000, PEDIATR CARDIOL, V21, P80, DOI 10.1007/s002469910010; Lauffenburger DA, 1998, CHEM BIOL, V5, pR257, DOI 10.1016/S1074-5521(98)90110-7; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Riccobene TA, 1999, J THEOR BIOL, V200, P207, DOI 10.1006/jtbi.1999.0988; SCHWAN HP, 1991, IEEE ENG MED BIOL, V10, P25, DOI 10.1109/51.84182; SEVERINGHAUS JW, 1992, ANESTHESIOLOGY, V76, P1018; Spelman FA, 1999, IEEE ENG MED BIOL, V18, P27, DOI 10.1109/51.765186; Stokes CL, 2000, AICHE J, V46, P430, DOI 10.1002/aic.690460302; WELLS PNT, 1969, PHYSICAL PRINCIPLES, P282; Yang GZ, 2000, IEEE ENG MED BIOL, V19, P120, DOI 10.1109/51.816253; YANNAS IV, 1989, P NATL ACAD SCI USA, V86, P933, DOI 10.1073/pnas.86.3.933; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y; ZOLLIKOFER CL, 1992, CARDIOVASC INTER RAD, V15, P272, DOI 10.1007/BF02733950	28	19	20	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					556	561		10.1001/jama.285.5.556	http://dx.doi.org/10.1001/jama.285.5.556			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176858	Bronze			2022-12-28	WOS:000166714200011
J	Capron, AM				Capron, AM			Reexamining organ transplantation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEATH		Univ So Calif, Sch Law, Los Angeles, CA 90089 USA	University of Southern California	Capron, AM (corresponding author), Univ So Calif, Sch Law, 699 Exposit Blvd, Los Angeles, CA 90089 USA.	acapron@law.usc.edu						[Anonymous], 1968, JAMA, V205, P337; BARNARD C N, 1967, South African Medical Journal, V41, P1271; Bunis Dena, 2000, ORANGE COUNTY R 0609; CAPRON AM, 1972, U PENN LAW REV, V121, P87, DOI 10.2307/3311148; CAPRON AM, 2000, TREATISE HLTH CARE L; CAPRON AM, 1974, NY TIMES        0224, P6; CHILDRESS JF, 1992, TRANSPLANT P, V24, P2143; DUKEMINI.J, 1968, NEW ENGL J MED, V279, P413, DOI 10.1056/NEJM196808222790807; FELLNER CH, 1971, NEW ENGL J MED, V284, P582, DOI 10.1056/NEJM197103182841105; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; *GALL ORG INC, 1985, AM PUBL ATT ORG DON; Gerson William N, 1987, N Y Univ J Int Law Polit, V19, P1013; HANSMANN H, 1989, ORGAN TRANSPLANTATIO; KATCHES M, 2000, ORANGE COUNTY R 0909, P1; Lynn Joanne, 1993, Kennedy Institute of Ethics Journal, V3, P167; POTTS JT, 1987, NONHEART BEATING ORG; President's Commission for the Study of Ethical Problems in Medicine, 1981, DEF DEATH REP MED LE; SADLER AM, 1969, NEW ENGL J MED, V280, P862, DOI 10.1056/NEJM196904172801605; SADLER HH, 1971, SEMIN PSYCHIAT, V3, P86; Sten J A, 1994, J Contemp Health Law Policy, V11, P197; Wendler D, 2001, JAMA-J AM MED ASSOC, V285, P329, DOI 10.1001/jama.285.3.329; YOUNGNER SJ, 1992, ARCH NEUROL-CHICAGO, V49, P570, DOI 10.1001/archneur.1992.00530290162028; 1969, COLUMBIA LAW REV, V69, P693	23	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2001	285	3					334	336		10.1001/jama.285.3.334	http://dx.doi.org/10.1001/jama.285.3.334			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390XD	11176845				2022-12-28	WOS:000166324300026
J	Chisholm, JRM; Kelley, R				Chisholm, JRM; Kelley, R			Marine ecology - Worms start the reef-building process	NATURE			English	Article									Observ Oceanol Europeen, Ctr Sci Monaco, MC-98000 Monaco, Monaco; Watermark Films, Townsville, Qld 4810, Australia		Chisholm, JRM (corresponding author), Observ Oceanol Europeen, Ctr Sci Monaco, Ave St Martin, MC-98000 Monaco, Monaco.							ADEY WH, 1985, ECOLOGY DEEP SHALLOW, V2, P163; JACKSON JBC, 1982, J EXP MAR BIOL ECOL, V57, P135, DOI 10.1016/0022-0981(82)90188-5; JACKSON JBC, 1986, B MAR SCI, V39, P588; JACKSON JBC, 1977, AM NAT, V111, P743, DOI 10.1086/283203; PARKER SP, 1982, SYNOPSIS CLASSIFICAT, V2, P18; Wood R., 1999, REEF EVOLUTION	6	11	12	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					152	152		10.1038/35051660	http://dx.doi.org/10.1038/35051660			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196630	Bronze			2022-12-28	WOS:000166316200031
J	Wagner, EH; Sandhu, N; Newton, KM; McCulloch, DK; Ramsey, SD; Grothaus, LC				Wagner, EH; Sandhu, N; Newton, KM; McCulloch, DK; Ramsey, SD; Grothaus, LC			Effect of improved glycemic control on health care costs and utilization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLICATIONS; BENEFITS; OUTCOMES; NIDDM; MODEL	Context Because of the additional costs associated with improving diabetes management, there is interest in whether improved glycemic control leads to reductions in health care costs, and, if so, when such cost savings occur, Objective To determine whether sustained improvements in hemoglobin A(1c) (HbA(1c)) levels among diabetic patients are followed by reductions in health care utilization and costs. Design and Setting Historical cohort study conducted in 1992-1997 in a staff-model health maintenance organization (HMO) in western Washington State. Participants All diabetic patients aged 18 years or older who were continuously enrolled between January 1992 and March 1996 and had HbA(1c) measured at least once per year in 1992-1994 (n = 4744). Patients whose HbA(1c) decreased 1% or more between 1992 and 1993 and sustained the decline through 1994 were considered to be improved (n=732), All others were classified as unimproved (n=4012). Main Outcome Measures Total health care costs, percentage hospitalized, and number of primary care and specialty visits among the improved vs unimproved cohorts in 1992-1997. Results Diabetic patients whose HbA(1c) measurements improved were similar demographically to those whose levels did not improve but had higher baseline HbA(1c) measurements (10.0% vs 7.7%; P<.001). Mean total health care costs were $685 to $950 less each year in the improved cohort for 1994 (P=.09), 1995 (P=.003), 1996 (P=.002), and 1997 (P=.01). Cost savings in the improved cohort were statistically significant only among those with the highest baseline HbA(1c) levels (<greater than or equal to>10%) for these years but appeared to be unaffected by presence of complications at baseline. Beginning in the year following improvement (1994), utilization was consistently lower in the improved cohort, reaching statistical significance for primary care visits in 1994 (P=.001), 1995 (P<.001), 1996 (P=.005), and 1997 (P=.004) and for specialty visits in 1997 (P=.02). Differences in hospitalization rates were not statistically significant in any year. Conclusion Our data suggest that a sustained reduction in HbA(1c) level among adult diabetic patients is associated with significant cost savings within 1 to 2 years of improvement.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, MacColl Inst Healthcare Innovat, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA	Group Health Cooperative; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Wagner, EH (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, MacColl Inst Healthcare Innovat, 1730 Minor Ave,Suite 1290, Seattle, WA 98101 USA.	wagner.e@ghc.org	Oliveira, Claudia DL/G-8618-2011					Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; Clark CM, 2000, JAMA-J AM MED ASSOC, V284, P363, DOI 10.1001/jama.284.3.363; DIABET CONTROL COMPLICATIONS TRIAL RES GRP, 1995, DIABETES CARE, V18, P1468; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; Fishman P, 1997, HEALTH AFFAIR, V16, P239, DOI 10.1377/hlthaff.16.3.239; Gilmer TP, 1997, DIABETES CARE, V20, P1847, DOI 10.2337/diacare.20.12.1847; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; McCulloch D K, 1998, Eff Clin Pract, V1, P12; Nathan DM, 1996, JAMA-J AM MED ASSOC, V276, P1409; Newton KM, 1999, J CLIN EPIDEMIOL, V52, P199, DOI 10.1016/S0895-4356(98)00161-9; O'Connor P J, 1992, J Am Board Fam Pract, V5, P381; Peters A L, 1995, HMO Pract, V9, P8; Ramsey SD, 1999, PHARMACOECONOMICS, V16, P285, DOI 10.2165/00019053-199916030-00005; Ramsey SD, 1999, DIABETES CARE, V22, P382, DOI 10.2337/diacare.22.3.382; RUTTENVANMOLKEN MPMH, 1994, HEALTH ECON, V3, P333, DOI 10.1002/hec.4730030507; Testa MA, 1998, JAMA-J AM MED ASSOC, V280, P1490, DOI 10.1001/jama.280.17.1490; WAGNER EH, 1995, ARCH INTERN MED, V155, P1789, DOI 10.1001/archinte.155.16.1789; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Wanger EH, 1998, ANN INTERN MED, V129, P654, DOI 10.7326/0003-4819-129-8-199810150-00015	21	371	380	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2001	285	2					182	189		10.1001/jama.285.2.182	http://dx.doi.org/10.1001/jama.285.2.182			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	389FB	11176811	Bronze			2022-12-28	WOS:000166227000026
J	Treloar, A; Philpot, M; Beats, B				Treloar, A; Philpot, M; Beats, B			Concealing medication in patients' food	LANCET			English	Editorial Material							ETHICAL DILEMMA; NURSE		Mem Hosp, Oxleas NHS Trust, London SE18 3RZ, England; Mem Hosp, Guys Med Sch, London SE18 3RZ, England; Mem Hosp, Kings Med Sch, London SE18 3RZ, England; Mem Hosp, St Thomas Med Sch, London SE18 3RZ, England; Inst Psychiat, London, England; S London & Maudsley NHS Trust, London, England; St Martins Hosp, London, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London; South London & Maudsley NHS Trust	Treloar, A (corresponding author), Mem Hosp, Oxleas NHS Trust, Shooters Hill, London SE18 3RZ, England.							*BMA LAW SOC, 1995, ASS MENT CAP GUID DO; Colenda CC, 1999, AM J GERIAT PSYCHIAT, V7, P12; DEDEYN P, 1999, INT J GERIATR PSYCH, V14, P459; Dyer C, 1998, BRIT MED J, V317, P1339, DOI 10.1136/bmj.317.7169.1339; Gormley N, 1999, INT J GERIATR PSYCH, V14, P509, DOI 10.1002/(SICI)1099-1166(199907)14:7<509::AID-GPS979>3.0.CO;2-H; Griffith D, 1996, BRIT MED J, V313, P1250, DOI 10.1136/bmj.313.7067.1250; Jones R., 1999, MENTAL HLTH ACT MANU; Kellett JM, 1996, BRIT MED J, V313, P1249, DOI 10.1136/bmj.313.7067.1249; *LORD HIGH CHANC, 1999, MAK DEC GOV PROP MAK; *N LAK HEALTHC N C, 2000, N LAK HEALTHC NHS TR; Pereira S., 1999, PSYCHIATR BULL, V23, P342, DOI DOI 10.1192/PB.23.6.342; Re C, 1994, WLR, V1, P290; Re MB, 1997, FLR, V2; *SCOTT EX, 1999, MAK RIGHT MOV RIGHTS; TRELOAR A, 1990, J ROY SOC MED, V93, P408; Treloar AJ, 1999, INT J GERIATR PSYCH, V14, P1039, DOI 10.1002/(SICI)1099-1166(199912)14:12<1039::AID-GPS60>3.0.CO;2-C; *UK CENTR COUNC NU, 1992, STAND ADM MED; Valmana A, 1997, BRIT MED J, V314, P300	18	23	24	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					62	64		10.1016/S0140-6736(00)03578-9	http://dx.doi.org/10.1016/S0140-6736(00)03578-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197375				2022-12-28	WOS:000166341500036
J	Leckie, MJ; ten Brinke, A; Khan, J; Diamant, Z; O'Connor, BJ; Walls, CM; Mathur, AK; Cowley, HC; Chung, KF; Djukanovic, R; Hansel, TT; Holgate, T; Sterk, PJ; Barnes, PJ				Leckie, MJ; ten Brinke, A; Khan, J; Diamant, Z; O'Connor, BJ; Walls, CM; Mathur, AK; Cowley, HC; Chung, KF; Djukanovic, R; Hansel, TT; Holgate, T; Sterk, PJ; Barnes, PJ			Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response	LANCET			English	Article							CYCLOSPORINE-A; HYPERREACTIVITY; INFLAMMATION; EXPRESSION; ANTI-IL-5; MODEL; IL-5	Background Interleukin-5 (IL-5) is essential for the formation of eosinophils, which are thought to have a major role in the pathogenesis of asthma and other allergic diseases. We aimed to assess the effects of monoclonal antibody to IL-5 on blood and sputum eosinophils, airway hyperresponsiveness, and the late asthmatic reaction to inhaled allergen in patients with mild asthma. Methods We did a double-blind randomised placebo-controlled trial, in which a single intravenous infusion of humanised (IgG-kappa) monoclonal antibody to IL-5 (SB-240563) was given at doses of 2 .5 mg/kg (n=8) or 10 .0 mg/kg (n=8). The effects of treatment on responses to inhaled allergen challenge, sputum eosinophils, and airway hyper-responsiveness to histamine were measured at weeks 1 and 4 with monitoring of blood eosinophil counts for up to 16 weeks. Findings Monoclonal antibody against IL-5 towered the mean blood eosinophil count at day 29 from 0 . 25x10(9)/L (95% Cl 0 . 16-0 . 34) in the placebo group to 0 . 04x10(9)/L (0 . 00-0 . 07) in the 10 mg/kg group (p<0<bullet>0001), and prevented the blood eosinophilia that follows allergen challenge. After inhaled allergen challenge, 9 days after treatment, the percentage sputum eosinophils were 12 .2% in the placebo group and lowered to 0 .9% (-1 .2 to 3 .0; p=0 . 0076) in the 10 mg/kg group, and this effect persisted at day 30 after the dose. There was no significant effect of monoclonal antibody to IL-5 on the late asthmatic response or on airway hyperresponsiveness to histamine. Interpretation A single dose of monoclonal antibody to IL-5 decreased blood eosinophils for up to 16 weeks and sputum eosinophils at 4 weeks, which has considerable therapeutic potential for asthma and allergy. However, our findings question the role of eosinophils in mediating the late asthmatic response and causing airway hyper-responsiveness.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands; SmithKline Beecham, Clin Pharmacol, Harlow, Essex, England; Univ Southampton, Resp Cell & Mol Biol Res Div, Southampton SO9 5NH, Hants, England	Imperial College London; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; GlaxoSmithKline; University of Southampton	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England.	p.j.barnes@ic.ac.uk	Larché, Margaret J/B-2327-2008; Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012; Sterk, P.J./AAK-8175-2020	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Djukanovic, Ratko/0000-0001-6039-5612; Mathur, Ashwini/0000-0002-2733-337X; Barnes, Peter/0000-0002-5122-4018; Larche, Maggie/0000-0002-9506-1249				BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CHAPMAN ID, 1993, CLIN EXP ALLERGY, V23, P168, DOI 10.1111/j.1365-2222.1993.tb00877.x; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; COYLE AJ, 1995, J CLIN INVEST, V95, P1735, DOI 10.1172/JCI117850; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; ELWOOD W, 1992, AM REV RESPIR DIS, V145, P1289, DOI 10.1164/ajrccm/145.6.1289; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Foster PS, 1999, AM J RESP CELL MOL, V21, P451, DOI 10.1165/ajrcmb.21.4.f167; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; HASELDEN B, 2000, AM J RESP CRIT CARE, V161, pA833; Hogan SP, 1998, J IMMUNOL, V161, P1501; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704, DOI 10.1164/ajrccm.156.3.9610033; INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7; Kips JC, 2000, AM J RESP CRIT CARE, V161, pA505; Lampinen M, 1999, CLIN EXP ALLERGY, V29, P314; Louis R, 1997, AM J RESP CRIT CARE, V155, P466, DOI 10.1164/ajrccm.155.2.9032180; Mathur M, 1999, AM J RESP CRIT CARE, V159, P580, DOI 10.1164/ajrccm.159.2.9712018; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MCKINNON M, 1999, INTERLEUKIN 5 MOL DR, P299; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; Redington AE, 1997, THORAX, V52, P310, DOI 10.1136/thx.52.4.310; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; Sihra BS, 1997, THORAX, V52, P447, DOI 10.1136/thx.52.5.447; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99, DOI 10.1164/ajrccm.158.1.9709091; Taylor DA, 2000, CLIN EXP ALLERGY, V30, P56; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; Van der Veen MJ, 1999, CLIN EXP ALLERGY, V29, P217; vanderPalen J, 1997, EUR RESPIR J, V10, P652; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; Weller PF, 1997, J ALLERGY CLIN IMMUN, V100, P283, DOI 10.1016/S0091-6749(97)70237-9	34	1361	1426	1	67	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2000	356	9248					2144	2148		10.1016/S0140-6736(00)03496-6	http://dx.doi.org/10.1016/S0140-6736(00)03496-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191542				2022-12-28	WOS:000165997300013
J	Bermudez, LE				Bermudez, LE			Operation Smile: plastic surgery with few resources	LANCET			English	Article									Mil Hosp, Dept Plast Surg, Div Craniofacial Surg & Microsurg, Bogota, Colombia; Mil Univ Nueva Granada, Granada, Spain		Bermudez, LE (corresponding author), Mil Hosp, Dept Plast Surg, Div Craniofacial Surg & Microsurg, Bogota, Colombia.								0	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S45	S45		10.1016/S0140-6736(00)92031-2	http://dx.doi.org/10.1016/S0140-6736(00)92031-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191503				2022-12-28	WOS:000166074900047
J	Knoppers, BM				Knoppers, BM			From medical ethics to "genethics"	LANCET			English	Article									Univ Montreal, Fac Droit, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Knoppers, BM (corresponding author), Univ Montreal, Fac Droit, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.								0	6	6	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S38	S38		10.1016/S0140-6736(00)92024-5	http://dx.doi.org/10.1016/S0140-6736(00)92024-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191495	Bronze			2022-12-28	WOS:000166074900040
J	Shibolet, O; Amit, G				Shibolet, O; Amit, G			Effects of physiologic pacing versus ventricular pacing	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Hadassah Univ Hosp, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Shibolet, O (corresponding author), Hadassah Univ Hosp, IL-91120 Jerusalem, Israel.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1418	1418						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183886				2022-12-28	WOS:000165152800024
J	Bentley, PI; Grigor, CJ; McNally, JD; Rigby, S; Higgens, CS; Frank, AO; Keat, A				Bentley, PI; Grigor, CJ; McNally, JD; Rigby, S; Higgens, CS; Frank, AO; Keat, A			Lesson of the week - Degenerative cervical disc disease causing cord compression in adults under 50	BRITISH MEDICAL JOURNAL			English	Review							SPONDYLOSIS; MYELOPATHY		Northwick Pk & St Marks NHS Trust, Dept Rheumatol, Harrow HA1 3UJ, Middx, England	Imperial College London	Keat, A (corresponding author), Northwick Pk & St Marks NHS Trust, Dept Rheumatol, Harrow HA1 3UJ, Middx, England.			Bentley, Paul/0000-0001-8036-7010				DUBUISSON A, 1993, ACTA NEUROCHIR, V125, P115, DOI 10.1007/BF01401837; EDWARDS WC, 1985, SPINE, V10, P42, DOI 10.1097/00007632-198501000-00007; EPSTEIN NE, 1984, NEUROSURGERY, V15, P489, DOI 10.1227/00006123-198410000-00003; GOOD DC, 1984, SURG NEUROL, V22, P285, DOI 10.1016/0090-3019(84)90016-8; GRANDALL PH, 1966, J NEUROSURG, V24, P57; GUPTA SK, 1982, CLIN RADIOL, V33, P681, DOI 10.1016/S0009-9260(82)80403-0; HELLER JG, 1992, ORTHOP CLIN N AM, V23, P381; HERKOWITZ HN, 1998, SPINE; Jayakumar PN, 1996, CLIN NEUROL NEUROSUR, V98, P142, DOI 10.1016/0303-8467(96)00004-2; LOURIE H, 1973, JAMA-J AM MED ASSOC, V226, P302, DOI 10.1001/jama.226.3.302; MONTGOMERY DM, 1992, ORTHOP CLIN N AM, V23, P487; PATTEN J, 1995, NEUROLOGICAL DIFFERE; SIMMONS Z, 1986, SPINE, V11, P869, DOI 10.1097/00007632-198611000-00004	13	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	2001	322	7283					414	415		10.1136/bmj.322.7283.414	http://dx.doi.org/10.1136/bmj.322.7283.414			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404JH	11179163	Green Published			2022-12-28	WOS:000167093600030
J	Olivier, M; Aggarwal, A; Allen, J; Almendras, AA; Bajorek, ES; Beasley, EM; Brady, SD; Bushard, JM; Bustos, VI; Chu, A; Chung, TR; De Witte, A; Denys, ME; Dominguez, R; Fang, NY; Foster, BD; Freudenberg, RW; Hadley, D; Hamilton, LR; Jeffrey, TJ; Kelly, L; Lazzeroni, L; Levy, MR; Lewis, SC; Liu, X; Lopez, FJ; Louie, B; Marquis, JP; Martinez, RA; Matsuura, MK; Misherghi, NS; Norton, JA; Olshen, A; Perkins, SM; Perou, AJ; Piercy, C; Piercy, M; Qin, F; Reif, T; Sheppard, K; Shokoohi, V; Smick, GA; Sun, WL; Stewart, EA; Tejeda, JF; Tran, NM; Trejo, T; Vo, NT; Yan, SCM; Zierten, DL; Zhao, SY; Sachidanandam, R; Trask, BJ; Myers, RM; Cox, DR				Olivier, M; Aggarwal, A; Allen, J; Almendras, AA; Bajorek, ES; Beasley, EM; Brady, SD; Bushard, JM; Bustos, VI; Chu, A; Chung, TR; De Witte, A; Denys, ME; Dominguez, R; Fang, NY; Foster, BD; Freudenberg, RW; Hadley, D; Hamilton, LR; Jeffrey, TJ; Kelly, L; Lazzeroni, L; Levy, MR; Lewis, SC; Liu, X; Lopez, FJ; Louie, B; Marquis, JP; Martinez, RA; Matsuura, MK; Misherghi, NS; Norton, JA; Olshen, A; Perkins, SM; Perou, AJ; Piercy, C; Piercy, M; Qin, F; Reif, T; Sheppard, K; Shokoohi, V; Smick, GA; Sun, WL; Stewart, EA; Tejeda, JF; Tran, NM; Trejo, T; Vo, NT; Yan, SCM; Zierten, DL; Zhao, SY; Sachidanandam, R; Trask, BJ; Myers, RM; Cox, DR			A high-resolution radiation hybrid map of the human genome draft sequence	SCIENCE			English	Article							PHYSICAL MAP; CHROMOSOMES; PANEL-2; PCR	We have constructed a physical map of the human genome by using a panel of 90 whole-genome radiation hybrids (the TNG panel) in conjunction with 40,322 sequence-tagged sites (STSs) derived from random genomic sequences as well as expressed sequences. Of 36,678 STSs on the TNC radiation hybrid map, only 3604 (9.8%) were absent from the unassembled draft sequence of the human genome. Of 20,030 STSs ordered on the TNG map as well as the assembled human genome draft sequence and the Celera assembled human genome sequence, 36% of the STSs had a discrepant order between the working draft sequence and the Celera sequence. The TNG map order was identical to one of the two sequence orders in 60% of these discrepant cases.	Stanford Univ, Stanford Human Genome Ctr, Sch Med, Palo Alto, CA 94304 USA; Inst Genome Res, Rockville, MD 20850 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA	Stanford University; J. Craig Venter Institute; Cold Spring Harbor Laboratory; Fred Hutchinson Cancer Center	Cox, DR (corresponding author), Stanford Univ, Stanford Human Genome Ctr, Sch Med, 975 Calif Ave, Palo Alto, CA 94304 USA.	cox@shgc.stanford.edu	sachidanandam, ravi/Q-6916-2019; Lazzeroni, Laura/F-2903-2010	sachidanandam, ravi/0000-0001-9844-4459; Lazzeroni, Laura/0000-0002-1846-6920	NIGMS NIH HHS [R01 GM062628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTCHUL SF, 1990, J MOL BIOL, V215, P403; BEASLEY EM, 1999, PCR APPL PROTOCOLS F, P55; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LUNETTA KL, 1994, GENOMICS, V21, P92, DOI 10.1006/geno.1994.1229; Lunetta KL, 1996, AM J HUM GENET, V59, P717; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; Schuler GD, 1998, TRENDS BIOTECHNOL, V16, P456, DOI 10.1016/S0167-7799(98)01232-3; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	23	89	92	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 16	2001	291	5507					1298	+		10.1126/science.1057437	http://dx.doi.org/10.1126/science.1057437			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	402MX	11181994				2022-12-28	WOS:000166993400040
J	Boskey, AL				Boskey, AL			Musculoskeletal disorders and orthopedic conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMORPHOUS CALCIUM-PHOSPHATE; RECEPTOR ANTAGONIST; BINDING-PROTEIN; GENE-THERAPY; BONE; MICE; ARTHROPLASTY; OSTEOPOROSIS; BIOSYNTHESIS; DEGRADATION	Ongoing advances in orthopedics include discoveries of functions of matrix proteins, development of new implant materials that are more durable and more compatible with magnetic resonance imaging, and identification of genes causing musculoskeletal disorders and disease. The Human Genome Project will further clarify the genetic basis of specific musculoskeletal disorders, enhancing risk factor identification, diagnosis, and therapy. Engineered, cell-based materials will replace metals and plastics in implants, and new composite materials will promote bone in-growth.	Hosp Special Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA	Cornell University; Cornell University	Boskey, AL (corresponding author), Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.	BoskeyA@HSS.edu		Boskey, Adele/0000-0002-6181-2219	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041325, R01AR037661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004141, R01DE004141] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR041325, AR037661] Funding Source: Medline; NIDCR NIH HHS [DE04141] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adler RS, 1999, RADIOL CLIN N AM, V37, P623, DOI 10.1016/S0033-8389(05)70119-6; Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Angele P, 1999, TISSUE ENG, V5, P545, DOI 10.1089/ten.1999.5.545; Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142-9612(99)00242-2; ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; Awad HA, 1999, TISSUE ENG, V5, P267, DOI 10.1089/ten.1999.5.267; Bauer TW, 1999, SKELETAL RADIOL, V28, P483, DOI 10.1007/s002560050552; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; BETTS F, 1975, P NATL ACAD SCI USA, V72, P2088, DOI 10.1073/pnas.72.6.2088; BODEN SD, 1999, CLIN ORTHOP S, V367, pS84; Boskey AL, 1997, J DENT RES, V76, P1433, DOI 10.1177/00220345970760080501; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; Cavagna R, 1999, J LONG-TERM EFF MED, V9, P403; CHOI YC, 1980, CONNECT TISSUE RES, V7, P105, DOI 10.3109/03008208009152295; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Cook SD, 1998, J ORTHOP TRAUMA, V12, P407, DOI 10.1097/00005131-199808000-00007; Cummings SR, 1996, BONE, V18, pS165, DOI 10.1016/8756-3282(95)00505-6; Davies B, 2000, P I MECH ENG H, V214, P129, DOI 10.1243/0954411001535309; Delmas PD, 2000, OSTEOPOROSIS INT, V11, P95, DOI 10.1007/PL00004181; DRAKE JM, 1991, NEUROSURGERY, V29, P27, DOI 10.1227/00006123-199107000-00005; Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523-1755.2000.00081.x; Engh GA, 2000, J BONE JOINT SURG AM, V82A, P516, DOI 10.2106/00004623-200004000-00007; Espehaug B, 1999, ACTA ORTHOP SCAND, V70, P12, DOI 10.3109/17453679909000949; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Evans CH, 1999, INTERNAL MED, V38, P233, DOI 10.2169/internalmedicine.38.233; Ezzell C, 2000, SCI AM, V283, P64, DOI 10.1038/scientificamerican0700-64; Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749-6632.1998.tb10105.x; Fitzgerald R, 2000, PHYS TODAY, V53, P23, DOI 10.1063/1.1292471; Furukawa T, 2000, J BIOMED MATER RES, V50, P410, DOI 10.1002/(SICI)1097-4636(20000605)50:3<410::AID-JBM16>3.0.CO;2-Y; Granchi D, 1998, J BONE JOINT SURG BR, V80B, P912, DOI 10.1302/0301-620X.80B5.8513; Grande DA, 1999, CLIN ORTHOP RELAT R, pS176; Guetens G, 2000, J CHROMATOGR B, V739, P139, DOI 10.1016/S0378-4347(99)00553-8; Hutchinson CR, 1998, CURR OPIN MICROBIOL, V1, P319, DOI 10.1016/S1369-5274(98)80036-2; Ingham E, 2000, P I MECH ENG H, V214, P21, DOI 10.1243/0954411001535219; Itonaga I, 2000, ANN RHEUM DIS, V59, P26, DOI 10.1136/ard.59.1.26; JACENKO O, 1994, AM J HUM GENET, V54, P163; Johnson EE, 2000, CLIN ORTHOP RELAT R, P61, DOI 10.1097/00003086-200002000-00008; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; KANG R, 2000, CLIN ORTHOP RELAT R, V375, P324; Kardos T B, 1982, Prog Clin Biol Res, V101, P45; KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606; Ko SC, 1996, CANCER RES, V56, P4614; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lark MW, 1999, J PHARMACOL EXP THER, V291, P612; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; LIAN JB, 1978, FED PROC, V37, P2615; Mendelsohn R, 1999, J BIOMED OPT, V4, P14, DOI 10.1117/1.429916; Menetrey J, 1999, TISSUE ENG, V5, P435, DOI 10.1089/ten.1999.5.435; Montgomery KD, 1997, J ORTHOP TRAUMA, V11, P330, DOI 10.1097/00005131-199707000-00006; Mooney DJ, 1999, SCI AM, V280, P60, DOI 10.1038/scientificamerican0499-60; Mosley JR, 2000, J REHABIL RES DEV, V37, P189; Nagano M, 1996, BIOMATERIALS, V17, P1771, DOI 10.1016/0142-9612(95)00357-6; Ohlstein EH, 2000, ANNU REV PHARMACOL, V40, P177, DOI 10.1146/annurev.pharmtox.40.1.177; OSBORN JF, 1980, BIOMATERIALS, V1, P108, DOI 10.1016/0142-9612(80)90009-5; Persson U, 1999, ACTA ORTHOP SCAND, V70, P163, DOI 10.3109/17453679909011256; Peterson L, 2000, CLIN ORTHOP RELAT R, P212, DOI 10.1097/00003086-200005000-00020; Potter HG, 2000, CLIN ORTHOP RELAT R, P9; Praemer A., 1992, MUSCULOSKELETAL COND, P143; Reginster J Y, 1999, Drugs R D, V1, P195, DOI 10.2165/00126839-199901030-00001; Richards M, 1999, J ORTHOP RES, V17, P900, DOI 10.1002/jor.1100170615; Rickard DJ, 1999, J CELL BIOCHEM, P123; Robey Pamela Gehron, 1996, P95; Robey PG, 2000, J CLIN INVEST, V105, P1489, DOI 10.1172/JCI10256; ROUGHLEY PJ, 1977, BIOCHEM J, V167, P639, DOI 10.1042/bj1670639; SANDHU HS, 2000, CLIN ORTHOP RELAT R, V371, P56; Sechriest VF, 2000, J BIOMED MATER RES, V49, P534, DOI 10.1002/(SICI)1097-4636(20000315)49:4<534::AID-JBM12>3.0.CO;2-#; Shapiro I M, 1999, Clin Orthod Res, V2, P42; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; Steinke B, 1999, SPINE, V24, P1, DOI 10.1097/00007632-199901010-00002; Takacs I, 2000, BONE, V27, P169, DOI 10.1016/S8756-3282(00)00296-9; TERMINE JD, 1981, J BIOL CHEM, V256, P403; Trayhurn P, 1999, INT J OBESITY, V23, P22, DOI 10.1038/sj.ijo.0800791; URIST MR, 1975, CALC TISS RES, V19, P73, DOI 10.1007/BF02563992; Veber DF, 1997, CURR OPIN CHEM BIOL, V1, P151, DOI 10.1016/S1367-5931(97)80003-8; WOO SL, 1999, CLIN ORTHOP S, V367, pS312; Wu YT, 1999, P NATL ACAD SCI USA, V96, P1574, DOI 10.1073/pnas.96.4.1574; Yamashita DS, 2000, CURR PHARM DESIGN, V6, P1, DOI 10.2174/1381612003401569; Yingling CD, 1999, PEDIATR SURG INT, V15, P535, DOI 10.1007/s003830050664; ZAMAN G, 1992, CALCIFIED TISSUE INT, V51, P132, DOI 10.1007/BF00298501	82	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					619	623		10.1001/jama.285.5.619	http://dx.doi.org/10.1001/jama.285.5.619			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176869	Bronze			2022-12-28	WOS:000166714200022
J	Hill, CL; Zhang, YQ; Sigurgeirsson, B; Pukkala, E; Mellemkjaer, L; Airio, A; Evans, SR; Felson, DT				Hill, CL; Zhang, YQ; Sigurgeirsson, B; Pukkala, E; Mellemkjaer, L; Airio, A; Evans, SR; Felson, DT			Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study	LANCET			English	Article							AMYOPATHIC DERMATOMYOSITIS; NASOPHARYNGEAL CARCINOMA; ASSOCIATION; MALIGNANCY; FINLAND; RISK	Background Dermatomyositis and polymyositis are associated with cancer, but previous nationwide studies have not had sufficient cases to test the association between myositis and specific cancer types. Our aim was to investigate the risk of specific cancer types in individuals with dermatomyositis and polymyositis. Methods We did a pooled analysis of published national data from Sweden. Denmark, and Finland. All patients with dermatomyositis and polymyositis (greater than or equal to 15 years old) were identified by discharge diagnosis from the Swedish National Board of Health (1964-83), Danish Hospital Discharge Registry (1977-89), and Finnish National Board of Health (1969-85). Personal details were matched to national cancer registries, to identify ail cases of cancer up to 1987 in Sweden, 1995 in Denmark, and 1997 in Finland, and to national death registries for the same periods. We calculated standardised incidence ratios (SIR) for individual cancer sites for dermatomyositis and polymyositis separately, using national cancer rates by country, sex, age, and date. Findings We identified 618 cases of dermatomyositis, of whom 198 had cancer. 115 of the 198 developed cancer after diagnosis of dermatomyositis. This disease was strongly associated with malignant disease (SIR 3.0, 95% CI 2.5-3.6), particularly ovarian (10.5, 6.1-18.1), lung (5.9, 3.7-9.2), pancreatic(3.8, 1.6-9.0), stomach (3.5, 1.7-7.3), and colorectal (2.5, 1.4-4.4) cancers, and non-Hodgkin lymphoma (3.6, 1.2-11.1). 137 of the 914 cases of polymyositis had cancer, which developed after diagnosis of polymyositis in 95. Polymyositis was associated with a raised risk of non-Hodgkin lymphoma (3.7, 1.7-8.2), and lung (2.8, 1.8-4.4) and bladder cancers (2.4, 1.3-4.7). In both dermatomyositis and polymyositis, risk of malignant disease was highest at time of myositis diagnosis. Interpretation Our results provide evidence that dermatomyositis is strongly associated with a wide range of cancers. The overall risk of malignant disease is also modestly increased among patients with polymyositis, with an excess for some cancers.	Boston Univ, Arthrit Ctr, Boston, MA 02118 USA; Karolinska Hosp, S-10401 Stockholm, Sweden; Landspitalinn, Dept Dermatol, Reykjavik, Iceland; Finnish Canc Registry, FIN-00170 Helsinki, Finland; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; Turku City Hosp, Turku, Finland	Boston University; Karolinska Institutet; Karolinska University Hospital; Finnish Cancer Registry; Danish Cancer Society; University of Turku	Felson, DT (corresponding author), Boston Univ, Arthrit Ctr, A203, Boston, MA 02118 USA.		Hill, Catherine L/AAE-7152-2019; Sigurgeirsson, Bardur/AAP-7755-2020; Sigurgeirsson, Bárður/B-6130-2011	Hill, Catherine L/0000-0001-8289-4922; Felson, David/0000-0002-2668-2447; Sigurgeirsson, Bardur/0000-0002-9733-9742; Zhang, Yuqing/0000-0001-7954-1149	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR20613] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIRIO A, 1995, J RHEUMATOL, V22, P1300; BARNES BE, 1976, ANN INTERN MED, V84, P68, DOI 10.7326/0003-4819-84-1-68; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BRADLEY WG, 1989, TXB RHEUMATOLOGY, P1263; Buchbinder R, 1998, ARTHRITIS RHEUM, V41, pS204; Callen JP, 2000, LANCET, V355, P53, DOI 10.1016/S0140-6736(99)05157-0; CHOW WH, 1995, CANCER CAUSE CONTROL, V6, P9, DOI 10.1007/BF00051675; Dalakas MC, 1991, NEW ENGL J MED, V325, P1498; Darnell RB, 1999, NEW ENGL J MED, V340, P1831, DOI 10.1056/NEJM199906103402311; Davis MDP, 1997, J AM ACAD DERMATOL, V37, P730, DOI 10.1016/S0190-9622(97)70109-9; Dickman PW, 1999, ACTA ONCOL, V38, P1; FUDMAN EJ, 1986, AM J MED, V80, P329, DOI 10.1016/0002-9343(86)90036-7; Fung WKJ, 1998, INT J DERMATOL, V37, P659, DOI 10.1046/j.1365-4362.1998.00453.x; Goyal S, 1999, J AM ACAD DERMATOL, V41, P874, DOI 10.1016/S0190-9622(99)70349-X; HAFTEL HM, 1993, NEW ENGL J MED, V327, P207; Klippel JH, 1998, RHEUMATOLOGY; Koopman W.J., 1996, ARTHRITIS ALLIED CON; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; PENG JC, 1995, ARCH OTOLARYNGOL, V121, P1298; SIGURGEIRSSON B, 1992, NEW ENGL J MED, V326, P363, DOI 10.1056/NEJM199202063260602; STORM HH, 1997, DAN MED B, V44, P549; SUNNENBERG TD, 1983, CANCER, V51, P2157, DOI 10.1002/1097-0142(19830601)51:11<2157::AID-CNCR2820511135>3.0.CO;2-Q; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; VERDUCCI MA, 1984, OBSTET GYNECOL, V64, P695; Voltz R, 1999, NEW ENGL J MED, V340, P1788, DOI 10.1056/NEJM199906103402303; ZANTOS D, 1994, J RHEUMATOL, V21, P1855	26	696	736	0	26	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					96	100		10.1016/S0140-6736(00)03540-6	http://dx.doi.org/10.1016/S0140-6736(00)03540-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197446				2022-12-28	WOS:000166476200010
J	Molyneux, E				Molyneux, E			Paediatric emergency care in developing countries	LANCET			English	Editorial Material									Univ Malawi, Coll Med, Dept Paediat, Blantyre 3, Malawi	University of Malawi	Molyneux, E (corresponding author), Univ Malawi, Coll Med, Dept Paediat, Blantyre 3, Malawi.							BUKONDA N, SETTING NATL HOSP AC; *INT MAN CHILDH IL, 1995, IMCI REF CAR PROJ; LANATA C, 2000, INF CONS POSS APPR I; MALEK E, 2000, INF CONS POSS APPR I; Southall DP, 2000, PEDIATRICS, V106, P1054, DOI 10.1542/peds.106.5.1054; THOMAS A, 2000, DRUG DEALS MED DEV H; World Health Organization, 2000, GUID CAR 1 REF LEV D	7	31	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					86	87		10.1016/S0140-6736(00)03536-4	http://dx.doi.org/10.1016/S0140-6736(00)03536-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197442				2022-12-28	WOS:000166476200006
J	Lakka, TA; Laukkanen, JA; Rauramaa, R; Salonen, R; Lakka, HM; Kaplan, GA; Salonen, JT				Lakka, TA; Laukkanen, JA; Rauramaa, R; Salonen, R; Lakka, HM; Kaplan, GA; Salonen, JT			Cardiorespiratory fitness and the progression of carotid atherosclerosis in middle-aged men	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; TIME PHYSICAL-ACTIVITY; ISCHEMIC-HEART-DISEASE; ALL-CAUSE MORTALITY; RISK-FACTOR; MYOCARDIAL-INFARCTION; LEISURE-TIME; CIGARETTE-SMOKING; MEDIA THICKNESS; WEIGHT-LOSS	Background: Good cardiorespiratory fitness has been associated with reduced risk for clinical events of atherosclerotic vascular diseases, but whether it is related to slower progression of early atherosclerosis is unclear. Objective: To study the association between cardiorespiratory fitness and the progression of early carotid atherosclerosis. Design: 4-year follow-up study. Setting: Eastern Finland. Participants: population-based sample of 854 men 42 to 60 years of age. Measurements: Maximal oxygen uptake (Vo(2)max [mL/kg per minute]) was measured directly by using respiratory gas exchange in a cycle ergometer exercise test Carotid atherosclerosis was assessed by using B-mode ultrasonography. Results: After adjustments for age, technical covariates, and cigarette smoking, Vo(2)max had strong, inverse, and graded associations with 4-year increases in maximal intima-media thickness (IMT) (standardized regression coefficient beta = -0.120; P = 0.002), plaque height (beta = -0.140; P < 0.001), surface roughness (<beta> = -0.147; P<0.001), and mean IMT (<beta> = -0.080; P = 0.035). These associations weakened but remained statistically significant after additional adjustment for systolic blood pressure. serum levels of apolipoprotein B, diabetes, and plasma fibrinogen levels. The increases in maximal IMT, surface roughness, and mean IMT (23%, 31%, and 100%, respectively) were larger among men in the lowest quartile of Vo(2)max (<26.1 mL/kg per minute) than among those in the highest quartile (>36.2 mL/kg per minute). Conclusions: Good cardiorespiratory fitness is associated with slower progression of early atherosclerosis in middle-aged men. These findings are important because they emphasize that middle-aged men can be evaluated for cardiorespiratory fitness to estimate their future risk for atherosclerotic vascular diseases. Additional research is warranted to investigate a possible causal relationship between cardiorespiratory fitness and atherosclerosis.	Univ Kuopio, Publ Hlth Res Inst, Kuopio Res Inst Exercise Med, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, SF-70210 Kuopio, Finland; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA	University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Michigan System; University of Michigan	Lakka, TA (corresponding author), Univ Kuopio, Publ Hlth Res Inst, Kuopio Res Inst Exercise Med, Box 1627, FIN-70211 Kuopio, Finland.	timo.lakka@uku.fi	Laukkanen, Jari Antero/N-2196-2019; Laukkanen, Jari A/I-4528-2017; Kaplan, George/AAJ-2398-2020	Laukkanen, Jari Antero/0000-0002-3738-1586; Laukkanen, Jari A/0000-0002-3738-1586; Lakka, Timo/0000-0002-9199-2871	NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen L. B., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P318; Astrand P.O., 1986, TXB WORK PHYSL PHYSL; BEERE PA, 1984, SCIENCE, V226, P180, DOI 10.1126/science.6484569; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; Bouchard C, 1998, MED SCI SPORT EXER, V30, P252, DOI 10.1097/00005768-199802000-00013; Bouchard C., 1997, GENETICS FITNESS PHY; CROUSE JR, 1993, CIRCULATION, V87, P17; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; Erikssen G, 1998, LANCET, V352, P759, DOI 10.1016/S0140-6736(98)02268-5; FOLSOM AR, 1994, STROKE, V25, P66, DOI 10.1161/01.STR.25.1.66; GOULD KL, 1992, AM J CARDIOL, V69, P845, DOI 10.1016/0002-9149(92)90781-S; HAGAN RD, 1986, MED SCI SPORT EXER, V18, P87; Hambrecht R, 2000, NEW ENGL J MED, V342, P454, DOI 10.1056/NEJM200002173420702; Hambrecht R, 1993, J AM COLL CARDIOL, V22, P468, DOI 10.1016/0735-1097(93)90051-2; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HIRSCH GL, 1985, J APPL PHYSIOL, V58, P1975, DOI 10.1152/jappl.1985.58.6.1975; KATZEL LI, 1995, JAMA-J AM MED ASSOC, V274, P1915, DOI 10.1001/jama.274.24.1915; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; Kraemer WJ, 1999, MED SCI SPORT EXER, V31, P1320, DOI 10.1097/00005768-199909000-00014; KRAMSCH DM, 1981, NEW ENGL J MED, V305, P1483, DOI 10.1056/NEJM198112173052501; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; Lakka TA, 1997, MED SCI SPORTS EXERC, V29, pS46; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; MORRIS JN, 1980, LANCET, V2, P1207; MORTON AR, 1985, EUR J APPL PHYSIOL O, V53, P348, DOI 10.1007/BF00422852; Niebauer J, 1997, CIRCULATION, V96, P2534, DOI 10.1161/01.CIR.96.8.2534; Niebauer J, 1996, J AM COLL CARDIOL, V28, P1652, DOI 10.1016/S0735-1097(96)00393-2; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; RAURAMAA R, 1995, ATHEROSCLEROSIS, V112, P213, DOI 10.1016/0021-9150(94)05416-G; SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645; SALONEN JT, 1993, CIRCULATION, V87, P56; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SEALS DR, 1984, J APPL PHYSIOL, V57, P1024, DOI 10.1152/jappl.1984.57.4.1024; Shephard RJ, 1999, CIRCULATION, V99, P963, DOI 10.1161/01.CIR.99.7.963; Siscovick DS, 1997, AM J EPIDEMIOL, V145, P977; Smith JK, 1999, JAMA-J AM MED ASSOC, V281, P1722, DOI 10.1001/jama.281.18.1722; SPSS, 1999, SPSS BAS 9 0 US GUID; Vasankari TJ, 1998, MED SCI SPORT EXER, V30, P1496, DOI 10.1097/00005768-199810000-00005; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; [No title captured]	47	122	127	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2001	134	1					12	20		10.7326/0003-4819-134-1-200101020-00008	http://dx.doi.org/10.7326/0003-4819-134-1-200101020-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386CV	11187415	Green Submitted			2022-12-28	WOS:000166043300002
J	Nakagawa, T; Sheng, M				Nakagawa, T; Sheng, M			Neurobiology - A stargazer foretells the way to the synapse	SCIENCE			English	Editorial Material							MUTANT MOUSE STARGAZER; IMPAIRMENT		Massachusetts Gen Hosp, Dept Neurobiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Nakagawa, T (corresponding author), Massachusetts Gen Hosp, Dept Neurobiol, Boston, MA 02114 USA.							CHEN L, IN PRESS NATURE; DiPasquale E, 1997, J NEUROPHYSIOL, V77, P621, DOI 10.1152/jn.1997.77.2.621; Hashimoto K, 1999, J NEUROSCI, V19, P6027, DOI 10.1523/JNEUROSCI.19-14-06027.1999; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Qiao XX, 1998, J NEUROSCI, V18, P6990; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755	9	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2270	+						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11188726				2022-12-28	WOS:000165995800029
J	Johnson, CF				Johnson, CF			Death from child abuse and neglect	LANCET			English	Article									Ohio State Univ, Childrens Hosp, Child Abuse Program, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Johnson, CF (corresponding author), Ohio State Univ, Childrens Hosp, Child Abuse Program, Columbus, OH 43205 USA.								0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S14	S14		10.1016/S0140-6736(00)92000-2	http://dx.doi.org/10.1016/S0140-6736(00)92000-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191469				2022-12-28	WOS:000166074900016
J	Rossi, A; Confalonieri, M				Rossi, A; Confalonieri, M			Burden of chronic obstructive pulmonary disease	LANCET			English	Article									Bergamo Gen Hosp, Resp Dept, I-24128 Bergamo, Italy		Rossi, A (corresponding author), Bergamo Gen Hosp, Resp Dept, I-24128 Bergamo, Italy.		Confalonieri, Marco/AAA-3665-2019	Confalonieri, Marco/0000-0002-4791-768X					0	6	6	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S56	S56		10.1016/S0140-6736(00)92042-7	http://dx.doi.org/10.1016/S0140-6736(00)92042-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191515				2022-12-28	WOS:000166074900058
J	Ference, BA; Chauhan, MS; Izumo, S				Ference, BA; Chauhan, MS; Izumo, S			Will genetics revolutionize medicine?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Ference, BA (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.							FERENCE BA, 1999, J COMM GEN, V2, P121	1	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1497	1498						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11184469				2022-12-28	WOS:000165271300026
J	Autran, B; Carcelain, G				Autran, B; Carcelain, G			AIDS - Boosting immunity to HIV - Can the virus help?	SCIENCE			English	Editorial Material							ACTIVE ANTIRETROVIRAL THERAPY; RESPONSES; DISCONTINUATION; INFECTION; VIREMIA; TYPE-1		Hop La Pitie Salpetriere, Lab Immunol Cellulaire & Tissulaire, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Autran, B (corresponding author), Hop La Pitie Salpetriere, Lab Immunol Cellulaire & Tissulaire, F-75013 Paris, France.	brigitte.autran@psl.ap-hop-paris.fr						CARCELAIN G, IN PRESS J VIROL; Dalod M, 1998, J INFECT DIS, V178, P61, DOI 10.1086/515587; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; Mollet L, 2000, J IMMUNOL, V165, P1692, DOI 10.4049/jimmunol.165.3.1692; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Ruiz L, 2000, AIDS, V14, P397, DOI 10.1097/00002030-200003100-00013	12	43	44	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	2000	290	5493					946	+		10.1126/science.290.5493.946	http://dx.doi.org/10.1126/science.290.5493.946			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11184735				2022-12-28	WOS:000165103200036
J	Kourtis, AP; Bulterys, M; Nesheim, SR; Lee, FK				Kourtis, AP; Bulterys, M; Nesheim, SR; Lee, FK			Understanding the timing of HIV transmission from mother to infant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; POLYMERASE-CHAIN-REACTION; CHILD TRANSMISSION; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION; ZIDOVUDINE PROPHYLAXIS; ORAL ZIDOVUDINE; COTE-DIVOIRE; PREVENTION; INFECTION		Emory Univ, Sch Med, Div Infect Dis Epidemiol & Immunol, Dept Pediat, Atlanta, GA 30303 USA; Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Atlanta, GA USA	Emory University; Centers for Disease Control & Prevention - USA	Kourtis, AP (corresponding author), Emory Univ, Sch Med, Div Infect Dis Epidemiol & Immunol, Dept Pediat, 69 Butler St SE, Atlanta, GA 30303 USA.	akourti@pol.net		Kourtis, Athena/0000-0003-1585-1310				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; BROSSARD Y, 1995, AIDS, V9, P359, DOI 10.1097/00002030-199509040-00007; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; Bulterys M, 2000, PEDIATR CLIN N AM, V47, P241, DOI 10.1016/S0031-3955(05)70203-0; BULTERYS M, 1999, 2 C GLOB STRAT PREV; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; DEROSSI A, 1993, AIDS, V7, P1528, DOI 10.1097/00002030-199311000-00020; Fiscus SA, 1999, J INFECT DIS, V180, P99, DOI 10.1086/314840; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Kalish LA, 1997, J INFECT DIS, V175, P712, DOI 10.1093/infdis/175.3.712; KANEDA T, 1997, J PEDIAT, V111, P877; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; Kourtis AP, 2000, AIDS, V14, P2429, DOI 10.1097/00002030-200011100-00003; Kuhn L, 1997, AIDS, V11, P429, DOI 10.1097/00002030-199704000-00005; Kuhn L, 1996, AIDS, V10, P1181, DOI 10.1097/00002030-199609000-00026; Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; Lin HH, 1996, OBSTET GYNECOL, V87, P244, DOI 10.1016/0029-7844(95)00385-1; Lin HH, 1996, LANCET, V347, P1116, DOI 10.1016/S0140-6736(96)90314-1; LIN HH, 1987, J PEDIATR-US, V111, P877, DOI 10.1016/S0022-3476(87)80210-X; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; MINKOFF H, 1995, AM J OBSTET GYNECOL, V173, P585, DOI 10.1016/0002-9378(95)90286-4; Mofenson L, 1998, IMMUNOL ALLERGY CLIN, V18, P441, DOI 10.1016/S0889-8561(05)70013-8; MOODLEY D, 2000, 13 INT AIDS C DURB S; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; NEWELL ML, 1994, LANCET, V343, P1464; Newell ML, 1998, AIDS, V12, P831, DOI 10.1097/00002030-199808000-00004; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Pascual A, 2000, AM J OBSTET GYNECOL, V183, P638, DOI 10.1067/mob.2000.106591; Rogers AB, 1998, J INFECT DIS, V178, P960, DOI 10.1086/515692; SABA J, 1999, 6 C RETR OPP INF JAN; Shaffer N, 1999, NEW ENGL J MED, V340, P1042; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Steketee RW, 1997, J INFECT DIS, V175, P707, DOI 10.1093/infdis/175.3.707; THOMPSON LF, 1984, J IMMUNOL, V133, P2513; *US PHS TASK FORC, 2001, MMWR-MORBID MORTAL W, V47, P1; Van Rompay KKA, 2000, J VIROL, V74, P1767, DOI 10.1128/JVI.74.4.1767-1774.2000; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; [No title captured]	44	111	119	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					709	712		10.1001/jama.285.6.709	http://dx.doi.org/10.1001/jama.285.6.709			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176886				2022-12-28	WOS:000166817200002
J	Schwetz, BA				Schwetz, BA			First drug for cervical dystonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Off Commissioner Food & Drugs, Rockville, MD 20857 USA		Schwetz, BA (corresponding author), Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					724	724		10.1001/jama.285.6.724-a	http://dx.doi.org/10.1001/jama.285.6.724-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176890				2022-12-28	WOS:000166817200007
J	Bumol, TF; Watanabe, AM				Bumol, TF; Watanabe, AM			Genetic information, genomic technologies, and the future of drug discovery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMBINATORIAL CHEMISTRY; PROTEIN; EXPRESSION; GENERATION; PROTEOMICS; DATABASE; THERAPY; PROJECT; LIGAND; MODEL	The completion of the first draft of the human genome has provided an unprecedented opportunity to understand the genetic and molecular basis of disease. Parallel developments of new biological technologies, such as transcript profiling, allow scientists to examine almost any biological system in high molecular resolution. Contemporary drug discovery research is now focusing on the identification and validation of pharmaceutical targets in the molecular pathways/systems embedded in this information. Novel therapeutic interventions are being developed and evaluated as a result of this research which will be the basis of innovative pharmaceuticals of the future.	Lilly Corp Ctr, Lilly Res Labs, Res Technol & Prot DC0444, Indianapolis, IN 46285 USA	Eli Lilly	Bumol, TF (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Res Technol & Prot DC0444, Indianapolis, IN 46285 USA.	bumol@lilly.com						Aebersold R, 2000, NAT BIOTECHNOL, V18, P359, DOI 10.1038/74325; Bray GA, 2000, NATURE, V404, P672, DOI 10.1038/35007544; Brent R, 2000, CELL, V100, P169, DOI 10.1016/S0092-8674(00)81693-1; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Collins FS, 2001, JAMA-J AM MED ASSOC, V285, P540, DOI 10.1001/jama.285.5.540; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; Ewing B, 2000, NAT GENET, V25, P232, DOI 10.1038/76115; Fishwild DM, 1996, NAT BIOTECHNOL, V14, P845, DOI 10.1038/nbt0796-845; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Grinnell BW, 1998, CORONARY ARTERY DIS, V9, P89; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Houghten RA, 2000, ANNU REV PHARMACOL, V40, P273, DOI 10.1146/annurev.pharmtox.40.1.273; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; King D J, 1999, Curr Opin Drug Discov Devel, V2, P110; Ladunga I, 2000, CURR OPIN BIOTECH, V11, P13, DOI 10.1016/S0958-1669(99)00048-8; LAMERDIN JE, 1995, GENOME RES, V5, P359, DOI 10.1101/gr.5.4.359; Lazo JS, 2000, J PHARMACOL EXP THER, V293, P705; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Maini RN, 2000, ANNU REV MED, V51, P207, DOI 10.1146/annurev.med.51.1.207; McCarthy JJ, 2000, NAT BIOTECHNOL, V18, P505, DOI 10.1038/75360; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Ohlstein EH, 2000, ANNU REV PHARMACOL, V40, P177, DOI 10.1146/annurev.pharmtox.40.1.177; Page MJ, 1999, DRUG DISCOV TODAY, V4, P55, DOI 10.1016/S1359-6446(98)01291-4; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; *PHARM RES MAN AM, 2000, NEW MED DEV BIOT 200, P1; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728; Rudmann DG, 1999, TOXICOL PATHOL, V27, P111, DOI 10.1177/019262339902700121; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Searls DB, 2000, DRUG DISCOV TODAY, V5, P135, DOI 10.1016/S1359-6446(99)01457-9; Shak S, 1999, SEMIN ONCOL, V26, P71; Shimkets RA, 1999, NAT BIOTECHNOL, V17, P798, DOI 10.1038/11743; Silverman L, 1998, CURR OPIN CHEM BIOL, V2, P397, DOI 10.1016/S1367-5931(98)80015-X; Sittampalam GS, 1997, CURR OPIN CHEM BIOL, V1, P384, DOI 10.1016/S1367-5931(97)80078-6; Thomson JA, 1998, SCIENCE, V282, P1827; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238; World Health Organization, 2000, WORLD HLTH REP 2000; Xia YP, 1999, J PATHOL, V188, P431, DOI 10.1002/(SICI)1096-9896(199908)188:4<431::AID-PATH362>3.0.CO;2-B; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189	49	25	27	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					551	555		10.1001/jama.285.5.551	http://dx.doi.org/10.1001/jama.285.5.551			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176857				2022-12-28	WOS:000166714200010
J	Crystal, RG				Crystal, RG			Research opportunities and advances in lung disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER RESPIRATORY-TRACT; CYSTIC-FIBROSIS GENE; ALPHA-1-ANTITRYPSIN DEFICIENCY; ELASTASE DEFENSES; MEDICAL PROGRESS; THERAPY; IDENTIFICATION; ADENOVIRUS; AEROSOL; INVIVO	Lung diseases cause morbidity, mortality, and economic burden. Susceptibility to pathogenesis of most lung diseases result from a complex interaction of a relevant challenge from the environment, genetic background, and the nature of the host responses. Cutting-edge research in lung disease now centers on understanding the lung as a genetically determined biological organ that functions to mediate gas exchange and defend against a hostile environment. A major challenge is to determine the hierarchy of gene expression that integrates the function of multiple cell types in this complex anatomy. Emerging therapies that will play a major role in the future treatment of lung disease include the use of recombinant proteins. including monoclonal antibodies, cell therapy (including stem cells), and gene therapy. Future advances will include the cure of the major hereditary lung disorders by gene therapy, new treatment for asthma, chronic obstructive pulmonary disease, and interstitial lung disease; development of vaccines to protect the lung from major lung pathogens; and pathogen-specific "designer" therapies to eradicate chronic lung infections.	Cornell Univ, Weill Med Coll, Inst Med Genet, New York, NY 10021 USA	Cornell University	Crystal, RG (corresponding author), Cornell Univ, Weill Med Coll, Inst Med Genet, 520 E 70th St,Suite 505, New York, NY 10021 USA.							Anderson WF, 1998, NATURE, V392, P25; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Arcasoy SM, 1999, NEW ENGL J MED, V340, P1081, DOI 10.1056/NEJM199904083401406; Barnes PJ, 1999, NEW ENGL J MED, V341, P2006, DOI 10.1056/NEJM199912233412610; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; BARNES PJ, 1997, ASTHMA; BECKLAKE MR, 2000, TXB RESP MED, P1811; BEWIG B, 1997, LUNG SCI FDN, P395; BITTERMAN PB, 1986, NEW ENGL J MED, V314, P1343, DOI 10.1056/NEJM198605223142103; Cannizzo SJ, 1997, NAT BIOTECHNOL, V15, P570, DOI 10.1038/nbt0697-570; Crystal R. G., 1997, LUNG SCI FDN; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; CRYSTAL RG, 1984, MED HLTH ANN, P271; CRYSTAL RG, 1988, CECIL TXB MED, P421; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Finkbeiner WE., 1997, LUNG SCI FDN, P415; FRIZZELL RA, 1999, PHYSIOL REV, V79, P1; GADEK JE, 1979, SCIENCE, V206, P1315, DOI 10.1126/science.316188; GALLIN J, 1992, INFLAMMATION, P983; GARVER RI, 1987, SCIENCE, V237, P762, DOI 10.1126/science.3497452; Goldhaber SZ, 1998, NEW ENGL J MED, V339, P93, DOI 10.1056/NEJM199807093390207; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Harvey BG, 1999, J CLIN INVEST, V104, P1245, DOI 10.1172/JCI7935; HARVEY BG, 1997, LUNG SCI FDN, P2339; HUBBARD RC, 1990, LUNG, V168, P565, DOI 10.1007/BF02718179; HUBBARD RC, 1989, ANN INTERN MED, V111, P206, DOI 10.7326/0003-4819-111-3-206; HUBBARD RC, 1989, J CLIN INVEST, V84, P1349, DOI 10.1172/JCI114305; JOBE AH, 1993, NEW ENGL J MED, V328, P861; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kikuchi T, 2000, NAT MED, V6, P1154, DOI 10.1038/80498; MASTRANGELI A, 1997, LUNG SCI FDN, P2795; MCELVANEY NG, 1997, LUNG SCI FDN, P2537; MCELVANEY NG, 1997, LUNG SCI FDN, P2219; McElvaney NG, 1997, LUNG SCI FDN, P2205; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Murin S, 1998, AM J RESP CRIT CARE, V158, P1369, DOI 10.1164/ajrccm.158.5.9712022; NAIDICH DP, 1998, COMPUTER TOMOGRAPHY; *NAT ASTHM ED PREV, 2000, NAT HEART LUNG BLOOD; *NAT HEART LUNG BL, 2000, NAT HEART LUNG BLOOD; NUKIWA T, 1986, J BIOL CHEM, V261, P5989; PARKES WR, 1994, OCCUPATIONAL LUNG DI; Perl AKT, 1999, CLIN GENET, V56, P14, DOI 10.1034/j.1399-0004.1999.560103.x; Rathbun SW, 2000, ANN INTERN MED, V132, P227, DOI 10.7326/0003-4819-132-3-200002010-00009; Remy-Jardin M, 1999, RADIOLOGY, V212, P615, DOI 10.1148/radiology.212.3.r99se02615; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Rose CS, 2000, TXB RESP MED, P1867; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Russi TJ, 1997, LUNG SCI FDN, V1, P371; SANFORD AJ, 2000, AM J RESP CRIT CARE, V161, pS202; Shields TLJ, 2000, GEN THORACIC SURG; Song S, 1998, P NATL ACAD SCI USA, V95, P14384, DOI 10.1073/pnas.95.24.14384; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; TOBIN MJ, 1998, PRINCIPLES PRACTICES; WALDRON HA, 1994, OCCUPATIONAL LUNG DI, P593; WANG KP, 1995, FLEXIBLE BRONCHOSCOP; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; Whitsett J, 1998, NAT GENET, V20, P7, DOI 10.1038/1654; WHITSETT JA, 1997, LUNG SCI FDN, P383; WHITSETT JA, 1997, LUNG SCI FDN, P2167; Wolff G., 1997, LUNG SCI FDN, P2509; WORSLEY D, 2000, TXB RESP MED, P697; 2000, NAT GENET S, V21, P1	69	10	11	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					612	618		10.1001/jama.285.5.612	http://dx.doi.org/10.1001/jama.285.5.612			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176868	Bronze			2022-12-28	WOS:000166714200021
J	Pham, P; Bertram, JG; O'Donnell, M; Woodgate, R; Goodman, MF				Pham, P; Bertram, JG; O'Donnell, M; Woodgate, R; Goodman, MF			A model for SOS-lesion-targeted mutations in Escherichia coli	NATURE			English	Article							DNA-POLYMERASE-III; MUTAGENESIS; REPAIR; RECA; PROTEINS; COMPLEX; DAMAGE; CLAMP	The UmuD'C-2 protein complex (Escherichia coli pol V)(1-3) is a low-fidelity DNA polymerase (pol) that copies damaged DNA in the presence of RecA, single-stranded-DNA binding protein (SSB) and the beta,gamma -processivity complex of E. coli pol III (ref. 4). Here we propose a model to explain SOS-lesion-targeted mutagenesis, assigning specific biochemical functions for each protein during translesion synthesis. (SOS lesion-targeted mutagenesis occurs when pol V is induced as part of the SOS response to DNA damage and incorrectly incorporates nucleotides opposite template lesions.) Pol V plus SSB catalyses RecA filament disassembly in the 3' to 5' direction on the template, ahead of the polymerase, in a reaction that does not involve ATP hydrolysis. Concurrent ATP-hydrolysis-driven filament disassembly in the 5' to 3' direction results in a bidirectional stripping of RecA from the template strand. The bidirectional collapse of the RecA filament restricts DNA synthesis by pol V to template sites that are proximal to the lesion, thereby minimizing the occurrence of untargeted mutations at undamaged template sites.	Univ So Calif, Dept Biol Sci & Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; NICHHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA	University of Southern California; Rockefeller University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci & Chem, Hedco Mol Biol Labs, Univ Pk, Los Angeles, CA 90089 USA.			Woodgate, Roger/0000-0001-5581-4616	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAILONE A, 1991, BIOCHIMIE, V73, P479, DOI 10.1016/0300-9084(91)90115-H; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Creighton S, 1995, METHOD ENZYMOL, V262, P232; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, V1, P407; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Goodman MF, 2000, TRENDS BIOCHEM SCI, V25, P189, DOI 10.1016/S0968-0004(00)01564-4; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; Lao Y, 2000, BIOCHEMISTRY-US, V39, P850, DOI 10.1021/bi991704s; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; Sutton MD, 1999, P NATL ACAD SCI USA, V96, P12373, DOI 10.1073/pnas.96.22.12373; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755	19	99	109	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					366	370		10.1038/35053116	http://dx.doi.org/10.1038/35053116			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201748				2022-12-28	WOS:000166434300053
J	Visscher, PM; Smith, D; Hall, SJG; Williams, JA				Visscher, PM; Smith, D; Hall, SJG; Williams, JA			A viable herd of genetically uniform cattle - Deleterious alleles seem to have been purged in a feral strain of inbred cows.	NATURE			English	Article							EXTINCTION		Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; De Montfort Univ, Sch Agr, Grantham NG32 3EP, England	University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; De Montfort University	Visscher, PM (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.		Visscher, Peter/ABB-6151-2020	Visscher, Peter/0000-0002-2143-8760; Hall, Stephen/0000-0003-2666-1715; Williams, John/0000-0001-5188-7957				ANDERSON C, 1992, NATURE, V355, P382; CABALLERO A, 1994, HEREDITY, V73, P657, DOI 10.1038/hdy.1994.174; Frankham R, 1998, NATURE, V392, P441, DOI 10.1038/33022; Goodman SJ, 1998, MOL BIOL EVOL, V15, P104, DOI 10.1093/oxfordjournals.molbev.a025907; HALL SJG, 1988, J ZOOL, V216, P479, DOI 10.1111/j.1469-7998.1988.tb02444.x; KIMURA M, 1955, P NATL ACAD SCI USA, V41, P144, DOI 10.1073/pnas.41.3.144; Lacy RC, 1998, EVOLUTION, V52, P900, DOI [10.2307/2411285, 10.1111/j.1558-5646.1998.tb03715.x]; MACHUGH DE, 1994, P ROY SOC B-BIOL SCI, V256, P25, DOI 10.1098/rspb.1994.0044; MANOTTIRAYMOND MA, 1995, J HERED, V86, P319; Paterson S, 1998, P NATL ACAD SCI USA, V95, P3714, DOI 10.1073/pnas.95.7.3714; Saccheri I, 1998, NATURE, V392, P491, DOI 10.1038/33136; STAM P, 1980, GENET RES, V35, P131, DOI 10.1017/S0016672300014002; WIENER G, 1992, ANIM PROD, V55, P89, DOI 10.1017/S0003356100037314	13	73	74	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					303	303		10.1038/35053160	http://dx.doi.org/10.1038/35053160			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201728	Bronze			2022-12-28	WOS:000166434300032
J	Watanabe, Y; Yokobayashi, S; Yamamoto, M; Nurse, P				Watanabe, Y; Yokobayashi, S; Yamamoto, M; Nurse, P			Pre-meiotic S phase is linked to reductional chromosome segregation and recombination	NATURE			English	Article							SISTER-CHROMATID COHESION; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; DNA-REPLICATION; MEIOSIS; PROTEIN; GENE; CENTROMERE; REC8	Meiosis is initiated from G1 of the cell cycle and is characterized by a pre-meiotic S phase followed by two successive nuclear divisions. The first of these, meiosis I, differs from mitosis in having a reductional pattern of chromosome segregation(1,2). Here we show that meiosis can be initiated from G2 in fission yeast cells by ectopically activating the meiosis-inducing network. The subsequent meiosis I occurs without a pre-meiotic S phase and with decreased recombination, and exhibits a mitotic pattern of equational chromosome segregation. The subsequent meiosis II results in random chromosome segregation. This behaviour is similar to that observed in cells lacking the meiotic cohesin Rec8 (refs 3, 4), which becomes associated with chromosomes at G1/S phase, including the inner centromere, a region that is probably critical for sister-centromere orientation(5). If the expression of Rec8 is delayed to S phase/G2, then the centromeres behave equationally. We propose that the presence of Rec8 in chromatin is required at the pre-meiotic S phase to construct centromeres that behave reductionally and chromosome arms capable of a high level of recombination, and that this explains why meiosis is initiated from G1 of the cell cycle.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan; Imperial Canc Res Fund, London WC2A 3PX, England	University of Tokyo; Japan Science & Technology Agency (JST); Cancer Research UK	Watanabe, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan.	ywatanab@ims.u-tokyo.ac.jp		Watanabe, Yoshinori/0000-0002-5488-4812				BAHLER J, 1991, CURR GENET, V19, P445, DOI 10.1007/BF00312735; Cha RS, 2000, GENE DEV, V14, P493; DEVEAUX LC, 1994, GENE DEV, V8, P203, DOI 10.1101/gad.8.2.203; Horie S, 1998, MOL CELL BIOL, V18, P2118, DOI 10.1128/MCB.18.4.2118; IINO Y, 1985, P NATL ACAD SCI USA, V82, P2447, DOI 10.1073/pnas.82.8.2447; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; LIN YK, 1994, GENETICS, V136, P769; MCLEOD M, 1988, NATURE, V332, P509, DOI 10.1038/332509a0; MOLNAR M, 1995, GENETICS, V141, P61; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; NIWA O, 1988, NATURE, V336, P430, DOI 10.1038/336430a0; Partridge JF, 2000, GENE DEV, V14, P783; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Watanabe Y, 1997, NATURE, V386, P187, DOI 10.1038/386187a0; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; Yamamoto M., 1997, MATING SPORULATION S, P1037	25	115	119	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2001	409	6818					359	363		10.1038/35053103	http://dx.doi.org/10.1038/35053103			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201746				2022-12-28	WOS:000166434300051
J	Jover, JA; Hernandez-Garcia, C; Morado, IC; Vargas, E; Banares, A; Fernandez-Gutierrez, B				Jover, JA; Hernandez-Garcia, C; Morado, IC; Vargas, E; Banares, A; Fernandez-Gutierrez, B			Combined treatment of giant-cell arteritis with methotrexate and prednisone - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMYALGIA-RHEUMATICA; TEMPORAL ARTERITIS; SUPPLEMENTATION; REGIMENS; THERAPY	Background: Corticosteroids remain the cornerstone of therapy far giant-cell arteritis, but relapse during dose tapering and corticosteroid-related adverse events often complicate management of this condition. Although several approaches, including combined therapy with cytotoxic agents, have been suggested to overcome these problems, no study has clearly shown benefits of alternate treatments. Objective: To analyze the safety and efficacy of combined therapy with corticosteroids and methotrexate in giant-cell arteritis. Design: Randomized, double-blind, placebo-controlled trial. Setting: University-based clinic. Patients: 42 patients with new-onset giant-cell arteritis according to biopsy. Intervention: High initial doses of corticosteroid were given; the dose was then tapered quickly until therapy was completely withdrawn. Methotrexate or placebo was given weekly from the start of corticosteroid therapy for 24 months. Measurements: Number of relapses, cumulative dose of corticosteroid, and number of adverse events were assessed on completion of follow-up. Results: Compared with combined prednisone and placebo therapy, treatment with prednisone and methotrexate reduced the proportion of patients who experienced at least one relapse (45% vs. 84.2%; P = 0.02) and the proportion of patients who experienced multiple relapses (P = 0.004). The mean cumulative dose of prednisone was 4187 +/- 1529 mg in the methotrexate group and 5489.5 +/- 1396 mg in the placebo group (mean difference, 1302 mg [95% Cl, 350 to 2253 mg]; P = 0.009). Overall, the rate and severity of adverse events were similar between groups, Treatment was discontinued in 3 patients in the methotrexate group who experienced definite drug-related adverse events. In sensitivity analysis:that included patients lost to follow-up, differences between groups in number of relapses and cumulative dose of prednisone were significant. Conclusions: Treatment with methotrexate plus corticosteroid is a safe alternative to corticosteroid therapy alone in patients with giant-cell arteritis and is more effective in controlling disease.	Hosp Clin San Carlos, Serv Reumatol, Madrid, Spain	Hospital Clinico San Carlos	Jover, JA (corresponding author), Hosp Clin San Carlos, Serv Reumatol, Calle Prof Martin Lagos S-N, Madrid, Spain.	jjover@hcsc.insalud.es	Vargas-Castrillón, Emilio/AAZ-7621-2021; Fernandez-Gutierrez, Benjamin/AAM-9063-2020	Vargas-Castrillón, Emilio/0000-0003-4828-6004; Fernandez-Gutierrez, Benjamin/0000-0002-6126-8786				Bahlas S, 1998, J RHEUMATOL, V25, P99; BEHN AR, 1983, ANN RHEUM DIS, V42, P374, DOI 10.1136/ard.42.4.374; Bressolle F, 1997, J RHEUMATOL, V24, P1903; DELECOEUILLERIE G, 1988, ANN RHEUM DIS, V47, P733, DOI 10.1136/ard.47.9.733; DESILVA M, 1986, ANN RHEUM DIS, V45, P136, DOI 10.1136/ard.45.2.136; DEVITA S, 1992, J INTERN MED, V232, P373; DOURY P, 1983, ARTHRITIS RHEUM, V26, P689, DOI 10.1002/art.1780260521; Gabriel SE, 1997, ARTHRITIS RHEUM, V40, P1873, DOI 10.1002/art.1780401022; GRAHAM E, 1981, BRIT MED J, V282, P269, DOI 10.1136/bmj.282.6260.269; HERNANDEZGARCIA C, 1994, SCAND J RHEUMATOL, V23, P295, DOI 10.3109/03009749409099276; HUSTON KA, 1978, ANN INTERN MED, V88, P162, DOI 10.7326/0003-4819-88-2-162; KRALL PL, 1989, CLEV CLIN J MED, V56, P253, DOI 10.3949/ccjm.56.3.253; KYLE V, 1989, ANN RHEUM DIS, V48, P662, DOI 10.1136/ard.48.8.662; KYLE V, 1989, ANN RHEUM DIS, V48, P658, DOI 10.1136/ard.48.8.658; Langford CA, 1997, RHEUM DIS CLIN N AM, V23, P841, DOI 10.1016/S0889-857X(05)70363-X; LUNDBERG I, 1990, J RHEUMATOL, V17, P1340; McKendry RJR, 1997, RHEUM DIS CLIN N AM, V23, P939, DOI 10.1016/S0889-857X(05)70367-7; MORGAN SL, 1990, ARTHRITIS RHEUM-US, V33, P9, DOI 10.1002/art.1780330102; MORGAN SL, 1994, ANN INTERN MED, V121, P833, DOI 10.7326/0003-4819-121-11-199412010-00002; Schaufelberger C, 1998, BRIT J RHEUMATOL, V37, P464; Simms RW, 1996, ARTHRITIS RHEUM-US, V39, P723; vanderVeen MJ, 1996, ANN RHEUM DIS, V55, P218, DOI 10.1136/ard.55.4.218; WEYAND CM, 1995, RHEUM DIS CLIN N AM, V21, P1027; WILKE WS, 1995, RHEUM DIS CLIN N AM, V21, P59; Wilke WS, 1997, BAILLIERE CLIN RHEUM, V11, P285, DOI 10.1016/S0950-3579(97)80047-7	25	324	331	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2001	134	2					106	114		10.7326/0003-4819-134-2-200101160-00010	http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391KW	11177313				2022-12-28	WOS:000166356000003
J	Lee, DS; Lee, JS; Oh, SH; Kim, SK; Kim, JW; Chung, JK; Lee, MC; Kim, CS				Lee, DS; Lee, JS; Oh, SH; Kim, SK; Kim, JW; Chung, JK; Lee, MC; Kim, CS			Deafness - Cross-modal plasticity and cochlear implants	NATURE			English	Article							AUDITORY-CORTEX; ACTIVATION		Seoul Natl Univ, Coll Med, Dept Nucl Med, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Biomed Engn, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Otolaryngol Head & Neck Surg, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Lee, DS (corresponding author), Seoul Natl Univ, Coll Med, Dept Nucl Med, 28 Yungun Dong, Seoul 110799, South Korea.	dsl@plaza.snu.ac.kr	Lee, Jae Sung/J-2781-2012; Lee, Dong Soo/J-2778-2012					Calvert GA, 1997, SCIENCE, V276, P593, DOI 10.1126/science.276.5312.593; CATALANAHUMADA M, 1993, BRAIN RES, V623, P287, DOI 10.1016/0006-8993(93)91439-Y; Cohen LG, 1999, EEG CL N SU, P174; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; Naito Y, 1997, ACTA OTO-LARYNGOL, V117, P490, DOI 10.3109/00016489709113426; Nishimura H, 1999, NATURE, V397, P116, DOI 10.1038/16376; Okazawa H, 1996, BRAIN, V119, P1297, DOI 10.1093/brain/119.4.1297; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0	9	299	316	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					149	150		10.1038/35051653	http://dx.doi.org/10.1038/35051653			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196628				2022-12-28	WOS:000166316200029
J	Norell, MA; Clarke, JA				Norell, MA; Clarke, JA			Fossil that fills a critical gap in avian evolution	NATURE			English	Article							BIRDS; RADIATION; PATAGONIA	Despite the discoveries of well-preserved Mesozoic birds(1-5), a key part of avian evolution, close to the radiation of all living birds (Aves), remains poorly represented(6). Here we report on a new taxon from the Late Cretaceous locality of Ukhaa Tolgod, Mongolia(7), that offers insight into this critically unsampled period. Apsaravis and the controversial alvarezsaurids(8) are the only avialan(9) taxa known from the continental deposits at Ukhaa Tolgod, which have produced hundreds of fossil mammals, lizards and other small inosaurs(7). The new taxon, Apsaravis ukhaana, is the best-preserved specimen of a Mesozoic ornithurine bird discovered in over a century. It provides data important for assessing morphological evolution across Avialae, with implications for, first, the monophyly of Enantiornithes and Sauriurae; second, the proposition that the Mesozoic sister taxa of extant birds, as part of an `ecological bottleneck', inhabited exclusively near-shore and marine environments(2); and third, the evolution of flight after its origin.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA	Yale University; American Museum of Natural History (AMNH)	Clarke, JA (corresponding author), Yale Univ, Dept Geol & Geophys, POB 208109, New Haven, CT 06520 USA.		/B-4978-2011	/0000-0003-2218-2637				Chiappe LM, 1998, NATURE, V392, P275, DOI 10.1038/32642; CHIAPPE LM, 1994, J VERTEBR PALEONTOL, V14, P230, DOI 10.1080/02724634.1994.10011554; CHIAPPE LM, 1991, ALCHERINGA, V15, P333, DOI 10.1080/03115519108619028; Chiappe LM, 1999, AM MUS NOVIT, V242, P1; Chiappe Luis M., 1996, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V30, P203; CLARKE JA, IN PRESS AM MUS NOVI; DASHZEVEG D, 1995, NATURE, V374, P446, DOI 10.1038/374446a0; Feduccia A., 1996, ORIGIN EVOLUTION BIR; FORESTER CA, 1996, SCIENCE, V382, P532; GAUTHIER JA, 1986, MEM CALIF ACAD SCI, V8, P1; Hou L., 1997, MESOZOIC BIRDS CHINA; Hou LH, 1996, SCIENCE, V274, P1164, DOI 10.1126/science.274.5290.1164; KUROCHKIN EN, 1996, NEW ENANTIORNITHID M; Marsh O.C., 1880, ODONTORNITHES MONOGR, DOI [10.5962/bhl.title.61298, DOI 10.5962/BHL.TITLE.61298]; Martin L.D., 1983, P291, DOI 10.1017/CBO9780511759994.011; MOLNAR RE, 1986, NATURE, V322, P736, DOI 10.1038/322736a0; Norell Mark A., 1999, American Museum Novitates, V3282, P1; Ostrom J.H., 1976, Smithsonian Contributions to Paleobiology, VNo. 27, P1; Ostrom J.H., 1974, Postilla, VNo. 165, P1; Ostrom John H., 1995, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V195, P253; Padian K, 1998, BIOL REV, V73, P1, DOI 10.1111/j.1469-185X.1997.tb00024.x; Sanz Jose L., 1995, American Museum Novitates, V3133, P1; SWOFFORD PL, 1998, PAUP STAR PHYLOGENET; VAZQUEZ RJ, 1994, ZOOMORPHOLOGY, V114, P59, DOI 10.1007/BF00574915; WALKER CA, 1981, NATURE, V292, P51, DOI 10.1038/292051a0	25	79	83	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					181	184		10.1038/35051563	http://dx.doi.org/10.1038/35051563			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196639				2022-12-28	WOS:000166316200041
J	Schmid, A; Dordick, JS; Hauer, B; Kiener, A; Wubbolts, M; Witholt, B				Schmid, A; Dordick, JS; Hauer, B; Kiener, A; Wubbolts, M; Witholt, B			Industrial biocatalysis today and tomorrow	NATURE			English	Review							2-LIQUID PHASE BIOCONVERSION; SALT-INDUCED ACTIVATION; ALPHA-AMINO-ACIDS; ORGANIC-SOLVENTS; PSEUDOMONAS-OLEOVORANS; SCALE PRODUCTION; IN-VITRO; ENZYMATIC RESOLUTION; KINETIC RESOLUTION; ALKANOL REMOVAL	The use of biocatalysis for industrial synthetic chemistry is on the verge of significant growth. Biocatalytic processes can now be carried out in organic solvents as well as aqueous environments, so that apolar organic compounds as well as water-soluble compounds can be modified selectively and efficiently with enzymes and biocatalytically active cells. As the use of biocatalysis for industrial chemical synthesis becomes easier, several chemical companies have begun to increase significantly the number and sophistication of the biocatalytic processes used in their synthesis operations.	ETH Honggerberg, Inst Biotechnol, CH-8093 Zurich, Switzerland; Rensselaer Polytech Inst, Dept Chem Engn, Troy, NY 12180 USA; BASF AG, D-67056 Ludwigshafen, Germany; Lonza Biotechnol, R&D, CH-3930 Visp, Switzerland; DSM Biotech GmbH, D-52428 Julich, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Rensselaer Polytechnic Institute; BASF	Schmid, A (corresponding author), ETH Honggerberg, Inst Biotechnol, CH-8093 Zurich, Switzerland.	dordick@rpi.edu; bernhard.hauer@basf-ag.de; andreas.kiener@lonzagroup.com; marcel.wubbolts@dsm-group.com; bw@biotech.biol.ethz.ch	Witholt, Bernard/A-7340-2012					Adlercreutz P, 1996, BIOCATAL BIOTRANSFOR, V14, P1, DOI 10.3109/10242429609106874; Arnold FH, 1999, CURR OPIN CHEM BIOL, V3, P54, DOI 10.1016/S1367-5931(99)80010-6; Balkenhohl F, 1997, J PRAK CHEM-CHEM ZTG, V339, P381, DOI 10.1002/prac.19973390166; Bergmann KE, 1996, J MED CHEM, V39, P3394, DOI 10.1021/jm950538t; BLINKOVSKY A M, 1992, Current Opinion in Biotechnology, V3, P124, DOI 10.1016/0958-1669(92)90140-E; Boesten W. H. J., 1996, [No title captured], Patent No. [WO 9623897, 9623897]; BOESTEN WHJ, 1998, Patent No. 905257; BOESTEN WHJ, 1996, Patent No. 9630376; BOESTEN WHJ, 1976, Patent No. 2526594; BOESTEN WHJ, 1977, Patent No. 1577087; Bommarius A.S., 1992, CHIRALITY IND, P371; Broxterman Q. B., 1997, Speciality Chemicals, V17, P186; BROXTERMAN R, 2000, PHARM MANUF INT, P61; Bruggink A, 1996, CHIMIA, V50, P431; Bruggink A, 1998, ORG PROCESS RES DEV, V2, P128, DOI 10.1021/op9700643; BUCHHOLZ H, 1997, BIOKATALYSATOREN ENZ; Buckland BC, 1999, METAB ENG, V1, P63, DOI 10.1006/mben.1998.0107; Certik M, 1999, J BIOSCI BIOENG, V87, P1, DOI 10.1016/S1389-1723(99)80001-2; Chaudhary AK, 1997, BIOTECHNOL PROGR, V13, P318, DOI 10.1021/bp970024i; Chenault H K, 1988, Biotechnol Genet Eng Rev, V6, P221; CLAIR NS, 2000, ANGEW CHEM INT EDIT, V39, P380; Demain AL, 2000, APPL BIOCHEM BIOTECH, V87, P135, DOI 10.1385/ABAB:87:2:135; DESMET MJ, 1981, J ORG CHEM, V46, P3128, DOI 10.1021/jo00328a031; DESMET MJ, 1981, APPL ENVIRON MICROB, V42, P811, DOI 10.1128/AEM.42.5.811-816.1981; DESMET MJ, 1983, ENZYME MICROB TECHNO, V5, P352; Dordick J.S., 1991, BIOCATALYSTS IND; Eichhorn E, 1997, TETRAHEDRON-ASYMMETR, V8, P2533, DOI 10.1016/S0957-4166(97)00256-5; Engbersen JFJ, 1996, PURE APPL CHEM, V68, P2171, DOI 10.1351/pac199668112171; Faber K, 2018, BIOTRANSFORMATIONS O, P134, DOI 10.1007/978-3-319-61590-5; FAVREBULLE O, 1991, BIO-TECHNOL, V9, P367, DOI 10.1038/nbt0491-367; GUNTHER H, 1995, BIOCATAL BIOTRANSFOR, V12, P1, DOI 10.3109/10242429508998147; Hauer B, 1999, CHIMIA, V53, P613; Held M, 1999, BIOTECHNOL BIOENG, V62, P641, DOI 10.1002/(SICI)1097-0290(19990320)62:6<641::AID-BIT3>3.0.CO;2-H; Held M, 1998, J MOL CATAL B-ENZYM, V5, P87, DOI 10.1016/S1381-1177(98)00012-5; HOLLMANN F, IN PRESS ANGEW CHEM; JENSEN VJ, 1987, METHOD ENZYMOL, V136, P356; Kaplan DL, 1998, ACS SYM SER, V684, P2; Kaptein B, 1996, CHIM OGGI, V14, P9; KAPTEIN B, 1993, TETRAHEDRON-ASYMMETR, V4, P1113, DOI 10.1016/S0957-4166(00)80217-7; KHMELNITSKY YL, 1994, J AM CHEM SOC, V116, P2647, DOI 10.1021/ja00085a066; Khmelnitsky YL, 1997, J AM CHEM SOC, V119, P11554, DOI 10.1021/ja973103z; KIENER A, 1992, ANGEW CHEM INT EDIT, V31, P774, DOI 10.1002/anie.199207741; Kiener A., 1996, International Patent, Patent No. [WO 96/35775, 9635775]; KIENER A, Patent No. 0686698; KIM Y, IN PRESS BIOTECHNOL; KIRCHNER G, 1997, Patent No. 832982; KLIBANOV AM, 1990, ACCOUNTS CHEM RES, V23, P114, DOI 10.1021/ar00172a004; Koizumi S, 1998, NAT BIOTECHNOL, V16, P847, DOI 10.1038/nbt0998-847; Krstenansky JL, 1999, BIOORGAN MED CHEM, V7, P2157, DOI 10.1016/S0968-0896(99)00145-5; KRUIZINGA WH, 1988, J ORG CHEM, V53, P5392, DOI 10.1021/jo00257a047; KULLA HG, 1991, CHIMIA, V45, P81; LAANE C, 1987, BIOTECHNOL BIOENG, V30, P81, DOI 10.1002/bit.260300112; Lalonde JJ, 1997, METHOD ENZYMOL, V286, P443; LAMARE S, 1993, TRENDS BIOTECHNOL, V11, P413, DOI 10.1016/0167-7799(93)90004-S; LEHKY P, Patent No. 0152948; Li Z, 1999, TETRAHEDRON-ASYMMETR, V10, P1323, DOI 10.1016/S0957-4166(99)00124-X; LONZA, Patent No. 0713869; LONZA, Patent No. 0578137; LONZA, Patent No. 0152949; Lye GJ, 1999, TRENDS BIOTECHNOL, V17, P395, DOI 10.1016/S0167-7799(99)01351-7; MacBeath G, 2000, SCIENCE, V289, P1760; Mathys RG, 1998, J CHEM TECHNOL BIOT, V71, P326, DOI 10.1002/(SICI)1097-4660(199804)71:4<326::AID-JCTB860>3.0.CO;2-7; Mathys RG, 1998, J CHEM TECHNOL BIOT, V71, P315, DOI 10.1002/(SICI)1097-4660(199804)71:4<315::AID-JCTB764>3.3.CO;2-U; Mathys RG, 1999, BIOTECHNOL BIOENG, V64, P459, DOI 10.1002/(SICI)1097-0290(19990820)64:4<459::AID-BIT9>3.0.CO;2-C; Michels PC, 1998, TRENDS BIOTECHNOL, V16, P210, DOI 10.1016/S0167-7799(98)01190-1; NAGASAWA T, 1990, PURE APPL CHEM, V62, P1441, DOI 10.1351/pac199062071441; NIKOLOVA P, 1993, J IND MICROBIOL, V12, P76, DOI 10.1007/BF01569905; Panke S, 1999, APPL ENVIRON MICROB, V65, P5619; Panke S, 1998, APPL ENVIRON MICROB, V64, P2032; Panke S, 1998, APPL ENVIRON MICROB, V64, P3546; Panke S, 2000, BIOTECHNOL BIOENG, V69, P91, DOI 10.1002/(SICI)1097-0290(20000705)69:1<91::AID-BIT11>3.0.CO;2-X; PARADKAR VM, 1994, J AM CHEM SOC, V116, P5009, DOI 10.1021/ja00090a065; Park OJ, 2000, BIOTECHNOL BIOENG, V70, P208, DOI 10.1002/1097-0290(20001020)70:2&lt;208::AID-BIT10&gt;3.0.CO;2-0; Pokora A. R., 1987, US Patent, Patent No. [4,647,952, 4647952]; Reipa V, 1997, P NATL ACAD SCI USA, V94, P13554, DOI 10.1073/pnas.94.25.13554; Resnick SM, 2000, APPL ENVIRON MICROB, V66, P2045, DOI 10.1128/AEM.66.5.2045-2051.2000; RESSLOSCHKE M, 1998, Patent No. 198448129; Roduit JP, 1997, HETEROCYCLES, V45, P1687; ROOS EC, 1992, J ORG CHEM, V57, P6769, DOI 10.1021/jo00051a019; Ru MT, 2000, J AM CHEM SOC, V122, P1565, DOI 10.1021/ja9935198; Ru MT, 1999, BIOTECHNOL BIOENG, V63, P233, DOI 10.1002/(SICI)1097-0290(19990420)63:2<233::AID-BIT12>3.0.CO;2-S; RUSSEL AJ, 1988, J BIOL CHEM, V263, P11626; RUSSELL AJ, 1994, CHEMTECH, V24, P33; Schmid A, 1998, BIOTECHNOL BIOENG, V60, P10, DOI 10.1002/(SICI)1097-0290(19981005)60:1<10::AID-BIT2>3.0.CO;2-3; Schmid A, 1998, EXTREMOPHILES, V2, P249, DOI 10.1007/s007920050067; Schoemaker HE, 1997, CHIMIA, V51, P308; SCHULZE B, 1998, SPEC CHEM, V18, P244; SCHULZE B, 1998, SPEC CHEM, V18, P246; SIMON H, 1985, ANGEW CHEM INT EDIT, V24, P539, DOI 10.1002/anie.198505391; Slade CJ, 1998, BIOTECHNOL BIOENG, V57, P211, DOI 10.1002/(SICI)1097-0290(19980120)57:2<211::AID-BIT9>3.0.CO;2-Q; SPANDE TF, 1992, J AM CHEM SOC, V114, P3475, DOI 10.1021/ja00035a048; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Tramper J, 1996, BIOTECHNOL BIOENG, V52, P290, DOI 10.1002/(SICI)1097-0290(19961020)52:2<290::AID-BIT8>3.0.CO;2-L; Wang P, 1997, NAT BIOTECHNOL, V15, P789, DOI 10.1038/nbt0897-789; WESTERHAUSEN D, 1992, ANGEW CHEM INT EDIT, V31, P1529; Wieser M, 1997, APPL MICROBIOL BIOT, V48, P174, DOI 10.1007/s002530051034; WITHOLT B, 1990, TRENDS BIOTECHNOL, V8, P46, DOI 10.1016/0167-7799(90)90133-I; Wubbolts MG, 1996, BIOTECHNOL BIOENG, V52, P301, DOI 10.1002/(SICI)1097-0290(19961020)52:2<301::AID-BIT10>3.0.CO;2-M; WUBBOLTS MG, 1994, ENZYME MICROB TECH, V16, P887, DOI 10.1016/0141-0229(94)90064-7; Yamada H, 1998, STUD ORG CHEM, V53, P13; YANG Z, 1995, J AM CHEM SOC, V117, P4843, DOI 10.1021/ja00122a014	101	1871	2004	22	740	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					258	268		10.1038/35051736	http://dx.doi.org/10.1038/35051736			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196655				2022-12-28	WOS:000166316200058
J	Pober, JS				Pober, JS			Is host endothelium a silver lining for allografts?	LANCET			English	Editorial Material							INSITU HYBRIDIZATION; RENAL-ALLOGRAFTS; Y-CHROMOSOME; CELLS; SENSITIVITY; ANTIBODIES; HEARTS; ORIGIN		Yale Univ, Sch Med, New Haven, CT 06510 USA	Yale University	Pober, JS (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06510 USA.							ANDERSEN CB, 1991, APMIS, V99, P645, DOI 10.1111/j.1699-0463.1991.tb01240.x; ASHARA T, 1997, SCIENCE, V275, P964; Bach FH, 1997, IMMUNOL TODAY, V18, P483, DOI 10.1016/S0167-5699(97)01129-8; BOGMAN MJJT, 1987, TRANSPLANT P, V19, P205; BURDICK JF, 1979, J IMMUNOL, V123, P1732; Colvin RB, 1997, J AM SOC NEPHROL, V8, P1930; HART DNJ, 1980, TRANSPLANTATION, V30, P73, DOI 10.1097/00007890-198007000-00016; HRUBAN RH, 1993, AM J PATHOL, V142, P975; Marelli-Berg FM, 1999, IMMUNOL REV, V172, P297; MEDAWAR PB, 1965, BRIT MED BULL, V21, P97, DOI 10.1093/oxfordjournals.bmb.a070392; MURRAY AG, 1994, P NATL ACAD SCI USA, V91, P9146, DOI 10.1073/pnas.91.19.9146; Pober JS, 1996, TRANSPLANTATION, V61, P343, DOI 10.1097/00007890-199602150-00001; SINCLAIR RA, 1972, BRIT MED J, V4, P15, DOI 10.1136/bmj.4.5831.15; WILLIAMS GM, 1973, TRANSPL P, V5, P819; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568	15	19	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					2	3		10.1016/S0140-6736(00)03558-3	http://dx.doi.org/10.1016/S0140-6736(00)03558-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197355				2022-12-28	WOS:000166341500002
J	Roberts, JM; Cooper, DW				Roberts, JM; Cooper, DW			Pathogenesis and genetics of pre-eclampsia	LANCET			English	Article							PREECLAMPSIA ECLAMPSIA; DELETION POLYMORPHISM; SUSCEPTIBILITY LOCUS; REMOTE PROGNOSIS; ENOS-GENE; HYPERTENSION; PREGNANCY; LINKAGE; REGION; WOMEN	After more than a century of intensive research, pre-eclampsia and eclampsia remain an enigmatic set of conditions. Aberration of the interaction between placental and maternal tissue is probably the primary cause, but the exact nature of the differences from normal pregnancy remain elusive. In this review attempts to understand the sequence of physiological changes have concentrated on vascular endothelium and oxidative stress issues. There are genetic components to susceptibility, but the relative contributions of maternal and fetal genotypes are still unclear. Whole-genome mapping could ultimately define the causative genes.	Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia; Magee Womens Res Inst, Pittsburgh, PA USA	Macquarie University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Cooper, DW (corresponding author), Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia.	dcooper@rna.bio.mq.edu.au						ARIAS F, 1993, AM J OBSTET GYNECOL, V168, P585, DOI 10.1016/0002-9378(93)90499-9; Arngrimsson R, 1999, HUM MOL GENET, V8, P1799, DOI 10.1093/hmg/8.9.1799; Arngrimsson R, 1997, AM J HUM GENET, V61, P354, DOI 10.1086/514843; ARNGRIMSSON R, 1995, HYPERTENS PREGNANCY, V14, P27, DOI 10.3109/10641959509058048; Brosens IA, 1979, OBSTET GYNECOLOGY AN, P177; Chappell LC, 1999, LANCET, V354, P810, DOI 10.1016/S0140-6736(99)80010-5; Chesley L, 1978, HYPERTENSIVE DISORDE; CHESLEY LC, 1976, AM J OBSTET GYNECOL, V124, P446, DOI 10.1016/0002-9378(76)90168-X; CHESLEY LC, 1968, OBSTET GYNECOL, V32, P303; Chikosi AB, 2000, S AFR MED J, V90, P128; Chikosi AB, 1999, BRIT J OBSTET GYNAEC, V106, P1219, DOI 10.1111/j.1471-0528.1999.tb08152.x; COOPER DW, 1979, J MED GENET, V16, P409, DOI 10.1136/jmg.16.6.409; COOPER DW, 1993, HYPERTENS PREGNANCY, V12, P1, DOI 10.3109/10641959309031050; COOPER DW, 1988, BRIT J OBSTET GYNAEC, V95, P644, DOI 10.1111/j.1471-0528.1988.tb06524.x; Curnow KM, 2000, J HYPERTENS, V18, P173, DOI 10.1097/00004872-200018020-00007; DAVIES AM, 1971, GEOGRAPHICAL EPIDEMI; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; Graves JAM, 1998, REPROD FERT DEVELOP, V10, P23, DOI 10.1071/R98014; Guo GL, 1999, HUM GENET, V105, P641, DOI 10.1007/s004390051156; Harrison GA, 1997, AM J HUM GENET, V60, P1158; HAYWARD C, 1992, AM J HUM GENET, V50, P749; Hubel CA, 1999, CLIN GENET, V56, P289; HUMPHREY KE, 1995, BRIT J OBSTET GYNAEC, V102, P707, DOI 10.1111/j.1471-0528.1995.tb11427.x; Kahn SR, 1998, OBSTET GYNECOL, V91, P812, DOI 10.1016/S0029-7844(97)00713-8; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Lachmeijer AMA, 1998, BRIT J OBSTET GYNAEC, V105, P1315, DOI 10.1111/j.1471-0528.1998.tb10012.x; Lade JA, 1999, HYPERTENS PREGNANCY, V18, P81, DOI 10.3109/10641959909009613; Lewis I, 1999, AM J HUM GENET, V64, P310, DOI 10.1086/302179; Li DK, 2000, AM J EPIDEMIOL, V151, P57, DOI 10.1093/oxfordjournals.aje.a010122; Lie RT, 1998, BRIT MED J, V316, P1343, DOI 10.1136/bmj.316.7141.1343; MILLS JL, 1991, JAMA-J AM MED ASSOC, V265, P70, DOI 10.1001/jama.265.1.70; Mogren I, 1999, EPIDEMIOLOGY, V10, P518, DOI 10.1097/00001648-199909000-00009; Morgan L, 1999, J HYPERTENS, V17, P765, DOI 10.1097/00004872-199917060-00007; Moses EK, 2000, AM J HUM GENET, V67, P1581, DOI 10.1086/316888; Page EW, 1939, AM J OBSTET GYNECOL, V37, P291; Pipkin FB, 1999, BIOL NEONATE, V76, P325, DOI 10.1159/000014175; Roberts JM, 1998, SEMIN REPROD ENDOCR, V16, P5, DOI 10.1055/s-2007-1016248; Roberts JM, 1999, LANCET, V354, P788, DOI 10.1016/S0140-6736(99)80002-6; Robillard PY, 1999, EUR J OBSTET GYN R B, V84, P37, DOI 10.1016/S0301-2115(98)00250-4; Ros HS, 2000, AM J MED GENET, V91, P256; STEVENS JM, 1975, MED J AUSTRALIA, V2, P949, DOI 10.5694/j.1326-5377.1975.tb106465.x; SUTHERLAND A, 1981, BRIT J OBSTET GYNAEC, V88, P785, DOI 10.1111/j.1471-0528.1981.tb01304.x; Suzuki Y, 1999, HYPERTENS PREGNANCY, V18, P261, DOI 10.3109/10641959909016199; Thornton JG, 1999, BRIT J OBSTET GYNAEC, V106, P570, DOI 10.1111/j.1471-0528.1999.tb08326.x; Trupin LS, 1996, EPIDEMIOLOGY, V7, P240, DOI 10.1097/00001648-199605000-00004; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; WILTON AN, 1990, LANCET, V336, P653, DOI 10.1016/0140-6736(90)92149-C; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9	48	948	995	4	59	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2001	357	9249					53	56		10.1016/S0140-6736(00)03577-7	http://dx.doi.org/10.1016/S0140-6736(00)03577-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197372				2022-12-28	WOS:000166341500034
J	Reeder, GS				Reeder, GS			Exercise testing in rapid-access clinics for assessment of chest pain	LANCET			English	Editorial Material									Mayo Clin & Mayo Fdn, Dept Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic	Reeder, GS (corresponding author), Mayo Clin & Mayo Fdn, Dept Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.							Farkouh ME, 1998, NEW ENGL J MED, V339, P1882, DOI 10.1056/NEJM199812243392603; Stein RA, 2000, CIRCULATION, V102, P1463, DOI 10.1161/01.CIR.102.12.1463	2	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2116	2116		10.1016/S0140-6736(00)03487-5	http://dx.doi.org/10.1016/S0140-6736(00)03487-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191534				2022-12-28	WOS:000165997300005
J	Draine, J				Draine, J			Mental or criminal?	LANCET			English	Article									Univ Penn, Sch Social Work, Social Work Mental Hlth Res Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania	Draine, J (corresponding author), Univ Penn, Sch Social Work, Social Work Mental Hlth Res Ctr, Philadelphia, PA 19104 USA.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S48	S48		10.1016/S0140-6736(00)92034-8	http://dx.doi.org/10.1016/S0140-6736(00)92034-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191506				2022-12-28	WOS:000166074900050
J	Hastings, A				Hastings, A			Ecology - The lion and the lamb find closure	SCIENCE			English	Editorial Material									Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA	University of California System; University of California Davis	Hastings, A (corresponding author), Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA.	amhastings@ucdavis.edu	Hastings, Alan/A-7423-2008; Hastings, Alan/O-6864-2019	Hastings, Alan/0000-0002-0717-8026				Bolker BM, 1999, AM NAT, V153, P575, DOI 10.1086/303199; Gause G. F., 1934, STRUGGLE EXISTENCE; HASTINGS A, 1977, THEOR POPUL BIOL, V12, P37, DOI 10.1016/0040-5809(77)90034-X; Keeling MJ, 2000, SCIENCE, V290, P1758, DOI 10.1126/science.290.5497.1758; Levin SA, 1997, SCIENCE, V275, P334, DOI 10.1126/science.275.5298.334; LOTKA AJ, 1925, ELEMENTS PHYSICAL BI; MURDOCH W W, 1975, P1; Nicholson A. J., 1935, P ZOOL SOC LOND, V105, P551, DOI DOI 10.1111/J.1096-3642.1935.TB01680.X; RAND D. A., 1999, ADV ECOLOGICAL THEOR, P100; Volterra V, 1926, NATURE, V118, P558, DOI 10.1038/118558a0	10	3	3	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	2000	290	5497					1712	1713		10.1126/science.290.5497.1712	http://dx.doi.org/10.1126/science.290.5497.1712			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11186394				2022-12-28	WOS:000165632400029
J	van Helden, PD; Hoal-van Helden, EG				van Helden, PD; Hoal-van Helden, EG			Molecular answers to tuberculous questions	LANCET			English	Article									Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Dept Biochem, ZA-7505 Tygerberg, South Africa	Stellenbosch University; Stellenbosch University	van Helden, PD (corresponding author), Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, POB 19063, ZA-7505 Tygerberg, South Africa.			Hoal, Eileen/0000-0002-6444-5688					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S61	S61		10.1016/S0140-6736(00)92047-6	http://dx.doi.org/10.1016/S0140-6736(00)92047-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191521				2022-12-28	WOS:000166074900063
J	Harthorne, JW				Harthorne, JW			Effects of physiologic pacing versus ventricular pacing	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Harthorne, JW (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							Connolly SJ, 2000, NEW ENGL J MED, V342, P1385, DOI 10.1056/NEJM200005113421902; Gesell RA, 1911, AM J PHYSIOL, V29, P32; Mines GR, 1913, J PHYSIOL-LONDON, V46, P349; Nielsen JC, 1998, CIRCULATION, V97, P987; STEWART WJ, 1984, AM J CARDIOL, V54, P308, DOI 10.1016/0002-9149(84)90188-7	5	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1417	1418						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183885				2022-12-28	WOS:000165152800023
J	Fishbein, EA				Fishbein, EA			What price mice?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Johns Hopkins Univ, Off Vice President & Gen Counsel, Baltimore, MD 21218 USA	Johns Hopkins University	Fishbein, EA (corresponding author), Johns Hopkins Univ, Off Vice President & Gen Counsel, 3400 N Charles St,113 Garland Hall, Baltimore, MD 21218 USA.							Loder N, 2000, NATURE, V404, P529, DOI 10.1038/35007202; *NIH, 2000, NIH PUBL, V8023; PILLING DP, 2000, FINANCIAL TIMES 0406; *RDS, 2000, RDS RES DEF SOC NEWS; Trull FL, 1999, SCIENCE, V284, P1463, DOI 10.1126/science.284.5419.1463; *US DHEW, 1963, GUID LAB AN FAC CAR	6	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					939	941		10.1001/jama.285.7.939	http://dx.doi.org/10.1001/jama.285.7.939			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402BE	11180739				2022-12-28	WOS:000166965500033
J	Michaud, CM; Murray, CJL; Bloom, BR				Michaud, CM; Murray, CJL; Bloom, BR			Burden of disease Implications for future research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH	One overall challenge for public health and medicine in the future is to allocate available resources effectively to reduce major causes of disease burden globally and to decrease health disparities between poor and affluent populations, The major risk factors for death and disability worldwide are malnutrition; poor water supply, sanitation, and personal and domestic hygiene; unsafe sexual behavior; tobacco use; alcohol use; occupational hazards; hypertension; physical inactivity; illicit drugs; and air pollution, The challenge for research in the 21st century is to maintain and improve life expectancy and the quality of life that was achieved for most of the world's population during the 20th century.	Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Michaud, CM (corresponding author), Ctr Populat & Dev Studies, 9 Bow St, Cambridge, MA 02138 USA.							Anand S, 1997, J HEALTH ECON, V16, P685, DOI 10.1016/S0167-6296(97)00005-2; [Anonymous], 2000, WORLD DEV REP 2000 2; [Anonymous], 1987, STANDARD LIVING; Blendon RJ, 1998, JAMA-J AM MED ASSOC, V280, P2122, DOI 10.1001/jama.280.24.2122; *DEP HUM SERV, 1999, VICT BURD DIS STUD M; *DEP HUM SERV PUBL, 1999, VICT BURD DIS STUD M; Howson CP, 1998, LANCET, V351, P586, DOI 10.1016/S0140-6736(97)11452-0; Johannesson M, 1997, J HEALTH ECON, V16, P589, DOI 10.1016/S0167-6296(96)00516-4; Mathers C., 1999, BURDEN DIS INJURY AU; Murray CJL, 1999, EPIDEMIOLOGY, V10, P594, DOI 10.1097/00001648-199909000-00029; Murray CJL, 1997, J HEALTH ECON, V16, P703, DOI 10.1016/S0167-6296(97)00004-0; MURRAY CJL, 1996, US PATTERNS MORTALIT; MURRAY CJL, 1998, US PATTERNS MORTALIT; The Commission on Health Research for Development, 1990, HLTH RES ESS LINK EQ; The World Bank, 1993, INV HLTH WORLD DEV I; *WHO AD HOC COMM H, 1996, INV HLTH RES DEV; World Health Organization, 2000, WORLD HLTH REP 2000; 1998, SUMMARIZING POPULATI	18	421	433	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					535	539		10.1001/jama.285.5.535	http://dx.doi.org/10.1001/jama.285.5.535			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176854				2022-12-28	WOS:000166714200007
J	Kushel, MB; Vittinghoff, E; Haas, JS				Kushel, MB; Vittinghoff, E; Haas, JS			Factors associated with the health care utilization of homeless persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-CITY; ADDICTION SEVERITY INDEX; EMERGENCY ROOM USE; MENTAL-HEALTH; URBAN HOMELESS; MEDICAL-CARE; LOS-ANGELES; SUBSTANCE-ABUSE; RISK-FACTORS; HOUSED POOR	Context Homeless persons face numerous barriers to receiving health care and have high rates of illness and disability. Factors associated with health care utilization by homeless persons have not been explored from a national perspective. Objective To describe factors associated with use of and perceived barriers to receipt of health care among homeless persons. Design and Setting Secondary data analysis of the National Survey of Homeless Assistance Providers and Clients. Subjects A total of 2974 currently homeless persons interviewed through homeless assistance programs throughout the United States in October and November 1996. Main Outcome Measures Self-reported use of ambulatory care services, emergency departments, and inpatient hospital services; inability to receive necessary care; and inability to comply with prescription medication in the prior year. Results Overall, 62.8% of subjects had 1 or more ambulatory care visits during the preceding year, 32.2% visited an emergency department, and 23.3% had been hospitalized. However, 24.6% reported having been unable to receive necessary medical care. Of the 1201 respondents who reported having been prescribed medication, 32.1% reported being unable to comply, After adjustment for age, sex, race/ethnicity, medical illness, mental health problems, substance abuse, and other covariates, having health insurance was associated with greater use of ambulatory care (odds ratio TOR], 2.54; 95% confidence interval [CI], 1.19-5.42), inpatient hospitalization (OR, 2.60; 95% CI, 1.16-5.81), and lower reporting of barriers to needed care (OR, 0.37; 95% CI, 0.15-0.90) and prescription medication compliance (OR, 0.35; 95% CI, 0.14-0.85). Insurance was not associated with emergency department visits (OR, 0.90; 95% CI, 0.47-1.75). Conclusions In this nationally representative survey, homeless persons reported high levels of barriers to needed care and used acute hospital-based care at high rates. Insurance was associated with a greater use of ambulatory care and fewer reported barriers. Provision of insurance may improve the substantial morbidity experienced by homeless persons and decrease their reliance on acute hospital-based care.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Haas, JS (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Gen Internal Med, Box 0936, San Francisco, CA 94143 USA.			HAAS, JENNIFER/0000-0001-7227-851X; Kushel, Margot/0000-0002-1361-6889	PHS HHS [5F D08 HP 50109] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Andersen R, 1979, TOTAL SURVEY ERROR; ARGERIOU M, 1994, J SUBST ABUSE TREAT, V11, P359, DOI 10.1016/0740-5472(94)90046-9; Barrow SM, 1999, AM J PUBLIC HEALTH, V89, P529, DOI 10.2105/AJPH.89.4.529; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BURT MR, 1999, HOMELESSNESS PROGRAM; Duchon LM, 1999, MED CARE, V37, P1282, DOI 10.1097/00005650-199912000-00011; FISCHER PJ, 1986, AM J PUBLIC HEALTH, V76, P519, DOI 10.2105/AJPH.76.5.519; FISCHER PJ, 1991, AM PSYCHOL, V46, P1115, DOI 10.1037/0003-066X.46.11.1115; FISCHER PJ, 1991, ALCOHOL DRUG ABUSE M; Forrest CB, 1998, AM J PUBLIC HEALTH, V88, P1330, DOI 10.2105/AJPH.88.9.1330; Gallagher TC, 1997, MED CARE, V35, P814, DOI 10.1097/00005650-199708000-00007; Gelberg L, 2000, HEALTH SERV RES, V34, P1273; Gelberg L, 1997, AM J PUBLIC HEALTH, V87, P217, DOI 10.2105/AJPH.87.2.217; GELBERG L, 1988, HOSP COMMUNITY PSYCH, V39, P510; Gelberg L, 1997, MED CARE, V35, P287, DOI 10.1097/00005650-199703000-00008; GELBERG L, 1989, J NERV MENT DIS, V177, P291, DOI 10.1097/00005053-198905000-00007; Glied S, 1998, INQUIRY-J HEALTH CAR, V35, P380; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; Hwang SW, 2000, JAMA-J AM MED ASSOC, V283, P2152, DOI 10.1001/jama.283.16.2152; Hwang SW, 1998, ARCH INTERN MED, V158, P1454, DOI 10.1001/archinte.158.13.1454; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1085; KRAUSS NA, 1999, AHJCPR PUBL; Kreider B, 1997, HEALTH ECON, V6, P31, DOI 10.1002/(SICI)1099-1050(199701)6:1<31::AID-HEC242>3.3.CO;2-D; Lewin ME, 2000, AM HLTH CARE SAFETY; LONG SH, 1994, HEALTH AFFAIR, V13, P211, DOI 10.1377/hlthaff.13.2.211; MARTELL JV, 1992, ANN INTERN MED, V116, P299, DOI 10.7326/0003-4819-116-4-299; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; *NAT CTR HLTH STAT, 2000, DHHS PUBL; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; O'Toole TP, 1999, J HEALTH POLIT POLIC, V24, P91, DOI 10.1215/03616878-24-1-91; O'Toole TP, 1999, J GEN INTERN MED, V14, P599, DOI 10.1046/j.1525-1497.1999.09258.x; PADGETT D, 1990, MED CARE, V28, P805, DOI 10.1097/00005650-199009000-00010; PADGETT DK, 1991, HOSP COMMUNITY PSYCH, V42, P834; PADGETT DK, 1995, SOC SCI MED, V41, P547, DOI 10.1016/0277-9536(94)00364-Y; Pearson SD, 1999, J GEN INTERN MED, V14, P461, DOI 10.1046/j.1525-1497.1999.06278.x; Robertson MJ, 1997, AM J PUBLIC HEALTH, V87, P221, DOI 10.2105/AJPH.87.2.221; Rosenheck R, 1998, MED CARE, V36, P1256, DOI 10.1097/00005650-199808000-00013; Salit SA, 1998, NEW ENGL J MED, V338, P1734, DOI 10.1056/NEJM199806113382406; Tourkin S., 1997, NATL SURVEY HOMELESS; United States Census Bureau, 1999, NAT SURV HOM ASS PRO; WENZEL SL, 1995, MED CARE, V33, P1132, DOI 10.1097/00005650-199511000-00006; ZANIS DA, 1994, J SUBST ABUSE TREAT, V11, P541, DOI 10.1016/0740-5472(94)90005-1; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455	43	471	475	0	33	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2001	285	2					200	206		10.1001/jama.285.2.200	http://dx.doi.org/10.1001/jama.285.2.200			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	389FB	11176814	Bronze			2022-12-28	WOS:000166227000029
J	da Costa, D; Al Khusaiby, S; Ghazal, H; Nair, A				da Costa, D; Al Khusaiby, S; Ghazal, H; Nair, A			Clinical picture: A newborn with gynaecomastia	LANCET			English	Article									Royal Hosp, Minist Hlth, Muscat, Oman	The Royal Hospital, Sultanate of Oman	da Costa, D (corresponding author), Royal Hosp, Minist Hlth, Muscat, Oman.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					14	14		10.1016/S0140-6736(00)03565-0	http://dx.doi.org/10.1016/S0140-6736(00)03565-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197353				2022-12-28	WOS:000166341500009
J	Charon, R				Charon, R			Narrative medicine: Form, function, and ethics	ANNALS OF INTERNAL MEDICINE			English	Article							CARE; STUDENTS		Columbia Univ Coll Phys & Surg, Div Gen Med, New York, NY 10032 USA	Columbia University	Charon, R (corresponding author), Columbia Univ Coll Phys & Surg, Div Gen Med, PH 9-E,Room 105,630 W 168th St, New York, NY 10032 USA.	rac5@columbia.edu						Anderson C. M., 2000, WRITING HEALING INFO; BORKAN J, 1999, PATIENTS DOCTORS LIF; BRANCH W, 1993, NEW ENGL J MED, V329, P1130, DOI 10.1056/NEJM199310073291518; Bruner JS, 1986, ACTUAL MINDS POSSIBL, DOI DOI 10.4159/9780674029019; CHARON R, 1986, LIT MED, V5, P58; Charon R, 2000, AM J MED SCI, V319, P285, DOI 10.1097/00000441-200005000-00004; Charon R, 2000, ACAD MED, V75, P23, DOI 10.1097/00001888-200001000-00008; Charon R, 2000, ANN INTERN MED, V132, P63, DOI 10.7326/0003-4819-132-1-200001040-00011; Charon R., 1993, EMPATHY PRACTICE MED, P147; CHRISTAKIS DA, 1993, ACAD MED, V68, P249, DOI 10.1097/00001888-199304000-00003; DOCTOR X, 1965, INTERN; EAKIN JP, 1985, FICTION AUTOBIOGRAPH; Feudtner C, 1998, J GEN INTERN MED, V13, P846, DOI 10.1046/j.1525-1497.1998.00251.x; GAWANDE A, 2000, NEW YORKER      0807, P60; GROOPMAN J, 2000, NEW YORKER      0529, P52; Hawkins A., 1999, RECONSTRUCTING ILLNE, V2nd; Hurwitz, 1998, NARRATIVE BASED MED; Inui TS, 1996, ANN INTERN MED, V125, P770, DOI 10.7326/0003-4819-125-9-199611010-00012; JAY P, 1983, BEING TEXT SELF REPR; Jones AH, 1997, LANCET, V349, P1243, DOI 10.1016/S0140-6736(97)03395-3; Katz AM, 2000, SOC SCI MED, V50, P851, DOI 10.1016/S0277-9536(99)00341-X; Klass Perri, 1992, BABY DOCTOR PEDIAT T; Kleinman A., 1988, ILLNESS NARRATIVES; KONNER H, 1987, BECOMING DOCTOR JOUR; KREISWIRTH M, 1992, NEW LITERARY HIST, V23, P629, DOI 10.2307/469223; McLellan F, 2000, ETHICAL ISSUES IN BIOMEDICAL PUBLICATION, P166; Miller SZ, 1999, ACAD MED, V74, P800, DOI 10.1097/00001888-199907000-00014; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; Mullan F., 1976, WHITE COAT CLENCHED; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Olney James., 1980, AUTOBIOGRAPHY ESSAYS; Reifler DR, 1996, LIT MED, V15, P183, DOI 10.1353/lm.1996.0024; Remen RN, 1996, KITCHEN TABLE WISDOM; SELZER R, 1998, DOCTOR STRORIES, P386; Shem Samuel, 1978, HOUSE GOD; Smyth JM, 1999, JAMA-J AM MED ASSOC, V281, P1304, DOI 10.1001/jama.281.14.1304; TRAUTMANN J, 1982, MOBIUS, V2, P23; Verghese A., 1994, MY OWN COUNTRY DOCTO; WILLIAMS WC, 1984, DOCTOR STORIES, P56	39	130	166	7	64	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2001	134	1					83	87		10.7326/0003-4819-134-1-200101020-00024	http://dx.doi.org/10.7326/0003-4819-134-1-200101020-00024			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386CV	11187429				2022-12-28	WOS:000166043300017
J	Hoffrage, U; Lindsey, S; Hertwig, R; Gigerenzer, G				Hoffrage, U; Lindsey, S; Hertwig, R; Gigerenzer, G			Medicine - Communicating statistical information	SCIENCE			English	Article									Max Planck Inst Human Dev, D-14195 Berlin, Germany; Univ Virginia, Dept Psychol, Charlottesville, VA 22903 USA	Max Planck Society; University of Virginia	Hoffrage, U (corresponding author), Max Planck Inst Human Dev, Lentzeallee 94, D-14195 Berlin, Germany.		Gigerenzer, Gerd/A-6250-2012; Gigerenzer, Gerd/M-5595-2013; Hertwig, Ralph/B-3468-2015	Gigerenzer, Gerd/0000-0002-6163-5419; Hertwig, Ralph/0000-0002-9908-9556				Breyer S, 1998, SCIENCE, V280, P537, DOI 10.1126/science.280.5363.537; CASSCELLS W, 1978, NEW ENGL J MED, V299, P999, DOI 10.1056/NEJM197811022991808; Eddy DM, 1982, JUDGMENT UNCERTAINTY, P249; GIGERENZER G, 1995, PSYCHOL REV, V102, P684, DOI 10.1037/0033-295X.102.4.684; Gigerenzer G, 1998, AIDS CARE, V10, P197, DOI 10.1080/09540129850124451; Gigerenzer G, 1999, PSYCHOL REV, V106, P425, DOI 10.1037/0033-295X.106.2.425; GIGERENZER G, 1993, HDB DATA ANAL BEHAV, P313; HERTWIG R, IN PRESS FREQUENCY P; Hoffrage U, 1998, ACAD MED, V73, P538, DOI 10.1097/00001888-199805000-00024; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Koehler J.J., 1993, JURIMETRICS J, V34, P21; Koehler J.J., 1995, JURIMETRICS J LAW SC, V35, P201; Koehler JJ, 1996, BEHAV BRAIN SCI, V19, P1, DOI 10.1017/S0140525X00041157; Koehler JJ, 1996, U COLO LAW REV, V67, P859; LINDSEY S, UNPUB; Mellers BA, 1999, PSYCHOL REV, V106, P417, DOI 10.1037/0033-295X.106.2.417; NYSTOM L, 1997, J MED SCREEN, V3, P85; STINE J, 1996, ACQUIRED IMMUNE DEFI; WEISS R, 2000, WASHINGTON POST 1202, pA10	19	365	368	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2261	2262		10.1126/science.290.5500.2261	http://dx.doi.org/10.1126/science.290.5500.2261			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	385GQ	11188724	Green Submitted			2022-12-28	WOS:000165995800024
J	Alam, M; Arndt, KA; Dover, JS				Alam, M; Arndt, KA; Dover, JS			Aesthetic surgery: coming of age	LANCET			English	Article									Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA 02467 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University	Alam, M (corresponding author), Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA 02467 USA.								0	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S60	S60		10.1016/S0140-6736(00)92046-4	http://dx.doi.org/10.1016/S0140-6736(00)92046-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191520				2022-12-28	WOS:000166074900062
J	Iwu, MM; Gbodossou, E				Iwu, MM; Gbodossou, E			The role of traditional medicine	LANCET			English	Article									PROMETRA, Dakar, Senegal; BDPC Int Off, Silver Spring, MD 20902 USA		Iwu, MM (corresponding author), BDPC Int Off, 11303 Amherst Ave 2, Silver Spring, MD 20902 USA.								0	10	10	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S3	S3		10.1016/S0140-6736(00)91989-5	http://dx.doi.org/10.1016/S0140-6736(00)91989-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191486	Bronze			2022-12-28	WOS:000166074900005
J	Orgel, L				Orgel, L			Origin of life - A simpler nucleic acid	SCIENCE			English	Editorial Material									Salk Inst Bimed Study, La Jolla, CA 92037 USA	Salk Institute	Orgel, L (corresponding author), Salk Inst Bimed Study, La Jolla, CA 92037 USA.							Beier M, 1999, SCIENCE, V283, P699, DOI 10.1126/science.283.5402.699; Joyce G. F., 1993, COLD SPRING HARB SYM, V24, P49; Koppitz M, 1998, J AM CHEM SOC, V120, P4563, DOI 10.1021/ja974190y; KOZLOV I, IN PRESS ANGEW CHEM; Nielsen PE, 1999, ACCOUNTS CHEM RES, V32, P624, DOI 10.1021/ar980010t; Reck F, 1999, ORG LETT, V1, P1531, DOI 10.1021/ol990184q; Schoning KU, 2000, SCIENCE, V290, P1347, DOI 10.1126/science.290.5495.1347	7	96	98	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 17	2000	290	5495					1306	1307		10.1126/science.290.5495.1306	http://dx.doi.org/10.1126/science.290.5495.1306			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11185405				2022-12-28	WOS:000165379800028
J	Li, GH; Baker, SP; Smialek, JE; Soderstrom, CA				Li, GH; Baker, SP; Smialek, JE; Soderstrom, CA			Use of alcohol as a risk factor for bicycling injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMA; SEVERITY	Context Bicycling is one of the leading causes of recreational injuries. Elevated blood alcohol concentrations (BACs) are found in about one third of fatally injured bicyclists aged 15 years or older. Objective To assess the relative risk of fatal and serious bicycling injury according to BAC. Design Matched case-control study. Setting and Subjects Bicyclists aged 15 years or older who were fatally or seriously injured while riding a bicycle during the day in Maryland in 1985-1997 (cases, n=124) and bicyclists aged 15 years or older who were interviewed and given a breath test for estimated BAC during roadside surveys that took place in June 1996 through May 1998 at the same site, time of day, day of week, and month of year in which a case bicyclist was injured (controls, n=342). Main Outcome Measure Odds ratio of bicycling injury according to estimated BAC. Results An estimated positive BAC (greater than or equal to0.02 g/dL) was detected in 12.9% of the case bicyclists (23.5% of the 34 fatally injured and 8.9% of the 90 seriously injured) compared with 2.9% of the control bicyclists (P<.001). Relative to an estimated BAC of less than 0.02 g/dL, the adjusted odds ratio of bicycling injury was 5.6 (95% confidence interval [Cl], 2.2-14.0) for a BAC of 0.02 g/dL or higher and was 20.2 (95% CI, 4.2-96.3) for a BAC of 0.08 g/dL or higher. Rates of helmet use at the time of injury or interview were 5% and 35%, respectively, for those with and without a positive BAC (P=.007). Conclusion Alcohol use while bicycle riding is associated with a substantially increased risk of fatal or serious injury.	Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD 21205 USA; Off Chief Med Examiner Maryland, Baltimore, MD USA; Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Div Trauma Surg, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Li, GH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, 1830 E Monument St,Suite 6-100, Baltimore, MD 21205 USA.							Baker S., 1993, INJURIES BICYCLISTS; Dunham C M, 1989, Md Med J, V38, P227; *FED HIGHW ADM, 1997, DOT PUBL FED HIGHW A; FRANK E, 1995, ACAD EMERG MED, V2, P200, DOI 10.1111/j.1553-2712.1995.tb03198.x; GIBB KA, 1984, ANN EMERG MED, V13, P516, DOI 10.1016/S0196-0644(84)80517-X; Li GH, 2000, ACCIDENT ANAL PREV, V32, P583, DOI 10.1016/S0001-4575(99)00089-5; LI GH, 1994, ACCIDENT ANAL PREV, V26, P543, DOI 10.1016/0001-4575(94)90045-0; Li GH, 1996, ALCOHOL CLIN EXP RES, V20, P1553, DOI 10.1111/j.1530-0277.1996.tb01698.x; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LI GH, 1994, AM J PUBLIC HEALTH, V84, P1402, DOI 10.2105/AJPH.84.9.1402; OLKKONEN S, 1994, ACCIDENT ANAL PREV, V22, P89; *SAS I INC, 1997, VERS 6 12 WIND; Schewe G, 1984, Blutalkohol, V21, P97; Schewe G, 1978, Beitr Gerichtl Med, V36, P239; Soderstrom CA, 1997, J TRAUMA, V42, P67, DOI 10.1097/00005373-199701000-00012; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; YELON JA, 1995, AM SURGEON, V61, P202	17	72	72	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					893	896		10.1001/jama.285.7.893	http://dx.doi.org/10.1001/jama.285.7.893			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	402BE	11180732	Bronze			2022-12-28	WOS:000166965500026
J	Evans, B; Duggan, W; Baker, J; Ramsay, M; Abiteboul, D				Evans, B; Duggan, W; Baker, J; Ramsay, M; Abiteboul, D		Occupational Exposure Surveillance	Exposure of healthcare workers in England, Wales, and Northern Ireland to bloodborne viruses between July 1997 and June 2000: analysis of surveillance data	BRITISH MEDICAL JOURNAL			English	Article									Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; Fac Bichat, Study Grp Occupat Blood Exposure, Paris 18, France	Public Health England; UDICE-French Research Universities; Universite Paris Cite	Evans, B (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England.		Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				Cardo DM, 1997, INFECT DIS CLIN N AM, V11, P331, DOI 10.1016/S0891-5520(05)70359-7; Dore GJ, 1997, BRIT MED J, V315, P333; *NEEDL TRANSM HTLV, 1984, LANCET, V2, P1376; UK Health Departments, 1998, GUID CLIN HLTH CAR W; *UK HLTH DEP, 2000, 2000020 UK HLTH DEP	5	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	2001	322	7283					397	398		10.1136/bmj.322.7283.397	http://dx.doi.org/10.1136/bmj.322.7283.397			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404JH	11179157	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000167093600025
J	Andrews, MR; Mitra, PP; deCarvalho, R				Andrews, MR; Mitra, PP; deCarvalho, R			Tripling the capacity of wireless communications using electromagnetic polarization	NATURE			English	Article								Wireless communications are a fundamental part of modern information infrastructure. But wireless bandwidth is costly(1), prompting a close examination of the data channels available using electromagnetic waves. Classically, radio communications have relied on one channel per frequency, although it is well understood that the two polarization states of planar waves(2) allow two distinct information channels; techniques such as 'polarization diversity' already take advantage of this(3). Recent work(4-7) has shown that environments with scattering, such as urban areas or indoors, also possess independent spatial channels that can be used to enhance capacity greatly. In either case, the relevant signal processing techniques come under the heading of 'multiple-input/multiple-output' communications, because multiple antennae are required to access the polarization or spatial channels. Here we show that, in a scattering environment, an extra factor of three in channel capacity can be obtained, relative to the conventional limit using dual-polarized radio signals. The extra capacity arises because there are six distinguishable electric and magnetic states of polarization at a given point, rather than two as is usually assumed.	Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA; Harvard Univ, Cambridge, MA 02138 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Harvard University	Andrews, MR (corresponding author), Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA.	mikea@bell-labs.com		Mitra, Partha/0000-0001-8818-6804				Afraimovich EL, 1999, RADIO SCI, V34, P1217, DOI 10.1029/1999RS900042; ANDRES EL, 2000, NY TIMES        0818; DECARVALHO R, 2000, NAT RAD SCI M 84 INT; Foschini G. J., 1998, Wireless Personal Communications, V6, P311, DOI 10.1023/A:1008889222784; HATKE GF, 1993, 27 AS C, P1365; Jackson J., 1975, CLASSICAL ELECTRODYN; KRAUS JD, 1988, ANTENNAS, P725; LEE WCY, 1967, IEEE T, V1, P25; MORGAN MG, 1951, P IRE, V39, P552, DOI 10.1109/JRPROC.1951.233139; Moustakas AL, 2000, SCIENCE, V287, P287, DOI 10.1126/science.287.5451.287; SINGER A, 1998, WIRELESS REV, V15, P164; Telatar E, 1999, EUR T TELECOMMUN, V10, P585, DOI 10.1002/ett.4460100604; WINTERS JH, 1987, IEEE J SEL AREA COMM, V5, P871, DOI 10.1109/JSAC.1987.1146600	13	308	360	7	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2001	409	6818					316	318		10.1038/35053015	http://dx.doi.org/10.1038/35053015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201734				2022-12-28	WOS:000166434300039
J	Curie, C; Panaviene, Z; Loulergue, C; Dellaporta, SL; Briat, JF; Walker, EL				Curie, C; Panaviene, Z; Loulergue, C; Dellaporta, SL; Briat, JF; Walker, EL			Maize yellow stripe1 encodes a membrane protein directly involved in Fe(III) uptake	NATURE			English	Article							IRON-DEFICIENCY; CHELATE REDUCTASE; PLANTS; PHYTOSIDEROPHORE; NICOTIANAMINE; TRANSPORT; YEAST; FE; EXPRESSION; KINETICS	Frequently, crop plants do not take up adequate amounts of iron from the soil, leading to chlorosis, poor yield and decreased nutritional quality. Extremely limited soil bioavailability of iron has led plants to evolve two distinct uptake strategies: chelation, which is used by the world's principal grain crops(1,2); and reduction, which is used by other plant groups(3-5). The chelation strategy involves extrusion of low-molecular-mass secondary amino acids (mugineic acids) known as 'phytosiderophores', which chelate sparingly soluble iron(6). The Fe(III)-phytosiderophore complex is then taken up by an unknown transporter at the root surface(7,8). The maize yellow stripe1 (ys1) mutant is deficient in Fe(III)-phytosiderophore uptake(7-10), therefore YS1 has been suggested to be the Fe(III)-phytosiderophore transporter. Here we show that ys1 is a membrane protein that mediates iron uptake. Expression of YS1 in a yeast iron uptake mutant restores growth specifically on Fe(III)-phytosiderophore media. Under iron-deficient conditions, ys1 messenger RNA levels increase in both roots and shoots. Cloning of ys1 is an important step in understanding iron uptake in grasses, and has implications for mechanisms controlling iron homeostasis in all plants.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; Univ Montpellier 2, Inst Natl Rech Agron, CNRS, UMR 5004, F-34060 Montpellier 1, France; Ecole Natl Super Agron Montpellier, F-34060 Montpellier 1, France; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	University of Massachusetts System; University of Massachusetts Amherst; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; Institut Agro; Montpellier SupAgro; Yale University	Walker, EL (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.		Walker, Elsbeth L./AAO-4166-2020	Walker, Elsbeth L./0000-0003-4237-9920	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038148] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038148-19, R01 GM038148] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagnaresi P, 1999, BIOCHEM J, V338, P499, DOI 10.1042/0264-6021:3380499; Briat JF, 1997, TRENDS PLANT SCI, V2, P187, DOI 10.1016/S1360-1385(97)85225-9; DELLAPORTA SL, 1993, MAIZE HDB, P219; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOPKINS BG, 1992, J PLANT NUTR, V15, P1599, DOI 10.1080/01904169209364425; JOLLEY V, 1991, J PLANT NUTR, V14, P45, DOI 10.1080/01904169109364182; Loulergue C, 1998, GENE, V225, P47, DOI 10.1016/S0378-1119(98)00531-9; MINET M, 1992, PLANT J, V2, P417; Mori S, 1999, CURR OPIN PLANT BIOL, V2, P250, DOI 10.1016/S1369-5266(99)80043-0; MORI S, 1991, PLANT SOIL, V130, P143, DOI 10.1007/BF00011869; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Robinson NJ, 1999, NATURE, V397, P694, DOI 10.1038/17800; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STEPHAN UW, 1994, PLANT SOIL, V165, P181, DOI 10.1007/BF00008060; Stephan UW, 1996, BIOMETALS, V9, P84, DOI 10.1007/BF00188095; Tagaki S., 1984, J PLANT NUTR, V7, P469, DOI 10.1080/01904168409363213; Thoiron S, 1997, PLANT CELL ENVIRON, V20, P1051, DOI 10.1111/j.1365-3040.1997.tb00681.x; von Wiren N, 1998, BBA-BIOMEMBRANES, V1371, P143, DOI 10.1016/S0005-2736(98)00022-4; von Wiren N, 1999, PLANT PHYSIOL, V119, P1107, DOI 10.1104/pp.119.3.1107; VONWIREN N, 1994, PLANT PHYSIOL, V106, P71, DOI 10.1104/pp.106.1.71; VONWIREN N, 1995, PHYSIOL PLANTARUM, V93, P611, DOI 10.1111/j.1399-3054.1995.tb05107.x; Yi Y, 1996, PLANT J, V10, P835, DOI 10.1046/j.1365-313X.1996.10050835.x	23	668	735	6	131	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					346	349		10.1038/35053080	http://dx.doi.org/10.1038/35053080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201743				2022-12-28	WOS:000166434300048
J	Tung, BY; Emond, MJ; Haggitt, RC; Bronner, MP; Kimmey, MB; Kowdley, KV; Brentnall, TA				Tung, BY; Emond, MJ; Haggitt, RC; Bronner, MP; Kimmey, MB; Kowdley, KV; Brentnall, TA			Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis	ANNALS OF INTERNAL MEDICINE			English	Article							PROTEIN-KINASE-C; FECAL BILE-ACIDS; INFLAMMATORY BOWEL-DISEASE; II PHOSPHOLIPASE A(2); COLORECTAL-CANCER; URSODEOXYCHOLIC ACID; REDUCED RISK; ASPIRIN USE; F344 RATS; CARCINOGENESIS	Background: Patients with ulcerative colitis and primary sclerosing cholangitis are at high risk for colonic dysplasia and cancer. This risk approaches 50% after 25 years of colitis. Ursodiol has been shown to protect against development of colorectal neoplasia in animal models. Objective: To assess the relationship between ursodiol use and colonic dysplasia, the precursor to colon cancer, in patients with ulcerative colitis and primary sclerosing cholangitis. Design: Cross-sectional study. Setting: University medical center. Patients: 59 patients with ulcerative colitis and primary sclerosing cholangitis who were undergoing colonoscopic surveillance for colonic dysplasia. Measurements: Use of ursodiol was assessed in all patients. The presence or absence of colonic dysplasia was evaluated by colonoscopic surveillance. Other variables assessed were age at onset and duration of ulcerative colitis; duration of primary sclerosing cholangitis; Child-Pugh classification; and use of sulfasalazine, other 5-aminosalicylic acid preparations, prednisone, cyclosporine, azathioprine, and methotrexate. Results: Ursodiol use was strongly associated with decreased prevalence of colonic dysplasia (odds ratio, 0.18 [95% CI, 0.05 to 0.61]; P = 0.005). The association between dysplasia and ursodiol use remained after adjustment for sex, age at onset of colitis, duration of colitis, duration of sclerosing cholangitis, severity of liver disease, and sulfasalazine use (adjusted odds ratio, 0.14 [Cl, 0.03 to 0.64]; P = 0.01). Younger age at onset of colitis was associated with an increased risk for dysplasia. Conclusions: Ursodiol use appears to be associated with a lower frequency of colonic dysplasia in patients with ulcerative colitis and primary sclerosing cholangitis. A randomized trial investigating the chemoprotective effect of ursodiol in patients with ulcerative colitis may be warranted.	Univ Washington, Div Gastroenterol, Sch Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Brentnall, TA (corresponding author), Univ Washington, Div Gastroenterol, Sch Med, 1959 NE Pacific St,Box 356424, Seattle, WA 98195 USA.	teribr@u.washingon.edu	Kowdley, Kris/AAF-5202-2019		NATIONAL CANCER INSTITUTE [P01CA074184, R01CA068124] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA68124, P01CA74184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batta AK, 1998, CANCER RES, V58, P1684; BAYERDORFFER E, 1993, GASTROENTEROLOGY, V104, P145, DOI 10.1016/0016-5085(93)90846-5; Brentnall TA, 1996, GASTROENTEROLOGY, V110, P331, DOI 10.1053/gast.1996.v110.pm8566577; BROOME U, 1994, GUT, V35, P84, DOI 10.1136/gut.35.1.84; BROOME U, 1995, HEPATOLOGY, V22, P1404, DOI 10.1016/0270-9139(95)90144-2; COHEN BI, 1980, J NATL CANCER I, V64, P573; EARNEST DL, 1994, CANCER RES, V54, P5071; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; FAUSA O, 1991, SEMIN LIVER DIS, V11, P31, DOI 10.1055/s-2008-1040420; GALLOWAY DJ, 1986, BRIT J SURG, V73, P233, DOI 10.1002/bjs.1800730327; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GUILLEM JG, 1987, ARCH SURG-CHICAGO, V122, P1475; GURBUZ AK, 1995, DIS COLON RECTUM, V38, P37, DOI 10.1007/BF02053855; HENDRICKSE CW, 1995, BRIT J SURG, V82, P475, DOI 10.1002/bjs.1800820415; HILL MJ, 1987, LANCET, V2, P185; Ikegami T, 1998, CANCER LETT, V134, P129, DOI 10.1016/S0304-3835(98)00248-1; KOPP R, 1991, CANCER RES, V51, P205; Kornfeld K, 1997, GUT, V41, P522, DOI 10.1136/gut.41.4.522; KUSUNOKI M, 1992, CANCER, V69, P24, DOI 10.1002/1097-0142(19920101)69:1<24::AID-CNCR2820690107>3.0.CO;2-1; Lindor KD, 1997, NEW ENGL J MED, V336, P691, DOI 10.1056/NEJM199703063361003; Loftus EV, 1996, GASTROENTEROLOGY, V110, P432, DOI 10.1053/gast.1996.v110.pm8566590; Martinez JD, 1998, NUTR CANCER, V31, P111, DOI 10.1080/01635589809514689; MCSHERRY CK, 1989, CANCER RES, V49, P6039; MINAMI T, 1994, GUT, V35, P1593, DOI 10.1136/gut.35.11.1593; Mitsuyoshi H, 1999, BIOCHEM BIOPH RES CO, V263, P537, DOI 10.1006/bbrc.1999.1403; Moody GA, 1996, EUR J GASTROEN HEPAT, V8, P1179, DOI 10.1097/00042737-199612000-00009; Narisawa T, 1998, JPN J CANCER RES, V89, P1009, DOI 10.1111/j.1349-7006.1998.tb00489.x; Ochsenkuhn T, 1999, CANCER, V85, P1664, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1664::AID-CNCR4>3.0.CO;2-O; OLSSON R, 1991, GASTROENTEROLOGY, V100, P1319; PINCZOWSKI D, 1994, GASTROENTEROLOGY, V107, P117, DOI 10.1016/0016-5085(94)90068-X; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; REDDY BS, 1977, CANCER-AM CANCER SOC, V39, P2533, DOI 10.1002/1097-0142(197706)39:6<2533::AID-CNCR2820390634>3.0.CO;2-X; REDDY BS, 1981, CANCER RES, V41, P3700; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; RODRIGUES CMP, 1995, GASTROENTEROLOGY, V109, P1835, DOI 10.1016/0016-5085(95)90750-5; Rosenberg L, 1998, CANCER-AM CANCER SOC, V82, P2326, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q; SAKANOUE Y, 1992, SCAND J GASTROENTERO, V27, P275, DOI 10.3109/00365529209000074; Seraj MJ, 1997, CANCER LETT, V115, P97, DOI 10.1016/S0304-3835(97)04719-8; Shetty K, 1999, AM J GASTROENTEROL, V94, P1643; STADLER J, 1988, CANCER LETT, V38, P315, DOI 10.1016/0304-3835(88)90023-7; SUGITA A, 1991, GUT, V32, P167, DOI 10.1136/gut.32.2.167; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; WALI RK, 1995, CANCER RES, V55, P5257; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404	44	326	333	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2001	134	2					89	95		10.7326/0003-4819-134-2-200101160-00008	http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391KW	11177311				2022-12-28	WOS:000166356000001
J	Mindell, JA; Maduke, M; Miller, C; Grigorieff, N				Mindell, JA; Maduke, M; Miller, C; Grigorieff, N			Projection structure of a CIC-type chloride channel at 6.5 angstrom resolution	NATURE			English	Article							TORPEDO ELECTROPLAX; PURPLE MEMBRANE; RECONSTITUTION; EXPRESSION; PORES	Virtually all cells in all eukaryotic organisms express ion channels of the ClC type, the only known molecular family of chloride-ion-selective channels. The diversity of ClC channels highlights the multitude and range of functions served by gated chloride-ion conduction in biological membranes, such as controlling electrical excitability in skeletal muscle, maintaining systemic blood pressure, acidifying endosomal compartments, and regulating electrical responses of GABA (gamma -aminobutyric acid)-containing interneurons in the central nervous system(1). Previously, we expressed and purified a prokaryotic ClC channel homologue(2). Here we report the formation of two-dimensional crystals of this ClC channel protein reconstituted into phospholipid bilayer membranes. Cryo-electron microscopic analysis of these crystals yields a projection structure at 6.5 Angstrom resolution, which shows off-axis water-filled pores within the dimeric channel complex.	Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; Brandeis Univ, WM Keck Inst Cellular Visualizat, Waltham, MA 02454 USA	Brandeis University; Howard Hughes Medical Institute; Brandeis University; Brandeis University	Mindell, JA (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA.		; Mindell, Joseph/P-4461-2017	Maduke, Merritt/0000-0001-7787-306X; Grigorieff, Nikolaus/0000-0002-1506-909X; Mindell, Joseph/0000-0002-6952-8247				Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; GRIGORIEFF N, 1995, J MOL BIOL, V254, P404, DOI 10.1006/jmbi.1995.0627; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Ludewig U, 1997, BIOPHYS J, V73, P789, DOI 10.1016/S0006-3495(97)78111-6; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Maduke M, 2000, ANNU REV BIOPH BIOM, V29, P411, DOI 10.1146/annurev.biophys.29.1.411; Maduke M, 1999, J GEN PHYSIOL, V114, P713, DOI 10.1085/jgp.114.5.713; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445	16	99	103	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2001	409	6817					219	223		10.1038/35051631	http://dx.doi.org/10.1038/35051631			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196649				2022-12-28	WOS:000166316200051
J	Hardy, J				Hardy, J			Consent for trials in palliative care	LANCET			English	Article									Royal Marsden Hosp, Dept Plliat Med, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust	Hardy, J (corresponding author), Royal Marsden Hosp, Dept Plliat Med, Downs Rd, Sutton SM2 5PT, Surrey, England.		Hardy, Janet/F-2501-2012	Hardy, Janet/0000-0003-1127-9951					0	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S44	S44		10.1016/S0140-6736(00)92030-0	http://dx.doi.org/10.1016/S0140-6736(00)92030-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191502				2022-12-28	WOS:000166074900046
J	Jacobs, C				Jacobs, C			The pharmaceutical industry - To whom is it accountable?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Hop La Pitie Salpetriere, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Jacobs, C (corresponding author), Hop La Pitie Salpetriere, F-75013 Paris, France.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1416	1417						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183878				2022-12-28	WOS:000165152800020
J	Schwarting, JS				Schwarting, JS			The pharmaceutical industry - To whom is it accountable?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Abilene Family Phys, Abilene, KS 67410 USA		Schwarting, JS (corresponding author), Abilene Family Phys, Abilene, KS 67410 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1416	1416						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183879				2022-12-28	WOS:000165152800015
J	Shen, XF; Siliciano, RF				Shen, XF; Siliciano, RF			AIDS - Preventing AIDS but not HIV-1 infection with a DNA vaccine	SCIENCE			English	Editorial Material							CYTOTOXIC-T-CELL; TYPE-1 INFECTION; LYMPHOCYTES; RESPONSES; VIREMIA; LOAD		Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Shen, XF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.							Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; *JOINT UN PROGR AI, 2000, REP GLOB HIV AIDS EP; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857	11	12	12	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 20	2000	290	5491					463	+		10.1126/science.290.5491.463	http://dx.doi.org/10.1126/science.290.5491.463			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	365HN	11183769				2022-12-28	WOS:000089946000034
J	Johnson, AP; Warner, M; Broughton, K; James, D; Efsratiou, A; George, RC; Livermore, DM				Johnson, AP; Warner, M; Broughton, K; James, D; Efsratiou, A; George, RC; Livermore, DM			Antibiotic susceptibility of streptococci and related genera causing endocarditis: analysis of UK reference laboratory referrals, January 1996 to March 2000	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFECTIVE ENDOCARDITIS; ENTEROCOCCI		Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England; Cent Publ Hlth Lab, Streptococcus & Diphtheria Reference Unit, Resp & Systemat Infect Lab, London NW9 5HT, England	Public Health England; Public Health England	Johnson, AP (corresponding author), Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England.	Ajohnson@phls.nhs.uk	Johnson, Alan P/F-4420-2014					COX RA, 1991, J ANTIMICROB CHEMOTH, V27, P1, DOI 10.1093/jac/27.1.1; Dyson C, 1999, J INFECTION, V38, P87, DOI 10.1016/S0163-4453(99)90074-9; Johnson AP, 1998, BMJ-BRIT MED J, V317, P629, DOI 10.1136/bmj.317.7159.629; Simmons NA, 1998, HEART, V79, P207; WILSON WR, 1995, JAMA-J AM MED ASSOC, V274, P1706, DOI 10.1001/jama.274.21.1706	5	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	2001	322	7283					395	396		10.1136/bmj.322.7283.395	http://dx.doi.org/10.1136/bmj.322.7283.395			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404JH	11179156	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000167093600024
J	Klein, I; Ojamaa, K				Klein, I; Ojamaa, K			Mechanisms of disease: Thyroid hormone and the cardiovascular system.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BETA-ADRENERGIC RESPONSIVENESS; CONGESTIVE-HEART-FAILURE; PLACEBO-CONTROLLED TRIAL; ATRIAL-FIBRILLATION; DOUBLE-BLIND; L-THYROXINE; INTRAVENOUS TRIIODOTHYRONINE; SUBCLINICAL HYPOTHYROIDISM; CARDIOPULMONARY BYPASS; DILATED CARDIOMYOPATHY		N Shore Univ Hosp, Dept Med, Div Endocrinol, Manhasset, NY 11030 USA; NYU, Sch Med, Dept Med, New York, NY USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Northwell Health; North Shore University Hospital; New York University; New York University	Klein, I (corresponding author), N Shore Univ Hosp, Dept Med, Div Endocrinol, 300 Community Dr, Manhasset, NY 11030 USA.							AMICO JA, 1984, ARCH INTERN MED, V144, P487, DOI 10.1001/archinte.144.3.487; Bartalena L, 1996, J CLIN ENDOCR METAB, V81, P2930, DOI 10.1210/jc.81.8.2930; Bengel FM, 2000, J CLIN ENDOCR METAB, V85, P1822, DOI 10.1210/jc.85.5.1822; BennettGuerrero E, 1996, JAMA-J AM MED ASSOC, V275, P687, DOI 10.1001/jama.275.9.687; Bettendorf M, 1997, PEDIATR RES, V41, P375, DOI 10.1203/00006450-199703000-00012; Bettendorf M, 2000, LANCET, V356, P529, DOI 10.1016/S0140-6736(00)02576-9; Biondi B, 1999, J CLIN ENDOCR METAB, V84, P2064, DOI 10.1210/jc.84.6.2064; BIONDI B, 1994, J CLIN ENDOCR METAB, V78, P1028, DOI 10.1210/jc.78.5.1028; BRENT GA, 1994, NEW ENGL J MED, V331, P847; Cacciatori V, 1996, J CLIN ENDOCR METAB, V81, P2828, DOI 10.1210/jc.81.8.2828; Chowdhury D, 1999, AM J CARDIOL, V84, P1107, DOI 10.1016/S0002-9149(99)00513-5; Cimochowski GE, 1997, J THORAC CARDIOV SUR, V113, P655, DOI 10.1016/S0022-5223(97)70222-8; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; CROWLEY WF, 1997, NEW ENGL J MED, V296, P1; DAVIS PJ, 1993, ANN THORAC SURG, V56, pS16, DOI 10.1016/0003-4975(93)90550-2; De Groot LJ, 1999, J CLIN ENDOCR METAB, V84, P151, DOI 10.1210/jc.84.1.151; DILLMANN WH, 1990, AM J MED, V88, P626, DOI 10.1016/0002-9343(90)90530-Q; Everts ME, 1996, ENDOCRINOLOGY, V137, P4235, DOI 10.1210/en.137.10.4235; FELDMAN T, 1986, J AM COLL CARDIOL, V7, P967, DOI 10.1016/S0735-1097(86)80213-3; FORFAR JC, 1985, Q J MED, V57, P857; FORFAR JC, 1979, AM J CARDIOL, V44, P9, DOI 10.1016/0002-9149(79)90243-1; FORFAR JC, 1982, NEW ENGL J MED, V307, P1165, DOI 10.1056/NEJM198211043071901; Franklyn JA, 1998, NEW ENGL J MED, V338, P712, DOI 10.1056/NEJM199803123381103; FRANKLYN JA, 1984, CLIN SCI, V67, P585, DOI 10.1042/cs0670585; FREDLUND BO, 1983, ACTA MED SCAND, V213, P231; GICK GG, 1990, J MEMBRANE BIOL, V115, P273, DOI 10.1007/BF01868642; Gilligan DM, 1996, AM J MED, V101, P413, DOI 10.1016/S0002-9343(96)00194-5; GRAETTINGER JS, 1959, J CLIN INVEST, V38, P1316, DOI 10.1172/JCI103906; Graves RJ, 1835, LOND MED SURG J, V7, P517; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; Hamilton MA, 1998, AM J CARDIOL, V81, P443, DOI 10.1016/S0002-9149(97)00950-8; HAMILTON MA, 1990, J AM COLL CARDIOL, V16, P91, DOI 10.1016/0735-1097(90)90462-X; Harjai KJ, 1997, ANN INTERN MED, V126, P63, DOI 10.7326/0003-4819-126-1-199701010-00009; Hoit BD, 1997, CIRCULATION, V96, P592, DOI 10.1161/01.cir.96.2.592; HOLLAND FW, 1991, ANN THORAC SURG, V52, P46, DOI 10.1016/0003-4975(91)91416-S; Katzeff HL, 1997, AM J PHYSIOL-ENDOC M, V273, pE951, DOI 10.1152/ajpendo.1997.273.5.E951; KEATING FR, 1961, PROG CARDIOVASC DIS, V3, P364, DOI 10.1016/S0033-0620(61)90004-4; Kiss E, 1998, CIRC RES, V83, P608, DOI 10.1161/01.RES.83.6.608; KISS E, 1994, CIRC RES, V75, P245, DOI 10.1161/01.RES.75.2.245; Klein I, 1998, ENDOCRIN METAB CLIN, V27, P51, DOI 10.1016/S0889-8529(05)70297-8; KLEIN I, 1994, ANN INTERN MED, V121, P281, DOI 10.7326/0003-4819-121-4-199408150-00010; KLEIN I, 1990, AM J MED, V88, P631, DOI 10.1016/0002-9343(90)90531-H; Klein I, 1998, AM J CARDIOL, V81, P490; KLEIN I, 2000, WERNER INGBARS THYRO, P596; Klein IL, 2000, WERNER INGBARS THYRO, P777; Klemperer JD, 1996, ANN THORAC SURG, V61, P1323, DOI 10.1016/0003-4975(96)00102-6; KLEMPERER JD, 1995, NEW ENGL J MED, V333, P1522, DOI 10.1056/NEJM199512073332302; Klemperer JD, 1996, PROG CARDIOVASC DIS, V38, P329, DOI 10.1016/S0033-0620(96)80017-X; KONTOS HA, 1965, J CLIN INVEST, V44, P947, DOI 10.1172/JCI105212; Krahn AD, 1996, ARCH INTERN MED, V156, P2221, DOI 10.1001/archinte.156.19.2221; LADENSON PW, 1992, P NATL ACAD SCI USA, V89, P8856; LEVEY GS, 1990, AM J MED, V88, P642, DOI 10.1016/0002-9343(90)90533-J; MAGNER J, 1988, W J MED, V110, P759; MAINWARING RD, 1994, J CARDIAC SURG, V9, P322, DOI 10.1111/j.1540-8191.1994.tb00851.x; Mainwaring RD, 2000, CIRCULATION, V101, P1423, DOI 10.1161/01.CIR.101.12.1423; Mercuro G, 2000, J CLIN ENDOCR METAB, V85, P159, DOI 10.1210/jc.85.1.159; MINTZ G, 1991, J CLIN ENDOCR METAB, V73, P146, DOI 10.1210/jcem-73-1-146; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; Moruzzi P, 1996, AM J MED, V101, P461, DOI 10.1016/S0002-9343(96)00281-1; Mullis-Jansson SL, 1999, J THORAC CARDIOV SUR, V117, P1128, DOI 10.1016/S0022-5223(99)70249-7; NAKAZAWA HK, 1982, AM J MED, V72, P903, DOI 10.1016/0002-9343(82)90850-6; NORDYKE RA, 1988, ARCH INTERN MED, V148, P626, DOI 10.1001/archinte.148.3.626; Novitzky D, 1996, CARDIOLOGY, V87, P509, DOI 10.1159/000177147; Ojamaa K, 2000, METABOLISM, V49, P275, DOI 10.1016/S0026-0495(00)92262-5; Ojamaa K, 1996, THYROID, V6, P505, DOI 10.1089/thy.1996.6.505; Ojamaa K, 2000, ENDOCRINOLOGY, V141, P2139, DOI 10.1210/en.141.6.2139; Ojamaa K, 1999, ENDOCRINOLOGY, V140, P3170, DOI 10.1210/en.140.7.3170; Ojamaa K, 1996, ENDOCRINOLOGY, V137, P802, DOI 10.1210/en.137.3.802; Padayatty S, 1998, J CLIN ENDOCR METAB, V83, P2607, DOI 10.1210/jc.83.7.2607; Park KW, 1997, ANESTH ANALG, V85, P734, DOI 10.1097/00000539-199710000-00005; PETERSEN P, 1988, STROKE, V19, P15, DOI 10.1161/01.STR.19.1.15; POLIKAR R, 1993, CIRCULATION, V87, P1435, DOI 10.1161/01.CIR.87.5.1435; Portman MA, 2000, J THORAC CARDIOV SUR, V120, P604, DOI 10.1067/mtc.2000.108900; RESNICK LM, 1982, LIFE SCI, V30, P585, DOI 10.1016/0024-3205(82)90273-9; Saatvedt K, 1996, SCAND J THORAC CARD, V30, P61, DOI 10.3109/14017439609107243; SANDLER G, 1959, Q J MED, V28, P347; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; THEILEN EO, 1967, J APPL PHYSIOL, V22, P207, DOI 10.1152/jappl.1967.22.2.207; VANDERPUMP MPJ, 2000, WERNER INGBARS THYRO, P467; WALKER JD, 1994, J THORAC CARDIOV SUR, V108, P672; Wiersinga WM, 1997, HANDB EXP PHARM, V128, P225; WIESHAMMER S, 1989, CAN J PHYSIOL PHARM, V67, P1007, DOI 10.1139/y89-158	82	1452	1550	3	139	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	2001	344	7					501	509		10.1056/NEJM200102153440707	http://dx.doi.org/10.1056/NEJM200102153440707			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401HL	11172193				2022-12-28	WOS:000166922100007
J	Lefkowitz, RJ; Willerson, JT				Lefkowitz, RJ; Willerson, JT			Prospects for cardiovascular research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ADRENERGIC-RECEPTOR KINASE; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; TRANSGENIC MICE; HEART-FAILURE; DILATED CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; BETA(2)-ADRENERGIC RECEPTOR; ATHEROSCLEROTIC PLAQUES	Cardiovascular disease is the greatest threat to human life and health. The past decade has seen remarkable progress in clinical and basic cardiovascular research, and many areas of opportunity are promising. The pace of current progress in clinical and basic research is such that remarkable improvement in the quality and length of life for those at risk for cardiovascular disease is likely.	Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Howard Hughes Med Inst, Chevy Chase, MD USA; Duke Univ, Dept Med, Durham, NC USA; Duke Univ, Dept Biochem, Durham, NC USA; Texas Heart Inst, Houston, TX 77025 USA	University of Texas System; Howard Hughes Medical Institute; Duke University; Duke University; Texas Heart Institute	Willerson, JT (corresponding author), Univ Texas, Sch Med, Dept Internal Med, 6431 Fannin,Suite 1-150, Houston, TX 77030 USA.		Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50179, HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1999, CIRCULATION, V100, P648, DOI 10.1161/01.CIR.100.6.648; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; Biasucci LM, 1999, CIRCULATION, V99, P2079, DOI 10.1161/01.CIR.99.16.2079; Bozkurt B, 1998, CIRCULATION, V97, P1382, DOI 10.1161/01.CIR.97.14.1382; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Bray MS, 2000, CIRCULATION, V101, P2877, DOI 10.1161/01.CIR.101.25.2877; BUJA LM, 1981, AM J CARDIOL, V47, P343, DOI 10.1016/0002-9149(81)90407-0; Carter AM, 1997, CIRCULATION, V96, P1424, DOI 10.1161/01.CIR.96.5.1424; Casscells W, 1996, LANCET, V347, P1447, DOI 10.1016/S0140-6736(96)91684-0; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Cho MC, 1999, J BIOL CHEM, V274, P22251, DOI 10.1074/jbc.274.32.22251; CONSTANT.P, 1966, J ATHEROSCLER RES, V6, P1, DOI 10.1016/S0368-1319(66)80056-X; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; DAVIES MJ, 1985, BRIT HEART J, V53, P363; Deswal A, 1999, CIRCULATION, V99, P3224, DOI 10.1161/01.CIR.99.25.3224; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; FALK E, 1983, BRIT HEART J, V50, P127; Fayad ZA, 2000, CIRCULATION, V102, P506; FOWLER MB, 1986, CIRCULATION, V74, P1290, DOI 10.1161/01.CIR.74.6.1290; Gao MH, 1999, CIRCULATION, V99, P1618, DOI 10.1161/01.CIR.99.12.1618; Gibbons GH, 1997, AM J CARDIOL, V79, P3, DOI 10.1016/S0002-9149(97)00122-7; Gimbrone MA, 1999, THROMB HAEMOSTASIS, V82, P722; Hendel RC, 2000, CIRCULATION, V101, P118, DOI 10.1161/01.CIR.101.2.118; Kersten JR, 1999, CARDIOVASC RES, V43, P44, DOI 10.1016/S0008-6363(99)00077-2; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Krushkal J, 1999, CIRCULATION, V99, P1407, DOI 10.1161/01.CIR.99.11.1407; KRUSKAL JB, 1987, NEW ENGL J MED, V317, P1361, DOI 10.1056/NEJM198711263172201; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Liggett SB, 2000, CIRCULATION, V101, P1707; Liggett SB, 1998, J CLIN INVEST, V102, P1534, DOI 10.1172/JCI4059; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Seta Y, 1996, J Card Fail, V2, P243, DOI 10.1016/S1071-9164(96)80047-9; Stefanadis C, 1999, CIRCULATION, V99, P1965, DOI 10.1161/01.CIR.99.15.1965; Sullivan GW, 2000, J LEUKOCYTE BIOL, V67, P591, DOI 10.1002/jlb.67.5.591; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; Vatner SF, 2000, CIRC RES, V86, P502, DOI 10.1161/01.RES.86.5.502; White DC, 2000, P NATL ACAD SCI USA, V97, P5428, DOI 10.1073/pnas.090091197; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; WILLERSON JT, 1986, J AM COLL CARDIOL, V8, P245, DOI 10.1016/S0735-1097(86)80121-8	50	79	85	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					581	587		10.1001/jama.285.5.581	http://dx.doi.org/10.1001/jama.285.5.581			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176863	Bronze			2022-12-28	WOS:000166714200016
J	Mentzer, WC; Kan, YW				Mentzer, WC; Kan, YW			Prospects for research in hematologic disorders - Sickle cell disease and thalassemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BETA-THALASSEMIA; DIAGNOSIS; ANEMIA; BLOOD; TRANSPLANTATION; OLIGONUCLEOTIDE; MANAGEMENT	Sickle cell anemia and thalassemia constitute the most common genetic diseases in the world. Affected patients carry a heavy burden of morbidity and early mortality. With improved understanding of the pathophysiology and molecular basis of these diseases, treatment is evolving from management of symptoms to more effective strategies that aim to modify diseased red blood cells or replace them with normal cells. Available treatment options include red blood cell transfusions, pharmacologic interventions to increase fetal hemoglobin levels, and stem cell transplantation. Improvements in these approaches or the development of means to replace defective genes with normal ones using techniques of gene transfer offer hope for the future.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Lab Med, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mentzer, WC (corresponding author), San Francisco Gen Hosp, Room 331,Bldg 100,1001 Potrero Ave, San Francisco, CA 94110 USA.							Arcasoy MO, 1999, SEMIN HEMATOL, V36, P328; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Cao A, 1996, SEMIN HEMATOL, V33, P66; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; Corash L, 1999, TRANSFUS MED REV, V13, P18, DOI 10.1016/S0887-7963(99)80085-6; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; Flake AW, 1999, BLOOD, V94, P2179, DOI 10.1182/blood.V94.7.2179.419k43_2179_2191; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hebbel RP, 2000, NEW ENGL J MED, V342, P1910, DOI 10.1056/NEJM200006223422512; Kren BT, 1999, P NATL ACAD SCI USA, V96, P10349, DOI 10.1073/pnas.96.18.10349; Loukopoulos D, 1996, SEMIN HEMATOL, V33, P76; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; Mentzer WC, 2000, CURR OPIN HEMATOL, V7, P95, DOI 10.1097/00062752-200003000-00004; Olivieri NF, 1999, NEW ENGL J MED, V341, P99, DOI 10.1056/NEJM199907083410207; Olivieri NF, 1996, SEMIN HEMATOL, V33, P24; Osarogiagbon UR, 2000, BLOOD, V96, P314, DOI 10.1182/blood.V96.1.314.013k39_314_320; Paszty C, 1997, Curr Opin Hematol, V4, P88; Persons DA, 2000, P NATL ACAD SCI USA, V97, P5022, DOI 10.1073/pnas.97.10.5022; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Steinberg MH, 1999, NEW ENGL J MED, V340, P1021, DOI 10.1056/NEJM199904013401307; Xu KP, 1999, JAMA-J AM MED ASSOC, V281, P1701, DOI 10.1001/jama.281.18.1701; Yoon K, 1996, P NATL ACAD SCI USA, V93, P2071, DOI 10.1073/pnas.93.5.2071	24	14	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					640	642		10.1001/jama.285.5.640	http://dx.doi.org/10.1001/jama.285.5.640			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176873	Bronze			2022-12-28	WOS:000166714200026
J	Steppan, CM; Bailey, ST; Bhat, S; Brown, EJ; Banerjee, RR; Wright, CM; Patel, HR; Ahima, RS; Lazar, MA				Steppan, CM; Bailey, ST; Bhat, S; Brown, EJ; Banerjee, RR; Wright, CM; Patel, HR; Ahima, RS; Lazar, MA			The hormone resistin links obesity to diabetes	NATURE			English	Article							PPAR-GAMMA; INSULIN-RESISTANCE; ADIPOSE-TISSUE; ADIPOCYTE DIFFERENTIATION; LEPTIN; MELLITUS; MICE; IDENTIFICATION; ADIPOGENESIS; ALPHA	Diabetes mellitus is a chronic disease that leads to complications including heart disease, stroke, kidney failure, blindness and nerve damage. Type 2 diabetes, characterized by target-tissue resistance to insulin, is epidemic in industrialized societies and is strongly associated with obesity; however, the mechanism by which increased adiposity causes insulin resistance is unclear. Here we show that adipocytes secrete a unique signalling molecule, which we have named resistin (for resistance to insulin). Circulating resistin levels are decreased by the anti-diabetic drug rosiglitazone, and increased in diet-induced and genetic forms of obesity. Administration of anti-resistin antibody improves blood sugar and insulin action in mice with diet-induced obesity. Moreover, treatment of normal mice with recombinant resistin impairs glucose tolerance and insulin action. Insulin-stimulated glucose uptake by adipocytes is enhanced by neutralization of resistin and is reduced by resistin treatment. Resistin is thus a hormone that potentially links obesity to diabetes.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.		Lazar, Mitchell A/AAF-3738-2019; Bailey, Shannon/B-8045-2014; Ahima, Rexford/W-1394-2019; Banerjee, Ronadip/U-6649-2019					Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; BODEN G, 1997, DIABETES, V46, P1; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Henry RR, 1997, ENDOCRIN METAB CLIN, V26, P553, DOI 10.1016/S0889-8529(05)70267-X; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Huang EY, 2000, GENE DEV, V14, P45; Kahn CR, 1996, ANNU REV MED, V47, P509; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Seed B, 1998, NAT MED, V4, P1004, DOI 10.1038/1990; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; SPEICHER DW, 1997, CURRENT PROTOCOLS PR; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STEPPAN CM, IN PRESS P NATL ACAD; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	35	3512	3936	11	510	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2001	409	6818					307	312		10.1038/35053000	http://dx.doi.org/10.1038/35053000			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201732				2022-12-28	WOS:000166434300037
J	Hales, CN				Hales, CN			Suicide of the nephron	LANCET			English	Article							INTRAUTERINE GROWTH-RETARDATION	There are various causes of renal disease. However, progressive renal disease is closely linked to the degree and duration of proteinuria. At first sight, this seems a perverse response in which a compromised organ unleashes a coordinated series of reactions that exacerbate the damage already done. Although the nephron has mechanisms whereby it can compensate for damage both by hypertrophy and hyperfunction after renal injury or ablation, these changes seem to provide only a temporary compensation. I and my colleagues found altered renal telomere shortening in the male rat linked to increased or decreased proteinuria and longevity, which suggests a mechanism whereby this compensatory process may be limited. I hypothesise that when the damaging or hypertrophic processes shorten renal telomeres to a critical length, the cells senesce with loss of function. I also suggest that the complex series of responses triggered in a protein-leaking nephron is normally a beneficial and limited process. It leads to the replacement by fibrosis of a malfunctioning unit in an otherwise healthy organ that has substantial spare capacity. The response only becomes life threatening when there is widespread nephron damage, the acceleration of which results in the ablation of all nephron function.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England	Addenbrooke's Hospital; University of Cambridge	Hales, CN (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Hills Rd, Cambridge CB2 2QR, England.	cnh1000@cam.ac.uk						BRENNER BM, 1985, AM J PHYSIOL, V249, pF324, DOI 10.1152/ajprenal.1985.249.3.F324; BURTON CJ, 1994, EXP NEPHROL, V2, P345; De Jong PE, 1999, LANCET, V354, P352, DOI 10.1016/S0140-6736(99)90122-8; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; HINCHLIFFE SA, 1992, BRIT J OBSTET GYNAEC, V99, P296, DOI 10.1111/j.1471-0528.1992.tb13726.x; INUI K, 1999, J AM SOC NEPHROL, V10, P548; IWASAKI K, 1988, J GERONTOL, V43, pB5, DOI 10.1093/geronj/43.1.B5; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Melk A, 2000, J AM SOC NEPHROL, V11, P444, DOI 10.1681/ASN.V113444; MERLETBENICHOU C, 1994, PEDIATR NEPHROL, V8, P175, DOI 10.1007/BF00865473; Oikawa S, 1999, FEBS LETT, V453, P365, DOI 10.1016/S0014-5793(99)00748-6; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Remuzzi G, 1999, CURR OPIN NEPHROL HY, V8, P655, DOI 10.1097/00041552-199911000-00001; RODRIGUEZLOPEZ AM, 1998, KIDNEY INT, V68, P536; Thomas ME, 1999, KIDNEY INT, V55, P890, DOI 10.1046/j.1523-1755.1999.055003890.x	17	20	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2001	357	9250					136	137		10.1016/S0140-6736(00)03553-4	http://dx.doi.org/10.1016/S0140-6736(00)03553-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197414				2022-12-28	WOS:000166476200033
J	Tognoni, G; Avanzini, F; Pangrazzi, J; Roncaglioni, MC; Bertele, V; de Gaetano, G; Caimi, V; Tombesi, M; Colombo, F; Barlera, S; Clerici, F; Palumbo, A; Sgaroni, G; Geraci, E; Del Favero, A; Decarli, A; Alli, C; Beghi, E; Coen, D; Volpi, A; Accattoli, P; Agneta, A; Alberino, S; Amoroso, U; Angeletti, M; Antiga, G; Ariutti, R; Armani, F; Bacci, G; Balzan, C; Banchi, G; Barba, G; Baron, P; Barone, A; Bartoli, M; Bartoli, PL; Barucca, G; Bedon, R; Bellini, M; Bencivenni, A; Benetti, R; Beretta, E; Bertini, L; Bertolissi, S; Berton, G; Besozzi, E; Bevilacqua, S; Bianchi, A; Bigotto, D; Bini, MI; Bizzarri, G; Boldini, L; Pioltelli, MB; Bossi, S; Bozzetto, RM; Brizzi, A; Bruno, B; Bussotti, A; Buzzatti, A; Cadioli, T; Caimi, V; Calciano, FP; Caldarini, L; Calienno, S; Caltaginone, P; Cancian, M; Cantamessa, GL; Caporali, N; Carli, M; Cascini, G; Casella, P; Casella, M; Caso, C; Cassanelli, M; Catalano, A; Cavallini, M; Cazzaniga, F; Cedaro, P; Celia, M; Cella, L; Chiara, P; Ciardullo, AV; Ciccone, G; Ciociano, C; Cipolla, A; Ciprietti, E; Cocco, L; Cocconi, F; Conio, S; Corasaniti, F; Cozzani, L; Cressotti, ML; Cuozzo, E; Cusmai, L; D'Errico, GB; D'Innocente, G; De Angelis, C; De Chirico, C; De Grandi, M; De Maria, E; De Matteis, C; De Matteis, D; Della Vedova, R; Di Giovambattista, E; Di Giuseppe, M; Di Santi, M; Dionette, MG; Egitto, A; Emma, V; Ermacora, T; Esposito, P; Falcoz, M; Civitillo, UF; Ferrara, FN; Ferrari, V; Ferreri, A; Ferroni, M; Filippo, S; Fortunato, S; Fossati, B; Frapporti, G; Frascati, A; Fucili, R; Fumagalli, MA; Gadducci, P; Galli, G; Galvani, O; Gamerini, V; Gangi, F; Gasparri, R; Gazzetta, F; Gentile, W; Germano, S; Germini, F; Ghionda, F; Giaretta, M; Giommoni, U; Giugliano, R; Giusta, F; Giusti, P; Grilli, P; Groppelli, G; Gualtieri, S; Guerrini, A; Guillaro, B; Ibello, L; Ingletti, MA; Klavora, MG; Lattuada, G; Lauri, D; Lenotti, M; Lepore, L; Licursi, G; Lombardi, P; Lombardo, M; Lorello, M; Lovisa, E; Luisetto, G; Luvisi, P; Maestri, P; Maggioni, R; Malavasi, P; Mao, M; Marcello, A; Marinacci, S; Marini, E; Marolla, M; Martini, C; Marulli, C; Masperi, M; Mastella, M; Mastrocola, M; Matteucci, A; Mazzu, M; Mellace, A; Mezzacapo, GM; Migaldi, D; Miluzio, A; Miradoli, R; Misiani, V; Monina, M; Montanari, U; Moretti, S; Morini, M; Moro, A; Moscardini, S; Moschitta, P; Mossa, V; Mureddu, G; Murgia, R; Mussini, AM; Nafra, G; Nasorri, R; Nati, G; Nicoletti, L; Nicoli, S; Nuccioni, S; Paci, C; Pagliani, S; Palatella, A; Palmieri, E; Panarese, G; Panigada, M; Panza, EG; Parma, E; Paroli, G; Patricelli, R; Perego, GB; Perrone, G; Perugini, I; Petracchini, V; Petrera, L; Petrucci, R; Piazza, G; Piccolo, F; Pignatti, M; Pignotti, DE; Pinto, D; Pirovano, E; Pirrotta, D; Pizzolon, F; Poggi, D; Prencipe, G; Quinterio, S; Rafanelli, P; Ragone, L; Ramunni, A; Ribetto, BM; Rinaldi, N; Riva, MG; Rocca, M; Rossitto, A; Sagnelli, C; Saitta, G; Salvi, S; Salvio, G; Sampaolo, G; Santangelo, A; Shianchi, P; Schirosa, G; Schirra, A; Scolarin, C; Serni, R; Serra, O; Seveso, MP; Silvestre, G; Simone, C; Simonetti, R; Sissa, F; Sizzano, E; Soave, P; Staffilano, N; Stranges, M; Suzzi, F; Suzzi, M; Tazza, AC; Telleschi, D; Titta, G; Tognolo, M; Tomasi, A; Tomba, A; Tombesi, M; Tonello, P; Tonon, R; Torella, M; Tornari, P; Uberti, M; Ursini, G; Varriale, A; Vece, R; Ventriglia, R; Venturini, O; Veramonti, I; Veronelli, G; Verrengia, L; Villa, A; Villa, F; Vincenti, G; Visca, MR; Visona, E; Vitali, F; Vitanza, A; Zappone, P; Zorzetti, G; Autoliatano, A; Artusa, M; Berto, I; Bajardi, P; Beretta, R; Costantini, C; Caldorola, P; Barile, N; Cavalera, C; Cristofari, M; D'Amico, S; Fiorenza, AM; Torri, A; Garavelli, G; Giardinieri, M; Nosotti, L; Guglielmi, M; Pietrofeso, R; Mattarei, M; Rossi, S; Pasotti, C; Capra, A; Ronchi, E; Palumbo, G; Stagni, B; Cappellari, G; Faronato, PP; Lagomanzini, P; Capuano, V; Castiglioni, G; Fantasia, R; Cosmi, F; De Vivo, L; De Caro, G; Pepe, G; Di Mauro, G; Gifuni, FE; Magliaro, A; Muzio, F; Piantadosi, FR; Scarlini, GF; D'Aguanno, G; Sodano, G; Vicari, L; Roncaglioni, MC; Avanzini, F; Colombo, F; Pangrazzi, J; Tognoni, G; Bertele, V; de Goetsme, G; Caimi, V; Tombesi, M				Tognoni, G; Avanzini, F; Pangrazzi, J; Roncaglioni, MC; Bertele, V; de Gaetano, G; Caimi, V; Tombesi, M; Colombo, F; Barlera, S; Clerici, F; Palumbo, A; Sgaroni, G; Geraci, E; Del Favero, A; Decarli, A; Alli, C; Beghi, E; Coen, D; Volpi, A; Accattoli, P; Agneta, A; Alberino, S; Amoroso, U; Angeletti, M; Antiga, G; Ariutti, R; Armani, F; Bacci, G; Balzan, C; Banchi, G; Barba, G; Baron, P; Barone, A; Bartoli, M; Bartoli, PL; Barucca, G; Bedon, R; Bellini, M; Bencivenni, A; Benetti, R; Beretta, E; Bertini, L; Bertolissi, S; Berton, G; Besozzi, E; Bevilacqua, S; Bianchi, A; Bigotto, D; Bini, MI; Bizzarri, G; Boldini, L; Pioltelli, MB; Bossi, S; Bozzetto, RM; Brizzi, A; Bruno, B; Bussotti, A; Buzzatti, A; Cadioli, T; Caimi, V; Calciano, FP; Caldarini, L; Calienno, S; Caltaginone, P; Cancian, M; Cantamessa, GL; Caporali, N; Carli, M; Cascini, G; Casella, P; Casella, M; Caso, C; Cassanelli, M; Catalano, A; Cavallini, M; Cazzaniga, F; Cedaro, P; Celia, M; Cella, L; Chiara, P; Ciardullo, AV; Ciccone, G; Ciociano, C; Cipolla, A; Ciprietti, E; Cocco, L; Cocconi, F; Conio, S; Corasaniti, F; Cozzani, L; Cressotti, ML; Cuozzo, E; Cusmai, L; D'Errico, GB; D'Innocente, G; De Angelis, C; De Chirico, C; De Grandi, M; De Maria, E; De Matteis, C; De Matteis, D; Della Vedova, R; Di Giovambattista, E; Di Giuseppe, M; Di Santi, M; Dionette, MG; Egitto, A; Emma, V; Ermacora, T; Esposito, P; Falcoz, M; Civitillo, UF; Ferrara, FN; Ferrari, V; Ferreri, A; Ferroni, M; Filippo, S; Fortunato, S; Fossati, B; Frapporti, G; Frascati, A; Fucili, R; Fumagalli, MA; Gadducci, P; Galli, G; Galvani, O; Gamerini, V; Gangi, F; Gasparri, R; Gazzetta, F; Gentile, W; Germano, S; Germini, F; Ghionda, F; Giaretta, M; Giommoni, U; Giugliano, R; Giusta, F; Giusti, P; Grilli, P; Groppelli, G; Gualtieri, S; Guerrini, A; Guillaro, B; Ibello, L; Ingletti, MA; Klavora, MG; Lattuada, G; Lauri, D; Lenotti, M; Lepore, L; Licursi, G; Lombardi, P; Lombardo, M; Lorello, M; Lovisa, E; Luisetto, G; Luvisi, P; Maestri, P; Maggioni, R; Malavasi, P; Mao, M; Marcello, A; Marinacci, S; Marini, E; Marolla, M; Martini, C; Marulli, C; Masperi, M; Mastella, M; Mastrocola, M; Matteucci, A; Mazzu, M; Mellace, A; Mezzacapo, GM; Migaldi, D; Miluzio, A; Miradoli, R; Misiani, V; Monina, M; Montanari, U; Moretti, S; Morini, M; Moro, A; Moscardini, S; Moschitta, P; Mossa, V; Mureddu, G; Murgia, R; Mussini, AM; Nafra, G; Nasorri, R; Nati, G; Nicoletti, L; Nicoli, S; Nuccioni, S; Paci, C; Pagliani, S; Palatella, A; Palmieri, E; Panarese, G; Panigada, M; Panza, EG; Parma, E; Paroli, G; Patricelli, R; Perego, GB; Perrone, G; Perugini, I; Petracchini, V; Petrera, L; Petrucci, R; Piazza, G; Piccolo, F; Pignatti, M; Pignotti, DE; Pinto, D; Pirovano, E; Pirrotta, D; Pizzolon, F; Poggi, D; Prencipe, G; Quinterio, S; Rafanelli, P; Ragone, L; Ramunni, A; Ribetto, BM; Rinaldi, N; Riva, MG; Rocca, M; Rossitto, A; Sagnelli, C; Saitta, G; Salvi, S; Salvio, G; Sampaolo, G; Santangelo, A; Shianchi, P; Schirosa, G; Schirra, A; Scolarin, C; Serni, R; Serra, O; Seveso, MP; Silvestre, G; Simone, C; Simonetti, R; Sissa, F; Sizzano, E; Soave, P; Staffilano, N; Stranges, M; Suzzi, F; Suzzi, M; Tazza, AC; Telleschi, D; Titta, G; Tognolo, M; Tomasi, A; Tomba, A; Tombesi, M; Tonello, P; Tonon, R; Torella, M; Tornari, P; Uberti, M; Ursini, G; Varriale, A; Vece, R; Ventriglia, R; Venturini, O; Veramonti, I; Veronelli, G; Verrengia, L; Villa, A; Villa, F; Vincenti, G; Visca, MR; Visona, E; Vitali, F; Vitanza, A; Zappone, P; Zorzetti, G; Autoliatano, A; Artusa, M; Berto, I; Bajardi, P; Beretta, R; Costantini, C; Caldorola, P; Barile, N; Cavalera, C; Cristofari, M; D'Amico, S; Fiorenza, AM; Torri, A; Garavelli, G; Giardinieri, M; Nosotti, L; Guglielmi, M; Pietrofeso, R; Mattarei, M; Rossi, S; Pasotti, C; Capra, A; Ronchi, E; Palumbo, G; Stagni, B; Cappellari, G; Faronato, PP; Lagomanzini, P; Capuano, V; Castiglioni, G; Fantasia, R; Cosmi, F; De Vivo, L; De Caro, G; Pepe, G; Di Mauro, G; Gifuni, FE; Magliaro, A; Muzio, F; Piantadosi, FR; Scarlini, GF; D'Aguanno, G; Sodano, G; Vicari, L; Roncaglioni, MC; Avanzini, F; Colombo, F; Pangrazzi, J; Tognoni, G; Bertele, V; de Goetsme, G; Caimi, V; Tombesi, M		Collaborative Grp Primary Preventi	Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice	LANCET			English	Article							CORONARY-HEART-DISEASE; CLINICAL-TRIALS; E CONSUMPTION; HYPERTENSION	Background In addition to the treatment of specific cardiovascular risk factors, intervention which interferes with the general mechanisms of atherosclerosis could further reduce the incidence of cardiovascular events. We aimed to investigate in general practice the efficacy of antiplatelets and antioxidants in primary prevention of cardiovascular events in people with one or more major cardiovascular risk factors. Methods We did a randomised controlled open 2x2 factorial trial to investigate low-dose aspirin (100 mg/day) and vitamin E (300 mg/day) in the prevention of cardiovascular events, in people with one or more of the following: hypertension, hypercholesterolaemia, diabetes, obesity, family history of premature myocardial infarction, or individuals who were elderly. Findings 4495 people (2583 female, mean age 64.4 years) were included in the trial. After a mean follow-up of 3.6 years the trial was prematurely stopped on ethical grounds when newly available evidence from other trials on the benefit of aspirin in primary prevention was strictly consistent with the results of the second planned interim analysis. Aspirin lowered the frequency of all the endpoints, being significant for cardiovascular death (from 1.4 to 0.8%; relative risk 0.56 [95% CI 0.31-0.99]) and total cardiovascular events (from 8.2 to 6.3%; 0.77 [0.62-0.95]). Severe bleedings were more frequent in the aspirin group than the no-aspirin group (1.1% vs 0.3%; p<0.0008). Vitamin E showed no effect on any prespecified endpoint. Analyses were by intention-to-treat. p<0.0008). Interpretation In women and men at risk of having a cardiovascular event because of the presence of at least one major risk factor, law-dose aspirin given in addition to treatment of specific risk factors contributes an additional preventive effect, with an acceptable safety profile. The results on vitamin E's cardiovascular primary preventive efficacy are not conclusive per se, although our results are consistent with the negative results of other large published trials on secondary prevention.	Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy; Ctr Studi & Ric Med Gen, Monza, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud	Roncaglioni, MC (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	roncaglioni@marionegri.it	Beghi, Ettore/AAA-7426-2020; Bertele, Vittorio/AAA-6461-2020; Decarli, Adriano/C-3129-2017; Groppelli, Gianluca/AAY-4050-2020; roncaglioni, maria carla/AAB-1875-2020; Decarli, Adriano/AAF-3314-2021; Ferreri, Andrés J. M./A-6662-2013	Beghi, Ettore/0000-0003-2542-0469; Bertele, Vittorio/0000-0002-0032-7033; Decarli, Adriano/0000-0003-1451-8292; roncaglioni, maria carla/0000-0002-2029-7847; Decarli, Adriano/0000-0003-1451-8292; Ferreri, Andrés J. M./0000-0001-9606-6124				ALLI C, 1992, J HUM HYPERTENS, V6, P281; Alli C, 1999, ARCH INTERN MED, V159, P1205, DOI 10.1001/archinte.159.11.1205; Avanzini F, 1997, LANCET, V350, P1633, DOI 10.1016/S0140-6736(05)64055-X; AVANZINI F, 1987, BRIT MED J, V294, P157, DOI 10.1136/bmj.294.6565.157; Brown M, 1999, LANCET, V354, P441, DOI 10.1016/S0140-6736(99)00253-6; CANDELISE L, 1994, CEREBROVASC DIS, V4, P341, DOI 10.1159/000108505; *COLL GROUP PRIM P, 1995, J CARDIOVASC RISK, V2, P137; Cornu C, 1999, LANCET, V353, P63, DOI 10.1016/S0140-6736(98)07611-9; COX DR, 1972, J R STAT SOC B, V34, P187; Fahey T, 1998, BRIT J GEN PRACT, V48, P1173; Garattini S, 1997, SCIENCE, V275, P287, DOI 10.1126/science.275.5298.287; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; GERACI E, 1992, J AM COLL CARDIOL, V20, P1302, DOI 10.1016/0735-1097(92)90393-2; *GISSI PREV, 1999, LANCET, V354, P1554; GREENBERG G, 1991, BMJ-BRIT MED J, V303, P940, DOI 10.1136/bmj.303.6808.940; Halliwell B, 2000, LANCET, V355, P1179, DOI 10.1016/S0140-6736(00)02075-4; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; MARUBINI E, 1995, ANAL SURVIVAL DATA C, P223; Meade TW, 1998, LANCET, V351, P233; Meade TW, 2000, BMJ-BRIT MED J, V321, P13, DOI 10.1136/bmj.321.7252.13; *MIN SOM, 1999, NORM RAZ SERV SAN NA, V132; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PRINGLE M, 1995, BRIT MED J, V311, P1382, DOI 10.1136/bmj.311.7017.1382; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rosser WW, 1999, LANCET, V353, P661, DOI 10.1016/S0140-6736(98)09103-X; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; TOGNONI G, 1991, BRIT MED J, V303, P969, DOI 10.1136/bmj.303.6808.969; TOGNONI G, 1990, STAT MED, V9, P17, DOI 10.1002/sim.4780090108; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Wood D, 1998, EUR HEART J, V19, P1434; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302	33	745	770	0	46	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 13	2001	357	9250					89	95						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393NH	11197445				2022-12-28	WOS:000166476200009
J	Attaran, A; Sachs, J				Attaran, A; Sachs, J			Defining and refining international donor support for combating the AIDS pandemic	LANCET			English	Article								The international aid effort against AIDS is greatly incommensurate with the severity of the epidemic. Drawing on the data that international aid donors self-reported to the Organization for Economic Cooperation and Development (OECD), we find that, between 1996 and 1998, finance from all rich countries to sub-Saharan Africa for projects designated as AIDS control averaged US$69 million annually, and, assuming a safe margin for under-reporting and misreporting, we estimate that total donor spending on HIV/AIDS control was perhaps twice that at most. Since the late 1980s, aid levels have dropped relative to the prevalence of HIV infection, and stood recently at about $3 per HIV-infected person. Lack of finance is now the primary constraint on progress against AIDS, notwithstanding the widespread belief that a lack of interest from the governments of poor countries is limiting. We argue that to produce a meaningful response to the pandemic, international assistance must be based on grants, not loans, for the poorest countries; be increased within the next 3 years to a minimum of $7.5 billion or more; be directed toward funding projects which are proposed and desired by the affected countries themselves, and which are judged as having epidemiological merit against the pandemic by a panel of independent scientific experts; and fund concurrent needs, including prevention, drug treatment (such as highly active antiretroviral therapy), and blocking mother-to-child HIV transmission. An effort of this scope and scale will both radically alter the prospects for intervention against AIDS in poor countries, and together with comparable efforts to control other infectious diseases, is easily afforded by the OECD donor economies, whose aggregate national income recently surpassed $21 trillion annually.	Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA	Harvard University	Attaran, A (corresponding author), Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA.							Ainsworth M, 2000, LANCET, V356, P55, DOI 10.1016/S0140-6736(00)02440-5; [Anonymous], INT ACT HIV AIDS AFR; DAYTON J, 1998, 389 WORLD BANK HIV A; GIBBONS A, 1990, SCIENCE, V248, P1306, DOI 10.1126/science.2356466; Hart CE, 1999, J INFECT DIS, V179, P871, DOI 10.1086/314656; *LOND SCH HYG TROP, 1999, MAL CONS 1999 LOND; Marseille E, 1999, LANCET, V354, P803, DOI 10.1016/S0140-6736(99)80009-9; Thaineua Vallop, 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P429; The Panos Institute, 1989, AIDS 3 WORLD; *UNAIDS, 1999, LEV FLOW NAT INT RES; *UNAIDS, 2000, REP GLOB HIV AIDS EP; UNICEF, 2000, PROGR NAT 2000; *US CENTR INT AG, 1999, GLOB INF DIS THREAT; Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006; *WHO, 2000, WHO WORLD HLTH REP	15	82	84	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					57	61		10.1016/S0140-6736(00)03576-5	http://dx.doi.org/10.1016/S0140-6736(00)03576-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197373				2022-12-28	WOS:000166341500035
J	Reid, IR				Reid, IR			Calcium supplements and nail quality.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ Auckland, Auckland 1, New Zealand	University of Auckland	Reid, IR (corresponding author), Univ Auckland, Auckland 1, New Zealand.							FORSLIND B, 1976, J INVEST DERMATOL, V67, P273, DOI 10.1111/1523-1747.ep12513463; VELLAR OD, 1970, AM J CLIN NUTR, V23, P1272	2	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2000	343	24					1817	1817		10.1056/NEJM200012143432419	http://dx.doi.org/10.1056/NEJM200012143432419			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	382FH	11185608				2022-12-28	WOS:000165812000028
J	Bayer, R; Fairchild, AL				Bayer, R; Fairchild, AL			Public health - Surveillance and privacy	SCIENCE			English	Article									Columbia Univ, Mailman Sch Publ Hlth, Div Sociomed Sci, Program Hist Publ Hlth & Med, New York, NY 10032 USA	Columbia University	Fairchild, AL (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Div Sociomed Sci, Program Hist Publ Hlth & Med, New York, NY 10032 USA.		Fairchild, Amy/F-1811-2018	Fairchild, Amy/0000-0002-1292-7212				[Anonymous], SURVEILLANCE HLTH DI; BRANDT A, 1987, NO MAGIC BULLET; *CDC, 1999, GUID NAT HUM IMM VIR, P1; Fox D M, 1975, Bull Hist Med, V49, P169; HAMMERS F, 1998, EUROSURVEILLANCE, V3, P51; *I MED, 2000, END NEGL EL TUB US; Leigh JP, 1997, ARCH INTERN MED, V157, P1557, DOI 10.1001/archinte.157.14.1557; LYNBERG MC, 1992, PUBLIC HEALTH SURVEILLANCE, P157; MUIR CS, 1985, IARC SCI PUBL, V66, P21; *NAT VACC ADV COMM, 1999, DEV COMM STAT BAS IM; SNOW W, 1917, P 2 PAN AM SCI C 1 1, V9, P491	11	14	18	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2000	290	5498					1898	1899		10.1126/science.290.5498.1898	http://dx.doi.org/10.1126/science.290.5498.1898			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382EL	11187045				2022-12-28	WOS:000165810000027
J	Allayee, H; Laffitte, BA; Lusis, AJ				Allayee, H; Laffitte, BA; Lusis, AJ			Biochemistry - An absorbing study of cholesterol	SCIENCE			English	Editorial Material							CELLULAR CHOLESTEROL; DIETARY-CHOLESTEROL; ABSORPTION; EFFLUX		Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Allayee, H (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA.	hallayee@ucla.edu; jlusis@mednet.ucla.edu						Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BHATTACHAYYA AK, 1973, J CLIN INVEST, V53, P1033; Bjorkhem I., 1995, METABOLIC MOL BASES, P2073; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Patel SB, 1998, J CLIN INVEST, V102, P1041, DOI 10.1172/JCI3963; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697	10	33	35	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	2000	290	5497					1709	1711		10.1126/science.290.5497.1709	http://dx.doi.org/10.1126/science.290.5497.1709			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	379FY	11186392				2022-12-28	WOS:000165632400027
J	Gostelow, L				Gostelow, L			Children in the midst of calamity	LANCET			English	Article									Save Children Fund, London SE5 8RD, England	Save the Children	Gostelow, L (corresponding author), Save Children Fund, 17 Grove Lane, London SE5 8RD, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S19	S19		10.1016/S0140-6736(00)92005-1	http://dx.doi.org/10.1016/S0140-6736(00)92005-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191474				2022-12-28	WOS:000166074900021
J	High, KA				High, KA			Gene therapy in haematology and oncology	LANCET			English	Article									Childrens Hosp Philadelphia, Abramson Res Ctr, Div Hematol, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania	High, KA (corresponding author), Childrens Hosp Philadelphia, Abramson Res Ctr, Div Hematol, Philadelphia, PA 19104 USA.		High, Katherine A./AAB-9322-2020						0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S8	S8		10.1016/S0140-6736(00)91994-9	http://dx.doi.org/10.1016/S0140-6736(00)91994-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191528				2022-12-28	WOS:000166074900010
J	Waiz, NK				Waiz, NK			Role of education in the use of contraception	LANCET			English	Article									Independent Univ Bangladesh, Populat Environm Dept, Dhaka 1212, Bangladesh	Independent University Bangladesh (IUB)	Waiz, NK (corresponding author), Independent Univ Bangladesh, Populat Environm Dept, House 19 Rd 3, Dhaka 1212, Bangladesh.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S51	S51		10.1016/S0140-6736(00)92037-3	http://dx.doi.org/10.1016/S0140-6736(00)92037-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191510				2022-12-28	WOS:000166074900053
J	Pouyssegur, J				Pouyssegur, J			Signal transduction - An arresting start for MAPK	SCIENCE			English	Editorial Material							RECEPTOR KINASES; PROTEIN		Inst Signaling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Pouyssegur, J (corresponding author), Inst Signaling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice, France.							Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7	9	22	22	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1515	+		10.1126/science.290.5496.1515	http://dx.doi.org/10.1126/science.290.5496.1515			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11185509				2022-12-28	WOS:000165446200027
J	Lincoln, T				Lincoln, T			Medicine - Cardiac arrest can be less of a gamble	NATURE			English	Editorial Material																		Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701	1	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					302	302		10.1038/35042660	http://dx.doi.org/10.1038/35042660			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11185494				2022-12-28	WOS:000165296000028
J	Weissman, NJ; Panza, JA; Tighe, JF; Gwynne, JT				Weissman, NJ; Panza, JA; Tighe, JF; Gwynne, JT			Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							APPETITE-SUPPRESSANT DRUGS; HEART-DISEASE; VALVE ABNORMALITIES; OBESE-PATIENTS; FENFLURAMINE; PHENTERMINE; PREVALENCE; ECHOCARDIOGRAPHY; INSUFFICIENCY; CESSATION	Background: Previous studies have reported small increases in the prevalence of low-grade aortic and mitral regurgitation in patients treated with dexfenfluramine compared with placebo. However, whether valvular abnormalities develop or progress 1 year after discontinuation of dexfenfluramine therapy has not been determined. Objective: To assess change in valvular regurgitation and morphologic characteristics 1 year after discontinuation of dexfenfluramine therapy. Design: Randomized, double-blind, placebo-controlled, multicenter study. Setting: outpatient obesity centers. Patients: obese perrons who had been treated for 2 to 3 months with dexfenfluramine. sustained-release dexfenfluramine, or placebo. Blinding was maintained, and patients returned for repeated echocardiography at 1 year. Measurements: Pain of echocardiograms were evaluated with a side-by-side reading method for change in grade of valvular regurgitation, structure, and function. A standardized acquisition and reading protocol was followed, and a core laboratory was used. Results: 914 patients who had initial echocardiography returned for repeated echocardiography 11.4 +/- 1.0 months (mean +/- SD) after discontinuing study medication (10.0 +/- 1.0 months after initial echocardiography). Compared with the placebo group, a greater proportion of patients in both dexfenfluramine groups had decreased aortic regurgitation (P = 0.003 for the dexfenfluramine group, P = 0.02 for the sustained-release group). No change in mitral regurgitation or any other measure of valvular structure or function was seen in any treatment group. Conclusions: After dexfenfluramine therapy is taken for 2 to 3 months and discontinued, development or progression of any valvular regurgitation over the following year is unlikely. Echocardiographic evidence suggests that aortic regurgitation regresses in some previously treated patients.	Washington Hosp Ctr, Inst Cardiovasc Res, Washington, DC 20010 USA; Wyeth Ayerst Res, Philadelphia, PA USA; NHLBI, Bethesda, MD 20892 USA	MedStar Washington Hospital Center; Pfizer; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Weissman, NJ (corresponding author), Washington Hosp Ctr, Inst Cardiovasc Res, 110 Irving St NW,Suite 4B-1, Washington, DC 20010 USA.							Burger AJ, 1999, J AM COLL CARDIOL, V34, P1153, DOI 10.1016/S0735-1097(99)00321-6; Cannistra LB, 1998, NEW ENGL J MED, V339, P771, DOI 10.1056/NEJM199809103391112; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Gardin JM, 2000, JAMA-J AM MED ASSOC, V283, P1703, DOI 10.1001/jama.283.13.1703; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; Hensrud DD, 1999, MAYO CLIN PROC, V74, P1191, DOI 10.4065/74.12.1191; Jick H, 1998, NEW ENGL J MED, V339, P719, DOI 10.1056/NEJM199809103391102; Jollis JG, 2000, CIRCULATION, V101, P2071, DOI 10.1161/01.CIR.101.17.2071; Khan MA, 1998, NEW ENGL J MED, V339, P713, DOI 10.1056/NEJM199809103391101; *MMWR, 1997, MMWR-MORBID MORTAL W, V46, P1061; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; Shively BK, 1999, CIRCULATION, V100, P2161, DOI 10.1161/01.CIR.100.21.2161; Wee CC, 1998, ANN INTERN MED, V129, P870, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00005; Weissman NJ, 1999, J AM COLL CARDIOL, V34, P2088, DOI 10.1016/S0735-1097(99)00445-3; Weissman NJ, 1998, NEW ENGL J MED, V339, P725, DOI 10.1056/NEJM199809103391103; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657	17	25	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					267	273		10.7326/0003-4819-134-4-200102200-00009	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NW	11182836				2022-12-28	WOS:000167050200002
J	Powell, P; Bentall, RP; Nye, FJ; Edwards, KHT				Powell, P; Bentall, RP; Nye, FJ; Edwards, KHT			Randomised controlled trial of patient education to encourage graded exercise in chronic fatigue syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COGNITIVE-BEHAVIOR THERAPY; SCALE; SF-36	Objective To assess the efficacy of an educational intervention explaining symptoms to encourage graded exercise in patients with chronic fatigue syndrome Design Randomised controlled trial. Setting Chromic fatigue clinic and infectious diseases outpatient clinic. Subjects 148 consecutively referred patients fulfilling Oxford criteria for chronic fatigue syndrome. Interventions Patients randomised to the control group received standardised medical care. Patients randomised to intervention received two individual treatment sessions and two telephone follow up calls, supported by a comprehensive educational pack, describing the role of disrupted physiological regulation in fatigue symptoms and encouraging home based graded exercise. The minimum intervention group had no further treatment, but the telephone intervention group received am additional seven follow up calls and the maximum intervention group an additional seven face to face sessions over four months. Main outcome measure A score of greater than or equal to 25 or an increase of greater than or equal to 10 on the SF-36 physical functioning subscale (range 10 to 30) 12 months after randomisation. Results 21 patients dropped out, mainly from the intervention groups. Intention to treat analysis showed 79 (69%) of patients in the intervention groups achieved a satisfactory outcome in physical functioning compared with two (6%) of controls, who received standardised medical care (P < 0.0001). Similar improvements were observed in fatigue, sleep, disability, and mood. No significant differences were found between the three intervention groups. Conclusions Treatment incorporating evidence based physiological explanations for symptoms was effective in encouraging self managed graded exercise. This resulted in substantial improvement compared with standardised medical care.	Univ Manchester, Dept Psychol, Manchester M13 9PL, Lancs, England; Aintree Univ Hosp NHS Fdn Trust, Reg Infect Dis Unit, Liverpool L9 7AL, Merseyside, England; Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England	University of Manchester; Aintree University Hospitals NHS Foundation Trust; University of Liverpool	Bentall, RP (corresponding author), Univ Manchester, Dept Psychol, Coupland 1, Manchester M13 9PL, Lancs, England.	bentall@psy.man.ac.uk	Winwood, Peter/A-6363-2008					CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CLEARE A, 1995, J AFFECT DISORDERS, V35, P293; De Lorenzo F, 1998, QJM-INT J MED, V91, P475, DOI 10.1093/qjmed/91.7.475; Deale A, 1997, AM J PSYCHIAT, V154, P408; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; EDWARDS R, 1994, CHRONIC FATIGUE SYND, P241; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Guy W., 1976, ASSESSMENT MANUAL PS, P218, DOI DOI 10.1186/1471-244X-7-7; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; Morriss RK, 1997, J PSYCHOSOM RES, V42, P597, DOI 10.1016/S0022-3999(97)89895-9; POWELL P, 1999, BEHAV COGN PSYCHOTH, V27, P249; Reid S, 2000, BMJ-BRIT MED J, V320, P292, DOI 10.1136/bmj.320.7230.292; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wearden AJ, 1998, BRIT J PSYCHIAT, V172, P485, DOI 10.1192/bjp.172.6.485; WESSELY S, 1993, NEUROLOGICAL REHABIL, P311; Wessely S, 1998, CHRONIC FATIGUE ITS; Williams G, 1996, CLIN PHYSIOL, V16, P327, DOI 10.1111/j.1475-097X.1996.tb00722.x; WILSON A, 1994, BRIT MED J, V308, P756, DOI 10.1136/bmj.308.6931.756; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	23	132	134	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	2001	322	7283					387	390		10.1136/bmj.322.7283.387	http://dx.doi.org/10.1136/bmj.322.7283.387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	404JH	11179154	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000167093600022
J	Soengas, MS; Capodieci, P; Polsky, D; Mora, J; Esteller, M; Opitz-Araya, X; McCombie, R; Herman, JG; Gerald, WL; Lazebnik, YA; Cordon-Cardo, C; Lowe, SW				Soengas, MS; Capodieci, P; Polsky, D; Mora, J; Esteller, M; Opitz-Araya, X; McCombie, R; Herman, JG; Gerald, WL; Lazebnik, YA; Cordon-Cardo, C; Lowe, SW			Inactivation of the apoptosis effector Apaf-1 in malignant melanoma	NATURE			English	Article							P53-DEPENDENT APOPTOSIS; METHYLATION; EXPRESSION; CASPASE-9; CHEMORESISTANCE; MUTATIONS; BCL-2; P53	Metastatic melanoma is a deadly cancer that fails to respond to conventional chemotherapy and is poorly understood at the molecular level(1). p53 mutations often occur in aggressive and chemoresistant cancers but are rarely observed in melanoma(1,2). Here we show that metastatic melanomas often lose Apaf-1, a cell-death effector that acts with cytochrome c and caspase-9 to mediate p53-dependent apoptosis(3). Loss of Apaf-1 expression is accompanied by allelic loss in metastatic melanomas, but can be recovered in melanoma cell lines by treatment with the methylation inhibitor 5-aza-2'-deoxycytidine (5aza2dC). Apaf-1-negative melanomas are invariably chemoresistant and are unable to execute a typical apoptotic programme in response to p53 activation. Restoring physiological levels of Apaf-1 through gene transfer or 5aza2dC treatment markedly enhances chemosensitivity and rescues the apoptotic defects associated with Apaf-1 loss. We conclude that Apaf-1 is inactivated in metastatic melanomas, which leads to defects in the execution of apoptotic cell death. Apaf-1 loss may contribute to the low frequency of p53 mutations observed in this highly chemoresistant tumour type.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Baltimore, MD 21231 USA	Cold Spring Harbor Laboratory; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Lowe, SW (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.org	Polsky, David/AAO-6254-2020; Soengas, Maria S/H-6455-2015; Clovis, Jeff/C-1020-2009; Esteller, Manel/L-5956-2014	Polsky, David/0000-0001-9554-5289; Soengas, Maria S/0000-0003-0612-6299; Esteller, Manel/0000-0003-4490-6093; McCombie, W. Richard/0000-0003-1899-0682; Mora, Jaume/0000-0002-9386-5980				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Capodieci P, 1998, DIAGN MOL PATHOL, V7, P69, DOI 10.1097/00019606-199804000-00002; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marcellus RC, 1996, CELL GROWTH DIFFER, V7, P1643; Mora J, 2000, J MOL DIAGN, V2, P37, DOI 10.1016/S1525-1578(10)60613-7; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 1999, J PATHOL, V187, P127; Selzer E, 1998, MELANOMA RES, V8, P197, DOI 10.1097/00008390-199806000-00001; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yamamoto H, 2000, CELL DEATH DIFFER, V7, P238, DOI 10.1038/sj.cdd.4400651; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	29	801	837	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2001	409	6817					207	211		10.1038/35051606	http://dx.doi.org/10.1038/35051606			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390UV	11196646				2022-12-28	WOS:000166316200048
J	Sargent, JD; Tickle, JJ; Beach, ML; Dalton, MA; Ahrens, MB; Heatherton, TF				Sargent, JD; Tickle, JJ; Beach, ML; Dalton, MA; Ahrens, MB; Heatherton, TF			Brand appearances in contemporary cinema films and contribution to global marketing of cigarettes	LANCET			English	Article							POPULAR FILMS; TOBACCO	Background The appearance of a cigarette brand in a cinema film gives the brand a certain distinction through its association with the characters and general tone of the film. Through the worldwide distribution of films, brands are promoted globally. We assessed the tobacco-brand appearances in a 10-year sample of contemporary films. Methods We viewed the contents of the top 25 US box-office films for each year of release, from 1988 to 1997 (250 films in total). We compared the prevalence of brand appearances for films produced before a voluntary ban on paid product placement by the tobacco industry (1988-90) with films produced after the ban (1991-97). Tobacco-brand appearance was defined as the screen appearance of a brand name, logo, or identifiable trademark on products or product packaging, billboards, store-front advertising, or tobacco promotional items. We defined actor endorsement of a brand as the display of a brand while being handled or used by an actor. Findings More than 85% of the films contained tobacco use. Tobacco brands appeared in 70 (28%) films. Brand appearances were as common in films suitable for adolescent audiences as they were in films for adult audiences (32 vs 35%), and were also present in 20% of those rated for children, Prevalence of brand appearance did not change overall in relation to the ban. However, there was a striking increase in the type of brand appearance depicted, with actor endorsement increasing from 1% of films before the ban to 11% after. Four US cigarette brands accounted for 80% of brand appearances. Revenues outside the USA accounted for 49% of total revenues for these films, indicating a large international audience. Interpretation Tobacco-brand appearances are common in films and are becoming increasingly endorsed by actors. The most highly advertised US cigarette brands account for most brand appearances, which suggests an advertising motive to this practice.	Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pediat, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Norris Cotton Canc Ctr, Hanover, NH 03756 USA; Dartmouth Coll, Dept Psychol & Brain Sci, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Sargent, JD (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dept Pediat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.		Heatherton, Todd F/H-5478-2011; Sargent, James D/I-2773-2013					BASIL MD, 1997, HEALTH COMMUN, V9, P190; Chapman S, 1997, Tob Control, V6, P269; COLFORD SW, 1990, ADVERTISING AGE, V17, P31; Distefan JM, 1999, PREV MED, V28, P1, DOI 10.1006/pmed.1998.0409; Everett SA, 1998, J COMMUN HEALTH, V23, P317, DOI 10.1023/A:1018727606500; Goldstein AO, 1999, JAMA-J AM MED ASSOC, V281, P1131, DOI 10.1001/jama.281.12.1131; HAZAN AR, 1994, AM J PUBLIC HEALTH, V84, P998, DOI 10.2105/AJPH.84.6.998; HIGGINS KT, 1985, ADVERTISING AGE, V19, P6; Karrh J.A., 1998, J CURRENT ISSUES RES, V20, P31, DOI DOI 10.1080/10641734.1998.10505081; KENOFF JS, 1993, ENTERTAINMENT LAW FI, V9, P4; KENOFF JS, 1993, ENTERTAINMENT LAW FI, V9, P1; LACKEY WB, 1993, CAN L LANE SMOKE MAR; McIntosh WD, 1998, ADDICT BEHAV, V23, P395, DOI 10.1016/S0306-4603(97)00071-3; Reed J.D., 1989, TIME, P103; Richards J W Jr, 1996, Tob Control, V5, P295, DOI 10.1136/tc.5.4.295; Shields DLL, 1999, TOB CONTROL, V8, P378, DOI 10.1136/tc.8.4.378; SNYDER SL, 1992, U ILLINOIS LAW REV, V1, P301; Stockwell T F, 1997, Tob Control, V6, P282, DOI 10.1136/tc.6.4.282; TERRE L, 1991, J APPL SOC PSYCHOL, V21, P1303, DOI 10.1111/j.1559-1816.1991.tb00472.x; TICKLE J, IN PRESS TOBACCO CON; 1990, ADVERTISING AGE, P27	21	87	87	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					29	32		10.1016/S0140-6736(00)03568-6	http://dx.doi.org/10.1016/S0140-6736(00)03568-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	391EQ	11197357				2022-12-28	WOS:000166341500012
J	Gray, PM; Krause, B; Atema, J; Payne, R; Krumhansl, C; Baptista, L				Gray, PM; Krause, B; Atema, J; Payne, R; Krumhansl, C; Baptista, L			Biology and music - The music of nature and the nature of music	SCIENCE			English	Editorial Material									Natl Acad Sci, Washington, DC 20016 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; Wild Sanctuary Inc, Woods Hole, MA 02543 USA; Ocean Alliance, Lincoln, MA 01773 USA; Cornell Univ, Dept Psychol, Ithaca, NY 14853 USA; Calif Acad Sci, San Francisco, CA USA	National Academies of Sciences, Engineering & Medicine; Marine Biological Laboratory - Woods Hole; Cornell University; California Academy of Sciences	Gray, PM (corresponding author), Natl Acad Sci, Washington, DC 20016 USA.							Armstrong EA, 1963, STUDY BIRD SONG; ATEMA J, 2000, BIOM S AAAS ANN M; BAPTISTA F, 1993, NETH J ZOOL, V43, P17; BAPTISTA LF, 2000, BIOM S AAAS ANN M; Baptista Luis F., 1997, P23, DOI 10.1017/CBO9780511758843.003; BORROR DONALD J., 1956, OHIO JOUR SCI, V56, P177; HARTSHORNE C, COMMUNICATION; Hartshorne C., 1973, BORN SING; KRAUSE B, 2000, BIOM S AAAS ANN M; KROODSMA DE, 1979, AUK, V103, P189; Krumhansl CL, 2000, COGNITION, V76, P13, DOI 10.1016/S0010-0277(00)00068-8; Krumhansl CL, 1999, MUSIC PERCEPT, V17, P151; MARTINEZGOMEZ JE, UNPUB; Noad MJ, 2000, NATURE, V408, P537, DOI 10.1038/35046199; PAYNE R, 2000, BIOM S AAAS ANN M; VERNER J, 1975, Living Bird, V14, P263; WING ANNE H., 1951, AUK, V68, P189; Wood G.A., 1984, Corella, V8, P94	18	50	51	3	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					52	54		10.1126/SCIENCE.1056960	http://dx.doi.org/10.1126/SCIENCE.1056960			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11192008				2022-12-28	WOS:000166259100027
J	Bishal, WR				Bishal, WR			Rekindling old controversy on elusive lair of latent tuberculosis	LANCET			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS		Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Bishal, WR (corresponding author), Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD 21205 USA.							BALASUBRAMANIAN V, 1994, TUBERCLE LUNG DIS, V75, P168, DOI 10.1016/0962-8479(94)90002-7; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Feldman WH, 1938, AM J PATHOL, V14, P473; Ghon A., 1923, AM REV TUBERC, V7, P314; Griffith AS, 1929, J PATHOL BACTERIOL, V32, P813, DOI 10.1002/path.1700320411; Opie EL, 1927, ARCH PATHOL LAB MED, V4, P1; RICH AR, 1944, PATHOGENESIS TUBERCU, P703; STANFORD JL, 1987, TUBERCLE, V68, P241, DOI 10.1016/0041-3879(87)90063-8; Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103; VANDIVIERE H M, 1956, Am J Med Sci, V232, P30, DOI 10.1097/00000441-195607000-00006; Wayne L. G., 1998, Tubercle and Lung Disease, V79, P127, DOI 10.1054/tuld.1998.0015; WAYNE LG, 1994, ANTIMICROB AGENTS CH, V38, P2054, DOI 10.1128/AAC.38.9.2054; WAYNE LG, 1982, INFECT IMMUN, V37, P1042, DOI 10.1128/IAI.37.3.1042-1049.1982	13	17	18	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2000	356	9248					2113	2114		10.1016/S0140-6736(00)03485-1	http://dx.doi.org/10.1016/S0140-6736(00)03485-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385HD	11191532				2022-12-28	WOS:000165997300003
J	Robbins, TW; Mehta, MA; Sahakian, BJ				Robbins, TW; Mehta, MA; Sahakian, BJ			Neuroscience - Boosting working memory	SCIENCE			English	Editorial Material							CEREBRAL BLOOD-FLOW; PREFRONTAL CORTEX; FRONTAL-CORTEX; SCOPOLAMINE; PERFORMANCE; INFORMATION; MODULATION; ATTENTION; DEMENTIA; SYSTEMS		Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; Imperial Coll, Sch Med, Hammersmith Hosp, MRC,Cyclotron Unit, London W12 0NN, England; Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England	University of Cambridge; Imperial College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Robbins, TW (corresponding author), Univ Cambridge, Dept Expt Psychol, Downing St, Cambridge CB2 3EB, England.		Mehta, Mitul/F-3960-2010; Sahakian, Barbara/AAW-1198-2020; Robbins, Trevor W/A-7551-2008	Sahakian, Barbara/0000-0001-7352-1745; Robbins, Trevor/0000-0003-0642-5977				AIGNER TG, 1986, BEHAV NEURAL BIOL, V45, P81, DOI 10.1016/S0163-1047(86)80008-5; Arnsten AFT, 1997, J PSYCHOPHARMACOL, V11, P151, DOI 10.1177/026988119701100208; Baddeley A.D., 1986, WORKING MEMORY THOUG; Coull JT, 1997, EUR J NEUROSCI, V9, P589, DOI 10.1111/j.1460-9568.1997.tb01635.x; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; Furey ML, 2000, BRAIN RES BULL, V51, P213, DOI 10.1016/S0361-9230(99)00219-1; Furey ML, 1997, P NATL ACAD SCI USA, V94, P6512, DOI 10.1073/pnas.94.12.6512; Furey ML, 2000, SCIENCE, V290, P2315, DOI 10.1126/science.290.5500.2315; Goldman-Rakic P, 2000, NEUROIMAGE, V11, P451, DOI 10.1006/nimg.2000.0575; GOLDMANRAKIC PS, 1987, HDB PHYSL NERVOUS SY, P373; GRANON S, 1995, PSYCHOPHARMACOLOGY, V119, P139, DOI 10.1007/BF02246154; GRASBY PM, 1992, EUR J NEUROSCI, V4, P1203, DOI 10.1111/j.1460-9568.1992.tb00145.x; LEWIS DA, 2000, STIMULANT DRUGS ADHD, P77; Luciana M, 1998, CEREB CORTEX, V8, P218, DOI 10.1093/cercor/8.3.218; Mehta MA, 2000, J NEUROSCI, V20; Mesulam Marek-Marsel, 1995, P135; MURPHY PC, 1991, NEUROSCIENCE, V40, P13, DOI 10.1016/0306-4522(91)90170-S; Petrides M, 1996, PHILOS T ROY SOC B, V351, P1455, DOI 10.1098/rstb.1996.0130; Robbins TW, 1997, PSYCHOPHARMACOLOGY, V134, P95, DOI 10.1007/s002130050430; Rushworth MFS, 1998, TRENDS COGN SCI, V2, P46, DOI 10.1016/S1364-6613(98)01127-9; SAHAKIAN B, 1989, BRIT J PSYCHIAT, V154, P797, DOI 10.1192/bjp.154.6.797; SAHAKIAN BJ, 1993, PSYCHOPHARMACOLOGY, V110, P395, DOI 10.1007/BF02244644; SAWAGUCHI T, PARKINSONISM REL DIS, V7, P9	23	13	13	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2000	290	5500					2275	+		10.1126/science.290.5500.2275	http://dx.doi.org/10.1126/science.290.5500.2275			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	385GQ	11188728				2022-12-28	WOS:000165995800033
J	Thomas, K; Sudhakar, K				Thomas, K; Sudhakar, K			Health-care inequalities: an Indian perspective	LANCET			English	Article									Christian Med Coll & Hosp, Clin Epidemiol Unit, Vellore 632004, Tamil Nadu, India; World Bank, New Delhi, India; Christian Med Coll, Clin Epidemiol Unit, Vellore, Tamil Nadu, India	Christian Medical College & Hospital (CMCH) Vellore; The World Bank; Christian Medical College & Hospital (CMCH) Vellore	Thomas, K (corresponding author), Christian Med Coll & Hosp, Clin Epidemiol Unit, Vellore 632004, Tamil Nadu, India.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S35	S35		10.1016/S0140-6736(00)92021-X	http://dx.doi.org/10.1016/S0140-6736(00)92021-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191492				2022-12-28	WOS:000166074900037
J	Klibanski, A; Adams-Campbell, L; Bassford, T; Blair, SN; Boden, SD; Dickersin, K; Gifford, DR; Glasse, L; Goldring, SR; Hruska, K; Johnson, SR; McCauley, LK; Russell, WE				Klibanski, A; Adams-Campbell, L; Bassford, T; Blair, SN; Boden, SD; Dickersin, K; Gifford, DR; Glasse, L; Goldring, SR; Hruska, K; Johnson, SR; McCauley, LK; Russell, WE		NIH Consensus Dev Panel Osteopor	Osteoporosis prevention, diagnosis, and therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BONE-MINERAL DENSITY; QUALITY-OF-LIFE; WOMEN AGED 45; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; HIP FRACTURE; ESTABLISHED OSTEOPOROSIS; RHEUMATOID-ARTHRITIS; SALMON-CALCITONIN; RANDOMIZED-TRIAL	Objectives To clarify the factors associated with prevention, diagnosis, and treatment of osteoporosis, and to present the most recent information available in these areas. Participants From March 27-29, 2000, a nonfederal, nonadvocate, 13-member panel was convened, representing the fields of internal medicine, family and community medicine, endocrinology, epidemiology, orthopedic surgery, gerontology, rheumatology, obstetrics and gynecology, preventive medicine, and cell biology. Thirty-two experts from these fields presented data to the panel and an audience of 699. Primary sponsors were the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institutes of Health Office of Medical Applications of Research. Evidence MEDLINE was searched for January 1995 through December 1999, and a bibliography of 2449 references provided to the panel. Experts prepared abstracts for presentations with relevant literature citations. Scientific evidence was given precedence over anecdotal experience. Consensus Process The panel, answering predefined questions, developed conclusions based on evidence presented in open forum and the literature. The panel composed a draft statement, which was read and circulated to the experts and the audience for public discussion. The panel resolved conflicts and released a revised statement at the end of the conference. The draft statement was posted on the Web on March 30, 2000, and updated with the panel's final revisions within a few weeks. Conclusions Though prevalent in white postmenopausal women, osteoporosis occurs in all populations and at all ages and has significant physical, psychosocial, and financial consequences. Risks for osteoporosis (reflected by low bone mineral density [BMD]) and for fracture overlap but are not identical. More attention should be paid to skeletal health in persons with conditions associated with secondary osteoporosis. Clinical risk factors have an important but poorly validated role in determining who should have BMD measurement, in assessing fracture risk, and in determining who should be treated. Adequate calcium and vitamin D intake is crucial to develop optimal peak bone mass and to preserve bone mass throughout life. Supplementation with these 2 nutrients may be necessary in persons not achieving recommended dietary intake. Gonadal steroids are important determinants of peak and lifetime bone mass in men, women, and children. Regular exercise, especially resistance and high-impact activities, contributes to development of high peak bone mass and may reduce risk of falls in older persons. Assessment of bone mass, identification of fracture risk, and determination of who should be treated are the optimal goals when evaluating patients for osteoporosis. Fracture prevention is the primary treatment goal for patients with osteoporosis. Several treatments have been shown to reduce the risk of osteoporotic fractures, including those that enhance bone mass and reduce the risk or consequences of falls. Adults with vertebral, rib, hip, or distal forearm fractures should be evaluated for osteoporosis and given appropriate therapy.	Harvard Univ, Sch Med, Boston, MA 02115 USA; Howard Univ, Ctr Canc, Washington, DC 20059 USA; Univ Arizona, Hlth Sci Ctr, Dept Family & Community Med, Tucson, AZ USA; Cooper Inst, Dallas, TX USA; Emory Univ, Sch Med, Decatur, GA 30033 USA; Brown Univ, Dept Community Hlth, Providence, RI 02912 USA; Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; Older Womens League, Poughkeepsie, NY USA; New England Baptist Bone & Joint Inst, Boston, MA USA; Washington Univ, Dept Med, St Louis, MO USA; Univ Iowa, Coll Med, Iowa City, IA USA; Univ Iowa, Coll Publ Hlth, Iowa City, IA USA; Univ Michigan, Dept Periodont Prevent Geriatr, Ann Arbor, MI USA; Vanderbilt Univ, Med Ctr, Div Pediat Endocrinol, Nashville, TN USA	Harvard University; Harvard Medical School; Howard University; University of Arizona; University of Arizona Health Sciences; Cooper Institute; Emory University; Brown University; Brown University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; New England Baptist Hospital; Washington University (WUSTL); University of Iowa; University of Iowa; University of Michigan System; University of Michigan; Vanderbilt University	Klibanski, A (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.		Russell, William/A-7307-2009; YAMAMOTO, MASAHIRO/F-9094-2011	YAMAMOTO, MASAHIRO/0000-0003-3859-0125				AGNUSDEI D, 1992, BONE MINER, V19, pS43, DOI 10.1016/0169-6009(92)90865-B; ALOIA JF, 1994, ANN INTERN MED, V120, P97, DOI 10.7326/0003-4819-120-2-199401150-00001; Bassey EJ, 1998, J BONE MINER RES, V13, P1805, DOI 10.1359/jbmr.1998.13.12.1805; BERKELHAMMER CH, 1988, AM J CLIN NUTR, V48, P1482, DOI 10.1093/ajcn/48.6.1482; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BONE HG, IN PRESS J ENDOCRINO; Bravo G, 1996, J AM GERIATR SOC, V44, P756, DOI 10.1111/j.1532-5415.1996.tb03730.x; Buckley LM, 1996, ANN INTERN MED, V125, P961, DOI 10.7326/0003-4819-125-12-199612150-00004; Burr DB, 1997, J BONE MINER RES, V12, P6, DOI 10.1359/jbmr.1997.12.1.6; CARROLL MD, 1983, VITAL HLTH STAT, V11, P231; CARTER DR, 1977, J BONE JOINT SURG AM, V59, P954, DOI 10.2106/00004623-197759070-00021; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Cheng SL, 1997, J BONE MINER RES, V12, P1075, DOI 10.1359/jbmr.1997.12.7.1075; Chesnut CH, 2000, AM J MED, V109, P267, DOI 10.1016/S0002-9343(00)00490-3; CHRISCHILLES E, 1994, BONE, V15, P377, DOI 10.1016/8756-3282(94)90813-3; CHU CQ, 1992, BRIT J RHEUMATOL, V31, P653; COMPSTON JE, 1994, BONE, V15, P463, DOI 10.1016/8756-3282(94)90267-4; CORDAIN L, IN PRESS AM J CLIN N; Cranney A, 1999, ARTHRIT CARE RES, V12, P425, DOI 10.1002/1529-0131(199912)12:6<425::AID-ART11>3.0.CO;2-A; Cumming RG, 1997, J BONE MINER RES, V12, P1321, DOI 10.1359/jbmr.1997.12.9.1321; Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; DAVIS JW, 1995, BONE, V17, P369, DOI 10.1016/S8756-3282(95)00249-9; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DEVINE A, 1995, AM J CLIN NUTR, V62, P740, DOI 10.1093/ajcn/62.4.740; Ebbesen EN, 1999, BONE, V25, P713, DOI 10.1016/S8756-3282(99)00216-1; EDDY DM, 1998, OSTEOPOROS INT S4, V8; ETTINGER B, 1988, MATURITAS, V10, P283, DOI 10.1016/0378-5122(88)90064-3; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; [Food and Nutrition Board Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference Intakes], 1997, DIET REF INT CALC PH, DOI 10.17226/5776; FRIEDLANDER AL, 1995, J BONE MINER RES, V10, P574, DOI 10.1002/jbmr.5650100410; Garnero P, 1996, J BONE MINER RES, V11, P1531; Genant HK, 1999, BONE, V25, P149, DOI 10.1016/S8756-3282(99)00109-X; Gold DT, 1996, BONE, V18, pS185, DOI 10.1016/8756-3282(95)00500-5; GOLD DT, 1996, J WOMENS HEALTH, V2, P149; Gold MR, 1996, COST EFFECTIVENESS H; GOLDSTEIN SA, 1993, CALCIFIED TISSUE INT, V53, pS127, DOI 10.1007/BF01673421; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grazier K, 1984, AM ACAD ORTHOP SURG, V1, P73; Greenspan SL, 1998, J BONE MINER RES, V13, P1431, DOI 10.1359/jbmr.1998.13.9.1431; Haapasalo H, 1996, J BONE MINER RES, V11, P864; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; HEANEY RP, IN PRESS FOOD CHEM T; HEANEY RP, IN PRESS CLIN NUTR E; HODGSON TA, 1982, MILBANK FUND Q, V60, P429, DOI 10.2307/3349801; Hoerger TJ, 1999, J WOMEN HEALTH GEN-B, V8, P1077, DOI 10.1089/jwh.1.1999.8.1077; Honkanen RJ, 1999, J BONE MINER RES, V14, pS181; Jonsson B, 1999, OSTEOPOROSIS INT, V10, P193, DOI 10.1007/s001980050215; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266; Komulainen MH, 1998, MATURITAS, V31, P45, DOI 10.1016/S0378-5122(98)00085-1; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; KOVACS AB, 1994, AGENTS ACTIONS, V41, P86, DOI 10.1007/BF01986400; Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LeidigBruckner G, 1997, J BONE MINER RES, V12, P663, DOI 10.1359/jbmr.1997.12.4.663; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; LOOKER AC, IN PRESS OSTEOPOROS; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; Lunt M, 1997, J BONE MINER RES, V12, P1883, DOI 10.1359/jbmr.1997.12.11.1883; Malmros B, 1998, OSTEOPOROSIS INT, V8, P215, DOI 10.1007/s001980050057; MARCUS R, 1994, J BONE MINER RES, V9, P1467, DOI 10.1002/jbmr.5650090920; Marcus R., 1996, PRINCIPLES BONE BIOL, P1435; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; Melton LJ, 1998, J BONE MINER RES, V13, P1915, DOI 10.1359/jbmr.1998.13.12.1915; Miller PD, 1997, AM J MED, V103, P468, DOI 10.1016/S0002-9343(97)00278-7; Mori S, 1997, BONE, V21, P521, DOI 10.1016/S8756-3282(97)00200-7; Myers ER, 1997, SPINE, V22, p25S, DOI 10.1097/00007632-199712151-00005; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; Nieves JW, 1998, AM J CLIN NUTR, V67, P18, DOI 10.1093/ajcn/67.1.18; Norman TL, 1997, BONE, V20, P375, DOI 10.1016/S8756-3282(97)00004-5; OVERGAARD K, 1989, CLIN ENDOCRINOL, V30, P435, DOI 10.1111/j.1365-2265.1989.tb00443.x; OVERGAARD K, 1989, BRIT MED J, V299, P477, DOI 10.1136/bmj.299.6697.477; OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556; PHILLIPS S, 1988, BONE, V9, P271, DOI 10.1016/8756-3282(88)90009-9; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; Potter SM, 1998, AM J CLIN NUTR, V68, p1375S, DOI 10.1093/ajcn/68.6.1375S; Praemer A., 1992, MUSCULOSKELETAL COND, P143; Praemer A, 1992, MUSCULOSKELETAL COND; PUN KK, 1989, CLIN THER, V11, P205; Randell A, 1995, OSTEOPOROSIS INT, V5, P427, DOI 10.1007/BF01626603; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; RICE JC, 1988, J BIOMECH, V21, P155, DOI 10.1016/0021-9290(88)90008-5; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; ROBERTO KA, 1988, WOMEN HEALTH, V14, P105; ROBERTO KA, 1990, J WOMEN AGING, V2, P33; ROBINSON TL, 1995, J BONE MINER RES, V10, P26; Rodino MA, 1998, AM J MED, V104, P459, DOI 10.1016/S0002-9343(98)00081-3; Ross P D, 1991, Osteoporos Int, V1, P134, DOI 10.1007/BF01625442; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; Schurch MA, 1998, ANN INTERN MED, V128, P801, DOI 10.7326/0003-4819-128-10-199805150-00002; SEBASTIAN A, 1994, NEW ENGL J MED, V330, P1776, DOI 10.1056/NEJM199406233302502; Seeman E, 1998, J CLIN ENDOCR METAB, V83, P1414, DOI 10.1210/jc.83.5.1414; Seeman E, 1997, J BONE MINER RES, V12, P509, DOI 10.1359/jbmr.1997.12.4.509; SHANE E, IN PRESS OSTEOPOROSI; SNOWHARTER C, 1992, J BONE MINER RES, V7, P761, DOI 10.1002/jbmr.5650070706; Taaffe DR, 1999, J AM GERIATR SOC, V47, P1208, DOI 10.1111/j.1532-5415.1999.tb05201.x; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; *US BUR CENS, 1996, P251130 US BUR CENS; Varney LF, 1999, J CLIN DENSITOM, V2, P275, DOI 10.1385/JCD:2:3:275; Wasnich RD, 1997, CLIN RHEUMATOL, V16, P337, DOI 10.1007/BF02242447; WELTEN DC, 1994, J BONE MINER RES, V9, P1089, DOI 10.1002/jbmr.5650090717; WYSHAK G, 1989, J ORTHOPAED RES, V7, P91, DOI 10.1002/jor.1100070113; ZANCHETTA JR, 1995, BONE, V16, pS393, DOI 10.1016/S8756-3282(95)80505-2; [No title captured]	111	3488	3639	38	783	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					785	795						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	399MP	11525451				2022-12-28	WOS:000166817200036
